PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bu, W; Su, LK				Bu, W; Su, LK			Regulation of microtubule assembly by human EB1 family proteins	ONCOGENE			English	Article						EB1; EBF3; microtubule-associated protein; microtubule; microtubule bundle	TUMOR-SUPPRESSOR PROTEIN; BINDING PROTEIN; CYTOPLASMIC DYNEIN; ALPHA-TUBULIN; DISTAL ENDS; CELL-CYCLE; APC; DYNAMICS; CANCER; YEAST	The EB1 family proteins are highly conserved microtubule-associated proteins, The EB1 protein in yeast has been shown to play an important role in regulating microtubule dynamics and chromosome segregation. Human EB1 family proteins include EB1, RP1 and EBF3. Although EB1 and RP1 have been shown to associate with microtubules, the subcellular localization of endogenous EBF3 had not been characterized. The function of human EB1 family proteins was also not clear. We therefore investigated the cellular localization of EBF3 and the regulation of microtubule organization by EB1 family proteins. As do EB1 and RP1, EBF3 was found to colocalize with microtubules, preferentially at their plus ends, throughout the cell cycle. Moreover, there was a very strong EBF3 signal at the centrosome in interphase cells and at the spindle poles in mitotic cells. When EB1 family proteins were overexpressed, they associated with the entire microtubule cytoskeleton, In addition, EB1 and EBF3 induced microtubule bundling in some cells overexpressing these proteins. These microtubule bundles were more resistant to nocodazole and were more acetylated than regular microtubules. Our results demonstrate for the first time that human EB1 family proteins could regulate microtubule assembly and stability.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Su, LK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA070371, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70371, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Pancer Z, 1996, CANCER LETT, V109, P155, DOI 10.1016/S0304-3835(96)04440-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Su LK, 2001, GENOMICS, V71, P142, DOI 10.1006/geno.2000.6428; SU LK, 1995, CANCER RES, V55, P2972; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Vaughan KT, 1999, J CELL SCI, V112, P1437	39	43	44	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3185	3192		10.1038/sj.onc.1204429	http://dx.doi.org/10.1038/sj.onc.1204429			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423968				2022-12-28	WOS:000169163500002
J	Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C				Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C			Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model	ONCOGENE			English	Article						ras transformation; DNA microarray; transcript imaging	MAST-CELLS; CANCER; IDENTIFICATION; PROLIFERATION; FIBROBLASTS; PROGRESSION; INTEGRIN; DISPLAY; CLONING; BCL-2	Mouse PB-3c mast cells stably transfected with the v-H-ras oncogene induce tumor formation in vivo when implanted into mice. Such tumor cells are characterized by an autocrine IL-3 loop. DNA microarrays allow simultaneous transcript imaging of several thousand genes and the technique was applied in this tumor model to analyse gene expression following malignant transformation. Using three independent tumor lines derived from the same precursor the expression of about 400 out of 11000 genes was modulated in each tumor. A subset of only 75 genes (0.68%) is shared and up- or downregulated in all three lines. A significant portion of this gene pool possesses functions related to tumorigenesis such as cell adhesion, signaling or transcriptional regulation. Apart from a number of expressed sequence tags (EST's) we find downregulation of four interferon-inducible genes in the tumor lines. Finally, when we extrapolate our data to the complete mouse genome, we estimate that about 500 genes are differentially expressed in tumor cells compared to the precursor cell PB-3c.	F Hoffmann La Roche & Co Ltd, Dept Roche Genet, CH-4070 Basel, Switzerland; Inst Med Microbiol, CH-4051 Basel, Switzerland	Roche Holding	Certa, U (corresponding author), F Hoffmann La Roche & Co Ltd, Dept Roche Genet, CH-4070 Basel, Switzerland.			Brem, Reto/0000-0002-0171-1248				ASHLEY DJB, 1969, BRIT J CANCER, V23, P313, DOI 10.1038/bjc.1969.41; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; Buess M, 1999, ONCOGENE, V18, P1487, DOI 10.1038/sj.onc.1202445; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CERTA U, 2001, IN PRESS DNA ARRAYS; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DOUGHERTY GJ, 1989, J BIOL CHEM, V264, P6509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; JALANKO H, 1978, INT J CANCER, V21, P453, DOI 10.1002/ijc.2910210409; Kleeff J, 1998, CANCER RES, V58, P3769; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Puthier D, 1999, LEUKEMIA, V13, P289, DOI 10.1038/sj.leu.2401302; RA C, 1989, J BIOL CHEM, V264, P15323; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SMITH TJ, 1994, IMMUNITY, V1, P393, DOI 10.1016/1074-7613(94)90070-1; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; Yan SQ, 1998, BIOL CHEM, V379, P113; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	30	23	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2854	2858		10.1038/sj.onc.1204403	http://dx.doi.org/10.1038/sj.onc.1204403			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420697				2022-12-28	WOS:000168712000013
J	Varley, JM; Attwooll, C; White, G; McGown, G; Thorncroft, M; Kelsey, AM; Greaves, M; Boyle, J; Birch, JM				Varley, JM; Attwooll, C; White, G; McGown, G; Thorncroft, M; Kelsey, AM; Greaves, M; Boyle, J; Birch, JM			Characterization of germline TP53 splicing mutations and their genetic and functional analysis	ONCOGENE			English	Article						TP53; Li-Fraumeni; splicing	LI-FRAUMENI FAMILIES; P53 MUTATIONS; HUMAN TUMORS; CANCER; EXPRESSION; SEQUENCE; PATIENT	Germline TP53 splicing mutations have been described infrequently (>2%) in the literature, however in a series of 40 patients and families identified by our group in which there are germline TP53 mutations, seven affect splicing (18%), The low figure reported in the literature might reflect the method of mutation detection, which in many studies does not include all splice junctions, These data indicate that a significant proportion of TP53 germline mutations are currently unrecognized. We have carried out detailed studies of the effects of the different mutations on splicing, and see distinct variations in the effects of the same mutation in different patients, Furthermore we have identified the usage of a nonconsensus splice donor site in four families with an intron 4 splice donor mutation.	Paterson Inst Canc Res, CRC, Canc Genet Grp, Manchester M20 4BX, Lancs, England; Royal Manchester Childrens Hosp, Dept Histopathol, Manchester M27 1HA, Lancs, England; Royal Manchester Childrens Hosp, CRC, PFCRG, Manchester M27 1HA, Lancs, England	Paterson Institute for Cancer Research; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Varley, JM (corresponding author), Paterson Inst Canc Res, CRC, Canc Genet Grp, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							BARTEK J, 1991, ONCOGENE, V6, P1699; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; Boyle JM, 1999, BRIT J CANCER, V79, P1657, DOI 10.1038/sj.bjc.6690265; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; BRUGIERES L, 1993, CANCER RES, V53, P452; Casey G, 1996, ONCOGENE, V13, P1971; Chen SY, 2000, P NATL ACAD SCI USA, V97, P593, DOI 10.1073/pnas.97.2.593; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; JOLLY KW, 1994, ONCOGENE, V9, P97; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; Sedlacek Z, 1998, NUCLEIC ACIDS RES, V26, P214, DOI 10.1093/nar/26.1.214; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Varley JM, 1998, BRIT J CANCER, V78, P1081, DOI 10.1038/bjc.1998.631; Varley JM, 1999, AM J HUM GENET, V65, P995, DOI 10.1086/302575; Varley JM, 1998, ONCOGENE, V16, P3291, DOI 10.1038/sj.onc.1201878; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Varley JM, 1997, CANCER RES, V57, P3245; VARLEY JM, 1995, J MED GENET, V32, P942, DOI 10.1136/jmg.32.12.942; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 1996, CANCER GENET CYTOGEN, V90, P14, DOI 10.1016/0165-4608(96)00059-3; Verselis SJ, 2000, ONCOGENE, V19, P4230, DOI 10.1038/sj.onc.1203758; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	31	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2647	2654		10.1038/sj.onc.1204369	http://dx.doi.org/10.1038/sj.onc.1204369			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420676				2022-12-28	WOS:000168652600005
J	Ebina, M; Martinez, A; Birrer, MJ; Linnoila, RI				Ebina, M; Martinez, A; Birrer, MJ; Linnoila, RI			In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers	ONCOGENE			English	Article						p53; lung cancer; immunohistochemistry; in situ PCR; in situ RT-PCR	TRANSFORMED-CELLS; MUTATIONS; RAS; ABNORMALITIES; ANTIGEN	Many solid tumors, including non-small cell lung cancers (NSCLCs), are characterized by heterogenous expression of p53 protein in the neoplastic cells. To analyse the molecular implications of this finding, we examined topographic distribution of p53 mutations using in situ polymerase chain reaction (PCR) in primary NSCLCs, showing distinct patterns of variable p53 overexpression by immunohistochemistry, Unique sets of primers for each mutation were designed, and optimal PCR conditions were determined by standard PCR using DNA from cloned mutants or cell lines established from these tumors. Ail tumor cell nuclei, regardless of the status of p53 overexpression, demonstrated homogeneous distribution of mutant p53 with specific primers, indicating that only subgroups of the mutated cells overexpressed p53 protein. In situ reverse transcription (RT)-PCR was applied to detect mutant mRNA in the individual tumor cells using specific primers. We found that in each case the distribution of mutant p53 mRNA coincided with that of immunohistochemical overexpression of p53 protein. Our results suggest that the regulation of mutant p53 expression, but not the genotype, is heterogeneous in the neoplastic cells, The topographic genomapping of p53 in NSCLC using in situ PCR provides a novel approach to view molecular mechanisms of lung carcinogenesis.	Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Sendai, Miyagi 9808575, Japan; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	Tohoku University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ebina, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Sendai, Miyagi 9808575, Japan.		Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044				BODNER SM, 1992, ONCOGENE, V7, P743; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Cha R S, 1992, PCR Methods Appl, V2, P14; EBINA M, 1994, CANCER RES, V54, P2496; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hall KL, 1997, GYNECOL ONCOL, V65, P330, DOI 10.1006/gyno.1997.4653; HASSE AT, 1990, P NATL ACAD SCI USA, V87, P4971; HORIO Y, 1993, CANCER RES, V53, P1; Kanazawa H, 2000, AM J PATHOL, V156, P1289, DOI 10.1016/S0002-9440(10)64999-1; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; MARTINEZ A, 1995, J HISTOCHEM CYTOCHEM, V43, P739, DOI 10.1177/43.8.7542678; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; NUOVO GJ, 1994, PCR IN SITU HYBRIDIZ, P169; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REIHSAUS E, 1990, ONCOGENE, V5, P137; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaw GL, 1996, J CELL BIOCHEM, P173; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	21	11	13	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2579	2586		10.1038/sj.onc.1204351	http://dx.doi.org/10.1038/sj.onc.1204351			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420668				2022-12-28	WOS:000168652500009
J	Boulanger, CA; Smith, GH				Boulanger, CA; Smith, GH			Reducing mammary cancer risk through premature stem cell senescence	ONCOGENE			English	Article						mammary; stem cell; cancer risk; cellular senescence; MMTV	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSGENE; TUMOR VIRUS; EXPRESSION; MICE; GLAND; DIFFERENTIATION; TISSUES	The reproductive capacity of the mammary epithelial stem cell is reduced coincident with the number of symmetric divisions it must perform. In a study of FVB/ N mice with the transgene, WAP-TGF beta1, we discovered that mammary epithelial stem tells were prematurely aged due to ectopic expression of TGF-beta1. To test whether premature aging of mammary epithelial stem cells would have an impart on susceptibility or resistance to mammary cancer, female littermates from FVB/ N x WAP-TGF-beta1 mating were injected with mouse mammary tumor virus (MMTV) at 8-10 weeks of age. A total of 44 females were inoculated, maintained as breeders and observed for tumor development for up to 18 months. Only one mammary tumor appeared in 17 TGF-beta1 females while 15 were collected from 29 wild type sisters. Premalignant mammary epithelial cells in infected glands were identified by transplantation of single cell(1 x 10(5)) suspensions into nulliparous hosts and testing for hyperplastic outgrowth. Although the number of positive takes was significantly reduced with TGF-beta1 cells, both MMTV-infected TGF-beta1 and wild type cells produced hyperplastic outgrowths suggesting that premalignant transformation was achieved in each group. The results suggest a positive correlation between the procreative life-span of mammary epithelial stem cells and mammary cancer risk.	NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, GH (corresponding author), NIH, Bldg 10,Room 8H07,9000 Rockville Pike, Bethesda, MD 20892 USA.							ARTHUR LO, 1978, INT J CANCER, V22, P433, DOI 10.1002/ijc.2910220411; BUGGIANO V, 2001, IN PRESS INT J CANC; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DANIEL CW, 1971, EXP GERONTOL, V6, P95, DOI 10.1016/0531-5565(71)90053-2; DANIEL CW, 1971, EXP CELL RES, V65, P27, DOI 10.1016/S0014-4827(71)80046-0; DEOME KB, 1959, CANCER RES, V19, P515; DEOME KB, 1978, CANCER RES, V38, P2103; DEOME KB, 1978, CANCER RES, V38, P4050; FELLUGA B, 1969, J NATL CANCER I, V43, P319; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; Hook LM, 2000, J VIROL, V74, P8876, DOI 10.1128/JVI.74.19.8876-8883.2000; IMAI S, 1994, J VIROL, V68, P3437, DOI 10.1128/JVI.68.5.3437-3442.1994; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Kamiya K, 1999, J RADIAT RES, V40, P128, DOI 10.1269/jrr.40.S128; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kordon EC, 1998, DEVELOPMENT, V125, P1921; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEDINA D, 1973, METHOD CANCER RES, V7, P3; NICOLL CHARLES S., 1965, LIFE SCI, V4, P993, DOI 10.1016/0024-3205(65)90203-1; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Rasmussen S. B., 2000, METHODS MAMMARY GLAN, P75; Ross SR, 1998, IMMUNOL RES, V17, P209, DOI 10.1007/BF02786445; ROUBINIAN JR, 1980, J NATL CANCER I, V65, P795, DOI 10.1093/jnci/65.4.795; SELL S, 1994, LAB INVEST, V70, P6; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; SMITH GH, 1984, CANCER RES, V44, P3426; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SQUARTINI F, 1983, CANCER RES, V43, P5879; VANNIE R, 1977, INT J CANCER, V19, P383, DOI 10.1002/ijc.2910190316; YANG HAS, 2000, P AM ASSOC CANC RES, V41, P225; YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531-5565(71)90048-9	35	73	73	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2264	2272		10.1038/sj.onc.1204312	http://dx.doi.org/10.1038/sj.onc.1204312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402321				2022-12-28	WOS:000168404500008
J	Wang, PL; Sait, F; Winter, G				Wang, PL; Sait, F; Winter, G			The 'wildtype' conformation of p53: epitope mapping using hybrid proteins	ONCOGENE			English	Article						p53 conformation; epitope mapping; recombination; p53-DNA interaction	HUMAN PAPILLOMAVIRUS TYPE-16; DNA-BINDING DOMAIN; TUMOR-SUPPRESSOR PROTEIN; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; MURINE P53; SIMIAN VIRUS-40; E6 ONCOPROTEIN; MUTATIONS; PRODUCE	The function of p53 correlates with its 'wildtype' conformation, specifically recognized by antibodies PAb1620 and PAb246, and many cancer-associated mutations cause loss of this conformation. The epitopes of these antibodies were identified using hybrid p53 proteins created by a new method. Plasmids carrying homologous genes cut at appropriate sites recombined efficiently when transformed into RecE(+) E, coli, PAb1620 and PAb246 recognize mouse but not chicken p53; we created mouse-chicken hybrids of the p53 core domain and tested antibody reactivity, PAb246 binding mapped to residues 201-212, while PAb1620 required both residues 145-157 and 201-212 (human p53 numbering used throughout). An alanine-scan show-ed that the key residues for PAb246 and PAb1620 are completely distinct: PAb246 recognizes residues 202-204 (Tyr-Pro-Glu) while PAb1620 recognizes residues Arg156, Leu206, Arg209, and Gln/Asn210, the last two residues being essential, Both antibody epitopes are far from the p53 interface with DNA, but near the epitope of the 'mutant' conformation antibody PAb240, These epitope locations may help in dissecting the interactions of p53, including those with E6/E6-AP and in its DNA-bound state.	Ctr Prot Engn, Cambridge CB2 2QH, England; Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Wang, PL (corresponding author), Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.							BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Cohen PA, 1999, FEBS LETT, V463, P179, DOI 10.1016/S0014-5793(99)01603-8; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lane DP, 1996, ONCOGENE, V12, P2461; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; McLure KG, 1996, ONCOGENE, V13, P1297; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILNER J, 1987, ONCOGENE, V1, P453; MOLINARI M, 1995, ONCOGENE, V10, P1849; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOJTESEK B, 1995, ONCOGENE, V10, P389; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG PL, 2001, DIS MARKERS, V16; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	44	39	40	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2318	2324		10.1038/sj.onc.1204316	http://dx.doi.org/10.1038/sj.onc.1204316			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402327				2022-12-28	WOS:000168404500014
J	Nelsen, CJ; Hansen, LK; Rickheim, DG; Chen, CS; Stanley, MW; Krek, W; Albrecht, JH				Nelsen, CJ; Hansen, LK; Rickheim, DG; Chen, CS; Stanley, MW; Krek, W; Albrecht, JH			Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2	ONCOGENE			English	Article						cyclins; gene therapy; liver regeneration; polyploidy; skp2	CELL-CYCLE; ECTOPIC EXPRESSION; DEPENDENT KINASES; GROWTH-FACTOR; ADENOVIRUS; REGENERATION; DEGRADATION; PROGRESSION; P27(KIP1); REPLICATION	Cells in culture become competent to replicate in the absence of growth factor after progressing beyond the late G1 restriction point, suggesting that a set of genes expressed during G1 phase is sufficient to trigger completion of the cell cycle. However, this has not been demonstrated in an in vivo system. In this study, we examined whether transfection of genes associated with the G1/S transition could trigger hepatocyte replication. Co-transfection of cyclin E and skp2 synergistically promoted cell cycle progression in cultured primary hepatocytes in the absence of mitogen or in the presence of growth inhibitors. Furthermore, transfection of hepatocytes in vivo with cyclin E and skp2 promoted abundant hepatocyte replication and hyperplasia of the liver. These studies confirm that transfection with a small number of genes can trigger proliferation of quiescent hepatocytes in vivo, and suggest that therapies to enhance liver regeneration by targeting cell cycle control genes may be feasible.	Hennepin Cty Med Ctr, Dept Med 865B, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; FMI, CH-4058 Basel, Switzerland	Hennepin County Medical Center; Hennepin County Medical Center; Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; Friedrich Miescher Institute for Biomedical Research	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr, Dept Med 865B, 701 Pk Ave, Minneapolis, MN 55415 USA.			Hansen, Linda/0000-0003-3651-0419	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056222, R01DK054921] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56222, DK54921] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bilodeau M, 1999, FEBS LETT, V452, P247, DOI 10.1016/S0014-5793(99)00629-8; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chowdhury JR, 1999, SEMIN LIVER DIS, V19, P1, DOI 10.1055/s-2007-1007092; Coelho CM, 2000, J CELL SCI, V113, P2927; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Ehrenfried JA, 1997, SURGERY, V122, P927, DOI 10.1016/S0039-6060(97)90334-2; FANG JWS, 1994, LANCET, V343, P820, DOI 10.1016/S0140-6736(94)92025-7; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gao CH, 1999, HEPATOLOGY, V30, P1405, DOI 10.1002/hep.510300602; Garcia P, 2000, ONCOGENE, V19, P1820, DOI 10.1038/sj.onc.1203494; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Ginsberg HS, 1996, B NEW YORK ACAD MED, V73, P53; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hansen LK, 1999, J CELL SCI, V112, P2971; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Ilan Y, 1999, SEMIN LIVER DIS, V19, P49, DOI 10.1055/s-2007-1007097; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; KAWASAKI S, 1992, GASTROENTEROLOGY, V102, P1351; Kay MA, 1997, MOL MED TODAY, V3, P108, DOI 10.1016/S1357-4310(96)10062-9; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TARAO K, 1994, CANCER, V73, P1149, DOI 10.1002/1097-0142(19940215)73:4<1149::AID-CNCR2820730405>3.0.CO;2-9; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045	48	47	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1825	1831		10.1038/sj.onc.1204248	http://dx.doi.org/10.1038/sj.onc.1204248			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313930				2022-12-28	WOS:000167908400003
J	Schwindinger, WF; Robishaw, JD				Schwindinger, WF; Robishaw, JD			Heterotrimeric G-protein beta gamma-dimers in growth and differentiation	ONCOGENE			English	Article						MAPK; PI3K	COUPLED RECEPTORS; PHOSPHOINOSITIDE 3-KINASE; MAP KINASE; TYROSINE KINASE; FARNESYLTRANSFERASE INHIBITORS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; ACTIVATION; RAS	Heterotrimeric C-proteins are components of the signal transduction pathways for the soluble and cell-contact signals that regulate normal growth and differentiation. There is now a greater appreciation of the role of the G beta gamma -dimer in the regulation of a variety of intracellular effecters, including ion channels, adenylyl cyclase, and phospholipase C beta, In many cases, G beta gamma -dimers are required for the activation of mitogen activated protein kinase (MAPK) pathways that promote cellular proliferation, although the underlying mechanisms have yet to be fully elucidated, Activation of phosphotidylinositol-3-kinase (PI3K) is a critical step in the intracellular transduction of survival signals. G beta gamma -dimers directly activate PI3K gamma as well as the more widely distributed PI3K beta. The activation of PI3K gamma by G beta gamma -dimers likely involves direct binding of specific G beta gamma -dimers to both subunits of PI3K gamma. Thus, G beta gamma -dimers transmit signals from numerous receptors to a variety of intracellular effecters in distinct cellular contexts. Five distinct G beta -subunits and 12 distinct G gamma -subunits have been identified. New experimental approaches are needed to elucidate the specific roles of individual G beta gamma -dimers in the pathways that transduce signals for proliferation and survival.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA	Geisinger Medical Center	Robishaw, JD (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.							Abrams CS, 1996, J BIOL CHEM, V271, P25192, DOI 10.1074/jbc.271.41.25192; Balcueva EA, 2000, EXP CELL RES, V257, P310, DOI 10.1006/excr.2000.4893; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Cacace AM, 1999, MOL CELL BIOL, V19, P229; CHOI KY, 1994, CELL, V78, P499; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cook LA, 1998, BIOCHEMISTRY-US, V37, P12280, DOI 10.1021/bi980230e; Coso OA, 1996, J BIOL CHEM, V271, P3963; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghahremani MH, 2000, MOL CELL BIOL, V20, P1497, DOI 10.1128/MCB.20.5.1497-1506.2000; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gutkind J.S, 2000, SCI STKE; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Klein S, 2000, P NATL ACAD SCI USA, V97, P3219, DOI 10.1073/pnas.050015797; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Morishita R, 1999, J NEUROCHEM, V73, P2369, DOI 10.1046/j.1471-4159.1999.0732369.x; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1999, TRENDS ENDOCRIN MET, V10, P122, DOI 10.1016/S1043-2760(98)00131-3; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Park JG, 1999, EMBO J, V18, P4004, DOI 10.1093/emboj/18.14.4004; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Rebois RV, 1997, CELL SIGNAL, V9, P141, DOI 10.1016/S0898-6568(96)00133-7; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sasaki T, 2000, NATURE, V406, P897, DOI 10.1038/35022585; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shibata K, 1999, CANCER RES, V59, P1096; Shibata K, 1998, BIOCHEM BIOPH RES CO, V246, P205, DOI 10.1006/bbrc.1998.8581; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; YI F, 1991, J BIOL CHEM, V266, P3900	65	161	163	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1653	1660		10.1038/sj.onc.1204181	http://dx.doi.org/10.1038/sj.onc.1204181			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313913				2022-12-28	WOS:000168089800016
J	Iwai, N; Kitajima, K; Sakai, K; Kimura, T; Nakano, T				Iwai, N; Kitajima, K; Sakai, K; Kimura, T; Nakano, T			Alteration of cell adhesion and cell cycle properties of ES cells by an inducible dominant interfering Myb mutant	ONCOGENE			English	Article						ES cells; cell adhesion; B-Myb	BETA-1 INTEGRIN GENE; EMBRYONIC STEM-CELLS; B-MYB; C-MYB; HEMATOPOIETIC PROGENITORS; S-PHASE; V-MYB; A-MYB; EXPRESSION; DIFFERENTIATION	The Myb transcription factors, c-Myb, A-Myb, and B-Myb, regulate cell differentiation and/or proliferation. To investigate the role of B-Myb in embryogenesis, we introduced an inducible dominant interfering Myb protein (MERT) into embryonic stem (ES) cells, which express B-Myb as an exclusive member of Myb family. Disruption of normal B-Myb function by the conditional activation of MERT caused a drastic morphological alteration of ES cells and G(1)-S cell cycle arrest. The inhibition of B-Myb function by MERT dissociated tightly packed ES cell colonies into dispersed single cells that subsequently detached from the culture dish. Cell adhesion analyses revealed that suppression of B-Myb function reduced the adhesion with extracellular matrix proteins, such as laminin, collagen, and fibronectin, This reduction was presumably due to decreased cell surface expression of beta1 integrin, Embryoid body formation was also severely retarded by the activation of MERT, This impairment was attributed to reduced expression of E-cadherin, which functions as a homophilic intercellular adhesion molecule. Simultaneously, blocking B-Myb function did not alter the expression of differentiation markers. Our data indicate that B-Myb plays important roles in regulating cell adhesion and cell cycle progression. These results are well consistent with the recent report on the phenotype of B-Myb null mice and show that the regulation of cell adhesion is an important B-Myb function that has not yet been assumed.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Osaka 5650871, Japan	Osaka University	Nakano, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Yamadaoka 3-1, Osaka 5650871, Japan.			Kimura, Tohru/0000-0001-9227-0996				ARSURA M, 1992, BLOOD, V79, P2708; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; JOYNER AL, 1993, IRL PRESS, V142, P1121; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kume A, 1999, STEM CELLS, V17, P226, DOI 10.1002/stem.170226; Larue L, 1996, DEVELOPMENT, V122, P3185; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Lipsick JS, 1996, ONCOGENE, V13, P223; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu ZJ, 1998, BLOOD, V92, P4700; Lyon JJ, 1996, GENE, V182, P123, DOI 10.1016/S0378-1119(96)00531-8; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sitzmann J, 1996, ONCOGENE, V12, P1889; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; WILES MV, 1993, METHOD ENZYMOL, V225, P900; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	41	22	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1425	1434		10.1038/sj.onc.1204236	http://dx.doi.org/10.1038/sj.onc.1204236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313886				2022-12-28	WOS:000167595200003
J	Kishi, S; Wulf, G; Nakamura, M; Lu, KP				Kishi, S; Wulf, G; Nakamura, M; Lu, KP			Telomeric protein Pin2/TRF1 induces mitotic entry and apoptosis in cells with short telomeres and is down-regulated in human breast tumors	ONCOGENE			English	Article						apoptosis; cancer; cell cycle; Pin2/TRF1; telomeres; telomeric protein	ATAXIA-TELANGIECTASIA GENE; M-PHASE PHOSPHOPROTEINS; FISSION YEAST; PHOSPHORYLATED EPITOPE; PROLYL ISOMERIZATION; DEFICIENT MICE; FLOW-CYTOMETRY; ATM; LENGTH; INHIBITION	Telomeres are essential for cell survival and have been implicated in the mitotic control. The telomeric protein Pin2/TRF1 controls telomere elongation and its expression is tightly regulated during cell cycle. We previously reported that overexpression of Pin2/TRF1 affects mitotic progression. However, the role of Pin2/TRF1 at the interface between cell division and cell survival remains to be determined. Here we show that overexpression of Pin2 induced apoptosis in cells containing short telomeres, but not in cells with long telomeres, Furthermore, before entering apoptosis, Pin2-expressing cells first accumulated in mitosis and strongly stained with the mitosis-specific MPM2 antibody. Moreover, Pin2-induccd apoptosis is potentiated by arresting cells in mitosis, but suppressed by accumulating cells in G1, In addition, overexpression of Pin2 also resulted in activation of caspase-3, and its proapoptotic activity was significantly reduced by inhibition of caspase-3, These results indicate that up-regulation of Pin2/TRF1 can specifically induce entry into mitosis and apoptosis, likely via a mechanism related to activation of caspase-3, Significantly, we also found that, out of 51 human breast cancer tissues and 10 normal controls examined, protein levels of Pin2/TRF1 in tumors were significantly lower than in normal tissues, as detected by immunoblotting analysis and immunocytochemistry, Since down-regulation of Pin2/TRF1 allows cells to maintain long telomeres, these results suggest that down-regulation of Pin2/TRF1 may be important for cancer cells to extend their proliferative potential.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, HIM 1047,330 Brookline Ave, Boston, MA 02215 USA.		Wulf, Gerburg/AAS-6713-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM56230] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 1999, GENETICS, V151, P1041; Aragona M, 2000, ONCOL REP, V7, P987; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Belloc F, 2000, CYTOMETRY, V40, P151, DOI 10.1002/(SICI)1097-0320(20000601)40:2<151::AID-CYTO9>3.0.CO;2-9; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Douglas RS, 1998, CYTOMETRY, V32, P57, DOI 10.1002/(SICI)1097-0320(19980501)32:1<57::AID-CYTO8>3.0.CO;2-C; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Young AC, 1997, SOMAT CELL MOLEC GEN, V23, P275, DOI 10.1007/BF02674418; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZIV Y, 1989, CANCER RES, V49, P2495	64	50	58	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1497	1508		10.1038/sj.onc.1204229	http://dx.doi.org/10.1038/sj.onc.1204229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313893				2022-12-28	WOS:000167595200010
J	Liu, RG; Li, BL; Qiu, MS				Liu, RG; Li, BL; Qiu, MS			Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha	ONCOGENE			English	Article						superoxide; H-ras; NADPH oxidase; signal transduction; WI-38VA-13 cells; TNF-alpha	CARCINOMA SCC-25 CELLS; REACTIVE OXYGEN; SIGNAL-TRANSDUCTION; NADPH OXIDASE; FREE-RADICALS; CHROMOSOMAL-ABERRATIONS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS	Accumulating evidence has suggested that cellular production of superoxide acts as an intracellular messenger to regulate gene expression and modulate cellular activities, In this report, we set out to investigate the role of active H-ras-mediated superoxide production on tumor cell malignancy in a SV-40 transformed human lung WI-38 VA-13 cell line, Stable transfection and expression of constitutively active mutant V12-H-ras (V12-H-ras) dramatically increased intracellular production of superoxide, The expression of V12-H-ras significantly enhanced cell proliferation, migration and resistance to TNF-alpha treatment compared to that of parental and vector control cells, while expression of wild type H-ras (WT-H-ras) only had modest effects. Upon scavenging by superoxide dismutase and other molecules that decrease the intracellular level of active H-ras mediated superoxide production, cell proliferation, migration and resistance to TNF-alpha were significantly reduced. Furthermore, we demonstrated that the activation of membrane NADPH oxidase activity by expression of active I-P-ras contributed to the intracellular superoxide production. The causal relationship between membrane superoxide production and increased cell proliferation, migration, and resistance to TNF-alpha by the expression of active H-ras, has provided direct evidence to demonstrate that superoxide acts as an intracellular messenger to cascade res oncogenic signal relay and to modulate turner malignant activity.	Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	University of Louisville; Eli Lilly	Liu, RG (corresponding author), Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.							Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bohler T, 2000, CYTOKINE, V12, P986, DOI 10.1006/cyto.1999.0633; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DAGHER MC, 1995, BIOCHIMIE, V77, P651, DOI 10.1016/0300-9084(96)88180-6; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; EMERIT I, 1981, NATURE, V293, P144, DOI 10.1038/293144a0; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Giri U, 1999, CANCER LETT, V135, P53; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IWATA K, 1984, TOXICOL LETT, V22, P75, DOI 10.1016/0378-4274(84)90048-1; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; KENNEDY AR, 1984, CARCINOGENESIS, V5, P1213, DOI 10.1093/carcin/5.10.1213; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li SJ, 2000, CANCER RES, V60, P3927; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Liu RG, 1999, RADIAT RES, V151, P133, DOI 10.2307/3579763; Liu RG, 2000, FREE RADICAL BIO MED, V28, P1197, DOI 10.1016/S0891-5849(00)00237-9; Liu RG, 1998, CELL GROWTH DIFFER, V9, P239; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOSCHEN G, 1974, FEBS LETT, V42, P6874; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; NAKAMURA Y, 1985, CARCINOGENESIS, V6, P229, DOI 10.1093/carcin/6.2.229; OBERLEY LW, 1979, CANCER RES, V39, P1141; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pani G, 2000, CANCER RES, V60, P4654; Pick E, 1986, Methods Enzymol, V132, P407; PRETONE WF, 1980, P NATL ACAD SCI USA, V77, P1159; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; SOFUNI T, 1984, MUTAT RES, V140, P27, DOI 10.1016/0165-7992(84)90067-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; Yan T, 1996, CANCER RES, V56, P2864; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Zhai QW, 2000, J CELL PHYSIOL, V184, P161, DOI 10.1002/1097-4652(200008)184:2<161::AID-JCP3>3.3.CO;2-E; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; ZIMMERMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P2085, DOI 10.1073/pnas.81.7.2085	59	37	39	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1486	1496		10.1038/sj.onc.1204214	http://dx.doi.org/10.1038/sj.onc.1204214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313892				2022-12-28	WOS:000167595200009
J	Slack, JK; Adams, RB; Rovin, JD; Bissonette, EA; Stoker, CE; Parsons, JT				Slack, JK; Adams, RB; Rovin, JD; Bissonette, EA; Stoker, CE; Parsons, JT			Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells	ONCOGENE			English	Article						focal adhesion kinase; Src; cell migration; prostate; signal transduction	PROTEIN-TYROSINE KINASE; SRC FAMILY KINASES; SUBSTRATE P130(CAS); DROSOPHILA HOMOLOG; IN-VIVO; PHOSPHORYLATION; INTEGRIN; CRK; ACTIVATION; PAXILLIN	Focal adhesion kinase (FAK) has been implicated in the regulation of cell migration. In addition, FAK expression is:increased in a number of highly metastatic tumor cell lines. Therefore, we investigated the role of FAK in regulating migration of prostate carcinoma cell lines with increasing metastatic potential. We show that highly tumorigenic PC3 and DU145 cells exhibit intrinsic migratory capacity, while poorly tumorigenic LNCaP cells require a stimulus to migrate, Increased metastatic potential of PC3 and DU145 cells correlates with increased FAK expression, overall tyrosine phosphorylation and activity, as measured by autophosphorylation of tyrosine 397, However, in PC3 and DU145 cells, FAK autophosphorylation is adhesion dependent whereas a second site of tyrosine phosphorylation, tyrosine 861, a Src specific site, is uncoupled from adhesion-dependent signaling events, Finally, inhibiting the FAK/Src signal transduction pathway by over expressing FRNK ((F) under bar ocal adhesion kinase-(R) under bar elated (N) under bar on-(K) under bar inase), an inhibitor of FAK activation, or treatment with PP2, a Src family kinase-inhibitor, significantly inhibited migration of prostate carcinoma cell lines, demonstrating that tumor cell migration continues to be dependent on signals emanating from this pathway.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Parsons, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.		Mordwinkin, Nicholas M/A-4347-2010		NATIONAL CANCER INSTITUTE [P01CA076465] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA76465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Han NM, 1997, ANN SURG ONCOL, V4, P264, DOI 10.1007/BF02306620; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hsu J., 1996, MULTIPLE COMP THEORY; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; KAIGHN ME, 1979, INVEST UROL, V17, P16; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KORNBERG LJ, 1992, J BIOL CHEM, V276, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOHLER JL, 1988, CANCER RES, V48, P4312; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Owen JD, 1999, MOL CELL BIOL, V19, P4806; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Tremblay L, 1996, MOL ENDOCRINOL, V10, P1010, DOI 10.1210/me.10.8.1010; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Zheng DQ, 1999, CANCER RES, V59, P1655	60	175	180	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1152	1163		10.1038/sj.onc.1204208	http://dx.doi.org/10.1038/sj.onc.1204208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313859				2022-12-28	WOS:000167570100002
J	Lewitzky, M; Kardinal, C; Gehring, NH; Schmidt, EK; Konkol, B; Eulitz, M; Birchmeier, W; Schaeper, U; Feller, SM				Lewitzky, M; Kardinal, C; Gehring, NH; Schmidt, EK; Konkol, B; Eulitz, M; Birchmeier, W; Schaeper, U; Feller, SM			The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif	ONCOGENE			English	Article						SH3; Grb2; Gab1; SLP-76	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; SRC HOMOLOGY-3 DOMAIN; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; RAS PATHWAY; CBL PROTOONCOGENE; MOLECULAR-CLONING; EGF-RECEPTOR	The adapter Grb2 is an important mediator of normal cell proliferation and oncogenic signal transduction events. It consists of a central SH2 domain flanked by two SH3 domains, While the binding specificities of the Grb2 SH2 and N-terminal SH3 domain [Grb2 SH3(N)] have been studied in detail, binding properties of the Grb2 SH3(C) domain remained poorly defined. Gab1, a receptor tyrosine kinase substrate which associates with Grb2 and the c-Met receptor, was previously shown to bind Grb2 via a region which lacks a Grb2 SH3(N)-typical motif (P-x-x-P-x-R), Precipitation experiments with the domains of Grb2 shaw now that Gab1 can bind stably to the Grb2 SH3(C) domain. For further analyses, Gab1 mutants mere generated by PCR to test in vivo residues thought to be crucial for Grb2 SH3(C) binding. The Grb2 SH3(C) binding region of Gab1 has significant homology to a region of the adapter protein SLP-76. Peptides corresponding to epitopes SLP-76, Gab1, SoS and other proteins with related sequences, as well as mutant peptides were synthesized and analysed by tryptophan-fluorescence spectrometry and by irt vitro competition experiments. These experiments define a 13 amino acid sequence with the unusual consensus motif P-x-x-x-R-x-x-(K) under bar-(P) under bar as required for a stable binding to the SH3(C) domain of Grb2. Additional analyses point to a distinct binding specificity of the Grb2-homologous adapter protein Mona (Gads), indicating that the proteins of the Grb2 adapter family may have partially overlapping, yet distinct protein binding properties.	Univ Wurzburg, MSZ, Mol Oncol Lab, D-97078 Wurzburg, Germany; GSF, Munich, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Mol Oncol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.							Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; COWBURN D, 1995, J BIOL CHEM, V270, P26738, DOI 10.1074/jbc.270.45.26738; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; KIESS M, 1995, ONCOGENE, V10, P61; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Park RK, 1998, J IMMUNOL, V160, P5018; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takenawa T, 1998, CURR TOP MICROBIOL, V228, P325; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Whisstock JC, 1999, TRENDS BIOCHEM SCI, V24, P132, DOI 10.1016/S0968-0004(99)01366-3; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678	73	83	86	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1052	1062		10.1038/sj.onc.1204202	http://dx.doi.org/10.1038/sj.onc.1204202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314042				2022-12-28	WOS:000167232100005
J	Perez, S; Vial, E; van Dam, H; Castellazzi, M				Perez, S; Vial, E; van Dam, H; Castellazzi, M			Transcription factor ATF3 partially transforms chick embryo fibroblasts by promoting growth factor-independent proliferation	ONCOGENE			English	Article						ATF3; Jun; AP1; chicken embryo fibroblasts; cell transformation	FORMATION IN-VIVO; V-JUN; C-JUN; DNA-BINDING; CELLULAR-TRANSFORMATION; LIVER-REGENERATION; STRESS RESPONSES; DOWN-REGULATION; TARGET GENE; CELLS	Activating Transcription Factor 3 (ATF3) is a member of the bZip family of transcription factors. Previous studies in mammalian cells suggested that like other bZip family members e.g. Jun and Fos, ATF3 might play a role in the control of cell proliferation and participate in oncogenic transformation, To investigate this putative ATF3 function directly, the rat ATF3 protein was compared with v-Jun for its ability to transform primary cultures of chick embryo fibroblasts (CEFs). Like CEFs accumulating v-Jun, CEFs accumulating the ATF3 protein displayed a typical, fusiform morphology, associated with an enhanced capacity to grow in medium with reduced amount of serum. However, in contrast to v-Jun-transformed CEFs, the ATF3 overexpressing cells could not promote colony formation from single cells in agar. Partial transformation induced by ATF3 was found to be associated with repression of multiple cellular genes that are also down-regulated by v-Jun, including those coding for the extracellular components fibronectin, decorin, thrombospondin 2, and the pro-apoptotic protein Par-4. These data demonstrate that, at least in primary avian cells, rat ATF3 possesses an intrinsic oncogenic potential. Moreover, the results suggest that ATF3 might induce growth factor independence by down-regulating a subset of the genes repressed by v-Jun.	Ecole Normale Super Lyon, INSERM U412, Unite Virol Humaine, F-69364 Lyon 07, France; Leiden Univ, Med Ctr, Dept Mol Cell Biol, Sylvius Labs, NL-2300 RA Leiden, Netherlands	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM U412, Unite Virol Humaine, F-69364 Lyon 07, France.			van Dam, Hans/0000-0002-8307-4325				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; BASSUK JA, 1993, EUR J BIOCHEM, V218, P117, DOI 10.1111/j.1432-1033.1993.tb18358.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; FREEMAN T, 1998, EXPRESSION MAPPING M; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HUGUES SH, 1987, J VIROL, V61, P3004; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 2000, JPN J CANCER RES, V91, P833, DOI 10.1111/j.1349-7006.2000.tb01021.x; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; JURDIC P, 1995, ONCOGENE, V11, P1699; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kilbey A, 1996, ONCOGENE, V12, P2409; LEHRACH H, 1978, P NATL ACAD SCI USA, V75, P5417, DOI 10.1073/pnas.75.11.5417; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MICHEL D, 1989, ONCOGENE RES, V4, P127; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; Trower MK, 1996, P NATL ACAD SCI USA, V93, P1366, DOI 10.1073/pnas.93.4.1366; TUCKER RP, 1993, DEVELOPMENT, V117, P347; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDEL L, 1995, ONCOGENE, V10, P495; Venkatesh B, 2000, FEBS LETT, V476, P3, DOI 10.1016/S0014-5793(00)01659-8; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; WALCHLI C, 1994, J CELL SCI, V107, P669; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700	52	54	55	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1135	1141		10.1038/sj.onc.1204200	http://dx.doi.org/10.1038/sj.onc.1204200			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314051				2022-12-28	WOS:000167232100014
J	Braliou, GG; Ciana, P; Klaassen, W; Gandrillon, O; Stunnenberg, HG				Braliou, GG; Ciana, P; Klaassen, W; Gandrillon, O; Stunnenberg, HG			The v-ErbA oncoprotein quenches the activity of an erythroid-specific enhancer	ONCOGENE			English	Article						v-ErbA; thyroid hormone; repression; erythroid enhancer; carbonic anhydrase II; GATA-sites	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; DNA-BINDING SPECIFICITY; BETA-GLOBIN GENE; TRANSCRIPTIONAL REPRESSION; C-ERBA; DEPENDENT TRANSACTIVATION; CELL-DIFFERENTIATION; HISTONE DEACETYLASE; ONCOGENE PRODUCT	v-ErbA is a mutated variant of thyroid hormone receptor (TR alpha /NR1A1) borne by the Avian Erythroblastosis virus causing erythroleukemia. TR alpha is known to activate transcription of specific genes in the presence of its cognate ligand, T3 hormone, while in its absence it represses it, v-ErbA is unable to bind ligand, and hence is thought to contribute to leukemogenesis by actively repressing erythroid-specific genes such as the carbonic anhydrase II gene (CA II). In the prevailing model, v-ErbA occludes liganded TR from binding to its cognate elements and constitutively interacts with the corepressors NCoR/ SMRT. We previously identified a v-ErbA responsive element (VRE) within a DNase I hypersensitive region (HS2) located in the second intron of the CA II gene. We now show that HS2 fulfils all the requirements for a genuine enhancer that functions independent of its orientation and position with a profound erythroid-specific activity in normal erythroid progenitors (T2ECs) and in leukemic erythroid cell lines. We find that the HS2 enhancer activity is governed by two adjacent GATA-factor binding sites. v-ErbA as well as unliganded TR prevent HS2 activity by nullifying the positive function of factors bound to GATA-sites. However, v-ErbA, in contrast to TR, does not convey active repression to silence the transcriptional activity intrinsic to a heterologous tk promoter. We propose that depending on the sequence and context of the binding site, v-ErbA contributes to leukomogenesis by occluding liganded TR as well as unliganded TR thereby preventing activation or repression, respectively.	Univ Nijmegen, NCMLS, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands; Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Stunnenberg, HG (corresponding author), Univ Nijmegen, NCMLS, Dept Mol Biol, Geert Groote Pl 26,POB 9101, NL-6500 HB Nijmegen, Netherlands.		Stunnenberg, Hendrik G./D-6875-2012; Ciana, Paolo/F-9224-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; CIANA, PAOLO/0000-0001-5771-5638				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Auwerx J, 1999, CELL, V97, P161; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASINI T, 1995, ONCOGENE, V11, P1019; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEMAGISTRIS L, 1988, NUCLEIC ACIDS RES, V16, P3141, DOI 10.1093/nar/16.8.3141; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Glass CK, 2000, GENE DEV, V14, P121; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; INNIS JW, 1983, MOL CELL BIOL, V3, P2203, DOI 10.1128/MCB.3.12.2203; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; PAIN B, 1990, New Biologist, V2, P284; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RASCLE A, 1994, ONCOGENE, V9, P2853; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHROEDER C, 1992, ONCOGENE, V7, P217; Seraphin B, 1996, NUCLEIC ACIDS RES, V24, P3276, DOI 10.1093/nar/24.16.3276; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; Stunnenberg HG, 1999, BBA-REV CANCER, V1423, pF15, DOI 10.1016/S0304-419X(98)00036-5; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; Thormeyer D, 1999, INT J MOL MED, V4, P351; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wahlstrom GM, 1996, ONCOGENE, V13, P843; Wahlstrom GM, 1998, MOL ENDOCRINOL, V12, P645, DOI 10.1210/me.12.5.645; Wang GF, 1998, MOL CELL BIOL, V18, P6023, DOI 10.1128/MCB.18.10.6023; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 1999, MOL CELL BIOL, V19, P6448	69	5	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					775	787		10.1038/sj.onc.1204159	http://dx.doi.org/10.1038/sj.onc.1204159			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314012	Bronze			2022-12-28	WOS:000166924400001
J	Fluge, O; Haugen, DRF; Akslen, LA; Marstad, A; Santoro, M; Fusco, A; Varhaug, JE; Lillehaug, JR				Fluge, O; Haugen, DRF; Akslen, LA; Marstad, A; Santoro, M; Fusco, A; Varhaug, JE; Lillehaug, JR			Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas	ONCOGENE			English	Article						ret; RNA splicing; ret/ptc; thyroid carcinoma	RET/PTC ONCOGENE ACTIVATION; TYROSINE KINASE; 3'-SPLICING VARIANTS; SIGNAL-TRANSDUCTION; HUMAN KIDNEY; PROTOONCOGENE; RECEPTOR; MUTATIONS; GENE; PHENOTYPES	Somatic rearrangements of the ret receptor tyrosine kinase have been consistently reported in papillary thyroid carcinomas (PTC), It is unclear whether the expression of wild-type c-ret may also be implicated in thyroid tumorigenesis, We studied ret mRNA expression in PTC from Norwegian patients. Using RT-PCR, wild-type ret mRNA was detected in all of 22 PTC and in a PTC cell line. c-ret mRNA was clearly overexpressed in PTC as compared to non-neoplastic thyroid tissue. Hybridization using ret exon DNA dot blot arrays and complex cDNA probes confirmed expression of ret RNA in thyroid biopsies. In accordance with the RNA data, Western immunoblotting showed evidence of wildtype Ret protein in PTC, Rearrangements generating the ret/PTC oncogenes co-existed with c-ret mRNA in PTC, Multiple alternative ret splicing variants were detected in PTC, Four novel I et splicing events were found in the region encoding the extracellular domain. The open reading frames of these transcripts were all in-frame with the Ret tyrosine kinase domain. In the central ret mRNA region encoding the cystein-rich, transmembrane, and main tyrosine kinase domains, no evidence of alternative splicing was detected. Two alternative splice events were detected in the I ct mRNA encoding the C-terminal part of Ret protein harboring tyrosine residues important for Ret signaling, excluding exon 19, or retaining intron 19, respectively. Ribonuclease protection assays confirmed the presence of I et alternative splicing events in thyroid biopsies. We conclude that in addition to ret/PTC rearrangements, wild-type c-ret mRNA and alternatively spliced ret transcripts are present in PTC, Transcriptional up-regulation and post-transcriptional mechanisms of c-l et RNA processing may contribute to differences in expression of Ret protein observed in PTC compared to non-neoplastic thyroid tissue.	Univ Bergen, Dept Mol Biol, N-5020 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; Univ Bergen, Haukeland Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway; CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Bergen, Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; University of Bergen; Haukeland University Hospital	Fluge, O (corresponding author), Univ Bergen, Dept Mol Biol, Thormohlens Gt 55, N-5020 Bergen, Norway.		Akslen, Lars A./AAG-6097-2021; Haugen, Dagny R. Faksvåg/AAX-7989-2021; Akslen, Lars A/C-1202-2017	Akslen, Lars A./0000-0003-2710-9543; Akslen, Lars A/0000-0003-2710-9543; Haugen, Dagny Faksvag/0000-0002-8592-4995; Fusco, Alfredo/0000-0003-3332-5197				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; Bunone G, 2000, CANCER RES, V60, P2845; Carson-Walter EB, 1998, ONCOGENE, V17, P367, DOI 10.1038/sj.onc.1201938; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; de Nigris F, 1998, CANCER RES, V58, P4745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; KWOK JBJ, 1993, ONCOGENE, V8, P2575; Lam AKY, 1998, HUM PATHOL, V29, P565, DOI 10.1016/S0046-8177(98)80004-X; Landsvater RM, 1996, HUM GENET, V97, P11, DOI 10.1007/BF00218825; Learoyd DL, 1998, J CLIN ENDOCR METAB, V83, P3631, DOI 10.1210/jc.83.10.3631; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MYERS SM, 1995, ONCOGENE, V11, P2039; Nikiforov YE, 1997, CANCER RES, V57, P1690; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Tallini G, 1998, CLIN CANCER RES, V4, P287; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Visser M, 1996, BRIT J HAEMATOL, V94, P236, DOI 10.1046/j.1365-2141.1996.d01-1789.x; Williams GH, 1996, BRIT J CANCER, V74, P585, DOI 10.1038/bjc.1996.405; Wilson KF, 1999, J BIOL CHEM, V274, P4166, DOI 10.1074/jbc.274.7.4166; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; XING SH, 1994, BIOCHEM BIOPH RES CO, V205, P1526, DOI 10.1006/bbrc.1994.2840	35	32	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					885	892		10.1038/sj.onc.1204161	http://dx.doi.org/10.1038/sj.onc.1204161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314023				2022-12-28	WOS:000166924400013
J	Kuo, ML; Chuang, SE; Lin, MT; Yang, SY				Kuo, ML; Chuang, SE; Lin, MT; Yang, SY			The involvement of PI3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interlenkin-6	ONCOGENE			English	Article						interleukin-6; Mcl-1; apoptosis; PI3-K/Akt pathway	BETA-INDUCED APOPTOSIS; 3-KINASE/AKT SIGNALING PATHWAY; PROTEIN-KINASE CASCADE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; LIVER-REGENERATION; TRANSDUCER GP130; C-JUN; AKT	Interleukin-6 (IL-6) is a pleitrophic cytokine that not only regulates growth and differentiation of many cell types, but also induces production of acute phase proteins (A4P) in hepatocytes. Our previous works have demonstrated that both PI 3-K/Akt and STAT3 pathways mere concomitantly activated and cooperatively mediated the anti-apoptotic effect of IL-6. This investigation reports that IL-6 protected cells against apoptosis induced by a variety of agents including, TGF-beta, Uv and retinoic acid (RA) in Hep3B cells, suggesting that IL-6 is a fundamental determinant of hepatic cell survival. Mel-1, but not other Bcl-2 family members, was rapidly up-regulated by IL-6, with a peak (approximately 3-4-fold) appearing at 4 h. Transient transfection of cells with a mcl-1 antisense vector, resulting in a 50-60% reduction of the anti-apoptotic effect of IL-6, indicating that Mcl-1 is a downstream effector of IL-6. Which signaling pathway transduced by IL-6 responsible for the Mcl-1 up-regulation was further investigated. In Hep3B cells, the JAK/STAT3, ERR, and PI 3-K/Abt pathways mere activated by IL-6 stimulation. Blocking JAK/STAT3 activation with a dominant-negative mutant STAT3F or a JAK inhibitor AG490 could not influence IL-6-mediated Mcl-1 up-regulation. Similarly, PD98059 treatment, a MEK specific inhibitor, also failed to inhibit Mcl-1 expression. However, the IL-6-induced Mcl-1 upregulation was effectively attenuated in the presence of PI 3-K inhibitors, LY294002 and wortmannin. Expression of dominant-negative Akt, but not Etk, could abrogate the IL-6-induced increase of Mcl-1. In conclusion, our results suggest that the anti-apoptotic effect of IL-6 is mediated, at least in part, bai Mcl-1 expression and that is mainly through the PI 3-K/Akt-dependent pathway.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10764, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan; Natl Taiwan Hosp, Dept Surg, Taipei, Taiwan	National Taiwan University; National Health Research Institutes - Taiwan	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10764, Taiwan.		Chuang, Shuang-En/D-2080-2010; Kuo, Min-Liang/C-4872-2009	LIN, MING-TSAN/0000-0001-7313-7057; KUO, MIN-LIANG/0000-0002-7139-0144				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Andrejko KM, 1998, AM J PHYSIOL-GASTR L, V275, pG1423, DOI 10.1152/ajpgi.1998.275.6.G1423; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hockenbery D M, 1992, Semin Immunol, V4, P413; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kuo ML, 1996, CARCINOGENESIS, V17, P815, DOI 10.1093/carcin/17.4.815; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Malaguarnera M, 1997, J GASTROENTEROL, V32, P211, DOI 10.1007/BF02936370; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Minshall C, 1996, J IMMUNOL, V156, P939; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Ogata A, 1997, J IMMUNOL, V159, P2212; Oyanagi Y, 1999, LIVER, V19, P464, DOI 10.1111/j.1478-3231.1999.tb00078.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Toretsky JA, 1999, CANCER RES, V59, P5745; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	50	127	129	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					677	685		10.1038/sj.onc.1204140	http://dx.doi.org/10.1038/sj.onc.1204140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314001				2022-12-28	WOS:000166806000003
J	Lecureur, V; Thottassery, JV; Sun, D; Schuetz, EG; Lahti, J; Zambetti, GP; Schuetz, JD				Lecureur, V; Thottassery, JV; Sun, D; Schuetz, EG; Lahti, J; Zambetti, GP; Schuetz, JD			Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo	ONCOGENE			English	Article						apoptosis; MDR; diethylnitrosamine	WILD-TYPE P53; RESISTANCE GENE-EXPRESSION; DNA-BINDING DOMAIN; RAT HEPATOMA-CELLS; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; LIVER CELLS; APOPTOSIS; PROTEIN; INDUCTION	The mdr1b gene is thought to be a "stress-responsive" gene, however it is unknown if this gene is regulated by p53 in the whole animal. Moreover, it is unknown if overexpression of mdr1b affects cell survival. The dependence of mdr1b upon p53 for upregulation was evaluated in p53 knockout mice. Wild-type (wt) or p53-/- mice were treated singly or in combination with gamma irradiation (IR) and/or the potent DNA damaging agent, diethylnitrosoamine (DEN), Both IR and DEN induced mdr1b in wild-type animals, but not in the p53-/- mice. IR also upregulated endogenous mdr lb in the H35 liver cell line, and the mdr lb promoter was activated by IR and activation correlated with p53 levels; moreover activation required an intact p53 binding site. Colony survival studies revealed that co-transfection of both mdr1b and p53 dramatically reduced colony numbers compared to cells transfected with either p53 or mdr1b alone and cells microinjected with both mdr1b and p53 had a more dramatic loss in viability compared to cells injected with either expression vector alone. Further studies using acridine orange and ethidium bromide to measure apoptosis revealed that mdr1b caused apoptosis and this was enhanced by p53, however the increased apoptosis required a functional p53 transactivation domain. These studies indicate that mdr1b is a downstream target of p53 in the whole animal and expression of mdr1b facilitates p53-mediated cell death.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.		Zambetti, Gerard/N-8093-2018; Schuetz, John D/N-2692-2018; Schuetz, Erin/N-8087-2018; LECUREUR, Valérie/J-9095-2015	Zambetti, Gerard/0000-0002-0929-5007; 	NCI NIH HHS [CA63203] Funding Source: Medline; NIEHS NIH HHS [ES08658, ES05851] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008658, R29ES005851, R01ES005851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; Chin LS, 1997, J NEUROSCI RES, V48, P122, DOI 10.1002/(SICI)1097-4547(19970415)48:2<122::AID-JNR4>3.0.CO;2-E; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DMITRIEVA N, 2000, IN PRESS J BIOL CHEM; Fardel O, 1998, BIOCHEM BIOPH RES CO, V245, P85, DOI 10.1006/bbrc.1998.8388; Furuya KN, 1997, CANCER RES, V57, P3708; Furuya KN, 1997, J BIOL CHEM, V272, P11518; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN J, 1995, GENE DEV, V8, P1235; LOTHSTEIN L, 1989, J BIOL CHEM, V264, P16054; MacCallum DE, 1996, ONCOGENE, V13, P2575; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Ralhan R, 1999, INT J CANCER, V84, P80, DOI 10.1002/(SICI)1097-0215(19990219)84:1<80::AID-IJC15>3.0.CO;2-G; Rasola A, 1999, FASEB J, V13, P1711, DOI 10.1096/fasebj.13.13.1711; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Roemer K, 1996, ONCOGENE, V12, P2069; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; Schrenk D, 1996, BIOCHEM PHARMACOL, V52, P1453, DOI 10.1016/S0006-2952(96)00512-6; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SINGH J, 1991, MUTAGENESIS, V6, P117, DOI 10.1093/mutage/6.2.117; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; SPECTOR DL, 1998, CELLS CULTURE BIOCH; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; Weisburg JH, 1999, J BIOL CHEM, V274, P10877, DOI 10.1074/jbc.274.16.10877; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1998, J BIOL CHEM, V273, P15387, DOI 10.1074/jbc.273.25.15387; Ziemann C, 1999, CARCINOGENESIS, V20, P407, DOI 10.1093/carcin/20.3.407	46	18	18	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					303	313		10.1038/sj.onc.1204065	http://dx.doi.org/10.1038/sj.onc.1204065			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313959				2022-12-28	WOS:000166411000004
J	Yordy, JS; Muise-Helmericks, RC				Yordy, JS; Muise-Helmericks, RC			Signal transduction and the Ets family of transcription factors	ONCOGENE			English	Review						Ets; transcription; MAP kinase; Ras; signal transduction	ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; THYROTROPIN-RELEASING-HORMONE; LOOP-HELIX PROTEINS; DNA-BINDING DOMAIN; C-FOS PROMOTER; MAP-KINASE; GENE-EXPRESSION; MESODERM INDUCTION	Cellular responses to environmental stimuli are controlled by a series of signaling cascades that transduce extracellular signals from ligand-activated cell surface receptors to the nucleus, Although most pathways were initially thought to be linear, it has become apparent that there is a dynamic interplay between signaling pathways that result in the complex pattern of cell-type specific responses required for proliferation, differentiation and survival. One group of nuclear effecters of these signaling pathways are the Ets family of transcription factors, directing cytoplasmic signals to the control of gene expression. This family is defined by a highly conserved DNA binding domain that binds the core consensus sequence GGAA/T, Signaling pathways such as the MAP kinases, Erk1 and 2, p38 and JNK, the PI3 kinases and Ca2+-specific signals activated by growth factors or cellular stresses, converge on the Ets family of factors, controlling their activity, protein partnerships and specification of downstream target genes, Interestingly, Ets family members can act as both upstream and downstream effecters of signaling pathways. As downstream effecters their activities are directly controlled by specific phosphorylations, resulting in their ability to activate or repress specific target genes. As upstream effecters they are responsible for the spacial and temporal expression or numerous growth factor receptors, This review provides a brief survey of what is known to date about how this family of transcription factors is regulated by cellular signaling with a special focus on Pas responsive elements (RREs), the MAP kinases (Erks, p38 and JNK) and Ca2+-specific pathways and includes a description of the multiple roles of Ets family members in the lymphoid system. Finally, we will discuss other potential mechanisms and pathways involved in the regulation of this important family of transcription factors.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Muise-Helmericks, RC (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA.							Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHEN HM, 1995, ONCOGENE, V11, P1549; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; CORNELL RA, 1994, DEVELOPMENT, V120, P453; Cowley DO, 2000, GENE DEV, V14, P366; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; DEED RW, 1993, ONCOGENE, V8, P599; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Gabay L, 1996, DEVELOPMENT, V122, P3355; GALANG CK, 1994, ONCOGENE, V9, P2913; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARA E, 1994, J BIOL CHEM, V269, P2139; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kimura A, 2000, J BIOL CHEM, V275, P3667, DOI 10.1074/jbc.275.5.3667; KISTLER B, 1995, ONCOGENE, V11, P1095; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Lecine P, 1997, MOL CELL BIOL, V17, P2351, DOI 10.1128/MCB.17.4.2351; LEUNG S, 1993, ONCOGENE, V8, P989; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lloberas J, 1999, IMMUNOL TODAY, V20, P184, DOI 10.1016/S0167-5699(99)01442-5; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; OHMICHI M, 1994, BIOCHEM BIOPH RES CO, V201, P642, DOI 10.1006/bbrc.1994.1749; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Panitz F, 1998, EMBO J, V17, P4414, DOI 10.1093/emboj/17.15.4414; PAPAS TS, 1989, CURR TOP MICROBIOL, V149, P143; Perkel JM, 1998, J IMMUNOL, V160, P241; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Rogge R, 1995, DEVELOPMENT, V121, P3947; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sarafova S, 1999, J BIOL CHEM, V274, P16126, DOI 10.1074/jbc.274.23.16126; Scholz H, 1997, MECH DEVELOP, V62, P79, DOI 10.1016/S0925-4773(96)00652-1; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; STERNER R, 1979, J BIOL CHEM, V254, P1577; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VALENTINE MA, 1995, J EXP MED, V182, P1943, DOI 10.1084/jem.182.6.1943; Villafranca JE, 1996, CURR OPIN BIOTECH, V7, P397; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang YH, 1999, MOL ENDOCRINOL, V13, P1094, DOI 10.1210/me.13.7.1094; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamada Toshiyuki, 1997, Leukemia (Basingstoke), V11, P480; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	160	263	267	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6503	6513		10.1038/sj.onc.1204036	http://dx.doi.org/10.1038/sj.onc.1204036			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175366				2022-12-28	WOS:000166595000012
J	Raffo, AJ; Kim, AL; Fine, RL				Raffo, AJ; Kim, AL; Fine, RL			Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis	ONCOGENE			English	Article						p53; Bax; nuclear complexes; apoptosis; chemotherapy	PROGRAMMED CELL-DEATH; WILD-TYPE P53; BAX GENE; P53-DEPENDENT APOPTOSIS; 3'-TO-5' EXONUCLEASE; IN-VIVO; MELANOMA; INHIBITION; EXCLUSION; PROTEIN	Mechanisms by which chemotherapeutic agents induce apoptosis are not completely understood. Current knowledge of the actual pharmacologic effects of chemotherapy and their biochemical mechanisms are better understood than the downstream events, which initiate the apoptotic cascade. The chemotherapeutic agent cisplatin causes DNA damage and can induce apoptosis in several types of human cancers. We found the formation of previously unreported nuclear complexes between the tumor suppressor protein p53 and the pro-apoptotic protein Bax, in human melanoma cell lines induced into apoptosis following cisplatin exposure. These detergent resistant complexes were detected: after wild type (wt) p53 and Bax increased in the nucleus; at the same time when active cytoplasmic apoptosis related protease, caspase 3/CPP32 appeared; and prior to the detection of apoptotic DNA fragmentation. Three channel fluorescence laser scanning confocal image microscopy revealed that the nuclear Bax/p53 complexes remained in the nucleus and localized proximal to DNA fragmentation sites as assayed by TUNEL after cisplatin exposure. Two human melanoma cell lines, expressing wt p53, were induced into apoptosis after cisplatin exposure, however they differed in the timing of this induction. In both cell lines the formation of nuclear Bax/p53 co-immunoprecipitable complexes correlated with the timing of the induction of apoptosis, The degree of apoptosis induced by different concentrations of cisplatin correlated with the amount of nuclear Bax/p53 complexes. The coimmunoprecipitation of Bax and p53 was found regardless of the antibodies tested and was specific since Bcl-x(L)/p53 complexes were not detected. Additionally, the human prostate cancer cell line, LNCaP, also formed nuclear Bax/p53 complexes only after apoptosis was induced by paclitaxel.	Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA	Columbia University	Fine, RL (corresponding author), Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, 650 W 168th St,Black Bldg,Room BB-20-25, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13696-27, 5 P30 CA13696] Funding Source: Medline; NCRR NIH HHS [1S10 RR10506] Funding Source: Medline; NIAMS NIH HHS [P30AR 44535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Dennis LK, 1999, ARCH DERMATOL, V135, P275, DOI 10.1001/archderm.135.3.275; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hall HI, 1999, J AM ACAD DERMATOL, V40, P35, DOI 10.1016/S0190-9622(99)70562-1; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ho YS, 1999, BIOCHEM PHARMACOL, V57, P143, DOI 10.1016/S0006-2952(98)00272-X; Janus F, 1999, MOL CELL BIOL, V19, P2155; Knippschild U, 1996, ONCOGENE, V12, P1755; Kobayashi T, 1998, ONCOGENE, V16, P1587, DOI 10.1038/sj.onc.1201681; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martin DS, 1997, CANCER INVEST, V15, P372, DOI 10.3109/07357909709039742; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakao Y, 1998, JPN J CANCER RES, V89, P1020, DOI 10.1111/j.1349-7006.1998.tb00491.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	36	51	61	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6216	6228		10.1038/sj.onc.1203995	http://dx.doi.org/10.1038/sj.onc.1203995			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175336				2022-12-28	WOS:000166210500005
J	Liu, D; Yang, XH; Yang, DL; Zhou, SY				Liu, D; Yang, XH; Yang, DL; Zhou, SY			Genetic screens in mammalian cells by enhanced retroviral mutagens	ONCOGENE			English	Article						genetic screen; retroviral mutagen; oncogene; epitope tagging	EMBRYONIC STEM-CELLS; SIGNAL-TRANSDUCTION PATHWAY; MURINE LEUKEMIA-VIRUS; HOMOLOGOUS RECOMBINATION; PROTEIN-KINASE; V-RAF; CLONING; EXPRESSION; ONCOGENE; ACTIVATION	Genetic approaches such as retrovirus-mediated mutagenesis and cDNA expression libraries have contributed greatly to our understanding of signal transduction in mammalian cells. However, previously described methods for retroviral insertional mutagenesis are hindered by low mutagenesis rates and difficulties in cloning mutated genes. cDNA expression library methods are usually cell-type dependent and bias towards abundant and short messages. With the near completion of the genome projects, alternative genetic methods are needed where large numbers of genes can be more easily isolated and biochemically studied. We have developed a novel retrovirus-mediated genetic screening method in cultured cells. To achieve efficient and regulated mutagenesis, we constructed Enhanced Retroviral Mutagen (ERR I) vectors that contained several engineered sequences (e.g., an ERM Tag and a splice donor) controlled by a tetracycline-responsive promoter. Endogenous genes can thus be randomly activated and tagged in a conditional system. NIH3T3 cells were used to screen for focus-forming genes using the ERM strategy. We showed that these added sequences increased the screening efficiency by >10-fold, and allowed more direct identification of the genes targeted. Sequence analysis of similar to 10% of the >600 focus clones recovered revealed both known oncogenes and novel factors such as protein kinases and GTP/GDP exchange proteins. The ERM strategy should help to facilitate large-scale gene identification in diverse pathways and integrate both genetic (with the completion of the genome projects) and functional information more readily.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							AHMED NN, 1993, ONCOGENE, V8, P1957; BARBACID M, 1978, J BIOL CHEM, V253, P1408; BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BERNS A, 1988, ARCH VIROL, V102, P1, DOI 10.1007/BF01315558; Brennan J, 1999, METH MOL B, V97, P123, DOI 10.1385/1-59259-270-8:123; BROWN DW, 1988, VIROLOGY, V162, P239, DOI 10.1016/0042-6822(88)90414-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chiarle R, 1999, CLIN IMMUNOL, V90, P157, DOI 10.1006/clim.1998.4636; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COFFIN JM, 1990, RETROVIRIDAE THEIR R; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DANDREA A, 1990, INT J CELL CLONING, V8, P173, DOI 10.1002/stem.5530080716; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DORIN JR, 1989, SCIENCE, V243, P1357; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GONDA MA, 1982, J VIROL, V44, P520, DOI 10.1128/JVI.44.2.520-529.1982; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GUNTAKA RV, 1993, MICROBIOL REV, V57, P511, DOI 10.1128/MMBR.57.3.511-521.1993; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; Jaenisch R, 1986, Symp Fundam Cancer Res, V39, P59; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; Kuwabara PE, 1997, TRENDS GENET, V13, P455, DOI 10.1016/S0168-9525(97)01253-5; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okano HJ, 1999, GENE DEV, V13, P2087, DOI 10.1101/gad.13.16.2087; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Robinson H L, 1983, Prog Clin Biol Res, V119, P37; Rorth P, 1998, DEVELOPMENT, V125, P1049; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; SIMON MA, 1992, COLD SPRING HARB SYM, V57, P375, DOI 10.1101/SQB.1992.057.01.042; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Sorensen AB, 1996, J VIROL, V70, P4063; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tate P, 1998, J CELL SCI, V111, P2575; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TSICHLIS PN, 1987, ANTICANCER RES, V7, P171; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; YOSHIDA M, 1995, TRANSGENIC RES, V4, P277, DOI 10.1007/BF01969122; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	64	35	35	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5964	5972		10.1038/sj.onc.1203992	http://dx.doi.org/10.1038/sj.onc.1203992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146547				2022-12-28	WOS:000165827900002
J	de Bruijn, DRH; dos Santos, NR; Thijssen, J; Balemans, M; Debernardi, S; Linder, B; Young, BD; van Kessel, AG				de Bruijn, DRH; dos Santos, NR; Thijssen, J; Balemans, M; Debernardi, S; Linder, B; Young, BD; van Kessel, AG			The synovial sarcoma associated protein SYT interacts with the acute leukemia associated protein AF10	ONCOGENE			English	Article						synovial sarcoma; SYT; yeast two hybrid; protein-protein interactions; AF10; acute leukemia	KRUPPEL-ASSOCIATED BOX; RING FINGER; TRANSCRIPTIONAL REPRESSION; T(10-11) TRANSLOCATION; DROSOPHILA-TRITHORAX; SET DOMAIN; GENE; SSX; MOTIF; FUSION	As a result of the synovial sarcoma associated t(X;18) translocation, the human SYT gene on chromosome 18 is fused to either the SSX1 or the SSX2 gene on the X chromosome. Although preliminary evidence indicates that the (fusion) proteins encoded by these genes may play a role in transcriptional regulation, little is known about their exact function. We set out to isolate interacting proteins through yeast two hybrid screening of a human cDNA library using SYT as a bait. Of the positive clones isolated, two were found to correspond to the acute leukemia t(10;11) associated AF10 gene, a fusion partner of MLL, Confirmation of these results was obtained via co-immunoprecipitation of endogenous and exogenous, epitope-tagged, SYT and AF10 proteins from cell line extracts and colocalization of epitope-tagged SYT and AF10 proteins in transfected cells. Subsequent sequential mutation analysis revealed a highly specific interaction of N-terminal SYT fragments with C-terminal AF10 fragments, The N-terminal interaction domain of the SYT protein was also found to be present in several SYT orthologs and homologs, The C-terminal interaction domain of AF10 is located outside known functional domains. Based on these results, a model is proposed in which the SYT and AF10 proteins act in concert as bipartite transcription factors. This model has implications for the molecular mechanisms underlying the development of both human synovial sarcomas and acute leukemias.	Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; St Bartholomews Hosp, Imperial Canc Res Fund, Med Oncol Unit, London EC1A 7BE, England	Radboud University Nijmegen; Cancer Research UK; University of London; Queen Mary University London	de Bruijn, DRH (corresponding author), Univ Nijmegen Hosp, Dept Human Genet, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010; dos Santos, Nuno Rodrigues/F-4411-2012; de Bruijn, D.R.H./L-4233-2015	dos Santos, Nuno Rodrigues/0000-0001-7347-2592; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; DEBRUIJN DRH, 2001, IN PRESS CYTOGENET C; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2000, CANCER RES, V60, P1654; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; EPSTEIN H, 1992, BIOESSAYS, V14, P411, DOI 10.1002/bies.950140612; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Linder B, 1998, BBA-GENE STRUCT EXPR, V1443, P285, DOI 10.1016/S0167-4781(98)00226-7; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SINGH PB, 1994, J CELL SCI, V107, P2653; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; vanKessel AG, 1997, CANCER GENET CYTOGEN, V95, P67, DOI 10.1016/S0165-4608(96)00241-5; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	51	38	41	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3281	3289		10.1038/sj.onc.1204419	http://dx.doi.org/10.1038/sj.onc.1204419			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423977				2022-12-28	WOS:000169163500011
J	Martin, CB; Mahon, GM; Klinger, MB; Kay, RJ; Symons, M; Der, CJ; Whitehead, IP				Martin, CB; Mahon, GM; Klinger, MB; Kay, RJ; Symons, M; Der, CJ; Whitehead, IP			The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways	ONCOGENE			English	Article						PAR-1; thrombin; transformation; RhoA	PROTEIN-COUPLED RECEPTOR; NUCLEOTIDE EXCHANGE FACTORS; ACTIN STRESS FIBERS; NIH 3T3 CELLS; RAS TRANSFORMATION; EXPRESSION CLONING; MALIGNANT TRANSFORMATION; STRUCTURAL SIMILARITIES; INDEPENDENT PATHWAYS; FAMILY PROTEINS	We utilized a cDNA expression library derived from the B6SutA(1) mouse myeloid progenitor cell line to search for novel oncogenes that promote growth transformation of NIH3T3 cells. A 2.2 kb transforming cDNA was recovered that encodes the wild type thrombin-stimulated G protein-coupled receptor PAR-I, In addition to its potent focus forming activity, constitutive overexpression of PAR-1 in NIH3T3 cells promoted the loss of anchorage- and serum-dependent growth. Although inhibitors of thrombin failed to block PAR-I transforming activity, a PAR-1 mutant that cannot be cleaved by thrombin was nontransforming. Since the foci of transformed cells induced by PAR-1 bear a striking resemblance to those induced by activated RhoA, we determined if PAR-1 transformation was due to the aberrant activation of a specific Rho family member. Like RhoA, PAR-I cooperated with activated Raf-l and caused synergistic enhancement of transforming activity, induced stress fibers when microinjected into porcine aortic endothelial cells, stimulated the activity of the serum response factor and NF-kappaB transcription factors, and PAR-1 transformation was blocked by co-expression of dominant negative RhoA, Finally, PAR-I transforming activity was blocked by pertussis toxin and by coexpression of the RGS domain of Lsc, implicating G alpha (i) and G alpha (12)/G alpha (13) subunits, respectively, as mediators of PAR-I transformation. Taken together, these observations suggest that PAR-1 growth transformation is mediated, in part, by activation of RhoA.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Picower Inst Med Res, Mol Oncol Lab, Manhasset, NY 11030 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Northwell Health; British Columbia Cancer Agency	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.			Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA55008, CA63071, CA77493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077493, R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Betuing S, 1998, J BIOL CHEM, V273, P15804, DOI 10.1074/jbc.273.25.15804; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fareed J, 1999, CLIN APPL THROMB-HEM, V5, pS45, DOI 10.1177/10760296990050S109; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Macey MG, 1996, LEUKEMIA, V10, P687; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; TORDAI A, 1993, J IMMUNOL, V150, P4876; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANOBBERGHENSCH.E, 1998, THROMBIN ITS RECEPTO; VANOBBERGHENSCHILLING E, 1993, THROMB HAEMOSTASIS, V70, P163; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	61	102	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1953	1963		10.1038/sj.onc.1204281	http://dx.doi.org/10.1038/sj.onc.1204281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360179				2022-12-28	WOS:000168043800003
J	O'Connor, RJ; Schaley, JE; Feeney, G; Hearing, P				O'Connor, RJ; Schaley, JE; Feeney, G; Hearing, P			The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters	ONCOGENE			English	Article						E2F; p107; p130; DNA binding; transcription repression	ADENOVIRUS E4-6/7 PROTEIN; CELLULAR TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; HISTONE DEACETYLASE; DEREGULATED EXPRESSION; COMPLEX-FORMATION; RNA-POLYMERASE; CYCLE; INDUCTION	E2F transcription factors are key players in the regulation of proliferation, apoptosis, and differentiation in mammalian cells. E2Fs are negatively regulated by members of the retinoblastoma protein family, Rb, p107 and p130, During adenovirus infection, viral proteins are expressed that displace Rb family members from E2Fs and recruit E2F complexes to viral and cellular promoter regions. This recruitment of E2F involves the induction of stable E2F binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters and induces both viral and cellular gene expression. The cellular p107 tumor suppressor also displays such regulation of E2F DNA binding activity. p107 induces stable E2F-4/DP binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters. The induction of E2F DNA binding by p107 minimally requires the sequences in p107 that mediate E2F interaction. The related tumor suppressor, p130, also effects this function. p107 levels increase substantially as cells progress through S phase. p107 induction of E2F DNA binding was observed primarily in S phase cells coincident with the increase in p107 protein levels. The results of promoter activity assays directly correlate the induction of E2F DNA binding by p107 with effective transcriptional repression. These results support a model in which p107 and p130 induce the stable binding of E2F complexes to promoters that drive expression of critical regulatory proteins such as E2F-1, Since p107 and p130 bind histone deacetylase complexes (HDACs) which repress promoter activity, p107-E2F and p130-E2F would stably recruit repressor complexes to effect efficient promoter repression.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hearing, P (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Guy CT, 1996, MOL CELL BIOL, V16, P685; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Schaley J, 2000, J VIROL, V74, P2084, DOI 10.1128/JVI.74.5.2084-2093.2000; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	13	13	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1882	1891		10.1038/sj.onc.1204278	http://dx.doi.org/10.1038/sj.onc.1204278			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313936				2022-12-28	WOS:000167908400009
J	Taylor, WR; Stark, GR				Taylor, WR; Stark, GR			Regulation of the G2/M transition by p53	ONCOGENE			English	Review						cell cycle; checkpoint; Cdc2; cyclin; p21; DNA damage	CELL-CYCLE ARREST; G(2) CHECKPOINT FUNCTION; DNA-DAMAGE CHECKPOINT; PAPILLOMAVIRUS E6 ONCOPROTEINS; LARGE T-ANTIGEN; DEPENDENT KINASES; NUCLEAR EXPORT; PROTEIN FAMILY; GROWTH ARREST; MOLECULAR-INTERACTIONS	p53 protects mammals from neoplasia by inducing apoptosis, DNA repair and cell cycle arrest in response to a variety of stresses. p53-dependent arrest of cells in the G1 phase of the cell cycle is an important component of the cellular response to stress. Here we review recent evidence that implicates p53 in controlling entry into mitosis when cells enter G2 with damaged DNA or when they are arrested in S phase due to depletion of the substrates required for DNA synthesis, Part of the mechanism by which p53 blocks cells at the G2 checkpoint involves inhibition of Cdc2, the cyclin-dependent kinase required to enter mitosis. Cdc2 is inhibited simultaneously by three transcriptional targets of p53, Gadd45, p21, and 14-3-3 sigma. Binding of Cdc2 to Cyclin B1 is required for its activity, and repression of the cyclin BI gene by p53 also contributes to blocking entry into mitosis, p53 also represses the cdc2 gene, to help ensure that cells do not escape the initial block. Genotoxic stress also activates p53-independent pathways that inhibit Cdc2 activity, activation of the protein kinases Chk1 and Chk2 by the protein kinases Atm and Atr, Chk1 and Chk2 inhibit Cdc2 by inactivating Cdc25, the phosphatase that normally activates Cdc2. Chk1, Chk2, Atm and Atr also contribute to the activation of p53 in response to genotoxic stress and therefore play multiple roles, p53 induces transcription of the reprimo, B99, and mcg10 genes, all of which contribute to the arrest of cells in G2, but the mechanisms of cell cycle arrest by these genes is not known. Repression of the topoisomer ase II gene by p53 helps to block entry into mitosis and strengthens the G2 arrest. In summary, multiple overlapping p53-dependent and p53-independent pathways regulate the G2/M transition in response to genotoxic stress.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Taylor, WR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM49345] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Boulaire J, 2000, PATHOL BIOL, V48, P190; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FAN SJ, 1995, CANCER RES, V55, P1649; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gao QS, 1999, MOL CELL BIOL, V19, P733; Ghosh S, 1996, EXP CELL RES, V227, P165, DOI 10.1006/excr.1996.0262; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hitomi M, 1998, ONCOGENE, V17, P959, DOI 10.1038/sj.onc.1202005; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jackson JR, 2000, CANCER RES, V60, P566; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1991, CANCER RES, V51, P6304; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Leach SD, 1998, CANCER RES, V58, P3231; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Park M, 2000, CANCER RES, V60, P542; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POWELL SN, 1995, CANCER RES, V55, P1643; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Shieh SY, 2000, GENE DEV, V14, P289; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Spacey SD, 2000, CAN J NEUROL SCI, V27, P184, DOI 10.1017/S0317167100000822; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STEWART N, 1995, ONCOGENE, V10, P109; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Winther B, 1998, AM J RHINOL, V12, P17, DOI 10.2500/105065898782102954; Withoff S, 1996, ANTICANCER RES, V16, P1867; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yoshida M, 1997, EXP CELL RES, V232, P225, DOI 10.1006/excr.1997.3538; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	126	1181	1226	1	154	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1803	1815		10.1038/sj.onc.1204252	http://dx.doi.org/10.1038/sj.onc.1204252			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313928				2022-12-28	WOS:000167908400001
J	O'Brien, PJ; Molino, M; Kahn, M; Brass, LF				O'Brien, PJ; Molino, M; Kahn, M; Brass, LF			Protease activated receptors: theme and variations	ONCOGENE			English	Review						protease-activated receptors; thrombin; platelets; endothielial cells; G proteins; G protein coupled receptors	PLATELET THROMBIN RECEPTOR; HUMAN-ENDOTHELIAL-CELLS; CATHEPSIN-G; TETHERED-LIGAND; MOLECULAR-CLONING; MAST-CELL; FUNCTIONAL EXPRESSION; AGONIST RECOGNITION; CROSS-REACTIVITY; CYTOPLASMIC TAIL	The four PAR family members are G protein coupled receptors that are normally activated by proteolytic exposure of an occult tethered ligand, Three of the family members are thrombin receptors, The fourth (PAR2) is not activated by thrombin, but can be activated by other proteases, including trypsin, tryptase and Factor Xa, This review focuses on recent information about the manner in which signaling through these receptors is initiated and terminated, including evidence for inter- as well as intramolecular modes of activation, and continuing efforts to identify additional, biologically-relevant proteases that can activate PAR family members.	Univ Penn, Dept Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy	University of Pennsylvania; University of Pennsylvania; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Brass, LF (corresponding author), Univ Penn, Dept Med, Ctr Expt Therapeut, Room 913 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		O'Brien, Peter J/B-5182-2013	O'Brien, Peter J/0000-0003-4127-2718	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Ani B, 1999, BRIT J PHARMACOL, V128, P1105, DOI 10.1038/sj.bjp.0702834; Alm AK, 2000, BIOCHEM BIOPH RES CO, V275, P77, DOI 10.1006/bbrc.2000.3267; Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BAHOU WF, 1994, BLOOD, V84, P4195, DOI 10.1182/blood.V84.12.4195.bloodjournal84124195; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bohm SK, 1996, J BIOL CHEM, V271, P22003; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRASS LF, 1992, J BIOL CHEM, V267, P13795; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; CHEN J, 1994, J BIOL CHEM, V269, P16041; Chen XL, 1996, BIOCHEM J, V314, P603, DOI 10.1042/bj3140603; Cheung WM, 1999, ARTERIOSCL THROM VAS, V19, P3014, DOI 10.1161/01.ATV.19.12.3014; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P282, DOI 10.1021/bi00726a017; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P2462, DOI 10.1021/bi00737a015; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HEIN L, 1994, J BIOL CHEM, V269, P27719; Hoekstra WJ, 1998, BIOORG MED CHEM LETT, V8, P1649, DOI 10.1016/S0960-894X(98)00292-3; Hollenberg MD, 1999, CAN J PHYSIOL PHARM, V77, P458, DOI 10.1139/cjpp-77-6-458; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; HOLLENBERG MD, 1992, MOL PHARMACOL, V42, P186; HORVAT R, 1995, J CELL SCI, V108, P1155; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; Iaccarino G, 1998, AM J PHYSIOL-HEART C, V275, pH1298, DOI 10.1152/ajpheart.1998.275.4.H1298; Ido M, 2000, THROMB HAEMOSTASIS, V83, P617, DOI 10.1055/s-0037-1613873; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jenkins AL, 2000, DEV DYNAM, V218, P465, DOI 10.1002/1097-0177(200007)218:3<465::AID-DVDY1013>3.3.CO;2-X; Jia M, 1999, J NEUROBIOL, V38, P369, DOI 10.1002/(SICI)1097-4695(19990215)38:3<369::AID-NEU6>3.0.CO;2-Q; Kahn ML, 1998, J BIOL CHEM, V273, P23290, DOI 10.1074/jbc.273.36.23290; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; LEROY EC, 1984, J CLIN INVEST, V74, P1003, DOI 10.1172/JCI111467; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; McComsey DF, 1999, BIOORG MED CHEM LETT, V9, P255, DOI 10.1016/S0960-894X(98)00731-8; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; MOLINO M, 1992, BIOCHEM J, V288, P741, DOI 10.1042/bj2880741; Molino M, 1997, J BIOL CHEM, V272, P6011, DOI 10.1074/jbc.272.9.6011; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Molino M, 1997, J BIOL CHEM, V272, P11133; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NATARAJAN S, 1995, INT J PEPT PROT RES, V45, P145; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NGAIZA JR, 1992, J CELL PHYSIOL, V151, P190, DOI 10.1002/jcp.1041510124; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; Petersen LC, 2000, THROMB HAEMOSTASIS, V83, P571; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Renesto P, 1997, BLOOD, V89, P1944, DOI 10.1182/blood.V89.6.1944; RIEWALD M, 2000, BLOOD S1; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; SEILER SM, 1995, BIOCHEM PHARMACOL, V49, P519, DOI 10.1016/0006-2952(94)00473-Y; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Suidan HS, 1996, BIOCHEM J, V315, P939, DOI 10.1042/bj3150939; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TOTANI L, 1994, ARTERIOSCLER THROMB, V14, P125, DOI 10.1161/01.ATV.14.1.125; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WEKSLER BB, 1989, BLOOD, V74, P1627; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; WOOLKALIS MJ, 1995, THROMB HAEMOSTASIS, V73, P929; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	115	190	198	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1570	1581		10.1038/sj.onc.1204194	http://dx.doi.org/10.1038/sj.onc.1204194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313904	Bronze			2022-12-28	WOS:000168089800007
J	Radhika, V; Dhanasekaran, N				Radhika, V; Dhanasekaran, N			Transforming G proteins	ONCOGENE			English	Article						G protein; oncogene; signal transduction; transformation; Ras; Rac	SERUM RESPONSE FACTOR; MUTANT ALPHA-SUBUNIT; RHO-DEPENDENT ACTIVATION; CELL-CYCLE PROGRESSION; N-TERMINAL KINASE; MAP KINASE; S-PHASE; TYROSINE KINASE; COOPERATIVE TRANSFORMATION; NEOPLASTIC TRANSFORMATION	Heterotrimeric guanine nucleotide binding proteins, commonly known as G proteins form a super-family of signal transduction proteins. They are peripherally associated with the plasma membrane and provide signal coupling to seven transmembrane surface receptors, G proteins are composed of monomers of alpha, beta, and gamma subunits, The beta- and gamma -subunits are tightly associated. The receptors activated by the appropriate 'signal', interact catalytically with specific G-proteins to mediate guanine nucleotide exchange at the GDP/GTP binding site of the G-protein alpha -subunits, thus displacing the bound GDP for GTP, The GTP bound form of the g-protein alpha -subunit and in some cases the free beta gamma -subunits initiate cellular response by altering the activity of specific effector molecules, Recent studies have indicated that the asynchronous activation of these proteins can lead to the oncogenic transformation of different cell types, The mechanism by which G-proteins regulate the various cell functions appear to involve a complex net-working between different signaling pathways. This review summarizes the signaling mechanisms involved in the regulation of cell proliferation by these transforming G proteins.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.				NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; Dermott JM, 1999, ONCOGENE, V18, P7185, DOI 10.1038/sj.onc.1203345; DERMOTT JM, 2001, IN PRESS METH ENZYMO; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Ham J, 1997, MOL CELL ENDOCRINOL, V127, P41, DOI 10.1016/S0303-7207(96)03987-1; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HERMOUET S, 1993, CELL SIGNAL, V5, P215, DOI 10.1016/0898-6568(93)90072-T; Hermouet S, 1996, CELL SIGNAL, V8, P159, DOI 10.1016/0898-6568(95)02049-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; HO, 2001, IN PRESS ONCOGENE; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; MUCA C, 1994, ONCOGENE, V9, P3647; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAM P, 2001, IN PRESS ONCOGENE; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWINDINGER WF, 2001, IN PRESS ONCOGENE; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; TORDJMAN K, 1993, J CLIN ENDOCR METAB, V77, P765, DOI 10.1210/jc.77.3.765; Vallar L, 1996, CANCER SURV, V27, P325; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1995, ONCOGENE, V10, P1927; WU DQ, 1992, J BIOL CHEM, V267, P1811; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zeiger MA, 1996, ENDOCRINOLOGY, V137, P5392, DOI 10.1210/en.137.12.5392; Zhang YH, 1996, ONCOGENE, V12, P2377; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	96	113	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1607	1614		10.1038/sj.onc.1204274	http://dx.doi.org/10.1038/sj.onc.1204274			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313908	Bronze			2022-12-28	WOS:000168089800011
J	Kim, SG; Kim, SN; Jong, HS; Kim, NK; Hong, SH; Kim, SJ; Bang, YJ				Kim, SG; Kim, SN; Jong, HS; Kim, NK; Hong, SH; Kim, SJ; Bang, YJ			Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta 1-induced apoptosis in human gastric cancer cells	ONCOGENE			English	Article						TGF-beta 1; apoptosis; caspase-3; cyclin-dependent kinase-2; p21(cip1); p27(kip1)	DEPENDENT PROTEIN-KINASES; FACTOR-BETA; TGF-BETA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; EPITHELIAL-CELLS; THYMOCYTE APOPTOSIS; HEPATOMA-CELLS; INHIBITION; DEATH	Although TGF-beta1, a growth inhibitor, is known to also induce apoptosis, the molecular mechanism of this apoptosis is largely undefined, Here, we identify the mechanism of TGF-beta1-induced apoptosis in SNU-16 human gastric cancer cells. Cell cycle and TUNEL analysis showed that, upon TGF-beta1 treatment, cells mere initially arrested at the G1 phase and then driven into apoptosis, Of note, caspase-3 was activated in accordance with TGF-beta1-induced G1 arrest, Activated caspase-3 is targeted to cleave p21(cip1), p27(kip1), and Rb, which play important roles in TGF-beta -induced G1 arrest, into;inactive fragments. Subsequently, Cdk2 was aberrantly activated due to the cleavage of p21 and p27, We found that the inhibition of Cdk2 activity efficiently blocks TGF-beta1-induced apoptosis, whereas it did; not prevent caspase-3 activation or the subsequent cleavage of target proteins, In contrast, the suppression of caspase-3 activity inhibited the cleavage of target proteins, the activation of Cdk2, and the induction of apoptosis. Taken together, our results suggest that activation of caspase-3 by TGF-beta1 may initiate the conversion from G1 cell cycle arrest to apoptosis via the cleavage of p21, p27 and Rb, which in turn causes Cdk2 activation and, most significantly, Cdk2 activation as a downstream effector of caspase is a critical step for the execution TGF-beta1-induced apoptosis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Canc Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Canc Res Inst, 28 Yongon Dong, Seoul 110744, South Korea.		Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fan GS, 1996, ONCOGENE, V12, P1909; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GIRARD F, 1991, CELL, V67, P1; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PARK JG, 1990, CANCER RES, V50, P2773; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schrantz N, 1999, ONCOGENE, V18, P3511, DOI 10.1038/sj.onc.1202718; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	45	45	46	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1254	1265		10.1038/sj.onc.1204203	http://dx.doi.org/10.1038/sj.onc.1204203			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313870				2022-12-28	WOS:000167570100013
J	Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H				Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H			Inhibition of NF-kappa B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin	ONCOGENE			English	Article						programmed cell death; DNA-damage; transcription factor; chemotherapy; anthracyclin; phyllotoxin	ALPHA-INDUCED APOPTOSIS; TOPOISOMERASE II-ALPHA; TRANSCRIPTION FACTOR; ACTIVATION; EXPRESSION; TNF; P53; RESISTANCE; CHEMOSENSITIVITY; DIFFERENTIATION	The transcription factor NF-kappaB has anti-apoptotic properties and may confer chemoresistance to cancer cells. Here, me describe human pancreatic carcinoma cell lines that differ in the responsiveness to the topoisomerase-2 inhibitors VP16 (20 muM) and doxorubicin (0.3 muM): Highly sensitive BxPC-3 and PT45-P1 cells, and Capan-1 and A818-4 cells that were almost resistant to both anti cancer drugs. VP16, but not doxorubicin, transiently induced NF-kappaB activity in all cell lines, whereas basal NF-kappaB binding was nearly undetectable in BxPc-3 and PT45-P1 cells, but rather high in Capan-1 and A818-4 cells, as demonstrated by gel-shift and luciferase assays. Treatment with various NF-kappaB inhibitors (Gliotoxin, MG132 and Sulfasalazine), or transfection with the I kappaB alpha super-repressor, strongly enhanced the apoptotic effects of VP16 or doxorubicin on resistant Capan-1 and 818-4 cells. Our results indicate that under certain conditions the resistance of pancreatic carcinoma cells to chemotherapy is due to their constitutive NF-kappaB activity rather than the transient induction of NF-kappaB by some anti-cancer drugs. Blockade of basal NF-kappaB activity by well established drugs efficiently reduces chemoresistance of pancreatic cancer cells and offers the potential for improved therapeutic strategies.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24098 Kiel, Germany; Univ Kiel, Dept Gen Surg, Res Unit Mol Oncol, D-24098 Kiel, Germany; Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, D-4630 Bochum, Germany	University of Kiel; University of Kiel; Ruhr University Bochum	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24098 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019; Kalthoff, Holger/B-1618-2010	Arlt, Alexander/0000-0002-6160-1059; 				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dingemans AMC, 1999, CLIN CANCER RES, V5, P2048; Egawa N, 1996, VIRCHOWS ARCH, V429, P59, DOI 10.1007/BF00196822; ESTIVAL A, 1992, GASTROENTEROLOGY, V103, P1851, DOI 10.1016/0016-5085(92)91444-9; FRY AM, 1991, CANCER RES, V51, P6592; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lam VT, 1999, LEUKEMIA RES, V23, P871, DOI 10.1016/S0145-2126(99)00102-2; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LONG BH, 1991, CANCER RES, V51, P5275; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; MAZO A, 1991, PANCREAS, V6, P37, DOI 10.1097/00006676-199101000-00006; McDade TP, 1999, J SURG RES, V83, P56, DOI 10.1006/jsre.1998.5560; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Ungefroren H, 1998, CANCER RES, V58, P1741; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	31	206	214	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					859	868		10.1038/sj.onc.1204168	http://dx.doi.org/10.1038/sj.onc.1204168			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314019				2022-12-28	WOS:000166924400009
J	Khoury, H; Dankort, DL; Sadekova, S; Naujokas, MA; Muller, WJ; Park, M				Khoury, H; Dankort, DL; Sadekova, S; Naujokas, MA; Muller, WJ; Park, M			Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor	ONCOGENE			English	Article						ErbB-2/Neu; epithelial-mesenchymal transition; morphogenesis; MDCK epithelial cells; Shc	HEPATOCYTE GROWTH-FACTOR; KIDNEY-CELLS REQUIRES; HUMAN BREAST-CANCER; ADAPTER PROTEIN; MAMMARY-GLAND; NEU ONCOGENE; C-MET; KINASE; MORPHOGENESIS; CARCINOMA	Tight control of cell proliferation and morphogenesis is required to ensure normal tissue patterning and prevent cancer formation. Overexpression of the ErbB-2/Neu receptor tyrosine kinase is associated with increased progression in human breast cancer, yet in breast explant cultures, the ErbB-2/Neu receptor contributes to alveolar differentiation. To examine the consequence of deregulated ErbB-2/Neu activation on epithelial morphogenesis, we have expressed a constitutively activated mutant of ErbB-2/Neu in a Madin-Darby canine kidney (MDCK) epithelial cell model. Using two-dimensional cultures we demonstrate that activated ErbB-2/Neu induces breakdown of cell-cell junctions, increased cell motility and dispersal of epithelial colonies. This correlates with reorganization of the actin cytoskeleton and fetal adhesions and loss of insoluble cell-cell junction complexes involving E-cadherin. Interestingly, a constitutively activated ErbB-2/Neu receptor promotes an invasive morphogenic program in MDCK cells in a three-dimensional matrix. We show that two tyrosines in the carboxy-terminal tail of ErbB-2/Neu, involved in the phosphorylation of the Shc adapter protein, are each sufficient to promote epithelial-mesenchymal like transition and enhanced cell motility in two-dimensional culture and cell invasion rather than a morphogenic response in matrix culture. This provides a model system to investigate ErbB-2/Neu induced signaling pathways required for epithelial cell dispersal and invasion versus morphogenesis.	McGill Univ Hosp Ctr, Dept Biochem, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ Hosp Ctr, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ Hosp Ctr, Dept Oncol, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON, Canada	McGill University; McGill University; McGill University; McMaster University	Park, M (corresponding author), McGill Univ Hosp Ctr, Dept Biochem, Mol Oncol Grp, H5-10-687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.			Dankort, David/0000-0002-5862-6829				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Boyer B, 1996, ACTA ANAT, V156, P227; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klapper LN, 2000, CANCER RES, V60, P3384; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Pawson T, 2000, GENE DEV, V14, P1027; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; PELICCI G, 1995, ONCOGENE, V10, P1631; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; RICCI A, 1995, ONCOGENE, V11, P1519; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Selli C, 1997, J UROLOGY, V158, P245, DOI 10.1097/00005392-199707000-00079; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zhang XH, 1997, UROLOGY, V50, P636, DOI 10.1016/S0090-4295(97)00258-6; ZHU H, 1994, J BIOL CHEM, V269, P29943	39	48	50	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					788	799		10.1038/sj.onc.1204166	http://dx.doi.org/10.1038/sj.onc.1204166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314013				2022-12-28	WOS:000166924400002
J	Inga, A; Monti, P; Fronza, G; Darden, T; Resnick, MA				Inga, A; Monti, P; Fronza, G; Darden, T; Resnick, MA			p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay	ONCOGENE			English	Article						p53; yeast; enhanced transactivation; dominance	TUMOR-SUPPRESSOR P53; WILD-TYPE; DNA-BINDING; SEQUENCE-SPECIFICITY; GENE-EXPRESSION; TERMINAL DOMAIN; CORE DOMAIN; CELL-LINES; CANCER; MUTATIONS	Changes in promoter specificity and binding affinity that may be associated with p53 mutations or post-translational modifications are useful in understanding p53 structure/ function relationships and categorizing tumor mutations. We have exploited variable expression of human p53 in yeast to identify mutants with novel phenotypes that would correspond to altered promoter selectivity and affinity. The p53 cDNA regions coding for the DNA binding and tetramerization domains were subjected to random PCR mutagenesis and were cloned directly by recombination in yeast into a vector with a GAL1 promoter whose level of expression could be easily varied. p53 variants exhibiting higher than wild type levels of transactivation (supertrans) for the RGC responsive element were identified at low level of p53 protein expression. All the p53 mutants obtained with this screen were located in the DNA binding domain. Two out of 17 supertrans mutants have been found in tumors. Six mutations were in the L1 loop region between amino acids 115 and 124, The transactivation potential of a panel of supertrans p53 mutants on different promoters was evaluated using the p53 responsive elements, RGC, PIG3, p21 and bax. Although all mutants retained some activity with all promoters, we found different patterns of induction based on strength and promoter specificity. In particular none of the mutants was supertrans for the p21 responsive element, Interestingly, further analysis in yeast showed that the transactivation function could be retained even in the presence of dominant-negative p53 tumor mutations that could inhibit wild type p53, Five mutants were also characterized in human cells in terms of growth suppression and transactivation of various promoters. These novel supertrans p53 mutants may be useful in studies aimed at dissecting p53 downstream pathways, understanding specific interactions between p53 and the DNA, and could replace wild type p53 in cancer gene therapy protocols. The approach may also prove useful in identifying p53 tumor mutations.	Natl Inst Environm Hlth Sci, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NCI, IST, Mutagenesis Lab, I-16132 Genoa, Italy; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, Mail Drop D3-01,111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.		Monti, Paola/Y-1118-2019; resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019	Monti, Paola/0000-0002-1978-4998; resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065079, ZIAES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Di Como CJ, 1998, ONCOGENE, V16, P2527; FERRIN TE, 1988, J MOL GRAPHICS, V6, P2, DOI 10.1016/0263-7855(88)80053-5; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREBOURG T, 1994, CANCER RES, V54, P878; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Okaichi K, 1999, INT J RADIAT ONCOL, V45, P975, DOI 10.1016/S0360-3016(99)00285-0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pan Y, 2000, ONCOGENE, V19, P3095, DOI 10.1038/sj.onc.1203663; Prives C, 1999, J PATHOL, V187, P112; Reis AM, 2000, CANCER RES, V60, P1571; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Shimada A, 1999, CANCER RES, V59, P2781; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298	57	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					501	513		10.1038/sj.onc.1204116	http://dx.doi.org/10.1038/sj.onc.1204116			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313981				2022-12-28	WOS:000166562500010
J	Taneja, N; Tjalkens, R; Philbert, MA; Rehemtulla, A				Taneja, N; Tjalkens, R; Philbert, MA; Rehemtulla, A			Irradiation of mitochondria initiates apoptosis in a cell free system	ONCOGENE			English	Article						ionizing radiation; apoptosis; caspase; mitochondria; cytochrome c; Bcl-X-L	RADIATION-INDUCED APOPTOSIS; NF-KAPPA-B; IONIZING-RADIATION; CHEMOTHERAPEUTIC DRUGS; ACTIVATION; APAF-1; GENE; CRMA; FAS; PERMEABILITY	The ability to modulate the sensitivity of mammalian cells to ionizing radiation (IR) (e.g. using chemotherapeutics) is dependent on our understanding of the primary target and biochemical pathway that leads to IR-induced apoptosis. We demonstrate using a cell free assay that irradiation of mitochondria is a primary event that initiates IR-induced apoptosis. IR results in loss of mitochondrial membrane potential, opening of the permeability transition pore (PTP) and the release of cytochrome c (cyto c). Apaf-1 and ATP were required to initiate apoptosis upon release of cyto c from mitochondria, The importance of mitochondrial events in the initiation of IR-induced apoptosis was also supported by the observation that inhibition of caspase-9 by the overexpression of dominant negative mutants resulted in the inhibition of IR-induced apoptosis. In contrast, inhibition of caspase-8 had only a minor impact on IR-induced apoptosis, Over-expression of Bcl-X-L inhibited the initiation of IR-induced apoptosis due to its ability to prevent the loss of mitochondrial membrane potential, PTP opening and cytochrome c release, In a cell free assay for apoptosis, mitochondria as web as cytosol derived from Bcl-X-L over-expressing cells were less efficient at supporting apoptosis in response to IR suggesting multiple roles for Bcl-X-L in the regulation of apoptosis.	Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Toxicol Program, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rehemtulla, A (corresponding author), Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA 78041] Funding Source: Medline; NIEHS NIH HHS [ES 08846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R55ES008846, R01ES008846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Booker JK, 1998, J IMMUNOL, V161, P4536; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Kataoka T, 1998, J IMMUNOL, V161, P3936; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Perkins CL, 2000, CANCER RES, V60, P1645; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rehemtulla Alnawaz, 1999, Neoplasia (New York), V1, P63, DOI 10.1038/sj.neo.7900013; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	40	52	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					167	177		10.1038/sj.onc.1204054	http://dx.doi.org/10.1038/sj.onc.1204054			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313941				2022-12-28	WOS:000166410900004
J	Kim, YC; Song, KS; Yoon, G; Nam, MJ; Ryu, WS				Kim, YC; Song, KS; Yoon, G; Nam, MJ; Ryu, WS			Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis	ONCOGENE			English	Article						hepatitis B virus; X gene; apoptosis; H-ras oncogene	NF-KAPPA-B; X-PROTEIN; TRANSGENIC MICE; HEPATOCELLULAR-CARCINOMA; IN-VIVO; C-MYC; EMBRYO FIBROBLASTS; TRANSCRIPTION; DEATH; EXPRESSION	The hepatitis B virus HBx protein is a promiscuous transactivator implicated in the development of hepatocellular carcinoma. The ectopic expression of HBx fails to transform both primary and immortalized rodent cells, but rather induces apoptosis, Furthermore, most transgenic mice harboring HBx do not develop liver tumors. Thus, it remains unclear whether and how HBx contributes to oncogenesis, Here, we show that HBx collaborates with activated H-ras to transform immortalized rodent cells. Indeed, REF52 cells transfected by both HBx and activated H-uas were morphologically transformed and were able to grow in soft agar, Remarkably, nude mice injected with REF52 cells transfected by both HBx and activated H-ras developed tumors, whereas the mice injected with REF52 cells transfected by either gene alone did not. Thus, we concluded that HBx could contribute to neoplastic transformation of cells in collaboration with other oncogenes, such as H-ras, that renders cells to overcome the HBx-mediated apoptosis, Further, we found that HBx mediated apoptosis was suppressed by activated H-ras through activation of the phosphatidylinositol-3 kinase and Akt pathway. Data presented here firmly established the oncogenic potential of HBx during multistage carcinogenesis.	Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Natl Inst Hlth, Div Canc Res, Seoul 122701, South Korea	Yonsei University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH)	Ryu, WS (corresponding author), Yonsei Univ, Dept Biochem, 134 Shinchondong, Seoul 120749, South Korea.			Kim, Young Chul/0000-0002-6782-2186; Ryu, Wang-Shick/0000-0002-0383-5666				BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOHL NE, 1987, ONCOGENE, V2, P41; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	53	69	84	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					16	23		10.1038/sj.onc.1203840	http://dx.doi.org/10.1038/sj.onc.1203840			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244501				2022-12-28	WOS:000166361400003
J	Maa, MC; Hsieh, CY; Leu, TH				Maa, MC; Hsieh, CY; Leu, TH			Overexpression of p97(Eps8) leads to cellular transformation: implication of pleckstrin homology domain in p97(Eps8)-mediated ERK activation	ONCOGENE			English	Article						p97(Eps8); pleckstrin homology domain; transformation; ERK	TYROSINE KINASE SUBSTRATE; BETA-GAMMA-SUBUNITS; PROTEIN-KINASE; HIGH-AFFINITY; PH DOMAIN; SH3 DOMAIN; EPS8; BINDING; PHOSPHORYLATION; GENE	Two isoforms of Eps8, p(97Eps8) and p68(Eps8), have been identified as the substrates for receptor tyrosine kinases, Our previous studies indicated that both tyrosyl phosphorylation and protein expression of Eps8 were elevated in v-Src transformed cells, In an attempt to examine the role played by p97(Eps8) in tumorigenesis, we have first obtained cells overexpressing p97(Eps8) and its pleckstrin homology (PH)-truncated variant. We then demonstrated that cells overexpressing p97(Eps8) not only exhibited the ability of focus formation in cell culture but also promoted the tumor formation in mice as compared to controls, Furthermore, elevated serum-induced extracellular responsive kinase (ERK) activation was observed in p97(Eps8) overexpressors, This enhanced ERK activation was sensitive to a MEK1 specific inhibitor PD98059 and was important for p97(Eps8)-mediated transformation, since transfection of vectors expressing dominant negative MEK1 and p97(Eps8) abrogated focus formation by p97(Eps8) In contrast, PH-truncated p97(Eps8) failed to localize at the plasma membrane and that the truncated variant also did not elevate ERK activation and cellular transformation in response to serum stimulation, Our results thus indicated that: (1) the gene encoding p97(Eps8) was an oncogene; (ii) p97(Eps8)-induced oncogenesis was partly mediated by ERK activation; and (iii) the PH domain of p97(Eps8) was critical for its cellular localization, ERK activation and its ability to transform cells.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung shan Med & Dent Coll, Inst Biochem, Taichung 402, Taiwan	National Cheng Kung University; Chung Shan Medical University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.				Animal center at NCKU; National Science Council Grant (NSC) [89-2320-B-006-007]; NHRI [DOH-87-HR-625, NHRIGT-EX89S932L]	Animal center at NCKU; National Science Council Grant (NSC); NHRI(National Health Research Institutes - Taiwan)	We thank Dr Sally Parsons and Dr Michael Weber for the pBabe (puro) expression vector and polyclonal ERK antibody (TR2) respectively, Dr Garry P Norlan and Dr Sue Lin-Chao for the virus-packaging cell line fNX-Eco and Dr Ching-Hsine Huang and Dr Hsin-Fang Yang-Yen for their critical comments on this manuscript. We appreciate the technical help provided by Ya-Chun Chuang, Hsaio-Hwai Chen and Hong-Ming Lin. We are also grateful to the animal center at NCKU for the care of animals. This work was supported by National Science Council Grant to M-C Maa (NSC 89-2320-B-006-007) and grants of NHRI to T-H Leu (DOH-87-HR-625, NHRIGT-EX89S932L).	Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; KARLSSON T, 1995, ONCOGENE, V10, P1475; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; MAA MC, 1992, ONCOGENE, V7, P2429; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WONG WT, 1994, ONCOGENE, V9, P3057	31	29	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					106	112		10.1038/sj.onc.1204069	http://dx.doi.org/10.1038/sj.onc.1204069			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244499				2022-12-28	WOS:000166361400012
J	Pestell, KE; Ducruet, AP; Wipf, P; Lazo, JS				Pestell, KE; Ducruet, AP; Wipf, P; Lazo, JS			Small molecule inhibitors of dual specificity protein phosphatases	ONCOGENE			English	Article						tyrosine phosphatases; dual specificity phosphatases; cdc25; cancer	INSULIN SIGNAL-TRANSDUCTION; NON-HODGKINS-LYMPHOMAS; TYROSINE-PHOSPHATASE; CELL-CYCLE; CDC25 PHOSPHATASE; C-MYC; TRYPANOSOMA-BRUCEI; CRYSTAL-STRUCTURE; PHASE-TRANSITION; INTACT-CELLS	One hallmark of neoplasia is the deregulation of eel cycle control mechanisms, which is secondary to altered protein phosphorylation, Dual specificity protein phosphatases uniquely dephosphorylate both phosphoserines/ threonines and phosphotyrosines on the same protein substrate. As a class they regulate intracellular signaling through the mitogen activated and stress activated kinases and govern cellular movement through G1/S and G2/M cell cycle checkpoints by affecting the activity of cyclin-dependent kinases, In particular, the Cdc25 phosphatases, which dephosphorylate cyclin-dependent kinases, are overexpressed in many human tumors and this increased expression is associated with a poor prognosis. In addition to expression levels, the intracellular activity of Cdc25 phosphatases is determined by their subcellular distribution and physical proximity to substrates. Small molecules that either inhibit the catalytic activity or alter the subcellular distribution of these dual specificity protein phosphatases could provide effective tools to interrogate the role of phosphorylation pathways and may afford new approaches to the management of cancer.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Biomed Sci Tower E1340,3550 Terrace & DeSoto St, Pittsburgh, PA 15261 USA.		Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863; Barnes, Katharine/0000-0003-4968-3028	NATIONAL CANCER INSTITUTE [R01CA043917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008424] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43917] Funding Source: Medline; NIGMS NIH HHS [T32 GM08424] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Bakalara N, 1995, EXP PARASITOL, V81, P302, DOI 10.1006/expr.1995.1121; Bakalara N, 1995, EUR J BIOCHEM, V234, P871, DOI 10.1111/j.1432-1033.1995.871_a.x; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Bergnes G, 1999, BIOORG MED CHEM LETT, V9, P2849, DOI 10.1016/S0960-894X(99)00497-7; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Blanchard JL, 1999, BIOORG MED CHEM LETT, V9, P2537, DOI 10.1016/S0960-894X(99)00431-X; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; BUTLER T, 1985, TXB MED, P1600; Cans C, 1999, ANTICANCER RES, V19, P1241; Cebula RE, 1997, BIOORG MED CHEM LETT, V7, P2015, DOI 10.1016/S0960-894X(97)00357-0; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; Chen W, 2000, BIOCHEMISTRY-US, V39, P10781, DOI 10.1021/bi000909u; COHN P, 1989, ANNU REV BIOCHEM, V58, P453; COOL DE, 1993, MOL CELL BIOCHEM, V128, P143, DOI 10.1007/BF01076765; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Dodo K, 2000, BIOORG MED CHEM LETT, V10, P615, DOI 10.1016/S0960-894X(00)00065-2; DRAETTA J, 1997, BIOCHIM BIOPHYS ACTA, V1332, pM53; Ducruet AP, 2000, BIOORGAN MED CHEM, V8, P1451, DOI 10.1016/S0968-0896(00)00069-9; Eckstein JW, 2000, INVEST NEW DRUG, V18, P149, DOI 10.1023/A:1006377913494; El-Subbagh HI, 1999, ARCH PHARM, V332, P19; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Fritzen EL, 2000, BIOORG MED CHEM LETT, V10, P649, DOI 10.1016/S0960-894X(00)00069-X; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gasparotto D, 1997, CANCER RES, V57, P2366; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUNSAKERA SP, 1996, J AM CHEM SOC, V118, P8759; Ham SW, 1998, BIOORG MED CHEM LETT, V8, P2507, DOI 10.1016/S0960-894X(98)00411-9; Ham SW, 1997, BIOORG CHEM, V25, P33, DOI 10.1006/bioo.1996.1052; Hernandez S, 1998, CANCER RES, V58, P1762; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; HORIGUCHI T, 1994, BIOCHEM PHARMACOL, V48, P2139, DOI 10.1016/0006-2952(94)90516-9; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kioschis P, 1996, GENOMICS, V33, P365, DOI 10.1006/geno.1996.0212; Kole HK, 1996, J BIOL CHEM, V271, P14302, DOI 10.1074/jbc.271.24.14302; Koufaki M, 1996, J MED CHEM, V39, P2609, DOI 10.1021/jm9509152; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lammer C, 1998, J CELL SCI, V111, P2445; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Minassian BA, 1999, ANN NEUROL, V45, P262, DOI 10.1002/1531-8249(199902)45:2<262::AID-ANA20>3.0.CO;2-9; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Otani T, 2000, J ANTIBIOT, V53, P337, DOI 10.7164/antibiotics.53.337; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peng HR, 2000, BIOORGAN MED CHEM, V8, P299, DOI 10.1016/S0968-0896(99)00284-9; Peng HR, 1998, J MED CHEM, V41, P4677, DOI 10.1021/jm980500r; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Takahashi M, 2000, BIOORG MED CHEM LETT, V10, P2571, DOI 10.1016/S0960-894X(00)00527-8; Tamura K, 2000, CANCER RES, V60, P1317; Tamura K, 1999, ONCOGENE, V18, P6989, DOI 10.1038/sj.onc.1203179; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Wu WG, 1998, CANCER RES, V58, P4082; Xia K, 1999, MOL CELL BIOL, V19, P4819; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	74	48	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6607	6612		10.1038/sj.onc.1204084	http://dx.doi.org/10.1038/sj.onc.1204084			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426646				2022-12-28	WOS:000167704000007
J	Senderowicz, AM				Senderowicz, AM			Small molecule modulators of cyclin-dependent kinases for cancer therapy	ONCOGENE			English	Article						cell cycle; flavopiridol; UCN-01; cyclin-dependent kinases; cyclin D1; protein kinases; apoptosis	BREAST-CARCINOMA CELLS; FLAVOPIRIDOL INDUCES APOPTOSIS; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN EPIDERMOID CARCINOMA; PROTEIN-KINASE; SELECTIVE INHIBITOR; 7-HYDROXYSTAUROSPORINE UCN-01; ANTITUMOR-ACTIVITY; IN-VITRO; RADIOSENSITIZING AGENT	The majority of human malignancies have aberrancies in the Retinoblastoma (Rb) pathway, Loss in Rb function results from the phosphorylation and inactivation of Rb by the cyclin-dependent kinases (cdks), main regulators of cell cycle progression, Thus, modulators of cdks mag have a role in the treatment of human malignancies. Flavopiridol, the first cdk modulator tested in clinical trials, demonstrates interesting preclinical features: cell cycle block, induction of apoptosis, promotion of differentiation, inhibition of angiogenic processes and modulation of transcriptional events. Initial clinical trials with infusional flavopiridol demonstrated activity in some patients with lymphomas and renal, colon gastric carcinomas. Main side effects were diarrhea and hypotension. Phase 2 trials with infusional flavopiridol, other schedules and combination with standard chemotherapies are ongoing, The second cdk modulator tested in clinical trials, UCN-01, is a PKC inhibitor that can also modulate cdk activity. Similar to flavopiridol, UCN-01 blocks cell cycle progression and promotes apoptosis. Moreover, UCN-01 may abrogate checkpoints induced by genotoxic stress due to inhibition of chk1 kinase. The first clinical trial of UCN-01 demonstrated very prolonged half-life (similar to 600 h), due to high binding affinity of UCN-01 to the human alpha-1-acid glycoprotein. Main side effects mere headaches, vomiting, hypoxemia and hyperglycemia. Clinical activity was observed in some patients with melanoma and lymphoma. Trials of shorter infusions of UCN-01 or in combination with standard chemotherapeutic agents are ongoing. Although several important basic and clinical questions remain unanswered, development of cdk modulators is a reasonable strategy for cancer therapy.	NIDCR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Senderowicz, AM (corresponding author), NIDCR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Room 211,30 Convent Dr, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000701] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1994, CANCER CHEMOTH PHARM, V33, P273; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; Akiyama T, 1997, CANCER RES, V57, P1495; Arguello F, 1998, BLOOD, V91, P2482; BENNETT S, 1999, P AM SOC CLIN ONCOLO, V18; Bible KC, 1996, CANCER RES, V56, P4856; Bible KC, 1997, CANCER RES, V57, P3375; Brusselbach S, 1998, INT J CANCER, V77, P146; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; Busby EC, 2000, CANCER RES, V60, P2108; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Carlson B, 1999, CANCER RES, V59, P4634; Carlson B. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P424; Carlson BA, 1996, CANCER RES, V56, P2973; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chien M, 1999, CANCER CHEMOTH PHARM, V44, P81, DOI 10.1007/s002800050948; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Fuse E, 1998, CANCER RES, V58, P3248; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GUEDEZ L, 1999, P 19 ANN M AM ASS CA; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hsueh CT, 1998, CLIN CANCER RES, V4, P2201; Husain A, 1997, CLIN CANCER RES, V3, P2089; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Kerr JS, 1999, ANTICANCER RES, V19, P959; Kitada S, 2000, BLOOD, V96, P393; Konig A, 1997, BLOOD, V90, P4307; Lahusen J, 2000, P 20 ANN M AM ASS CA; Lee HR, 1999, INT J ONCOL, V15, P161; Li YW, 2000, INT J ONCOL, V17, P755; Li YW, 2000, CLIN CANCER RES, V6, P223; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Melillo G, 1999, CANCER RES, V59, P5433; MICHALIDES R, 1995, CANCER RES, V55, P975; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Okami K, 1999, ONCOGENE, V18, P3541, DOI 10.1038/sj.onc.1202837; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Pollack IF, 1996, J NEUROSURG, V84, P1024, DOI 10.3171/jns.1996.84.6.1024; Rickert P, 1996, ONCOGENE, V12, P2631; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Schwartz GK, 1997, CLIN CANCER RES, V3, P1467; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shao RG, 1997, CANCER RES, V57, P4029; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu E, 1996, ONCOLOGY-BASEL, V53, P494; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Tsuchida E, 1997, INT J RADIAT ONCOL, V39, P1153, DOI 10.1016/S0360-3016(97)00549-X; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zaharevitz DW, 1999, CANCER RES, V59, P2566	77	99	106	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6600	6606		10.1038/sj.onc.1204085	http://dx.doi.org/10.1038/sj.onc.1204085			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426645				2022-12-28	WOS:000167704000006
J	Benvenuto, G; Li, SW; Brown, SJ; Braverman, R; Vass, WC; Cheadle, JP; Halley, DJJ; Sampson, JR; Wienecke, R; DeClue, JE				Benvenuto, G; Li, SW; Brown, SJ; Braverman, R; Vass, WC; Cheadle, JP; Halley, DJJ; Sampson, JR; Wienecke, R; DeClue, JE			The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination	ONCOGENE			English	Article						tuberous sclerosis (TSC); tumor suppressor genes; growth inhibition; ubiquitination	EKER RAT; NEOPLASTIC PHENOTYPE; PROTEASOME PATHWAY; RENAL-CARCINOMA; TARGET RAP1; IN-VIVO; COMPLEX; PROTEIN; DEGRADATION; HETEROZYGOSITY	We report here that overexpression of the tuberous sclerosis-1 (TSC1) gene product hamartin results in the inhibition of growth, as well as changes in cell morphology, Growth inhibition was associated with an increase in the endogenous level of the product of the tuberous sclerosis-2 (TSC2) gene, tuberin. As over-expression of tuberin inhibits cell growth, and hamartin is known to bind tuberin, these results suggested that hamartin stabilizes tuberin and this contributes to the inhibition of cell growth. Indeed, transient transfection of TSC1 increased the endogenous level of tuberin, and transient co-transfection of TSC1 with TSC2 resulted in higher tuberin levels. The stabilization was explained by the finding that tuberin is highly ubiquitinated in cells, while the fraction of tuberin that is bound to hamartin is not ubiquitinated, Go-expression of tuberin stabilized hamartin, which is weakly ubiquitinated, in transiently transfected cells. The amino-terminal two-thirds of tuberin was responsible for its ubiquitination and for stabilization of hamartin, A mutant of tuberin from a patient missense mutation of TSC2 was also highly ubiquitinated, and was unable to stabilize hamartin, We conclude that hamartin is a growth inhibitory protein whose biological effect is likely dependent on its interaction with tuberin.	NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA; Cardiff Univ, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales; Erasmus Univ, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; Univ Munich, Dept Dermatol, Klinikum Innenstadt, D-80337 Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cardiff University; Erasmus University Rotterdam; University of Munich	DeClue, JE (corresponding author), NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA.		Warfield, Simon/B-3352-2009	Warfield, Simon/0000-0002-7659-3880; BENVENUTO, Giovanna/0000-0001-7155-2935				Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Ciechanover A, 2000, J CELL BIOCHEM, P40; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Maki CG, 1996, CANCER RES, V56, P2649; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mizuguchi M, 2000, ACTA NEUROPATHOL, V99, P503, DOI 10.1007/s004010051152; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Plank TL, 1999, MODERN PATHOL, V12, P539; Plank TL, 1998, CANCER RES, V58, P4766; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	42	186	190	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6306	6316		10.1038/sj.onc.1204009	http://dx.doi.org/10.1038/sj.onc.1204009			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175345				2022-12-28	WOS:000166210500014
J	Strom, A; Arai, N; Leers, J; Gustafsson, JA				Strom, A; Arai, N; Leers, J; Gustafsson, JA			The hairy and enhancer of split homologue-1 (HES-1) mediates the proliferative effect of 17 beta-estradiol on breast cancer cell lines	ONCOGENE			English	Article						proliferation; HES-1; PCNA; antiestrogen; 17 beta-estradiol	LOOP-HELIX FACTORS; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTORS; MAMMALIAN HAIRY; EXPRESSION; GENE; INHIBITION; PROTEINS	The mechanism behind hormone dependent growth of breast cancer is presently not well understood. We show that the HES-1 protein level in the breast cancer cell lines T47D and MCF-7 is down regulated by 17 beta -estradiol treatment. This regulation could be reversed by addition of the anti-estrogens 4OH tamoxifen, raloxifen and Imperial Chemical Industries (ICI) 182,780, In T47D cells with inducible exogenous HES-1 expression, induced expression of HES-1 protein presented the proliferative Effect of 17 beta -estradiol and subsequent up regulation of proliferating cell nuclear antigen (PCNA), An inverse correlation between the HES-1 and PCNA protein levels respectively,vas found in colon cancer cell lines. These findings point to a potential role of HES-l as a tumor suppressor in epithelial cells, and as a mediator of 17 beta -estradiols proliferative effect on breast cancer cells.	Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden; Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Bunkyo Ku, Tokyo 1138549, Japan; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; Tokyo Medical & Dental University (TMDU); Karolinska Institutet	Strom, A (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden.							Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FRIEDL A, 1994, EUR J CANCER, V30A, P1559, DOI 10.1016/0959-8049(94)00293-E; Harlow E., 1988, ANTIBODIES LAB MANUA; Hong JT, 1998, ONCOL REP, V5, P1025; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kyo S, 1999, CANCER RES, V59, P5917; Lundin A, 2000, METHOD ENZYMOL, V305, P346; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8	20	37	41	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5951	5953		10.1038/sj.onc.1203990	http://dx.doi.org/10.1038/sj.onc.1203990			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127827				2022-12-28	WOS:000165563100015
J	Deroo, BJ; Archer, TK				Deroo, BJ; Archer, TK			Glucocorticoid receptor-mediated chromatin remodeling in vivo	ONCOGENE			English	Review						glucocorticoid receptor; chromatin; mouse mammary tumor virus; BRG1; Swi/Snf; histone	HUMAN BREAST-CANCER; TUMOR VIRUS PROMOTER; LINKER HISTONE H1; TRANSCRIPTION IN-VIVO; YEAST SWI/SNF COMPLEX; SWI-SNF COMPLEX; GENE-EXPRESSION; MMTV PROMOTER; RAPID EXCHANGE; LIVING CELLS	The compaction of DNA into chromatin provides an additional level of gene regulation in eukaryotes that may not be available to prokaryotes. When packaged as chromatin, most promoters are transcriptionally repressed, and transcription factors have reduced access to their binding sites. The glucocorticoid receptor (GR) is a ligand-activated transcription factor that regulates the activity of genes involved in many physiological processes. To regulate eukaryotic genes, the GR binds to target sites within promoter regions of genes assembled as chromatin, This interaction alters the nucleosomal architecture to allow binding of other transcription factors, and formation of the preinitiation complex. The mouse mammary tumor virus (MMTV) promoter has been used extensively as a model to explore the processes by which the GR remodels chromatin and activates transcription. Significant progress has been made in our understanding of the mechanisms used by the GR to modify chromatin structure, and the limits placed on the GR by post-translational modifications of histones, We will describe recent developments in the processes used by the GR to activate transcription in vivo via chromatin remodeling complexes, histone H1 phosphorylation, and recruitment of diverse coactivators.	NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Archer TK, 1997, TRENDS ENDOCRIN MET, V8, P384, DOI 10.1016/S1043-2760(97)00159-8; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1989, STEROID THYROID HORM, P221; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175; Fryer CJ, 2000, J BIOL CHEM, V275, P17771, DOI 10.1074/jbc.M908729199; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER GL, 1991, NUCLEAR HORMONE RECE, P217; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kinyamu HK, 2000, J BIOL CHEM, V275, P20061, DOI 10.1074/jbc.M001142200; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Mizzen CA, 1999, J BIOL CHEM, V274, P14533, DOI 10.1074/jbc.274.21.14533; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MYMRYK JS, 1995, GENE DEV, V9, P1366, DOI 10.1101/gad.9.11.1366; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Windahl SH, 1999, J STEROID BIOCHEM, V71, P93, DOI 10.1016/S0960-0760(99)00128-4; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wong AKC, 2000, CANCER RES, V60, P6171; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	60	69	71	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3039	3046		10.1038/sj.onc.1204328	http://dx.doi.org/10.1038/sj.onc.1204328			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420719				2022-12-28	WOS:000169308500007
J	Mahmoudi, T; Verrijzer, CP				Mahmoudi, T; Verrijzer, CP			Chromatin silencing and activation by Polycomb and trithorax group proteins	ONCOGENE			English	Review						polycomb; trithorax; chromatin; epigenetics; transcription	POSITION-EFFECT VARIEGATION; DROSOPHILA BITHORAX COMPLEX; GAGA TRANSCRIPTION FACTOR; CHROMOSOME-BINDING-SITES; HOMEOTIC GENE-EXPRESSION; MYC TRANSGENIC MICE; CELL-CYCLE ARREST; EXTRA-SEX-COMBS; DNA-BINDING; EPIGENETIC INHERITANCE	The Polycomb group (PcG) of repressors and the trithorax group (trxG) of activators maintain the correct expression of several keg developmental regulators, including the homeotic genes. PcG and trxG proteins function in distinct multiprotein complexes that are believed to control transcription by changing the structure of chromatin, organizing it into either a 'closed' or an 'open' conformation. The hallmark of gene regulation by PcG/trxG proteins is that it can lead to a mitotically stable pattern of gene expression, often referred to as epigenetic regulation. Although much remains to be learned, recent studies have provided insights into how this epigenetic switch is set, holy PcG/trxG proteins might be linked to cis-acting DNA elements and what potential mechanisms underlie stable inheritance of gene expression status over multiple cell divisions. Finally, the study of the evolutionarily conserved PcG/trxG factors has recently gained additional urgency with the realization that they play a pertinent role in certain human cancers.	Leiden Univ, Med Ctr, MGC Ctr Biomed Genet, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Verrijzer, CP (corresponding author), Leiden Univ, Med Ctr, MGC Ctr Biomed Genet, Dept Mol Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.							Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BREEN TR, 1993, DEVELOPMENT, V117, P119; Breen TR, 1999, GENETICS, V152, P319; Breiling A, 1999, MOL CELL BIOL, V19, P8451; Brizuela BJ, 1997, MECH DEVELOP, V65, P209, DOI 10.1016/S0925-4773(97)00081-6; BRIZUELA BJ, 1994, GENETICS, V137, P803; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Busturia A, 1997, DEVELOPMENT, V124, P4343; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Cavalli G, 1999, SCIENCE, V286, P955, DOI 10.1126/science.286.5441.955; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHEN JD, 1993, EMBO J, V12, P2075, DOI 10.1002/j.1460-2075.1993.tb05856.x; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; CHIANG A, 1995, DEVELOPMENT, V121, P1681; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Fritsch C, 1999, DEVELOPMENT, V126, P3905; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GINDHART JG, 1995, GENETICS, V139, P797; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hagstrom K, 1997, GENETICS, V146, P1365; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; INGHAM P, 1980, MOL GEN GENET, V179, P607, DOI 10.1007/BF00271751; INGHAM PW, 1983, NATURE, V306, P591, DOI 10.1038/306591a0; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; JUDD BH, 1995, GENETICS, V141, P245; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kal AJ, 2000, GENE DEV, V14, P1058; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KASSIS JA, 1994, GENETICS, V136, P1025; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; LANEY JD, 1992, GENE DEV, V6, P1531, DOI 10.1101/gad.6.8.1531; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LONIE A, 1994, DEVELOPMENT, V120, P2629; Lyko F, 1999, BIOESSAYS, V21, P824; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Mihaly J, 1998, MOL CELL, V1, P1065, DOI 10.1016/S1097-2765(00)80107-0; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Ohtsuki S, 1998, GENE DEV, V12, P3325, DOI 10.1101/gad.12.21.3325; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Paro R, 2000, NATURE, V406, P579, DOI 10.1038/35020675; PELEGRI F, 1994, GENETICS, V136, P1341; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PHILLIPS MD, 1990, GENETICS, V125, P91; PILLUS L, 1995, CHROMATIN STRUCTURE, P123; PIRROTTA V, 1988, GENE DEV, V2, P1839, DOI 10.1101/gad.2.12b.1839; PIRROTTA V, 1994, BIOESSAYS, V16, P549, DOI 10.1002/bies.950160808; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1999, BBA-REV CANCER, V1424, pM1; Platero JS, 1998, J CELL BIOL, V140, P1297; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rosen C, 1998, GENETICS, V148, P1865; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; SCHLOSSHERR J, 1994, MOL GEN GENET, V243, P453; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SEDKOV Y, 1994, DEVELOPMENT, V120, P1907; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sharp EJ, 1997, CHROMOSOMA, V106, P70, DOI 10.1007/s004120050226; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; STJOHNSTON D, 1992, CELL, V68, P201; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tie F, 1998, DEVELOPMENT, V125, P3483; Tillib S, 1999, MOL CELL BIOL, V19, P5189; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Vazquez M, 1999, DEVELOPMENT, V126, P733; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wade PA, 1999, CURR BIOL, V9, pR221, DOI 10.1016/S0960-9822(99)80134-1; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	148	118	120	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3055	3066		10.1038/sj.onc.1204330	http://dx.doi.org/10.1038/sj.onc.1204330			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420721				2022-12-28	WOS:000169308500009
J	Robertson, KD				Robertson, KD			DNA methylation, methyltransferases, and cancer	ONCOGENE			English	Review						DNA methylation; cancer; DNA methyltransferase; ICF syndrome	DE-NOVO METHYLATION; MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENE; EMBRYONIC STEM-CELLS; CPG ISLAND; ICF SYNDROME; HISTONE DEACETYLASE; CHROMOSOME INSTABILITY; NUCLEAR-MATRIX; SATELLITE DNA	The field of epigenetics has recently moved to the forefront of studies relating to diverse processes such as transcriptional regulation, chromatin structure, genome integrity, and tumorigenesis. Recent work has revealed how DNA methylation and chromatin structure are linked at the molecular level and how methylation anomalies play a direct causal role in tumorigenesis and genetic disease. Much new information has also come to light regarding the cellular methylation machinery, known as the DNA methyltransferases, in terms of their roles in mammalian development and the types of proteins they are known to interact with, This information has forced a new view for the role of DNA methyltransferases. Rather than enzymes that act in isolation to copy methylation patterns after replication, the types of interactions discovered thus far indicate that DNA methyltransferases may be components of larger complexes actively involved in transcriptional control and chromatin structure modulation. These new findings will likely enhance our understanding of the myriad roles of DNA methylation in disease as well as point the may to novel therapies to prevent or repair these defects.	NCI, Epigenet Gene Regulat & Canc Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Robertson, KD (corresponding author), NCI, Epigenet Gene Regulat & Canc Sect, NIH, Bldg 41,41 Lib Dr, Bethesda, MD 20892 USA.			Robertson, Keith/0000-0002-7508-3328				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Altieri F, 1996, BIOCHEM BIOPH RES CO, V225, P448, DOI 10.1006/bbrc.1996.1193; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bachman KE, 1999, CANCER RES, V59, P798; Barwise JL, 1996, FEBS LETT, V394, P213, DOI 10.1016/0014-5793(96)00950-7; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; BURDON RH, 1985, BIOCHIM BIOPHYS ACTA, V825, P70, DOI 10.1016/0167-4781(85)90080-6; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CAMPANERO MR, 2000, P NATL ACAD SCI US; Cao XF, 2000, P NATL ACAD SCI USA, V97, P4979, DOI 10.1073/pnas.97.9.4979; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Carotti D, 1996, BIOCHEMISTRY-US, V35, P11660, DOI 10.1021/bi9606051; CARPENTER NJ, 1988, J PEDIATR-US, V112, P757, DOI 10.1016/S0022-3476(88)80698-X; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Corn PG, 1999, CANCER RES, V59, P3352; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dobrovic A, 1997, CANCER RES, V57, P3347; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eads CA, 1999, CANCER RES, V59, P2302; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Endres M, 2000, J NEUROSCI, V20, P3175, DOI 10.1523/JNEUROSCI.20-09-03175.2000; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2000, CANCER RES, V60, P2368; FEINBERG AP, 1988, CANCER RES, V48, P1159; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; FRANCESCHINI P, 1995, EUR J PEDIATR, V154, P840, DOI 10.1007/BF01959794; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Geiman TM, 2000, P NATL ACAD SCI USA, V97, P4772, DOI 10.1073/pnas.97.9.4772; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GOTO K, 1994, DIFFERENTIATION, V56, P39, DOI 10.1046/j.1432-0436.1994.56120039.x; GRAFF JR, 1995, CANCER RES, V55, P5195; Grassi M, 1999, GENE, V233, P59, DOI 10.1016/S0378-1119(99)00156-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hough RF, 1997, RNA, V3, P356; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kane MF, 1997, CANCER RES, V57, P808; KASTAN MB, 1982, CELL, V30, P509, DOI 10.1016/0092-8674(82)90248-3; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kawano S, 1999, BLOOD, V94, P1113; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOCHANEK S, 1995, FEBS LETT, V360, P115, DOI 10.1016/0014-5793(95)00068-K; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Maloisel L, 1998, GENE DEV, V12, P1381, DOI 10.1101/gad.12.9.1381; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; MINIOU P, 1994, HUM MOL GENET, V3, P2093, DOI 10.1093/hmg/3.12.2093; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Myohanen SK, 1998, CANCER RES, V58, P591; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Narayan A, 2000, MUTAT RES-FUND MOL M, V456, P1, DOI 10.1016/S0027-5107(00)00103-2; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Ohsawa K, 1996, J NEUROCHEM, V67, P89, DOI 10.1046/j.1471-4159.1996.67010089.x; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Picketts DJ, 1996, HUM MOL GENET, V5, P1899, DOI 10.1093/hmg/5.12.1899; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Puget N, 1997, CANCER RES, V57, P828; Qian XLC, 1997, CANCER RES, V57, P3672; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Raynal P, 1996, FEBS LETT, V392, P263, DOI 10.1016/0014-5793(96)00827-7; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAWYER JR, 1995, AM J MED GENET, V56, P203, DOI 10.1002/ajmg.1320560218; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Small K, 1997, NAT GENET, V16, P96, DOI 10.1038/ng0597-96; SMEETS DFCM, 1994, HUM GENET, V94, P240; STEWART AF, 1996, TIBS, V21, P87; Stirzaker C, 1997, CANCER RES, V57, P2229; SZYF M, 1991, J BIOL CHEM, V266, P10027; TAGARRO I, 1994, HUM GENET, V93, P383; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhang XY, 1996, FEBS LETT, V392, P179, DOI 10.1016/0014-5793(96)00810-1	162	557	587	0	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3139	3155		10.1038/sj.onc.1204341	http://dx.doi.org/10.1038/sj.onc.1204341			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420731				2022-12-28	WOS:000169308500019
J	Chinni, SR; Li, YW; Upadhyay, S; Koppolu, PK; Sarkar, FH				Chinni, SR; Li, YW; Upadhyay, S; Koppolu, PK; Sarkar, FH			Indole3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells	ONCOGENE			English	Article						G1 cell cycle arrest; apoptosis; indole-3-carbinol (I3C); prostate cancer (PCa)	DEPENDENT KINASE INHIBITOR; FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; ESTRADIOL METABOLISM; POTENTIAL MEDIATOR; EPITHELIAL-CELLS; LEUKEMIC-CELLS; CDK INHIBITOR; DNA-ADDUCTS; INDOLE-3-CARBINOL	Prostate cancer is one of the most common cancers in men and it is the second leading cause of cancer related death in men in the United States. Recent dietary and epidemiological studies have suggested the benefit of dietary intake of fruits and vegetables in lowering the incidence of prostate cancer. A diet rich in fruits and vegetables provides phytochemicals, particularly indole-3-carbinol (I3C), which may be responsible for the prevention of many types of cancer, including hormone-related cancers such as prostate. Studies to elucidate the role and the molecular mechanism(s) of action of I3C in prostate cancer, however, have not been conducted. In the current study, we investigated whether I3C had any effect against prostate cancer cells and, if so, attempts were made to identify the potential molecular mechanism(s) by which I3C elicits its biological effects on prostate cancer cells. Here we report for the first time that I3C inhibits the growth of PC-3 prostate cancer cells. Induction of G1 cell cycle arrest was also observed in PC-3 cells treated with I3C, which may be due to the observed effects of I3C in the up-regulation of p21(WAF1) and p27(Klp1) CDK inhibitors, followed by their association with cyclin D1 and E and down-regulation of CDK6 protein kinase levels and activity. The induction of p21(WAF1) appears to be transcriptionally upregulated and independent of the p53 responsive element. In addition, I3C inhibited the hyperpohosphorylation of the Retinoblastoma (Rb) protein in PC-3 cells. Induction of apoptosis was also observed in this cell line when treated with I3C, as measured by DNA laddering and poly (ADP-ribose) polymersae (PARP) cleavage. We also found an up-regulation of Bax, and down-regulation of Bcl-2 in I3C-treated cells. These effects may also be mediated by the down-regulation of NF-kappaB observed in I3C treated PC-3 cells. From these results, we conclude that I3C inhibits the growth of PC-3 prostate cancer cells by inducing G1 cell cycle arrest leading to apoptosis, and regulates the expression of apoptosis-related genes. These findings suggest that I3C may be an effective chemopreventive or therapeutic agent against prostate! cancer. Oncogene (2001) 20, 2927-2936.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.							*ACS, 2000, CANC FACTS FIG; BAILEY G, 1987, ENVIRON HEALTH PERSP, V71, P147, DOI 10.2307/3430422; BEIER RC, 1990, REV ENVIRON CONTAM T, V113, P47; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRADFIELD CA, 1991, ADV EXP MED BIOL, V289, P153; Broadbent TA, 1998, CURR MED CHEM, V5, P469; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Costello JF, 1997, CANCER RES, V57, P1250; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; CRAM EJ, 2000, AM ASS CANC RES, V91, P10; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dashwood RH, 1998, CHEM-BIOL INTERACT, V110, P1, DOI 10.1016/S0009-2797(97)00115-4; DASHWOOD RH, 1989, CARCINOGENESIS, V10, P175, DOI 10.1093/carcin/10.1.175; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feldman D., 1996, SYNTHETIC POLYM, DOI [DOI 10.1002/(SICI)1097-4644(1996)25+<1::AID-JCB1>3.0.CO;2-4, 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G, DOI 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G]; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Herman DG, 1995, CARCINOGENESIS, V16, P2931, DOI 10.1093/carcin/16.12.2931; Huang P, 1997, CANCER RES, V57, P3407; Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X; Katdare M, 1998, ONCOL REP, V5, P311; Kim DJ, 1997, CARCINOGENESIS, V18, P377, DOI 10.1093/carcin/18.2.377; KOJIMA T, 1994, CANCER RES, V54, P1446; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Krongrad A, 1998, Semin Urol Oncol, V16, P30; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Michnovicz JJ, 1997, JNCI-J NATL CANCER I, V89, P718, DOI 10.1093/jnci/89.10.718; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NIWA T, 1994, STEROIDS, V59, P523, DOI 10.1016/0039-128X(94)90070-1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Telang NT, 1997, P SOC EXP BIOL MED, V216, P246, DOI 10.3181/00379727-216-44174; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wong GYC, 1997, J CELL BIOCHEM, P111; Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429	57	254	270	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2927	2936		10.1038/sj.onc.1204365	http://dx.doi.org/10.1038/sj.onc.1204365			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420705				2022-12-28	WOS:000168901800008
J	Baba, M; Hirai, S; Kawakami, S; Kishida, T; Sakai, N; Kaneko, S; Yao, M; Shuin, T; Kubota, Y; Hosaka, M; Ohno, S				Baba, M; Hirai, S; Kawakami, S; Kishida, T; Sakai, N; Kaneko, S; Yao, M; Shuin, T; Kubota, Y; Hosaka, M; Ohno, S			Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth	ONCOGENE			English	Article						VHL; tumor suppressor; contact inhibition; renal cell carcinoma; epithelial cells	HIPPEL-LINDAU GENE; BIOLOGICALLY-ACTIVE PRODUCT; F-BOX PROTEIN; BETA-CATENIN; DEPENDENT PROTEOLYSIS; SOMATIC MUTATIONS; UBIQUITIN LIGASE; RENAL-CARCINOMA; HUMAN TISSUES; CYCLE ARREST	In spite of the general recognition of von Hippel-Lindau (VHL) as a tumor suppressor gene, the physiological and pathological importance of VHL protein in cell growth regulation and tumorigenesis remains unclear, Here we show that in normal human renal proximal tubule epithelial cells (RPTEC), the steady-state amount of VHL protein is strictly regulated by cell density. The cellular VHL content is more than 100-fold higher in dense cultures than in sparse cultures, The increase in VHL protein at high cell density was also observed for NIH3T3 fibroblasts, suggesting the generality of the phenomenon. The growth rates of renal cell carcinoma cells lacking an intact VHL gene and their derivatives with wild-type or mutant VHL expression vector do not differ significantly when they are growing in log-phase. Importantly, however, there is a difference when they reach confluency: cells lacking wild-type VHL grew continuously, while cells expressing exogenous VHL protein showed relatively limited cell growth. Using an ecdysone-inducible VHL expressing cell line, we also show that the growth inhibition at high cell density can be released by attenuating the VHL expression, Taken together, we propose that VHL protein functions as a growth suppressor at high cell density, and this might be the basis of the tumor suppressor function of VHL.	Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 2360004, Japan; Kochi Med Sch, Dept Urol, Kochi 7838505, Japan	Yokohama City University; Yokohama City University; Kochi University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.		Baba, Masaya/ABE-4893-2020; Baba, Masaya/L-7490-2013; Ohno, Shigeo/B-1768-2010	Baba, Masaya/0000-0002-5308-6683; Ohno, Shigeo/0000-0002-1294-5269				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GAO JZ, 1995, CANCER RES, V55, P743; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; JUDAH F, 1995, NAT MED, V1, P27; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHUIN T, 1994, CANCER RES, V54, P2852; Soler C, 1999, FEBS LETT, V442, P178, DOI 10.1016/S0014-5793(98)01648-2; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7	50	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2727	2736		10.1038/sj.onc.1204397	http://dx.doi.org/10.1038/sj.onc.1204397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420685				2022-12-28	WOS:000168712000001
J	Jin, SQ; Fan, FY; Fan, WH; Zhao, HC; Tong, T; Blanck, P; Alomo, I; Rajasekaran, B; Zhan, QM				Jin, SQ; Fan, FY; Fan, WH; Zhao, HC; Tong, T; Blanck, P; Alomo, I; Rajasekaran, B; Zhan, QM			Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage	ONCOGENE			English	Article						GADD45; p53; DNA damage; transcription; factor Oct-1; NF-YA	TUMOR-SUPPRESSOR P53; HISTONE H2B GENE; HUMAN-CELLS; EXPRESSION; ACTIVATION; PROTEINS; GROWTH; INHIBITION; PROMOTER; ELEMENTS	The p53-regulated GADD45 gene is one of the important players in cellular response to DNA damage, and probably involved in the control of cell cycle checkpoint, apoptosis and DNA repair, There are both the p53-dependent and -independent pathways that regulate GADD45 induction. Following ionizing radiation, induction of the GADD45 gene is regulated by p53 through the p53-binding motif located in the third intron of the GADD45 gene. In contrast, GADD45 induction by methyl methanesulfonate (MMS), UV radiation (UV), and medium starvation is independent of p53 status although p53 may contribute to these responses. However, the regulatory elements that control the p53-independent induction of GADD45 remain uncertain. In this report, we have performed detailed analyses to characterize the responsive components that are required for the induction of the GADD45 promoter. We have found that the region between -107 and -62 of the GADD45 promoter is crucial for the induction. Sequence analysis indicates that there are two OCT-1 sites and one CAAT box located in this region. Site-directed mutations of both OCT-1 and CAAT motifs substantially abrogate the induction of the GADD45 promoter by DNA damage. In addition, both Oct-1 protein (binding to OCT-1 site) and NP-YA protein (binding to CAAT hox) are induced after cell exposure to DNA damaging agents. Moreover, the Electrophoretic Mobility Shift Assay (EMSA) has demonstrated the direct bindings of Oct-1 and NF-YA proteins to their consensus sequences in the GADD45 promoter. Therefore, these results have presented the novel observation that transcription factors Oct-1 and NF-YA participate in the cellular response to DNA damage and are involved in the regulation of stress-inducible genes.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Inst Canc, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.							BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MIYASHITA T, 1995, CELL, V80, P293; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Prives C, 1999, J PATHOL, V187, P112; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; STURM RA, 1988, NUCLEIC ACIDS RES, V16, P8571, DOI 10.1093/nar/16.17.8571; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao HC, 2000, CANCER RES, V60, P6276	35	92	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2683	2690		10.1038/sj.onc.1204390	http://dx.doi.org/10.1038/sj.onc.1204390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420680				2022-12-28	WOS:000168652600009
J	Paggi, MG; Bonetto, F; Severino, A; Baldi, A; Battista, T; Bucci, F; Felsani, A; Lombardi, D; Giordano, A				Paggi, MG; Bonetto, F; Severino, A; Baldi, A; Battista, T; Bucci, F; Felsani, A; Lombardi, D; Giordano, A			The retinoblastoma-related Rb2/p130 gene is an effector downstream of AP-2 during neural differentiation	ONCOGENE			English	Article						AP-2; Rb2/p130; differentiation; NGF; PC12	TRANSCRIPTION FACTOR AP-2; NERVE GROWTH-FACTOR; PC12 CELLS; NEUROBLASTOMA-DIFFERENTIATION; EXPRESSION; PROTEINS; FAMILY; P107; P130; PROMOTER	Rb2/p130, a member of the Retinoblastoma family of growth and tumour suppressor genes, is extensively implicated in the control of cell cycle and differentiation. The minimal promoter region of Rb2/p130 in T98G human glioblastoma cells was identified and its analysis revealed the presence of a KER1 palindromic sequence able to bind the transcription factor AP-2, a regulatory protein that plays a crucial role in ectodermal differentiation, This KER1 site interacted in vitro with AP-2, and AP-2 overexpression increased Rb2/p130 transcription and translation, We also found that rat PC12 pheochromocytoma cells, when induced to differentiate by NGF, displayed an increase of AP-2 protein levels and of Rb2/p130 transcription and protein levels, AP-2-transfected PC12 cells displayed enhanced transcription and translation of Rb2/p130 and of the cdk inhibitor p21(WAF1/CIP1), a gene known to be under the control of AP-2, but unable by itself to elicit PC12 differentiation. Overexpression of either AP-2 or Rb2/p130 elicited per se cell differentiation in the absence of NGF, while coexpression of AP-IB, a negative regulator of AP-2 transcriptional activity, inhibited only AP-2-induced differentiation, Altogether, these results indicate that Rb2/p130 is a critical effector of AP-2 in sustaining ectodermal differentiation.	Regina Elena Canc Inst, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Jefferson University	Paggi, MG (corresponding author), Regina Elena Canc Inst, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, Via Messi Doro 156, I-00158 Rome, Italy.		Baldi, Alfonso/ABG-2397-2021; Felsani, Armando/D-1784-2010; Giordano, Antonio/F-1927-2010; Paggi, Marco G./K-3494-2018; Severino, Anna/S-3417-2019	Felsani, Armando/0000-0001-8851-6295; Giordano, Antonio/0000-0002-5959-016X; Severino, Anna/0000-0002-6276-7747; Baldi, Alfonso/0000-0002-8693-3842	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 60999-01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BENNETT GS, 1985, DEV BIOL, V107, P94, DOI 10.1016/0012-1606(85)90379-3; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fajas L, 2000, FEBS LETT, V471, P29, DOI 10.1016/S0014-5793(00)01363-6; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTELLI F, 1994, ONCOGENE, V9, P3579; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLOPADE OI, 1992, CANCER RES, V52, P2523; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; Puri PL, 1998, CANCER RES, V58, P1325; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEINMAN RA, 1994, ONCOGENE, V9, P3389; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; Wu F, 1998, NUCLEIC ACIDS RES, V26, P4837, DOI 10.1093/nar/26.21.4837; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	53	13	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2570	2578		10.1038/sj.onc.1204356	http://dx.doi.org/10.1038/sj.onc.1204356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420667				2022-12-28	WOS:000168652500008
J	Angel, P; Szabowski, A; Schorpp-Kistner, M				Angel, P; Szabowski, A; Schorpp-Kistner, M			Function and regulation of AP-1 subunits in skin physiology and pathology	ONCOGENE			English	Review						epidermis; Fos; Jun; proliferation; differentiation; target genes	ACTIVATOR PROTEIN-1 ACTIVITY; STIMULATING FACTOR PROMOTER; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR EXPRESSION; MOUSE EPIDERMAL-CELLS; HUMAN INVOLUCRIN GENE; C-JUN; TRANSGENIC MICE; TRANSCRIPTION FACTORS; MATRIX METALLOPROTEINASES	The mouse skin has become the model of choice to study the regulation and function of AP-1 subunits in many physiological and pathological processes in vivo and in vitro. Genetically modified mice, in vitro reconstituted skin equivalents and epidermal cell lines were established, in which AP-1-regulated genetic programs of cell proliferation, differentiation and tumorigenesis can be analysed. Since the epidermis, as our interface with the environment, is subjected to radiation and injury, signal transduction pathways and critical AP-1 members regulating the mammalian stress response could be identified. Regulated expression of important components of the cytokine network, cell surface receptors and proteases, which orchestrate the process of wound healing has been found to rely on AP-1 activity. Here we review our current knowledge on the function of AP-1 subunits and AP-1 target genes in these fascinating fields of skin physiology and pathology.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; Barthelman M, 1998, CANCER RES, V58, P711; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BELMAN S, 1972, CANCER RES, V32, P450; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bernerd F, 1998, CELL DEATH DIFFER, V5, P792, DOI 10.1038/sj.cdd.4400413; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; Bullard KM, 1999, ANN SURG, V230, P260, DOI 10.1097/00000658-199908000-00017; CAO X, 1993, J BIOL CHEM, V268, P27371; CARRASCO D, 1995, ONCOGENE, V10, P1069; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; CRIPE T P, 1990, New Biologist, V2, P450; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; FINCH PW, 1995, J BIOL CHEM, V270, P11230, DOI 10.1074/jbc.270.19.11230; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Fisher GJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P154, DOI 10.1111/j.1751-1097.1999.tb03268.x; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; FUSENIG NE, 1994, KERATINOCYTE HDB, P71; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GILLARDON F, 1994, ONCOGENE, V9, P3219; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatamochi A, 1996, J DERMATOL SCI, V11, P97, DOI 10.1016/0923-1811(95)00425-4; HU L, 1994, J BIOL CHEM, V269, P183; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; Jaakkola P, 1998, ONCOGENE, V17, P1279, DOI 10.1038/sj.onc.1202002; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Konicek BW, 1998, DNA CELL BIOL, V17, P799, DOI 10.1089/dna.1998.17.799; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LEVER WF, 1983, HISTOPATHOLOGY SKIN, P139; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Matsui T, 1996, BIOCHEM BIOPH RES CO, V220, P405, DOI 10.1006/bbrc.1996.0418; Mauviel A, 1996, J BIOL CHEM, V271, P24824, DOI 10.1074/jbc.271.40.24824; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Monzon RI, 1996, CELL GROWTH DIFFER, V7, P1751; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; Nishida K, 1997, BIOCHEM BIOPH RES CO, V241, P258, DOI 10.1006/bbrc.1997.7808; Olsen J, 2000, BIOCHEM J, V347, P407, DOI 10.1042/0264-6021:3470407; PHILIPS N, 1995, J BIOL CHEM, V270, P9313, DOI 10.1074/jbc.270.16.9313; PROFFITT J, 1995, GENE, V152, P173, DOI 10.1016/0378-1119(94)00701-S; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Ramaswamy NT, 1998, ONCOGENE, V16, P1501, DOI 10.1038/sj.onc.1201628; Rhodes K, 1998, J BIOL CHEM, V273, P26534, DOI 10.1074/jbc.273.41.26534; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SAIAG P, 1985, SCIENCE, V230, P669, DOI 10.1126/science.2413549; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Sato H, 1997, PHOTOCHEM PHOTOBIOL, V65, P908, DOI 10.1111/j.1751-1097.1997.tb01942.x; SCHRODER JM, 1995, J INVEST DERMATOL, V105, pS20, DOI 10.1111/1523-1747.ep12315192; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SHALABY F, 1994, ONCOGENE, V9, P2579; Shino Y, 1997, J VIROL, V71, P4310, DOI 10.1128/JVI.71.6.4310-4318.1997; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; SMITH MF, 1992, J IMMUNOL, V149, P2000; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; Soriani M, 2000, PHOTOCHEM PHOTOBIOL, V71, P551, DOI 10.1562/0031-8655(2000)071<0551:MOCJAC>2.0.CO;2; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Stefanidou MP, 1999, BRIT J DERMATOL, V141, P1040, DOI 10.1046/j.1365-2133.1999.03202.x; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; Teofoli P, 1999, J DERMATOL SCI, V22, P31, DOI 10.1016/S0923-1811(99)00040-7; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; UNEMORI EN, 1994, EXP CELL RES, V211, P212, DOI 10.1006/excr.1994.1080; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; Xing Z, 1997, LAB INVEST, V77, P615; Ye JP, 1996, MOL CELL BIOL, V16, P157; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; Ziober BL, 1996, J BIOL CHEM, V271, P22915, DOI 10.1074/jbc.271.37.22915; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	125	322	328	2	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	2001	20	19					2413	2423		10.1038/sj.onc.1204380	http://dx.doi.org/10.1038/sj.onc.1204380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402337				2022-12-28	WOS:000168568700008
J	Gimm, O; Dziema, H; Brown, J; Cuong, HV; Hinze, R; Dralle, H; Mulligan, LM; Eng, C				Gimm, O; Dziema, H; Brown, J; Cuong, HV; Hinze, R; Dralle, H; Mulligan, LM; Eng, C			Over-representation of a germline variant in the gene encoding RET co-receptor GFR alpha-1 but not GFR alpha-2 or GFR alpha-3 in cases with sporadic medullary thyroid carcinoma	ONCOGENE			English	Article						MEN 2; RET; common low penetrance alleles; polymorphisms; thyroid	ENDOCRINE-NEOPLASIA TYPE-2B; TYROSINE KINASE; NEUROTROPHIC FACTOR; GDNF FAMILY; HIRSCHSPRUNG-DISEASE; FUNCTIONAL RECEPTOR; CODON-918 MUTATION; MICE LACKING; PROTOONCOGENE; PROTEIN	In contrast to the hereditary form of medullary thyroid carcinoma (MTC), little is known about the etiology of sporadic MTC, Somatic gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase, are found in an average of 40% of sporadic MTC, We analysed 31 sporadic MTC for somatic and germline variants in GFRA1, GFRA2 and GFRA3 which encode the co-receptors of RET, Although there were no somatic mutations in any of the three genes, a sequence variant (-193C>G) in the 5'-UTR of GFRA1 was found in 15% of cases. Three patients were heterozygous (het); another three patients homozygous (hom) for the G variant. The G allele was not observed in 31 race-matched normal controls. Hence, the relative frequency of this variant in sporadic MTC cases and controls differed significantly (P<0.05). Since this variant lies in the 5' UTR, likely at the transcriptional start site, we analysed for differential expression of GFR<alpha>-1 at the transcript and protein levels. At the mRNA level, GFRA1 was over-expressed in tumors harboring the rare variant (P=0.06), The presence of the G polymorphic allele seemed to be associated with increased expression by immunostaining for GFR alpha -1. Interestingly, cytoplasmic staining was stronger in intensity for het patients and nuclear staining predominant in hom cases. In conclusion, mutation analysis of GFRA1, GFRA2 and GFRA3 revealed over-representation of a rare variant in GFRA1 (- 193C > G) in the germline of sporadic MTC cases. Our data suggest that the mechanism is related to over-expression of GFR alpha -1 and differential subcellular compartmentalization but the precise mechanism as to how it acts as a low penetrance susceptibility allele for the development of sporadic MTC remains to be elucidated.	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Univ Halle Wittenberg, Inst Pathol, Halle, Germany; Queens Univ, Dept Pathol, Kingston, ON K7L 3NR, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3NR, Canada; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Univ Halle Wittenberg, Dept Gen Surg, Halle, Germany	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Martin Luther University Halle Wittenberg; Queens University - Canada; Queens University - Canada; CRUK Cambridge Institute; University of Cambridge; Martin Luther University Halle Wittenberg	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 420 W 12th Ave,Suite 690 TMRF, Columbus, OH 43210 USA.		Dralle, Henning/ABD-4454-2020	Eng, Charis/0000-0002-3693-5145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039058] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline; NICHD NIH HHS [1RO1HD39058-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Ceccherini I, 1999, AM J HUM GENET, V65, pA266; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Gimm O, 1999, ONCOGENE, V18, P1369, DOI 10.1038/sj.onc.1202418; Gimm O, 2000, HUM MOL GENET, V9, P1633, DOI 10.1093/hmg/9.11.1633; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gimm O, 1999, BRIT J CANCER, V80, P383, DOI 10.1038/sj.bjc.6690367; Gimm O, 1999, J CLIN ENDOCR METAB, V84, P2784, DOI 10.1210/jc.84.8.2784; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Myers SM, 1999, J MED GENET, V36, P217; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; ONOCHIE CI, 2000, IN PRESS J MED GENET; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667	37	25	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2161	2170		10.1038/sj.onc.1204289	http://dx.doi.org/10.1038/sj.onc.1204289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360200				2022-12-28	WOS:000168116700011
J	Ho, MKC; Wong, YH				Ho, MKC; Wong, YH			G(z) signaling: emerging divergence from G(i) signaling	ONCOGENE			English	Review						G protein; G(z); signal transduction	GUANINE-NUCLEOTIDE-BINDING; PROTEIN ALPHA-SUBUNIT; HETEROTRIMERIC G-PROTEINS; NEUROBLASTOMA SH-SY5Y CELLS; GTPASE-ACTIVATING PROTEIN; NATURAL-KILLER-CELLS; II ADENYLYL-CYCLASE; METABOTROPIC GLUTAMATE RECEPTORS; RETROGRADE AXONAL-TRANSPORT; RAT SYMPATHETIC NEURONS	A large variety of neurotransmitters, hormones, and chemokines regulate cellular functions via cell surface receptors that are coupled to guanine nucleotide-binding regulatory proteins (G proteins) belonging to the G(i) subfamily. All members of the G(i) subfamily, with the sole exception of G(z), are substrates for the pertussis toxin ADP-ribosyl transferase. G(z) also exhibits unique biochemical and regulatory properties, Initial portrayals of the cellular functions of G(z) bear high resemblance to those of other G(i) proteins both in terms of the receptors and effecters linked to G(z), However, recent discoveries have begun to insinuate a distinct role for G(z) in cellular communication. Functional interactions of the alpha subunit of G(z) (G alpha (z)) with the NKR-P1 receptor, G alpha (z)-specific regulator of G protein signaling, p21-activated kinase, G protein-regulated inducers of neurite outgrowth, and the Eya2 transcription cofactor have been demonstrated. These findings provide possible links for G(z) to participate in cellular development, survival, proliferation, differentiation and even apoptosis, In this review, we have drawn a sketch of a signaling network with G(z) as the centerpiece. The emerging picture is one that distinguishes G(z) from other members of the G(i) subfamily.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.		Ho, Maurice K/A-5993-2010; Ho, Maurice K/C-3145-2015	Ho, Maurice K/0000-0002-1211-2347; Ho, Maurice K/0000-0002-1211-2347				Al-Aoukaty A, 1998, IMMUNOLOGY, V95, P618; AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; AlAoukaty A, 1997, J BIOL CHEM, V272, P31604, DOI 10.1074/jbc.272.50.31604; AMMER H, 1994, J NEUROCHEM, V62, P1310; AMMER H, 1993, BIOCHEM J, V295, P263, DOI 10.1042/bj2950263; Ammer H, 1996, BRAIN RES, V707, P235, DOI 10.1016/0006-8993(95)01265-6; Ammer H, 1996, EUR J PHARMACOL, V302, P199, DOI 10.1016/0014-2999(96)00082-9; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Belcheva MM, 2000, CELL SIGNAL, V12, P481, DOI 10.1016/S0898-6568(00)00095-4; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Chan ASL, 2000, J PHARMACOL EXP THER, V295, P1094; CHAN JSC, 1995, J NEUROCHEM, V65, P2682; Chan JSC, 1998, J NEUROCHEM, V71, P2203; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROUCH MF, 1994, EUR J NEUROSCI, V6, P626, DOI 10.1111/j.1460-9568.1994.tb00307.x; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Erlich R, 1998, MOL CELL ENDOCRINOL, V142, P87, DOI 10.1016/S0303-7207(98)00113-0; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Francken BJB, 2000, MOL PHARMACOL, V57, P1034; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; Garzon J, 1997, EUR J NEUROSCI, V9, P1194, DOI 10.1111/j.1460-9568.1997.tb01474.x; Garzon J, 1997, J PHARMACOL EXP THER, V281, P549; Garzon J, 1998, EUR J NEUROSCI, V10, P2557, DOI 10.1046/j.1460-9568.1998.t01-1-00267.x; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 2000, SCI STKE, V40; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HENDRY IA, 1995, BRAIN RES, V700, P157, DOI 10.1016/0006-8993(95)00945-M; Hendry IA, 2000, BRAIN RES, V870, P10, DOI 10.1016/S0006-8993(00)02387-8; HINTON DR, 1990, J NEUROSCI, V10, P2763; Ho MKC, 2000, MOL PHARMACOL, V58, P993, DOI 10.1124/mol.58.5.993; Ho MKC, 1997, J NEUROCHEM, V68, P2514; Ho MKC, 2000, BIOL SIGNAL RECEPT, V9, P21; Ho MKC, 1998, BIOL SIGNAL RECEPT, V7, P80; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jackson EK, 1999, J PHARMACOL EXP THER, V291, P329; Jeong SW, 1998, NEURON, V21, P1201, DOI 10.1016/S0896-6273(00)80636-4; Jiang MS, 1997, RECEPTOR CHANNEL, V5, P187; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kawakami K, 2000, BIOESSAYS, V22, P616, DOI 10.1002/1521-1878(200007)22:7<616::AID-BIES4>3.3.CO;2-I; Kelleher KL, 1998, DEV BRAIN RES, V107, P247, DOI 10.1016/S0165-3806(98)00020-0; KIMURA K, 1995, J BIOL CHEM, V270, P14672, DOI 10.1074/jbc.270.24.14672; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Kostenis E, 1998, J BIOL CHEM, V273, P17886, DOI 10.1074/jbc.273.28.17886; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; LAI HWL, 1995, FEBS LETT, V360, P97, DOI 10.1016/0014-5793(95)00088-Q; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; Maghazachi AA, 1997, BIOCHEM BIOPH RES CO, V236, P270, DOI 10.1006/bbrc.1997.6937; MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969; Maghazachi AA, 1996, J IMMUNOL, V157, P5308; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marsh SR, 1998, MOL PHARMACOL, V53, P981; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Mody SM, 2000, MOL PHARMACOL, V57, P13; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PARKER EM, 1991, J BIOL CHEM, V266, P519; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; PAULSSEN EJ, 1991, MOL CELL ENDOCRINOL, V76, P45, DOI 10.1016/0303-7207(91)90258-T; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; Raap DK, 1999, J PHARMACOL EXP THER, V288, P561; Raap DK, 2000, NEUROPHARMACOLOGY, V39, P1823, DOI 10.1016/S0028-3908(99)00264-6; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; SanchezBlazquez P, 1995, J PHARMACOL EXP THER, V275, P1590; SANCHEZBLAZQUEZ P, 1994, LIFE SCI, V55, pPL445, DOI 10.1016/0024-3205(94)90098-1; SANCHEZBLAZQUEZ P, 1993, LIFE SCI, V53, pP381, DOI 10.1016/0024-3205(93)90166-Z; Serres F, 2000, J NEUROSCI, V20, P3095, DOI 10.1523/JNEUROSCI.20-09-03095.2000; SHAPIRO MS, 1994, NEURON, V12, P1319, DOI 10.1016/0896-6273(94)90447-2; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SHUM JK, 1995, BIOCHEM BIOPH RES CO, V208, P223, DOI 10.1006/bbrc.1995.1327; Sidhu A, 1998, J NEUROCHEM, V70, P2459; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Spiegel AM, 2000, HORM RES, V53, P17, DOI 10.1159/000023526; Sullivan BM, 2000, MOL BIOL CELL, V11, P3155, DOI 10.1091/mbc.11.9.3155; Tanaka M, 1999, P NATL ACAD SCI USA, V96, P14106, DOI 10.1073/pnas.96.24.14106; Tso PH, 2000, J NEUROCHEM, V74, P1685, DOI 10.1046/j.1471-4159.2000.0741685.x; Tso PH, 2000, J PHARMACOL EXP THER, V295, P168; TSU RC, 1995, MOL PHARMACOL, V47, P835; Tsu RC, 1997, MOL PHARMACOL, V52, P38, DOI 10.1124/mol.52.1.38; TSU RC, 1995, J NEUROCHEM, V64, P2700; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; WONG YH, 1995, ONCOGENE, V10, P1927; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Yamaguchi T, 2000, FEBS LETT, V470, P25, DOI 10.1016/S0014-5793(00)01284-9; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	117	57	57	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1615	1625		10.1038/sj.onc.1204190	http://dx.doi.org/10.1038/sj.onc.1204190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313909				2022-12-28	WOS:000168089800012
J	Sheng, W; Decaussin, G; Sumner, S; Ooka, T				Sheng, W; Decaussin, G; Sumner, S; Ooka, T			N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2	ONCOGENE			English	Article						EBV; malignant transforming activity; Bcl-2; c-myc; rodent fibroblast	LYMPHOCYTE GROWTH TRANSFORMATION; LATENT MEMBRANE-PROTEIN; OPEN READING FRAME; KAPPA-B; NASOPHARYNGEAL CARCINOMA; CELL-DEATH; C-MYC; EMBRYO FIBROBLASTS; EXPRESSION; EBV	The BARF1 gene encoded by the Epstein-Barr virus induces morphological changes, loss of contact inhibition and anchorage independence in established rodent Balb/c3T3 fibroblast, BARF1 gene was also capable of inducing malignant transformation in a human Louckes B cell line. Our recent study showed that BARF1 gene had an ability to immortalize primary epithelial cells. However we do not know which region(s) of BARF1 protein is(are) responsible for inducing malignant transformation in established rodent cells. Using the deletion mutants, we now localized malignant transforming region in N-terminal of BARF1 protein. The mutants lacking this region were unable to transform the cells in malignant state, Furthermore, we demonstrated that only the mutants containing this region rendered the cells resistant to apoptosis induced by serum deprivation. Surprisingly, the BARF1 gene was capable of:activating anti-apoptotic Bcl-2 expression and this activation was due to the N-terminal transforming region. These data suggest that the cooperation of BARF1 with Bcl-2 is essential for the induction of malignant transformation.	Univ Lyon 1, Fac Med RTH Laennec, Mol Virol Lab, CNRS,UMR 5537, F-69372 Lyon 08, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ooka, T (corresponding author), Univ Lyon 1, Fac Med RTH Laennec, Mol Virol Lab, CNRS,UMR 5537, Rue Guillaume Paradin, F-69372 Lyon 08, France.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; de Turenne-Tessier M, 1997, VIRUS RES, V52, P73, DOI 10.1016/S0168-1702(97)00101-9; Decaussin G, 2000, CANCER RES, V60, P5584; DECAUSSIN G, 1995, J VIROL, V69, P7309, DOI 10.1128/JVI.69.11.7309-7314.1995; DETHE G, 1982, HERPESVIRUSES, V1, P25; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY; KLEIN G, 1973, HERPESVIRUSES, P521; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OOKA T, 1991, SPRINGER SEMIN IMMUN, V13, P233, DOI 10.1007/BF00201471; OOKA T, 1983, J VIROL, V46, P187, DOI 10.1128/JVI.46.1.187-195.1983; OOKA T, 1980, VIROLOGY, V104, P219, DOI 10.1016/0042-6822(80)90379-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; RICKINSON AB, 1996, FIELDS VIROLOGY, V2, P2396; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SbihLammali F, 1996, VIROLOGY, V222, P64, DOI 10.1006/viro.1996.0398; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; STOCKBINE LD, 1998, J VIROL, V72, P4015; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; TAO Q, 1994, J CLIN PATHOL, V47, P589, DOI 10.1136/jcp.47.7.589; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988; zur Hausen A, 2000, CANCER RES, V60, P2745	54	62	70	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1176	1185		10.1038/sj.onc.1204217	http://dx.doi.org/10.1038/sj.onc.1204217			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313861				2022-12-28	WOS:000167570100004
J	Mitsutake, N; Namba, H; Shklyaev, SS; Tsukazaki, T; Ohtsuru, A; Ohba, M; Kuroki, T; Ayabe, H; Yamashita, S				Mitsutake, N; Namba, H; Shklyaev, SS; Tsukazaki, T; Ohtsuru, A; Ohba, M; Kuroki, T; Ayabe, H; Yamashita, S			PKC delta mediates ionizing radiation-induced activation of c-Jun NH2-terminal kinase through MKK7 in human thyroid cells	ONCOGENE			English	Article						PKC delta; JNK; MKK7; thyroid cell; ionizing radiation	SIGNAL-TRANSDUCTION PATHWAYS; CERAMIDE-INDUCED APOPTOSIS; N-TERMINAL KINASE; KIDNEY 293 CELLS; PROTEIN-KINASE; MAP KINASE; TYROSINE KINASE; PROTEOLYTIC ACTIVATION; REGULATED KINASE; ISOFORMS	The thyroid gland is one of the most sensitive organs in ionizing radiation (IR)-induced carcinogenesis. To determine, therefore, the specific cascade of IR-induced signal transduction in human thyroid cells, we investigated the functional role of protein kinase C (PKC), especially its interlocking activation of c-Jun NH2-terminal kinase (JNK) pathway. In the present study, using adenovirus expression vectors for diverse dominant-negative (DN) types of PKC isoforms (alpha, beta2, delta, epsilon and zeta) expressed in primary cultured human thyroid cells, only DN/PKC delta suppressed IR-induced JNK activation. In addition, Rottlerin, a PKC delta specific inhibitor, inhibited IR-induced JNK activation. IR-induced activation of transcription factor AP-1, downstream target of JNK, was also attenuated by DN/PKC delta. To examine the involvement of upstream kinases of JNK, we performed immune-complex kinase assays of mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. IR activated MKK7 but not MKK4, and this activation was inhibited by Rottlerin. Furthermore, IR-induced JNK activation was suppressed by overexpression of kinase-deficient MKK7. Our results indicate that IR selectively activates the cascade of PKC delta -MKK7-JNK-AP-1 in human thyroid cells, suggesting a not apoptotic but radio-resistant role of PKC delta in human thyroid cells following IR.	Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Surg 1, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Anat 1, Nagasaki 8528523, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Showa University	Namba, H (corresponding author), Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan.		Mitsutake, Norisato/U-9626-2018; Kuroki, Toshio/A-9500-2011; Yamashita, Shunichi/GVS-9508-2022	Mitsutake, Norisato/0000-0002-2744-8046; Kuroki, Toshio/0000-0001-6369-4351; Yamashita, Shunichi/0000-0001-6399-6261				Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hara T, 1998, BIOCHEM BIOPH RES CO, V244, P41, DOI 10.1006/bbrc.1998.8210; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KAWABE Y, 1989, J CLIN ENDOCR METAB, V68, P1174, DOI 10.1210/jcem-68-6-1174; Kawakami Y, 1998, J IMMUNOL, V161, P1795; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NAMBA H, 1995, CANCER RES, V55, P2075; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sautin Y, 2000, THYROID, V10, P733, DOI 10.1089/thy.2000.10.733; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WANG XD, 1995, THYROID, V5, P137, DOI 10.1089/thy.1995.5.137; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xu X, 1996, ONCOGENE, V13, P135; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	54	58	61	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					989	996		10.1038/sj.onc.1204179	http://dx.doi.org/10.1038/sj.onc.1204179			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314034				2022-12-28	WOS:000167097000010
J	Sablina, AA; Chumakov, PM; Levine, AJ; Kopnin, BP				Sablina, AA; Chumakov, PM; Levine, AJ; Kopnin, BP			p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling	ONCOGENE			English	Article						p53; cell cycle checkpoints; cell adhesion; microtubules	CELL-CYCLE CHECKPOINT; TUMOR-SUPPRESSOR P53; FOCAL ADHESIONS; DNA-DAMAGE; PHOSPHORYLATE P53; PROTEIN-KINASE; BAX GENE; IN-VIVO; PATHWAYS; ARREST	The p53 tumor suppressor is activated in response to various stresses driving the cells into growth arrest or apoptosis. We have addressed the question of how disintegration of microtubule system induces activation of p53. Depolymerization of microtubules by colcemid in rat and human quiescent fibroblasts resulted in accumulation of transcriptionally active p53 that caused cell-cycle arrest at the G1/S boundary. The p53 activation correlated with prominent activation of Erk1/2 MAP kinases that resulted from colcemid-stimulated development of focal adhesions. Inhibition of focal contacts development hy plating of cells onto poly-L-lysine abrogated both Erk1/2 and p53 activations in colcemid-treated cells, while plating of cells onto fibronectin caused transient up-regulation of p53 even in the absence of colcemid. Pre-treatment of cells with the specific MEK1 inhibitor PD098059 also attenuated colcemid-induced p53 activation and G1 cell cycle arrest. Cell types which either failed to develop focal adhesions in response to colcemid treatment (human MCF-7 epithelial cells), or lacked colcemid-induced sustained Erk activation (primary mouse embryo fibroblasts and 12(1) cells) showed virtually no p53 up-regulation in response to disruption of microtubules during G0/G1. Our results indicate that p53 activation is not triggered by disintegration of microtubule system by itself, but rather originates from some of the consequences of such disintegration, in particular, from the development of focal adhesions leading to activation of Erk signaling pathway.	Russian Canc Res Ctr, Inst Cancerogenesis, Moscow, Russia; RAS, VA Engelhardt Mol Biol Inst, Moscow, Russia; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Princeton University	Chumakov, PM (corresponding author), RAS, VA Engelhardt Mol Biol Inst, Moscow, Russia.		Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019; Sablina, Anna/P-2818-2019; Sablina, Anna/B-2217-2017	Kopnin, Boris/0000-0003-3100-2212; Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; Chehab NH, 2000, GENE DEV, V14, P278; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Harris CC, 1996, ENVIRON HEALTH PERSP, V104, P435, DOI 10.2307/3432799; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Khan SH, 1998, CANCER RES, V58, P396; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pletjushkina OJ, 1998, CELL ADHES COMMUN, V5, P121, DOI 10.3109/15419069809040286; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; RITTLING SR, 1992, ONCOGENE, V7, P935; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; Sablina AA, 1998, J CELL SCI, V111, P977; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542	45	51	54	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					899	909		10.1038/sj.onc.1204156	http://dx.doi.org/10.1038/sj.onc.1204156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314025				2022-12-28	WOS:000167097000001
J	Inagaki-Ohara, K; Yada, S; Takamura, N; Reaves, M; Yu, XH; Liu, ER; Rooney, I; Nicholas, S; Castro, A; Ware, CF; Green, DR; Lin, T				Inagaki-Ohara, K; Yada, S; Takamura, N; Reaves, M; Yu, XH; Liu, ER; Rooney, I; Nicholas, S; Castro, A; Ware, CF; Green, DR; Lin, T			p53-dependent radiation-induced crypt intestinal epithelial cells apoptosis is mediated in part through TNF-TNFR1 system	ONCOGENE			English	Article						apoptosis; intestinal epithelial cells; p53; TNF	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; FAS LIGAND EXPRESSION; VERSUS-HOST DISEASE; IN-VIVO; INTRAEPITHELIAL LYMPHOCYTES; GASTROINTESTINAL-TRACT; IONIZING-RADIATION; GAMMA-IRRADIATION; DNA DAMAGE	Radiation induces apoptosis of crypt intestinal epithelial cells (IEC) through a pathway that is largely dependent on p53. However, exactly how p53 mediates IEC apoptosis is unclear, Studies irt vitro suggest that one mechanism by which p53 mediates apoptosis is through its ability to transactivate members of the TNF receptor family of (Death Receptors', Here, we examined the role of one of its member, TNF receptor type 1 (TNFR1), in an in viva model of p53-dependent radiation-induced LEC apoptosis, We demonstrate that mice genetically engineered to be deficient in TNF receptor type 1 (TNFR1(-/-)) and mice injected with TNFR1-fusion chimeric protein (TNFR1-Fc; a competitive inhibitor of TNFR1) were partially protected (30-40%) from p53-dependent radiation-induced IEC apoptosis, However, we found no evidence to support the possibility p53 transcriptionally regulates the expression of TNFR1 nor increases the susceptibility of TEC to TNF-mediated apoptosis, Interestingly, we found that injection of TNF readily induced LEC apoptosis and that radiation induced a p53-dependent increase in the intestinal level of TNF. Furthermore, injection of a neutralizing anti-TNF mAb reduced p53-dependent radiation-induced IEC apoptosis by approximately 60%. Overall, these results suggest that p53-dependent radiation-induced IEC apoptosis is mediated in part through ability of p53 to regulate TNF, which subsequently induces IEC apoptosis through TNFR1.	Northwestern Univ, Sch Med, Dept Med, Gastroenterol Sect, Chicago, IL 60611 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	Northwestern University; La Jolla Institute for Immunology; La Jolla Institute for Immunology	Lin, T (corresponding author), Northwestern Univ, Sch Med, Dept Med, Gastroenterol Sect, Chicago, IL 60611 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI 44828] Funding Source: Medline; NIDDK NIH HHS [DK02445, DK56605-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056605, K08DK002445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; GALLAND RB, 1987, BRIT J SURG, V74, P742, DOI 10.1002/bjs.1800740833; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; Higgins LM, 1999, J IMMUNOL, V162, P486; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; InagakiOhara K, 1997, EUR J IMMUNOL, V27, P2885, DOI 10.1002/eji.1830271121; IWAMOTO KS, 1994, RADIAT RES, V139, P103, DOI 10.2307/3578739; KASTAN MB, 1991, CANCER RES, V51, P6304; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYASHITA T, 1995, CELL, V80, P293; NOVAK JM, 1979, J CLIN GASTROENTEROL, V1, P9, DOI 10.1097/00004836-197903000-00003; Piguet PF, 1998, EUR J IMMUNOL, V28, P3499, DOI 10.1002/(SICI)1521-4141(199811)28:11<3499::AID-IMMU3499>3.0.CO;2-Q; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sheikh MS, 1998, CANCER RES, V58, P1593; Shiraishi M, 1998, WORLD J SURG, V22, P491, DOI 10.1007/s002689900422; VAN AD, 1996, SCIENCE, V274, P787; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	38	22	25	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					812	818		10.1038/sj.onc.1204172	http://dx.doi.org/10.1038/sj.onc.1204172			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314015				2022-12-28	WOS:000166924400004
J	Sibley, K; Cuthbert-Heavens, D; Knowles, MA				Sibley, K; Cuthbert-Heavens, D; Knowles, MA			Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma	ONCOGENE			English	Article						bladder; cancer; FGFR3; mutation	GROWTH-FACTOR RECEPTOR-3; BLADDER-CARCINOMA; URINARY-BLADDER; ACTIVATING MUTATIONS; INCREASED EXPRESSION; CHROMOSOME PATTERN; MULTIPLE-MYELOMA; TISSUE-CULTURE; ALLELIC LOSS; NUDE-MICE	4p16,3 has previously been identified as a region of nonrandom LOH in transitional cell carcinoma, suggesting the presence of a tumour suppressor gene. One candidate within this region is fibroblast growth factor receptor 3 (FGFR3). Germline mutations in FGFR3 are known to cause several autosomal dominant skeletal dysplasias, the severity of which depends on the position and nature of the mutation in the protein. We investigated the frequency and nature of FGFR3 mutations in a panel of transitional cell carcinomas and cell lines and studied the possible link between mutation and loss of heterozygosity (LOH) on 4p16.3. FGFR3 coding sequence from 63 transitional cell carcinomas (TCC) of various stages and grades, and 18 cell lines,vas analysed by fluorescent SSCP, Samples with abnormal migration patterns were sequenced to identify the mutation or polymorphism. Thirty-one of the 63 tumours had previously been assessed to have LOH at 4p16,3, Twenty -six of the 63 tumours (41%) and 4/18 (22%) of the cell lines had missense mutations in FGFR3. All mutations detected in our panel have been reported in the germline where all apart from one cause lethal conditions. One tumour contained K652Q which has recently been identified in less severe cases of skeletal dysplasia. Tumours with and without LOH at 4p16,3 had mutations in FGFR3 suggesting that these tno events are not causally linked. The frequency of FGFR3 mutation indicates that this protein plays an important role in TCC.	St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin Canc, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Imperial Canc Res Fund, Mutat Detect Family, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin Canc, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Heavens, Darren/0000-0001-5418-7868; Knowles, Margaret/0000-0002-9363-8657				Antonarakis SE, 1998, HUM MUTAT, V11, P1; BELLUS GA, 2000, IN PRESS AM J HUM GE; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Caron H, 1996, HUM GENET, V97, P834; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; ELDER PA, 1994, ONCOGENE, V9, P3433; ELLIOTT AY, 1974, JNCI-J NATL CANCER I, V53, P1341, DOI 10.1093/jnci/53.5.1341; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GEY GO, 1952, CANCER RES, V12, P264; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hadano S, 1998, DNA Res, V5, P177, DOI 10.1093/dnares/5.3.177; HASTINGS RJ, 1981, INT J CANCER, V27, P15, DOI 10.1002/ijc.2910270104; *HMSO, 1994, CANC REG STAT; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; KNOWLES MA, 1994, CANCER RES, V54, P531; KYRIAZIS AA, 1984, CANCER RES, V44, P3997; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; Mostofi FK, 1973, HISTOLOGICAL TYPING; NAWROZ H, 1994, CANCER RES, V54, P1152; Onose H, 1999, EUR J ENDOCRINOL, V140, P169, DOI 10.1530/eje.0.1400169; OTOOLE C, 1978, BRIT J CANCER, V38, P64, DOI 10.1038/bjc.1978.164; OTOOLE C, 1976, INT J CANCER, V17, P707, DOI 10.1002/ijc.2910170604; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PAULI BU, 1983, J UROLOGY, V129, P646, DOI 10.1016/S0022-5347(17)52271-5; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; POLASCIK TJ, 1995, CANCER RES, V55, P5396; Pribill I, 1997, SOMAT CELL MOLEC GEN, V23, P413, DOI 10.1007/BF02673751; RASHEED S, 1977, J NATL CANCER I, V58, P881, DOI 10.1093/jnci/58.4.881; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SATO T, 1991, CANCER RES, V51, P5118; Shivapurkar N, 1999, CANCER RES, V59, P3576; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Tartaglia M, 1998, MOL CELL PROBE, V12, P335, DOI 10.1006/mcpr.1998.0189; *UICC, 1978, CLASS MAL TUM BLADD; VILIEN M, 1983, EUR J CANCER CLIN ON, V19, P775, DOI 10.1016/0277-5379(83)90010-X; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WILLIAMS RD, 1980, INVEST UROL, V17, P359; Yustein AS, 1999, CANCER RES, V59, P1437; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149	51	89	92	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					686	691		10.1038/sj.onc.1204110	http://dx.doi.org/10.1038/sj.onc.1204110			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314002				2022-12-28	WOS:000166806000004
J	Hubinger, G; Muller, E; Scheffrahn, I; Schneider, C; Hildt, E; Singer, BB; Sigg, I; Graf, J; Bergmann, L				Hubinger, G; Muller, E; Scheffrahn, I; Schneider, C; Hildt, E; Singer, BB; Sigg, I; Graf, J; Bergmann, L			CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299	ONCOGENE			English	Article						CD30; TNF receptor; cell cycle arrest; anaplastic large cell lymphoma (ALCL)	TNF RECEPTOR SUPERFAMILY; KAPPA-B ACTIVATION; NEGATIVE SELECTION; HODGKINS-DISEASE; FACTORS TRAFS; T-CELLS; DEATH; APOPTOSIS; INDUCTION; CD30	One of the major characteristics of anaplastic large cell lymphomas (ALCL) is the expression of the Ki-1/CD30 antigen. While the receptor mediates NF-kappaB-activation in Hodgkin's lymphomas, some data suggest the CD30-mediated apoptosis of other CD30-expressing cells. We were able to demonstrate that activation of CD30 leads to different effects regarding cell proliferation of the ALCL-derived cell lines Karpas 299 and JB6, Western and Northern blotting analysis re, revealed that CD30-induced growth inhibition of Karpas 299 cells correlated with a strong upregulation of the cell cycle inhibitor p21(CIP1/WAF1). We found a non activating point mutation at codon 273 in exon 8 of the p53 gene in Karpas 299 cells which indicates an p53-independent mechanism for induced p21 expression. Abundant p21 protein expression resulted in hypophosphorylation of the retinoblastoma protein (Rb) and inhibition of the proliferating cell nuclear antigen (PCNA). CD30-stimulated cells showed no indications of apoptotic cell death, like genomic DNA fragmentation or cleavage of the caspase3 target protein poly (ADP-ribose) polymerase (PARP), Our results indicate that CD30 is able to mediate an p21-associated cell cycle arrest in ALCL with possible implications for prognosis and clinical treatment.	Karolinska Inst, Dept Cellular & Mol Biol, Stockholm, Sweden; Robert Koch Inst, Dept Mol Biol, D-1000 Berlin, Germany; Univ Frankfurt, Dept Internal Med 3, D-6000 Frankfurt, Germany; Univ Ulm, Dept Internal Med 3, Ulm, Germany	Karolinska Institutet; Robert Koch Institute; Goethe University Frankfurt; Ulm University	Hubinger, G (corresponding author), Univ Ulm Klinikum, Dept Internal Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.		Singer, Bernhard B./AAP-9999-2020; Hildt, Eberhard/A-1040-2015					Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baker SJ, 1996, ONCOGENE, V12, P1; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chiarle R, 1999, J IMMUNOL, V163, P194; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FALINI B, 1995, BLOOD, V85, P1; Givol I, 1998, ONCOGENE, V16, P3115, DOI 10.1038/sj.onc.1201849; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Marches R, 1999, P NATL ACAD SCI USA, V96, P8711, DOI 10.1073/pnas.96.15.8711; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Singer BB, 2000, CANCER RES, V60, P1236; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	37	51	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					590	598		10.1038/sj.onc.1204128	http://dx.doi.org/10.1038/sj.onc.1204128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313991				2022-12-28	WOS:000166755000006
J	Monaco, C; Visconti, R; Barone, MV; Pierantoni, GM; Berlingieri, MT; De Lorenzo, C; Mineo, A; Vecchio, G; Fusco, A; Santoro, M				Monaco, C; Visconti, R; Barone, MV; Pierantoni, GM; Berlingieri, MT; De Lorenzo, C; Mineo, A; Vecchio, G; Fusco, A; Santoro, M			The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane	ONCOGENE			English	Article						tyrosine kinase; transformation; thyroid; coiled coil; dimerization	THYROID PAPILLARY CARCINOMAS; A ANCHORING PROTEIN; TYROSINE KINASE; MOLECULAR CHARACTERIZATION; REARRANGED FORM; ONCOGENE; GENE; PROTOONCOGENE; RECEPTOR; COACTIVATOR	The RET/PTC3 oncogene arises from the fusion between the N-terminal encoding domain of the RFG gene and the tyrosine kinase encoding domain of RET receptor, RET/PTC3 is,very frequent in papillary thyroid carcinomas, especially in children exposed to the Chernobyl accident. We have studied the functional consequences of the RFG - RET fusion, Here we show, that the N-terminal coiled-coil domain of RGF mediates oligomerization and activation of the kinase and of the transforming capability of RET/PTC3, In addition, the RFG coiled-coil domain mediates a physical association between RET/PTC3 and RGF proteins, rendering RFG a bona fide substrate of RET/PTC3 kinase, Finally, we show that the coiled-coil domain of RGF is essential for the distribution of the RET/PTC3 protein at the membrane/particulate cell compartment level, where also most of the RFG protein is localized. We propose that fusion to the RFG coiled-coil domain provides RET kinase with a scaffold that mediates oligomerization and re-localization of the RET/PTC3 protein, a process that may be crucial for the signalling of this specific RET/PTC variant.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dept Organ & Biol Chem, I-80134 Naples, Italy; Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		Pierantoni, Giovanna Maria/O-7527-2015; Visconti, Roberta/C-5299-2009	Pierantoni, Giovanna Maria/0000-0003-4078-8528; De Lorenzo, Claudia/0000-0002-6195-5631; BARONE, Maria Vittoria/0000-0001-6190-4917; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1998, ONCOGENE, V16, P671, DOI 10.1038/sj.onc.1201526; Klugbauer S, 1998, CANCER RES, V58, P198; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierotti MA, 1998, RECENT RES CANCER, V154, P237; Powell DJ, 1998, CANCER RES, V58, P5523; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Salassidis K, 2000, CANCER RES, V60, P2786; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; Tong Q, 1997, J BIOL CHEM, V272, P9043; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	33	43	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					599	608		10.1038/sj.onc.1204127	http://dx.doi.org/10.1038/sj.onc.1204127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313992				2022-12-28	WOS:000166755000007
J	Stivala, LA; Riva, F; Cazzalini, O; Savio, M; Prosperi, E				Stivala, LA; Riva, F; Cazzalini, O; Savio, M; Prosperi, E			p21(waf1/cip1)-null human fibroblasts are deficient in nucleotide excision repair downstream the recruitment of PCNA to DNA repair sites	ONCOGENE			English	Article						p21(waf1/cip1); nucleotide excision repair; PCNA; p21-null fibroblasts	CELL NUCLEAR ANTIGEN; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION-COUPLED REPAIR; AGENTS 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; ULTRAVIOLET-IRRADIATION; QUIESCENT FIBROBLASTS; GLIOBLASTOMA CELLS; COMPLEX-FORMATION; POLYMERASE-DELTA; BINDING DOMAINS	The cyclin-dependent kinase inhibitor p21(waf1/cip1) is known to impair DNA synthesis by binding to PCNA, the cofactor of DNA polymerases delta and epsilon. However, a positive role for p21 in nucleotide excision repair (NER) has been suggested. In this study, the sensitivity to DNA damage and DNA repair efficiency were investigated in p21-null human fibroblasts obtained by targeted homologous recombination. After UV-C irradiation, p21(sic) cells showed a threefold reduction in clonogenic survival and an increased susceptibility to apoptosis, as compared with parental p21(+/+) cells. Removal of cyclobutane pyrimidine dimers was significantly reduced in p21(-/-) cells both in the whole genome, and at the level of the rDNA gene cluster, as determined by immunoassay and Southern blot, respectively. After DNA damage, the recruitment of PCNA as detergent-insoluble form associated to DNA repair sites in p21(sic) fibroblasts, was comparable to that observed in parental p21(+/+) cells, However, PCNA remained associated with DNA for a longer period in p21(sic) than in p21(+/+) cells, These results suggest that in human cells, p21 is required for NER at a step located downstream the recruitment of PCNA to DNA repair sites.	CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Pavia	Prosperi, E (corresponding author), CNR, Ctr Studio Istochim, Piazza Botta 10, I-27100 Pavia, Italy.		Prosperi, Ennio/A-3439-2014	Prosperi, Ennio/0000-0001-5391-5157				ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fotedar R, 1996, ONCOGENE, V12, P2155; Fritz LK, 1996, J BIOL CHEM, V271, P12972, DOI 10.1074/jbc.271.22.12972; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MITCHELL DL, 1990, BIOESSAYS, V12, P74, DOI 10.1002/bies.950120205; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; Ruan S, 1998, CANCER RES, V58, P1538; Ruan SB, 1999, CLIN CANCER RES, V5, P197; Savio M, 1996, ONCOGENE, V13, P1591; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Van Sloun PPH, 1999, NUCLEIC ACIDS RES, V27, P3276, DOI 10.1093/nar/27.16.3276; VINK AA, 1994, J PHOTOCH PHOTOBIO B, V24, P25, DOI 10.1016/1011-1344(94)07005-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	58	44	44	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					563	570		10.1038/sj.onc.1204132	http://dx.doi.org/10.1038/sj.onc.1204132			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313988				2022-12-28	WOS:000166755000003
J	Champagne, N; Pelletier, N; Yang, XJ				Champagne, N; Pelletier, N; Yang, XJ			The monocytic leukemia zinc finger protein MOZ is is histone acetyltransferase	ONCOGENE			English	Article						histone acetyltransferase; MYST; MOZ; MORF; leukemia	ACUTE MYELOID-LEUKEMIA; CREB-BINDING-PROTEIN; HUMAN GENES; CBP; YEAST; FUSION; MLL; TRANSCRIPTION; TRANSLOCATION; COACTIVATOR	The monocytic leukemia zinc finger protein (MOZ) gene is rearranged in t(8;16)(p11;p13), t(8;22)(p11;q13) and inv(8)(p11q13) associated with acute myeloid leukemia. The other fusion partners involved are CBP, p300 and TIF2, transcriptional coactivators with known or potential histone acetyltransferase (HAT) activity. MOZ itself is a 2004-residue protein containing a putative acetyl CoA-binding motif, so it was hypothesized that MOZ is a HAT. Here we present direct evidence that MOZ has intrinsic HAT activity. Moreover, MOZ possesses a transcriptional repression domain at its N-terminal part and an activation domain at its C-terminal part. The activation domain does not show sequence similarity to any yeast proteins, but when tethered, it is able to activate transcription in yeast. Therefore, MOZ is a HAT with characteristics of a transcriptional coregulator, supporting the hypothesis that aberrant acetylation by abnormal MOZ proteins leads to leukemogenesis.	McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	McGill University	Yang, XJ (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada.							Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; John S, 2000, GENE DEV, V14, P1196; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Thomas T, 2000, DEVELOPMENT, V127, P2537; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	46	95	98	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					404	409		10.1038/sj.onc.1204114	http://dx.doi.org/10.1038/sj.onc.1204114			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313971				2022-12-28	WOS:000166411000016
J	Harari, D; Yarden, Y				Harari, D; Yarden, Y			Molecular mechanisms underlying ErbB2/HER2 action in breast cancer	ONCOGENE			English	Review						carcinoma; growth factor; signal transduction; tyrosine kinase; cyclin D1; Waf1	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; RECEPTOR TYROSINE KINASES; INHIBITORY MONOCLONAL-ANTIBODIES; HEREGULIN INDUCES APOPTOSIS; MAMMARY-GLAND DEVELOPMENT; ERBB SIGNALING NETWORK; CELL-CYCLE ARREST; NIH 3T3 CELLS; EGF RECEPTOR	Overexpression of ErbB2, a receptor-like tyrosine kinase, is shared by several types of human carcinomas. In breast tumors the extent of overexpression has a prognostic value, thus identifying the oncoprotein as a target for therapeutic strategies. Already, antibodies to ErbB2 are used in combination with chemotherapy in the treatment of metastasizing breast cancer. The mechanisms underlying the oncogenic action of ErbB2 involve a complex network in which ErbB2 acts as a ligand-less signaling subunit of three other receptors that directly bind a large repertoire of stroma-derived growth factors. The major partners of ErbB2 in carcinomas are ErbB1 (also called EGFR) and ErbB3, a kinase-defective receptor whose potent mitogenic action is activated in the context of heterodimeric complexes. Why ErbB2-containing heterodimers are relatively oncopotent is a function of a number of processes. Apparently, these heterodimers evade normal inactivation processes, by decreasing the rate of ligand dissociation, internalizing relatively slowly and avoiding the degradative pathway by returning to the cell surface. On the other hand, the heterodimers strongly recruit survival and mitogenic pathways such as the mitogen-activated protein kinases and the phosphatidylinositol 3-kinase. Hyper-activated signaling through the ErbB-signaling network results in dysregulation of the cell cycle homeostatic machinery, with upregulation of active cyclin-D/CDK complexes. Recent data indicate that cell cycle regulators are also linked to chemoresistance in ErbB2-dependent breast carcinoma. Together with D-type cyclins, it seems that the CDK inhibitor p21(Waf1) plays an important role in evasion from apoptosis. These recent findings herald a preliminary understanding of the output layer which connects elevated ErbB-signaling to oncogenesis and chemoresistance.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012					Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Alroy I, 1999, MOL CELL BIOL, V19, P1961; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bacus SS, 1996, ONCOGENE, V12, P2535; Bacus SS, 1996, AM J PATHOL, V148, P549; BACUS SS, 1992, CANCER RES, V52, P2580; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARNES DM, 1992, EUR J CANCER, V28A, P644, DOI 10.1016/S0959-8049(05)80117-0; Barsky SH, 1997, J PATHOL, V183, P188; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BATTAGLIA F, 1988, ONCOLOGY, V45, P424, DOI 10.1159/000226658; Baulida J, 1996, J BIOL CHEM, V271, P5251; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BROWER ST, 1995, ANN SURG ONCOL, V2, P440, DOI 10.1007/BF02306378; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burris HA, 2000, SEMIN ONCOL, V27, P19; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; CIARDIELLO F, 1991, ANN ONCOL, V2, P169; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Cohen BM, 1996, J BIOL CHEM, V271, P4813; Courjal F, 1996, INT J CANCER, V69, P247; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Czubayko F, 1997, GENE THER, V4, P943, DOI 10.1038/sj.gt.3300483; Daly JM, 1997, CANCER RES, V57, P3804; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Digiuseppe JA, 1999, IN VIVO, V13, P1; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; FLANAGAN JG, 1988, P NATL ACAD SCI USA, V85, P8057, DOI 10.1073/pnas.85.21.8057; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GASPARINI G, 1994, EUR J CANCER, V30A, P16, DOI 10.1016/S0959-8049(05)80010-3; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GIAI M, 1994, ANTICANCER RES, V14, P1441; GILLETT C, 1994, CANCER RES, V54, P1812; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Harris A L, 1992, J Natl Cancer Inst Monogr, P181; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; JONGEWARD GD, 1995, GENETICS, V139, P1553; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPRZYK PG, 1992, CANCER RES, V52, P2771; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klapper LN, 2000, CANCER RES, V60, P3384; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Krane IM, 1996, ONCOGENE, V12, P1781; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; LONARDO F, 1990, New Biologist, V2, P992; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; LUNDY J, 1991, AM J PATHOL, V138, P1527; Mack L, 1997, HUM PATHOL, V28, P974, DOI 10.1016/S0046-8177(97)90014-9; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Mueller H, 1995, BIOCHEM BIOPH RES CO, V217, P1271, DOI 10.1006/bbrc.1995.2905; Naidu R, 1998, BRIT J CANCER, V78, P1385, DOI 10.1038/bjc.1998.689; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Newby JC, 1997, CLIN CANCER RES, V3, P1643; Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; OConnor PM, 1997, CANCER RES, V57, P4285; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Petit AMV, 1997, AM J PATHOL, V151, P1523; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Pietras RJ, 1999, CANCER RES, V59, P1347; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QUINN CM, 1994, HISTOPATHOLOGY, V25, P247, DOI 10.1111/j.1365-2559.1994.tb01324.x; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; ROUXDOSSETO M, 1989, BIOMED PHARMACOTHER, V43, P641, DOI 10.1016/0753-3322(89)90082-6; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Sjogren S, 1998, J CLIN ONCOL, V16, P462; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; SORKIN A, 1993, ONCOGENE, V8, P3021; Srinivasan R, 2000, CANCER RES, V60, P1483; Tang CK, 1996, CANCER RES, V56, P3350; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Torregrosa D, 1997, CLIN CHIM ACTA, V262, P99, DOI 10.1016/S0009-8981(97)06542-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Travis A, 1996, BRIT J CANCER, V74, P229, DOI 10.1038/bjc.1996.342; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VanAgthoven T, 1995, INT J CANCER, V63, P790, DOI 10.1002/ijc.2910630607; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Vogt U, 1998, GENE, V223, P375, DOI 10.1016/S0378-1119(98)00454-5; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Xia WY, 1999, CLIN CANCER RES, V5, P4164; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319; Yu DH, 1998, ONCOGENE, V16, P2087, DOI 10.1038/sj.onc.1201729; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	197	440	504	1	63	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6102	6114		10.1038/sj.onc.1203973	http://dx.doi.org/10.1038/sj.onc.1203973			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156523				2022-12-28	WOS:000166121400003
J	Pizon, V; Baldacci, G				Pizon, V; Baldacci, G			Rap1A protein interferes with various MAP kinase activating pathways in skeletal myogenic cells	ONCOGENE			English	Article						Rap1A; Ras-like protein; MAP kinases; myogenic differentiation	FIBROBLAST GROWTH-FACTOR; RAS-DEPENDENT ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE DIFFERENTIATION; INDEPENDENT PATHWAYS; HUMAN-PLATELETS; IN-VITRO; C-ZETA; SPECIFICITY; RECEPTOR	Constitutive expression of the activated Rap1A protein inhibits differentiation of myogenic C2 cells whereas the inactivated Rap1A protein favours cell differentiation and induces late endocytic compartments clustering. Although the role of Rap1A in MAPK activation has been analysed in various cell;types, the signalling pathways activated by Rap1A have not been explored in myogenic cells. In this study, me investigated MAP kinase activity in control C2 myoblasts and in stable C2 cell lines expressing mutated Rap1A proteins. We provide evidence that Rap1A mutants promote ERK activation and that the active protein induces a more sustained activation than the inactive protein. In addition, we established that various pathways mediate transient ERK activation in control cells and in cells expressing the inactivated Rap1A protein. In these cells, ERK are activated by a Raf/MEK-dependent pathway, a PI3K/Raf-independent pathway and a third undetermined pathway. In cells expressing the activated Rap1A protein, a PI3K/Raf/MEK-dependent pathway mediates transient ERK activation. However, MAPK activation appears more complex since, according to the state of the myoblasts or the duration of MAPK stimulation, we observed that Rap1A protein could interfere or not with ERK activation.	Inst Andre Lwoff, UPR 1983, F-94801 Villejuif, France; Univ Paris Sud, Inst Curie, UMR 2027, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Pizon, V (corresponding author), Inst Andre Lwoff, UPR 1983, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.		Pizon, Veronique/M-5590-2018	Pizon, Veronique/0000-0003-3596-8313				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; Dremier S, 2000, BIOCHEM BIOPH RES CO, V267, P7, DOI 10.1006/bbrc.1999.1919; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; PIZON V, 1994, J CELL SCI, V107, P1661; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TOKER A, 1994, J BIOL CHEM, V269, P32358; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YANO H, 1993, J BIOL CHEM, V268, P25846; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	47	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6074	6081		10.1038/sj.onc.1203984	http://dx.doi.org/10.1038/sj.onc.1203984			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146560				2022-12-28	WOS:000165827900015
J	Leone, A; Mitsiades, N; Ward, Y; Spinelli, B; Poulaki, V; Tsokos, M; Kelly, K				Leone, A; Mitsiades, N; Ward, Y; Spinelli, B; Poulaki, V; Tsokos, M; Kelly, K			The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma	ONCOGENE			English	Article						Gem; neuroblastoma; ganglia; morphology; RGK proteins; cytoskeleton	RAS-FAMILY; MEMBER; CELLS; PHOSPHORYLATION; ACTIVATION; KIR; REM	Gem is a small GTP-binding protein within the Ras superfamily whose function has not been determined. We report here that ectopic Gem expression is sufficient to stimulate cell flattening and neurite extension in N1E-115 and SH-SY5Y neuroblastoma cells, suggesting a role for Gem in cytoskeletal rearrangement and/or morphological differentiation of neurons. Consistent with this potential function, in clinical samples of neuroblastoma, Gem protein was most highly expressed within cells which had differentiated to express ganglionic morphology. Gem was also observed in developing trigeminal nerve ganglia in 12.5 day mouse embryos, demonstrating that Gem expression is a property of normal ganglionic development. Although Gem expression is rare in epithelial and hematopoietic cancer cell lines, constitutive Gem levels were detected in several neuroblastoma cell lines and could be further induced as much as 10-fold following treatment with PMA or the acetylcholine muscarinic agonist, carbachol.	NCI, Div Clin Sci, Med Branch, Cell & Canc Biol Dept, Bethesda, MD 20892 USA; NCI, Pathol Lab, Div Clin Sci, Pediat Tumor Biol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kelly, K (corresponding author), NCI, Div Clin Sci, Med Branch, Cell & Canc Biol Dept, Bldg 10,Room 3B43,9000, Bethesda, MD 20892 USA.		Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 				AMBROS IM, 1995, EUR J CANCER, V31A, P429, DOI 10.1016/0959-8049(95)00051-J; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Cool RH, 1999, MOL CELL BIOL, V19, P6297; Dorin D, 1995, ONCOGENE, V11, P2267; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; HACHITANDA Y, 1994, HUM PATHOL, V25, P67, DOI 10.1016/0046-8177(94)90173-2; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Pan JY, 2000, J CELL BIOL, V149, P1107, DOI 10.1083/jcb.149.5.1107; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; SHIMADA H, 1985, HUM PATHOL, V16, P471, DOI 10.1016/S0046-8177(85)80085-X; Son JH, 1996, MOL BRAIN RES, V36, P300, DOI 10.1016/0169-328X(95)00255-Q; Vanhove B, 1997, ENDOTHELIUM-J ENDOTH, V5, P51, DOI 10.3109/10623329709044158; Wess J, 1997, LIFE SCI, V60, P1007, DOI 10.1016/S0024-3205(97)00041-6	21	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3217	3225		10.1038/sj.onc.1204420	http://dx.doi.org/10.1038/sj.onc.1204420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423971				2022-12-28	WOS:000169163500005
J	Barton, MC; Crowe, AJ				Barton, MC; Crowe, AJ			Chromatin alteration, transcription and replication: What's the opening line to the story?	ONCOGENE			English	Review						chromatin; replication; transcription; polymerase; remodeling	RNA-POLYMERASE-II; CHROMOSOMAL DNA-REPLICATION; BETA-GLOBIN LOCUS; HISTONE ACETYLATION; REMODELING COMPLEX; INTERGENIC TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; TRANSCRIBING POLYMERASE; NUCLEOSOME STRUCTURE; ACTIVATION DOMAIN	Polymerase accessibility to chromatin is a limiting step in both RNA and DNA synthesis. Unwinding DNA and nucleosomes during polymerase complex binding and processing likely requires priming by chromatin restructuring. The initiating step in these processes remains an area of speculation, This review focuses on the physical handling of chromatin during transcription and replication, the fate of nucleosomes assembled on DNA during unwinding and processing the chromatin substrate, and how these alterations in chromatin structure may affect gene expression, Transcription or replication may alter chromatin structure during synthesis, enabling regulatory factor binding and, potentially, future rounds of transcription. As chromatin remodeling and transcription factor binding augment transcription and replication, and are themselves increased by these processes, a temporal model of structural alterations and gene activation is built that mag be more circular than linear.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Texas System; UTMD Anderson Cancer Center; University of Washington; University of Washington Seattle	Barton, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.			Barton, Michelle/0000-0002-4042-1374				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; BASTOS RN, 1977, CELL, V11, P641, DOI 10.1016/0092-8674(77)90081-2; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Brown SA, 1997, GENE DEV, V11, P3116, DOI 10.1101/gad.11.23.3116; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crowe AJ, 2000, MOL CELL BIOL, V20, P4169, DOI 10.1128/MCB.20.11.4169-4180.2000; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; Flanagan JF, 1999, NUCLEIC ACIDS RES, V27, P2022, DOI 10.1093/nar/27.9.2022; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROUDINE M, 1981, CELL, V24, P393, DOI 10.1016/0092-8674(81)90329-9; Groudine M, 1989, Prog Clin Biol Res, V316A, P15; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; IMAIZUMI T, 1973, P NATL ACAD SCI USA, V70, P1122, DOI 10.1073/pnas.70.4.1122; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kodadek T, 1998, TRENDS BIOCHEM SCI, V23, P79, DOI 10.1016/S0968-0004(97)01165-1; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Li R, 1999, J BIOL CHEM, V274, P30310, DOI 10.1074/jbc.274.42.30310; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; Litt MD, 1997, J BIOL CHEM, V272, P14921, DOI 10.1074/jbc.272.23.14921; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; Muller M, 2000, MOL CELL, V5, P767, DOI 10.1016/S1097-2765(00)80317-2; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Travers A, 1999, P NATL ACAD SCI USA, V96, P13634, DOI 10.1073/pnas.96.24.13634; Venturi CB, 2000, MOL CELL BIOL, V20, P6435, DOI 10.1128/MCB.20.17.6435-6448.2000; Verreault A, 2000, GENE DEV, V14, P1430; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; WOLFFE AP, 1991, J CELL SCI, V99, P201; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	67	13	13	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3094	3099		10.1038/sj.onc.1204334	http://dx.doi.org/10.1038/sj.onc.1204334			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420725				2022-12-28	WOS:000169308500013
J	Chene, P				Chene, P			The role of tetramerization in p53 function	ONCOGENE			English	Review						p53; tetramerization; cancer	TUMOR-SUPPRESSOR P53; DNA-BINDING DOMAIN; GAIN-OF-FUNCTION; FRAUMENI LIKE FAMILY; XENOPUS-LAEVIS P53; OLIGOMERIZATION DOMAIN; MUTANT P53; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; IN-VITRO	The tumour suppressor gene p53 is extensively studied for its importance in cancer, In its active conformation, p53 is tetrameric and one domain - the tetramerization domain - permits the oligomerization of this protein. Until recently, little attention was given to this domain because, in contrast to the DNA-binding domain, it is not often mutated in cancer, However, various experimental studies have shown evidence that the tetramerization domain is essential for DNA binding, protein-protein interactions, post-translational modifications, and p53 degradation. Moreover, single mutations in the tetramerization domain can inactivate the wild-type protein in a manner similar to that seen with mutations in the DNA-binding domain, Interestingly, the phenotype of several tetramerization domain mutants differs from that observed with DNA-binding domain mutants. In this review, current knowledge about the importance of the tetramerization domain to the function of p53 will be summarized.	Novartis, CH-4002 Basel, Switzerland		Chene, P (corresponding author), Novartis, K125 420, CH-4002 Basel, Switzerland.							Appella E, 2000, PATHOL BIOL, V48, P227; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; Chene P, 2000, BIOTECHNIQUES, V28, P240; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; Chene P, 1999, J MOL BIOL, V288, P883, DOI 10.1006/jmbi.1999.2734; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ELIYAHU D, 1988, ONCOGENE, V3, P313; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; Hixon ML, 2000, HISTOL HISTOPATHOL, V15, P551, DOI 10.14670/HH-15.551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin Y, 1997, CANCER RES, V57, P5137; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Mateu MG, 1999, NAT STRUCT BIOL, V6, P191; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; McCoy M, 1997, EMBO J, V16, P6230, DOI 10.1093/emboj/16.20.6230; McLure KG, 1996, ONCOGENE, V13, P1297; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Rollenhagen C, 1998, INT J CANCER, V78, P372, DOI 10.1002/(SICI)1097-0215(19981029)78:3<372::AID-IJC19>3.0.CO;2-8; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SANG BC, 1994, ONCOGENE, V9, P853; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; Shieh SY, 2000, GENE DEV, V14, P289; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1990, ONCOGENE, V5, P945; Stavridi ES, 1999, PROTEIN SCI, V8, P1773, DOI 10.1110/ps.8.9.1773; Steele RJC, 1998, BRIT J SURG, V85, P1460; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SURRIDGE C, 1994, NATURE, V372, P482, DOI 10.1038/372482a0; TARUNINA M, 1993, ONCOGENE, V8, P3165; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Varley JM, 1996, ONCOGENE, V12, P2437; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, ONCOGENE, V10, P779; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; ZHANG W, 1994, ONCOGENE, V9, P2513	105	192	194	1	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2611	2617		10.1038/sj.onc.1204373	http://dx.doi.org/10.1038/sj.onc.1204373			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420672				2022-12-28	WOS:000168652600001
J	Herdegen, T; Waetzig, V				Herdegen, T; Waetzig, V			AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration	ONCOGENE			English	Review						Fos; JNK; JunD	N-TERMINAL KINASE; C-JUN EXPRESSION; SIGNAL-TRANSDUCTION PATHWAY; REPETITIVE ELECTROCONVULSIVE SEIZURES; CEREBELLAR GRANULE NEURONS; CEREBRAL-ARTERY OCCLUSION; RETINAL GANGLION-CELLS; IN-SITU HYBRIDIZATION; RAT-BRAIN; TRANSCRIPTION FACTORS	Jun and Fos proteins are induced and activated following most physiological and pathophysiological stimuli in the brain. Only few data allow conclusions about distinct functions of AP-1 proteins in neurodegeneration and neuroregeneration, and these functions mainly refer to c-Jun and its activation by JNKs, Apoptotic functions of activated c-Jun affect hippocampal, nigral and primary cultured neurons following excitotoxic stimulation and destruction of the neuron-target-axis including withdrawal of trophic molecules. The inhibition of JNKs might exert neuroprotection by subsequent omission of c-Jun activation. Besides endogenous neuronal functions, the c-Jun/AP-1 proteins can damage the nervous system by upregulation of harmful programs in non-neuronal cells (e,g, microglia) with release of neurodegenerative molecules. In contrast, the differentiation with neurite extension and maturation of neural cells in vitro indicate physiological and potentially neuroprotective functions of c-Jun and JNKs including sensoring for alterations in the cytoskeleton, This review summarizes the multiple molecular interfunctions which are involved in the shift from the physiological role to degenerative effects of the Jun/JNK-axis such as cell type-specific expression and intracellular localization of scaffold proteins and upstream activators, antagonistic phosphatases, interaction with other kinase systems, or the activation of transcription factors competing for binding to JNK proteins and AP-1 DNA elements.	Inst Pharmacol, D-24105 Kiel, Germany		Herdegen, T (corresponding author), Inst Pharmacol, Hosp Str 4, D-24105 Kiel, Germany.		herdegen, thomas/E-5135-2010					ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; Anguelova E, 2000, J NEUROSCI RES, V59, P209, DOI 10.1002/(SICI)1097-4547(20000115)59:2<209::AID-JNR7>3.0.CO;2-I; Arts J, 1996, EUR J BIOCHEM, V241, P393, DOI 10.1111/j.1432-1033.1996.00393.x; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Beer J, 1998, BRAIN RES, V794, P255, DOI 10.1016/S0006-8993(98)00233-9; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Boss V, 2001, J NEUROSCI, V21, P18, DOI 10.1523/JNEUROSCI.21-01-00018.2001; Brecht S, 1999, MOL BRAIN RES, V68, P101, DOI 10.1016/S0169-328X(99)00069-8; Carboni L, 1998, MOL BRAIN RES, V60, P57, DOI 10.1016/S0169-328X(98)00166-1; CARLETTI R, 1995, NEUROSCIENCE, V69, P1103, DOI 10.1016/0306-4522(95)00284-P; Chen JS, 1997, J NEUROSCI, V17, P4933; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; COFFER P, 1995, ONCOGENE, V10, P985; Coffey ET, 2000, J NEUROSCI, V20, P7602; Cruzalegui FH, 1999, EMBO J, V18, P1335, DOI 10.1093/emboj/18.5.1335; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Edelstein K, 2000, BRAIN RES, V870, P54, DOI 10.1016/S0006-8993(00)02401-X; Eilers A, 1998, J NEUROSCI, V18, P1713; Elliott RC, 2000, J NEUROSCI, V20, P2142; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; FERRELL JE, 2000, SCI STKE, V52, P1; Ferrer I, 1997, NEUROSCIENCE, V80, P449, DOI 10.1016/S0306-4522(97)00126-7; GASS P, 1993, EUR J NEUROSCI, V5, P933, DOI 10.1111/j.1460-9568.1993.tb00944.x; Giasson BI, 1999, J NEUROCHEM, V72, P1081, DOI 10.1046/j.1471-4159.1999.0721081.x; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Grimm R, 1997, LEARN MEMORY, V3, P402, DOI 10.1101/lm.3.5.402; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Hata R, 2000, J CEREBR BLOOD F MET, V20, P306, DOI 10.1097/00004647-200002000-00012; Hayashi T, 2000, NEUROSCI LETT, V284, P195, DOI 10.1016/S0304-3940(00)01024-7; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Herzog KH, 1999, J NEUROSCI, V19, P4349; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Hsieh TF, 1998, EXP NEUROL, V149, P161, DOI 10.1006/exnr.1997.6686; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ikeuchi T, 1998, Hum Cell, V11, P125; Ito M, 1999, MOL CELL BIOL, V19, P7539; JONES KJ, 1993, BRAIN RES BULL, V30, P491, DOI 10.1016/0361-9230(93)90283-H; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kenney AM, 1998, J NEUROSCI, V18, P1318; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kim IJ, 1999, J NEUROCHEM, V72, P1335, DOI 10.1046/j.1471-4159.1999.721335.x; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kita Y, 1998, J CELL SCI, V111, P907; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kreutz MR, 1999, MOL BRAIN RES, V69, P232, DOI 10.1016/S0169-328X(99)00113-8; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kurokawa T, 1999, INVEST OPHTH VIS SCI, V40, P3006; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LEAH JD, 1991, BRAIN RES, V566, P198, DOI 10.1016/0006-8993(91)91699-2; LEE CY, 1970, NEW YORKS FOOD LIFE, V1, P1; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Levresse V, 2000, J NEUROSCI RES, V62, P799; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; Low W, 1999, ONCOGENE, V18, P3737, DOI 10.1038/sj.onc.1202702; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Maroney AC, 1998, J NEUROSCI, V18, P104; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MartinezAnaya MA, 1996, FOOD SCI TECHNOL INT, V2, P35, DOI 10.1177/108201329600200105; Marushige K, 1999, ANTICANCER RES, V19, P3865; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Migheli A, 1997, J NEUROPATH EXP NEUR, V56, P1314, DOI 10.1097/00005072-199712000-00006; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; Oren A, 1999, MOL CELL BIOL, V19, P1742; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Paratcha G, 2000, MOL BRAIN RES, V78, P120, DOI 10.1016/S0169-328X(00)00083-8; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; Pena E, 2000, EXP CELL RES, V256, P179, DOI 10.1006/excr.2000.4814; Pennypacker KR, 2000, NEUROSCI LETT, V289, P1, DOI 10.1016/S0304-3940(00)01250-7; Perez-Otano I, 1998, MOL BRAIN RES, V53, P41, DOI 10.1016/S0169-328X(97)00269-6; PURKISS RJ, 1993, EUR J NEUROSCI, V5, P1653, DOI 10.1111/j.1460-9568.1993.tb00233.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Rizzo MT, 1999, PROSTAG LEUKOTR ESS, V60, P187, DOI 10.1054/plef.1999.0024; ROBINSON GA, 1995, MOL BRAIN RES, V30, P61, DOI 10.1016/0169-328X(94)00277-L; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sadot E, 1998, J NEUROCHEM, V70, P428; Salehi M, 1999, MECH AGEING DEV, V107, P61, DOI 10.1016/S0047-6374(98)00137-7; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Sgambato V, 1998, J NEUROSCI, V18, P214; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Skinner M, 1997, MOL CELL BIOL, V17, P2372, DOI 10.1128/MCB.17.5.2372; Small DL, 1999, BRAIN RES, V842, P376, DOI 10.1016/S0006-8993(99)01852-1; SOMMER C, 1995, BRAIN PATHOL, V5, P135, DOI 10.1111/j.1750-3639.1995.tb00587.x; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Telfeian AE, 2000, NEUROBIOL DIS, V7, P362, DOI 10.1006/nbdi.2000.0294; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Vaudano E, 1998, EUR J NEUROSCI, V10, P2644, DOI 10.1046/j.1460-9568.1998.t01-1-00282.x; Virdee K, 1997, J NEUROCHEM, V69, P550; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Watanabe Y, 1996, J NEUROSCI, V16, P3827; Winter C, 1998, BRAIN RES, V801, P198, DOI 10.1016/S0006-8993(98)00601-5; WOLLNIK F, 1995, EUR J NEUROSCI, V7, P388, DOI 10.1111/j.1460-9568.1995.tb00334.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	129	173	178	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2424	2437		10.1038/sj.onc.1204387	http://dx.doi.org/10.1038/sj.onc.1204387			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402338				2022-12-28	WOS:000168568700009
J	Wagner, EF				Wagner, EF			AP-1 - Introductory remarks	ONCOGENE			English	Editorial Material						AP-1; Fos; Jun; oncogene; signal transduction; transcription factor		This issue attempts to give a 'state of the art' overview of the AP-1 transcription factor family, a fundamental class of transcriptional regulators. The AP-1 family consists of several bZIP (basic region leucine zipper) domain proteins, the Jun, the Fos, and the ATF subfamilies, which all have to dimerize before they can bind to their DNA target sites, AP-1 has been a paradigm for transcription factors that regulate many aspects of cell physiology in response to environmental changes such as stress, radiation, or to growth factor signals thereby acting like an environmental biosensor, Although we have come a long way from discovering its major components, the heterodimer between c-Fos and c-Jun, it is daunting to realize that we still lack a detailed molecular knowledge of how these factors interact with DNA to activate or repress genes in the nucleus, It is also not clear how the response of AP-1 to growth factor signaling from the cell surface to the nucleus a interpreted at the molecular level and whether AP-1 is relevant for human disease.	Res Inst Mol Pathol, IMP, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, IMP, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196					0	113	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	2001	20	19					2334	2335		10.1038/sj.onc.1204416	http://dx.doi.org/10.1038/sj.onc.1204416			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402330				2022-12-28	WOS:000168568700001
J	Lebrin, F; Chambaz, EM; Bianchini, L				Lebrin, F; Chambaz, EM; Bianchini, L			A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit alpha	ONCOGENE			English	Article						proliferation; casein kinase 2; BrdU; dominant-negative	CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; BETA-SUBUNIT; MOLECULAR-CLONING; NA+/H+ ANTIPORTER; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; PHOSPHATASE 2A; GROWTH	Protein kinase CK2 is an ubiquitous and pleiotropic Ser/Thr protein kinase composed of two catalytic (alpha and/or alpha') and two regulatory (B) subunits generally combined to form alpha (2)beta (2), alpha alpha'beta (2), or alpha'(2)beta (2) heterotetramers, To gain more insight into the role of CK2 in the control of proliferation in mammalian cells, overexpression of isolated CK2 subunits alpha, alpha', or beta was carried out in two fibroblast cell lines: NIH3T3 and CCL39, To interfere with CK2 cellular functions, cells were also transfected with a kinase-inactive mutant of CK2 alpha catalytic subunit: CK2 alpha -K68A. In NIH3T3 cells, overexpression of either wild-type subunit (alpha, alpha' or beta) had no effect on cell proliferation, In contrast, overexpression of the CK2 alpha kinase-deficient mutant induced a marked inhibition of cell proliferation, This resulted from a defect in G1/S progression as demonstrated in transient transfection experiments in both NIH3T3 and CCL39 cells using BrdU incorporation measurements and in CCL39 clones stably overexpressing the CK2 alpha -K68A mutant by growth curve analysis. We demonstrated that the kinase-negative mutant has the capacity to integrate the endogenous CK2 subunit pool both as an isolated kinase-inactive alpha subunit and as associated to the beta subunit in a kinase-inactive tetramer. Finally we showed that expression of the kinase-inactive mutant interferes with phosphorylation of an endogenous CK2 substrate; we speculate that optimal phosphorylation of target proteins by CK2 is required to achieve optimal cell cycle progression.	CEA, BRCE, DBMS, INSERM U244, F-38054 Grenoble 9, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bianchini, L (corresponding author), Fac Sci, Ctr Biochim, UMR 6543 CNRS, Parc Valrose, F-06108 Nice 2, France.			lebrin, franck/0000-0002-1650-6757				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Cosmelli D, 1997, FEBS LETT, V410, P391, DOI 10.1016/S0014-5793(97)00625-X; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; Egyhazi E, 1999, MOL CELL BIOCHEM, V191, P149; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Korn I, 1999, MOL CELL BIOCHEM, V191, P75, DOI 10.1023/A:1006818513560; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; Lorenz P, 1999, FEBS LETT, V448, P283, DOI 10.1016/S0014-5793(99)00388-9; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19	39	60	63	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2010	2022		10.1038/sj.onc.1204307	http://dx.doi.org/10.1038/sj.onc.1204307			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360185				2022-12-28	WOS:000168043800009
J	Chen, CA; Manning, DR				Chen, CA; Manning, DR			Regulation of G proteins by covalent modification	ONCOGENE			English	Article						N-myristoylation; palmitoylation; phosphorylation; G protein	PLASMA-MEMBRANE LOCALIZATION; G-BETA-GAMMA; KINASE-C PHOSPHORYLATES; GTP-BINDING-PROTEIN; ALPHA-SUBUNIT; ADENYLYL-CYCLASE; TYROSINE PHOSPHORYLATION; LIPID MODIFICATIONS; HUMAN-PLATELETS; BIOCHEMICAL-CHARACTERIZATION	Heterotrimeric G protein alpha,beta, and gamma subunits are subject to several kinds of co- and post-translational covalent modifications, Among those relevant to G protein-coupled receptor signaling in normal cell function are lipid modifications and phosphorylation, N-myristoylation is a co-translational modification occurring for members of the (G)i family of G alpha subunits, while palmitoylation is a post-translational modification that occurs for these and most other G alpha subunits, One or both modifications are required for plasma membrane targeting and contribute to regulating strength of interaction with the G beta gamma heterodimer, effecters, and regulators of G protein signaling (RGS proteins). G alpha subunits, including those with transforming activity, are often inactive when unable to be modified with lipids, The reversible nature of palmitoylation is intriguing in this regard, as it lends itself to a regulation integrated with the activation state of the G protein, Several G alpha subunits are substrates for phosphorylation by protein kinase C and at least one is a substrate for phosphorylation by the p21-activated protein kinase, Phosphorylation in both instances inhibits the interactions of these subunits with the G beta gamma heterodimer and RGS proteins. Several G alpha subunits are also substrates for tyrosine phosphorylation, A G gamma subunit is phosphorylated by protein kinase C, with the consequence that it interacts tightly with a G alpha subunit but less well with an effector.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bano MC, 1998, BIOCHEM J, V330, P723, DOI 10.1042/bj3300723; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; Das AK, 1997, J BIOL CHEM, V272, P11021; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gurdal H, 1997, MOL PHARMACOL, V52, P1064, DOI 10.1124/mol.52.6.1064; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Hohenegger M, 1996, MOL PHARMACOL, V49, P73; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; Klinker JF, 1999, EUR J BIOCHEM, V261, P72, DOI 10.1046/j.1432-1327.1999.00209.x; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MILLER T, 1995, BYTE, V20, P18; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schroeder H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/jcb.134.3.647; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SONG KS, 1997, CELL MOL BIOL, V43, P292; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Ueda H, 1999, J BIOL CHEM, V274, P12124, DOI 10.1074/jbc.274.17.12124; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WIELAND T, 1992, J BIOL CHEM, V267, P20791; WIELAND T, 1993, J BIOL CHEM, V268, P18111; Wise A, 1997, FEBS LETT, V407, P257, DOI 10.1016/S0014-5793(97)00300-1; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	94	154	155	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1643	1652		10.1038/sj.onc.1204185	http://dx.doi.org/10.1038/sj.onc.1204185			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313912				2022-12-28	WOS:000168089800015
J	Ram, PT; Iyengar, R				Ram, PT; Iyengar, R			G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation	ONCOGENE			English	Article						G protein alpha subunit; Src; Stat3; transformation	MUTANT ALPHA-SUBUNIT; NIH 3T3 CELLS; SERINE PHOSPHORYLATION; V-SRC; TYROSINE PHOSPHORYLATION; JAK/STAT PATHWAY; BINDING PROTEINS; CHROMAFFIN CELLS; IN-VIVO; KINASE	Extracellular signals when routed through signaling pathways that use heterotrimeric G proteins can engage multiple signaling pathways leading to diverse biological consequences, One locus at which signal sorting occurs is at the level of G proteins, G protein a-subunits appear to be capable of interacting with different effecters leading to engagement of distinct signaling pathways. Regulation of different pathways in turn leads to different biological outcomes, The process of neoplastic transformation is controlled to a large extent through the activation and inhibition of signaling pathways, Signaling pathways such as the Ras-MAPK, v-Src-Stat3 pathways are activated in the process of transformation. Expression of activated G alpha subunits have been shown to cause transformation of cells, While activation of the MAPK 1,2 pathway by various G alpha subunits has been reported for several years, recent studies show the activation and involvement of Src and Stat3 pathways in G alphao and G alphai mediated transformation of cells. Recent studies also suggest that both G alphai and G alphas may be able to interact with and activate Src, The activation of Src and Stat3 by G proteins has also been demonstrated by Ligand-induced activation of G protein receptors, So increasingly it is becoming clear that the Src and Stat3 pathways are potential effecters for G proteins and that they may play a role in G protein function.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ram, PT (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.			Ram, Prahlad/0000-0003-4739-3166	NATIONAL CANCER INSTITUTE [R01CA081050, F32CA079134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA79134, CA81050] Funding Source: Medline; NIGMS NIH HHS [GM54508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Buggy JJ, 1998, BIOCHEM J, V331, P211, DOI 10.1042/bj3310211; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; FFRENCHMULLEN JMH, 1994, J PHYSIOL-LONDON, V474, P21, DOI 10.1113/jphysiol.1994.sp019998; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Hermouet S, 1996, CELL SIGNAL, V8, P159, DOI 10.1016/0898-6568(95)02049-7; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEER EJ, 1984, J BIOL CHEM, V259, P4222; Niu GL, 1999, CANCER RES, V59, P5059; Nusse O, 1996, J CELL SCI, V109, P221; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Shen Y, 1996, J CLIN ENDOCR METAB, V81, P4159, DOI 10.1210/jc.81.11.4159; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 2000, J BIOL CHEM, V275, P27634; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	99	111	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1601	1606		10.1038/sj.onc.1204186	http://dx.doi.org/10.1038/sj.onc.1204186			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313907				2022-12-28	WOS:000168089800010
J	Benedit, P; Paciucci, R; Thomson, TM; Valeri, M; Nadal, M; Caceres, C; de Torres, I; Estivill, X; Lozano, JJ; Morote, J; Reventos, J				Benedit, P; Paciucci, R; Thomson, TM; Valeri, M; Nadal, M; Caceres, C; de Torres, I; Estivill, X; Lozano, JJ; Morote, J; Reventos, J			PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks	ONCOGENE			English	Article						prostate; prostate adenocarcinoma; androgens; molecular markers	DIFFERENTIALLY EXPRESSED GENES; INTRAEPITHELIAL NEOPLASIA; SERINE-PROTEASE; ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; CARCINOMA; TISSUE; DISPLAY; SEARCH; FAMILY	In a search for molecular markers of progression in prostate cancer by means of differential display, me have identified a new gene, which we have designated PTO VI, Semiquantitative RT-PCR has established that nine out of 11 tumors overexpress PTOV1 at levels significantly higher than benign prostatic hyperplasia or normal prostate tissue. The human PTOV1 protein consists almost entirely of two repeated blocks of homology of 151 and 147 amino acids, joined by a short linker peptide, and is encoded by a 12-exon gene localized in chromosome 19q13.3, A Drosophila melanogaster PTOV1 homolog also contains two tandemly arranged PTOV blocks. A second gene, PTOV2, was identified in humans and Drosophila, coding for proteins with a single PTOV homology block and unrelated amino- and carboxyl-terminal extensions. A 1.8-Kb PTOV1 transcript was detected abundantly in normal human brain, heart, skeletal muscle, kidney and liver, and at low levels in normal prostate. Immunocytochemical analysis and expression of chimeric GFP-PTOV1 proteins in cultured cells showed a predominantly perinuclear localization of PTOV1, In normal prostate tissue and in prostate adenomas, PTOV1 was undetectable or expressed at low levels, whereas nine out of 11 prostate adenocarcinomas showed a strong immunoreactivity, with a focal distribution in areas of carcinoma and prostatic intraepithelial neoplasia, Therefore, PTOV1 is a previously unknown gene, overexpressed in early and late stages of prostate cancer. The PTOV homology block represents a new class of conserved sequence blocks present in human, rodent and fly proteins.	Hosp Gen Valle Hebron, Hosp Materno Infantil, Unitat Rec Biomed, Barcelona, Spain; CSIC, Inst Mol Biol, Barcelona, Spain; Inst Rec Oncol, Ctr Genet Mol, Barcelona, Spain; Hosp Gen Valle Hebron, Serv Anat Patol, Barcelona, Spain; Inst Municipal Invest Med, Inst Rec Informat Med, Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Hosp Gen Valle Hebron, Urol Serv, Barcelona, Spain	Hospital Universitari Vall d'Hebron; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Hospital Universitari Vall d'Hebron; Pompeu Fabra University; Hospital Universitari Vall d'Hebron	Thomson, TM (corresponding author), Hosp Gen Valle Hebron, Hosp Materno Infantil, Unitat Rec Biomed, Barcelona, Spain.		Estivill, Xavier/E-2957-2012; Paciucci, Rosanna/AGP-3844-2022; Reventos, Jaume/I-1633-2012; Morote, Juan/M-6914-2017; Estivill, Xavier/A-3125-2013; Thomson, Timothy/Z-6271-2019	Paciucci, Rosanna/0000-0001-5651-5933; Morote, Juan/0000-0002-2168-323X; Estivill, Xavier/0000-0002-0723-2256; Thomson, Timothy/0000-0002-4670-9440; Lozano, Juan Jose/0000-0001-7613-3908; Nadal, Marga/0000-0002-5739-1693				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLOK LJ, 1995, PROSTATE, V26, P213, DOI 10.1002/pros.2990260407; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W; Bostwick DG, 1997, PROSTATE, V33, P32, DOI 10.1002/(SICI)1097-0045(19970915)33:1<32::AID-PROS6>3.0.CO;2-B; Brooks JD, 1996, CANCER RES, V56, P3814; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chang GTG, 1997, CANCER RES, V57, P4075; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fernandez PL, 1999, J PATHOL, V187, P563, DOI 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; Goyal J, 1998, CANCER RES, V58, P4782; Guate JL, 1999, BJU INT, V84, P495; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; Harper ME, 1998, J PATHOL, V186, P169, DOI 10.1002/(SICI)1096-9896(1998100)186:2<169::AID-PATH164>3.0.CO;2-W; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Jenster G, 1999, SEMIN ONCOL, V26, P407; Johnson MI, 1998, PROSTATE, V37, P223, DOI 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO;2-O; Kallioniemi OP, 1996, ADV CANCER RES, V68, P225, DOI 10.1016/S0065-230X(08)60355-3; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin BY, 1999, CANCER RES, V59, P4180; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Lucas S, 1998, CANCER RES, V58, P743; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; Montironi R, 1999, J CLIN PATHOL, V52, P350, DOI 10.1136/jcp.52.5.350; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Rondinelli RH, 1999, CLIN CANCER RES, V5, P1595; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stubbs AP, 1999, AM J PATHOL, V154, P1335, DOI 10.1016/S0002-9440(10)65387-4; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; Sun YL, 1997, CANCER RES, V57, P18; TROYER JK, 1995, INT J CANCER, V62, P552, DOI 10.1002/ijc.2910620511; Wang FL, 1996, CANCER RES, V56, P3634; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yousef GM, 2000, GENOMICS, V63, P88, DOI 10.1006/geno.1999.6072; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; ZHAU HYE, 1992, MOL CARCINOGEN, V5, P320, DOI 10.1002/mc.2940050413	43	53	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2001	20	12					1455	1464		10.1038/sj.onc.1204233	http://dx.doi.org/10.1038/sj.onc.1204233			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313889				2022-12-28	WOS:000167595200006
J	Maeda, R; Mood, K; Jones, TL; Aruga, J; Buchberg, AM; Daar, IO				Maeda, R; Mood, K; Jones, TL; Aruga, J; Buchberg, AM; Daar, IO			Xmeis1, a protooncogene involved in specifying neural crest cell fate in Xenopus embryos	ONCOGENE			English	Article						Xmeis1; neural crest; homeodomain; Xenopus	HEDGEHOG SIGNALING PATHWAY; COOPERATIVE DNA-BINDING; HOMEOBOX GENES; FLOOR PLATE; MESSENGER-RNA; GLI PROTEINS; NUCLEAR-LOCALIZATION; ZIC FAMILY; HOX GENES; EXPRESSION	Meis1 (Myeloid Ecotropic viral Integration Site 1) is a homeobox gene that was originally isolated as a common site of viral integration in myeloid tumors of the BXH-2 recombinant inbred mice strain. We previously isolated a Xenopus homolog of Meis1 (Xmeis1), Here we show that Xmeis1 may play a significant role in neural crest development. In developing Xenopus embryos, Xmeis1 displays a broad expression pattern, but strong expression is observed in tissue of neural cell fate, such as midbrain, hindbrain, the dorsal portion of the neural tube, and neural crest derived branchial arches. In animal cap explants, overexpression of Xmeis1b, an alternatively spliced form of Ymeis1, induces expression of neural crest marker genes in the absence of mesoderm, Moreover, Xmeis1b induces XGli-3 and XZic3, pre-pattern genes involved at the earliest stages of neural crest development, and like these two genes, can induce ectopic pigmented cell masses when overexpressed in developing embryos. Misexpression of Ymeis1b also induces ectopic expression of neural crest markers along the antero-posterior axis of the neural tube in developing Xenopus embryos. In contrast, Xmeis1a, another splice variant, is much less effective at inducing these effects. These data suggest that Xmeis1b is involved in neural crest cell fate specification during embryogenesis, and can functionally intersect with the Gli/Zic signal transduction pathway.	NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); RIKEN; Jefferson University	Daar, IO (corresponding author), NCI, Regulat Cell Growth Lab, Bldg 560 Room 22-3, Frederick, MD 21702 USA.		Aruga, Jun/H-5837-2011	Aruga, Jun/0000-0001-7936-1375; Buchberg, Arthur/0000-0002-0543-5631; Daar, Ira/0000-0003-2657-526X	NCI NIH HHS [N01-CO-5600] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Ding Q, 1998, DEVELOPMENT, V125, P2533; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kurant E, 1998, DEVELOPMENT, V125, P1037; LaBonne C, 1999, ANNU REV CELL DEV BI, V15, P81, DOI 10.1146/annurev.cellbio.15.1.81; LaBonne C, 1998, DEVELOPMENT, V125, P2403; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LU QA, 1995, MOL CELL BIOL, V15, P3786; Maeda R, 1997, DEVELOPMENT, V124, P2553; Mancilla A, 1996, DEV BIOL, V177, P580, DOI 10.1006/dbio.1996.0187; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mayor R, 1999, CURR TOP DEV BIOL, V43, P85; MAYOR R, 1995, DEVELOPMENT, V121, P767; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; MIYATANI S, 1986, J CELL BIOL, V103, P1957, DOI 10.1083/jcb.103.5.1957; Mizuseki K, 1998, NEURON, V21, P77, DOI 10.1016/S0896-6273(00)80516-4; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; Nakata K, 2000, MECH DEVELOP, V99, P83, DOI 10.1016/S0925-4773(00)00480-9; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; Salzberg A, 1999, MECH DEVELOP, V80, P3, DOI 10.1016/S0925-4773(98)00187-7; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; SUZUKI A, 1993, ZOOL SCI, V10, P175; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Tada M, 1997, DEVELOPMENT, V124, P2225; Theil T, 1998, DEVELOPMENT, V125, P443; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wallingford JB, 1999, TRENDS GENET, V15, P385, DOI 10.1016/S0168-9525(99)01800-4; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005; Yang SS, 1998, J BIOL CHEM, V273, P13746, DOI 10.1074/jbc.273.22.13746; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	81	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1329	1342		10.1038/sj.onc.1204250	http://dx.doi.org/10.1038/sj.onc.1204250			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313877				2022-12-28	WOS:000167495000007
J	Stepczynska, A; Lauber, K; Engels, IH; Janssen, O; Kabelitz, D; Wesselborg, S; Schulze-Osthoff, K				Stepczynska, A; Lauber, K; Engels, IH; Janssen, O; Kabelitz, D; Wesselborg, S; Schulze-Osthoff, K			Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation	ONCOGENE			English	Article						anticancer drugs; apoptosis; caspase; staurosporine; CD95	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CYTOCHROME-C; CELL-DEATH; AKT PHOSPHORYLATION; WILD-TYPE; CD95; FAS; PROTEASE; RELEASE; MITOCHONDRIA	Apoptosis can be induced by various stimuli including DNA-damaging anticancer drugs and the protein kinase inhibitor staurosporine, It is generally believed that the molecular events during execution of apoptosis are shared, as both anticancer drugs and staurosporine derivatives induce mitochondrial damage, cytochrome c release and the activation of the caspase-9 proteolytic cascade. In the present study we show that overexpression of a dominant-negative caspase-9 mutant abolished the activation of endogenous caspase-9, caspase-3 and the cleavage of the caspase substrate Bid in response to anticancer drug treatment, Surprisingly, however, only marginal effects were observed during staurosporine-induced apoptosis, Furthermore, we describe a Jurkat T-cell clone that is completely resistant towards different anticancer drugs, but remains sensitive towards staurosporine-induced apoptosis, In these cells only staurosporine, but neither anti-CD95 nor anticancer drugs were able to trigger caspase activity and the cleavage of caspase substrates. Our results therefore suggest that the mechanism of staurosporine-induced apoptosis is more complex and at least partially differs from anticancer drug-induced caspase activation. These distinct features of staurosporine may allow to bypass chemoresistance of tumor cells and may encourage further clinical trials for the use of staurosporine derivatives in antitumor therapy.	Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Tubingen, Dept Internal Med 1, D-72074 Tubingen, Germany; Univ Kiel, Inst Immunol, D-24098 Kiel, Germany	University of Munster; Eberhard Karls University of Tubingen; University of Kiel	Schulze-Osthoff, K (corresponding author), Univ Munster, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013; Kabelitz, Dieter/AAB-4199-2021; Janssen, Ottmar/E-9735-2010; Janssen, Ottmar/N-8769-2019; Kabelitz, Dieter/A-2757-2010	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Janssen, Ottmar/0000-0002-9612-8900; Janssen, Ottmar/0000-0002-9612-8900; Wesselborg, Sebastian/0000-0002-5236-942X				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Fulda S, 1997, CANCER RES, V57, P3823; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Gescher A, 1998, GEN PHARMACOL, V31, P721, DOI 10.1016/S0306-3623(98)00069-X; Han Z, 2000, CELL DEATH DIFFER, V7, P521, DOI 10.1038/sj.cdd.4400681; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Janssen O, 1996, IMMUNOL LETT, V49, P63, DOI 10.1016/0165-2478(95)02482-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Villunger A, 1997, CANCER RES, V57, P3331; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	54	118	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1193	1202		10.1038/sj.onc.1204221	http://dx.doi.org/10.1038/sj.onc.1204221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313863				2022-12-28	WOS:000167570100006
J	Droin, N; Rebe, C; Bichat, F; Hammann, A; Bertrand, R; Solary, E				Droin, N; Rebe, C; Bichat, F; Hammann, A; Bertrand, R; Solary, E			Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization	ONCOGENE			English	Article						apoptosis; caspase-2 isoforms; nuclear changes	CELL-DEATH; DNA FRAGMENTATION; ADAPTER MOLECULE; MESSENGER-RNA; UP-REGULATION; CASPASE-2; ACTIVATION; EXPRESSION; PROTEIN; ANTIGEN	Procaspase-2 is one of the cysteine aspartate proteases involved in apoptotic cell death. Alternative splicing of CASP-2 messenger RNA generates a long isoform, procaspase-2L, whose overexpression induces cell death and a truncated isoform, procaspase-2S, whose function remains poorly defined. The present study explored the consequences of procaspase-2S overexpression in U937 human leukemic cells exposed to the topoisomerase If inhibitor etoposide as an apoptotic stimulus, Overexpression of procaspase-2S in U937 cells partially prevented nuclear changes associated with etoposide-induced cell death, as determined by Hoechst 33342 staining of nuclear chromatin and electron microscopy studies, Procaspase-2S also prevented the maturation of apoptotic bodies, delayed phosphatidylserine externalization on the plasma membrane and prevented the cleavage and activation of procaspase-2L, These effects were not observed when the cysteine 289 in the consensus QACRG motif was mutated into a serine. Wild-type procaspase-2S overexpression did not influence the cleavage of procaspase-3, procaspase-7 and poly(ADP-ribose)polymerase nor the fragmentation of nuclear DNA into nucleosome-sized fragments. Altogether, these results indicate that the short isoform of procaspase-2 negatively interferes with selective features of apoptosis, an activity that is suppressed by mutation of the cysteine 289.	Fac Med, INSERM U517, F-21033 Dijon, France; Fac Pharm, INSERM U517, F-21033 Dijon, France; Ctr Univ Montreal Hosp Ctr, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Montreal	Solary, E (corresponding author), Fac Med, INSERM U517, 7 Blvd Jeanne Arc, F-21033 Dijon, France.		REBE, Cédric/AAD-4316-2019; Droin, Nathalie M/Y-5506-2018	REBE, Cédric/0000-0001-8831-145X; Droin, Nathalie M/0000-0002-6099-5324; Solary, Eric/0000-0002-8629-1341				Ahmad M, 1997, CANCER RES, V57, P615; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BERTRAND R, 1991, CANCER RES, V51, P6280; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; Buendia B, 1999, J CELL SCI, V112, P1743; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fujimura M, 1999, J CANCER RES CLIN, V125, P389, DOI 10.1007/s004320050291; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kojima M, 1998, NEUROSCI RES, V31, P211, DOI 10.1016/S0168-0102(98)00039-X; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; McIlroy D, 2000, GENE DEV, V14, P549; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pelassy C, 2000, BIOCHEM PHARMACOL, V59, P855, DOI 10.1016/S0006-2952(99)00383-4; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Ronchetti A, 1999, J IMMUNOL, V163, P130; Rovere P, 1998, J IMMUNOL, V161, P4467; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1999, CANCER RES, V59, P999; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99	56	33	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					260	269		10.1038/sj.onc.1204066	http://dx.doi.org/10.1038/sj.onc.1204066			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313953				2022-12-28	WOS:000166410900013
J	Skalsky, YM; Ajuh, PM; Parker, C; Lamond, AI; Goodwin, G; Cooper, CS				Skalsky, YM; Ajuh, PM; Parker, C; Lamond, AI; Goodwin, G; Cooper, CS			PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors	ONCOGENE			English	Article						TFE3; PRCC; transcription activation; pre-mRNA splicing	HELIX-LOOP-HELIX; ACTIVATOR INHIBITOR-1 GENE; BETA-INDUCED TRANSCRIPTION; CELL CARCINOMA; BINDING PROTEIN; SMAD PROTEINS; RNA-BINDING; DNA-BINDING; TRANSLOCATION; P54(NRB)	In papillary renal cell carcinomas the TFE3 transcription factor becomes fused to the PSF and NonO pre-mRNA splicing factors and most commonly to a protein of unknown function designated PRCC, In this: study we have examined the ability of the resulting PRCC-TFE3 and NonO-TFE3 fusions to activate transcription from the plasminogen activator inhibitor-1 (PAI-1) promoter. The results shea that only fusion to PRCC enhanced transcriptional activation, indicating that the ability to enhance the level of transcription from endogenous TFE3 promoters is not a consistent feature of TFE3 fusions, In investigations of the normal function of PRCC,ve observed that PRCC expressed as a green fluorescent fusion protein colocalizes within the nucleus with Sm pre-RNA splicing factors. It was also found that endogenous PRCC is coimmunoprecipitated by antibodies that recognize a variety of pre-mRNA splicing factors including SC35, PRL1 and CDC5. Association with the cellular splicing machinery is therefore, a common feature of the proteins that become fused to TFE3 in papillary renal cell carcinomas.	Inst Canc Res, Mol Carcinogenesis Sect, Haddow Labs, Sutton SM2 5NG, Surrey, England; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	University of London; Institute of Cancer Research - UK; University of Dundee	Skalsky, YM (corresponding author), Inst Canc Res, Mol Carcinogenesis Sect, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Lamond, Angus/0000-0001-6204-6045				ANGLARD P, 1992, CANCER RES, V52, P348; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Basu A, 1997, MOL CELL BIOL, V17, P677, DOI 10.1128/MCB.17.2.677; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; Groenen PMA, 1998, GENOMICS, V49, P218, DOI 10.1006/geno.1998.5254; Groenen PMA, 1996, GENOMICS, V38, P141, DOI 10.1006/geno.1996.0609; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kreivi JP, 1996, CURR BIOL, V6, P802, DOI 10.1016/S0960-9822(02)00599-7; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; REEVES BR, 1989, ONCOGENE, V4, P373; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Shinozaki A, 1999, INT J BIOCHEM CELL B, V31, P1279, DOI 10.1016/S1357-2725(99)00101-6; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Tian G, 1999, MOL CELL BIOL, V19, P2946; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593	44	49	50	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					178	187		10.1038/sj.onc.1204056	http://dx.doi.org/10.1038/sj.onc.1204056			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313942				2022-12-28	WOS:000166410900005
J	Mashour, GA; Ratner, N; Khan, GA; Wang, HL; Martuza, RL; Kurtz, A				Mashour, GA; Ratner, N; Khan, GA; Wang, HL; Martuza, RL; Kurtz, A			The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells	ONCOGENE			English	Article						neurofibromatosis; midkine; pleiotrophin; schwann cells	FIBROBLAST GROWTH-FACTORS; TYPE-1 GENE-PRODUCT; DIFFERENTIAL EXPRESSION; ADULT-RAT; PLEIOTROPHIN; SURVIVAL; TUMORS; BRAIN; MOUSE; MK	Loss of the tumor suppressor gene NF1 in neurofibromatosis type 1 (NF1) contributes to the development of a variety of tumors, including malignant peripheral nerve sheath tumors (MPNST) and benign neurofibromas, Of the different cell types found in neurofibromas, Schwann cells usually provide between 40 and 80%, and are thought to be critical for tumor growth. Here we describe the identification of growth factors that are upregulated in NF1-/- mouse Schwann cells and are potential regulators of angiogenesis and cell growth. Basic fibroblast growth factor (FGF-2), platelet-derived growth factor (PDGF) and midkine (MK) were found to be induced by loss of neurofibromin and MK was further characterized. MK was induced in human neurofibromas, schwannomas, and various nervous system tumors associated with NF1 or NF2; midkine showed an expression pattern overlapping but distinct from its homolog pleiotrophin (PTN), Immunohistochemistry revealed expression of MK in S-100 positive Schwann cells of dermal and plexiform neurofibromas, and in endothelial cells of tumor blood vessels, but not in normal blood vessels, Furthermore, MK demonstrated potent mitogenic activity for human systemic and brain endothelial cells in vitro and stimulated proliferation and soft agar colony formation of human MPNST derived S100 positive cells and fibroblastoid cells derived from an NF1 neurofibroma, The data support a possible central role for MK as a mediator of angiogenesis and neurofibroma growth in NF1.	Harvard Univ, Sch Med, MGH, Charlestown, MA 02129 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Georgetown Univ, Sch Med, Dept Neurosurg, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Harvard University; University System of Ohio; University of Cincinnati; Georgetown University	Kurtz, A (corresponding author), Harvard Univ, Sch Med, MGH, Bldg 149,13th St, Charlestown, MA 02129 USA.			Kurtz, Andreas/0000-0003-3301-6546; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037895, R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS28840, R29-NS37895] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN JK, 1991, J NEUROSCI RES, V30, P321, DOI 10.1002/jnr.490300207; Choudhuri R, 1997, CANCER RES, V57, P1814; COSTELLO P, 1990, J NEURO-ONCOL, V8, P231, DOI 10.1007/BF00177356; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Dugoff L, 1996, AM J MED GENET, V66, P7, DOI 10.1002/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, METABOLIC MOL BASES, P667; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; Kaname T, 1996, BIOCHEM BIOPH RES CO, V219, P256, DOI 10.1006/bbrc.1996.0214; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kato S, 1999, J NEUROPATH EXP NEUR, V58, P430, DOI 10.1097/00005072-199905000-00002; KIKUCHI S, 1993, NEUROSCI LETT, V160, P9, DOI 10.1016/0304-3940(93)90904-Y; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; Mashour GA, 1999, J INVEST DERMATOL, V113, P398, DOI 10.1046/j.1523-1747.1999.00699.x; MATSUMOTO K, 1994, NEUROSCI LETT, V178, P216, DOI 10.1016/0304-3940(94)90762-5; Milhiet PE, 1998, J ENDOCRINOL, V158, P389, DOI 10.1677/joe.0.1580389; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; OBrien T, 1996, CANCER RES, V56, P2515; Ohtani Y, 1999, INT J ONCOL, V15, P453; PANOSKALTSISMORTARI A, 1995, BIOTECHNIQUES, V18, P300; RATNER N, 1990, ANN NEUROL, V27, P298, DOI 10.1002/ana.410270312; Salvesen HB, 1999, INT J CANCER, V84, P539; SCHUBERT D, 1992, J NEUROBIOL, V23, P143, DOI 10.1002/neu.480230205; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Zhang N, 1999, Curr Opin Hematol, V6, P44, DOI 10.1097/00062752-199901000-00008; Zoller MET, 1997, CANCER-AM CANCER SOC, V79, P2125	51	99	106	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					97	105		10.1038/sj.onc.1204026	http://dx.doi.org/10.1038/sj.onc.1204026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244508				2022-12-28	WOS:000166361400011
J	Belmokhtar, CA; Hillion, J; Segal-Bendirdjian, E				Belmokhtar, CA; Hillion, J; Segal-Bendirdjian, E			Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms	ONCOGENE			English	Article						staurosporine; apoptosis; caspase; L1210	CELL-DEATH; CROSS-RESISTANCE; GRANZYME-B; PROTEASES; LEUKEMIA; ACTIVATION; CLEAVAGE; NECROSIS; PATHWAY; FAMILY	Sensitivity of tumor cells to anticancer therapy depends on the ability of the drug to induce apoptosis, However, multiple signaling pathways control this induction and thus determine this sensitivity. We report here that staurosporine, a well known inducer of apoptosis in a wide range of cell lines, displays distinct ability to trigger apoptosis in two different L1210 sublines (termed 1,1210/ S and L1210/0). Staurosporine treatment resulted in an early cell death (within 3 h) in L1210/S cells, while in L1210/0 cells, death occurred only after 12 h. In both instances, death occurred by apoptosis. A broad spectrum caspase inhibitor, z-VAD-fmk, blocked early apoptosis in L1210/S cells but did not confer any protection on late apoptosis in L1210/0 cells. Protection by z-VAD-fmk observed in L1210/S cells was not lasting and unmasked a secondary process of cell death that also exhibited characteristics of apoptosis. Thus, staurosporine induces apoptotic cell death through at least two redundant parallel pathways. These two pathways normally coexist in L1210/S cells. However, the early cell death mechanism depending on caspase activation disguises the late caspase-independent apoptotic process. Staurosporine-induced apoptosis in L1210/0 cells develops only by the caspase-independent mechanism due to a general defect in caspase activation.	Hop St Louis, INSERM, U496, Ctr G Hayem, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Segal-Bendirdjian, E (corresponding author), Hop St Louis, INSERM, U496, Ctr G Hayem, 1 Ave Claude Vellefaux, F-75010 Paris, France.			Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BURCHENAL JH, 1977, CANCER RES, V37, P3455; Coelho D, 2000, BRIT J CANCER, V83, P642, DOI 10.1054/bjoc.2000.1322; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deas O, 1998, J IMMUNOL, V161, P3375; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1981, BIOCHEM PHARMACOL, V30, P2721, DOI 10.1016/0006-2952(81)90546-3; FERNANDES RS, 1993, ANTICANCER RES, V13, P1253; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Kim WJ, 2000, EXP EYE RES, V71, P225, DOI 10.1006/exer.2000.0872; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LANOTTE M, 1991, BLOOD, V77, P1080; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; LAW LW, 1949, J NATL CANCER I, V10, P179; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MOORE GE, 1966, JNCI-J NATL CANCER I, V36, P405; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; SARRE AT, 1999, CANCER RES, V59, P3565; SEGALBENDIRDJIAN E, 1995, EXP CELL RES, V218, P201, DOI 10.1006/excr.1995.1148; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; Tainton KM, 2000, BIOCHEM BIOPH RES CO, V276, P231, DOI 10.1006/bbrc.2000.3459; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	40	311	316	0	33	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3354	3362		10.1038/sj.onc.1204436	http://dx.doi.org/10.1038/sj.onc.1204436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423986				2022-12-28	WOS:000169248800006
J	Rietveld, LEG; Caldenhoven, E; Stunnenberg, HG				Rietveld, LEG; Caldenhoven, E; Stunnenberg, HG			Avian erythroleukemia: a model for corepressor function in cancer	ONCOGENE			English	Review						erythroleukemia; corepressor; v-ErbA; histone deacetylase; carbonic anhydrase II; methylation	THYROID-HORMONE-RECEPTOR; RECRUIT HISTONE DEACETYLASE; TRANSCRIPTION FACTOR GATA-1; PLZF-RAR-ALPHA; V-ERBA; N-COR; BINDING PROTEIN; DNA METHYLTRANSFERASE; SMRT COREPRESSOR; C-ERBA	Transcriptional regulation at the level of chromatin plays crucial roles during eukaryotic development and differentiation. A plethora of studies revealed that the acetylation status of histones is controlled by multiprotein complexes containing (de)acetylase activities. In the current model, histone deacetylases and acetyltransferases are recruited to chromatin by DNA-bound repressors and activators, respectively. Shifting the balance between deacetylation, i.e. repressive chromatin and acetylationl i.e. active chromatin can lead to aberrant gene transcription and cancer, In human acute promyelocytic leukemia (APL) and avian erythroleukemia (AEL), chromosomal translocations and/or mutations in nuclear hormone receptors, RAR alpha [NR1B1] and TR alpha [NR1A1], yielded oncoproteins that deregulate transcription and alter chromatin structure. The oncogenic receptors are locked in their 'off' mode thereby constitutively repressing transcription of genes that are critical for differentiation of hematopoietic cells. AEL involves an oncogenic version of the chicken TR alpha, v-ErbA, Apart from repression by v-ErbA, ia recruitment of corepressor compleses, other repressors and corepressors appear to be involved in repression of v-ErbA target genes, such as carbonic anhydrase II (CAII), Reactivation of repressed genes in APL and AEL by chromatin modifying agents such as inhibitors of histone deacetylase or of methylation provides nem therapeutic strategies in the treatment of acute myeloid leukemia.	NCMLS, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands		Stunnenberg, HG (corresponding author), NCMLS, Dept Mol Biol, Geert Grootepl Zuid 26,POB 9101, NL-6500 HB Nijmegen, Netherlands.		Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRALIOU GG, 2000, IN PRESS ONCOGENE; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CASINI T, 1995, ONCOGENE, V11, P1019; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HERMANN T, 1993, ONCOGENE, V8, P55; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Huang EY, 2000, GENE DEV, V14, P45; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kao HY, 2000, GENE DEV, V14, P55; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LIMONTA M, 1993, LEUKEMIA RES, V17, P977, DOI 10.1016/0145-2126(93)90045-M; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutz M, 2000, BIOCHEM SOC T, V28, P386, DOI 10.1042/0300-5127:0280386; Lutz M, 2000, NUCLEIC ACIDS RES, V28, P1707, DOI 10.1093/nar/28.8.1707; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; PAIN B, 1990, New Biologist, V2, P284; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; RASCLE A, 1994, ONCOGENE, V9, P2853; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; RICHEL DJ, 1991, BRIT J CANCER, V64, P144, DOI 10.1038/bjc.1991.258; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Willard HF, 1999, NAT GENET, V23, P127, DOI 10.1038/13751; Wolffe AP, 1999, P NATL ACAD SCI USA, V96, P5894, DOI 10.1073/pnas.96.11.5894; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	123	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3100	3109		10.1038/sj.onc.1204335	http://dx.doi.org/10.1038/sj.onc.1204335			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420726				2022-12-28	WOS:000169308500014
J	Wade, PA				Wade, PA			Methyl CpG binding proteins: coupling chromatin architecture to gene regulation	ONCOGENE			English	Review						DNA methylation; MeCP2; Rett syndrome; histone deacetylase; chromatin	TRANSCRIPTIONAL REPRESSOR MECP2; HISTONE DEACETYLASE COMPLEX; LINKED MENTAL-RETARDATION; RETT-SYNDROME MUTATIONS; DNA METHYLATION; CHROMOSOMAL PROTEIN; DOMAIN; MBD4; METHYLTRANSFERASES; GIRLS	A correlation between DNA methylation and transcriptional silencing has existed for many Sears. Recently, substantial progress has been reported in the search for proteins that interpret the regulatory information inherent in DNA methylation and translate this information into functional states, resulting in the identification of a family of highly conserved proteins, the MBD family. Direct connections between these proteins and histone modification enzymes have emerged as a common theme, implying that DNA methylation exerts its effects primarily through repressive chromatin architecture. Recent structural determinations of the DNA binding domain of two MBD family members, MeCP2 and MBD1, provide a framework to model the interactions of this family with DNA, Comparative sequence analysis and experimental DNA binding data can be interpreted using this structural framework allowing one to contrast the members of the MBD family with each other and to predict the properties of new family members. The identification of mutations in MeCP2, the founding member of this family, as causal for the neurological developmental disorder Rett Syndrome provides additional information regarding amino acid residues crucial to the functions of this interesting protein family.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Wade, PA (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Woodruff Mem Res Bldg,Room 7105B,1639 Pierce Dr, Atlanta, GA 30322 USA.		Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X	NICHD NIH HHS [1K22 HD01238-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K22HD001238] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Amir RE, 2000, ANN NEUROL, V47, P670, DOI 10.1002/1531-8249(200005)47:5<670::AID-ANA20>3.3.CO;2-6; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Buyse IM, 2000, AM J HUM GENET, V67, P1428, DOI 10.1086/316913; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Cheadle JP, 2000, HUM MOL GENET, V9, P1119, DOI 10.1093/hmg/9.7.1119; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dragich J, 2000, HUM MOL GENET, V9, P2365, DOI 10.1093/hmg/9.16.2365; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; HAGBERG B, 1985, ACTA PAEDIATR SCAND, V74, P405, DOI 10.1111/j.1651-2227.1985.tb10993.x; Hampson K, 2000, J MED GENET, V37, P610, DOI 10.1136/jmg.37.8.610; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Huppke P, 2000, HUM MOL GENET, V9, P1369, DOI 10.1093/hmg/9.9.1369; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kim SJ, 2000, HUM MUTAT, V15, P382, DOI 10.1002/(SICI)1098-1004(200004)15:4<382::AID-HUMU16>3.0.CO;2-8; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Macleod D, 1999, NAT GENET, V23, P139, DOI 10.1038/13767; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Meloni I, 2000, AM J HUM GENET, V67, P982, DOI 10.1086/303078; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Obata K, 2000, J MED GENET, V37, P608, DOI 10.1136/jmg.37.8.608; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Orrico A, 2000, FEBS LETT, V481, P285, DOI 10.1016/S0014-5793(00)01994-3; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rett A, 1966, Wien Med Wochenschr, V116, P723; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Stancheva I, 2000, GENE DEV, V14, P313; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690; Xiang FQ, 2000, J MED GENET, V37, P250, DOI 10.1136/jmg.37.4.250; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	60	156	164	0	17	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3166	3173		10.1038/sj.onc.1204340	http://dx.doi.org/10.1038/sj.onc.1204340			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420733				2022-12-28	WOS:000169308500021
J	Ao, Y; Rohde, LH; Naumovski, L				Ao, Y; Rohde, LH; Naumovski, L			p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis	ONCOGENE			English	Article						53BP2; p53; apoptosis; doxorubicin; paclitaxel	P53; PROGRESSION; INTERACTS; DOMAINS; BINDS; DEATH	53BP2 was initially identified as a protein interacting with p53 in a yeast two-hybrid screen and subsequently shown to enhance p53 transcriptional transactivation and induce apoptosis when transiently overexpressed in cell lines. In order to further study the biologically relevant effects of 53BP2, we have constructed HEK293 stable cell lines where 53BP2 expression can be regulated using an ecdysone inducible expression system. Our results indicate that the response of cells is dependent on the amount of 53BP2 that is expressed, High levels of 53BP2 expression(greater than or equal to 140-fold above endogenous) impede cell cycle progression and induce apoptosis, Lower levels of 53BP2 expression (6-11-fold above endogenous) suppress colony formation hut do not lead to detectable perturbations in the cell cycle or apoptosis, Lower levels of 53BP2 expression sensitized cells to apoptosis induced by DNA damaging chemotherapy agents doxorubicin, ara-C and VP16, but not microtubule active agents paclitaxel and vinblastine, Our results demonstrate that high levels of 53BP2 expression have profound biological effects ultimately leading to apoptosis, whereas lower levels of 53BP2 expression have more subtle effects on growth and sensitize cells to some chemotherapy agents.	Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA	Stanford University	Naumovski, L (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol, 269 Campus Dr,CCSR Rm 1215, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R01CA076316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76316] Funding Source: Medline; NHLBI NIH HHS [HL09552] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NAUMOVSKI L, 1994, BLOOD, V83, P2261; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904	13	27	32	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2720	2725		10.1038/sj.onc.1204352	http://dx.doi.org/10.1038/sj.onc.1204352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420684				2022-12-28	WOS:000168652600013
J	Graveel, CR; Jatkoe, T; Madore, SJ; Holt, AL; Farnham, PJ				Graveel, CR; Jatkoe, T; Madore, SJ; Holt, AL; Farnham, PJ			Expression profiling and identification of novel genes in hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; representational difference analysis; expression profiling; oligonucleotide microarrays	REPRESENTATIONAL DIFFERENCE ANALYSIS; C3H/HEJ MICE; OSTEOPONTIN; CANCER; RNA; HEPATOCARCINOGENESIS; C57BL/6J; DOMAINS; GROWTH; TUMORS	Liver cancer is the fifth most common cancer worldwide and unlike certain other cancers, such as colon cancer, a mutational model has not Set been developed. We have performed gene expression profiling of normal and neoplastic livers in C3H/HeJ mice treated with diethylnitrosamine. Using oligonucleotide microarrays, we compared gene expression in liver tumors to three different states of the normal liver: quiescent adult, regenerating adult, and newborn. Although each comparison revealed hundreds of differentially expressed genes, only 22 genes were found to be deregulated in the tumors in all three comparisons. Three of these genes were examined in human hepatocellular carcinomas and were found to be upregulated. As a second method of analysis, we used Representational Difference Analysis (RDA) to clone mRNA fragments differentially expressed in Ih er tumors versus regenerating livers. We cloned several novel mRNAs that are differentially regulated in murine liver tumors. Here we report the sequence of a novel cDNA whose expression is upregulated in both murine and human hepatocellular carcinomas. Our results suggest that DEN-treated mice provide an excellent model for human hepatocellular carcinomas.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Pfizer Inc, Genom & Bioinformat, Ann Arbor, MI 48105 USA	University of Wisconsin System; University of Wisconsin Madison; Pfizer	Farnham, PJ (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA22484] Funding Source: Medline; NIGMS NIH HHS [GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariel I, 1998, J CLIN PATHOL-MOL PA, V51, P21, DOI 10.1136/mp.51.1.21; BENNETT LM, 1995, MOL CARCINOGEN, V14, P46, DOI 10.1002/mc.2940140109; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; FARBER E, 1976, LIVER CELL CANCER, P243; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Kojiro M, 1999, SEMIN LIVER DIS, V19, P287, DOI 10.1055/s-2007-1007118; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P1269, DOI 10.1164/ajrccm.160.4.9807094; Singhal H, 1997, CLIN CANCER RES, V3, P605; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; Yamada Y, 1999, LAB INVEST, V79, P1059; Ye XQ, 1997, BIOCHEM BIOPH RES CO, V239, P660, DOI 10.1006/bbrc.1997.7529; Yoong KF, 1999, HEPATOLOGY, V30, P100, DOI 10.1002/hep.510300147	24	76	83	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2704	2712		10.1038/sj.onc.1204391	http://dx.doi.org/10.1038/sj.onc.1204391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420682				2022-12-28	WOS:000168652600011
J	Liu, Y; Wang, Y; Yamakuchi, M; Masuda, S; Tokioka, T; Yamaoka, S; Maruyama, I; Kitajima, I				Liu, Y; Wang, Y; Yamakuchi, M; Masuda, S; Tokioka, T; Yamaoka, S; Maruyama, I; Kitajima, I			Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax	ONCOGENE			English	Article						PI3K; Akt; NF-kappa B; Tax; transformation; PI5K; HTLV-I; IKK gamma	NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PROTEIN; AKT; APOPTOSIS; ONCOGENE; SUBUNIT	Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt are essential for the fibroblast transformation induced by many viral products. Tax, encoded by human T-cell leukemia virus type I (HTLVI), has been demonstrated to induce the transformation of rat fibroblast Rat-1 cell through NF-kappaB activation, By stable transfection of Rat-1 cells with expressing constructs of Tax and its mutant M47, which is defective in HTLV-I LTR transactivation, we selected their transformed clones, which have characteristics of NF-kappaB activation and colony formation beyond the cell monolayer (a malignant phenotype), However, these two characteristics in the transformed clones of Tax and M47 disappear after these cells have been treated with wortmannin, a specific inhibitor of PI3K. Further, increased activity of the PI3K/Akt is observed in the transformed clones of Tax and M47 as compared to the clones of empty vector Neo and the M148, which is defective in NF-kappaB activation and cell transformation, Increased activity of PI5K is present in the transformed clones of both Tax and M47 and in the M148 clone as compared to that in the Neo cell, It is known that the efficiency of Tax-induced cell transformation is not high; a minority of Tax-expressing clones show transformation, although the majority of Tax-expressing clones show activated NF-kappaB, A Tax-expressing, nontransformed clone after transfection with an active form of the catalytic subunit of PI3K, p110 alpha, becomes transformed, Consistent with these results, a Tax highly-expressing human T-cell line MT2 exhibits both higher polyphosphoinositide turnover and higher activities of PI3K and PI5K than those of Jurkat or MT1 and HTLV-I-negative and a Tax-unexpressing cell line, respectively, These results demonstrate that the activation of the PI3K/Akt signaling pathway, excepting for the NF-kappaB, is also required for the cell transformation induced by Tax.	Toyama Med & Pharmaceut Univ, Dept Lab Med, Toyama 9300194, Japan; Kagoshima Univ, Fac Med, Dept Lab & Mol Med, Kagoshima 8908520, Japan; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	University of Toyama; Kagoshima University; Tokyo Medical & Dental University (TMDU)	Kitajima, I (corresponding author), Toyama Med & Pharmaceut Univ, Dept Lab Med, 2630 Sugitani, Toyama 9300194, Japan.							Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BEIMLING P, 1989, ONCOGENE, V4, P511; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Borlado LR, 2000, FASEB J, V14, P895; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GIAM CZ, 1986, P NATL ACAD SCI USA, V83, P7192, DOI 10.1073/pnas.83.19.7192; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kitajima I, 1997, ARTHRITIS RHEUM, V40, P2118, DOI 10.1002/art.1780401205; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1991, J CLIN INVEST, V88, P1315, DOI 10.1172/JCI115436; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mori N, 1999, BLOOD, V93, P2360; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Osada M, 1999, MOL CELL BIOL, V19, P6333; Ozes ON, 1999, NATURE, V401, P82; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RIZZO MT, 1994, CANCER RES, V54, P2611; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SINGHAL RL, 1994, CANCER RES, V54, P5574; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	61	58	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2514	2526		10.1038/sj.onc.1204364	http://dx.doi.org/10.1038/sj.onc.1204364			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420661				2022-12-28	WOS:000168652500002
J	Shah, N; Thomas, TJ; Lewis, JS; Klinge, CM; Shirahata, A; Gelinas, C; Thomas, T				Shah, N; Thomas, TJ; Lewis, JS; Klinge, CM; Shirahata, A; Gelinas, C; Thomas, T			Regulation of estrogenic and nuclear factor kappa B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells	ONCOGENE			English	Review						polyamines; nuclear factor kappa B; estrogen receptor; breast cancer	SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; CREB-BINDING PROTEIN; ORNITHINE DECARBOXYLASE; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASES; INDUCIBLE CHEMORESISTANCE; GROWTH-INHIBITION; RESPONSE ELEMENT; CARCINOMA-CELLS; GENE-EXPRESSION	The natural polyamines -putrescine, spermidine, and spermine- are essential for cell growth and differentiation. Polyamines are involved in several gene regulatory functions, although their mechanism(s) of action has not been elucidated. We investigated the role of polyamines in the function of NF-kappaB and estrogen receptor-alpha (ER alpha), two transcription factors implicated in breast cancer cell proliferation and cell survival, using MCF-7 breast cancer cells. We found that spermine facilitated the binding of ER alpha and NF-kappaB to estrogen response element (ERE)- and NF-kappaB response element (NRE), respectively, and enhanced ER alpha -mediated transcriptional activation in transient transfection experiments. We also found that the association of the co-regulatory protein CBP/p300 with ER alpha and NF-kappaB was increased by spermine treatment of MCF-7 cells. Spermine also increased the nuclear translocation of NF-kappaB compared to the control. In contrast, treatment of MCF-7 cells with polyamine analogs, BE-3-4-3 and BE-3-3-3, resulted in transcriptional inhibition of both ERE- and NRE-driven reporter plasmids, in addition, polyamine analogs inhibited the association of ER alpha and NF-kappaB with CBP/p300 and were unable to facilitate nuclear translocation of NF-kappaB, APO-BRDU assay demonstrated that polyamine analogs induced apoptosis, with a loss of the anti-apoptotic protein Bcl-2, These data show a gene regulatory function of polyamines involving transcriptional activation of ER alpha and NF-kappaB, potentially leading to the up-regulation of genes involved in breast cancer cell proliferation. Our results with BE-3-4-3 and BE-3-3-3 suggest that down-regulation of ER alpha- and NF-kappaB-regulated genes is a possible mechanism for the action of polyamine analogs in inducing apoptosis of breast cancer cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Community Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, New Brunswick, NJ 08903 USA; Rutgers State Univ, Nutr Sci Grad Program, New Brunswick, NJ 08903 USA; Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA; Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 35002, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Louisville; Josai University	Thomas, T (corresponding author), 125 Paterson St,Clin Acad Bldg,Room 7090, New Brunswick, NJ 08901 USA.			Klinge, Carolyn/0000-0002-3358-4378; Shah, Neha/0000-0002-9286-3801	NCI NIH HHS [CA 42439, CA 80163, CA 73058] Funding Source: Medline; NIDDK NIH HHS [DK 53220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA042439, R01CA080163, R01CA042439, R01CA073058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berchtold CM, 1998, J CELL PHYSIOL, V174, P380, DOI 10.1002/(SICI)1097-4652(199803)174:3<380::AID-JCP12>3.0.CO;2-D; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BISWAD SK, 2000, P NATL ACAD SCI USA, V97, P8542; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryans M, 1996, BIOCHEM BIOPH RES CO, V226, P618, DOI 10.1006/bbrc.1996.1405; Canizares F, 1999, CLIN CANCER RES, V5, P2035; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CELANO P, 1989, J BIOL CHEM, V264, P8922; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Cusack JC, 2000, CANCER RES, V60, P2323; DAVIDSON NE, 1993, CANCER RES, V53, P2071; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; Delzenne NM, 2000, J NUTR, V130, P2456, DOI 10.1093/jn/130.10.2456; Desiderio MA, 1999, FEBS LETT, V455, P149, DOI 10.1016/S0014-5793(99)00873-X; Doerre S, 1999, J IMMUNOL, V163, P269; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Faaland CA, 2000, BIOCHEM CELL BIOL, V78, P415, DOI 10.1139/bcb-78-4-415; FAALAND CA, 1995, CELL GROWTH DIFFER, V6, P115; FEUERSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271, DOI 10.1093/nar/18.5.1271; Gabrielson EW, 1999, CLIN CANCER RES, V5, P1638; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; IGARASHI K, 1995, CANCER RES, V55, P2615; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Kramer DL, 1997, CANCER RES, V57, P5521; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurebayashi S, 1997, J STEROID BIOCHEM, V60, P11, DOI 10.1016/S0960-0760(96)00175-6; Leveque J, 1999, ANTICANCER RES, V19, P2275; Leveque J, 2000, BREAST CANCER RES TR, V60, P99, DOI 10.1023/A:1006319818530; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MANNI A, 1995, CANCER LETT, V92, P49, DOI 10.1016/0304-3835(95)03763-M; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MUNOZ E, 1994, J VIROL, V68, P8035; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; OBRIEN MJ, 1992, CANCER-AM CANCER SOC, V70, P1317, DOI 10.1002/1097-0142(19920901)70:3+<1317::AID-CNCR2820701519>3.0.CO;2-X; OBrien TG, 1997, CANCER RES, V57, P2630; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PANAGIOTIDIS CA, 1995, NUCLEIC ACIDS RES, V23, P1800, DOI 10.1093/nar/23.10.1800; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PERA PJ, 1986, CANCER RES, V46, P1148; Porter C W, 1988, Adv Exp Med Biol, V250, P677; PORTER CW, 1994, CANCER RES, V54, P5917; PORTER CW, 1990, BIOCHEM J, V268, P207, DOI 10.1042/bj2680207; Rauch BH, 2000, FEBS LETT, V481, P3, DOI 10.1016/S0014-5793(00)01957-8; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Rouet-Benzineb P, 2000, J MOL CELL CARDIOL, V32, P1767, DOI 10.1006/jmcc.2000.1211; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P37, DOI 10.1016/0303-7207(91)90057-Y; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Sharma A, 1997, CLIN CANCER RES, V3, P1239; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TABIB A, 1994, BIOCHEM BIOPH RES CO, V202, P720, DOI 10.1006/bbrc.1994.1990; Tabib A, 1999, INT J BIOCHEM CELL B, V31, P1289, DOI 10.1016/S1357-2725(99)00098-9; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; THOMAS T, 1995, J STEROID BIOCHEM, V54, P89, DOI 10.1016/0960-0760(95)00126-K; Thomas T, 1999, J MOL ENDOCRINOL, V22, P131, DOI 10.1677/jme.0.0220131; Thomas T, 1997, NUCLEIC ACIDS RES, V25, P2396, DOI 10.1093/nar/25.12.2396; THOMAS T, 1993, BREAST CANCER RES TR, V29, P189; Thomas TJ, 1998, BREAST CANCER RES TR, V47, P181, DOI 10.1023/A:1005925931215; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang GJ, 1998, ONCOL REP, V5, P1211; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	112	45	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1715	1729		10.1038/sj.onc.1204247	http://dx.doi.org/10.1038/sj.onc.1204247			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313919				2022-12-28	WOS:000167750900005
J	Agathanggelou, A; Honorio, S; Macartney, DP; Martinez, A; Dallol, A; Radar, J; Fullwood, P; Chauhan, A; Walker, R; Shaw, JA; Hosoe, S; Lerman, MI; Minna, JD; Maher, ER; Latif, F				Agathanggelou, A; Honorio, S; Macartney, DP; Martinez, A; Dallol, A; Radar, J; Fullwood, P; Chauhan, A; Walker, R; Shaw, JA; Hosoe, S; Lerman, MI; Minna, JD; Maher, ER; Latif, F			Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours	ONCOGENE			English	Article						3p; tumour suppressor gene; methylation; lung cancer; breast cancer	HUMAN-CHROMOSOME 3P21.3; SUPPRESSOR GENE; HOMOZYGOUS DELETION; SMALL-CELL; SHORT ARM; CANCER; IDENTIFICATION; 3P; LOCUS; CARCINOMA	Previously we analysed overlapping homozygous deletions in lung and breast tumours/tumour lines and defined a small region of 120 kb (part of LCTSGR1) at 3p21.3 that contained putative lung and breast cancer tumour suppressor gene(s) (TSG), Eight genes including RASSF1 were isolated from the minimal region. However, extensive mutation analysis in lung tumours and tumour lines revealed only rare inactivating mutations. Recently, de novo methylation at a CpG island associated with isoform A of RASSF1 (RASSF1A) was reported in lung tumours and tumour lines. To investigate RASSF1A as a candidate TSG for various cancers, we investigated: (a) RASSF1A methylation status in a large series of primary tumour and tumour lines; (b) chromosome 3p allele loss in lung tumours and (c) RASSF1 mutation analysis in breast tumours, RASSF1A promoter region CpG island methylation was detected in 72% of SCLC, 34% of NSCLC, 9% of breast, 10% of ovarian and 0% of primary cervical tumours and in 72% SCLC, 36% NSCLC, 80% of breast and 40% of ovarian tumour lines. In view of the lower frequency of RASSF1 methylation in primary breast cancers me proceeded to RASSF1 mutation analysis in 40 breast cancers. No mutations were detected, but six single nucleotide polymorphisms were identified. Twenty of 26 SCLC tumours with 3p21.3 allelic loss had RASSF1A methylation, while only six out of 22 NSCLC with 3p21.3 allele loss had RASSF1A methylation (P = 0.0012), one out of five ovarian and none out of six cervical tumours with 3p21.3 loss had RASSF1A methylation. These results suggest that (a) RASSF1A inactivation by two hits (methylation and loss) is a critical step in SCLC tumourigenesis and (b) RASSF1A inactivation is of lesser importance in NSCLC, breast, ovarian and cervical cancers in which other genes within LCTSGR1 are likely to be implicated.	Univ Birmingham, Sch Med, Dept Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Univ Leicester, Glenfield Hosp, Breast Canc Res Unit, Leicester, Leics, England; Natl Kinki Chuo Hosp, Dept Internal Med, Osaka, Japan; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21701 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	University of Birmingham; Washington University (WUSTL); University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008; Dallol, Ashraf/H-8661-2012	MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X; Shaw, Jacqui/0000-0003-4227-503X; Macartney-Coxson, Donia/0000-0002-1051-537X	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline; Breast Cancer Now [1999:98] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Now		BURBEE DG, 2001, IN PRESS J NATL CANC; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Fullwood P, 1999, CANCER RES, V59, P4662; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lerman MI, 2000, CANCER RES, V60, P6116; Partridge M, 1999, INT J CANCER, V83, P318, DOI 10.1002/(SICI)1097-0215(19991029)83:3<318::AID-IJC6>3.0.CO;2-V; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Reed AL, 1996, CANCER RES, V56, P3630; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; VOS MD, 2000, IN PRESS J BIOL CHEM; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349	32	343	381	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2001	20	12					1509	1518		10.1038/sj.onc.1204175	http://dx.doi.org/10.1038/sj.onc.1204175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313894				2022-12-28	WOS:000167595200011
J	Luo, JC; Shibuya, M				Luo, JC; Shibuya, M			A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1 alpha, 2 alpha and 3 alpha)	ONCOGENE			English	Article						nuclear localization signal; hypoxia inducible factor; ubiquitin-proteasome system; von hippellindau tumor suppressor; protein stability	TUMOR-SUPPRESSOR PROTEIN; ARYL-HYDROCARBON RECEPTOR; HIPPEL-LINDAU PROTEIN; EXPORT SIGNALS; EXPRESSION; BINDING; DOMAIN; ALPHA; FACTOR-1-ALPHA; STABILIZATION	Hypoxia inducible factors (HTF1, 2 and 3), consisting of alpha and beta subunits, play an essential role in various responses to hypoxia. Nuclear entry of alpha subunits is a necessary step for the formation of DNA-binding complex with beta subunit, which is constitutively localized in the nucleus. We show here that the nuclear accumulation of HIF2 alpha induced by hypoxia is mediated through a novel variant of bipartite-type nuclear localization signal (NLS) in the C-terminus of the protein, which has an unusual length of spacer sequence between two adjacent basic domains. We further show that when the ubiquitin-proteasome system was deficient or inhibited, HIF2a accumulated in the nucleus even under normoxia, also mediated through the bipartite NLS, These findings indicate that the protein stability is critical for the nuclear localization of HIF2a and hypoxia is not a necessary factor for the process. Importantly, the NLS of HIF2a is also conserved in the other HIF family members, HIF1 alpha and HIF3 alpha. Mutational analyses proved that the NLS mediating the nuclear localization of HIF1 alpha is indeed bipartite-, but not monopartite-type as thought before, Our results suggest that the newly identified NLS is crucial for the functional regulation of HIF family.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan.		Jin Cai, Luo/A-7900-2011					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bear J, 1999, MOL CELL BIOL, V19, P6306; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; Chilov D, 1999, J CELL SCI, V112, P1203; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Luo JC, 1998, CANCER RES, V58, P2652; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	28	65	68	2	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1435	1444		10.1038/sj.onc.1204228	http://dx.doi.org/10.1038/sj.onc.1204228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313887				2022-12-28	WOS:000167595200004
J	Dihlmann, S; Siermann, A; Doeberitz, MV				Dihlmann, S; Siermann, A; Doeberitz, MV			The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling	ONCOGENE			English	Article						WNT; NSAID; colorectal cancer; transcriptional regulation; tumor prevention	NF-KAPPA-B; BETA-CATENIN; CYCLOOXYGENASE-2 INHIBITORS; COLORECTAL-CANCER; SULINDAC SULFIDE; COLON-CANCER; CYCLIN D1; APC; TARGET; CELLS	Increasing epidemiological and experimental evidence implicates non-steroidal anti-inflanmatory drugs (NSAIDs) as anti-tumorigenic agents. The precise mechanisms whereby NSAIDs exert their anti-neoplastic effects remain poorly understood. Studies from hereditary and sporadic colorectal cancer (CRC) patients suggest that NSAIDs may interfere with initiating steps of carcinogenesis, i.e. disturbances,within the beta -catenin signaling pathway. We therefore investigated beta -catenin/ TCF signaling in response to aspirin or indomethacin, respectively, in four CRC cell lines (SW948, SW480, HCT116, LoVo). Both, aspirin and indomethacin inhibited transcription of a beta -catenin/TCF-responsive reporter gene In a dose dependent manner, In addition, the beta -catenin/TCF transcriptional target cyclin D1 was downregulated by both drugs, Endogenous beta -catenin levels remained unaffected by either drug. Moreover, indirect immunofluorescence studies revealed no significant changes of subcellular beta -catenin localization in either cell line after NSAID treatment, Likewise, binding of the beta -catenin/TCF complex to its specific DNA-binding sites was not altered, as demonstrated by electrophoretic mobility shift assay (EMSA) of nuclear extracts derived from NSAID treated cells, These results strongly suggest that aspirin and indomethacin attenuate the transcription of beta -catenin/TCF-responsive gents, by modulating TCF activity without disrupting beta -catenin/ TCF complex formation.	Heidelberg Univ, Dept Surg, Div Mol Diagnost & Therapy, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Dept Surg, Div Mol Diagnost & Therapy, D-69120 Heidelberg, Germany.			Dihlmann, Susanne/0000-0002-3737-7755				AHNEN DJ, 1988, EUR J SURG S, V582, P111; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bordonaro M, 1999, CELL GROWTH DIFFER, V10, P713; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dihlmann S, 1999, CANCER RES, V59, P1857; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Goodman L. S., 1996, PHARM BASIS THERAPEU; Goppelt-Struebe M, 2000, N-S ARCH PHARMACOL, V361, P636, DOI 10.1007/s002100000231; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Mahmoud NN, 1997, CANCER RES, V57, P5045; Mahmoud NN, 1998, SURGERY, V124, P225, DOI 10.1016/S0039-6060(98)70124-2; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McEntee MF, 1999, CARCINOGENESIS, V20, P635, DOI 10.1093/carcin/20.4.635; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Patten EJ, 1999, CANCER LETT, V147, P95, DOI 10.1016/S0304-3835(99)00282-7; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ricchi P, 1997, INT J CANCER, V73, P880; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Subbegowda R, 1998, CANCER RES, V58, P2772; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	45	163	172	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					645	653		10.1038/sj.onc.1204123	http://dx.doi.org/10.1038/sj.onc.1204123			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313997				2022-12-28	WOS:000166755000012
J	Blagosklonny, MV				Blagosklonny, MV			Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors	ONCOGENE			English	Review						p53; VHL; HIF-1 alpha; mdm-2; beta-catenin	INDUCIBLE FACTOR 1-ALPHA; DNA-DAMAGE; PROTEIN; HYPOXIA; GENE; TRANSCRIPTION; STABILIZATION; ACTIVATION; STABILITY; PROMOTES	Recently it has been shown that the VHL tumor suppressor targets the hypoxia-inducible transcription factor (HIF-1) for ubiquitin-dependent degradation by the proteasome, Past mysteries of the p53 tumor suppressor help to solve the present puzzles of the VHL tumor suppressor. Thus, Mdm-2 targets the p53 tumor suppressor for ubiquitin-dependent degradation by the proteasome, but, in addition, the p53 transcription factor induces Mdm-2, thus, establishing a feedback loop. Hypoxia or DNA damage by abrogating binding of HIF-1 with VHL and p53 with Mdm-2, respectively, leads to stabilization and accumulation transcriptionally active HIF-1 and p53, More detailed analysis depicts the VHL/HIF-1 pair as the p53/mdm-2 pair that is turned upside down, suggesting that VHL may be a HIF-1-inducible gene of the feedback loop. The extended model proposes that an oncoprotein and a tumor suppressor due to transactivation coupled with feedback protein degradation might form functional pairs (Rb/E7, E2F/Rb, E2F/Mdm-2, catenin/APC, p27, cyclin D1, Rb/gankyrin), thus, predicting missing links.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blagosklonny, MV (corresponding author), NCI, Med Branch, NIH, Bethesda, MD 20892 USA.							An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Renbaum P, 1996, HUM GENET, V98, P666, DOI 10.1007/s004390050281; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salnikow K, 2000, CANCER RES, V60, P38; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhong H, 1999, CANCER RES, V59, P5830; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	37	28	30	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					395	398		10.1038/sj.onc.1204055	http://dx.doi.org/10.1038/sj.onc.1204055			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313969	Bronze			2022-12-28	WOS:000166411000014
J	Huang, ZW				Huang, ZW			Bcl-2 family proteins as targets for anticancer drug design	ONCOGENE			English	Article						Bcl-2; apoptosis; caspase; cancer; chemoresistance; drug design	PROGRAMMED CELL-DEATH; CYTOCHROME-C; ISOLATED-MITOCHONDRIA; ANTISENSE THERAPY; TUMOR-CELLS; APOPTOSIS; BCL-X(L); BINDING; DOMAIN; BAX	Bcl-2 family proteins are key regulators of programmed cell death or apoptosis that is implicated in many human diseases, particularly cancer. In recent years, they have attracted intensive interest in both basic research to understand the fundamental principles of cell survival and cell death and drug discovery to develop a new class of anticancer agents. The Bcl-2 family includes both anti-and pro-apoptotic proteins with opposing biological functions in either inhibiting or promoting cell death. High expression of anti-apoptotic members such as Bcl-2 and Bcl-x(L) commonly found in human cancers contributes to neoplastic cell expansion and interferes with the therapeutic action of many chemotherapeutic drugs. The functional blockade of Bcl-2 or Bcl-x(L) could either restore the apoptotic process in tumor cells or sensitize these tumors for chemo- and radiotherapies. This article reviews the recent progress in the design and discovery of small molecules that block the anti-apoptotic function of Bcl-2 or Bcl-x(L). These chemical inhibitors are effective modulators of apoptosis and promising leads for the further development of new anticancer agents.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Huang, ZW (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; BOYD JM, 1995, ONCOGENE, V11, P1921; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Huang ZW, 2000, PHARMACOL THERAPEUT, V86, P201, DOI 10.1016/S0163-7258(00)00052-8; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MORGAN BA, 2000, 91 ANN M AM ASS CANC, V42, P4693; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakashima T, 2000, CANCER RES, V60, P1229; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Piche A, 1998, CANCER RES, V58, P2134; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOKUTAKE N, 1994, BBA-BIOENERGETICS, V1185, P271, DOI 10.1016/0005-2728(94)90241-0; TOMITA F, 1980, J ANTIBIOT, V33, P668, DOI 10.7164/antibiotics.33.668; TZUNG SP, 1999, AACR NCI EORTIC INT, P87; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yu NF, 2000, TETRAHEDRON LETT, V41, P6993, DOI 10.1016/S0040-4039(00)01195-3; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	33	176	191	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 27	2000	19	56					6627	6631		10.1038/sj.onc.1204087	http://dx.doi.org/10.1038/sj.onc.1204087			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426648				2022-12-28	WOS:000167704000009
J	Weiner, LM; Adams, GP				Weiner, LM; Adams, GP			New approaches to antibody therapy	ONCOGENE			English	Article						antibody therapy; radioimmunotherapy; bispecific antibodies	SINGLE-CHAIN FV; BISPECIFIC MONOCLONAL-ANTIBODY; PHASE-I TRIAL; B-CELL LYMPHOMA; ENZYME PRODRUG THERAPY; FUSION PROTEIN; RADIOLABELED-ANTIBODY; TARGETING C-ERBB-2; OVARIAN-CARCINOMA; COLORECTAL-CANCER	Antibody-based therapy of human cancers has led to several remarkable outcomes, particularly in the therapy of breast cancer and lymphoma. Many solid tumors have proven less responsive, due in part to difficulties in the tumor-selective delivery of antibodies and potential cytolytic effecters. However, antibodies that directly perturb signaling mechanisms in cells derived from epithelial malignancies have shown benefit; examples include antibodies directed against the extracellular domains of HER2/neu and epidermal growth factor receptor. A long-term goal of immunotherapy has been to induce anti-tumor inflammatory responses that can directly cause tumor regression or induct adaptive responses against tumor-related antigens. This review focuses on the use of antibodies to provide a means for initiating anti-tumor immune responses, and on the use of antibodies as delivery vehicles of radionuclides.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Weiner, LM (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Adams, Gregory/ABE-8245-2020		NATIONAL CANCER INSTITUTE [P30CA006927, R01CA050633, R01CA065559] Funding Source: NIH RePORTER; NCI NIH HHS [CA65559, CA06927, CA50633] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 1998, CANCER RES, V58, P485; ADAMS GP, 1993, CANCER RES, V53, P4026; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; ADAMS GP, 1995, CANCER IMMUNOL IMMUN, V40, P299, DOI 10.1007/BF01519629; Alpaugh RK, 1998, CLIN CANCER RES, V4, P1903; ANDERSON WT, 1987, NATL CANCER I MONOGR, V3, P149; Axworthy D, 1996, TUMOR TARGET, V2, P156; Bagshawe K D, 1993, Adv Pharmacol, V24, P99, DOI 10.1016/S1054-3589(08)60935-7; BAGSHAWE KD, 1991, DIS MARKERS, V9, P233; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; CANEVARI S, 1995, JNCI-J NATL CANCER I, V87, P1463, DOI 10.1093/jnci/87.19.1463; Challita-Eid PM, 1998, J IMMUNOL, V161, P3729; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Clark JI, 1997, CANCER IMMUNOL IMMUN, V44, P265, DOI 10.1007/s002620050382; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; COLCHER D, 1988, CANCER RES, V48, P4597; Curnow RT, 1997, CANCER IMMUNOL IMMUN, V45, P210, DOI 10.1007/s002620050435; DEPALAZZO IG, 1990, CANCER RES, V50, P7123; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; GALLINGER S, 1993, CANCER RES, V53, P271; Giantonio BJ, 1997, J CLIN ONCOL, V15, P1994, DOI 10.1200/JCO.1997.15.5.1994; GILLIES SD, 1992, P NATL ACAD SCI USA, V89, P1428, DOI 10.1073/pnas.89.4.1428; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOODWIN DA, 1988, J NUCL MED, V29, P226; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Hu SZ, 1996, CANCER RES, V56, P3055; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JAIN RK, 1987, CANCER RES, V47, P3039; JUWEID M, 1992, CANCER RES, V52, P5144; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Knox SJ, 2000, CLIN CANCER RES, V6, P406; KUDO T, 1991, J IMMUNOL METHODS, V145, P119, DOI 10.1016/0022-1759(91)90317-9; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; LI S, 1986, J IMMUNOL, V137, P3378; LINK BK, 1993, BLOOD, V81, P3343; Link BK, 1998, INT J CANCER, V77, P251, DOI 10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.3.CO;2-O; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; MALONEY DG, 1994, BLOOD, V84, P2457; Martin J, 1997, CANCER CHEMOTH PHARM, V40, P189, DOI 10.1007/s002800050646; NITTA T, 1990, LANCET, V335, P368, DOI 10.1016/0140-6736(90)90205-J; OBRIST R, 1988, BIOCHEM BIOPH RES CO, V155, P1139, DOI 10.1016/S0006-291X(88)81259-2; ORDER SE, 1986, INT J RADIAT ONCOL, V12, P277, DOI 10.1016/0360-3016(86)90110-0; PAGANELLI G, 1988, INT J CANCER, P121; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; PRESSMAN D, 1953, CANCER, V6, P619, DOI 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y; RENNER C, 1995, EUR J IMMUNOL, V25, P2027, DOI 10.1002/eji.1830250734; SABZEVARI H, 1994, P NATL ACAD SCI USA, V91, P9626, DOI 10.1073/pnas.91.20.9626; SCHEINBERG DA, 1991, J CLIN ONCOL, V9, P478, DOI 10.1200/JCO.1991.9.3.478; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCHIER R, 1995, IMMUNOTECHNOLOGY, V1, P73, DOI 10.1016/1380-2933(95)00007-0; SCONOCCHIA G, 1994, J IMMUNOL, V153, P5473; SEGAL DM, 1988, CANCER INVEST, V6, P83, DOI 10.3109/07357908809077031; Siemers NO, 1997, BIOCONJUGATE CHEM, V8, P510, DOI 10.1021/bc9700751; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; SILVERSTEIN AM, 1994, CELL IMMUNOL, V158, P1, DOI 10.1006/cimm.1994.1253; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA377; STEPLEWSKI Z, 1983, SCIENCE, V221, P865, DOI 10.1126/science.6879183; Thomas MC, 1998, HUM GENE THER, V9, P835, DOI 10.1089/hum.1998.9.6-835; TIBBEN JG, 1993, J NATL CANCER I, V85, P1003, DOI 10.1093/jnci/85.12.1003; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; Valerius T, 1997, BLOOD, V90, P4485, DOI 10.1182/blood.V90.11.4485.4485_4485_4492; VALONE FH, 1995, J CLIN ONCOL, V13, P2281, DOI 10.1200/JCO.1995.13.9.2281; WEINER GJ, 1994, J IMMUNOL, V152, P2385; WEINER LM, 1995, CANCER RES, V55, P4586; WEINER LM, 1993, CANCER RES, V53, P94; WEINER LM, 1993, J IMMUNOL, V151, P2877; WEINER LM, 1995, TUMOR TARGET, V1, P51; Weinstein S., 1986, MODERN MED, V1, P5; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Wu AM, 1996, IMMUNOTECHNOLOGY, V2, P21, DOI 10.1016/1380-2933(95)00027-5	72	77	85	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6144	6151		10.1038/sj.onc.1204000	http://dx.doi.org/10.1038/sj.onc.1204000			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156528				2022-12-28	WOS:000166121400008
J	Kim, JS; Pirnia, F; Choi, YH; Nguyen, P; Knepper, B; Tsokos, M; Schulte, TW; Birrer, MJ; Blagosklonny, MV; Schaefer, O; Mushinski, JF; Trepel, JB				Kim, JS; Pirnia, F; Choi, YH; Nguyen, P; Knepper, B; Tsokos, M; Schulte, TW; Birrer, MJ; Blagosklonny, MV; Schaefer, O; Mushinski, JF; Trepel, JB			Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G-1 checkpoint	ONCOGENE			English	Article						lovastatin; differentiation; apoptosis; ESFT	PROSTATE CARCINOMA-CELLS; CYCLIN-DEPENDENT KINASES; EWINGS-SARCOMA; THYMOCYTE APOPTOSIS; DNA-BINDING; PHASE-I; CANCER; E2F-1; INHIBITION; INDUCTION	To develop a new approach to the treatment of primitive neuroectodermal tumors we evaluated the effect of the HMG-CoA reductase inhibitor lovastatin on the Ewing's sarcoma cell line CHP-100, Lovastatin induced neural morphology and markers including neuron-specific enolase and neurofilament protein. The acquisition of neural morphology required nem mRNA synthesis, and cDNA microarray analysis confirmed that lovastatin altered the program of gene expression. After morphologic differentiation the cells underwent rapidly progressive apoptosis. In normal development of neuronal progenitors, differentiation signals trigger p21(WAF1) accumulation, RB hypophosphorylation, enhanced RB-E2F-1 association, and G1 arrest, and these events have been shown to protect from apoptosis. In contrast, in the Ewing's sarcoma cells lovastatin triggered differentiation without causing cell cycle arrest: p21(WAF1) was not induced, RE remained hyperphosphorylated, and RE protein expression and RE-E2F-1 association were markedly downregulated, suggesting that loss of an RE-regulated G1 checkpoint promoted apoptosis. Consistent with this hypothesis, adenoviral p21(WAF1) decreased DNA synthesis and partially protected from lovastatin-induced cytotoxicity. The data demonstrate a new model for examining the genetic regulation of cell fate in a neural progenitor tumor and suggest a new approach to the treatment of this neoplasm.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NCI, Genet Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Trepel, JB (corresponding author), NCI, Med Branch, NIH, Bldg 10,Room 12N230, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC008727, ZIABC008727] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BERNAL S, 1983, CANCER RES, V43, P1256; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 1997, INT J ONCOL, V11, P1165; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denny CT, 1996, CANCER INVEST, V14, P83, DOI 10.3109/07357909609018438; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fontaine C, 1997, ANN ONCOL, V8, P691, DOI 10.1023/A:1008271903643; GrayBablin J, 1997, CANCER RES, V57, P604; GUDAS JM, 1993, CELL GROWTH DIFFER, V4, P421; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hense HW, 1999, ANN ONCOL, V10, P1073, DOI 10.1023/A:1008357018737; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ISHIZAWA M, 1991, NUCLEIC ACIDS RES, V19, P5792, DOI 10.1093/nar/19.20.5792; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Jang JS, 1999, ONCOGENE, V18, P1789, DOI 10.1038/sj.onc.1202497; Jurgens H F, 1994, Curr Opin Oncol, V6, P391; Kaelin WG, 1999, J CLIN INVEST, V104, P1503, DOI 10.1172/JCI8888; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Kovar H, 1998, Sarcoma, V2, P3, DOI 10.1080/13577149878109; LADENSTEIN R, 1995, BONE MARROW TRANSPL, V15, P697; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; LIPINSKI M, 1987, CANCER RES, V47, P183; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Macaulay RJB, 1999, J NEURO-ONCOL, V42, P1, DOI 10.1023/A:1006164406202; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Muller C, 1999, INT J MOL MED, V3, P63; MUNRO E, 1994, EUR J CLIN INVEST, V24, P766, DOI 10.1111/j.1365-2362.1994.tb01074.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PACHTER JS, 1984, DEV BIOL, V103, P200, DOI 10.1016/0012-1606(84)90021-6; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Ross SD, 1999, ARCH INTERN MED, V159, P1793, DOI 10.1001/archinte.159.15.1793; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Stewart ZA, 1999, CANCER RES, V59, P3831; Thibault A, 1996, CLIN CANCER RES, V2, P483; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tsokos M, 1992, Perspect Pediatr Pathol, V16, P27; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	58	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6082	6090		10.1038/sj.onc.1204008	http://dx.doi.org/10.1038/sj.onc.1204008			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146561				2022-12-28	WOS:000165827900016
J	Rokhlin, OW; Guseva, N; Tagiyev, A; Knudson, CM; Cohen, MB				Rokhlin, OW; Guseva, N; Tagiyev, A; Knudson, CM; Cohen, MB			Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis	ONCOGENE			English	Article						Bcl-2; prostatic neoplasms; TRAIL; apoptosis	CYTOCHROME-C; CD95 APO-1/FAS; MITOCHONDRIAL; DEATH; FAS; CASPASE-8; FAMILY; RELEASE; LIGAND; LOCALIZATION	The role of Bcl-2 in TRAIL-induced apoptosis has been investigated in lymphoid cells, Here we show that the human prostatic carcinoma cell line PC3 was sensitive to TRAIL treatment whereas PC3 overexpressing of Bcl-2 was resistant. TRAIL receptors ligation in PC3 activated caspases -2, -3, -7, -8, and -9, induced Bid processing, dissipation of mitochondrial transmembrane potential (Delta Psi (m)), and cytochrome c release. We have detected caspases -8 and -3 only in the cytosolic fraction of cells, but caspases -2, -7, and -9 were found both in cytosolic and mitochondrial fractions. Bcl-2 overexpression did not affect caspase-8 activation although it did change the processing pattern of caspase-3, At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9, Bcl-2 also abrogated TRAIL-induced cytochrome c release and dissipation of Delta Psi (m). These findings suggest that TRAIL-induced apoptosis in the epithelial cell line PC3 depends both on mitochondrial integrity and caspase activation.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Cohen, MB (corresponding author), Univ Iowa, Dept Pathol, 200 Hawkins Dr,1117 ML, Iowa City, IA 52242 USA.			Knudson, Charles Michael/0000-0003-3964-5466	NCI NIH HHS [CA 76673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bonavida B, 1999, INT J ONCOL, V15, P793; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Gewies A, 2000, CANCER RES, V60, P2163; Gotow T, 2000, CELL DEATH DIFFER, V7, P666, DOI 10.1038/sj.cdd.4400694; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rokhlin OW, 1997, CANCER RES, V57, P1758; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, ONCOGENE, V13, P21; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WILLEY SR, 1995, IMMUNITY, V3, P673; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	39	67	71	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2836	2843		10.1038/sj.onc.1204410	http://dx.doi.org/10.1038/sj.onc.1204410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420695				2022-12-28	WOS:000168712000011
J	Kannan, K; Amariglio, N; Rechavi, G; Jakob-Hirsch, J; Kela, I; Kaminski, N; Getz, G; Domany, E; Givol, D				Kannan, K; Amariglio, N; Rechavi, G; Jakob-Hirsch, J; Kela, I; Kaminski, N; Getz, G; Domany, E; Givol, D			DNA microarrays identification of primary and secondary target genes regulated by p53	ONCOGENE			English	Article						DNA microarray; cycloheximide; ts-p53; target genes; expression profile, clustering	CELL-CYCLE; EXPRESSION; GROWTH; INDUCTION; STABILITY; PROMOTER; REVEALS; BINDING; ARREST; MUTANT	The transcriptional program regulated by the tumor suppressor p53 was analysed using oligonucleotide microarrays. A human lung cancer cell line that expresses the temperature sensitive murine p53 was utilized to quantitate mRNA levels of various genes at different time points after shifting the temperature to 32 degreesC. Inhibition of protein synthesis by cycloheximide (CHX) was used to distinguish between primary and secondary target genes regulated by p53. In the absence of CHX, 259 and 125 genes were up or down-regulated respectively; only 38 and 24 of these genes were up and down-regulated by p53 also in the presence of CHX and are considered primary targets in this cell line. Cluster analysis of these data using the super paramagnetic clustering (SPC) algorithm demonstrate that the primary genes can be distinguished as a single cluster among a large pool of p53 regulated genes. This procedure identified additional genes that co-cluster with the primary targets and can also be classified as such genes, In addition to cell cycle (e.g. p21, TGF-beta, Cyclin E) and apoptosis (e.g, Fas, Bak, IAP) related genes, the primary targets of p53 include genes involved in many aspects of cell function, including cell adhesion (e.g, Thymosin, Smoothelin), signaling (e.g. H-Ras, Diacylglycerol kinase), transcription (e.g. ATF3, LISCH7), neuronal growth (e.g. Ninjurin, NSCL2) and DNA repair (e.g. BTG2, DDB2), The results suggest that p53 activates concerted opposing signals and exerts its effect through a diverse network of transcriptional changes that collectively alter the cell phenotype in response to stress.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Funct Genom Unit, Tel Aviv, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		DOMANY, EYTAN/K-1560-2012	Kaminski, Naftali/0000-0001-5917-4601				Ausubel FA, 1990, CURRENT PROTOCOLS MO; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Getz G, 2000, PHYSICA A, V279, P457, DOI 10.1016/S0378-4371(99)00524-5; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Sherlock G, 2000, CURR OPIN IMMUNOL, V12, P201, DOI 10.1016/S0952-7915(99)00074-6; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhao RB, 2000, GENE DEV, V14, P981	30	274	291	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2225	2234		10.1038/sj.onc.1204319	http://dx.doi.org/10.1038/sj.onc.1204319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402317				2022-12-28	WOS:000168404500004
J	Wang, HC; Zeng, ZC; Bui, TA; Sonoda, E; Takata, M; Takeda, S; Iliakis, G				Wang, HC; Zeng, ZC; Bui, TA; Sonoda, E; Takata, M; Takeda, S; Iliakis, G			Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group	ONCOGENE			English	Review						double-strand breaks (DSB); homologous recombination; RAD51; RAD51B; RAD52; RAD54; KU70; repair	DEPENDENT PROTEIN-KINASE; RECOMBINATIONAL REPAIR GENE; FIELD GEL-ELECTROPHORESIS; HOMOLOGY-DIRECTED REPAIR; SENSITIVE IRS MUTANTS; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; IONIZING-RADIATION; LIGASE IV; PROKARYOTIC RECA	Rejoining of ionizing radiation (IR) induced DNA DSBs usually follows biphasic kinetics with a fast (t(50): 5-30 min) component attributed to DNA-PK-dependent non-homologous endjoining (NHEJ) and a slow (t(50): 1-20 h), as of yet uncharacterized, component. To examine whether homologous recombination (HR) contributes to DNA DSB rejoining, a systematic genetic study was undertaken using the hyper-recombinogenic DT40 chicken cell line and a series of mutants defective in HR, We show that DT40 cells rejoin IR-induced DNA DSBs with half times of 13 min and 4.5 h and contributions by the fast (78%) and the slow (22%) components similar to those of other vertebrate cells with 1000-fold lower levels of HR, We also show that deletion of RAD51B, RAD52 and RAD54 leaves unchanged the rejoining half times and the contribution of the slow component, as does also a conditional knock out mutant of RAD51, A significant reduction (to 37%) in the contribution of the fast component is observed in Ku70 / DT40 cells, but the slow component, operating with a half time of 18.4 h, is still able to rejoin the majority (63%) of DSBs, ri double mutant Ku70(-/-)/RAD54 / shows similar half times to Ku70(-/-) cells. Thus, variations in HR by several orders of magnitude leave unchanged the kinetics of rejoining of DNA DSBs, and fail to modify the contribution of the slow component in a way compatible with a dependence on HR, We propose that, in contrast to yeast, cells of vertebrates are 'hard-wired' in the utilization of NHEJ as the main pathway for rejoining of IR-induced DNA DSBs and speculate that the contribution of homologous recombination repair (HRR) is at a stage after the initial rejoining.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Kyoto Univ, Fac Med, Bayer Chair Dept Mol Immunol & Allergol, Sakyo Ku, Kyoto 6068501, Japan; JST, CREST, Tsukuba, Ibaraki, Japan	Jefferson University; Kyoto University; Japan Science & Technology Agency (JST)	Iliakis, G (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Thompson Bldg Room B-1, Philadelphia, PA 19107 USA.			Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991	NCI NIH HHS [P30-CA56036, CA42026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042026, P30CA056036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; BASES R, 1986, RADIAT RES, V105, P259, DOI 10.2307/3576551; BASES R, 1990, INT J RADIAT BIOL, V58, P35, DOI 10.1080/09553009014551421; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bennett CB, 1997, CANCER RES, V57, P1970; Bennett CB, 1996, MOL CELL BIOL, V16, P4414; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; CHEONG N, 1992, MUTAT RES, V274, P111, DOI 10.1016/0921-8777(92)90058-B; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; CONTOPOULOU CR, 1987, YEAST, V3, P71, DOI 10.1002/yea.320030203; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; Dibiase SJ, 2000, CANCER RES, V60, P1245; DIKOMEY E, 1986, INT J RADIAT BIOL, V50, P893, DOI 10.1080/09553008614551311; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Evans JW, 1996, RADIAT RES, V145, P39, DOI 10.2307/3579193; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; FRANKENBURGSCHWAGER M, 1994, INT J RADIAT BIOL, V66, P543, DOI 10.1080/09553009414551591; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENNER WD, 1983, J BIOL CHEM, V258, P711; HO KSY, 1975, MUTAT RES, V30, P327, DOI 10.1016/0165-1218(75)90058-0; ILIAKIS G, 1992, INT J RADIAT BIOL, V61, P315, DOI 10.1080/09553009214550991; ILIAKIS G, 1991, BIOESSAYS, V13, P641; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P343, DOI 10.1080/09553009114550321; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P321, DOI 10.1080/09553009114550311; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; Lewis LK, 1999, GENETICS, V152, P1513; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; METZGER L, 1991, INT J RADIAT BIOL, V59, P1325, DOI 10.1080/09553009114551201; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Nevaldine B, 1997, RADIAT RES, V147, P535, DOI 10.2307/3579619; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OKAYASU R, 1993, RADIAT RES, V138, P34; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Peng L, 1998, GENOMICS, V54, P529, DOI 10.1006/geno.1998.5536; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Rothstein R, 2000, GENE DEV, V14, P1; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Siede W, 1996, GENETICS, V142, P91; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VAINIO O, 1995, IMMUNOL TODAY, V16, P365, DOI 10.1016/0167-5699(95)80002-6; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20; WIEBEZAHN KF, 1981, NUCLEIC ACIDS RES, P3139; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	105	126	132	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2212	2224		10.1038/sj.onc.1204350	http://dx.doi.org/10.1038/sj.onc.1204350			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402316				2022-12-28	WOS:000168404500003
J	Iwanaga, R; Ohtani, K; Hayashi, T; Nakamura, M				Iwanaga, R; Ohtani, K; Hayashi, T; Nakamura, M			Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I	ONCOGENE			English	Article						cell cycle; E2F; HTLV-I; NF-kappa B; tax; cyclin D2	RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL ACTIVATOR; HTLV-I; E2F; EXPRESSION; FAMILY; LINE; ACCUMULATION; GROWTH; GENES	The trans-activator protein Tax of human T-cell leukemia virus type I(HTLV-I) plays an important role in the development of adult T-cell leukemia through, at least in part, its ability to stimulate cell growth. We previously reported that Tax induced cell cycle progression from G0/G1 phase to S and G2/M phases in human T-cell line Kit 225 cells. To elucidate molecular mechanism of Tax-induced cell cycle progression, we systematically examined the effects of Tax on biochemical events associated with cell cycle progression, Introduction of Tax into resting Kit 225 cells induced activation of the G1/S transition regulation cascade consisting of activation of cyclin dependent kinase 2 (CDK2) and CDK4, phosphorylation of the Rb family proteins and an increase in free E2F, The kinase activation was found to result from Tax-induced expression of genes for cell cycle regulatory molecules including cyclin D2, cyclin E, E2F1, CDK2, CDK4 and CDK6, and Tax-induced reduction of CDK inhibitors p19(INK4d) and p27(Kip1), These modulations by Tax always paralleled the ability of Tax to activate the NF-kappaB transcription pathway. These results indicate the important role of Tax-mediated trans-activation of the genes for cell cycle regulatory molecules in Tax-induced cell cycle progression.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-4-45 Yushima, Tokyo 1138510, Japan.							AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GESSAIN A, 1985, LANCET, V2, P407; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HORI T, 1987, BLOOD, V70, P1069; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	43	109	110	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2055	2067		10.1038/sj.onc.1204304	http://dx.doi.org/10.1038/sj.onc.1204304			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360190				2022-12-28	WOS:000168116700001
J	Sharma, SV; Oneyama, C; Yamashita, Y; Nakano, H; Sugawara, K; Hamada, M; Kosaka, N; Tamaoki, T				Sharma, SV; Oneyama, C; Yamashita, Y; Nakano, H; Sugawara, K; Hamada, M; Kosaka, N; Tamaoki, T			UCS15A, a non-kinase inhibitor of Src signal transduction	ONCOGENE			English	Article						Src; UCS15A; bone resorption inhibitor; protein-protein interaction	PP60C-SRC PROTEIN-KINASE; FOCAL ADHESION KINASE; RESORPTION IN-VITRO; C-SRC; BONE-RESORPTION; SH3 DOMAIN; OSTEOCLAST FUNCTION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GROWTH-FACTOR	Src tyrosine kinase plays key roles in signal transduction following growth factor stimulation and integrin-mediated cell-substrate adhesion. Since src-signal transduction defects are implicated in a multitude of human diseases, we have sought to develop new ways to identify small molecule inhibitors using a yeast-based, activated-src over-expression system, In the present study, we describe the identification of a unique src-signal transduction inhibitor, UCS15A, UCS15A was found to inhibit the src specific tyrosine phosphorylation of numerous proteins in v-src-transformed cells, Two of these phosphoproteins were identified as bona-fide src substrates, cortactin and Sam68, UCS15A differed from conventional src-inhibitors in that it did not inhibit the tyrosine kinase activity of src, In addition, UCS15A appeared to differ from src-destabilizing agents such as herbimycin and radicicol that destabilize src by interfering with Hsp90. Our studies suggest that UCS15A exerted its src-inhibitory effects by a novel mechanism that involved disruption of protein-protein interactions mediated by src, One of the biological consequences of src-inhibition by UCS15A was its ability to inhibit the bone resorption activity of osteoclasts in vitro, These data suggest that UCS15A may inhibit the bone resorption activity of osteoclasts, not by inhibiting src tyrosine kinase activity, but by disrupting the interaction of proteins associated with src, thereby modulating downstream events in the src signal transduction pathway.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan; Kyowa Hakko Kogyo Co Ltd, Pharmaceut Res Labs, Nagaizumi, Shizuoka 411, Japan; Natl Inst Basic Biol, Okazaki Natl Res Inst, Div Morphogenesis, Okazaki, Aichi 4448585, Japan	Kyowa Kirin Ltd; Kyowa Kirin Ltd; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Sharma, SV (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Machida, Tokyo 194, Japan.							AKATSU T, 1992, J BONE MINER RES, V7, P1297; Blair HC, 1996, J CELL BIOCHEM, V61, P629, DOI 10.1002/(SICI)1097-4644(19960616)61:4<629::AID-JCB17>3.0.CO;2-A; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Fischer RS, 2000, VIROLOGY, V269, P404, DOI 10.1006/viro.2000.0232; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HALL GE, 1987, CALCIFIED TISSUE INT, V40, P212, DOI 10.1007/BF02556624; HALL TJ, 1994, BIOCHEM BIOPH RES CO, V199, P1237, DOI 10.1006/bbrc.1994.1363; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huang JQ, 1999, ONCOGENE, V18, P4099, DOI 10.1038/sj.onc.1202779; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACOBS C, 1983, CANCER RES, V43, P1696; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Miyazaki T, 2000, J BONE MINER RES, V15, P41, DOI 10.1359/jbmr.2000.15.1.41; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKAMURA H, 1994, ONCOGENE, V9, P2293; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Sugawara K, 1998, ANAL BIOCHEM, V255, P204, DOI 10.1006/abio.1997.2474; SUZUKI G, 1983, Patent No. 58116686; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; Viola R, 1999, KNEE SURG SPORT TR A, V7, P25, DOI 10.1007/s001670050116; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; ZHAO JF, 1995, ONCOGENE, V11, P161; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	69	45	48	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2068	2079		10.1038/sj.onc.1204296	http://dx.doi.org/10.1038/sj.onc.1204296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360191				2022-12-28	WOS:000168116700002
J	Teckchandani, AM; Feshchenko, EA; Tsygankov, AY				Teckchandani, AM; Feshchenko, EA; Tsygankov, AY			c-Cbl facilitates fibronectin matrix production by v-Abl-transformed NIH3T3 cells via activation of small GTPases	ONCOGENE			English	Article						c-Cbl; fibronectin; adhesion; morphology; tyrosine phosphorylation; ubiquitination	NUCLEOTIDE-RELEASING FACTOR; INTEGRIN SIGNALING PATHWAY; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; DEPENDENT ACTIVATION; NEGATIVE REGULATOR	The protooncogenic protein c-Cbl has been shown to act as a multivalent adaptor and a negative regulator of protein tyrosine kinase-mediated signaling, Recent studies have implicated it in the regulation of cell adhesion-related events. We have previously shown that c-Cbl facilitates adhesion and spreading of v-Abl-transformed fibroblasts, and that these effects are dependent on its tyrosine phosphorylation, However, the mechanisms mediating effects of c-Cbl on fibroblast adhesion remain poorly understood. In this study we demonstrate that the tyrosine phosphorylation-dependent effect of c-Cbl on adhesion of v-Abl-transformed fibroblasts is primarily mediated by an increase in fibronectin matrix deposition by these cells. This increase in fibronectin matrix deposition and, hence, in cell adhesion is dependent on cytoskeletal rearrangements induced by RhoA, Rad and, possibly, Rapt activation caused by c-Cbl, The observed activation of these GTPases is mediated by the recruitment of phosphatidylinositol-3' kinase, CrkL and Vav2 to the C-terminal tyrosine residues of c-Cbl, The results of this study also demonstrate that ubiquitination is essential for the observed effects of c-Cbl on fibronectin matrix production and cell adhesion.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, Rm 506,3400 N Broad St, Philadelphia, PA 19140 USA.		Tsygankov, Alexander Y/K-6205-2017	Teckchandani, Anjali/0000-0002-2237-9598	NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu H, 1996, CANCER RES, V56, P4541; Akiyama S K, 1996, Hum Cell, V9, P181; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Andoniou CE, 1996, ONCOGENE, V12, P1981; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Christopher RA, 1997, J CELL SCI, V110, P569; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Herzhoff K, 1999, BRIT J DERMATOL, V141, P218; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; Kumar CC, 1999, ANN NY ACAD SCI, V886, P122, DOI 10.1111/j.1749-6632.1999.tb09407.x; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu KS, 1999, TERR ATMOS OCEAN SCI, V10, P377, DOI 10.3319/TAO.1999.10.2.377(T); Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Marengere LEM, 1997, J IMMUNOL, V159, P70; MCKILLOP DFA, 1994, J MUSCLE RES CELL M, V15, P309; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RAJARAMAN R, 1983, EXP CELL BIOL, V51, P9; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scardigli R, 1996, EXP CELL RES, V227, P223, DOI 10.1006/excr.1996.0271; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; VAHERI A, 1978, BIOCHIM BIOPHYS ACTA, V516, P1, DOI 10.1016/0304-419X(78)90002-1; Vaheri A, 1978, Ann N Y Acad Sci, V312, P343, DOI 10.1111/j.1749-6632.1978.tb16812.x; VOLBERG T, 1994, CELL MOTIL CYTOSKEL, V29, P321, DOI 10.1002/cm.970290405; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WALSH A, 1997, ONCOGENE, V16, P2553; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	73	16	17	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1739	1755		10.1038/sj.onc.1204246	http://dx.doi.org/10.1038/sj.onc.1204246			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313921				2022-12-28	WOS:000167750900007
J	Acquati, F; Morelli, C; Cinquetti, R; Bianchi, MG; Porrini, D; Varesco, L; Gismondi, V; Rocchetti, R; Talevi, S; Possati, L; Magnanini, C; Tibiletti, MG; Bernasconi, B; Daidone, MG; Shridhar, V; Smith, DI; Negrini, M; Barbanti-Brodano, G; Taramelli, R				Acquati, F; Morelli, C; Cinquetti, R; Bianchi, MG; Porrini, D; Varesco, L; Gismondi, V; Rocchetti, R; Talevi, S; Possati, L; Magnanini, C; Tibiletti, MG; Bernasconi, B; Daidone, MG; Shridhar, V; Smith, DI; Negrini, M; Barbanti-Brodano, G; Taramelli, R			Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27	ONCOGENE			English	Article						ovarian carcinoma; senescence; chromosome 6q27; Class II tumor suppressor gene; ribonuclease	NON-HODGKIN-LYMPHOMA; 2 DISTINCT REGIONS; CANCER CELL-LINES; SELF-INCOMPATIBILITY; NICOTIANA-ALATA; LONG ARM; BREAST CARCINOMAS; ALLELIC IMBALANCE; EPITHELIAL-CELLS; FREQUENT LOSS	Cytogenetic, molecular and functional analysis has shown that chromosome region 6q27 harbors a senescence inducing gene and a tumor suppressor gene involved in several solid and hematologic malignancies. We have cloned at 6q27 and characterized the RNASE6PL gene which belongs to a family of cytoplasmic RNases highly conserved from plants, to man. Analysis of 55 primary ovarian tumors and several ovarian tumor cell lines indicated that the RNASE6PL gene is not mutated in tumor tissues, but its expression is significantly reduced in 30% of primary ovarian tumors and: in 75% of ovarian tumor cell lines. The promoter region of the gene was unaffected in tumors cell lines. Transfection of RNASE6PL cDNA into HEY4 and SG10G ovarian tumor cell lines suppressed tumorigenicity in nude mice. When tumors were induced by RNASE6PL-transfected cells, they completely lacked expression of RNASE6PL cDNA. Tumorigenicity was suppressed also in RNASE6PL-transfected pRPcT1/ H6c12T cells, derived from a human/mouse monochromosomic hybrid carrying a human chromosome 6 deleted at 6q27. Moreover, 63.6% of HEY4 clones and 42.8% of the clones of XP12ROSV, a Xeroderma pigmentosum SV40-immortalized cell line, transfected with RNASE6PL cDNA, developed a marked senescence process during in vitro growth. We therefore propose that RNASE6PL may be a candidate for the 6q27 senescence inducing and class II tumor suppressor gene in ovarian cancer.	Univ Insubria, Dipartimento Biol Strutturale & Funz, Varese, Italy; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Ancona, Ist Sci Biomed, I-60131 Ancona, Italy; Osped Circolo, Lab Anat Patol, Varese, Italy; Ist Nazl Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA	University of Insubria; University of Ferrara; University of Genoa; IRCCS AOU San Martino IST; Marche Polytechnic University; Ospedale Circolo & Fondazione Macchi; Fondazione IRCCS Istituto Nazionale Tumori Milan; Mayo Clinic	Taramelli, R (corresponding author), Univ Insubria, Dipartimento Biol Strutturale & Funz, Varese, Italy.		Negrini, Massimo/J-2377-2016; smith, jeremy c/B-7287-2012; Varesco, Liliana/AAF-6521-2019; Daidone, Maria Grazia/E-9232-2017	Negrini, Massimo/0000-0002-0007-1920; smith, jeremy c/0000-0002-2978-3227; Varesco, Liliana/0000-0003-4871-6668; Daidone, Maria Grazia/0000-0002-4786-1321; Gismondi, Viviana/0000-0002-1115-0325				Abdollahi A, 1997, CANCER RES, V57, P2029; ACQUATI F, 2000, IN PRESS METH MOL BI; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; ARDELT W, 1991, J BIOL CHEM, V266, P245; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bruening W, 1999, CANCER RES, V59, P4973; BUICK RN, 1985, CANCER RES, V45, P3668; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; COOKE I, 1996, GENE CHROMOSOME CANC, V15, P13; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVELLE P, 1991, ONCOGENE, V6, P1705; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FRANCESCONI M, 1984, CANCER, V53, P1927, DOI 10.1002/1097-0142(19840501)53:9<1927::AID-CNCR2820530920>3.0.CO;2-#; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Garzetti G. G., 1992, European Journal of Gynaecological Oncology, V13, P514; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Hauptschein RS, 1998, GENOMICS, V50, P170, DOI 10.1006/geno.1998.5321; HAYASHI Y, 1990, BLOOD, V76, P1626; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIME G, 1995, GENE, V158, P203, DOI 10.1016/0378-1119(94)00896-Z; Honchel R, 1996, CANCER RES, V56, P145; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lin HC, 1999, CANCER RES, V59, P807; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MEADOR J, 1990, GENE, V95, P1, DOI 10.1016/0378-1119(90)90406-H; MILLIKIN D, 1991, CANCER RES, V51, P5449; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Mok SC, 1996, ONCOGENE, V12, P1895; MORITA R, 1991, CANCER RES, V51, P5817; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; Queimado L, 1998, ONCOGENE, V16, P83, DOI 10.1038/sj.onc.1201480; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; SIMON L, 1981, CARCINOGENESIS, V2, P567, DOI 10.1093/carcin/2.6.567; Smith MR, 1999, EXP CELL RES, V247, P220, DOI 10.1006/excr.1998.4317; Tahara H, 1996, CANCER RES, V56, P599; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1997, BRIT J CANCER, V75, P1831, DOI 10.1038/bjc.1997.312; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214	55	59	65	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					980	988		10.1038/sj.onc.1204178	http://dx.doi.org/10.1038/sj.onc.1204178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314033				2022-12-28	WOS:000167097000009
J	Nip, J; Strom, DK; Eischen, CM; Cleveland, JL; Zambetti, GP; Hiebert, SW				Nip, J; Strom, DK; Eischen, CM; Cleveland, JL; Zambetti, GP; Hiebert, SW			E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation	ONCOGENE			English	Article						E2F-1; p53; stability; cell cycle progression; apoptosis	WILD-TYPE P53; S-PHASE ENTRY; TRANSCRIPTION FACTOR E2F-1; ARF TUMOR-SUPPRESSOR; CELL-CYCLE CONTROL; E1B 19K PROTEIN; RETINOBLASTOMA PROTEIN; GENE-PRODUCT; DNA-SYNTHESIS; P53-DEPENDENT APOPTOSIS	E2F-1 induces p53 accumulation and E2F-1 and p53 form a physical complex, which affects the ability of E2F-1 to activate transcription. We mapped the domains on E2F-1 that interact with p53 and found two p53-binding domains. To understand the functional consequences of the E2F-1/p53 association on p53 activities we identified the domains of E2F-1 that were responsible for the accumulation of p53. Unexpectedly, we found that the E2F-1 transactivation domain was dispensable for p53 induction. By contrast, further deletion of the DP-1 interaction/'marked' box domain eliminated p53 accumulation. Radiolabeling pulse/chase analysis demonstrated that E2F-1 caused post-translational stabilization of p53. Although E2F-1 caused the stabilization of p53, E2F-1 expression impaired p53-dependent transactivation. Thus, the E2F-1:p53 interaction may provide a checkpoint function to inactivate overactive E2F-1, but the association may also inactivate p53 transactivation to allow cell cycle progression.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	Vanderbilt University; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.		Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007	NATIONAL CANCER INSTITUTE [R01CA063230, R01CA064140, R01CA077274, R01CA076379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013726] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA27165, CA76379, CA64140, CA77274, CA63230] Funding Source: Medline; NIA NIH HHS [AG13726] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline; PHS HHS [C09346] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; OLSON DC, 1993, ONCOGENE, V8, P2353; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SALA A, 1994, CANCER RES, V54, P1402; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	83	37	37	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					910	920		10.1038/sj.onc.1204171	http://dx.doi.org/10.1038/sj.onc.1204171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314026				2022-12-28	WOS:000167097000002
J	Stoneley, M; Spencer, JP; Wright, SC				Stoneley, M; Spencer, JP; Wright, SC			An internal ribosome entry segment in the 5 ' untranslated region of the mnt gene	ONCOGENE			English	Article						mnt; 5 ' UTR; internal initiation; IRES	MESSENGER-RNA; C-MYC; TRANSLATION; INITIATION; PROTEIN; REPRESSION; CELLS; SITES; MAX; BIP	Mnt is a transcriptional repressor related to the Myc/ Mad family of transcription factors. It is expressed in proliferating, resting and differentiating cells and is believed to antagonize the function of Myc. Here we have characterized the major transcription initiation site of the mnt gene. In doing so we noted a remarkable level of sequence conservation between the murine and human 5' untranslated regions, Our experiments revealed that this sequence contains an internal ribosome entry segment (IRES), In addition, we show that sequences at both the 5' and 3' end of the IRES are essential for its function. These findings indicate that mnt can be translated by internal initiation. Such a mechanism may allow efficient Mnt synthesis when cap-dependent translation initiation is reduced.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Wright, SC (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.							Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	17	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					893	897		10.1038/sj.onc.1204157	http://dx.doi.org/10.1038/sj.onc.1204157			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314024				2022-12-28	WOS:000166924400014
J	Offer, H; Milyavsky, M; Erez, N; Matas, D; Zurer, I; Harris, CC; Rotter, V				Offer, H; Milyavsky, M; Erez, N; Matas, D; Zurer, I; Harris, CC; Rotter, V			Structural and functional involvement of p53 in BER in vitro and in vivo	ONCOGENE			English	Article						p53; BER; transactivation; DNA repair	NUCLEOTIDE-EXCISION-REPAIR; INHIBITS DNA-REPLICATION; TATA-BINDING PROTEIN; CELL NUCLEAR ANTIGEN; TRANSCRIPTIONAL ACTIVATION; TERMINAL DOMAIN; 3'-TO-5' EXONUCLEASE; WILD-TYPE; IN-VIVO; APOPTOSIS	p53 is involved in several DNA repair pathways. Some of these require the specific transactivation of p53-dependent genes and others involve direct interactions between the p53 protein and DNA repair associated proteins. Previously, we have shown that p53 acts directly in Base Excision Repair (BER) when assayed under in vitro conditions. Our present data indicate that this involvement is independent of the transcriptional activity of the p53 molecule. We found that under both in vitro and in vivo conditions, a p53 transactivation-deficient molecule, p53-22-23,was more efficient in BER activity than was wild type p53. However, mutations in the core domain or C-terminal alterations strongly reduced p53-mediated BER activity, These results are consistent with the hypothesis that the involvement of p53 in BER activity, a housekeeping DNA repair pathway, is a prompt and immediate one that does not involve the activation of D53 transactivation-dependent mechanisms, but rather concerns with the p53 protein itself. In an endogenous DNA damage status p53 is active in BER pathways as a protein and not as a transcription factor.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20896 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Milyavsky, Michael/E-8306-2011	Erez, Neta/0000-0001-6506-9074				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN IT, 1995, ONCOGENE, V11, P1931; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HENDERSON EE, 1989, MUTAT RES, V220, P151, DOI 10.1016/0165-1110(89)90021-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNGER HD, 1994, ANAL BIOCHEM, V217, P98, DOI 10.1006/abio.1994.1088; Hussain SP, 1998, CANCER RES, V58, P4023; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; KANEKO Y, 1995, CANCER LETT, V91, P11, DOI 10.1016/0304-3835(95)03709-6; KASTAN MB, 1991, CANCER RES, V51, P4279; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lloyd DR, 2000, CANCER RES, V60, P517; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Miller DL, 1997, WETLANDS, V17, P31, DOI 10.1007/BF03160716; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Myung K, 1998, P NATL ACAD SCI USA, V95, P7664, DOI 10.1073/pnas.95.13.7664; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Peled A, 1996, CANCER RES, V56, P2148; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang W, 1999, CANCER RES, V59, P2562; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Yokote H, 1998, MUTAT RES-DNA REPAIR, V409, P147, DOI 10.1016/S0921-8777(98)00052-4; Zhou XL, 1999, CANCER RES, V59, P843	48	63	64	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					581	589		10.1038/sj.onc.1204120	http://dx.doi.org/10.1038/sj.onc.1204120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313990	Bronze			2022-12-28	WOS:000166755000005
J	Yu, PW; Huang, B; Shen, M; Lau, C; Chan, E; Michel, J; Xiong, Y; Payan, DG; Luo, Y				Yu, PW; Huang, B; Shen, M; Lau, C; Chan, E; Michel, J; Xiong, Y; Payan, DG; Luo, Y			p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues	ONCOGENE			English	Article						PCNA; p21; tumor; PIP box	CELL NUCLEAR ANTIGEN; C-TERMINAL REGION; D-TYPE CYCLINS; DNA-REPLICATION; BINDING; P21; P21(WAF1/CIP1); PROGNOSIS; INHIBITOR; CARCINOMA	Proliferating cell nuclear antigen (PCNA) is an essential protein in both DNA replication and DNA damage repair. A novel 15 kD protein, p15(PAF), was identified as a PCNA-associated factor in a yeast two-hybrid screen using PCNA as the bait, p15(PAF) is localized primarily in the nucleus. p15(PAF) shares the conserved PCNA binding motif with several other PCNA binding proteins including CDK inhibitor p21. Overexpression of p15(PAF) competes with p21-PCNA binding. Mutation of this motif in p15(PAF) abolished its PCNA-binding activity. Notably, p15(PAF) expression in several types of tumor tissues was significantly increased, especially in esophageal tumors. Like PCNA, p15(PAF) may possess prognostic significance in a broad array of human cancers.	Rigel Pharmaceut Inc, S San Francisco, CA 94080 USA; Univ N Carolina, Lineberger Canc Ctr 22012, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Luo, Y (corresponding author), Rigel Pharmaceut Inc, 240 E Grand Ave, S San Francisco, CA 94080 USA.							Baekelandt M, 1999, CLIN CANCER RES, V5, P2848; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kuwahara M, 1999, DIS ESOPHAGUS, V12, P116, DOI 10.1046/j.1442-2050.1999.00034.x; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Natsugoe S, 1999, CLIN CANCER RES, V5, P2445; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Russell A, 1999, ONCOGENE, V18, P6454, DOI 10.1038/sj.onc.1203030; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	26	90	98	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					484	489		10.1038/sj.onc.1204113	http://dx.doi.org/10.1038/sj.onc.1204113			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313979				2022-12-28	WOS:000166562500008
J	Desbois-Mouthon, C; Cadoret, A; Blivet-Van Eggelpoel, MJ; Bertrand, F; Cherqui, G; Perret, C; Capeau, J				Desbois-Mouthon, C; Cadoret, A; Blivet-Van Eggelpoel, MJ; Bertrand, F; Cherqui, G; Perret, C; Capeau, J			Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3 beta inhibition and Ras activation	ONCOGENE			English	Article						insulin; IGF-1; beta-catenin; PI 3-kinase; GSK-3 beta; Ras	GLYCOGEN-SYNTHASE KINASE-3; GROWTH-FACTOR-II; RECEPTOR SUBSTRATE-1 OVEREXPRESSION; HUMAN HEPATOCELLULAR CARCINOMAS; INTEGRIN-LINKED KINASE; APC TUMOR-SUPPRESSOR; HEPATITIS-B; INCREASED EXPRESSION; SIGNALING PATHWAY; GENE-PRODUCT	We examined the interplay between the insulin/LGF-1- and beta -catenin-regulated pathways, both of which are suspected to play a role in hepatocarcinogenesis. Insulin and IGF-1 stimulated the transcription of a Lef/Tcf-dependent luciferase reporter gene by 3-4-fold in HepG2 cells, This stimulation was mediated through the activation of phosphatidylinositol 3-kinase (PI 3-K)/Akt and the inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) since the effects of insulin and IGF-I were inhibited by dominant-negative mutants of PI 3-K or Akt and an uninhibitable GSK-3 beta. Together with inhibiting GSK-3 beta, insulin and IGF-I increased the cytoplasmic levels of beta -catenin, The PI 3-K/Akt/GSK-3 beta pathway was not the sole to mediate insulin and IGF-1 stimulation of Lef/Tcf-dependent transcription. The Ras signalling pathway was also required as (i) the stimulatory effects of insulin and IGF-I were inhibited by dominant-negative Ras or the MEK1 inhibitor PD98059 and (ii) activated Ha-Res or constitutively active MEK synergized with catalytically inactive GSK-3 beta to stimulate Lef/Tcf-dependent transcription. This study provides the first evidence that insulin and IGF-I stimulate the beta -catenin pathway through tw a signalling cascades bifurcating downstream of PI 3-K and involving GSK-3 beta inhibition and Ras activation. These findings demonstrate for the first time the ability of insulin and IGF-I to activate the beta -catenin pathway in hepatoma cells and thereby provide new insights into the role of these factors in hepatocarcinogenesis.	Univ Paris 06, INSERM U402, F-75571 Paris 12, France; INSERM, U129, ICGM, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Desbois-Mouthon, C (corresponding author), Univ Paris 06, INSERM U402, 27 Rue Chaligny, F-75571 Paris 12, France.		Perret-Mayeux, Christine/L-3297-2017; Cadoret, Axelle/L-2529-2017; Desbois-Mouthon, Christele/M-7076-2017	Cadoret, Axelle/0000-0002-4283-6864; Desbois-Mouthon, Christele/0000-0002-0772-1711; perret, christine/0000-0003-4710-7051				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Buchmann A, 1999, CELL DEATH DIFFER, V6, P190, DOI 10.1038/sj.cdd.4400475; CARIANI E, 1988, CANCER RES, V48, P6844; CARIANI E, 1991, HEPATOLOGY, V13, P644, DOI 10.1002/hep.1840130406; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kim SO, 1996, CANCER RES, V56, P3831; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moradpour D, 1994, J Viral Hepat, V1, P17, DOI 10.1111/j.1365-2893.1994.tb00058.x; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogawa K, 1999, CANCER RES, V59, P1830; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Tanaka S, 1996, CANCER RES, V56, P3391; Tanaka S, 1997, HEPATOLOGY, V26, P598; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Tsujiuchi T, 1999, CANCER RES, V59, P3904; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Weihl CC, 1999, J NEUROSCI, V19, P5360; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	52	265	273	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					252	259		10.1038/sj.onc.1204064	http://dx.doi.org/10.1038/sj.onc.1204064			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313952				2022-12-28	WOS:000166410900012
J	Lamorte, L; Kamikura, DM; Park, M				Lamorte, L; Kamikura, DM; Park, M			A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein	ONCOGENE			English	Article						Crk; cytoskeleton; Gab1; JNK; Met tyrosine kinase; transformation	FOCAL ADHESION KINASE; ADAPTER PROTEIN CRK; TYROSINE PHOSPHORYLATION; SCATTER FACTOR; PROTOONCOGENE PRODUCT; COMPLEX-FORMATION; CARBOXY-TERMINUS; GRB2 BINDING; V-CRK; MIGRATION	Cell transformation is associated with anchorage independent growth and morphological changes characterized by reduced adhesion and spreading, The molecular signals that control these events are poorly understood. The Met receptor tyrosine kinase is deregulated in human tumors and an oncogenic derivative of this receptor transforms cells. In this paper we demonstrate that fibroblasts transformed by the Met oncoprotein display decreased cell spreading consistent with the loss of actin stress fibers and vinculin staining focal adhesions. In contrast to control cells, focal adhesion kinase, p130Cas and paxillin are weakly or not detectably tyrosine phosphorylated in Met transformed cells. Moreover, although paxillin and p130Cas associate with the Crk adapter protein in control cells, they fail to associate with Crk in Met transformed cells, yet these cells are motile and capable of wound closure to the same extent as control cells. In Met transformed cells, Crk predominantly associates with the CM and Gab1 docking proteins in a tyrosine phosphorylation dependent manner. The coupling of Gab1, but not Cbl, with Crk is retained in cells grown in suspension and enhances JNK activation. We propose that the loss of adhesion dependent signals required for cell cycle progression is compensated through Met induced Gab1/Crk signals.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Mol Oncol Grp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hosp, Mol Oncol Grp, 687 Pine Ave W,Room H5-10, Montreal, PQ H3A 1A1, Canada.							Andoniou CE, 1996, ONCOGENE, V12, P1981; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cary LA, 1996, J CELL SCI, V109, P1787; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FERRACINI R, 1995, ONCOGENE, V10, P739; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Koochekpour S, 1997, CANCER RES, V57, P5391; Lo SS, 1999, MOL CARCINOGEN, V25, P150; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAWASDIKOSOLA S, 2000, BIOCHIM BIOPHYS ACTA, V1471, P1; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sieg DJ, 1999, J CELL SCI, V112, P2677; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	55	50	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5973	5981		10.1038/sj.onc.1203977	http://dx.doi.org/10.1038/sj.onc.1203977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146548				2022-12-28	WOS:000165827900003
J	Mukherjee, S; Louie, SG; Campbell, M; Esserman, L; Shyamala, G				Mukherjee, S; Louie, SG; Campbell, M; Esserman, L; Shyamala, G			Ductal growth is impeded in mammary glands of C-neu transgenic mice	ONCOGENE			English	Article						estrogen; estrogen receptor; C-neu; mammary gland; ductal growth	HUMAN-BREAST-CANCER; PROGESTERONE RECEPTORS; ESTROGEN-RECEPTOR; ERBB RECEPTORS; A-FORM; EXPRESSION; MORPHOGENESIS; PROTOONCOGENE; ABNORMALITIES; SUPERFAMILY	The steroid hormone, estradiol, is essential for both the growth of normal breast and induction of mammary carcinomas, The growth promoting effects of estrogen are presumed to be mediated by growth factors, in particular, epidermal growth factor, which mediates its effects through erbB receptors, erbB1 and erbB2/C-neu. C-neu is amplified and over-expressed in a large number of human cancers and transgenic mice over-expressing C-neu also develop mammary tumors, However, as set, the impact of C-neu over-expression on estrogen action during normal mammary development and hence, its precise role in carcinogenesis, remains unclear, In the present studies, we demonstrate that estradiol-dependent mammary ductal growth accompanying puberty is impaired in transgenic mice expressing wild type C-neu, and is intrinsic to the tissue. The impairment is not due to an overall impairment in estrogen action, since progesterone receptor expression is unaffected in C-neu mice. It is also not due to an intrinsic inability of the epithelial cells to proliferate, since impeded ductal growth co-exists,vith alveolar growth during pregnancy. Therefore, we propose that, depending on the physiological state, C-neu may either promote or inhibit the growth of mammary epithelial cells, and discuss its potential significance to carcinogenesis.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Shyamala, G (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,Bldg 74, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA066541] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; BRESCIANI FRANCESCO, 1968, CELL TISSUE KINET, V1, P51, DOI 10.1111/j.1365-2184.1968.tb00193.x; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DeckardJanatpour K, 1997, INT J ONCOL, V11, P235; DEOME KB, 1959, CANCER RES, V78, P515; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Raafat AM, 1999, ENDOCRINOLOGY, V140, P2570, DOI 10.1210/en.140.6.2570; READ LD, 1990, CANCER RES, V50, P3947; RUSSELL KS, 1992, CANCER RES, V52, P6624; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1997, J STEROID BIOCHEM, V63, P251, DOI 10.1016/S0960-0760(97)00128-3; SHYAMALA G, 1992, RECEPTOR, V2, P121; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Shyamala G., 1980, Perspectives in steroid receptor research, P193; SHYAMALA G, 1987, ENDOCRINOLOGY, P127; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SILBERSTEIN GB, 1994, ENDOCRINOLOGY, V134, P84, DOI 10.1210/en.134.1.84; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244	36	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5982	5987		10.1038/sj.onc.1203964	http://dx.doi.org/10.1038/sj.onc.1203964			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146549				2022-12-28	WOS:000165827900004
J	Landesman-Bollag, E; Romieu-Mourez, R; Song, DH; Sonenshein, GE; Cardiff, RD; Seldin, DC				Landesman-Bollag, E; Romieu-Mourez, R; Song, DH; Sonenshein, GE; Cardiff, RD; Seldin, DC			Protein kinase CK2 in mammary gland tumorigenesis	ONCOGENE			English	Article						casein kinase II; CK2; transgenic mice; breast cancer; NF-kappa B; beta-catenin	NF-KAPPA-B; CASEIN KINASE-2; TRANSGENIC MICE; C-MYC; BREAST-CANCER; BETA-CATENIN; PEST DOMAIN; HA-RAS; EXPRESSION; ACTIVATION	Protein kinase CK2 is a ubiquitous and evolutionarily conserved serine/threonine kinase that is upregulated in many human cancers and can serve as an oncogene in lymphocytes. Recently, we have demonstrated that CK2 potentiates Wnt/beta -catenin signaling in mammary epithelial cells. To determine whether CK2 overexpression contributes to mammary tumorigenesis, we have performed comparative studies of human and rat breast cancer specimens and we have engineered transgenic mice with dysregulated expression of CK2 alpha in the mammary gland. We find that CK2 is highly expressed in human breast tumor specimens and in carcinogen-induced rat mammary tumors. Overexpression of CK2 alpha in the mammary gland of transgenic mice, under control of the MMTV-LTR, causes hyperplasia and dysplasia of the female mammary gland. Thirty per cent of the female MMTV-CK2 alpha transgenic mice develop mammary adenocarcinomas at a median of 23 months of age, often associated with Wnt pathway activation, as evidenced by upregulation of beta -catenin protein, NF-kappaB activation and upregulation of c-Myc also occur frequently. Thus, in mice, rats, and humans, dysregulated expression of CK2 is associated with and is capable of contributing to mammary tumorigenesis, Targeted inhibition of CK2 could be useful in the treatment of breast cancer.	Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Boston Univ, Dept Chem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA	Boston Medical Center; Boston University; Boston University; Boston University; Boston University; University of California System; University of California Davis	Seldin, DC (corresponding author), Boston Med Ctr, Dept Med, 650 Albany St,426A, Boston, MA 02118 USA.			Seldin, David C/0000-0003-0168-2333	NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 82742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dale TC, 1996, CANCER RES, V56, P4320; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Foo SY, 1999, TRENDS GENET, V15, P229; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HOWARD DK, 1983, IN VITRO CELL DEV B, V19, P58, DOI 10.1007/BF02617995; HUGGINS C, 1961, NATURE, V189, P204, DOI 10.1038/189204a0; HUGUET EL, 1994, CANCER RES, V54, P2615; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MESTRES P, 1994, ACTA ANAT, V149, P13; Mitev Vanio, 1994, Journal of Dermatological Science, V8, P45, DOI 10.1016/0923-1811(94)90320-4; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORRIS JJ, 1992, MED HYPOTHESES, V38, P177, DOI 10.1016/0306-9877(92)90090-Y; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEBERT DW, 1987, BIOCHEM SOC T, V15, P586, DOI 10.1042/bst0150586; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OHI Y, 1992, VIRCHOWS ARCH B, V62, P365, DOI 10.1007/BF02899705; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pancetti F, 1996, BIOCHEM BIOPH RES CO, V218, P35, DOI 10.1006/bbrc.1996.0007; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PENA JM, 1983, CANCER RES, V43, P1172; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PEREZ M, 1988, FEBS LETT, V238, P273, DOI 10.1016/0014-5793(88)80495-2; PERFETTI V, 1991, LEUKEMIA, V5, P1110; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117; ROGERS AE, 1981, CANCER RES, V41, P3735; Roig J, 1999, MOL CELL BIOCHEM, V191, P229, DOI 10.1023/A:1006808816770; ROMIEUMOUREZ R, 2001, IN PRESS CANC RES; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; SAFE S, 1984, CRC CR REV TOXICOL, V13, P319, DOI 10.3109/10408448409023762; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729	80	254	270	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3247	3257		10.1038/sj.onc.1204411	http://dx.doi.org/10.1038/sj.onc.1204411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423974				2022-12-28	WOS:000169163500008
J	Ferreira, R; Naguibneva, I; Pritchard, LL; Ait-Si-Ali, S; Harel-Bellan, A				Ferreira, R; Naguibneva, I; Pritchard, LL; Ait-Si-Ali, S; Harel-Bellan, A			The Rb/chromatin connection and epigenetic control: opinion	ONCOGENE			English	Review						Rb; cell cycle; differentiation; histone deacetylase; heterochromatin; methylation	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; CELL-CYCLE; DNA METHYLATION; NUCLEAR-ENVELOPE; CENTROMERIC HETEROCHROMATIN; TRANSCRIPTIONAL REPRESSION; CHROMOSOME TERRITORIES; CHROMATIN STRUCTURE; CPG METHYLATION	The balance between cell differentiation and proliferation is regulated at the transcriptional level, In the cell cycle, the transition from G1 to S phase (G1/S transition) is of paramount importance in this regard, Indeed, it is only before this point that cells can be oriented toward the differentiation pathway: beyond, cells progress into the cycle in an autonomous manner. The G1/S transition is orchestrated by the transcription factor E2F, E2F controls the expression of a group of checkpoint genes whose products are required either for the G1-to-S transition itself or for DNA replication (e.g. DNA polymerase alpha), E2F activity is repressed in growth-arrested cells and in early G1, and is activated at mid-to-late G1, E2F is controlled by the retinoblastoma tumor suppressor protein Rb, Rb represses E2F mainly by recruiting chromatin remodeling factors (histone deacetylases and SWI/SNF complexes), the DNA methyltransferase DNMT1, and a histone methyltransferase, This review will focus on the molecular mechanisms of E2F repression by Rb during the cell cycle and during cell-cycle exit by differentiating cells. A model in which Rb irreversibly represses E2F-regulated genes in differentiated cells by an epigenetic mechanism linked to heterochromatin, and involving histone H3 and promoter DNA methylation, is discussed.	Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Harel-Bellan, A (corresponding author), Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.		Harel-Bellan, Annick/M-9795-2015	Naguibneva, Irina/0000-0001-9566-6152; Harel-Bellan, Annick/0000-0002-2339-153X				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HENIKOFF S, 1995, GENETICS, V140, P1007; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kourmouli N, 2000, EMBO J, V19, P6558, DOI 10.1093/emboj/19.23.6558; Kurz A, 1996, J CELL BIOL, V135, P1195, DOI 10.1083/jcb.135.5.1195; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SCHARDIN M, 1985, HUM GENET, V71, P281, DOI 10.1007/BF00388452; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Takahashi Y, 2000, GENE DEV, V14, P804; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WADE PA, 1997, CURR BIOL, V7, P82; Wansink DG, 1996, J CELL BIOCHEM, V62, P10, DOI 10.1002/(SICI)1097-4644(199607)62:1<10::AID-JCB2>3.0.CO;2-4; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; WEINBERG RA, 1992, CANCER SURV, V12, P43; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	73	67	69	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3128	3133		10.1038/sj.onc.1204337	http://dx.doi.org/10.1038/sj.onc.1204337			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420729				2022-12-28	WOS:000169308500017
J	Stallcup, MR				Stallcup, MR			Role of protein methylation in chromatin remodeling and transcriptional regulation	ONCOGENE			English	Review						protein methylation; coactivators; histones; transcriptional regulation; chromatin	YEAST ARGININE METHYLTRANSFERASE; STEROID-RECEPTOR COACTIVATOR-1; HISTONE H3; IN-VITRO; SUBCELLULAR-LOCALIZATION; N-METHYLTRANSFERASE; CRYSTAL-STRUCTURE; ACETYLATION; CELLS; ACETYLTRANSFERASE	Recent findings suggest that lysine and arginine-specific methylation of histones may cooperate with other types of post-translational histone modification to regulate chromatin structure and gene transcription. Proteins that methylate histones on arginine residues can collaborate with other coactivators to enhance the activity of specific transcriptional activators such as nuclear receptors, Lysine methylation of histones is associated with transcriptionally active nuclei, regulates other types of histone modifications, and is necessary for proper mitotic cell divisions. The fact that some transcription factors and proteins involved in RNA processing can also be methylated suggests that protein methylation may also contribute in other ways to regulation of transcription and post-transcriptional steps in gene regulation. In future work, it will be important to develop methods for evaluating the precise roles of protein methylation in the regulation of native genes in physiological settings, e.g. by using chromatin immunoprecipitation assays, differentiating cell culture systems, and genetically altered cells and animals. It will also be important to isolate additional protein methyltransferases by molecular cloning and to characterize new methyltransferase substrates, the regulation of methyltransferase activities, and the roles of new methyltransferases and substrates.	Univ So Calif, Dept Pathol, HMR 301, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301, 2011 Zonal Ave, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055274, R37DK055274] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55274] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Glass CK, 2000, GENE DEV, V14, P121; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEE YW, 2001, UNPUB; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Ma H, 1999, MOL CELL BIOL, V19, P6164; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAIK WK, 1974, ARCH BIOCHEM BIOPHYS, V165, P369, DOI 10.1016/0003-9861(74)90175-1; PAIK WK, 1973, BIOCHEM BIOPH RES CO, V51, P781, DOI 10.1016/0006-291X(73)91383-1; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VANHOLDE KE, 1989, CHROMATIN, P111; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Westin S, 2000, ADV PHARMACOL, V47, P89; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	64	147	152	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3014	3020		10.1038/sj.onc.1204325	http://dx.doi.org/10.1038/sj.onc.1204325			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420716				2022-12-28	WOS:000169308500004
J	Oehler, MK; Norbury, C; Hague, S; Rees, MCP; Bicknell, R				Oehler, MK; Norbury, C; Hague, S; Rees, MCP; Bicknell, R			Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth	ONCOGENE			English	Article						adrenomedullin; Bcl-2; hypoxia; apoptosis; cell death; survival	ANGIOGENIC FACTOR ADRENOMEDULLIN; GENE-RELATED PEPTIDE; BREAST-CANCER; IN-VIVO; PROTEIN FAMILY; APOPTOSIS; EXPRESSION; TAMOXIFEN; PREVENTION; INDUCTION	Regions of hypoxia are a common feature of solid tumours, When tumour cells are exposed to hypoxic stress, transcription of a battery of genes is initiated. The angiogenic factor adrenomedullin (ADM) is a hypoxia regulated gene, ADM is thought to act through the G protein-coupled receptor calcitonin receptor-like receptor (CRLR), with specificity being conferred by the receptor associated modifying protein 2 (RAMP2), Here we report for the! first time that ADM treated or stably transfected Ishikawa cells overexpressing ADM show increased resistance to hypoxia induced apoptosis, These cells also show an upregulation of the oncoprotein Bcl-2, which is protective against hypoxic cell death when transiently transfected into Ishikawa cells. Since Ishikawa cells express the putative ADM-receptor CRLR-RAMP2 the production and secretion of ADM with the consecutive upregulation of Bcl-2 could establish an autocrine/paracrine mechanism rescuing malignant cells from hypoxic cell death. These results, taken together with our previous findings that ADM is an angiogenic factor which is upregulated by the nonsteroidal antiestrogen tamoxifen (TAM) in endometrial cells, implicate this peptide as a promoter of tumour growth and a possible target for anticancer strategies. Oncogene (2001) 20, 2937-2945.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Mol Angiogenesis Lab, Oxford OX3 9DS, England; Univ Oxford, Cell Cycle Grp, Oxford OX3 9DS, England; Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Mol Angiogenesis Lab, Oxford OX3 9DS, England.			Bicknell, Roy/0000-0002-0941-8919				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alarcon RM, 1996, CANCER RES, V56, P4315; Barakat RR, 1996, CLIN OBSTET GYNECOL, V39, P629, DOI 10.1097/00003081-199609000-00012; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Carthew P, 2000, CARCINOGENESIS, V21, P793, DOI 10.1093/carcin/21.4.793; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; CORY S, 1999, CANCER RES, V59, P1685; Cuzick J, 2000, EUR J CANCER, V36, P1298, DOI 10.1016/S0959-8049(00)00106-4; Elkas J, 2000, OBSTET GYNECOL, V95, P697, DOI 10.1016/S0029-7844(99)00660-2; Evans SM, 1997, CANCER RES, V57, P5155; FURMAN E, 1992, J STEROID BIOCHEM, V43, P189, DOI 10.1016/0960-0760(92)90207-Y; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hague S, 2000, CLIN CANCER RES, V6, P2808; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hockel M, 1999, CANCER RES, V59, P4525; Hofbauer KH, 2000, AM J PHYSIOL-REG I, V278, pR513, DOI 10.1152/ajpregu.2000.278.2.R513; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; McGill Gael, 1997, Frontiers in Bioscience (online), V2, pD353; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Parameswaran N, 1999, EUR J PHARMACOL, V372, P85, DOI 10.1016/S0014-2999(99)00022-9; Pellegrini M, 1999, J CLIN IMMUNOL, V19, P365, DOI 10.1023/A:1020598632068; PETERSEN NE, 1995, CLIN CHEM, V41, P1605; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Sakuragi N, 1998, INT J CANCER, V79, P153, DOI 10.1002/(SICI)1097-0215(19980417)79:2<153::AID-IJC10>3.0.CO;2-B; Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; THOMLINSON R, 1995, BRIT J CANCER, V9, P539; Vaupel Peter W., 1993, P53; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Yamabe K, 1998, BIOCHEM BIOPH RES CO, V243, P217, DOI 10.1006/bbrc.1997.7925; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	47	100	112	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2937	2945		10.1038/sj.onc.1204422	http://dx.doi.org/10.1038/sj.onc.1204422			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420706				2022-12-28	WOS:000168901800009
J	Bentires-Alj, M; Dejardin, E; Viatour, P; Van Lint, C; Froesch, B; Reed, JC; Merville, MP; Bours, V				Bentires-Alj, M; Dejardin, E; Viatour, P; Van Lint, C; Froesch, B; Reed, JC; Merville, MP; Bours, V			Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines	ONCOGENE			English	Article						Bax; apoptosis; cancer; transcription factors.; NF-kappa B	NECROSIS-FACTOR-ALPHA; CREB-BINDING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; BCL-X EXPRESSION; VIRUS TYPE-1 TAX; INDUCED APOPTOSIS; BREAST-CANCER; IN-VIVO; P53; GENE	The NF-kappaB transcription factor has been shown to inhibit apoptosis in several experimental systems. We therefore investigated whether the expression of the Bax proapoptotic protein could be influenced by NF-kappaB activity. Increased Bax protein expression was detected in HCT116, OVCAR-3 and MCF7 cells stably expressing a mutated unresponsive I kappaB-alpha inhibitory protein that blocks NF-kappaB activity. Northern blots showed that bax mRNA expression was increased as a consequence of mutated I kappaB-alpha expression in HCT116 cells. A careful examination of the human bax gene promoter sequence showed three putative binding sites for NF-kappaB, and the kappa B2 site at position -687 could indeed bind NF-kappaB complexes in vitro. Transient transfection of a bax promoter luciferase construct in HCT116 cells showed that NF-kappaB proteins could partially inhibit the transactivation of the bax promoter by p53, Mutations or deletions of the kappaB sites, including kappa B2, indicated that this NF-kappaB-dependent inhibitory effect did not require NF-kappaB DNA-binding, and was thus an indirect effect. However, cotransfection of expression vectors for several known cofactors failed to identify a competition between p53 and NF-kappaB for a transcription coactivator. Our findings thus demonstrate for the first time that NF-kappaB regulates, through an indirect pathway, the bax gene expression.	Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium; Free Univ Brussels, Dept Mol Biol, Biol Chem Lab, Brussels, Belgium; Burnham Inst, La Jolla, CA 92037 USA	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Sanford Burnham Prebys Medical Discovery Institute	Bours, V (corresponding author), Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021; Mohamed, Bentires-Alj/F-4484-2015	Mohamed, Bentires-Alj/0000-0001-6344-1127				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Perera PY, 1996, INFECT IMMUN, V64, P878, DOI 10.1128/IAI.64.3.878-884.1996; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 1998, CANCER RES, V58, P4531; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Scolnick DM, 1997, CANCER RES, V57, P3693; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	64	103	106	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2805	2813		10.1038/sj.onc.1204343	http://dx.doi.org/10.1038/sj.onc.1204343			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420692				2022-12-28	WOS:000168712000008
J	Curtin, JC; Dragnev, KH; Sekula, D; Christie, AJ; Dmitrovsky, E; Spinella, MJ				Curtin, JC; Dragnev, KH; Sekula, D; Christie, AJ; Dmitrovsky, E; Spinella, MJ			Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function	ONCOGENE			English	Article						retinoic acid; differentiation; embryonal carcinoma; teratocarcinoma; p53	GERM-CELL TUMORS; CISPLATIN-INDUCED APOPTOSIS; DNA-DAMAGE; HUMAN TERATOCARCINOMAS; TESTICULAR-TUMORS; GENE-EXPRESSION; DOWN-REGULATION; DIFFERENTIATION; CANCER; PROTEIN	Although retinoids are known to regulate gene transcription by activating retinoid receptors, the targets of retinoid receptors are largely unknown. This study indicates effective all-trans retinoic acid (RA)-induced differentiation of human embryonal carcinoma cells engages p53, Unexpectedly, RA has been found to activate the transactivation function of p53 in the human embryonal carcinoma cell line, NT2/D1, in a retinoid receptor-dependent manner. A derived RA-resistant line, NT2/D1-R1, is deficient in this activity and is co-resistant to cisplatin, This indicates that RA and cisplatin responses may share a common pathway involving p53 in embryonal carcinomas. RA has no effect on p53 steady-state protein levels in either line. RA enhances endogenous p53 transactivation activity in NT2/D1 but not NT2/D1-R1 cells. In addition, RA induces transactivation activity of a gal4-p53 fusion protein, suggesting that RA activates p53 independent of increasing p53 levels or sequence-specific DNA binding. This activity is absent in retinoic acid receptor gamma (RAR gamma)-deficient NT2/D1-R1 cells but can be restored upon co-transfection with specific RARs. Transient transfection of a dominant-negative p53 construct in NT2/D1 cells blocks the RA-mediated transcriptional decline of a differentiation-sensitive reporter plasmid and enhances survival of NT2/D1 cells following cisplatin treatment. Taken together, these findings indicate that RA activates the intrinsic activation function of p53 by a novel mechanism independent of effects on p53 stability or DNA binding and that this activation may be a general mechanism that contributes to RA-mediated G1 arrest.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [R01 CA54494, CA75154, R01 CA87546] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154, R01CA054494, R01CA087546] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Armstrong Robert B., 1994, P545; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; Boyle JO, 2001, CLIN CANCER RES, V7, P259; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Chresta CM, 1996, CANCER RES, V56, P1834; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; DMITROVSKY E, 1990, CANCER SURV, V9, P369; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GUCHELAAR HL, 1993, INT J CANCER, V55, P442, DOI 10.1002/ijc.2910550320; HALL PA, 1997, CURR BIOL, V7, P144; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hecker D, 1996, ONCOGENE, V12, P953; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HONG WK, 1977, CANCER, V40, P2987, DOI 10.1002/1097-0142(197712)40:6<2987::AID-CNCR2820400634>3.0.CO;2-A; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Hussain SP, 1998, CANCER RES, V58, P4023; JETTEN AM, 1979, NATURE, V278, P180, DOI 10.1038/278180a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; Mangelsdorf David J., 1994, P319; Matin A, 1998, APMIS, V106, P174, DOI 10.1111/j.1699-0463.1998.tb01333.x; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PENG HQ, 1993, CANCER RES, V53, P3574; PERA MF, 1990, CANCER SURV, V9, P243; Rapley E, 1998, APMIS, V106, P64; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shin DM, 1997, CLIN CANCER RES, V3, P875; Shin DM, 2000, J NATL CANCER I, V92, P69, DOI 10.1093/jnci/92.1.69; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	59	48	48	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2559	2569		10.1038/sj.onc.1204370	http://dx.doi.org/10.1038/sj.onc.1204370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420666				2022-12-28	WOS:000168652500007
J	Howard, JC; Li, Q; Chu, W; Zochodne, B; Kapoor, M; Ung, Y; Rosen, K; Ben-David, Y				Howard, JC; Li, Q; Chu, W; Zochodne, B; Kapoor, M; Ung, Y; Rosen, K; Ben-David, Y			Bcl-2 expression in F-MuLV-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression	ONCOGENE			English	Article						Friend erythroleukemia; Bcl-2; p53; tumor progression	VIRUS-INDUCED ERYTHROLEUKEMIA; CELLULAR P53 GENE; CHROMOSOMAL BREAKPOINT; TOPOISOMERASE-II; IN-VITRO; C-MYC; X-L; CELLS; GROWTH; ERYTHROPOIETIN	Erythroleukemias induced by various strains of Friend virus are multistage malignancies that result from the accumulation of genetic mutations, including the activation of proto-oncogenes and the inactivation of tumor suppressor genes. in this study, we demonstrate that Bcl-2 expression is activated in the majority of F-MuLV-induced erythroleukemia cell lines. In contrast, Bcl-2 was not expressed in any of the FV-P-induced erythroleukemia cell lines and protein levels were low or negligible in FV-A-induced erythroleukemia cell lines examined. In vivo, Bcl-2 expression levels gradually increased in F-MuLV-induced erythroleukemic cells prior to adaptation to culture. High expression of Bcl-2 in F-MuLV-induced erythroleukemic cells was shown to proceed the emergence of p53 mutation suggesting that Bcl-2 expression may delay p53 mutation in the leukemic cells, This is further supported by the demonstration that the majority of F-MuLV-induced erythroleukemia cell lines established from primary tumors induced in p53 mutant mice express low to negligible levels of Bcl-2, We have shown that the high levels of Bcl-2 expression in FV-P-induced erythroleukemic cells inhibited apoptosis induced by etoposide, low serum and p53 expression. Similarly, ectopic Bcl-2 expression within these cells also provided protection from apoptosis induced by etoposide and growth in low serum. These results suggest that the anti-apoptotic action of Bcl-2 may confer a selective in vivo and in vitro growth advantage to F-MuLV-induced erythroleukemic cells, which is not shared by FV-P/ FV-A-induced erythroleukemic cells. The observed induction of Bcl-2 expression in vivo constitutes a novel but late oncogenic event associated with the progression of F-MuLV-induced erythroleukemias.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol, 2075 Bayview Ave,Room S216, Toronto, ON M4N 3M5, Canada.			Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAVID YB, 1988, ONCOGENE, V3, P179; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DOLE M, 1994, CANCER RES, V54, P3253; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzog CE, 1995, CLIN CANCER RES, V1, P1391; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KAMESAKI S, 1993, CANCER RES, V53, P4251; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAJNO G, 1995, AM J PATHOL, V146, P3; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITCHELL T, 1993, J VIROL, V67, P3665, DOI 10.1128/JVI.67.6.3665-3670.1993; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; OLIFF A, 1981, BLOOD, V58, P244; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Reed JC, 1995, TOXICOL LETT, V82-3, P155, DOI 10.1016/0378-4274(95)03551-6; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	60	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2291	2300		10.1038/sj.onc.1204348	http://dx.doi.org/10.1038/sj.onc.1204348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402324				2022-12-28	WOS:000168404500011
J	Ma, WB; Xia, CZ; Ling, P; Qiu, MS; Luo, Y; Tan, TH; Liu, MY				Ma, WB; Xia, CZ; Ling, P; Qiu, MS; Luo, Y; Tan, TH; Liu, MY			Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes	ONCOGENE			English	Article						adaptor protein Grap2; HPK1; JNK; T-cells	N-TERMINAL KINASE; CELL ANTIGEN RECEPTOR; GERMINAL CENTER KINASE; TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVITY; LINKER PROTEIN; RAS PATHWAY	Immune cell-specific adaptor proteins create various combinations of multiprotein complexes and integrate signals from cell surface receptors to the nucleus, modulating the specificity and selectivity of intracellular signal transduction, Grap2 is a newly identified adaptor protein specifically expressed in lymphoid tissues. This protein shares 40-50% sequence homology in the SH3 and the SH2 domain with Grb2 and Grap, However, the Grap2 protein has a unique 120-amino acid glutamine-and proline-rich domain between the SH2 and C-terminal SH3 domains, The expression of Grap2 is highly restricted to lymphoid organs and T lymphocytes. In order to understand the role of this specific adaptor protein in immune cell signaling and activation, we searched for the Grap2 interacting protein in T lymphocytes. We found that Grap2 interacted with the hematopoietic progenitor kinase 1 (HPK1) in vitro and in Jurkat T cells. The interaction was mediated by the carboxyl-terminal SH3 domain of Grap2 with the second proline-rich motif of HPK1, Coexpression of Grap2 with HPK1 not only increased the kinase activity of HPK1 in the cell, but also had an additive effect on HPK1 mediated JNK activation. Furthermore, over expression of Grap2 and HPK1 induced significant transcriptional activation of c-Jun in the JNK signaling pathway and IL-2 gene reporter activity in stimulated Jurkat T cells, Therefore, our data suggest that the hematopoietic specific proteins Grap2 and HPK1 form a signaling complex to mediate the c-Jun NH2-terminal kinase (JNK) signaling pathway in T cells.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Ctr Canc Biol & Nutr,Inst Biosci & Technol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Univ Louisville, Dept Anat Sci & Neurobiol, Sch Med, Louisville, KY 40202 USA; Shanghai Genom Inc, Shanghai 201204, Peoples R China	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Louisville	Liu, MY (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Ctr Canc Biol & Nutr,Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Ma, Wenbin/0000-0001-8774-7593	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649, R01AI042532] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI42532, R01-AI38649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell DA, 1996, CANCER SURV, V27, P165; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen YR, 2000, INT J ONCOL, V16, P651; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHOI KY, 1994, CELL, V78, P499; Clements JL, 1998, J IMMUNOL, V161, P3880; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hua SB, 1997, PLASMID, V38, P91, DOI 10.1006/plas.1997.1305; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; LOWE VPW, 1991, ENVIRON POLLUT, V70, P1, DOI 10.1016/0269-7491(91)90128-J; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	65	43	46	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1703	1714		10.1038/sj.onc.1204224	http://dx.doi.org/10.1038/sj.onc.1204224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313918				2022-12-28	WOS:000167750900004
J	Lee, YJ; Lee, KH; Kim, HRC; Jessup, JM; Seol, DW; Kim, TH; Billiar, TR; Song, YK				Lee, YJ; Lee, KH; Kim, HRC; Jessup, JM; Seol, DW; Kim, TH; Billiar, TR; Song, YK			Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells	ONCOGENE			English	Article						TRAIL; apoptosis; SNP; nitric oxide; mitochondria; caspase; cytochrome c; Bcl-2	CYTOCHROME-C RELEASE; OXIDE-MEDIATED APOPTOSIS; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; DEATH DOMAIN; PERMEABILITY TRANSITION; CASPASE ACTIVATION; DECOY RECEPTORS; CANCER-CELLS; IN-VIVO	The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo-2L) is a recently characterized member of the family of programmed cell death-inducing ligands that includes TNF-alpha and CD95L (FasL), It is well known that TRAIL binds to the death signaling receptors, DR4 and DR5, and initiates the TRAIL death pathway, Activation of this pathway, mediated through a caspase cascade, causes apoptosis, In this study, we hypothesized that oxidative stress facilitates TRAIL-induced apoptosis by promoting caspase activity through cytochrome c release from mitochondria, Human colorectal carcinoma CX-1 cells were treated with various concentrations of TRAIL (12.5-200 ng/ml) and/or sodium nitroprusside (SNP; 0.03-1 mM) for 12 h, SNP, a nitric oxide donor, which had little toxic effect by itself, enhanced TRAIL-induced cytotoxicity, For example, TRAIL-induced apoptosis (200 ng/ml) was increased by a factor of 2.5-fold in the presence of 1 mM SNP. The combined treatment also caused an increase in cytochrome c release, caspase-3 activity, and PARR cleavage, Overexpression of Bcl-2 completely blocked the SNP-promoting effects, but only moderately inhibited TRAIL-induced apoptosis, Similar results were observed in the presence of hydrogen peroxide or peroxynitrite. Taken together, the present studies suggest that SNP enhances TRAIL-induced cytotoxicity by facilitating the mitochondria-mediated caspase signal transduction pathway.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Inst Canc, Pittsburgh, PA 15213 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wayne State University; University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Inst Canc, E1056 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA064139, R29CA064139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NCI NIH HHS [CA48000, CA64139] Funding Source: Medline; NIGMS NIH HHS [GM44100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bal-Price A, 1999, ANN NY ACAD SCI, V893, P376, DOI 10.1111/j.1749-6632.1999.tb07859.x; BIANCO FJ, 1995, AM J PATHOL, V146, P75; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; IRMIER M, 1997, NATURE, V388, P190; ITOH N, 1993, J IMMUNOL, V151, P621; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Nagane M, 2000, CANCER RES, V60, P847; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhou YW, 1998, CELL IMMUNOL, V186, P103, DOI 10.1006/cimm.1998.1297; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	53	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1476	1485		10.1038/sj.onc.1204225	http://dx.doi.org/10.1038/sj.onc.1204225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313891				2022-12-28	WOS:000167595200008
J	Machado, JC; Oliveira, C; Carvalho, R; Soares, P; Berx, G; Caldas, C; Seruca, R; Carneiro, F; Sobrinho-Simoes, M				Machado, JC; Oliveira, C; Carvalho, R; Soares, P; Berx, G; Caldas, C; Seruca, R; Carneiro, F; Sobrinho-Simoes, M			E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma	ONCOGENE			English	Article						E-cadherin; mutation; methylation; gastric cancer; stomach; diffuse cancer	LOBULAR BREAST CANCERS; MUTATIONS PROVIDE; EXPRESSION; HYPERMETHYLATION; CELLS; PROGRESSION; PATTERNS; ADHESION; ISLAND	In diffuse gastric carcinoma, despite common E-cadherin gene (CDH1) mutations, tumors show absence of CDH1 loss of heterozigosity (LOH) in most cases. This observation challenges the classical two-hit model of tumor suppresser gene inactivation. In order to investigate whether or not CDH1 promoter methylation may function as the second hit we analysed a series of 23 sporadic gastric carcinomas for the presence of CDH1 mutations, CDH1 promoter methylation, LOH and E-cadherin expression. CDH1 mutations were detected in nine of the 16 (56.3%) diffuse gastric carcinomas and in none of the seven intestinal gastric carcinomas. In diffuse gastric carcinomas harboring CDH1 mutations, LOH was observed in a single case. Loss of plasma membrane E-cadherin expression was consistently found in all nine cases with CDH1 mutation, suggesting that tumors inactivated the remaining CDH1 allele via a different mechanism. CDH1 promoter methylation was observed in nine of the 16 (56.3%) diffuse-type gastric carcinoma cases, including six of the nine cases (66.7%) harboring CDH1 mutations. CDH1 promoter methylation was also seen in two (28.6%) intestinal-type cases. Our results show that CDH1 promoter methylation is the second hit in more than half of the sporadic diffuse gastric carcinoma cases harboring CDH1 mutations.	IPATIMUP, P-4200 Oporto, Portugal; Univ Cambridge, Dept Oncol, Cambridge CB2 2XY, England; VIB Ghent Univ, KL, Dept Mol Biol, B-9000 Ghent, Belgium; Univ Porto, Fac Med, P-4200 Oporto, Portugal	University of Cambridge; Flanders Institute for Biotechnology (VIB); Ghent University; Universidade do Porto	Machado, JC (corresponding author), IPATIMUP, Rua Roberto Frias S-N, P-4200 Oporto, Portugal.		Soares, Paula/B-6054-2008; Caldas, Carlos/U-7250-2019; Carneiro, Fatima/J-6432-2013; Caldas, Carlos/A-7543-2008; Oliveira, Carla/F-8188-2011; Carneiro, Fatima/AAV-8677-2021; Machado, Jose Carlos/C-5907-2009; seruca, raquel/F-8187-2011; Sobrinho-Simões, Manuel/J-8290-2013	Soares, Paula/0000-0001-9607-6998; Caldas, Carlos/0000-0003-3547-1489; Carneiro, Fatima/0000-0002-1964-1006; Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; Machado, Jose Carlos/0000-0003-4741-8415; Seruca, Raquel/0000-0002-8851-4166; Berx, Geert/0000-0001-5770-2458; Sobrinho-Simoes, Manuel/0000-0003-1613-1235				BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Gayther SA, 1998, CANCER RES, V58, P4086; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Lee YY, 1997, CANCER, V80, P1889, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1889::AID-CNCR3>3.0.CO;2-J; Leung SY, 1999, CANCER RES, V59, P159; Luber B, 2000, CELL ADHES COMMUN, V7, P391, DOI 10.3109/15419060009109021; Machado JC, 1998, INT J SURG PATHOL, V6, P135, DOI 10.1177/106689699800600302; Machado JC, 1999, LAB INVEST, V79, P459; Shin JY, 2000, CANCER RES, V60, P262; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569	23	215	234	0	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1525	1528		10.1038/sj.onc.1204234	http://dx.doi.org/10.1038/sj.onc.1204234			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313896				2022-12-28	WOS:000167595200013
J	Bowers, G; Reardon, D; Hewitt, T; Dent, P; Mikkelsen, RB; Valerie, K; Lammering, G; Amir, C; Schmidt-Ullrich, RK				Bowers, G; Reardon, D; Hewitt, T; Dent, P; Mikkelsen, RB; Valerie, K; Lammering, G; Amir, C; Schmidt-Ullrich, RK			The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells	ONCOGENE			English	Review						radiation; ErbB; EGF; tyrphostins; mammary carcinoma cells	EPIDERMAL GROWTH-FACTOR; IONIZING-RADIATION; HYDROGEN-PEROXIDE; CANCER-CELLS; FACTOR-ALPHA; ACTIVATION; EXPRESSION; PHOSPHORYLATION; PATHWAY; HETERODIMERIZATION	Activation of the epidermal growth receptor (ErbB1) occurs within minutes of a radiation exposure. Immediate downstream consequences of this activation are currently indistinguishable from those obtained with growth factors (GF), e.g. stimulation of the pro-proliferative mitogen-activated protein kinase (MAPK). To identify potential differences, the effects of GFs and radiation on other members of the ErbB family have been compared in mammary carcinoma cell lines differing in their ErbB expression profiles. Treatment of cells with EGF (ErbB1-specific) or heregulin (ErbB4-specific) resulted in a hierarchic transactivations of ErbB2 and ErbB3 dependent on GF binding specificity. In contrast, radiation indiscriminately activated all ErbB species with the activation profile reflecting that cell's ErbB expression profile. Downstream consequences of these ErbB interactions were examined with MAPK after specifically inhibiting ErbB1 (or 4) with tyrphostin AG1478 or ErbB2 with tyrphostin AG825. MAPK activation by GFs or radiation was completely inhibited by AG1478 indicating total dependance on ErbB1 (or 4) depending on which ErbB is expressed. Inhibiting ErbB2 caused an enhanced MAPK response simulating an amplified ErbB1 (or 4) response. Thus ErbB2 is a modulator of ErbB1 (or 4) function leading to different MAPK response profiles to GF or radiation exposure.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA; Univ Louisiana, Dept Basic Pharmaceut Sci, Monroe, LA USA; Univ Dusseldorf, Dept Radiat Oncol, Duesseldorf, Germany	Virginia Commonwealth University; Emory University; University of Louisiana System; University of Louisiana Monroe; Heinrich Heine University Dusseldorf	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [R01 CA 65896, P01 CA 72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Chen BK, 2000, MOL PHARMACOL, V57, P153; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Frederick L, 2000, CANCER RES, V60, P1383; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gulliford TJ, 1997, ONCOGENE, V15, P2219, DOI 10.1038/sj.onc.1201595; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI NX, 1994, ONCOGENE, V9, P3457; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Park JS, 1999, MOL BIOL CELL, V10, P4231, DOI 10.1091/mbc.10.12.4231; Park JS, 2000, J BIOL CHEM, V275, P18, DOI 10.1074/jbc.275.1.18; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; Tsai CM, 1996, CANCER RES, V56, P1068; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443	44	141	148	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1388	1397		10.1038/sj.onc.1204255	http://dx.doi.org/10.1038/sj.onc.1204255			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313882				2022-12-28	WOS:000167495000012
J	Eymin, B; Karayan, L; Seite, P; Brambilla, C; Brambilla, E; Larsen, CJ; Gazzeri, S				Eymin, B; Karayan, L; Seite, P; Brambilla, C; Brambilla, E; Larsen, CJ; Gazzeri, S			Human ARF binds E2F1 and inhibits its transcriptional activity	ONCOGENE			English	Article						ARF; E2F1; mdm2; tumour suppressor; transcription regulation	P19(ARF) TUMOR-SUPPRESSOR; CELL LUNG-CANCER; P53-DEPENDENT APOPTOSIS; RETINOBLASTOMA PROTEIN; NUCLEOLAR LOCALIZATION; BETA-TRANSCRIPT; STABILIZES P53; DNA-SYNTHESIS; GENE-PRODUCT; MDM2	The INK4a/ARF locus which is frequently inactivated in human tumours encodes two different tumour suppressive proteins, p16(INK4a) and ARF, p16(INK4a) is a major component of the RE pathway. ARF is part of an ARF-mdm2-p53 network that exerts a negative control on hyperproliferative signals emanating from oncogenic stimuli. Among these is the transcription factor E2F1, a final effector of the RE pathway, that induces ARF expression. Recent data suggest that ARF function is not restricted to the p53 pathway. However, ARF target(s) implicated in this p53-independent function remains to be identified. We show that ARF is able to inhibit the proliferation of human cell lines independently of their p53 status. In this context, we demonstrate that ARF interacts physically with E2F1 and inhibits its transcriptional activity. Moreover, we show that mdm2 is required for the modulation of E2F1 activity by ARF, Beside the well-known p53 and mdm2 partners, these results identify E2F1 as a new ARF target. Thus, ARF can be viewed as a dual-acting tumour suppressor protein in both the p53 and RE pathways, further emphasizing its role in tumour surveillance.	Inst Albert Bonniot, INSERM EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France; CHU La Miletrie, CNRS ESA 6031, Lab Immunol & Biochim Prot, F-86021 Poitiers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CHU Poitiers; Universite de Poitiers	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019	gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; Seite, Paule/0000-0002-7809-7610				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EYMIN B, 2001, IN PRESS ONCOGENE; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Gazzeri S, 1998, CANCER RES, V58, P3926; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTIN F, 1995, NATURE, V373, P691; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; NEVINS JR, 1992, SCIENCE, V258, P424; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	37	148	154	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1033	1041		10.1038/sj.onc.1204220	http://dx.doi.org/10.1038/sj.onc.1204220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314038	Green Submitted, Bronze			2022-12-28	WOS:000167232100003
J	Habuchi, T; Takahashi, T; Kakinuma, H; Wang, LZ; Tsuchiya, N; Satoh, S; Akao, T; Sato, K; Ogawa, O; Knowles, MA; Kato, T				Habuchi, T; Takahashi, T; Kakinuma, H; Wang, LZ; Tsuchiya, N; Satoh, S; Akao, T; Sato, K; Ogawa, O; Knowles, MA; Kato, T			Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer	ONCOGENE			English	Article						bladder cancer; methylation; DBCCR1; chromosome 9q	DNA METHYLATION; HOMOZYGOUS DELETION; CELL CARCINOMA; CPG ISLANDS; GENE; INACTIVATION; LOCUS	Transcriptional silencing by CpG island hypermethylation of gene regulatory regions is one mechanism for inactivation of tumour suppressor genes. Chromosome 9q deletion is frequently found in transitional cell carcinoma (TCC) of the bladder and upper urinary tract and one of the putative tumour suppressor loci has been mapped to 9q32-33, A gene designated as DBCCR1 was identified in the candidate region and its mRNA expression is thought to be suppressed by hypermethylation, To understand the role of hypermethylation in TCC, we evaluated the methylation status of 20 CpG sites of the DBCCR1 5'-CpG island region in a total of 69 tumours from 45 patients, 21 normal urothelial specimens, and six bladder cancer cell lines. Aberrant hypermethylation levels mere found in 36 (52%) of 69 tumours without any association with tumour grade or stage. Methylation was weakly detected in the normal urothelium in association with ageing. Although recurrent tumours tended to have higher methylation levels than the initial tumours, the methylation pattern was mostly maintained between multifocal TCCs in individual patients. The results suggest that hypermethylation of the DBCCR1 region is one of the earliest alterations in the development of TCCs and there may be an age-related hypermethylation-based field defect in normal urothelium. Methylator or methylation-resistant phenotype seems to be maintained during multifocal development or recurrence of most TCCs.	Akita Univ, Sch Med, Dept Urol, Akita 0108543, Japan; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan; St Jamess Univ Hosp, ICRF, Canc Med Unit, Leeds, W Yorkshire, England	Akita University; Kyoto University; Saint James's University Hospital; University of Leeds	Kato, T (corresponding author), Akita Univ, Sch Med, Dept Urol, 1-1-1 Hondo, Akita 0108543, Japan.		Wang, Lizhong/J-4268-2019; Tsuchiya, Norihiko/H-6538-2019	Wang, Lizhong/0000-0003-1980-4730; Knowles, Margaret/0000-0002-9363-8657				Ahuja N, 1998, CANCER RES, V58, P5489; CEDER H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1; Choi EK, 1996, MUTAT RES-FUND MOL M, V354, P123, DOI 10.1016/0027-5107(96)00056-5; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hermanek P, 1992, TNM CLASSIFICATION M; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1997, CANCER RES, V57, P1678; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; KNOWLES MA, 1994, CANCER RES, V54, P531; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; Maesawa C, 1996, CANCER RES, V56, P3875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESSING EM, 1998, CAMPBELLS UROLOGY, P2327; Mostofi FK, 1973, HISTOLOGICAL TYPING; Muto S, 2000, CANCER RES, V60, P4021; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; SAKAI T, 1991, AM J HUM GENET, V48, P880; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; Takahashi T, 1998, CANCER RES, V58, P5835; Toyota M, 1999, CANCER RES, V59, P5438; van Tilborg AAG, 1999, BRIT J CANCER, V80, P489, DOI 10.1038/sj.bjc.6690383	34	59	64	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					531	537		10.1038/sj.onc.1204122	http://dx.doi.org/10.1038/sj.onc.1204122			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313984				2022-12-28	WOS:000166562500013
J	Tsuji, T; Usui, S; Aida, T; Tachikawa, T; Hu, GF; Sasaki, A; Matsumura, T; Todd, R; Wong, DTW				Tsuji, T; Usui, S; Aida, T; Tachikawa, T; Hu, GF; Sasaki, A; Matsumura, T; Todd, R; Wong, DTW			Induction of epithelial differentiation and DNA demethylation in hamster malignant oral keratinocyte by ornithine decarboxylase antizyme	ONCOGENE			English	Article						oral cancer; hamster; ornithine decarboxylase antizyme; differentiation; DNA demethylation	MOUSE-TISSUE INHIBITOR; POUCH CARCINOGENESIS MODEL; ALPHA-DIFLUOROMETHYLORNITHINE; METHYLTRANSFERASE ACTIVITY; POLYAMINE LEVELS; GENE-EXPRESSION; RETINOIC ACID; COLON-CANCER; ANTITUMOR-ACTIVITY; METHYLATION STATUS	The hamster ornithine decarboxylase antizyme (ODC-Az) cDNA was transfected into the hamster malignant oral keratinocyte cell line, HCPC-1, Ectopic expression of ODC-Az resulted in the reversion of malignant phenotypes and alteration of DNA methylation status of CCGG sites. The phenotypes examined include ODC enzymatic activity, doubling time, morphological change, anchorage dependent growth, tumorigenicity in nude mice, induction of epithelial differentiation marker protein (involucrin), and change of cell cycle position. Comparison of CCGG DNA methylation status of the ODC-Az and control vector transfectants revealed a significant increase in demethylation of 5-methyl cytosines (m(5)C) of CCGG sites in the ODC-Az transfectants. Ectopic expression of ODC-Az gene in hamster malignant oral keratinocytes led to reduce ODC activity and the subsequent demethylation of 5-methyl cytosines, presumably via the ODC/ polyamines/ decarboxylated S-adenosylmethionine (dc-AdoMet) pathways. Our data suggest that ODC-Az shared the same pathway of polyamines/ dc-AdoMet/DNA methyltransferase (DNA MTase), We propose that ODC-Az mediates a novel mechanism in tumor suppression by DNA demethylation and presumably re-activation of key cellular genes silenced by DNA hypermethylation during cancer development.	Showa Univ, Sch Dent, Dept Oral Pathol, Tokyo 1428555, Japan; Harvard Univ, Sch Med, Dept Radiol, Ctr Biochem & Biophys Sci & Med, Boston, MA 02115 USA; Okayama Univ, Sch Dent, Dept Oral & Maxillofacial Surg 2, Okayama 7008525, Japan; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA	Showa University; Harvard University; Harvard Medical School; Okayama University; Harvard University; Massachusetts General Hospital	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Pathol, Boston, MA 02115 USA.				NIDCR NIH HHS [DE-12529, DE-11983, DE-12467] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE011983, R03DE012529, P01DE012467] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bachman KE, 1999, CANCER RES, V59, P798; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Chao C, 1996, CANCER RES, V56, P4811; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLIFFORD A, 1995, CANCER RES, V55, P1680; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Duranton B, 1998, EXP CELL RES, V243, P319, DOI 10.1006/excr.1998.4148; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEUERSTEIN BG, 1991, J CELL BIOCHEM, V46, P37, DOI 10.1002/jcb.240460107; Freshney RI, 1994, CULTURE ANIMAL CELLS; Frostesjo L, 1997, J BIOL CHEM, V272, P4359, DOI 10.1074/jbc.272.7.4359; GAINES DW, 1988, ANAL BIOCHEM, V174, P88, DOI 10.1016/0003-2697(88)90522-2; GIMENEZCONTI IB, 1993, J CELL BIOCHEM, P83; GIMENEZCONTI IB, 1992, ADV EXP MED BIOL, V320, P63; GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2; Harper JW, 1997, CANCER SURV, V29, P91; HAWTREY AO, 1984, MED HYPOTHESES, V15, P125, DOI 10.1016/0306-9877(84)90117-8; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; Heby O, 1995, INT J DEV BIOL, V39, P737; Heby O, 1988, Adv Exp Med Biol, V250, P291; Henkel AW, 1999, CELL TISSUE RES, V296, P229, DOI 10.1007/s004410051284; HICKOK NJ, 1992, J INVEST DERMATOL, V98, P327, DOI 10.1111/1523-1747.ep12499799; Iismaa T P, 1999, Results Probl Cell Differ, V26, P257; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Ito T, 1999, HISTOL HISTOPATHOL, V14, P895, DOI 10.14670/HH-14.895; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Janssen BLM, 1999, MELANOMA RES, V9, P213, DOI 10.1097/00008390-199906000-00002; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kim SY, 1997, CANCER RES, V57, P38; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDEN M, 1985, J CELL PHYSIOL, V125, P273, DOI 10.1002/jcp.1041250215; LUNDELL L, 1986, SCAND J GASTROENTERO, V21, P829, DOI 10.3109/00365528609011126; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MAO Y, 1993, BIOCHEM J, V295, P641, DOI 10.1042/bj2950641; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; McCarty MF, 1997, MED HYPOTHESES, V48, P297, DOI 10.1016/S0306-9877(97)90098-0; MEGOSH L, 1995, CANCER RES, V55, P4205; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell JLA, 1996, BIOCHEM J, V317, P811, DOI 10.1042/bj3170811; Monzon RI, 1996, CELL GROWTH DIFFER, V7, P1751; ODUKOYA O, 1983, JNCI-J NATL CANCER I, V71, P1252; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; RADFORD DM, 1990, CANCER RES, V50, P6146; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; ROMANO M, 1986, INT J BIOL MARKER, V2, P77; Salzberg A, 1996, GENETICS, V144, P183; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SEILER N, 1985, J CHROMATOGR, V339, P45, DOI 10.1016/S0378-4347(00)84626-5; SHIN DM, 1990, CANCER RES, V50, P2505; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P747; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TAKIGAWA M, 1983, CANCER RES, V43, P3732; TAMORI A, 1994, HEPATOLOGY, V20, P1179, DOI 10.1002/hep.1840200512; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tsuji T, 1998, ONCOGENE, V16, P3379, DOI 10.1038/sj.onc.1201887; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; VERES DA, 1989, J INVEST DERMATOL, V93, P687, DOI 10.1111/1523-1747.ep12319883; VERMA AK, 1980, CANCER RES, V40, P308; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WILLIAMS HK, 1995, J ORAL PATHOL MED, V24, P322, DOI 10.1111/j.1600-0714.1995.tb01193.x; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	83	44	49	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					24	33		10.1038/sj.onc.1204051	http://dx.doi.org/10.1038/sj.onc.1204051			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244502				2022-12-28	WOS:000166361400004
J	Dhordain, P; Albagli, O; Honore, N; Guidez, F; Lantoine, D; Schmid, M; De The, H; Zelent, A; Koken, MHM				Dhordain, P; Albagli, O; Honore, N; Guidez, F; Lantoine, D; Schmid, M; De The, H; Zelent, A; Koken, MHM			Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF	ONCOGENE			English	Article						nuclear body; PML; APL; non Hodgkin lymphoma	ACUTE PROMYELOCYTIC LEUKEMIA; ALPHA FUSION PROTEIN; GERMINAL-CENTER FORMATION; B-CELL LYMPHOMA; PML-RAR-ALPHA; RETINOIC ACID; TRANSCRIPTIONAL REPRESSION; POZ-DOMAIN; HISTONE DEACETYLASE; BTB/POZ DOMAIN	Most acute promyelocytic leukemia (APL) cases are associated with recurrent translocations between the gene of retinoic receptor alpha and that of PML (t(15;17)) or PLZF (t(11;17)), PML localizes onto discrete intranuclear domains, the PML-nuclear bodies, and displays anti-oncogenic and pro-apoptotic properties. PLZF encodes a transcription factor belonging to the (PO) under barZ/domain and Kruppel zinc finger (POK) family which interacts directly with PML, PLZF is related to another POK protein, LAZ3(BCL6), which is structurally altered, and presumably misexpressed, in many non-Hodgkin lymphoma (NHL) cases. PLZF and LAZ3 share many functional properties: both inhibit cell growth, concentrate into punctated nuclear subdomains and are sequence-specific transcriptional repressors recruiting a histone deacetylase-repressing complex. Given these similarities, we tested whether both proteins could be targeted by each other, Here, LAZ3 and PLZF are shown to colocalize onto nuclear dots. Moreover, truncated derivatives of one protein, which display a diffuse nuclear localization, are recruited onto nuclear dots by the full-length other. The colocalization and the reciprocal 'rescue' is the result of a direct interaction between LAZ3 and PLZF, as indicated by yeast two hybrid assays, in vitro immunoprecipitations, and GST pull down experiments. In contrast to LAZ3 homomerization, LAZ3/PLZF heteromerization in yeast does not solely depend on POZ/POZ contacts but rather also relies on interactions between the two zinc finger regions and 'cross' contacts between the zinc finger region and the POZ domain of each partner, Likewise, LAZ3 shows some colocalization with the PLZF partner PML upon stable overexpression of both proteins in CHO cells and interacts with PML in yeast. Finally, endogenous LAZ3 and PLZF are co-induced and partially colocalized in myeloid MDS cells, These data indicate that a physical interaction between LAZ3 and PLZF underlies their simultaneous recruitment onto multiproteic nuclear complexes, presumably involved in transcriptional silencing and whose integrity (for APL) and/or function (for APL and NHL) may be altered in oncogenesis.	Univ Paris 07, CNRS UPR 9051, Unite Conventionnee, Hop St Louis, F-75475 Paris 10, France; IRCL, INSERM U524, F-59045 Lille, France; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Hop St Louis, INSERM U462, F-75475 Paris 10, France; UPR 1983, F-94801 Villejuif, France; MNHN, Stn Biol Marine, F-29182 Concarneau, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Museum National d'Histoire Naturelle (MNHN)	Koken, MHM (corresponding author), Univ Paris 07, CNRS UPR 9051, Unite Conventionnee, Hop St Louis, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		koken, marcel/J-8154-2012; Zelent, Arthur/B-3532-2009; koken, marcel/N-1349-2019; Guidez, Fabien/B-3750-2009; Guidez, Fabien/P-4220-2019	koken, marcel/0000-0002-0839-0125; Guidez, Fabien/0000-0003-1380-4473; Zelent, Arthur/0000-0002-7968-9888				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; BANERJEE R, 1992, P NATL ACAD SCI USA, V89, P9996, DOI 10.1073/pnas.89.21.9996; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1999, BLOOD, V94, p368A; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; James P, 1996, GENETICS, V144, P1425; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Li XM, 1999, CANCER RES, V59, P5275; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MACLEY JP, 1998, TIBS, V23, P1; MIKI T, 1994, BLOOD, V83, P26; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Niu HF, 1999, BLOOD, V94, p693A; Numoto M, 1999, BIOCHEM BIOPH RES CO, V256, P573, DOI 10.1006/bbrc.1999.0375; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rose MD., 1990, METHODS YEAST GENETI; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	62	61	62	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6240	6250		10.1038/sj.onc.1203976	http://dx.doi.org/10.1038/sj.onc.1203976			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175338				2022-12-28	WOS:000166210500007
J	Roh, H; Pippin, JA; Green, DW; Boswell, CB; Hirose, CT; Mokadam, N; Drebin, JA				Roh, H; Pippin, JA; Green, DW; Boswell, CB; Hirose, CT; Mokadam, N; Drebin, JA			HER2/neu antisense targeting of human breast carcinoma	ONCOGENE			English	Article						HER2/neu; breast cancer; antisense oligonucleotides; oncogenes; apoptosis; cell cycle	HER2/NEU-OVEREXPRESSING METASTATIC BREAST; MONOCLONAL-ANTIBODIES; CANCER CELLS; OVARIAN-CANCER; TUMOR-GROWTH; NEU ONCOGENE; PHASE-II; IN-VIVO; RECEPTOR; OVEREXPRESSION	Overexpression of the HER2/neu oncogene is observed in approximately 30% of human breast carcinoma specimens. HER2/neu overexpression is a negative prognostic factor in breast cancer patients. Cancer cells that overexpress HER2/neu may also be less sensitive to chemotherapy. In order to further define mechanisms by which HER2/neu overexpression drives neoplastic cell growth and chemoresistance, antisense oligonucleotides (ODNs) have been utilized to selectively down-regulate HER2/neu expression in human breast cancer cells. Such antisense ODNs suppress HER2/neu mRNA and protein levels in a dose-dependent, sequence-specific manner. Down-regulation of HER2/neu expression in HER2/neu overexpressing breast cancer cells inhibits cell cycle progression in G(0)/G(1) and results in apoptotic cell death. In tissue culture studies, combined treatment of HER2/neu overexpressing breast cancer cells with HER2/neu antisense ODNs and conventional chemotherapeutic agents results in synergistic inhibition of cancer cell growth and activation of apoptotic cell death mechanisms. These studies have been extended to demonstrate synergistic antitumor effects following systemic treatment with antisense ODNs plus doxorubicin in nude mice bearing human breast carcinoma xenografts. Collectively these findings demonstrate that HER2/neu overexpression stimulates anti-apoptotic cell survival mechanisms and suggest that HER2/neu antisense ODNs may be of use in cancer therapeutics.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA	Washington University (WUSTL)	Drebin, JA (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [T32CA009621, T32CA009141] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09621, CA09141] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1997, Oncology (Williston Park), V11, P43; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BERCHUCK A, 1990, CANCER RES, V50, P4087; Brodowicz T, 1997, INT J CANCER, V73, P875, DOI 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1985, CELL, V41, P95; Ghetie MA, 1997, P NATL ACAD SCI USA, V94, P7509, DOI 10.1073/pnas.94.14.7509; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Green DW, 2000, J AM COLL SURGEONS, V191, P93, DOI 10.1016/S1072-7515(00)00305-7; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KERN JA, 1990, CANCER RES, V50, P5184; Kita Y, 1996, BIOCHEM BIOPH RES CO, V226, P59, DOI 10.1006/bbrc.1996.1311; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Roh H, 1999, SURGERY, V126, P413, DOI 10.1016/S0039-6060(99)70186-8; Roh H, 1998, J SURG RES, V77, P85, DOI 10.1006/jsre.1998.5353; Roh H, 2000, CANCER RES, V60, P560; Shen K, 1997, BIOCHEM BIOPH RES CO, V230, P89, DOI 10.1006/bbrc.1996.5896; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; WEBB SJ, 1997, ADV PHARMACOL, V40, P1; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246	34	29	42	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6138	6143		10.1038/sj.onc.1204001	http://dx.doi.org/10.1038/sj.onc.1204001			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156527				2022-12-28	WOS:000166121400007
J	Kimura, SH; Ikawa, M; Ito, A; Okabe, M; Nojima, H				Kimura, SH; Ikawa, M; Ito, A; Okabe, M; Nojima, H			Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery	ONCOGENE			English	Article						cyclin G1; cyclin G1-disrupted mouse; p53; G2/M arrest	CELL-CYCLE; CHROMOSOMAL LOCALIZATION; P53-MEDIATED APOPTOSIS; GENOMIC INTEGRITY; GENE-TRANSFER; P53; EXPRESSION; PROTEIN; RNA; MICE	Cyclin G1 is one of the target genes of the transcription factor p53, and is induced in a p53-dependent manner in response to DNA damage. Although cyclin G1 has been implicated in a range of biological phenomena, its precise function remains unclear. Here we present an analysis of the physiological role of cyclin Ct using mice homozygous for a targeted disruption of the cyclin G1 gene. In order to clarify the role of cyclin G1 in the p53 pathway, downstream events such as apoptosis, cell growth and cell cycle checkpoint control were analysed in thymocytes and embryonic fibroblasts derived from cyclin G1-disrupted mice. No difference was detected in induction of apoptosis between mouse embryo fibroblasts (MEFs) derived from cyclin G1(+/+) and cyclin G1(-/-) mice. Following irradiation, cyclin G1(-/-) MEFs proliferated more slowly and reached lower cell densities in culture dishes than cyclin G1(+/+) MEFs, Analysis of cell survival showed that cyclin G1(-/-) MEFs were about twice as sensitive as cyclin G1(+/+) MEFs to gamma radiation or UV radiation. Cyclin G1(-/-) mice were more sensitive to gamma radiation than wild-type mice. Flow cytometeric analysis revealed that the number of cyclin G1(-/-) MEFs in G2/M phase after irradiation was reduced by 50% relative to cyclin G1(+/+) MEFs, Our results demonstrate that cyclin ct plays roles in G2/M arrest, damage recovery and growth promotion after cellular stress.	Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, Suita, Osaka 5650871, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Nojima, H (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Asahina H, 1999, MUTAT RES-DNA REPAIR, V435, P255, DOI 10.1016/S0921-8777(99)00051-8; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, ONCOGENE, V13, P1103; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; FANTES P, 1993, CELL CYCLE PRACTICAL, P6; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hunt T, 1991, Semin Cell Biol, V2, P213; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kimura SH, 1997, GENOMICS, V46, P483, DOI 10.1006/geno.1997.5034; Kimura SH, 1997, GENOMICS, V44, P179, DOI 10.1006/geno.1997.4873; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita N, 1996, J NEUROSCI, V16, P5961; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Robertson E, 1987, TERATOCARCINOMAS EMB; ROSSI CC, 1998, TOXICOL LETT, V102, P491; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 2002, MOL CLONING LAB MANU; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SKOTZKO M, 1995, CANCER RES, V55, P5493; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	53	116	126	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3290	3300		10.1038/sj.onc.1204270	http://dx.doi.org/10.1038/sj.onc.1204270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423978				2022-12-28	WOS:000169163500012
J	Jang, SJ; Chiba, I; Hirai, A; Hong, WK; Mao, L				Jang, SJ; Chiba, I; Hirai, A; Hong, WK; Mao, L			Multiple oral squamous epithelial lesions: are they genetically related?	ONCOGENE			English	Article						multiple oral lesion; microsatellite alteration; clonality	COMMON CLONAL ORIGIN; ANDROGEN-RECEPTOR GENE; CELL LUNG-CANCER; NECK-CANCER; MICROSATELLITE ALTERATIONS; FIELD CANCERIZATION; PRIMARY TUMORS; CHROMOSOME 3P; PRIMARY HEAD; CARCINOMA	The development of second primary tumors (SPTs) in patients with head and neck squamous cell carcinoma (HNSCC) has become an increasingly important factor in clinical treatment decison, Currently, clinical and histologic parameters are used to determine whether or not SPT is present. Recent studies suggest that many SPTs in the upper aerodigestive tract have a common clonal origin, challenging the longstanding multiclonal origin concept, To determine genetic relationships among multiple oral cancerous and precancerous lesions (MOCP), we analysed 100 lesions from 26 Japanese patients, Lesion development was synchronous and metachronous. We looked for patterns of microsatellite alterations (MA) using seven markers at chromosomes 3p14, 9p21, and 17p13, where MA occurs early in oral carcinogenesis. Loss of heterozygosity (LOH) was found in 52.6% (41/78), 62.5% (60/96), and 59.3% (32/54) of informative MOCP at 3p14, 9p21, and 17p13, respectively, Microsatellite instability (MI) was observed in II, 26 and 13% of the samples at 3p14, 9p21, and 17p13 markers, respectively. Patterns of MA were concordant in only nine (14%) of 63 lesions from four (18%) of 22 patients who initially presented with noninvasive lesions. However, two of four patients with invasive cancer as indexed lesion showed 16 (43%) clonally related MOCP among 37 lesions (P=0.003). The results suggest that the majority of MOCP arise from clonally independent cells affected by field cancerization. However, the probability of mucosal spread of clonal malignant or premalignant cells may increase along with malignant progression.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA; Hokkaido Univ, Sch Dent, Sapporo, Hokkaido 060, Japan	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University	Mao, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA52051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Bedi GC, 1996, CANCER RES, V56, P2484; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYLE J, 1998, CANCER RES, V58, P4477; Buller RE, 1998, AM J OBSTET GYNECOL, V178, P641, DOI 10.1016/S0002-9378(98)70473-9; Califano J, 1996, CANCER RES, V56, P2488; CHUNG KY, 1993, CANCER RES, V53, P1676; Cianfriglia F, 1999, ORAL ONCOL, V35, P157, DOI 10.1016/S1368-8375(98)00105-5; EINHORN J, 1967, CANCER, V20, P2184, DOI DOI 10.1038/NRC1477; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; Field JK, 1996, ANTICANCER RES, V16, P2421; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jang SJ, 2000, CANCER RES, V60, P864; JONES AS, 1995, CANCER, V75, P1343, DOI 10.1002/1097-0142(19950315)75:6<1343::AID-CNCR2820750617>3.0.CO;2-T; Kim SK, 1997, CANCER RES, V57, P400; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Lydiatt WM, 1998, CANCER, V82, P1376, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1376::AID-CNCR22>3.0.CO;2-2; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1998, J NATL CANCER I, V90, P1545, DOI 10.1093/jnci/90.20.1545; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; NAWROZ H, 1994, CANCER RES, V54, P1152; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Prevo LJ, 1999, CANCER RES, V59, P4784; Roz L, 1996, CANCER RES, V56, P1228; Scholes AGM, 1998, CANCER RES, V58, P2003; SCHWARTZ LH, 1994, CANCER, V74, P1933, DOI 10.1002/1097-0142(19941001)74:7<1933::AID-CNCR2820740718>3.0.CO;2-X; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SILVERMAN S, 1984, CANCER, V53, P563; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SOZZI G, 1995, CANCER RES, V55, P135; Tseng JE, 1999, CANCER RES, V59, P4798; VANDERRIET P, 1994, CANCER RES, V54, P1156; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WORSHAM MJ, 1995, HUM PATHOL, V26, P251, DOI 10.1016/0046-8177(95)90054-3	34	74	80	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2235	2242		10.1038/sj.onc.1204311	http://dx.doi.org/10.1038/sj.onc.1204311			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402318				2022-12-28	WOS:000168404500005
J	Brooks, DG; James, RM; Patek, CE; Williamson, J; Arends, MJ				Brooks, DG; James, RM; Patek, CE; Williamson, J; Arends, MJ			Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19(ARF)	ONCOGENE			English	Article						K-ras; DNA damage; ES cells; apoptosis	ONCOGENIC RAS; N-RAS; TUMOR SUPPRESSION; MATRIX ADHESION; PLASMA-MEMBRANE; C-MYC; P53; ACTIVATION; TRANSFORMATION; KINASE	The roles of K-ras in neoplasia are not entirely understood, although there is evidence that K-ras affects susceptibility to apoptosis, modulating survival of DNA damaged cells which would otherwise be eliminated. In this study, we investigated the effects of mutant K-ras on apoptosis in vitro following DNA damage. To avoid complications resulting from mutations in other cancer-related genes and from the presence of endogenous K-ras, we derived K-ras null embryonic stem cells. Expression of either wild-type or mutant K-vas was reconstructed by stable plasmid transfection, The cell lines were treated with etoposide, cisplatin and UV radiation and apoptosis measured flow cytometrically. Mutant K-ras potentiated the effect of etoposide-derived DNA damage by increasing apoptosis, whereas absence of K-ras had the opposite effect. This pattern was similar but less marked with cisplatin, whereas UV yielded no difference in apoptosis with regard to K-ras status, suggesting that the effect of K-ras on apoptosis is dependent on the nature of the DNA damage, To investigate possible mechanisms, we examined the expression of p19(ARF) mRNA by RT-PCR, Cells expressing mutant K-ras produced elevated levels of p19(ARF) mRNA, which could link K-ras status with p53 expression and hence susceptibility to DNA damage-induced apoptosis.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; Univ Edinburgh, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh	Arends, MJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Hills Rd, Cambridge CB2 2QQ, England.							Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; CHEN F, 1994, PROCESS BIOCHEM, V29, P245, DOI 10.1016/0032-9592(94)80064-2; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Orecchia R, 2000, J PATHOL, V190, P423; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; REIHSAUS E, 1990, ONCOGENE, V5, P137; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Vater CA, 1996, ONCOGENE, V13, P739; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2144	2152		10.1038/sj.onc.1204309	http://dx.doi.org/10.1038/sj.onc.1204309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360198				2022-12-28	WOS:000168116700009
J	Strathdee, G; Sansom, OJ; Sim, A; Clarke, AR; Brown, R				Strathdee, G; Sansom, OJ; Sim, A; Clarke, AR; Brown, R			A role for mismatch repair in control of DNA ploidy following DNA damage	ONCOGENE			English	Article						mismatch repair; cell cycle; polyploidy; p53; DNA damage	CELL-CYCLE CHECKPOINT; MICROSATELLITE INSTABILITY; TUMOR-CELLS; SPINDLE CHECKPOINT; DRUG-RESISTANCE; P53 PROTEIN; APOPTOSIS; MUTATION; CISPLATIN; MICE	Many reports have shown a link between mismatch repair (MMR) deficiency and loss of normal cell cycle control, particularly loss of G2 arrest. However almost all of these studies utilized transformed cell lines, and thus the involvement of other genes in this phenotype cannot be excluded. We have examined the effects of cisplatin treatment on primary embryo fibroblasts (MEFs) derived from mice in which the MMR gene Msh2 had been inactivated (Msh2(-/-)). This analysis determined that both primary Msh2(-/-) and wild type (WT) fibroblasts exhibited an essentially identical G2 arrest following cisplatin treatment. Similarly, we observed a cisplatin-induced G2 arrest in immortalized MMR deficient (Mlh1 (/) and Pms2(-/-)) and WT MEFs, p53 deficient primary MEFs (p53(-/-)) exhibited both a clear G2 arrest and an increase in cells with a DNA content of 8N in response to cisplatin, When the Msh2 and p53 defects were combined (p53(-/-)/Msh2(-/-)) the G2 arrest was essentially identical to the p53(-/-) fibroblasts. However, the p53(-/-)/Msh2(-/-) fibroblasts demonstrated a further increase in cells with an 8N DNA content, above that seen in the p53 (/) fibroblasts, These results suggest that loss of MMR on its own is not enough to overcome G2 arrest following exposure to cisplatin but does play a role in preventing polyploidization, or aberrant DNA reduplication, in the absence of functional p53.	Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Beatson Institute; University of Glasgow; University of Edinburgh; Cardiff University	Brown, R (corresponding author), Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Brown, Robert/0000-0001-7960-5755; Sansom, Owen J./0000-0001-9540-3010; Strathdee, Gordon/0000-0001-9681-8429; Clarke, Alan/0000-0002-4281-426X				Anthoney DA, 1996, CANCER RES, V56, P1374; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davis TW, 1998, CANCER RES, V58, P767; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fink D, 1998, CLIN CANCER RES, V4, P1; Gong JG, 1999, NATURE, V399, P806; HAWN MT, 1995, CANCER RES, V55, P3721; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KOI M, 1994, CANCER RES, V54, P4308; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Nehme A, 1997, CANCER RES, V57, P3253; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687	28	29	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1923	1927		10.1038/sj.onc.1204276	http://dx.doi.org/10.1038/sj.onc.1204276			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313940				2022-12-28	WOS:000167908400013
J	Yang, W; Shen, J; Wu, M; Arsura, M; FitzGerald, M; Suldan, Z; Kim, DW; Hofmann, CS; Pianetti, S; Romieu-Mourez, R; Freedman, LP; Sonenshein, GE				Yang, W; Shen, J; Wu, M; Arsura, M; FitzGerald, M; Suldan, Z; Kim, DW; Hofmann, CS; Pianetti, S; Romieu-Mourez, R; Freedman, LP; Sonenshein, GE			Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc	ONCOGENE			English	Article						c-Myc; Max; p27(Kip1); WEHI 231 cells; smooth muscle cells; breast cancer	RECEPTOR-MEDIATED APOPTOSIS; GROWTH-FACTOR-BETA; B-CELL LYMPHOMAS; PRIMARY BREAST-CANCER; CD40 LIGAND RESCUE; FACTOR-KAPPA-B/REL; PROGNOSTIC-SIGNIFICANCE; CONTACT INHIBITION; MESSENGER-RNA; CDK INHIBITOR	Upon engagement of the B Cell Receptor (BCR) of WEHI 231 immature B cells, a drop in c-Myc expression is followed by activation of the cyclin-dependent kinase inhibitor (CKI) p27(kip1), which induces growth arrest and apoptosis, Here, we report inverse patterns of p27 and c-Myc protein expression follow BCR engagement, We present evidence demonstrating, for the first time, that the p27(Kip1) gene is a target of transcriptional repression by c-Myc, Specifically, the changes in p27 protein levels correlated with changes in p27 mRNA levels, and gene transcription, Induction of p27 promoter activity followed BCR engagement of WEHI 231 cells, and this induction could be repressed upon co-transfection of a c-Myc expression vector. Inhibition of the TATA-less p27 promoter by c-Myr was also observed in Jurkat T cells, vascular smooth muscle, and Hs578T breast canter cells, extending the observation beyond immune cells, Consistent with putative Inr element CC (A) under bar GACC (where +1 is underlined) at the start site of transcription in the p27 promoter, deletion of Myc homology box II reduced the extent of repression, Furthermore, enhanced repression was observed upon transfection of the c-Myc 'super-repressor', with mutation of Phe115 to Leu, The sequences mediating transcriptional activity and c-Myc repression were mapped to bp -20 to +20 of the p27 gene, Finally, binding of Max was shown to facilitate c-Myc binding and repression of p27 promoter activity, Overall, these studies identify the p27 CKI gene as a new target whereby c-Myc can control cell proliferation, survival and neoplastic transformation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Boston University; Memorial Sloan Kettering Cancer Center	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.				NATIONAL CANCER INSTITUTE [R01CA082742, T32CA064070, R01CA036355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NCI NIH HHS [CA64070, CA 82742, CA 36355] Funding Source: Medline; NHLBI NIH HHS [HL13262, HL07429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Arsura M, 2000, BLOOD, V96, P1013, DOI 10.1182/blood.V96.3.1013.015k06_1013_1020; ARSURA M, 2001, TRANSCRIPTION FACTOR, P521; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BERNS EMJJ, 1992, CANCER RES, V52, P1107; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BOYD AW, 1981, J IMMUNOL, V126, P2466; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; CLARK HM, 1994, CANCER RES, V54, P3383; Dang CV, 1999, MOL CELL BIOL, V19, P1; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FitzGerald MJ, 1999, ONCOGENE, V18, P2489, DOI 10.1038/sj.onc.1202611; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Kamesaki H, 1998, J IMMUNOL, V160, P770; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lee CCR, 1999, CARCINOGENESIS, V20, P1697, DOI 10.1093/carcin/20.9.1697; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; NORVELL A, 1995, J IMMUNOL, V154, P4404; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Runge D, 1997, BIOL CHEM, V378, P873, DOI 10.1515/bchm.1997.378.8.873; Schauer SL, 1998, J IMMUNOL, V160, P4398; Schauer SL, 1996, J IMMUNOL, V157, P81; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; Steiner P, 1996, Prog Cell Cycle Res, V2, P73; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsuchiya A, 1999, J SURG ONCOL, V70, P230, DOI 10.1002/(SICI)1096-9098(199904)70:4<230::AID-JSO6>3.0.CO;2-I; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang W, 1999, J IMMUNOL, V162, P314; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wu M, 1999, J IMMUNOL, V163, P6530; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yanagisawa K, 1999, J BIOCHEM-TOKYO, V125, P36, DOI 10.1093/oxfordjournals.jbchem.a022265; YANO T, 1993, ONCOGENE, V8, P2741; Yi AK, 1996, J IMMUNOL, V157, P4918	93	218	230	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1688	1702		10.1038/sj.onc.1204245	http://dx.doi.org/10.1038/sj.onc.1204245			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313917				2022-12-28	WOS:000167750900003
J	Adams, JW; Brown, JH				Adams, JW; Brown, JH			G-proteins in growth and apoptosis: lessons from the heart	ONCOGENE			English	Review						cardiac; Gq; heart failure; hypertrophy; cardiomyocyte	RAT VENTRICULAR MYOCYTES; MYOCARDIAL-CELL HYPERTROPHY; CARDIAC GENE-EXPRESSION; BETA-ADRENERGIC PATHWAY; II-INDUCED HYPERTROPHY; KINASE-C-EPSILON; TRANSGENIC MICE; IN-VIVO; PRESSURE-OVERLOAD; PERTUSSIS-TOXIN	The acute contractile function of the heart is controlled by the effects of released nonepinephrine (NE) on cardiac adrenergic receptors, NE can also act in a more chronic fashion to induce cardiomyocyte growth, characterized by cell enlargement (hypertrophy), increased protein synthesis, alterations in gene expression and addition of sarcomeres. These responses enhance cardiomyocyte contractile function and thus allow the heart to compensate for increased stress. The hypertrophic effects of NE are mediated through Gq-coupled alpha (1)-adrenergic receptors and are mimicked by the actions of other neurohormones (endothelin, prostaglandin F-2 alpha angiotensin II) that also act on Gq-coupled receptors, Activation of phospholipase C by Gq is necessary for these responses, and protein kinase C and MAP kinases have also been implicated. Gq stimulated cardiac hypertrophy is also evident in transgenic mouse models. In contrast, stimulation of G(s)-coupled beta -adrenergic receptors or G(i)-coupled receptors do not directly effect cardiomyocyte hypertrophy, Apoptosis is also induced by G-protein-coupled receptor stimulation in cardiomyocytes, Sustained or excessive activation of either Gq- or Gs-signaling pathways results in apoptotic loss of cardiomyocytes both in vitro and in vivo, Apoptosis is associated with decreased ventricular function in the failing heart, Cardiomyocytes provide an ideal model system for understanding the basis for G-protein mediated hypertrophy and apoptosis, and the mechanisms responsible for the transition from compensatory to deleterious levels of signaling. This information may prove critical for designing interventions that prevent the pathophysiological consequences of heart failure.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,0636, La Jolla, CA 92093 USA.							Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; Asai K, 1999, J CLIN INVEST, V104, P551, DOI 10.1172/JCI7418; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BOHM M, 1994, J MOL CELL CARDIOL, V26, P133, DOI 10.1006/jmcc.1994.1017; BROWN LA, 1992, BRIT J PHARMACOL, V106, P115, DOI 10.1111/j.1476-5381.1992.tb14302.x; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; Cigola E, 1997, EXP CELL RES, V231, P363, DOI 10.1006/excr.1997.3477; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; Ehmke H, 1999, HYPERTENSION, V33, P954, DOI 10.1161/01.HYP.33.4.954; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Fortuno MA, 1998, HYPERTENSION, V32, P280, DOI 10.1161/01.HYP.32.2.280; Geng YJ, 1999, CIRC RES, V84, P34; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Goussev A, 1998, AM J PHYSIOL-HEART C, V275, pH626, DOI 10.1152/ajpheart.1998.275.2.H626; Grupp IL, 1998, AM J PHYSIOL-HEART C, V275, pH1338, DOI 10.1152/ajpheart.1998.275.4.H1338; Harada K, 1998, CIRC RES, V82, P779, DOI 10.1161/01.RES.82.7.779; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; HILALDANDAN R, 1997, J BIOL CHEM, V272, pH130; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Iwase M, 1997, AM J PHYSIOL-HEART C, V272, pH585, DOI 10.1152/ajpheart.1997.272.1.H585; Iwase M, 1996, CIRC RES, V78, P517, DOI 10.1161/01.RES.78.4.517; Izumo S, 1998, J Card Fail, V4, P263, DOI 10.1016/S1071-9164(98)90231-7; Jalili T, 1999, CARDIOVASC RES, V44, P5, DOI 10.1016/S0008-6363(99)00211-4; Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Katz AM, 1995, EUR HEART J, V16, P110, DOI 10.1093/eurheartj/16.suppl_O.110; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Li ZH, 1997, AM J PHYSIOL-HEART C, V272, pH2313, DOI 10.1152/ajpheart.1997.272.5.H2313; Liggett SB, 2000, CIRCULATION, V101, P1707; LINZ W, 1992, J CARDIOVASC PHARM, V20, pS83, DOI 10.1097/00005344-199200209-00015; LONG CS, 1992, BASIC RES CARDIOL, V87, P19; Matkovich SJ, 2000, J BIOL CHEM, V275, P10845, DOI 10.1074/jbc.275.15.10845; McWhinney C, 2000, J BIOL CHEM, V275, P2087, DOI 10.1074/jbc.275.3.2087; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Miyauchi T, 1999, TRENDS PHARMACOL SCI, V20, P210, DOI 10.1016/S0165-6147(99)01297-3; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; REDMAN CM, 2000, P NATL ACAD SCI USA, V97, P4826; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Sabbah HN, 1999, CLIN CARDIOL, V22, pV16; Sabri A, 2000, CIRC RES, V86, P1054, DOI 10.1161/01.RES.86.10.1054; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Sakata Y, 1998, CIRCULATION, V97, P1488; Sekiguchi K, 1999, CIRC RES, V85, P1000; Shizukuda Y, 1998, AM J PHYSIOL-HEART C, V275, pH961, DOI 10.1152/ajpheart.1998.275.3.H961; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; Simpson PC, 1999, CIRCULATION, V99, P334, DOI 10.1161/01.CIR.99.3.334; STEINBERG SF, 1995, J MOL CELL CARDIOL, V27, P141, DOI 10.1016/S0022-2828(08)80014-4; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Takeishi Y, 2000, CIRC RES, V86, P1218, DOI 10.1161/01.RES.86.12.1218; Tamamori M, 1996, J CLIN INVEST, V97, P366, DOI 10.1172/JCI118424; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Thurmann PA, 1998, CIRCULATION, V98, P2037, DOI 10.1161/01.CIR.98.19.2037; Varma DR, 2000, CAN J PHYSIOL PHARM, V78, P267, DOI 10.1139/cjpp-78-4-267; Vatner DE, 2000, CIRC RES, V86, P802, DOI 10.1161/01.RES.86.7.802; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yamazaki T, 1999, HYPERTENS RES-CLIN E, V22, P113, DOI 10.1291/hypres.22.113; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; Zaugg M, 2000, CIRCULATION, V102, P344; Zhu YC, 1997, AM J CARDIOL, V80, pA110, DOI 10.1016/S0002-9149(97)00465-7; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417	103	93	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1626	1634		10.1038/sj.onc.1204275	http://dx.doi.org/10.1038/sj.onc.1204275			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313910				2022-12-28	WOS:000168089800013
J	Yolcu, E; Sayan, BS; Yagci, T; Cetin-Atalay, R; Soussi, T; Yurdusev, N; Ozturk, M				Yolcu, E; Sayan, BS; Yagci, T; Cetin-Atalay, R; Soussi, T; Yurdusev, N; Ozturk, M			A monoclonal antibody against DNA binding helix of p53 protein	ONCOGENE			English	Article						p53; hybridoma; DNA binding helix	MUTATIONS; MUTANTS; REGION; CANCER; CELLS	Three monoclonal antibodies (Mabs) were generated against p53 DNA-binding core domain. When tested by immunoprecipitation, Western blot and immunofluorescence techniques, Mab 9E4, as well as 7D3 and 6B10 reacted with both wild-type and various mutant p53 proteins. The epitopes recognized by Mabs 7D3, 9E4 and 6B10 were located respectively within the amino acid residues 211-220, 281-290 and 291-300 of human p53 protein. The epitope recognized by 9E4 Mab coincides with helix 2, also called p53 DNA binding helix, which allows the direct contact of the protein with its target DNA sequences. This antibody may be useful to study transcription-dependent and transcription-independent activities of wild-type and mutant p53 proteins.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey; Bilkent Univ, BilGen Genet & Biotechnol Ctr, TR-06533 Ankara, Turkey; TUBITAK MRC, Res Inst Genet Engn & Biotechnol, Dept Mol Oncol, Gebze, Kocaeli, Turkey; Inst Curie, Paris, France	Ihsan Dogramaci Bilkent University; Ihsan Dogramaci Bilkent University; Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014; Cetin-Atalay, Rengul/O-9826-2014; Cetin-Atalay, Rengul/F-5780-2013	OZTURK, MEHMET/0000-0002-6092-9706; Cetin-Atalay, Rengul/0000-0003-2408-6606; Cetin-Atalay, Rengul/0000-0003-2408-6606; soussi, thierry/0000-0001-8184-3293				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	15	5	6	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1398	1401		10.1038/sj.onc.1204240	http://dx.doi.org/10.1038/sj.onc.1204240			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313883	Green Published			2022-12-28	WOS:000167495000013
J	Barette, C; Jariel-Encontre, I; Piechaczyk, M; Piette, J				Barette, C; Jariel-Encontre, I; Piechaczyk, M; Piette, J			Human cyclin C protein is stabilized by its associated kinase cdk8, independently of its catalytic activity	ONCOGENE			English	Article						cyclin C; cdk8; degradation; proteasome; ubiquitin	RNA-POLYMERASE-II; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; TRANSCRIPTIONAL CONTROL; RAPID DEGRADATION; MEDIATOR COMPLEX; MAMMALIAN-CELLS; MESSENGER-RNA; CLN FUNCTION; DNA-REPAIR	Cyclin C belongs to the cyclin family of proteins that control cell cycle transitions through activation of specific catalytic subunits, the cyclin-dependent kinases (CDKs), However, there is as yet no evidence, for any role of cyclin C and its partner, cdk8, in cell cycle regulation. Rather, the cyclin C-cdk8 complex was found associated with the RNA polymerase II transcription machinery. The periodic degradation of bona fide cyclins is crucial for cell-cycle progression and depends on the catalytic activity of the associated CDK. Here we,ve show that endogenous cyclin C protein is quite stable with a half-life of 4 h, In contrast, exogenously expressed cyclin C is very unstable (half-life 15 min) and degraded by the ubiquitin-proteasome pathway. Co-expression with its associated cdk, however, strongly stabilizes cyclin C and results in a protein half-life near that of endogenous cyclin C. In stark contrast to data reported for other members of the cyclin family, both catalytically active and inactive cdk8 induce cyclin C stabilization. Moreover, this stabilization is accompanied in both cases by phosphorylation of the cyclin,which is not detectable when unstable. Our results indicate that cyclin C has apparently diverged from other cyclins in the regulation of its stability by its CDK partner.	CNRS, UMR 5535, Inst Genet Mol, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piette, J (corresponding author), CNRS, UMR 5535, Inst Genet Mol, IFR24,1919 Route Mende, F-34293 Montpellier 5, France.		PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; BARETTE, Caroline/0000-0003-0999-7751				Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; CARLSON M, 1984, GENETICS, V107, P19; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hautbergue G, 1999, MOL CELL BIOL, V19, P2527; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Rickert P, 1996, ONCOGENE, V12, P2631; Sambrook J., 2002, MOL CLONING LAB MANU; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158	53	28	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					551	562		10.1038/sj.onc.1204129	http://dx.doi.org/10.1038/sj.onc.1204129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313987				2022-12-28	WOS:000166755000002
J	Lee, SH; Shin, MS; Kim, HS; Lee, HK; Park, WS; Kim, SY; Lee, JH; Han, SY; Park, JY; Oh, RR; Kang, CS; Kim, KM; Jang, JJ; Nam, SW; Lee, JY; Yoo, NJ				Lee, SH; Shin, MS; Kim, HS; Lee, HK; Park, WS; Kim, SY; Lee, JH; Han, SY; Park, JY; Oh, RR; Kang, CS; Kim, KM; Jang, JJ; Nam, SW; Lee, JY; Yoo, NJ			Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma	ONCOGENE			English	Article						mutation; TRAIL-receptor 1; TRAIL-receptor 2; non-Hodgkin's lymphoma	TRAIL-INDUCED APOPTOSIS; FAS APO-1/CD95 GENE; LIGAND TRAIL; RECEPTOR; DEATH; CELLS; REGIONS; FADD; DNA	Tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. TRAIL-RI and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL), Because TRAIL/TRAIL, receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-RI and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL, In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-RI gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-RI gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-RI and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-RI and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R2 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL.	Catholic Univ Korea, Coll Med, Dept Pathol, Socho Gu, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110799, South Korea; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	Catholic University of Korea; Catholic University of Korea; Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Socho Gu, 505 Banpo Dong, Seoul 137701, South Korea.		Jang, JaJune/F-6647-2011; Yoo, Nam Jin/GNM-9060-2022; kim, Hong Sug/G-2731-2014					Arai T, 1998, CANCER LETT, V133, P197, DOI 10.1016/S0304-3835(98)00230-4; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; EMI M, 1992, CANCER RES, V52, P5368; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gronbaek K, 1998, BLOOD, V92, P3018; HARRIS NL, 1994, BLOOD, V84, P1361; KAGAN J, 1995, ONCOGENE, V11, P2121; Keane MM, 1999, CANCER RES, V59, P734; Kim KH, 2000, CLIN CANCER RES, V6, P335; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 1999, CANCER RES, V59, P3068; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Monni O, 1996, BLOOD, V87, P5269, DOI 10.1182/blood.V87.12.5269.bloodjournal87125269; Mori S, 1999, J IMMUNOL, V162, P5616; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Thomas WD, 1998, J IMMUNOL, V161, P2195; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wistuba II, 1999, CANCER RES, V59, P1973; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhang XD, 1999, CANCER RES, V59, P2747	37	121	125	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					399	403		10.1038/sj.onc.1204103	http://dx.doi.org/10.1038/sj.onc.1204103			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313970				2022-12-28	WOS:000166411000015
J	Cohen, SB; Waha, A; Gelman, IH; Vogt, PK				Cohen, SB; Waha, A; Gelman, IH; Vogt, PK			Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts	ONCOGENE			English	Article						oncogenic transformation; differential gene expression; DNA micro-array; tumor suppressor	KINASE-C SUBSTRATE; PROTEIN-KINASE; RETROVIRAL VECTORS; GENE-TRANSFER; EMBRYO CELLS; ACTIVATION; IDENTIFICATION; FOS; SRC; MYC	Line 10T1/2 mouse fibroblast overexpressing the v-Jun oncoprotein mere morphologically altered, grew into multilayered foci in culture and formed colonies when suspended in agar, The growth rate of the v-Jun-transformed 10T1/2 cells was not changed significantly from that of the untransformed parental cells, but the saturation density of the transformed cultures exceeded that of normal controls by a factor of 2, mRNA extracted from v-Jun-transformed 10T1/2 cells was analysed for differential gene expression with DNA micro-array technology. One of the targets downregulated by v-Jun was identified as SSeCKS (Src-suppressed C kinase substrate). Re-expression of SSeCKS in v-Jun-transformed fibroblasts reversed the transformed phenotype of the cells. Their ability to form foci was reduced to background levels, the number and size of agar colonies was lowered by a factor of 10 and the saturation density was significantly diminished. However, expression of SSeCKS had little effect on the morphology of v-Jun-transformed 10T1/2 cells. These data suggest that the SSeCKS protein has growth-attenuating properties. Down-regulation of SSeCKS may be essential for Jun-induced transformation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Gen Probe Inc, San Diego, CA 92121 USA	Scripps Research Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA42564] Funding Source: Medline; NIDDK NIH HHS [5 T23 DK 07022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; ALT M, 1993, ONCOGENE, V8, P1421; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; COLLEDGE WH, 1989, ONCOGENE, V4, P753; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GRODEN J, 1995, CANCER RES, V55, P1531; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; MORGAN IM, 1994, ONCOGENE, V9, P2793; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NISHIMURA T, 1988, ONCOGENE, V3, P659; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; Xu JC, 2000, CANCER RES, V60, P1677; ZHANG M, 1995, CANCER RES, V55, P2537	39	22	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					141	146		10.1038/sj.onc.1204077	http://dx.doi.org/10.1038/sj.onc.1204077			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313943				2022-12-28	WOS:000166410900001
J	Bearss, DJ; Hurley, LH; Von Hoff, DD				Bearss, DJ; Hurley, LH; Von Hoff, DD			Telomere maintenance mechanisms as a target for drug development	ONCOGENE			English	Review						telomere; telomerase; G-quadruplex; drug targets	CATALYTIC SUBUNIT GENE; TERMINAL TRANSFERASE; POLY(ADP-RIBOSE) POLYMERASE; REVERSE-TRANSCRIPTASE; CATIONIC PORPHYRINS; HUMAN-CHROMOSOMES; QUADRUPLEX DNA; IMMORTAL CELLS; TUMOR-CELLS; ACTIVE-SITE	The shortening of the telomeric DNA sequences at the ends of chromosomes is thought to play a critical role in regulating the lifespan of human cells. Since all dividing cells are subject to the loss of telomeric sequences, cells with long proliferative lifespans need mechanisms to maintain telomere integrity. It appears that the activation of the enzyme telomerase is the major mechanism by which these cells maintain their telomeres, The proposal that a critical step in the process of the malignant transformation of cells is the upregulation of expression of telomerase has made this enzyme a potentially useful prognostic and diagnostic marker for cancer, as well as a new target for therapeutic intervention for the treatment of patients with cancer, It is now clear that simply inhibiting telomerase may not result in the anticancer effects that were originally hypothesized. While telomerase may not be the universal target for cancer therapy, we certainly believe that targeting the telomere maintenance mechanisms will be important in future research aimed toward a successful strategy for curing cancer.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Coll Pharm, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Von Hoff, DD (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.		Bearss, David/Q-9141-2019	Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NATIONAL CANCER INSTITUTE [U19CA067760] Funding Source: NIH RePORTER; NCI NIH HHS [CA67760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; AGBANDJE M, 1992, J MED CHEM, V35, P1418, DOI 10.1021/jm00086a010; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Anantha NV, 1998, BIOCHEMISTRY-US, V37, P2709, DOI 10.1021/bi973009v; Bare LA, 1998, DRUG DEVELOP RES, V43, P109, DOI 10.1002/(SICI)1098-2299(199802)43:2<109::AID-DDR4>3.0.CO;2-O; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; Bhattacharyya A, 1997, P NATL ACAD SCI USA, V94, P2823, DOI 10.1073/pnas.94.7.2823; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Briem H, 1996, J MED CHEM, V39, P3401, DOI 10.1021/jm950800y; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; Gilley D, 1996, MOL CELL BIOL, V16, P66; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamilton SE, 1999, CHEM BIOL, V6, P343, DOI 10.1016/S1074-5521(99)80046-5; Hamilton SE, 1997, BIOCHEMISTRY-US, V36, P11873, DOI 10.1021/bi970438k; Han FXG, 1999, J AM CHEM SOC, V121, P3561, DOI 10.1021/ja984153m; HAN H, 2000, BIOCHEMISTRY-US, V39, P5295; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Han HY, 1999, BIOCHEMISTRY-US, V38, P6981, DOI 10.1021/bi9905922; Haq I, 1999, J AM CHEM SOC, V121, P1768, DOI 10.1021/ja981554t; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, TELOMERES, P247; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1995, TELOMERES, P11; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; Izbicka E, 1999, CANCER RES, V59, P639; IZBICKA E, 1999, P AM SOC CANC ONCOL, V18, pA631; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Kushner DM, 2000, GYNECOL ONCOL, V76, P183, DOI 10.1006/gyno.1999.5668; Kyo S, 1997, CANCER RES, V57, P610; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marco-Haviv Y, 1999, J MOL BIOL, V286, P45, DOI 10.1006/jmbi.1998.2461; MEHLE C, 1994, CANCER RES, V54, P236; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Multani AS, 1998, INT J ONCOL, V13, P923; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Niida H, 2000, MOL CELL BIOL, V20, P4115, DOI 10.1128/MCB.20.11.4115-4127.2000; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; ODAGIRI E, 1994, CANCER, V73, P2975; Ohashi K, 1996, CANCER, V77, P1747, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1747::AID-CNCR50>3.0.CO;2-W; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pandit B, 1998, BIOCHEM BIOPH RES CO, V251, P620, DOI 10.1006/bbrc.1998.9509; Park KH, 1998, INT J ONCOL, V13, P489; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Raymond E, 1996, CURR OPIN BIOTECH, V7, P583, DOI 10.1016/S0958-1669(96)80068-1; RAYMOND E, 1996, P 6 ANN S CANC RES S, V23; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Schuitmaker JJ, 1996, J PHOTOCH PHOTOBIO B, V34, P3, DOI 10.1016/1011-1344(96)07342-3; SCIADINI MF, 1994, P AN M AM SOC CLIN, V13, P129; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sommerfeld HJ, 1996, CANCER RES, V56, P218; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; Strahl C, 1996, MOL CELL BIOL, V16, P53; SUN D, 1997, J MED CHEM, V8, P1063; TANIOUS FA, 1992, BIOCHEMISTRY-US, V31, P11632, DOI 10.1021/bi00161a050; Tsao JI, 1997, CLIN CANCER RES, V3, P627; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wheelhouse R. T., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P430; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yashima K, 1997, CANCER RES, V57, P2373; Yasumoto S, 1996, ONCOGENE, V13, P433	121	62	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6632	6641		10.1038/sj.onc.1204092	http://dx.doi.org/10.1038/sj.onc.1204092			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426649				2022-12-28	WOS:000167704000010
J	Gudi, T; Casteel, DE; Vinson, C; Boss, GR; Pilz, RB				Gudi, T; Casteel, DE; Vinson, C; Boss, GR; Pilz, RB			NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation	ONCOGENE			English	Article						nitric oxide; cGMP-dependent protein kinase; c-fos; CREB	DEPENDENT PROTEIN-KINASE; MULTIPLE SEQUENCE ELEMENTS; SOLUBLE GUANYLATE-CYCLASE; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; CYCLIC-GMP; C-FOS; GENE-EXPRESSION; BINDING PROTEIN; DNA-BINDING	We have shown that nitric oxide (NO) regulates c-fos gene expression via cGMP-dependent protein kinase (G-kinase), but NO's precise mechanism of action is unclear, We now demonstrate that: (1) NO targets two transcriptional elements in the fos promoter, i,e., the fos AP-1 binding site and the cAMP-response element (CRE); (2) NO activation of these two enhancer elements requires the CRE binding protein CREB because a dominant negative CREB fully inhibits NO transactivation of reporter genes whereas dominant negative Fos or CCAAT enhancer binding proteins have no effect; (3) CREB is phosphorylated by G-kinase in vitro and its phosphorylation increases in vivo when G-kinase is activated either directly by cGMP or indirectly by NO via soluble guanylate cyclase; (4) NO activation of fos promoter elements requires nuclear translocation of G-kinase but not activation of mitogen-activated protein kinases.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; NCI, Met Lab, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07233-24] Funding Source: Medline; NIGMS NIH HHS [R01GM055586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOSCOFELLEY E, 1994, AM J RESP CELL MOL B, V11, P159; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Callsen D, 1998, J IMMUNOL, V161, P4852; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P174; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GAUTHIERROUVIERE C, 1992, ONCOGENE, V7, P363; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; HABY C, 1994, J NEUROCHEM, V62, P496; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; Lu YF, 1999, J NEUROSCI, V19, P10250; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Moon C, 1999, P NATL ACAD SCI USA, V96, P14605, DOI 10.1073/pnas.96.25.14605; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; NAKANE M, 1990, J BIOL CHEM, V265, P16841; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; Qiang M, 1999, BEHAV PHARMACOL, V10, P215, DOI 10.1097/00008877-199903000-00010; Roberson ED, 1999, J NEUROSCI, V19, P4337; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WYATT TA, 1991, J BIOL CHEM, V266, P21274; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	61	75	80	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6324	6333		10.1038/sj.onc.1204007	http://dx.doi.org/10.1038/sj.onc.1204007			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175347				2022-12-28	WOS:000166210500016
J	Hara, K; Kudoh, H; Enomoto, T; Hashimoto, Y; Masuko, T				Hara, K; Kudoh, H; Enomoto, T; Hashimoto, Y; Masuko, T			Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain	ONCOGENE			English	Article						CD98; transfectant; extracellular domain	AMINO-ACID-TRANSPORT; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY 4F2; CELL-SURFACE ANTIGEN; XENOPUS-LAEVIS OOCYTES; ACTIVATED LYMPHOCYTES; INTEGRIN ACTIVATION; RAS TRANSFORMATION; INHIBIT ACTIVATION; MEMBRANE-PROTEIN	GP125/CD98 is a heterodimeric 125-kDa glycoprotein, which consists of an 85-kDa heavy chain the) and a 40-kDa light chain (Ic), and is strongly expressed on the cell surface of various tumor cells, irrespective of their tissue of origin. We have recently demonstrated that over-expression of the CD98hc cDNA causes malignant transformation of NIH3T3 cells. To investigate the function of the extracellular domain of CD98hc in cell proliferation and malignant transformation, we established two NIH3T3-derived clones transfected with human truncated CD98hc cDNAs, and compared their characteristics with parental NIH3T3 and clones transfected with full-length CD98hc cDNA, Truncated as well as full-length CD98hc-transfected clones grew to a higher saturation density than control cells. Efficiency of colony formation in soft agar was augmented in all CD98hc-transfected clones, and the degrees of augmented colony formation of the transfectants expressing full-length CD98hc of 529 a.a. or truncated CD98hc of 418 a,a, were reduced by anti-human CD98hc antibodies, while that of the transfectant expressing truncated CD98hc of 237 a,a, lacking the epitopes recognized by anti-human CD98hc antibodies was not affected by the addition of antibodies. CD98hc-transfected clones developed tumors in athymic mice, and tumor growth of truncated CD98hc-transfected clones was faster than that of full-length CD98hc-transfected clones.	Kinki Univ, Sch Pharmaceut Sci, Cell Biol Lab, Higashiosaka, Osaka 5778502, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Mol Cell Biol Lab, Aoba Ku, Sendai, Miyagi 9808578, Japan; Sasaki Inst, Chikusa Ku, Tokyo 101, Japan	Kindai University (Kinki University); Tohoku University	Masuko, T (corresponding author), Kinki Univ, Sch Pharmaceut Sci, Cell Biol Lab, 4-1 Kowakae 3 Chome, Higashiosaka, Osaka 5778502, Japan.							BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Bouck N, 1979, Methods Enzymol, V58, P296; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; COOPER GM, 1980, NATURE, V284, P418, DOI 10.1038/284418a0; DIXON WT, 1990, INT J CANCER, V45, P59, DOI 10.1002/ijc.2910450113; Dong S, 1996, FEBS LETT, V395, P165, DOI 10.1016/0014-5793(96)01031-9; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Hara K, 1999, BIOCHEM BIOPH RES CO, V262, P720, DOI 10.1006/bbrc.1999.1051; Hashimoto Y, 1983, Gan, V74, P819; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KAMMA H, 1989, CANCER RES, V49, P5118; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KROUS MH, 1987, EMBO J, V6, P605; LUMADUE JA, 1987, P NATL ACAD SCI USA, V84, P9204, DOI 10.1073/pnas.84.24.9204; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; MARTIN GS, 1986, CANCER SURV, V5, P199; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MASUKO T, 1985, JPN J CANCER RES, V76, P386; MICHALAK M, 1986, J BIOL CHEM, V261, P92; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; PATTERSON JAK, 1984, J INVEST DERMATOL, V83, P210, DOI 10.1111/1523-1747.ep12263581; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; POSILLICO JT, 1987, J CLIN ENDOCR METAB, V64, P43, DOI 10.1210/jcem-64-1-43; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P8618; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SANG JS, 1995, CANCER RES, V55, P1152; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Shin S, 1979, Methods Enzymol, V58, P370; Shishido T, 2000, INT J CANCER, V87, P311, DOI 10.1002/1097-0215(20000801)87:3<311::AID-IJC1>3.0.CO;2-W; TANAKA T, 1989, JPN J CANCER RES, V80, P380, DOI 10.1111/j.1349-7006.1989.tb02323.x; TANAKA T, 1988, J BIOCHEM-TOKYO, V103, P644, DOI 10.1093/oxfordjournals.jbchem.a122322; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; Tsurudome M, 1999, J IMMUNOL, V162, P2462; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WELLS RG, 1992, J BIOL CHEM, V267, P15285; YAGITA H, 1986, J IMMUNOL, V136, P2062; YAGITA H, 1986, CANCER RES, V46, P1478; YAGITA H, 1986, J IMMUNOL, V136, P2055; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	56	24	26	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6209	6215		10.1038/sj.onc.1204019	http://dx.doi.org/10.1038/sj.onc.1204019			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175335				2022-12-28	WOS:000166210500004
J	Brennan, PJ; Kumogai, T; Berezov, A; Murali, R; Greene, MI				Brennan, PJ; Kumogai, T; Berezov, A; Murali, R; Greene, MI			HER2/Neu: mechanisms of dimerization/oligomerization	ONCOGENE			English	Article						erbB; kinase; growth factor; signaling; tumor	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NIH 3T3 CELLS; EGF-RECEPTOR; TRANSMEMBRANE DOMAIN; NEU-ONCOGENE; EXTRACELLULAR DOMAIN; LIGAND-BINDING; SIGNAL-TRANSDUCTION; POINT MUTATION		Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.		Mieszkowska, Magdalena/O-6753-2017	Murali, Ramachandran/0000-0002-8384-2793				Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BEGUINOT L, 1995, J CELL BIOCH A S, V19, P11; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P679, DOI 10.1007/BF01025608; BRANDTRAUF PW, 1995, J PROTEIN CHEM, V14, P33, DOI 10.1007/BF01902842; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAMETT DC, 1997, J BIOL CHEM, V272, P12052; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; Chamberlin SG, 1998, BBA-PROTEIN STRUCT M, V1384, P223, DOI 10.1016/S0167-4838(97)00203-3; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Chen LI, 1997, J CELL BIOL, V137, P619, DOI 10.1083/jcb.137.3.619; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Jorissen RN, 2000, PROTEIN SCI, V9, P310; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE DC, 1995, PHARMACOL REV, V47, P51; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEVEA CM, 1993, RECEPTOR, V3, P293; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; Moscatello DK, 1996, ONCOGENE, V13, P85; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; Sajot N, 2000, EUR BIOPHYS J BIOPHY, V28, P648, DOI 10.1007/s002490050005; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Saxon ML, 1999, J BIOL CHEM, V274, P28356, DOI 10.1074/jbc.274.40.28356; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Shak S, 1999, SEMIN ONCOL, V26, P71; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; SOROKIN A, 1995, ONCOGENE, V11, P1531; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEBER W, 1984, J BIOL CHEM, V259, P4631; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	89	127	138	3	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6093	6101		10.1038/sj.onc.1203967	http://dx.doi.org/10.1038/sj.onc.1203967			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156522				2022-12-28	WOS:000166121400002
J	Dauphinot, L; De Oliveira, C; Melot, T; Sevenet, N; Thomas, V; Weissman, BE; Delattre, O				Dauphinot, L; De Oliveira, C; Melot, T; Sevenet, N; Thomas, V; Weissman, BE; Delattre, O			Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57(KIP2) and c-Myc expression	ONCOGENE			English	Article						Ewing tumour; cell cycle; EWS-FLI-1; c-Myc; p57(KIP2)	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; DNA-BINDING; P53 MUTATIONS; GENE; FUSION; DOMAIN; PROTEIN; TRANSLOCATION; ONCOPROTEINS	Ewing tumour is characterized by specific chromosome translocations which fuse EU'S to a subset of genes encoding ETS transcription factors, most frequently FLI-1. We report the analysis of the expression of various cell cycle regulators both in Ewing tumour derived cell lines and in different cellular models with either inducible or constitutive EWS-FLI-1 cDNA expression. In Ewing cell lines, cyclin D1, CDK4, Rb, p27(KIP1) and c-Myc were consistently highly expressed whereas p57(KIP2), p15(INK4B) and p14(ARF) demonstrated undetectable or low expression levels. The amount of p16(INK4A), p21(CIP1), p18(INKAC) and CDK6 was variable from one cell line to the other, The inducible expression of EWS-FLI-1 led to a strong upregulation of c-MSc and a considerable downregulation of p57(KIP2). Other proteins did not show evident modification. High c-Myc and very low p57(KIP2) expression levels were also observed in neuroblastoma NGP cells constitutively expressing EWS-FLI-1 as compared to parental cells. Analysis of the p57(KIP2) promoter indicated that EWS-FLI-1 downregulates, possibly through an indirect mechanism, the transcription of this gene, Finally, we show that ectopic expression of p57(KIP2) in Ewing cells blocks proliferation through a complete G1 arrest. These results suggest that the modulation of p57(KIP2) expression by EWS-FLI-1 is a fundamental step in Ewing tumorigenesis.	Inst Curie, Lab Pathol Mol Canc, INSERM U509, F-75248 Paris 05, France; Univ N Carolina, Lineberger Canc Ctr 345, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of North Carolina; University of North Carolina Chapel Hill	Delattre, O (corresponding author), Inst Curie, Lab Pathol Mol Canc, INSERM U509, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Feinberg AP, 1999, CANCER RES, V59, p1743S; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Im YH, 2000, CANCER RES, V60, P1536; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; KOMURO H, 1993, CANCER RES, V53, P5284; KOVAR H, 1993, ONCOGENE, V8, P2683; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin JY, 1996, MOL CELL BIOL, V16, P1786; MAO XH, 1994, J BIOL CHEM, V269, P18216; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; PETER M, 1995, BRIT J CANCER, V72, P96, DOI 10.1038/bjc.1995.283; Reid LH, 1996, CANCER RES, V56, P1214; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Thompson AD, 1996, ONCOGENE, V13, P2649; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Xing EP, 1999, CLIN CANCER RES, V5, P2704	35	130	138	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3258	3265		10.1038/sj.onc.1204437	http://dx.doi.org/10.1038/sj.onc.1204437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423975				2022-12-28	WOS:000169163500009
J	Berger, SL				Berger, SL			An embarrassment of niches: the many covalent modifications of histones in transcriptional regulation	ONCOGENE			English	Review						chromatin; transcription; histone acetylation; histone phosphorylation; histone methylation; histone ubiquitination	MITOTIC CHROMOSOME CONDENSATION; H3 PHOSPHORYLATION; IN-VIVO; ACETYLTRANSFERASE ACTIVITY; GENE ACTIVATION; YEAST GCN5P; DNA-DAMAGE; ACETYLATION; COMPLEX; DOMAIN		Wistar Inst, Mol Genet Program, Philadelphia, PA 19104 USA	The Wistar Institute	Berger, SL (corresponding author), Wistar Inst, Mol Genet Program, Philadelphia, PA 19104 USA.			Berger, Shelley/0000-0001-5398-4400				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Berger SL, 2000, NATURE, V408, P412, DOI 10.1038/35044160; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SOLOW S, 2000, IN PRESS BIOL CHEM; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Van Hooser A, 1998, J CELL SCI, V111, P3497; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	60	86	94	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3007	3013		10.1038/sj.onc.1204324	http://dx.doi.org/10.1038/sj.onc.1204324			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420715				2022-12-28	WOS:000169308500003
J	Hans, F; Dimitrov, S				Hans, F; Dimitrov, S			Histone H3 phosphorylation and cell division	ONCOGENE			English	Review						histone H3; phosphorylation; mitosis; meiosis	MITOTIC CHROMOSOME CONDENSATION; TRANSCRIPTION FACTOR-BINDING; EARLY GENE INDUCTION; ASPERGILLUS-NIDULANS; PROTEIN-KINASE; NUCLEOSOMAL DNA; CHROMATIN DISRUPTION; LINKER HISTONES; BUDDING YEAST; EGG EXTRACTS	Histone H3 is specifically phosphorylated during both mitosis and meiosis in patterns that are specifically coordinated in both space and time. Histone H3 phosphorylation may initiate at different phases of the cell division in different organisms, but metaphase chromosomes are always found to be heavily phosphorylated. Upon exit of mitosis/meiosis a global dephosphorylation of H3 takes place. Potential candidates for H3 kinases are described and their hypothetical mechanism of action on highly condensed chromatin templates is discussed. In addition, a novel hypothesis for the role of histone HS phosphorylation during cell division is proposed. This hypothesis, termed the 'ready production label' model, explains the results in the literature and suggests that phosphorylation of histone H3 is a part of a complex signaling mechanism.	Inst Albert Bonniot, Equipe Mecanismes Assemblage Mat Genet, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Dimitrov, S (corresponding author), Inst Albert Bonniot, Equipe Mecanismes Assemblage Mat Genet, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309, Domaine Merci, F-38706 La Tronche, France.		dimitrov, stefan/M-7697-2013	dimitrov, stefan/0000-0002-1326-3630				Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHAN CSM, 1993, GENETICS, V135, P677; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, BIOL CELL, V91, P461, DOI 10.1016/S0248-4900(99)80087-2; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Houchmandzadeh B, 1997, J CELL BIOL, V139, P1, DOI 10.1083/jcb.139.1.1; Houchmandzadeh B, 1999, J CELL BIOL, V145, P215, DOI 10.1083/jcb.145.2.215; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kaszas E, 2000, J CELL SCI, V113, P3217; Khochbin S, 1997, FEBS LETT, V419, P157, DOI 10.1016/S0014-5793(97)01423-3; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAKAROV VL, 1984, BIOCHEM BIOPH RES CO, V122, P1021, DOI 10.1016/0006-291X(84)91193-8; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PERRY M, 1982, J BIOL CHEM, V257, P7336; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner BM, 1999, SEMIN CELL DEV BIOL, V10, P165, DOI 10.1006/scdb.1999.0297; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Van Hooser A, 1998, J CELL SCI, V111, P3497; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Ye XS, 1997, METHOD ENZYMOL, V283, P520	64	372	379	3	28	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3021	3027		10.1038/sj.onc.1204326	http://dx.doi.org/10.1038/sj.onc.1204326			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420717				2022-12-28	WOS:000169308500005
J	Nishiyama, H; Gill, JH; Pitt, E; Kennedy, W; Knowles, MA				Nishiyama, H; Gill, JH; Pitt, E; Kennedy, W; Knowles, MA			Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1	ONCOGENE			English	Article						transitional cell carcinoma; DBCCR1; cell cycle	CELL-CYCLE; TGF-BETA; CANCER; DELETION; PROTEIN; LOCUS; RETINOBLASTOMA; METHYLATION; 9Q32-Q33; REGION	Deletion of all or part of chromosome 9q is the most common genetic alteration in all stages and grades of bladder cancer. DBCCR1 (deleted in bladder cancer chromosome region candidate I) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer, Although no mutations of DBCCR1 have been detected in bladder tumours, expression of DBCCR1 is silenced by promoter hypermethylation in 50% of bladder cancer cell lines analysed. Here we sought to provide functional evidence to authenticate DBCCR1 as a tumour suppressor using gene-transfer methods. Exogenous expression of DBCCR1 protein or an HA epitope-tagged fusion protein, HA-DBCCR1 in NIH3T3 cells and human bladder tumour cell lines resulted in suppression of proliferation. Cell cycle analyses in NIH3T3 cells revealed that DBCCR1-mediated growth inhibition,vas due to an increase in the number of cells in the G(1) phase of the cell cycle, The levels of apoptosis were not altered. These results demonstrate a role for DBCCR1 in cell cycle control, thereby supporting the hypothesis that this is the tumour suppressor gene targeted by 9q32-33 deletion in bladder cancer. Oncogene (2001) 20, 2956-2964.	St Jamess Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St Jamess Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657; Gill, Jason/0000-0002-7564-7787				CAIRNS P, 1993, ONCOGENE, V8, P1083; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; HABUCHI T, 2001, IN PRESS ONCOGENE; Hartmann A, 1999, AM J PATHOL, V154, P721, DOI 10.1016/S0002-9440(10)65318-7; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Nishiyama H, 1999, GENOMICS, V59, P335, DOI 10.1006/geno.1999.5891; *OFF NAT STAT, 1996, MB1961 ONS; OLUMI AF, 1990, CANCER RES, V50, P7081; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Salem C, 2000, CANCER RES, V60, P2473; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; WU SQ, 1991, CANCER RES, V51, P3323	28	49	53	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2956	2964		10.1038/sj.onc.1204432	http://dx.doi.org/10.1038/sj.onc.1204432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420708				2022-12-28	WOS:000168901800011
J	Yasui, Y; Goto, H; Matsui, S; Manser, E; Lim, L; Nagata, K; Inagaki, M				Yasui, Y; Goto, H; Matsui, S; Manser, E; Lim, L; Nagata, K; Inagaki, M			Protein kinases required for segregation of vimentin filaments in mitotic process	ONCOGENE			English	Article						mitosis; vimentin; phosphorylation; Rho-kinase; protein kinase C (PKC); vimentin-Ser72 kinase	RHO-ASSOCIATED KINASE; CELL-CYCLE CONTROL; POLO-LIKE KINASES; INTERMEDIATE-FILAMENTS; CLEAVAGE FURROW; PHOSPHORYLATION; CYTOKINESIS; MITOSIS; SITE; CYTOSKELETON	Vimentin, one of type III intermediate filament (IF) proteins, is expressed not only in mesenchymal cells but also in most types of tumor cells. In the present study, rye introduced several types of vimentin mutated at putative phosphorylation sites in its amino-terminal head domain into type III IF-negative T24 cells. Site-specific mutation induced the formation of an unusually long bridge-like IF structure between the unseparated daughter cells, although these mutants formed the filament network similar to wild type in interphase cells. Together with sites phosphorylated by Rho-kinase and protein kinase C (PKC), vimentin-Ser72, which can not be phosphorylated by any known vimentin kinase, was one of the mutation sites essential for this phenotype, We further demonstrated that vimentin-Ser72 was phosphorylated specifically at the cleavage furrow during cytokinesis. These observations suggest the existence of a novel protein kinase responsible for vimentin filament separation through the cleavage furrow-specific vimentin phosphorylation, We propose that Rho-kinase, PKC, and an unidentified vimentin-Ser72 kinase may play important roles in vimentin filament separation during cytokinesis, Oncogene (2001) 20, 3868-2876.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 117609, Singapore; Nagoya City Univ, Fac Pharmaceut Sci, Dept Biol Chem, Nagoya, Aichi 4678603, Japan; UCL, Inst Neurol, London WC1N 1PJ, England	Aichi Cancer Center; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; Nagoya City University; University of London; University College London	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016; Manser, Edward/ABD-2301-2020	Goto, Hidemasa/0000-0002-6796-4467				Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; EVANS RM, 1984, J BIOL CHEM, V259, P5372; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GOSS VL, 1994, J BIOL CHEM, V269, P19074; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2000, MICROSC RES TECHNIQ, V49, P173, DOI 10.1002/(SICI)1097-0029(20000415)49:2<173::AID-JEMT10>3.0.CO;2-A; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kosako H, 1997, J BIOL CHEM, V272, P10333; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Passalacqua M, 1999, FEBS LETT, V453, P249, DOI 10.1016/S0014-5793(99)00729-2; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	43	76	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2868	2876		10.1038/sj.onc.1204407	http://dx.doi.org/10.1038/sj.onc.1204407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420699				2022-12-28	WOS:000168901800002
J	Hammond, DE; Urbe, S; Woude, GFV; Clague, MJ				Hammond, DE; Urbe, S; Woude, GFV; Clague, MJ			Down-regulation of MET, the receptor for hepatocyte growth factor	ONCOGENE			English	Article						Met; hepatocyte growth factor; endocytosis; proteasome	LIGAND-INDUCED INTERNALIZATION; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; FACTOR BETA-RECEPTOR; UBIQUITIN; PROTEIN; DEGRADATION; ENDOCYTOSIS; POLYUBIQUITINATION; IDENTIFICATION	The ligand-dependent degradation of activated tyrosine kinase receptors provides a means by which mitogenic signalling can be attenuated. In many cell types the ligand-dependent degradation of the tyrosine kinase receptor Met is completely dependent on the activity of the 26S proteasome (Jeffers et al,, 1997b), We now show that degradation also requires trafficking to late endosomal compartments and the activity of acid dependent proteases as determined by the effects of a dominant negative form of dynamin (K44A) and a vacuolar-ATPase inhibitor, concanamycin, We show that in the presence of the proteasome inhibitor lactacystin, Met fails to redistribute from the plasma membrane to intracellular compartments. This observation is most consistent with the interpretation that proteasome activity is required for Met internalization and only indirectly for its degradation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England; Van Andel Res Inst, Grand Rapids, MI 49503 USA	University of Liverpool; Van Andel Institute	Clague, MJ (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.		Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; Hammond, Dean/0000-0002-6326-8739; Urbe, Sylvie/0000-0003-4735-9814				Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GIORDANO S, 1989, ONCOGENE, V4, P1383; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOU D, 1994, J BIOL CHEM, V269, P14244; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1995, BIOCHEM BIOPH RES CO, V217, P224, DOI 10.1006/bbrc.1995.2767; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	38	134	137	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2761	2770		10.1038/sj.onc.1204475	http://dx.doi.org/10.1038/sj.onc.1204475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420688				2022-12-28	WOS:000168712000004
J	Makino, K; Yu, DH; Hung, MC				Makino, K; Yu, DH; Hung, MC			Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis	ONCOGENE			English	Article						cDNA array; Taxol; p55Cdc; p34(cdc2); apoptosis	GENE-EXPRESSION PATTERNS; DNA MICROARRAY; MITOTIC BLOCK; MYELOID CELLS; KINASE; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; MECHANISM; COMPLEX	Paclitaxel (Taxol) is a potent and highly effective antineoplastic agent for the treatment of advanced, drug-refractory, metastatic breast cancers. Taxol not only induces tubulin polymerization, stabilizes microtubules, blocks cell cycle progression, and induces apoptosis, but it also alters gene expression. Here, we have identified that Taxol can upregulate expression of the gene encoding the cell cycle protein p55Cdc by using cDNA array technique. Taxol induced p55Cdc mRNA expression through activation of the p55Cdc promoter, which led to increase p55Cdc protein expression. Taxol also activated p55Cdc-associated kinase, In addition, overexpression of the p55Cdc gene resulted in cell death in both HeLa cells and NIH3T3 cells in a dose-dependent manner. A dominant-negative mutant of p34(cdc2) blocked Taxol-induced p55Cdc activation and inhibited p55Cdc-induced and Taxol-induced cell death. Our data suggest that transcriptional upregulation of p55Cdc and activation of p55Cdc by Taxol-mediated p34(cdc2) activation play a critical role in Taxol-induced cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [P50CA083639, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, P50 CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGDAN C, 1992, J LEUKOCYTE BIOL, V52, P119, DOI 10.1002/jlb.52.1.119; CHOI WJ, 1990, BIOCHEM BIOPH RES CO, V172, P1324, DOI 10.1016/0006-291X(90)91594-I; DeRisi J, 1996, NAT GENET, V14, P457; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kao CT, 1996, ONCOGENE, V13, P1221; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; KUMAR N, 1981, J BIOL CHEM, V256, P435; Lin M, 1998, EXP HEMATOL, V26, P1000; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359	29	18	21	2	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2537	2543		10.1038/sj.onc.1204366	http://dx.doi.org/10.1038/sj.onc.1204366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420663	Bronze			2022-12-28	WOS:000168652500004
J	van Dam, H; Castellazzi, M				van Dam, H; Castellazzi, M			Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis	ONCOGENE			English	Review						Jun; Fos; ATF; Maf; E1A; chicken embryo fibroblasts; oncogenesis	CHICKEN-EMBRYO FIBROBLASTS; AP-1 TRANSCRIPTION FACTORS; HETEROLOGOUS HOMODIMERIZATION DOMAIN; PROTEIN-KINASE ACTIVATION; LEUCINE ZIPPER MOTIF; FORMATION IN-VIVO; C-JUN; DNA-BINDING; V-JUN; CELLULAR-TRANSFORMATION	Jun:Fos and Jun:ATF complexes represent two classes of AP-1 dimers that (1) preferentially bind to, either heptameric or octameric AP-1 binding sites, and (2) are differently regulated by cellular signaling pathways and oncogene products. To discriminate between the functions of Jun:Fos, Jun: ATF and Jun:Jun, mutants were developed that restrict the ability of Jun to dimerize either to itself, or to Fos(-like) or ATF(-like) partners. Introduction of these mutants in chicken embryo fibroblasts shows that Jun:Fra2 and Jun:ATF2 dimers play distinct, complementary roles in in vitro oncogenesis by inducing either anchorage independence or growth factor independence, respectively. v-Jun:ATF2 rather than v-Jun:Fra2 triggers the development of primary fibrosarcomas in the chicken wing. Genes encoding extracellular matrix components seem to constitute an important subset of v-Jun:ATF2-target genes. Repression of the matrix component SPARC by Jun is essential for the induction of fibrosarcomas, Avian primary cells transformed by either Jun:Fra2 or Jun:ATF2 thus provide powerful tools for the investigation of the downstream pathways involved in oncogenesis, Further genetic studies with Jun dimerization mutants will be required to be precise and extend the specific roles of the Jun:Fos and Jun:ATF dimers during cancer progression in avian and mammalian systems.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Ecole Normale Super Lyon, Unite Virol Humaine, INSERM U412, F-69364 Lyon 07, France	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	van Dam, H (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Sylvius Labs, POB 9503, NL-2300 RA Leiden, Netherlands.			van Dam, Hans/0000-0002-8307-4325				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENJAMIN T, 1990, VIROLOGY, V1, P317; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BUCHOU T, 1993, ONCOGENE, V8, P1765; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHATTON B, 1994, ONCOGENE, V9, P375; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; CHIN R, 1988, CELL, V54, P541; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; Duyndam MCA, 1999, ONCOGENE, V18, P2311, DOI 10.1038/sj.onc.1202584; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; FLINT KJ, 1991, ONCOGENE, V6, P2019; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Hadman M, 1996, ONCOGENE, V12, P135; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1992, CELL GROWTH DIFFER, V3, P909; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; HOFMANN M, 1993, CANCER RES, V53, P1516; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; IBA H, 1988, ONCOGENE RES, V2, P121; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JURDIC P, 1995, ONCOGENE, V11, P1699; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kilbey A, 1996, ONCOGENE, V12, P2409; Kim D, 1996, BBA-GENE STRUCT EXPR, V1309, P183, DOI 10.1016/S0167-4781(96)00158-3; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; MORGAN IM, 1992, ONCOGENE, V7, P1119; MORGAN IM, 1994, ONCOGENE, V9, P2793; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SONOBE MH, 1995, ONCOGENE, V10, P689; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDAM H, 1994, FOS JUN FAMILIES TRA, P261; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	125	354	358	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2453	2464		10.1038/sj.onc.1204239	http://dx.doi.org/10.1038/sj.onc.1204239			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402340				2022-12-28	WOS:000168568700011
J	Okan, E; Drewett, V; Shaw, PE; Jones, P				Okan, E; Drewett, V; Shaw, PE; Jones, P			The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism	ONCOGENE			English	Article						RalA; c-Src; c-Jun; ATF2; uPAR; Ras	GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; SIGNALING PATHWAY; PROTEIN-KINASE; CELLULAR-TRANSFORMATION; HA-RAS; CELLS; FAMILY; JUN; PHOSPHORYLATION	The urokinase plasminogen activator receptor (uPAR) focuses extracellular protease activity to the cell surface, modulates cell adhesion and activates intracellular signal transduction pathways. In a range of cancers uPAR expression often has a negative correlation with prognosis, Here we show that uPAR transcription is stimulated by V12 H-Ras, the effector loop mutant V12 H-Ras G37 and constitutively-active RalA 72L, RalA-dependent transcription required the presence of the ATF2-like AP1-site at -70 bp and the c-Jun binding motif at -184 bp in the uPAR promoter. Consistent with this, both Ga14-c-Jun- and Ga14-ATF2-fusion proteins were activated by RalA signalling through phosphorylation of their activation domains at Ser63 and Ser73 of c-Jun or Thr69 and Thr71 of ATF2, A transdominant inhibitory mutant of c-Jun N-terminal kinase (JNK) failed to inhibit uPAR transcription demonstrating that JNK activation is not a prerequisite for RalA-dependent uPAR transcription, A dominant negative inhibitor of c-Src effectively inhibited RalA-dependent uPAR transcription identifying it as a downstream effector in the RalA signalling pathway. These data provide evidence for the existence of a novel signalling pathway that links RalA to the activation of uPAR transcription via a c-Src intermediate and activation of AP1.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Jones, P (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.			SHAW, Peter/0000-0002-2598-4283				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; de Bruyn KMT, 2000, J BIOL CHEM, V275, P29761, DOI 10.1074/jbc.M001160200; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JANKUN J, 1991, CANCER RES, V51, P1221; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kindzelskii AL, 1997, BIOPHYS J, V73, P1777, DOI 10.1016/S0006-3495(97)78208-0; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Koshelnick Y, 1999, THROMB HAEMOSTASIS, V82, P305, DOI 10.1055/s-0037-1615847; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muller SM, 2000, BIOCHEM BIOPH RES CO, V270, P892, DOI 10.1006/bbrc.2000.2531; Murai H, 1997, J BIOL CHEM, V272, P10483; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xue W, 1997, CANCER RES, V57, P1682; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	57	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1816	1824		10.1038/sj.onc.1204260	http://dx.doi.org/10.1038/sj.onc.1204260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313929				2022-12-28	WOS:000167908400002
J	Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E				Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E			Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma	ONCOGENE			English	Article						carcinogenesis; cell cycle; E2F1; expression; lung tumour	S-PHASE ENTRY; ACTIVE TRANSCRIPTIONAL REPRESSION; NUCLEAR ACCUMULATION; P53; GENE; RETINOBLASTOMA; PROTEIN; DEGRADATION; APOPTOSIS; P16(INK4A)	The transcription factor E2F1 is a keg component of cell cycle that acts to transactivate genes required for S phase entry. Thus, it plays an important role in cellular proliferation, oncogenesis and differentiation. In order to investigate its potential implication in human lung carcinogenesis, we studied E2F1 protein expression by Western blotting and immunohistochemistry in a series of 58 human lung tumours of all histological types. We showed that E2F1 product was overexpressed in 92% (24/26) of small cell lung carcinoma (SCLC) and in 50% (5/10) of large cell neuroendocrine carcinoma (LCNEC) whereas it was undetectable in 90% (10/11) of adenocarcinoma and 82% (9/11) of squamous carcinoma when compared to corresponding normal lung. No amplification was found but an increase in E2F1 mRNA expression was detected in 75% (18/24) of SCLC overexpressing E2F1 product. In these tumours and in contrast with NSCLC, upregulation of E2F1 product was associated with its nuclear accumulation and with overexpression of several of its target-genes. Moreover, E2F1 overexpression in NE lung tumours was significantly associated with a high K167 index (P < 0.0001) as well as a Bcl-2:Bax ratio >1 (P<0.001), Overall, these results demonstrate a distinct pattern of E2F1 expression in human lung tumours and suggest that its deregulation could be involved in the carcinogenesis of SCLC.	Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Brambilla, E (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France.		Eymin, Beatrice/M-1962-2013; Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013; gazzeri, sylvie/U-4669-2019; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810				Allen KE, 1997, J CELL SCI, V110, P2819; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Brambilla E, 1996, AM J PATHOL, V149, P1941; BRAMBILLA E, 1997, J PATHOL, V188, P351; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P18, DOI 10.1165/ajrcmb.19.1.3077; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GERDES J, 1984, J IMMUNOL, V133, P1710; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KELLEY MJ, 1997, J NATL CANCER I, V87, P756; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Travis W. D., 1999, WHO INT HISTOLOGICAL; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Volm M, 1998, INT J CANCER, V79, P294, DOI 10.1002/(SICI)1097-0215(19980619)79:3<294::AID-IJC15>3.3.CO;2-0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yatabe Y, 1998, CANCER RES, V58, P1042; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	55	108	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1678	1687		10.1038/sj.onc.1204242	http://dx.doi.org/10.1038/sj.onc.1204242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313916	Green Submitted			2022-12-28	WOS:000167750900002
J	Rosenkilde, MM; Waldhoer, M; Luttichau, HR; Schwartz, TW				Rosenkilde, MM; Waldhoer, M; Luttichau, HR; Schwartz, TW			Virally encoded 7TM receptors	ONCOGENE			English	Review						viral chemokine receptors; vGPCR; viral 7TM; constitutive signalling	SARCOMA-ASSOCIATED HERPESVIRUS; PROTEIN-COUPLED RECEPTOR; CHEMOKINE BINDING-PROTEIN; KAPOSIS-SARCOMA; HUMAN CYTOMEGALOVIRUS; MULTIPLE-SCLEROSIS; CX3C CHEMOKINE; DNA-SEQUENCES; NUCLEOTIDE-SEQUENCE; INVERSE AGONISTS	A number of herpes- and poxviruses encode 7TM G-protein coupled receptors most of which clearly are derived from their host chemokine system as well as induce high expression of certain 7TM receptors in the infected cells. The receptors appear to be exploited by the virus for either immune evasion, cellular reprogramming, tissue targeting or for cell entry. Through their efficient evolutionary machinery and through in vivo selection performed directly on the human cellular and molecular targets, virus have been able to optimize the encoded receptors for distinct pharmacological profiles to help in various parts of the viral life cyclus, Most of the receptors encoded by human pathogenic virus are still orphan receptors, i.e. the endogenous ligand is unknown, In the few cases where it has been possible to characterize these receptors pharmacologically, they have been found to bind a broad spectrum of either CC chemokines, US28 from human cytomegalovirus, or CXC chemokines, ORF74 from human herpesvirus 8, Nevertheless, US28 has been specifically optimized for recognition of the membrane bound chemokine, fractalkine, conceivably involved in cell-cell transfer of virus; whereas ORF74 among the endogenous CXC chemokines has selected angiogenic chemokines as agonists and angiostatic/modulatory chemokines as inverse agonists, ORF74 possess substantial cell-transforming properties and signals with high constitutive activity through the phospholipase C and MAP kinase pathways. Interestingly, transgenic expression of this single gene in certain lymphocyte cell lineages leads to the development of lesions which are remarkably similar to Kaposi's sarcoma, a human herpesvirus 8 associated disease. Thus, this and other virally encoded 7TM receptors appear to be attractive future drug targets.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark; 7TM Pharma AS, DK-2100 Copenhagen, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen	Rosenkilde, MM (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark.		; Waldhoer, Maria/HDO-0619-2022	Schwartz, Thue W./0000-0002-0261-6904; Luttichau, Hans Rudolf/0000-0002-5428-4075; Rosenkilde, Mette Marie/0000-0001-9600-3254; Waldhoer, Maria/0000-0003-3534-1959				Ahuja SK, 1999, CONT IMMUN, V8, P235; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 1998, J VIROL, V72, P2352, DOI 10.1128/JVI.72.3.2352-2363.1998; Beisser PS, 1999, J VIROL, V73, P7218, DOI 10.1128/JVI.73.9.7218-7230.1999; Billstrom MA, 1999, AM J RESP CELL MOL, V21, P163, DOI 10.1165/ajrcmb.21.2.3673; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; Carlquist JF, 1999, J INFECT DIS, V179, P1094, DOI 10.1086/314734; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHAMBEY ET, 2000, J VIROL, V74, P1973; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Daibata M, 1998, LEUKEMIA, V12, P1002, DOI 10.1038/sj.leu.2401036; Daibata M, 1999, BLOOD, V94, P1545, DOI 10.1182/blood.V94.5.1545.417a25_1545_1549; Dairaghi DJ, 1998, SEMIN VIROL, V8, P377, DOI 10.1006/smvy.1997.0146; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Enbom M, 1999, CLIN DIAGN LAB IMMUN, V6, P545, DOI 10.1128/CDLI.6.4.545-549.1999; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703; HASEGAWA H, 1994, J VIROL, V68, P5326, DOI 10.1128/JVI.68.8.5326-5329.1994; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Jung JU, 1999, SEMIN CANCER BIOL, V9, P231, DOI 10.1006/scbi.1998.0115; Kirshner JR, 1999, J VIROL, V73, P6006, DOI 10.1128/JVI.73.7.6006-6014.1999; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; Lee LF, 2000, P NATL ACAD SCI USA, V97, P6091, DOI 10.1073/pnas.97.11.6091; LUPPI M, 1993, J MED VIROL, V40, P44, DOI 10.1002/jmv.1890400110; Luppi M, 1996, HAEMATOLOGICA, V81, P265; Luttichau H R, 2000, Curr Opin Drug Discov Devel, V3, P610; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; MELNICK JL, 1983, LANCET, V2, P644; Menotti L, 1999, J VIROL, V73, P325, DOI 10.1128/JVI.73.1.325-333.1999; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Mirandola P, 1999, NEUROLOGY, V53, P1367, DOI 10.1212/WNL.53.6.1367-a; Moore BB, 1998, TRENDS CARDIOVAS MED, V8, P51, DOI 10.1016/S1050-1738(97)00128-X; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murphy PM, 2000, PHARMACOL REV, V52, P145; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Nieto FJ, 1999, AM HEART J, V138, pS453, DOI 10.1016/S0002-8703(99)70274-7; Orenstein JM, 1997, AIDS, V11, pF35, DOI 10.1097/00002030-199705000-00001; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Parry CM, 2000, J EXP MED, V191, P573, DOI 10.1084/jem.191.3.573; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Pleskoff O, 1998, J VIROL, V72, P6389, DOI 10.1128/JVI.72.8.6389-6397.1998; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Shibutani T, 1997, J CLIN INVEST, V100, P2054, DOI 10.1172/JCI119738; Simas JP, 1998, TRENDS MICROBIOL, V6, P276; Sodhi A, 2000, CANCER RES, V60, P4873; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Van Berkel V, 2000, J VIROL, V74, P6741, DOI 10.1128/JVI.74.15.6741-6747.2000; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Wang JM, 1999, CONT CANC RES, P129; Wells TNC, 1997, CURR OPIN BIOTECH, V8, P741, DOI 10.1016/S0958-1669(97)80129-2; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470; Zou P, 1999, J VIROL, V73, P5926, DOI 10.1128/JVI.73.7.5926-5933.1999	102	83	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1582	1593		10.1038/sj.onc.1204191	http://dx.doi.org/10.1038/sj.onc.1204191			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313905				2022-12-28	WOS:000168089800008
J	Arevalo, JC; Conde, B; Hempstead, BI; Chao, MV; Martin-Zanca, D; Perez, P				Arevalo, JC; Conde, B; Hempstead, BI; Chao, MV; Martin-Zanca, D; Perez, P			A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation	ONCOGENE			English	Article						receptor; tyrosine kinases; dimerization; cell transformation	NERVE GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; FACTOR BINDING-SITE; LEUCINE-RICH MOTIF; LIGAND-BINDING; SIGNAL-TRANSDUCTION; DIMERIZATION; DELETIONS; SPECIFICITY; ONCOGENES	The TrkA NGF receptor extracellular region contains three leucine repeats flanked by cysteine clusters and two immunoglobulin-like domains that are required for specific ligand binding. Deletion of the immunoglobulinlike domains abolishes NGF binding and causes ligand independent activation of the receptor. Here we report a specific mutation that increases the binding affinity of the TrkA receptor for NGF, A change of proline 203 to alanine (P203A) in the linker region between the leucine repeats and the first Ig-like domain increased NGF binding by decreasing the ligand rate of dissociation, This mutated receptor was appropriately expressed on the cell surface and promoted ligand-independent neurite outgrowth in PC12nnr5 cells. The mutant receptor was capable of spontaneous dimerization and was constitutively phosphorylated in the absence of ligand, Moreover, expression of TrkA-P203A receptor in fibroblasts induced DNA synthesis and transformation and generated tumours in nude mice. These data suggest that domains outside of the immunoglobulin-like structure contribute to ligand binding and constitutive activation of Trk receptors.	Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca 37007, Spain; Univ Zaragoza, Dept Ciencias Morfol, E-50009 Zaragoza, Spain; Cornell Univ, Coll Med, Div Hematol Oncol, New York, NY 10021 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Physiol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Neurosci, New York, NY 10016 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Zaragoza; Cornell University; New York University; New York University; New York University	Perez, P (corresponding author), Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca 37007, Spain.		Arévalo, Juan Carlos/J-8154-2014; Perez, Pilar/B-4948-2010	Arévalo, Juan Carlos/0000-0003-1994-3095; Perez, Pilar/0000-0003-3557-2247; Chao, Moses/0000-0002-6969-3744				Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; EZOE K, 1995, AM J HUM GENET, V56, P58; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Greco A, 1997, GENE CHROMOSOME CANC, V19, P112, DOI 10.1002/(SICI)1098-2264(199706)19:2<112::AID-GCC7>3.0.CO;2-1; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Smith DK, 1997, J MOL BIOL, V274, P530, DOI 10.1006/jmbi.1997.1432; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; WETTERS TV, 1992, EMBO J, V11, P551, DOI 10.1002/j.1460-2075.1992.tb05086.x; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	35	36	37	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1229	1234		10.1038/sj.onc.1204215	http://dx.doi.org/10.1038/sj.onc.1204215			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313867				2022-12-28	WOS:000167570100010
J	Ciullo, I; Diez-Roux, G; Di Domenico, M; Migliaccio, A; Avvedimento, EV				Ciullo, I; Diez-Roux, G; Di Domenico, M; Migliaccio, A; Avvedimento, EV			cAMP signaling selectively influences Ras effectors pathways	ONCOGENE			English	Article						transduction; cAMP-dependent kinase; Ras and GTP binding proteins; PI3-kinases; growth; thyroid differentiation	DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; THYROTROPIN RECEPTOR; THYROID-CELLS; DNA-SYNTHESIS; CELLULAR RAS; INHIBITION; ACTIVATION; PROLIFERATION; GROWTH	Thyrotropin (TSH) stimulates survival and growth of thyroid cells via a seven transmembrane G protein-coupled receptor. TSH elevates the intracellular cyclic AMP (cAMP) levels activating protein kinase A (PKA), Recent evidence indicates that p21 Ras is required for TSH-induced mitogenesis, but the molecular mechanism(s) is not known. Here we report that Ras p21 activity is necessary for the Go- G1 transition in TSH induced cycle and that the downstream effector of Ras upon TSH signaling is p85-p110 PI3K, We show that PI3K inhibitors block TSH-induced DNA synthesis, cAMP-PKA stimulate the formation of the complex PI3K-p21 Ras and reduce the complex Ras-Raf1 in thyroid and other cells types. Moreover, PKA phosphorylates immunoprecipitated p85 and PKA phosphorylation of cell extracts significantly stimulates the formation of the complex PI3K-Ras, We suggest that PKA phosphorylates p85 and stabilizes the complex p110-p85, enhancing the interaction PI3K and p21 Ras, Simultaneously, cAMP inhibits Raf-1-ERK signaling by decreasing Raf1 availability to Ras, Under these circumstances PI3K signaling is favored. These results indicate that PI3K is an important mediator of Ras effects in cAMP-induced proliferation and illustrates how cAMP can selectively influence Ras effector pathways.	Univ Naples Federico II, Fac Med,Policlin 2, Dipartimento Biol & Patol Mol & Cellulare, CNR, I-80131 Naples, Italy; Univ Catanzaro, Fac Med, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Naples 2, Ist Patol Gen, I-80138 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita della Campania Vanvitelli	Avvedimento, EV (corresponding author), Univ Naples Federico II, Fac Med,Policlin 2, Dipt Biol & Patol Mol & Cell, CNR, Via S Pansini 5, I-80131 Naples, Italy.		Migliaccio, Antimo/AAB-3376-2019	Di Domenico, Marina/0000-0002-6201-4200; Migliaccio, Antimo/0000-0002-4197-2055				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BONAPACE IM, 1990, MOL CELL BIOL, V10, P1033, DOI 10.1128/MCB.10.3.1033; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHEATHAM B, 1997, MOL CELL BIOL, V14, P4902; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DEVITA G, 2000, IN PRESS CANC RES; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MEINKOTH JL, 1991, THYROIDOLOGY, V3, P97; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; PORCELLINI A, 1995, ONCOGENE, V11, P1089; PORCELLINI A, 1997, ONCOGENE, V14, P2233; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	84	86	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1186	1192		10.1038/sj.onc.1204219	http://dx.doi.org/10.1038/sj.onc.1204219			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313862				2022-12-28	WOS:000167570100005
J	Goldstone, S; Pavey, S; Forrest, A; Sinnamon, J; Gabrielli, B				Goldstone, S; Pavey, S; Forrest, A; Sinnamon, J; Gabrielli, B			Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR	ONCOGENE			English	Article						cell cycle checkpoint; DNA damage; ATM/ATR	DNA-DAMAGE CHECKPOINT; CDC25B PHOSPHATASE; G(2) CHECKPOINT; TYROSINE DEPHOSPHORYLATION; DEPENDENT KINASE-2; HUMAN FIBROBLASTS; PROTEIN-KINASE; HELA-CELLS; S-PHASE; PHOSPHORYLATION	Cyclin A/cdk2 is active during S and G2 phases of the cell cycle, but its regulation and function during G2 phase is poorly understood. In this study we have examined the regulation of cyclin A/cdk2 activity during normal G2 phase progression and in genotoxin-induced G2 arrest. We show that cyclin A/cdk2 is activated in early G2 phase by a cdc25 activity. In the G2 phase checkpoint arrest initiated in response to various forms of DNA damage, the cdc25-dependent activation of both cyclin A/cdk2 and cyclin B1/cdc2 is blocked. Ectopic expression of cdc25B, but not cdc25C, in G2 phase arrested cells efficiently activated both cyclin A/cdk2 and cyclin B1/cdc2. Finally, we demonstrate that the block in cyclin A/cdk2 activation in the G2 checkpoint arrest is independent of ATM/ATR. We speculate that the ATM/ ATR-independent block in G2 phase cyclin A/cdk2 activation may act as a further layer of checkpoint control, and that blocking G2 phase cyclin A/cdk2 activation contributes to the G2 phase checkpoint arrest.	Univ Queensland, Queensland Inst Med Res, Queensland Canc Fund Res Unit, Brisbane, Qld, Australia; Univ Queensland, Dept Pathol, Joint Expt Oncol Program, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Queensland Inst Med Res, Queensland Canc Fund Res Unit, Brisbane, Qld, Australia.		Pavey, Sandra/B-3662-2011; Forrest, Alistair/A-6597-2008; Gabrielli, Brian G/B-3655-2011	Pavey, Sandra/0000-0003-4519-5932; Forrest, Alistair/0000-0003-4543-1675; Gabrielli, Brian G/0000-0003-3933-1651				Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HERZINGER T, 1995, ONCOGENE, V11, P2151; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lammer C, 1998, J CELL SCI, V111, P2445; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; Maity A, 1996, ONCOGENE, V13, P1647; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; Ramsay J, 1998, BRIT J CANCER, V77, P11, DOI 10.1038/bjc.1998.2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Tamura K, 2000, CANCER RES, V60, P1317; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Wang XQ, 1996, CANCER RES, V56, P2510	45	74	78	2	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					921	932		10.1038/sj.onc.1204177	http://dx.doi.org/10.1038/sj.onc.1204177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314027				2022-12-28	WOS:000167097000003
J	Kumar, A; Jasmin, A; Eby, MT; Chaudhary, PM				Kumar, A; Jasmin, A; Eby, MT; Chaudhary, PM			Cytotoxicity of tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines	ONCOGENE			English	Article						Ewing's sarcoma; TRAIL; Apo2L; apoptosis; MRIT; NF-kappa B	NF-KAPPA-B; L929 CELLS; TRAIL; DEATH; ACTIVATION; SENSITIVITY; INHIBITION; RECEPTOR; PATHWAY; FAMILY	Death ligands of the Tumor Necrosis Factor (TNF) family are known to induce apoptosis upon binding to their cognate receptors. However, the clinical utility of these cytokines as anticancer agents has been limited due to unacceptable toxicity. TRAIL is a recently isolated death ligand that possesses selective anti-tumor activity against a number of cancer cell lines without significant systemic toxicity. In this report we present evidence that cell lines derived from Ewing's Sarcoma (ES) are uniformly sensitive to TRAIL-mediated apoptosis. Furthermore, unlike TNF-alpha, treatment with TRAIL fails to induce the anti-apoptotic and pro-inflammatory NF-kappaB pathway in the ES cell lines. Our results suggest that TRAIL may prove to be a useful agent for the treatment of Ewing's sarcoma and related peripheral neuroectodermal tumors.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Kumar, Arvind/B-6094-2009; Chaudhary, Preet/E-1970-2018					Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Griffith TS, 1998, J IMMUNOL, V161, P2833; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HENGERER B, 1996, PROMEGA NOTES, V58, P40; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Leverkus M, 2000, CANCER RES, V60, P553; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386	18	22	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					1010	1014		10.1038/sj.onc.1204154	http://dx.doi.org/10.1038/sj.onc.1204154			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314037				2022-12-28	WOS:000167097000013
J	Chen, YR; Shrivastava, A; Tan, TH				Chen, YR; Shrivastava, A; Tan, TH			Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate	ONCOGENE			English	Article						JNK; phosphatase; oxidation; metal ions	TUMOR-NECROSIS-FACTOR; PROTEIN-KINASES; SIGNAL-TRANSDUCTION; INTRACELLULAR LEVEL; GAMMA-RADIATION; CELL-DEATH; METAL-IONS; APOPTOSIS; PATHWAY; STRESS	Oxidative stress activates the c-Jun N-terminal kinase (JNK) pathway. However, the exact mechanisms by which reactive oxygen species (ROS) activate JNK are unclear. We found that the ability of hydrogen peroxide (H2O2) to induce JNK activation varied in different cell types. Pyrrolidine dithiocarbamate (PDTC), a presumed antioxidant, induced JNK activation on its own and enhanced JNK activation by H2O2 in many cell types, including Jurkat, HEK293, and LNCaP and Tsu-Prl prostate cancer cells. The activation of JNK by PDTC, in the presence or absence of exogenous H2O2, was dependent on its chelating ability to metal ions, most likely copper ions, Despite the strong JNK-activating ability, H2O2 plus PDTC did not induce significant activation of the upstream kinases, SEK1/MKK4 and MKK7. However, the JNK inactivation rate was slower in cells treated with H2O2 pins PDTC compared with the rate in cells treated with ultraviolet C CUV-C), Treatment of H2O2 pins PDTC significantly decreased the expression levels of a JNK phosphatase, M3/6 (also named hVH-5), but not the levels of other phosphatases (PP2A and PP4), In contrast, UV-C irradiation did not cause the down-regulation of M3/6, These results suggest that JNK activation by H2O2 plus PDTC resulted from the down-regulation of JNK phosphatases. Our data also reveal a necessity to carefully evaluate the pharmacological and biochemical properties of PDTC.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.		Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/E-3991-2010; Tan, Tse-Hua/ABD-7080-2021	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170	NCI NIH HHS [P50-CA58204] Funding Source: Medline; NIAID NIH HHS [R01-AI38649, R01-AI42532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; delArco PG, 1996, J BIOL CHEM, V271, P26335; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fuchs D, 1997, OXIDATIVE STRESS MOL, P139; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1635; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAUPTMANN N, 1997, OXIDATIVE STRESS MOL, P1; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kim CH, 1999, FEBS LETT, V449, P28, DOI 10.1016/S0014-5793(99)00390-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENTNER C, 1984, GEIGY SCI TABLES, V3, P85; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	41	70	78	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					367	374		10.1038/sj.onc.1204105	http://dx.doi.org/10.1038/sj.onc.1204105			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313966				2022-12-28	WOS:000166411000011
J	NicAmhlaoibh, R; Shtivelman, E				NicAmhlaoibh, R; Shtivelman, E			Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro	ONCOGENE			English	Article						angiogenesis; metastasis; CC3	TAT-ACTIVATED TRANSCRIPTION; LUNG-CARCINOMA; THROMBOSPONDIN; ANGIOPOIETIN-1; PROLIFERATION; CHEMOKINE; APOPTOSIS; COFACTOR; GROWTH; FAMILY	Resistance to apoptosis and ability to promote angiogenesis are integral features of the metastatic phenotype. Human gene CC3 is a metastasis suppressor for variant small cell lung carcinoma and a mouse melanoma in vivo. We have shown previously that metastasis-suppressing function of CC3 might be due at least in part to the ability of CC3 protein to predispose tumor cells to apoptosis, Here we demonstrate that CC3 has a previously unidentified effect on the ability of tumor cells to induce angiogenesis in vitro. Expression of CC3 in three different tumor cell lines significantly diminished their angiogenic character as manifested in the in vitro proliferation and migration assays with endothelial cells of both macro- and microvascular origin. Expression of CC3 induced changes in RNA levels of several angiogenic modulators consistent with the overall reduction in angiogenic properties. These results indicate that expression of CC3 has a dual effect on phenotype of tumor cells ultimately inhibiting their metastatic potential.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Shtivelman, E (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA071422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Addison CL, 2000, HUM GENE THER, V11, P247, DOI 10.1089/10430340050015996; Baker ME, 1999, CURR BIOL, V9, pR471, DOI 10.1016/S0960-9822(99)80297-8; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; Gentilini G, 1999, BLOOD, V93, P25, DOI 10.1182/blood.V93.1.25.401a47_25_33; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Liu Y, 1999, J BIOL CHEM, V274, P13338, DOI 10.1074/jbc.274.19.13338; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Whitman S, 2000, MOL CELL BIOL, V20, P583, DOI 10.1128/MCB.20.2.583-593.2000; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	24	46	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					270	275		10.1038/sj.onc.1204075	http://dx.doi.org/10.1038/sj.onc.1204075			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313954				2022-12-28	WOS:000166410900014
J	Lehembre, F; Muller, S; Pandolfi, PP; Dejean, A				Lehembre, F; Muller, S; Pandolfi, PP; Dejean, A			Regulation of Pax3 transcriptional activity by SUMO-1-modified PML	ONCOGENE			English	Article						PML; SUMO; Pax3; Daxx; nuclear bodies	TUMOR ALVEOLAR RHABDOMYOSARCOMA; PROMYELOCYTIC LEUKEMIA FUSES; NUCLEAR-PORE COMPLEX; PAIRED BOX GENE; COVALENT MODIFICATION; WAARDENBURG SYNDROME; INTERACTING PROTEIN; BINDING PROTEIN; DOMAIN GENE; RAR-ALPHA	Pax3 is an evolutionarily conserved transcription factor that plays a major role in a variety of developmental processes, Mutations in Pax3 lead to severe malformations as seen in human Waardenburg syndrome and in the Splotch mutant mice. The transcriptional activity of Pax3 was recently shown to be repressed by Daxx whereas the oncogenic fusion protein Pax3-FKHR is unresponsive to this repressive action. Here we demonstrate that Daxx-mediated repression of Pax3 can be inhibited by the nuclear body (NB)-associated protein PML, Interestingly, this suppression of Daxx properties correlates with its recruitment to the NBs, Factors such as arsenicals and interferons that enhance NE formation, trigger both the targeting of Daxx to these nuclear structures and the relief of the repressive activity of Daxx, Conversely, lack of structurally intact NBs profoundly impairs Pax3 transcriptional activity, likely by increasing the pool of available nucleoplasmic Daxx, Moreover, a PML mutant that can not be modified by the ubiquitin-related SUMO-1 modifier is no more able to interact with Daxx, Consistently, such a mutant fails both to inhibit the Daxx repressing effect on Pax3 and to induce its accumulation into the NBs, Taken together, these results argue that SUMO-I modified PML can derepress Pax3 transcriptional activity through sequestration of the Daxx repressor into the NBs and suggest a role for these nuclear structures in the transcriptional control by Pax proteins.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Dejean, A (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	Muller, Stefan/0000-0002-8792-7700				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kiriakidou M, 1997, DNA CELL BIOL, V16, P1289, DOI 10.1089/dna.1997.16.1289; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pluta AF, 1998, J CELL SCI, V111, P2029; Schul W, 1998, J CELL BIOCHEM, V70, P159, DOI 10.1002/(SICI)1097-4644(19980801)70:2<159::AID-JCB2>3.0.CO;2-N; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1992, J CELL SCI, V101, P773; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	50	92	95	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					1	9		10.1038/sj.onc.1204063	http://dx.doi.org/10.1038/sj.onc.1204063			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244500				2022-12-28	WOS:000166361400001
J	Wang, Q; Zhang, HT; Fishel, R; Greene, MI				Wang, Q; Zhang, HT; Fishel, R; Greene, MI			BRCA1 and cell signaling	ONCOGENE			English	Article						BRCA1; gene transcription; DNA damage repair	TRANSCRIPTION-COUPLED REPAIR; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; GROWTH-ARREST; MISMATCH REPAIR; MEIOTIC CELLS; MYC REPRESSES; GENE GADD45; C-MYC	The breast cancer and ovarian cancer susceptibility gene BRCA1 encodes a nucleoprotein whose mutations or aberrant expression is associated with both inherited and sporadic cancers. Studies over the last 6 years have suggested that BRCA1 may function as a scaffold in the assembly of a multi-protein complex, which plays a role in gene transcription, DNA damage repair, and transcription-coupled DNA damage repair. In this review, we discuss the implications drawn from the studies of BRCA1-interacting proteins and the cellular signaling pathways that may be involved in controlling the functions of BRCA1.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	University of Pennsylvania; Jefferson University	Wang, Q (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.		Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049	NATIONAL CANCER INSTITUTE [R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA067007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Constance CM, 1996, MOL CELL BIOL, V16, P3878; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gatei M, 2000, CANCER RES, V60, P3299; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jensen DE, 1999, ANN NY ACAD SCI, V886, P191, DOI 10.1111/j.1749-6632.1999.tb09414.x; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Leadon SA, 1997, CANCER RES, V57, P3784; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1997, AM J HUM GENET, V61, P761, DOI 10.1086/515515; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Y, 2000, GENE DEV, V14, P927; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhang H, 1999, CANCER RES, V59, P3021; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	83	69	71	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6152	6158		10.1038/sj.onc.1203974	http://dx.doi.org/10.1038/sj.onc.1203974			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156529				2022-12-28	WOS:000166121400009
J	Kosako, H; Yoshida, T; Matsumura, F; Ishizaki, T; Narumiya, S; Inagaki, M				Kosako, H; Yoshida, T; Matsumura, F; Ishizaki, T; Narumiya, S; Inagaki, M			Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow	ONCOGENE			English	Article						cell cycle; cytokinesis; Rho-kinase; myosin light chain; ERM proteins	ERM PROTEINS; CULTURED-CELLS; ACTIN CYTOSKELETON; SMALL GTPASE; ADHESION; ASSOCIATION; PHOSPHATASE; FILAMENTS; ACTIVATION; MOESIN	The small GTPase Rho and one of its targets, Rho-kinase (also termed ROK or ROCK), are implicated in various cellular functions including stress fiber formation, smooth muscle contraction, tumor cell invasion and cell motility, We have previously reported that Rho-kinase accumulates at the cleavage furrow during cytokinesis in several cultured cells. Here, using Rho-kinase inhibitors, Y-27632 and HA1077, we found that Rho-kinase is responsible for the phosphorylation of myosin regulatory light chain at Ser(19) in the cleavage furrow during cytokinesis. On the other hand, phosphorylation of ezrin/radixin/moesin (ERM) proteins at the cleavage furrow was enhanced by the addition of the above Rho-kinase inhibitors, Treatment with Y-27632 strongly enhanced the accumulation of Rho-kinase but not RhoA and citron kinase at the cleavage furrow. Furthermore, the furrow ingression in cytokinesis was significantly prolonged in the presence of Y-27632, These results suggest that Rho-kinase is involved in the progression of cytokinesis through the phosphorylation of several proteins including myosin light chain at the cleavage furrow.	Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, Tokyo 1130033, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Nagoya, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Pathol, Tsu, Mie 5148507, Japan; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan	University of Tokyo; Aichi Cancer Center; Mie University; Rutgers State University New Brunswick; Kyoto University	Kosako, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Inagaki, Masaki/B-9920-2016; Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217; Matsumura, Fumio/0000-0002-8204-153X				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gerisch G, 2000, CURR OPIN CELL BIOL, V12, P126, DOI 10.1016/S0955-0674(99)00066-6; Hales KG, 1999, CURR OPIN CELL BIOL, V11, P717, DOI 10.1016/S0955-0674(99)00042-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hayashi K, 1999, J CELL SCI, V112, P1149; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	27	176	181	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6059	6064		10.1038/sj.onc.1203987	http://dx.doi.org/10.1038/sj.onc.1203987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146558				2022-12-28	WOS:000165827900013
J	Lara-Pezzi, E; Roche, S; Andrisani, OM; Sanchez-Madrid, F; Lopez-Cabrera, M				Lara-Pezzi, E; Roche, S; Andrisani, OM; Sanchez-Madrid, F; Lopez-Cabrera, M			The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner	ONCOGENE			English	Article						cadherin; catenin; HCC; metastasis; tyrosine phosphorylation	HUMAN HEPATOCELLULAR CARCINOMAS; E-CADHERIN; X-PROTEIN; TRANSGENIC MICE; BETA-CATENIN; CELL-ADHESION; MEDIATED ADHESION; TYROSINE KINASES; GENE-EXPRESSION; LIVER-CANCER	Chronic hepatitis B virus infection is strongly associated with the development of hepatocellular carcinoma (HCC). Epithelial tumors are frequently characterized by loss of cadherin expression or function. Cadherin-dependent adhesion prevents the acquisition of a migratory and invasive phenotype, and loss of its function is itself enough for the progression from adenoma to carcinoma, The HBx protein of hepatitis B virus is thought to contribute to the development of the carcinoma, however, its role in the oncogenic and metastatic processes is far from being fully understood. We report herein the ability of HBx to disrupt intercellular adhesion in three different cell lines stably transfected with an inducible HBx expression vector. The linkage between the actin cytoskeleton and cadherin complex, which is essential for its function, is disrupted in the presence of HBx, as indicated by detergent solubility and immunoprecipitation experiments, In addition, beta -catenin was tyrosine phosphorylated in HBx-expressing cells, Inhibition of the src family of tyrosine kinases resulted in the prevention of the disruption of adherens junctions. These results suggest that HBx is able to disrupt intercellular adhesion in a src-dependent manner, and provide a novel mechanism by which HBx may contribute to the development of HCC.	Hosp Univ Princesa, Unidad Biol Mol, Madrid 28006, Spain; Hosp Univ Princesa, Serv Inmunol, Madrid 28006, Spain; Ctr Rech Biochem Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France; Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Hospital de La Princesa; Hospital de La Princesa; Centre National de la Recherche Scientifique (CNRS); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Lopez-Cabrera, M (corresponding author), Hosp Univ Princesa, Unidad Biol Mol, Diego de Leon 62, Madrid 28006, Spain.		Lara-Pezzi, Enrique/E-2350-2015; Sanchez-Madrid, Francisco/M-7889-2016; Cabrera, Manuel López/AAA-5463-2019	Lara-Pezzi, Enrique/0000-0002-2743-1033; Sanchez-Madrid, Francisco/0000-0001-5303-0762; roche, serge/0000-0003-3413-3859; Lopez Cabrera, Manuel/0000-0002-0976-9719; Andrisani, Ourania/0000-0002-6230-0303				Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Chisari FV, 2000, AM J PATHOL, V156, P1117, DOI 10.1016/S0002-9440(10)64980-2; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Feitelson MA, 1997, AM J PATHOL, V150, P1141; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Kozyraki R, 1996, GASTROENTEROLOGY, V110, P1137, DOI 10.1053/gast.1996.v110.pm8613003; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LARAPEZZI E, 2001, IN PRESS HEPATOLOGY; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LUDUENA MA, 1977, J CELL PHYSIOL, V91, P119, DOI 10.1002/jcp.1040910112; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	43	68	73	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3323	3331		10.1038/sj.onc.1204451	http://dx.doi.org/10.1038/sj.onc.1204451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423982				2022-12-28	WOS:000169248800002
J	Minucci, S; Nervi, C; Lo Coco, F; Pelicci, PG				Minucci, S; Nervi, C; Lo Coco, F; Pelicci, PG			Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?	ONCOGENE			English	Review						histone deacetylases; acute myeloid leukemias; PML-RAR; differentiation therapy	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; PLZF-RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; FUSION PROTEIN; EXPRESSION; ETO; PML; OLIGOMERIZATION	Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML), Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein, Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias, Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Vita Salute, Dept Gen Pathol, I-20100 Milan, Italy; Univ La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Univ La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy	IRCCS European Institute of Oncology (IEO); Vita-Salute San Raffaele University; Sapienza University Rome; Sapienza University Rome	Minucci, S (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Minucci, Saverio/J-9669-2012	NERVI, Clara/0000-0001-9341-0188				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Deininger M W, 1998, Curr Opin Hematol, V5, P302; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; FERRARA F, 2001, IN PRESS CANC RES; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glass CK, 2000, GENE DEV, V14, P121; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2000, GENE DEV, V14, P1048; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; Huang EY, 2000, GENE DEV, V14, P45; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KASTNER P, 2001, IN PRESS BLOOD; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lo Coco F, 1999, BLOOD, V94, P12, DOI 10.1182/blood.V94.1.12.413a44_12_22; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang JX, 1999, CANCER RES, V59, P2766; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	47	164	183	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3110	3115		10.1038/sj.onc.1204336	http://dx.doi.org/10.1038/sj.onc.1204336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420727				2022-12-28	WOS:000169308500015
J	Kim, H; You, SK; Kim, IJ; Foster, LK; Farris, J; Ambady, S; de Leon, FAP; Foster, DN				Kim, H; You, SK; Kim, IJ; Foster, LK; Farris, J; Ambady, S; de Leon, FAP; Foster, DN			Alterations in p53 and E2F-1 function common to immortalized chicken embryo fibroblasts	ONCOGENE			English	Article						chicken embryo fibroblast; immortalization; p53; E2F-1; telomerase	HUMAN-CELLS; SACCHAROMYCES-CEREVISIAE; CELLULAR SENESCENCE; TELOMERASE ACTIVITY; TUMOR-CELLS; GENE; DEGRADATION; EXPRESSION; MECHANISM; PATTERNS	A number of non-virally and non-chemically immortalized chicken embryo fibroblast (CEF) cells have been established recently in continuous cell culture. All immortal CEF cells tested showed common genetic alterations in the expression patterns of p53 and E2F-1 mRNA and protein which were down- and up-regulated, respectively, The biological effects of differentially regulated p53 and E2F-1 were determined by reporter gene transcriptional activity assays, DNA binding assays, and Northern blot analysis of the expression patterns of down-stream genes, In addition, expression of most of the cyclin genes was up-regulated in immortal CEF cells, which may be associated with the rapid cell division rates and serum-independent growth patterns seen in immortal CEF cells. The telomeric lengths and chromosome integrity were maintained in all immortal CEF cell lines without detectable telomerase activity. Although the functional inactivations of the p53 and Rb regulatory pathways are known to be common events for cellular immortalization, the genetic changes leading to alteration of p53 and E2F-1 function through transcriptional and post-transcriptional regulation seem to be unique in immortal CEF cells.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), 495 AnSci VetMed, 1988 Fitch AVe, St Paul, MN 55108 USA.		Kim, Hyunggee/F-2673-2013; Kang, Phil Jun/F-4716-2013; You, Seungkwon/H-3067-2015	Kim, Hyunggee/0000-0002-4738-0990; Ponce de Leon, Federico/0000-0001-8645-553X				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DELEON FAP, 1992, J HERED, V83, P36, DOI 10.1093/oxfordjournals.jhered.a111154; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Jha KK, 1998, EXP CELL RES, V245, P1, DOI 10.1006/excr.1998.4272; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Venkatesan RN, 1998, P NATL ACAD SCI USA, V95, P14763, DOI 10.1073/pnas.95.25.14763; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	36	35	43	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2671	2682		10.1038/sj.onc.1204378	http://dx.doi.org/10.1038/sj.onc.1204378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420679				2022-12-28	WOS:000168652600008
J	Aigner, A; Juhl, H; Malerczyk, C; Tkybusch, A; Benz, CC; Czubayko, F				Aigner, A; Juhl, H; Malerczyk, C; Tkybusch, A; Benz, CC; Czubayko, F			Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation	ONCOGENE			English	Article						HER2; c-erbB2 (neu); HER2-ECD; gastric cancer; breast cancer; ribozyme	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; BREAST-CANCER; OVARIAN-CANCER; GENE ENCODES; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; FACTOR RECEPTOR; MESSENGER-RNA	Overexpression of the HER2 (neu/c-erbB-2) oncogene frequently coincides with an aggressive clinical course of certain human adenocarcinomas. Expression and secretion of aberrant HER2 splice variants has been reported in various cell lines and tissues and can interfere with the oncogenic HER2 activity. Here we demonstrate, using two different approaches, that expression of a truncated 100 kDa HER2 variant which encodes the extracellular domain of HER2 (HER-ECD) inhibits growth factor-mediated tumour cell proliferation. A HER2-ECD cDNA encoding the truncated variant was overexpressed in MCF7 breast cancer cells, HER2-ECD overexpression decreased spontaneous proliferation of MCF7 cells as well as heregulin-mediated soft agar colony formation, Concomitantly, heregulin-induced phosphorylation of HER4 as well as downstream activation of p44/p42 MAP-kinases was decreased. To confirm these data, ribozymes were targeted to the 3'-untranslated region of the 2.3 kb HER2-ECD mRNA which is spontaneously expressed in MKN7 gastric cancer cells. HER2-ECD-targeted ribozymes downregulated HER2-ECD expression and enhanced EGF-mediated soft agar colony formation of MKN7 cells. In parallel, EGF-induced activation of p44/p42 MAP-kinases and activation of c-Fos expression were increased in ribozyme-transfected MKN7 cells. Finally, in RT-PCR we found a trend towards a progressive loss of 2.3 kb HER2-ECD mRNA expression in more advanced gastric tumours, These data show that the HER2-ECD variant inhibits growth factor-mediated tumour cell proliferation suggesting an important role during the progression of human cancer.	Univ Marburg, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany; Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA; Univ Hosp Kiel, Dept Surg, D-24105 Kiel, Germany; Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA	Philipps University Marburg; Georgetown University; University of Kiel; Schleswig Holstein University Hospital; University of California System; University of California San Francisco	Czubayko, F (corresponding author), Univ Marburg, Dept Pharmacol & Toxicol, Karl von Frisch Str 1, D-35033 Marburg, Germany.		Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256	NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Allgayer H, 2000, J CLIN ONCOL, V18, P2201, DOI 10.1200/JCO.2000.18.11.2201; Colomer R, 2000, CLIN CANCER RES, V6, P2356; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; Gebhardt F, 1998, BIOCHEM BIOPH RES CO, V247, P319, DOI 10.1006/bbrc.1998.8779; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hsieh SS, 2000, INT J CANCER, V86, P644, DOI 10.1002/(SICI)1097-0215(20000601)86:5<644::AID-IJC7>3.0.CO;2-T; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lewis GD, 1996, CANCER RES, V56, P1457; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	30	41	49	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2101	2111		10.1038/sj.onc.1204305	http://dx.doi.org/10.1038/sj.onc.1204305			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360194				2022-12-28	WOS:000168116700005
J	Harris, VK; Kagan, BL; Ray, R; Coticchia, CM; Liaudet-Coopman, ED; Wellstein, A; Riegel, AT				Harris, VK; Kagan, BL; Ray, R; Coticchia, CM; Liaudet-Coopman, ED; Wellstein, A; Riegel, AT			Serum induction of the fibroblast growth factor-binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP-regulated transcription	ONCOGENE			English	Article						FGF-BP; serum; p38 MAPK; C/EBP; transcription	SIGNAL-TRANSDUCTION PATHWAYS; GENE-EXPRESSION; PHOSPHORYLATION; ISOFORMS; ELEMENT	The fibroblast growth factor-binding protein (FGF-BP) modulates FGF activity through binding and release from the extracellular matrix, Consequently, the expression of FGF-BP in certain tumor types is a rate-limiting regulator of FGF-mediated angiogenesis. FGF-BP is upregulated in squamous cell carcinoma by treatment with mitogens such as EGF or TPA, In this study, we investigated the regulation of FGF-BP gene expression by serum. Treatment of serum-starved ME-180 cells with fetal bovine serum (FBS) resulted in a rapid increase in steady-state levels of FGF-BP mRNA and in the rate of FGF-BP gene transcription. Serum induction of FGF-BP mRNA was not mediated through EGF receptor activation but was dependent on PKC, as well as ERK kinase (MEK) and p38 MAP kinase activation. Promoter analysis showed that C/EBP is the main promoter element required for the serum response. Unlike EGF-activation of FGF-BP, transcriptional induction by serum is not significantly regulated through the AP-I or E-box sites in the promoter. These results illustrate differences between the mechanism of induction in response to serum and EGF.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Harris, VK (corresponding author), CUNY, Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, 1425 Madison Ave,Box 1130,East Bldg,Rm 15-52, New York, NY 10029 USA.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA71508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Harris VK, 2000, J BIOL CHEM, V275, P28539, DOI 10.1074/jbc.M001677200; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU DQ, 1991, J BIOL CHEM, V266, P16778	24	21	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1730	1738		10.1038/sj.onc.1204249	http://dx.doi.org/10.1038/sj.onc.1204249			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313920				2022-12-28	WOS:000167750900006
J	Chai, YL; Chipitsyna, G; Cui, JQ; Liao, BS; Liu, S; Aysola, K; Yezdani, M; Reddy, ESP; Rao, VN				Chai, YL; Chipitsyna, G; Cui, JQ; Liao, BS; Liu, S; Aysola, K; Yezdani, M; Reddy, ESP; Rao, VN			c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells	ONCOGENE			English	Article						c-Fos; BRCA1/BRCA1a/1b; Elk-1; growth suppression; breast cancer; protein-protein interaction	ETS TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; DNA-BINDING; PROTEIN ELK-1; IN-VIVO; EXPRESSION; ACTIVATION; GENE; DOMAINS; COMPLEX	Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain family of transcriptional factors, plays an important role in the induction of immediate early gene expression in response to a variety of extracellular signals. In this study, we demonstrate for the first time the in, vitro and in vivo interaction of Elk-1 with BRCA1 splice variants BRCA1a and BRCA1b using GST-pull down assays, co-imunoprecipitations/Western blot analysis of cell extracts from breast cancer cells and mammalian two-hybrid assays. We have localized the BRCA1 interaction domain of Elk-1 protein to the conserved ETS domain, a motif involved in DNA binding and protein-protein interactions. We also observed binding of BRCA1 proteins to other ETS-domain transcription factors SAP1, ETS-1, ERG-2 and Fli-1 but not to Elk-1 splice variant Delta Elk-1 and c-Fos protooncogene, Both BRCA1a and BRCA1b splice variants function as growth suppressors of human breast cancer cells. interestingly, our studies reveal that although both Elk-1 and SAP-1 are highly homologous members of a subfamily of ETS domain proteins called ternary complex factors, it is only Elk-1 but not SAP-I that can augment the growth suppressive function of BRCA1a/1b proteins in breast cancer cells, Thus Elk-1 could be a potential downstream target of BRCA1 in its growth control pathway, Furthermore, we hare observed inhibition of c-Fos promoter activity in BRCA1a transfected stable breast cancer cells and over expression of BRCA1a/1b attenuates MEK-induced SRE activation in vivo. These results demonstrate for the first time a link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 protein, All these results taken together suggest that one of the mechanisms by which BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos.	Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, 245 N 15th St,New Coll Bldg,MS 481, Philadelphia, PA 19102 USA.				NATIONAL CANCER INSTITUTE [R01CA085343, R01CA057322, R01CA058642] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA85343, 1RO1CA57322, 1RO1CA58642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1995, AM J HUM GENET, V57, P1457; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Katsama A, 2000, CANCER LETT, V150, P165, DOI 10.1016/S0304-3835(99)00386-9; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Lu ML, 1996, CANCER RES, V56, P4578; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; Ozcelik H, 1998, INT J CANCER, V77, P1; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SHYAM E, 1990, CANCER RES, V50, P5013; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	59	45	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1357	1367		10.1038/sj.onc.1204256	http://dx.doi.org/10.1038/sj.onc.1204256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313879				2022-12-28	WOS:000167495000009
J	Decesse, JT; Medjkane, S; Datto, MB; Cremisi, CE				Decesse, JT; Medjkane, S; Datto, MB; Cremisi, CE			RB regulates transcription of the p21/WAF1/CIP1 gene	ONCOGENE			English	Article						RB; p21(WAF1/CIP); Spl; epithelial cells; differentiation	CDK-INHIBITOR P21(WAF1/CIP1); SV40 T-ANTIGEN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; SP1-MEDIATED TRANSCRIPTION; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; PRODUCT RB; EXPRESSION; DIFFERENTIATION	We have previously shown that RB plays an important role in the maintenance of the epithelial phenotype, p21 is also involved in several terminal differentiation systems including keratinocytes. We report here that p21 is an RB target gene in epithelial cells, but not in fibroblasts where RB is unable to transactivate p21 transcriptional expression. In epithelial cells, when RB family factors were inactivated by SV40 T antigen (LT), p21 expression was strongly repressed, whereas its expression was not affected when the cells were transformed by a mutated LT leaving RB active but inactivating p53. Moreover, retransformation by RB of LT transformed epithelial cells totally restored p21 expression. By cotransfection experiments and using deletions and point mutations of the p21 promoter, we show that the minimal region required for the RB-mediated transcriptional activation maps to a GC-rich region located between -83 and -74. This region is shown to interact specifically with the transcription factor Sp1 and Sp3. Thus for the first time, we show a positive transcriptional relationship between RB and p21 in epithelial cells. Since p21 keeps RB in a hypophosphorylated state important for its transcriptional activity during differentiation, our results imply an auto-loop of regulation between RB and p21 that may be essential for the maintenance of the differentiation state. We propose that this transcriptional relationship might be necessary of their roles in cell cycle arrest and in several differentiation pathways.	Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, F-94801 Villejuif, France; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); Duke University	Cremisi, CE (corresponding author), Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.			Medjkane, Souhila/0000-0001-7973-7707				Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUCHS E, 1993, J CELL SCI, P197; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; JIANG HP, 1994, ONCOGENE, V9, P3397; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martel C, 1997, CELL GROWTH DIFFER, V8, P165; Martel C, 1996, CELL DEATH DIFFER, V3, P285; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	43	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					962	971		10.1038/sj.onc.1204169	http://dx.doi.org/10.1038/sj.onc.1204169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314031				2022-12-28	WOS:000167097000007
J	Fukuchi, Y; Kizaki, H; Yamato, K; Kawamura, C; Umezawa, A; Hata, J; Nishihara, T; Ikeda, Y				Fukuchi, Y; Kizaki, H; Yamato, K; Kawamura, C; Umezawa, A; Hata, J; Nishihara, T; Ikeda, Y			Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells	ONCOGENE			English	Article						activin A; CML apoptosis; differentiation; Mcl-1	GLOBIN GENE-EXPRESSION; FSH-RELEASING PROTEIN; BCL-2 FAMILY-MEMBERS; ERYTHROID-DIFFERENTIATION; SIGNALING PATHWAY; PROLIFERATION; LEUKEMIA; INHIBIN; PURIFICATION; DELAYS	Activin A, one member of the transforming grow th factor (TGF)-beta superfamily, is known to be a commitment factor for cell death and differentiation. In the present study, we demonstrate that human chronic myeloid leukemia (CML) cell lines, KU812 and K562 cells, either induced apoptosis or differentiation, respectively, by treatment with activin A. During these cell fate decisive events caused by activin A, rapid and transient up-regulation of Mcl-1 nas observed in both cell lines, In activin A-induced apoptosis of KU812 cells, continuous up-regulation of Bas was observed. After the decrease in Mcl-1 expression had occurred, activation of caspase-9 and caspase-3 and cleavage of DFF45 were shown to take place in KU812 cells, resulting in the fragmentation of the genomic DNA of the cells. In contrast, the dean-regulation of Mcl-1 without up-regulation of Bas caused accumulation of hemoglobin (Hb) contents in activin A-treated K562 cells. Interestingly, erythropoietin (EPO) prevented activin A-induced apoptosis with continuous expression of Mcl-1 and caused KU812 cells to undergo erythroid differentiation. To address the role of Mcl-1 in activin A-treated CML cells, KU812 and K562 cells were stably transfected with cDNA encoding Mcl-1 (designated as KU812/mcl and K562/mcl cells). As in combined effect of activin A and EPO on the parental KU812 cells, activin A induced differentiation, but not apoptosis, of KU812/mcl cells without modulating Bas levels. Activin A-treated K562/mcl cells, as well as parental cells, were only differentiated to erythroid cells, These results suggest that Mcl-1 is an early inducible gene activated by the activin A signaling pathway for both cellular differentiation and apoptosis, and continuous expression of Mcl-1 mag be contributed to differentiation signals to the erythroid lineage in CML cells.	Keio Univ, Sch Med, Div Hematol, Dept Internal Med & Pathol,Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci,Dept Oral Funct, Sect Mol Cellular Oncol Microbiol, Tokyo 1138519, Japan; Kyushu Dent Coll, Dept Oral Microbiol, Kitakyushu, Fukuoka 8038580, Japan	Keio University; Tokyo Medical & Dental University (TMDU); Kyushu Dental University	Kizaki, H (corresponding author), Keio Univ, Sch Med, Div Hematol, Dept Internal Med & Pathol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							Ando T, 1998, JPN J CANCER RES, V89, P1326, DOI 10.1111/j.1349-7006.1998.tb00530.x; BILEZIKJIAN LM, 1992, TRENDS ENDOCRIN MET, V3, P218, DOI 10.1016/1043-2760(92)90031-U; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; CHAMPLIN RE, 1985, BLOOD, V65, P1039; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; DEPAOLO LV, 1991, P SOC EXP BIOL MED, V198, P500; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FRIGON NL, 1992, BLOOD, V79, P765; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MIYAMOTO Y, 1990, BIOCHEM BIOPH RES CO, V168, P1149, DOI 10.1016/0006-291X(90)91149-M; MIZUGUCHI T, 1993, BLOOD, V81, P2891; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; NISHIMURA M, 1991, BIOCHEM BIOPH RES CO, V181, P1042, DOI 10.1016/0006-291X(91)92042-I; Peters R, 1998, BLOOD, V92, P2041, DOI 10.1182/blood.V92.6.2041.418k34_2041_2052; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SHAO LE, 1992, BLOOD, V79, P773; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shiozaki M, 1998, BIOCHEM BIOPH RES CO, V242, P631, DOI 10.1006/bbrc.1997.8020; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; TALPAZ M, 1995, ANN INTERN MED, V122, P728, DOI 10.7326/0003-4819-122-9-199505010-00013; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang JM, 1999, MOL CELL BIOL, V19, P6195; YAMASHITA T, 1991, J BIOL CHEM, V266, P3888; Yamato K, 1997, MOL ENDOCRINOL, V11, P1044, DOI 10.1210/me.11.8.1044; YAMATO K, 1996, JPN J CLIN HEMATOL, V37, P564; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YU J, 1989, BLOOD, V73, P952; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	45	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					704	713		10.1038/sj.onc.1204142	http://dx.doi.org/10.1038/sj.onc.1204142			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314004				2022-12-28	WOS:000166806000006
J	Liu, JM; Yuan, Y; Huan, J; Shen, ZY				Liu, JM; Yuan, Y; Huan, J; Shen, ZY			Inhibition of breast and brain cancer cell growth by BCCIP alpha, an evolutionarily conserved nuclear protein that interacts with BRCA2	ONCOGENE			English	Article						BRCA2; calcium-binding protein; BCCIP	SUSCEPTIBILITY GENE BRCA2; TUMOR-SUPPRESSOR LOCI; LONG ARM; RADIATION HYPERSENSITIVITY; TERMINAL DELETION; HUMAN GLIOMAS; ALLELIC LOSS; RAD51; CHROMOSOME-10; 10Q	BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis, Although important functions have been assigned to a few conserved domains of BRCA2, little is known about the longest internal conserved domain encoded by exons 14-24.,We identified a novel protein, designated BCCIP alpha, that interacts with part of the internal conserved region of human BRCA2, Human BCCIP represents a family of proteins that are evolutionarily conserved, and contain three distinct domains: an N-terminus acidic domain (NAD) of 30-60 amino acids, an internal conserved domain (ICD) of 180-220 amino acids, and a C-terminus variable domain (CVD) of 30-60 amino acids, The N-terminal half of the human BCCIP ICD shares moderate homology with regions of calmodulin and ill-calpain, suggesting that BCCIP may also bind Ca. Human cells express both a longer, BCCIP alpha, and a shorter, BCCIP beta, form of the protein, which differ in their CVD, BCCIP is a nuclear protein highly expressed in testis, Although BCCIP beta expression is relatively consistent in cancer cells, the expression of BCCIP alpha varies in cancer cell Lines. The BCCIP alpha gene is located at chromosome 10q25.3-26.2, a region frequently altered in brain and other cancers. Furthermore, expression of BCCIP alpha inhibits breast and brain cancer cell growth,but fails to inhibit HT1080 cells and a non-transformed human skin fibroblast, These results suggest that BCCIP alpha is an important cofactor for BRCA2 in tumor suppression.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ Illinois, Coll Med, Grad Program Mol Genet, Chicago, IL 60607 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shen, ZY (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008353, R01ES008353] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08353] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Gayther SA, 1998, DIS MARKERS, V14, P1; Ittmann M, 1996, CANCER RES, V56, P2143; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Koul A, 1999, GENE CHROMOSOME CANC, V24, P207, DOI 10.1002/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nordling M, 1998, CANCER RES, V58, P1372; PEAR WS, 1997, GENE THERAPY PROTLCO, P41; PEIFFER SL, 1995, CANCER RES, V55, P1922; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; Pontremoli S, 1999, CALCIUM AS A CELLULAR REGULATOR, P371; RASHEED BKA, 1991, CANCER METAST REV, V10, P289; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Robertson GP, 1999, CANCER RES, V59, P3596; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shen ZY, 1996, MUTAT RES-DNA REPAIR, V364, P81, DOI 10.1016/0921-8777(96)00025-0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanabe S, 1999, PEDIATR INT, V41, P565, DOI 10.1046/j.1442-200x.1999.01105.x; TAYSI K, 1982, ANN GENET-PARIS, V25, P141; VIDAL M, 1997, YEAST 2 HYBRID SYSTE, P109; Waggoner DJ, 1999, AM J MED GENET, V86, P1; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; YJANDRA N, 1999, CALCIUM CELL REGULAT, P152; Yuan SSF, 1999, CANCER RES, V59, P3547	37	76	80	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					336	345		10.1038/sj.onc.1204098	http://dx.doi.org/10.1038/sj.onc.1204098			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313963				2022-12-28	WOS:000166411000008
J	Balana, ME; Labriola, L; Salatino, M; Movsichoff, F; Peters, G; Charreau, EH; Elizalde, PV				Balana, ME; Labriola, L; Salatino, M; Movsichoff, F; Peters, G; Charreau, EH; Elizalde, PV			Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells	ONCOGENE			English	Article						ErbB receptors; mammary tumorigenesis; progestin; type I insulin-like growth factor receptor	HUMAN-BREAST-CANCER; MEDROXYPROGESTERONE-ACETATE; CARCINOMA-CELLS; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; PROGESTIN REGULATION; BALB/C MICE; EXPRESSION; PROLIFERATION; PROTEIN	The present study focused on interactions between signaling pathways activated by progestins and by type I and II receptor tyrosine kinases (RTKs) in mammary tumors. An experimental model in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice was used. MPA-stimulated proliferation, both in vivo and in vitro, of progestin-dependent tumors induced up-regulation of ErbB-2 protein levels and tyrosine phosphorylation of this receptor. Combinations of antisense oligodeoxynucleotides (ASODNs) directed to ErbB-2 mRNA with ASODNs directed to the insulin-like growth factor-I receptor (IGF-IR) were used to study the effect of the simultaneous block of these receptors on the MPA-induced proliferation of epithelial cells from the progestin-dependent C4HD line. Neither synergistic nor additive effects on the inhibition of MPA-induced proliferation of C4HD cells were observed as a result of the combination of these ASODNs, Suppression of IGF-IR expression by ASODNs resulted in complete abrogation of MPA-induced phosphorylation of ErbB-2 in C4HD cells, whereas blockage of ErbB-2 did not affect ICF-IR phosphorylation, These results show the existence of a hierarchical interaction between IGF-IR and ErbB-2, by means of which IGF-IR directs ErbB-2 phosphorylation, We demonstrated, for the first time, that this hierarchical interaction involves physical association of both receptors, resulting in the formation of a heteromeric complex, Furthermore, confocal laser microscopy experiments demonstrated that MPA was able to induce co-localization of ErbB-2 and IGF-IR, This hetero-oligomer was also found in MCF-7 human breast cancer cells in which association of IGF-IR and Erbs-2 was induced by heregulin and IGF-I.	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires	Elizalde, PV (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Labriola, Leticia/ABF-9079-2020; Labriola, Leticia/E-9059-2012	Labriola, Leticia/0000-0003-3899-6088; Labriola, Leticia/0000-0003-3899-6088; Peters, Maria/0000-0002-9271-4590; Elizalde, Patricia V./0000-0002-5923-9898				BACKER JM, 1993, J BIOL CHEM, V268, P8204; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; BASERGA R, 1995, CANCER RES, V55, P249; BRAUNSBERG H, 1987, EUR J CANCER CLIN ON, V23, P563, DOI 10.1016/0277-5379(87)90321-X; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DATI C, 1990, ONCOGENE, V5, P1001; De Bortoli M, 1997, J MAMMARY GLAND BIOL, V2, P175, DOI 10.1023/A:1026308015763; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DRAN G, 1995, BREAST CANCER RES TR, V35, P173, DOI 10.1007/BF00668207; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELIZALDE PV, 1990, J EXP CLIN CANC RES, V9, P193; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KISS R, 1986, JNCI-J NATL CANCER I, V77, P173; KORDON EC, 1994, INT J CANCER, V59, P196, DOI 10.1002/ijc.2910590210; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANARI C, 1989, INT J CANCER, V43, P845, DOI 10.1002/ijc.2910430518; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lewis GD, 1996, CANCER RES, V56, P1457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MANNI A, 1987, CANCER RES, V47, P3066; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MODIANO JF, 1991, J CELL BIOCHEM, V45, P196, DOI 10.1002/jcb.240450211; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; MURPHY LC, 1988, CANCER RES, V48, P4555; MURPHY LJ, 1986, CANCER RES, V46, P728; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; READ LD, 1990, CANCER RES, V50, P3947; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SARUP JC, 1988, CANCER RES, V48, P5071; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Woods Ignatoski Kathleen M., 1999, Endocrinology, V140, P3615; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	59	101	105	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					34	47		10.1038/sj.onc.1204050	http://dx.doi.org/10.1038/sj.onc.1204050			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244498	Green Published			2022-12-28	WOS:000166361400005
J	Hart, AH; Reventar, R; Bernstein, A				Hart, AH; Reventar, R; Bernstein, A			Genetic analysis of ETS genes in C-elegans	ONCOGENE			English	Article						LIN-1; ETS; C. elegans; transcription factor	DNA-BINDING DOMAIN; TERNARY COMPLEX FACTORS; TRANSCRIPTION FACTOR; CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; MAP-KINASE; REVERSE GENETICS; CELL FATES; FLI-1 GENE; EXPRESSION	The recent completion of the Caenorhabditis elegans genome has revealed that this nematode worm has 10 members of the ETS gene family. Isolation and analysis of C. elegans mutants and subsequent screens to identify interacting genes can proceed very quickly in this model organism. Molecular genetic analysis of the receptor tyrosine kinase-Ras-MAP kinase signaling pathway in C, elegans identified the ETS family transcription factor Lin-1 as a nuclear effector of this evolutionarily conserved signal transduction pathway. Here we review classical genetic approaches used to discover the role of Lin-1 in the Ras-MAP kinase signaling pathway and describe new technologies that can be applied to the analyses of signaling pathways and transcription factor regulatory networks in C. elegans.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Canadian Inst Hlth Res, Ottawa, ON K1A 0W9, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Institute for Work & Health	Hart, AH (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave,Room 983, Toronto, ON M5G 1X5, Canada.		Hart, Adam/C-1196-2011	Hart, Adam/0000-0001-8129-3877				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BEN DY, 1991, GENE DEV, V5, P908; BENIAN GM, 1993, GENETICS, V134, P1097; Bochert MA, 1998, BIOCHEM BIOPH RES CO, V246, P176, DOI 10.1006/bbrc.1998.8560; BRETONGORIUS J, 1995, BLOOD, V85, P1805, DOI 10.1182/blood.V85.7.1805.bloodjournal8571805; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chang C, 1999, CANCER METAST REV, V18, P203, DOI 10.1023/A:1006317206443; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; FERGUSON EL, 1985, GENETICS, V110, P17; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HART AH, 1995, ONCOGENE, V10, P1423; Hodgkin J, 1998, TRENDS GENET, V14, P352, DOI 10.1016/S0168-9525(98)01543-1; Jacobs D, 1998, GENETICS, V149, P1809; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Kaji H, 2000, ELECTROPHORESIS, V21, P1755, DOI 10.1002/(SICI)1522-2683(20000501)21:9&lt;1755::AID-ELPS1755&gt;3.0.CO;2-S; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KOIZUMI S, 1990, ONCOGENE, V5, P675; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Kuwabara PE, 1997, TRENDS GENET, V13, P455, DOI 10.1016/S0168-9525(97)01253-5; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LELIEVRECHOTTEAU A, 1994, FEBS LETT, V354, P62, DOI 10.1016/0014-5793(94)01091-9; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Martinelli SD, 1997, SEMIN CELL DEV BIOL, V8, P459, DOI 10.1006/scdb.1997.0171; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; Michaelis RC, 1998, AM J MED GENET, V76, P222, DOI 10.1002/(SICI)1096-8628(19980319)76:3<222::AID-AJMG5>3.0.CO;2-S; Miller DM, 1999, BIOTECHNIQUES, V26, P914, DOI 10.2144/99265rr01; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Miyazaki Y, 1996, ONCOGENE, V13, P1721; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; PLASTERK RHA, 1992, BIOESSAYS, V14, P629, DOI 10.1002/bies.950140911; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qi S., 1992, DNA Sequence, V3, P127, DOI 10.3109/10425179209034008; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Sarafi-Reinach TR, 2000, GENE DEV, V14, P2472, DOI 10.1101/gad.832300; SCHOLZ H, 1993, GENETICS, V135, P455; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Wood WB, 1988, NEMATODE CAENORHABDI; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	76	23	23	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6400	6408		10.1038/sj.onc.1204040	http://dx.doi.org/10.1038/sj.onc.1204040			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175356				2022-12-28	WOS:000166595000002
J	Child, ES; Mann, DJ				Child, ES; Mann, DJ			Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence	ONCOGENE			English	Article						Human Herpesvirus 8; Kaposi's sarcoma; cyclin; cyclin-dependent kinase; retinoblastoma protein phosphorylation; quiescence	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; CATALYTIC SUBUNIT; STRUCTURAL BASIS; NUCLEAR IMPORT; S-PHASE; P27(KIP1); ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Viral DNA replication is generally dependent upon circumventing host cell cycle control to force S phase entry in an otherwise quiescent cell. Here we describe novel attributes of the cyclin encoded by Human Herpesvirus 8 (K cyclin) that enable it to subvert the quiescent state. K cyclin is most similar to the mammalian D-type cyclins in primary sequence but displays properties more akin to those of cyclin E. K cyclin (like cyclin E) can autonomously couple with its cognate cdk subunit and localize to the nucleus, D-type cyclins require mitogen stimulated accessory factors (such as p21(Cip1) and p27(Kip1)) to facilitate both of these processes. A striking difference between K cyclin and mammalian cyclins is that K cyclin binding to cdk6 can substantially activate the catalytic activity of the complex without the requirement for cyclin H/cdk7 phosphorylation of the cdk T-loop; this phosphorylation is obligatory for endogenous cyclin/cdk activity. However, K cyclin/cdk6 complexes are not totally immune from cell cycle control since CAK phosphorylation is necessary for complete activation, Thus, CAK phosphorylated K cyclin/cdk6 targets multiple sites in the retinoblastoma protein (pRb) whereas the unphosphorylated complex targets a single site. The restricted substrate specificity of the non-CAK phosphorylated K cyclin/cdk6 complex is insufficient to enable K cyclin-mediated S phase entry. Thus, the viral K cyclin is reliant upon endogenous CAK activity to subvert the quiescent state.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	Imperial College London	Mann, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.							Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; BATES S, 1994, ONCOGENE, V9, P71; BRIDGER JM, 1993, J CELL SCI, V104, P297; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Card GL, 2000, EMBO J, V19, P2877, DOI 10.1093/emboj/19.12.2877; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9	51	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3311	3322		10.1038/sj.onc.1204447	http://dx.doi.org/10.1038/sj.onc.1204447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423981				2022-12-28	WOS:000169248800001
J	Minamoto, T; Buschmann, T; Habelhah, H; Matusevich, E; Tahara, H; Boerresen-Dale, AL; Harris, C; Sidransky, D; Ronai, Z				Minamoto, T; Buschmann, T; Habelhah, H; Matusevich, E; Tahara, H; Boerresen-Dale, AL; Harris, C; Sidransky, D; Ronai, Z			Distinct pattern of p53 phosphorylation in human tumors	ONCOGENE			English	Article						p53; phosphorylation; human tumor; JNK; ATM; p38 Chk	DNA-DAMAGE; FUNCTION PHENOTYPE; CELL-CYCLE; IN-VITRO; KINASE; ACTIVATION; DOMAIN; BINDING; PROTEIN; MDM2	The protein product of the tumor suppressor gene p53 is phosphorylated on multiple residues by several protein kinases. Using a battery of 10 antibodies developed against different phosphorylated and acetylated residues of p53, we compared the pattern of p53 phosphorylation and acetylation in tumor-derived cell lines, tumor samples, and non-neoplastic cells. Irrespective of tumor types or the presence of p53 mutation, phosphorylation and acetylation of p53 was substantially higher in samples obtained from tumor tissues than those found in non-transformed samples. Among the 10 sites analysed, phosphorylation of residues 15, 81, 392, and acetylation were among the more frequent modifications. Analysis of two of the more abundant phosphorylation or acetylation sites on p53 is sufficient to detect 72% of tumor-derived p53 proteins. The distinct pattern of p53 phosphorylation and acetylation in human tumors may offer a new means to monitor the status and activity of p53 in the course of tumor development and progression.	Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 920, Japan; Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Hiroshima, Japan; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway; NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA	Icahn School of Medicine at Mount Sinai; Kanazawa University; Hiroshima University; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave Levy Pl,Box 1130, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400; Habelhah, Hasem/0000-0003-4097-1007	NCI NIH HHS [CA78419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Fernandez PL, 1998, J CLIN PATHOL-MOL PA, V51, P305, DOI 10.1136/mp.51.6.305; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALL PA, 1993, ONCOGENE, V8, P203; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PRICE BD, 1995, ONCOGENE, V11, P73; Prives C, 1999, J PATHOL, V187, P112; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542	35	80	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3341	3347		10.1038/sj.onc.1204458	http://dx.doi.org/10.1038/sj.onc.1204458			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423984				2022-12-28	WOS:000169248800004
J	Yin, XY; Grove, LE; Prochownik, EV				Yin, XY; Grove, LE; Prochownik, EV			Mmip-2/Rnf-17 enhances c-Myc function and regulates some target genes in common with glucocorticoid hormones	ONCOGENE			English	Article						RING finger proteins; Mad; Max; apoptosis; ornithine decarboxylase; gamma-interferon	TRANSCRIPTION FACTOR NETWORK; CELL-CYCLE PROGRESSION; RING-FINGER DOMAIN; DNA-BINDING; ONCOGENIC ACTIVITY; LEUCINE-ZIPPER; MAX; PROTEIN; GROWTH; DIFFERENTIATION	Members of the Mad family of basic-helix-loop-helix-leucine zipper proteins inhibit the transcriptional activity of the c-Myc oncoprotein. Mmip-2/Rnf-17 is a RING-finger protein that interacts with all four known Mad proteins, redistributes them to the cytoplasm, and thus enhances c-Myc function, We generated cell lines in in which Mmip-2/Rnf-17 was rendered glucocorticoid (GC)-inducible, Stable expression of Mmip-/Rnf-17 resulted in the expected transport of the most abundant endogenous mad protein, Mxi1, to the cytoplasm, Compensatory increases in Mxi1 and Mad3 transcripts, similar to those previously described in Mad1 null hematopoietic cells, genes were also seen, Mmip-2/Rnf-17 also sensitized cells to several different pro-apoptotic stimuli and regulated a subset of c-Myc target genes, Unexpectedly, some of these genes were also found to be modulated solely by GCs, Thus, the inhibition of Mad proteins by Mmip-2/Rnf-17 modulates c-Myc function by enhancing its ability to regulate a subset of its potential target genes, Our results also identify a previously unrecognized overlap between genes regulated by c-Myc- and GCs and provide a potential molecular basis for their regulation of common cellular functions. Oncogene (2001) 20, 2908-2917.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Program Mol Genet, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R33CA083219] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA83219] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; GOLDE DW, 1976, J CLIN INVEST, V57, P57, DOI 10.1172/JCI108269; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; LONGENECKER JP, 1984, J CELL BIOL, V98, P534, DOI 10.1083/jcb.98.2.534; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RHEE K, 1995, CANCER RES, V55, P4188; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SCHER W, 1978, P NATL ACAD SCI USA, V75, P3851, DOI 10.1073/pnas.75.8.3851; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THULASI R, 1993, J BIOL CHEM, V268, P18306; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	68	15	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2908	2917		10.1038/sj.onc.1204417	http://dx.doi.org/10.1038/sj.onc.1204417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420703				2022-12-28	WOS:000168901800006
J	Rincon, M; Flavell, RA; Davis, RJ				Rincon, M; Flavell, RA; Davis, RJ			Signal transduction by MAP kinases in T lymphocytes	ONCOGENE			English	Review						c-Jun; p38; ERK; JNK	ACTIVATED PROTEIN-KINASE; INTERLEUKIN-2 MESSENGER-RNA; C-JUN; NEGATIVE SELECTION; ERK ACTIVATION; CELL-ACTIVATION; PKC-THETA; P38; JNK; APOPTOSIS		Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Vermont, Dept Med, Immunobiol Program, Burlington, VT 05405 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont; Howard Hughes Medical Institute; Yale University; Yale University	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.							AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bommhardt U, 2000, J IMMUNOL, V164, P2326, DOI 10.4049/jimmunol.164.5.2326; Bommhardt U, 1999, J IMMUNOL, V163, P715; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Constant SL, 2000, J IMMUNOL, V165, P2671, DOI 10.4049/jimmunol.165.5.2671; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Conze D, 2000, MOL IMMUNOL, V37, P503, DOI 10.1016/S0161-5890(00)00078-X; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Fernandez E, 2000, BLOOD, V95, P1356, DOI 10.1182/blood.V95.4.1356.004k23_1356_1361; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lilic M, 1999, EUR J IMMUNOL, V29, P3971, DOI 10.1002/(SICI)1521-4141(199912)29:12<3971::AID-IMMU3971>3.0.CO;2-5; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mariathasan S, 2000, EUR J IMMUNOL, V30, P1060, DOI 10.1002/(SICI)1521-4141(200004)30:4<1060::AID-IMMU1060>3.0.CO;2-2; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Michie AM, 1999, J EXP MED, V190, P1647, DOI 10.1084/jem.190.11.1647; Mori A, 1999, J IMMUNOL, V163, P4763; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rincon Mercedes, 1997, Genes and Function, V1, P51; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer PH, 1999, J IMMUNOL, V162, P7110; Sen J, 1996, J IMMUNOL, V156, P4535; Sharp LL, 1999, J IMMUNOL, V163, P6598; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swat W, 1998, IMMUNITY, V8, P625, DOI 10.1016/S1074-7613(00)80567-1; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374	73	101	102	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2490	2497		10.1038/sj.onc.1204382	http://dx.doi.org/10.1038/sj.onc.1204382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402343				2022-12-28	WOS:000168568700014
J	Huang, SM; Schonthal, AH; Stallcup, MR				Huang, SM; Schonthal, AH; Stallcup, MR			Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1	ONCOGENE			English	Article						Zac1; p53; E6 protein; transcriptional coactivator; transcriptional activation	HUMAN-PAPILLOMAVIRUS TYPE-16; ZINC-FINGER PROTEIN; HUMAN BREAST-CANCER; RECEPTOR SIGNALING PATHWAYS; TUMOR-SUPPRESSOR P53; NEGATIVE REGULATOR; E6 ONCOPROTEIN; CELLS; EXPRESSION; GROWTH	A recently discovered potential tumor suppressor protein, Zac1, was previously shown to promote cell cycle arrest and apoptosis, and to act as a positive or negative transcriptional cofactor for nuclear receptors, Since these activities are common to Zac1 and p53, we tested for a functional interaction between these two proteins by investigating possible effects of Zac1 on the transcriptional activator function of p53. Zac1 specifically enhanced the activity of p53-responsive promoters in cells expressing wild type p53, The same promoters were not activated by Zac1 in cells lacking functional p53, but the Zac1 effect was restored by co-expression of p53. Zac1 bound to p53 and enhanced the activity of p53 or its N-terminal transcriptional activation domain fused to the DNA binding domain of Gal4. These results indicate that Zac1 served as a transcriptional coactivator for p53. The enhancement of p53 activity by Zac1 was much more dramatic in HeLa cells than in other cell Lines tested. HeLa cells express human papillomavirus type 18 E6 protein which inactivates and causes the degradation of p53. Physical and functional interactions observed between Zac1 and E6 protein indicated that the dramatic activity of Zac1 in HeLa cells was due not only to Zac1's coactivator effect on p53, but also to the ability of Zac1 to reverse E6 inhibition of p53.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653	NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER; NCI NIH HHS [CA74278] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTEK J, 1990, ONCOGENE, V5, P893; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASEY G, 1991, ONCOGENE, V6, P1791; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoffmann A, 1998, ANN NY ACAD SCI, V865, P49, DOI 10.1111/j.1749-6632.1998.tb11162.x; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLE JB, 1987, CANCER RES, V47, P4229; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; TAM SW, 1994, ONCOGENE, V9, P2663; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	31	88	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2134	2143		10.1038/sj.onc.1204298	http://dx.doi.org/10.1038/sj.onc.1204298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360197				2022-12-28	WOS:000168116700008
J	Annis, MG; Zamzami, N; Zhu, WJ; Penn, LZ; Kroemer, G; Leber, B; Andrews, DW				Annis, MG; Zamzami, N; Zhu, WJ; Penn, LZ; Kroemer, G; Leber, B; Andrews, DW			Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event	ONCOGENE			English	Article						apoptosis; Bax; Bcl-2; cytochrome c; endoplasmic reticulum	MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-DEATH; CASPASE ACTIVATION; FAMILY PROTEINS; RELEASE; COMPLEX; MYC; DNA; PRO-CASPASE-3; SUPPRESSION	The disruption of mitochondrial function is a key component of apoptosis in most cell types. Localization of Bcl-2 to the outer mitochondrial and endoplasmic reticulum membranes is consistent with a role in the inhibition of many forms of apoptosis, In Rat-1 cells, a Bcl-2 mutant targeted exclusively to the endoplasmic reticulum (Bcl-cb5) was effective at inhibiting apoptosis induced by serum starvation/myc, or ceramide but not apoptosis induced by etoposide, The former conditions cause a decrease in mitochondrial transmembrane potential (Delta psi (m)) as an early event that precedes the release of cytochrome c from mitochondria, By contrast, when cells are exposed to etoposide, a situation in which cytochrome c release and membrane localization of the pro-apoptotic protein Bax precede loss of Delta psi (m), wild type Bcl-2 but not Bcl-cb5 prevents apoptosis, Therefore, Bcl-2 functions in spatially distinct pathways of apoptosis distinguished by the order of cytochrome c release and loss of Delta psi (m).	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Inst Gustave Roussy, CNRS UMR1599, F-94805 Villejuif, France; McMaster Univ, Dept Med & Lab Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Toronto; UNICANCER; Gustave Roussy; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Annis, Matthew/0000-0002-8776-004X; Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480; Penn, Linda/0000-0001-8133-5459				Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOYD JM, 1995, ONCOGENE, V11, P1921; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	108	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1939	1952		10.1038/sj.onc.1204288	http://dx.doi.org/10.1038/sj.onc.1204288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360178				2022-12-28	WOS:000168043800002
J	Ruteshouser, EC; Ashworth, LK; Huff, V				Ruteshouser, EC; Ashworth, LK; Huff, V			Absence of PPP2R1A mutations in Wilms tumor	ONCOGENE			English	Article						PPP2R1A; protein phosphatase 2A; Wilms tumor; FWT2; tumor suppressor	PROTEIN PHOSPHATASE 2A; BETA-CATENIN; SUPPRESSOR LOCUS; OKADAIC ACID; PPP1R3 GENE; SUBUNIT; EXPRESSION; ANTIGEN; CANCER; AXIN	Evidence from genetic linkage analysis indicates that a gene located at 19q13.4, FWT2, is responsible for predisposition to Wilms tumor in many Wilms tumor families. This region has also been implicated in the etiology of sporadic Wilms tumor through loss of heterozygosity analyses, The PPP2R1A gene, encoding the alpha isoform of the heterotrimeric serine/threonine protein phosphatase 2A (PP2A), is located within the FWT2 candidate region and is altered in breast and lung carcinomas. PPP2R1B, encoding the beta isoform, is mutated in Lung, colon, and breast cancers. These findings suggested that both PPP2R1A and PPP2R1B may be tumor suppressor genes. Additionally, PP2A is important in fetal kidney growth and differentiation and has an expression pattern similar to that of the Wilms tumor suppressor gene WT1, Since PPP2R1A was therefore a compelling candidate for the FWT2 gene, we analysed the coding region of PPP2R1A in DNA and RNA samples from affected members of four Wilms tumor families and 30 sporadic tumors and identified no mutations in PPP2R1A in any of these 34 samples. We conclude that PPP2R1A is not the 19q familial Wilms tumor gene and that mutation of PPP2R1A is not a common event in the etiology of sporadic Wilms tumor.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, Houston, TX 77030 USA; Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Huff, V (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA78257, CA34936, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672, R01CA078257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, CANCER RES, V53, P1777; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Everett AD, 1999, J AM SOC NEPHROL, V10, P1737; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUBB GR, 1994, LAB INVEST, V71, P472; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huff V, 1997, CANCER RES, V57, P1859; HUFF V, 1990, HUM GENET, V84, P253; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Koesters R, 1999, CANCER RES, V59, P3880; Kohno T, 1999, CANCER RES, V59, P4170; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Maiti S, 2000, CANCER RES, V60, P6288; MANNENS M, 1990, CANCER RES, V50, P3279; MAW MA, 1992, CANCER RES, V52, P3094; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; McDonald JM, 1998, CANCER RES, V58, P1387; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SVENNILSON J, 1995, KIDNEY INT, V48, P103, DOI 10.1038/ki.1995.273; Takakura S, 2000, ONCOGENE, V19, P836, DOI 10.1038/sj.onc.1203388; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	42	8	8	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2050	2054		10.1038/sj.onc.1204301	http://dx.doi.org/10.1038/sj.onc.1204301			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360189				2022-12-28	WOS:000168043800013
J	Brodie, SG; Xu, XL; Li, CL; Kuo, A; Leder, P; Deng, CX				Brodie, SG; Xu, XL; Li, CL; Kuo, A; Leder, P; Deng, CX			Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis	ONCOGENE			English	Article						p53; erbB2; cyclin D1; tumorigenesis; cooperation; parotid gland	TRANSGENIC MICE; BREAST-CANCER; CELL-CYCLE; CARCINOMAS; AMPLIFICATION; EXPRESSION; NEOPLASMS; HER-2/NEU; DEATH; D1	Transgenic mice expressing specific oncogenes usually develop tumors in a stochastic fashion suggesting that tumor progression is a multi-step process. To gain further understanding of the interactions between oncogenes and tumor suppressor genes during tumorigenesis, we have crossed a transgenic strain (TG,NK) carrying an activated c-neu oncogene driven by the MMTV enhancer/promoter with p53-deficient mice. c-neu transgenic mice have stochastic breast tumor formation and normal appearing salivary glands. However, c-neu mice heterozygous for a p53 deletion develop parotid gland tumors and loose their wild type p53 allele, c-neu mice with a homozygous p53 deletion have increased rates of parotid tumor onset suggesting that inactivation of p53 is required and sufficient for parotid gland transformation in the presence of activated c-neu. In contrast to the dramatic effect of p53 in parotid gland transformation, p53 loss has little effect on the rate or stochastic appearance of mammary tumors. In addition, p53 loss was accompanied by the down regulation of p21 in parotid gland tumors but not breast tumors, The parotid gland tumors were aneuploid and demonstrated increased levels of Cyclin D1 expression. These observations suggest that in c-neu transgenic mice, p53 alterations have differential tissue effects and may be influenced by the tissue specific expression of genes influencing p53 activity.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Califano J, 1999, OTOLARYNG CLIN N AM, V32, P861, DOI 10.1016/S0030-6665(05)70178-X; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSON A, 1995, ONCOGENE, V11, P181; EVANS E P, 1987, P93; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Hand AR, 1999, ARCH ORAL BIOL, V44, pS3, DOI 10.1016/S0003-9969(99)00042-4; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Hynes NE, 1996, J MAMMARY GLAND BIOL, V1, P199, DOI 10.1007/BF02013643; Isola J, 1999, CLIN CANCER RES, V5, P4140; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez RE, 2000, MODERN PATHOL, V13, P37, DOI 10.1038/modpathol.3880007; Kamio N, 1996, VIRCHOWS ARCH, V428, P75; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1997, CANCER RES, V57, P1171; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MULLER S, 1994, MODERN PATHOL, V7, P628; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OSWALD F, 1994, ONCOGENE, V9, P2029; Pignataro L, 1998, ANTICANCER RES, V18, P1287; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRESS MF, 1994, CANCER RES, V54, P5675; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Rice DH, 1999, OTOLARYNG CLIN N AM, V32, P875, DOI 10.1016/S0030-6665(05)70179-1; Samuelson LC, 1996, ANNU REV PHYSIOL, V58, P209, DOI 10.1146/annurev.physiol.58.1.209; SCHULZE A, 1994, ONCOGENE, V9, P3475; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; Tonin PN, 2000, SEMIN SURG ONCOL, V18, P281, DOI 10.1002/(SICI)1098-2388(200006)18:4<281::AID-SSU2>3.0.CO;2-Q; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P	57	23	23	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1445	1454		10.1038/sj.onc.1204222	http://dx.doi.org/10.1038/sj.onc.1204222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313888				2022-12-28	WOS:000167595200005
J	Huang, YP; Ohtani, K; Iwanaga, R; Matsumura, Y; Nakamura, M				Huang, YP; Ohtani, K; Iwanaga, R; Matsumura, Y; Nakamura, M			Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I	ONCOGENE			English	Article						cell cycle; CREB; HTLV-I; NF-kappa B; tax; cyclin D2	EXPRESSION; PROTEIN; E2F; CANCER; LINES; ESTABLISHMENT; TRANSCRIPTION; ACCUMULATION; LYMPHOCYTES; PROGRESSION	Cyclins are one of the pivotal determinants regulating cell cycle progression. We previously reported that the trans-activator Tax of human T-cell leukemia virus type I(HTLV-I) induces endogenous cyclin D2 expression along with cell cycle progression in a resting human T-cell line, Kit 225, suggesting a role of cyclin D2 in Tax-mediated cell cycle progression, The cyclin D2 gene has a typical E2F binding element, raising the possibility that induction of cyclin D2 expression is a consequence of cell cycle progression. In this study, we examined the role and molecular mechanism of induction of the endogenous human cyclin D2 gene by Tax. Introduction of p19(INK4d), a cyclin dependent kinase (CDK) inhibitor of the INK4 family specific for D-type CDK, inhibited Tax-mediated activation of E2F, indicating requirement of D-type CDK in Tax-mediated activation of E2F, Previously indicated E2F binding element and, two NF-kappaB-like binding elements in the 1.6 kbp cyclin D2 promoter fragment had little, if any, effect on responsiveness to Tax, We found that trans-activation of the cyclin D2 promoter by Tax was mainly mediated by a newly identified NF-kappaB-like element with auxiliary contribution of a CRE-like element residing in sequences downstream of -444 which were by themselves sufficient for transactivation by Tax. These results indicate that Tax directly trans-activates the cyclin D2 gene, resulting in growth promotion and perhaps leukemogenesis through activation of D-type CDK.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HORI T, 1987, BLOOD, V70, P1069; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takano Y, 1999, J PATHOL, V189, P194; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	31	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1094	1102		10.1038/sj.onc.1204198	http://dx.doi.org/10.1038/sj.onc.1204198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314046	Bronze			2022-12-28	WOS:000167232100009
J	Kokontis, JM; Wagner, AJ; O'Leary, M; Liao, S; Hay, N				Kokontis, JM; Wagner, AJ; O'Leary, M; Liao, S; Hay, N			A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function	ONCOGENE			English	Article						p53; apoptosis; transactivation; transrepression; cell cycle arrest	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; MYC-MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; EXPRESSION; GROWTH; BCL-2; IDENTIFICATION; REPRESSION	The tumor suppressor p53 is an inducer of cell cycle arrest and programmed cell death (apoptosis), The ability of p53 to induce cell cycle arrest is linked to its ability to induce transcription of genes such as the cyclin-dependent kinase inhibitor p21, However, the dependence of p53-mediated apoptosis on transcriptional activation remains control versial. Ectopic expression of a temperature-sensitive (ts) p53 allele induced expression of p53 target genes and elicited both G1 and G2/M cell cycle arrest upon shift to the permissive temperature. Ectopic expression of the same ts p53 allele with two additional point mutations (Gln22, Ser23) that abolish p53-transcriptional activation did not induce p53 target genes and G1 nor G2/M cell cycle arrest. In HCT116 colon carcinoma cells ectopic expression of wild type p53 does not elicit apoptosis whereas p53 mutant deficient in trans-activation induces apoptosis, The ability of wild type p53 to induce apoptosis is restored in HCT116 cells that are null for p21, However, the trans-activation deficient mutant of p53 is still more potent mediator of apoptosis than wild type p53 in the p21 null cells. Although the ability of Gln22,Ser23 to trans-activate p53 target genes is diminished, it retains the ability to repress Bcl-2 expression. Thus, we conclude that while ectopic expression of wild type p53 can induce both G1 and G2/M;I arrest, in a p21 dependent manner, without apoptosis, a p53 mutant defective in transactivation elicits apoptosis without inducing cell cycle arrest. Further, the anti-apoptotic function of p53 is dependent on trans-activation and is linked to cell cycle arrest. The results strongly suggest that the transactivation deficient mutant is a more potent inducer of apoptosis because it lost its anti-apoptotic function and retains its ability to repress pro-apoptotic genes such as Bcl-2, Taken together, the results imply that employing a trans-activation deficient p53 in gene therapy approaches or the use of drugs that convert mutant p53 to a transactivation-independent mediator of apoptosis may be much more efficient therapeutic approaches than current approaches that employ wild type p53.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Hay, N (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA058073, U24CA078174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78174, CA-58073] Funding Source: Medline; NIA NIH HHS [AG-16927] Funding Source: Medline; NIDDK NIH HHS [DK-41670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANNON JV, 1990, EMBO J, V9, P1595; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TA, 2000, GENE DEV, V14, P1584; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Harn HJ, 1996, HISTOPATHOLOGY, V28, P317, DOI 10.1046/j.1365-2559.1996.d01-431.x; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; ISAACS WB, 1991, CANCER RES, V51, P4716; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	40	71	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					659	668		10.1038/sj.onc.1204139	http://dx.doi.org/10.1038/sj.onc.1204139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11313999				2022-12-28	WOS:000166806000001
J	Blyth, K; Terry, A; Mackay, N; Vaillant, F; Bell, M; Cameron, ER; Neil, JC; Stewart, M				Blyth, K; Terry, A; Mackay, N; Vaillant, F; Bell, M; Cameron, ER; Neil, JC; Stewart, M			Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging	ONCOGENE			English	Article						Runx2; Cbfa1; Myc; oncogene collaboration; retroviral tagging; runt domain	MURINE LEUKEMIA-VIRUS; PROVIRAL INSERTION SITE; T-CELL LYMPHOMAGENESIS; PIM-1 TRANSGENIC MICE; ZINC-FINGER PROTEIN; C-MYC; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; P53-DEFICIENT MICE; NERVOUS-SYSTEM	The Runx2 (Cbfa1, Pebp2 alphaA, Aml3) gene was previously identified as a frequent target for transcriptional activation by proviral insertion in T-cell lymphomas of CD2-MYC transgenic mice. We have recently shown that over-expression of the full-length, most highly expressed Runx2 isoform in the thymus perturbs T-cell development, leads to development of spontaneous lymphomas at low frequency and is strongly synergistic with MSc. To gain further insight into the relationship of Runx2 to other lymphomagenic pathways, me tested the effect of combining the CD2-Runx2 transgene either with a Pim1 transgene (E mu -Pim1) or with the p53 null genotype, as each of these displays independent synergy with Myc, In both cases we observed synergistic tumour development. However, Runx2 appeared to have a dominant effect on the tumour phenotype in each case, with most tumours conforming to the CD3(+), CD8(+), CD4(+/-) phenotype seen in CD2-Runx2 mice, Neonatal infection of CD2-Runx2 mice with Moloney murine leukaemia virus (Moloney MLV) also led to a dramatic acceleration of tumour onset. Analysis of known Moloney MLV target genes in these lymphomas showed a high frequency of rearrangement at c-Myc or N-Myc (82%), and a significant number at Pim1 or Pim2 (23%), and at Pal1/Gfi1 (18%), These results indicate that Runx2 makes a distinct contribution to T-cell lymphoma development which does not coincide with any of the oncogene complementation groups previously identified by retroviral tagging.	Univ Glasgow, Sch Vet, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Stewart, M (corresponding author), Univ Glasgow, Sch Vet, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Baxter EW, 1996, J VIROL, V70, P2095, DOI 10.1128/JVI.70.4.2095-2100.1996; Berns A, 1999, CANCER RES, V59, p1773S; BLYTH K, 1995, ONCOGENE, V10, P1717; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; BLYTH K, 1996, THESIS U GLASGOW VET; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; CUYPERS HT, 1984, CELL, V37, P141; DEPINHO R, 1999, ONCOGENE REV MOUSE M, pRG21; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAZO PA, 1990, J VIROL, V64, P3948, DOI 10.1128/JVI.64.8.3948-3959.1990; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LILLY M, 1997, CANCER RES, V57, P5248; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Meyers S, 1996, ONCOGENE, V13, P303; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; STEWART M, 1993, INT J CANCER, V53, P1023; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VIJAYA S, 1987, J VIROL, V61, P1164, DOI 10.1128/JVI.61.4.1164-1170.1987; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	50	89	90	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					295	302		10.1038/sj.onc.1204090	http://dx.doi.org/10.1038/sj.onc.1204090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313958				2022-12-28	WOS:000166411000003
J	Gual, P; Giordano, S; Anguissola, S; Parker, PJ; Comoglio, PM				Gual, P; Giordano, S; Anguissola, S; Parker, PJ; Comoglio, PM			Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling	ONCOGENE			English	Article						HGF; Gab1; Ser/Thr phosphorylation; negative regulation; invasive growth; PKC	HEPATOCYTE GROWTH-FACTOR; PROTEIN-KINASE-C; FACTOR SCATTER FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; INSULIN-RECEPTOR; DOCKING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; EPITHELIAL MORPHOGENESIS; MET RECEPTOR	Signal transduction by HGF receptor, the tyrosine kinase encoded by the MET oncogene, switches on a genetic program called 'invasive growth' inducing epithelial cell dissociation, migration, growth? and ultimately leading to differentiation into branched tubular structures. Sustained tyrosine phosphorylation of the downstream adaptor protein Gab1 is required for the HGF response, Here we show that serine/threonine phosphorylation of Gab1 provides a control mechanism for negative regulation. Treatment,vith okadaic acid, a potent inhibitor of the serine/threonine protein phosphatases PP1 and PP2A, was followed by activation of a number of serine/threonine kinases, hyper-phosphorylation in serine and threonine of Gab1 and se, ere inhibition of the HGF-induced biological responses, Under these conditions, Gab1 nas found to be concomitantly hypophosphorylated in tyrosine, and thus endowed with reduced ability to recruit SH2 containing signal transducers such as PI3 kinase. Among the serine-threonine kinases activated bg PP1 and PP2A inhibition, we found that PKC-alpha and PKC-beta1 are required for negative regulation of Gab1, These data pro,ide a novel negative mechanism for the HGF receptor signaling pathways and highlight a potentially useful target for inhibitors of invasive growth.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Cancer Research UK	Gual, P (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Gual, Philippe/P-9833-2019; Giordano, Silvia/J-9858-2018; Parker, Peter j/D-5192-2013; Comoglio, Paolo/G-6323-2011	Gual, Philippe/0000-0001-7393-8356; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; parker, peter/0000-0002-6218-2933				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, CIBA F SYMP, V212, P133; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BARON V, 1992, J BIOL CHEM, V267, P23290; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; CHIN JE, 1993, J BIOL CHEM, V268, P6338; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUAL P, 1995, ENDOCRINOLOGY, V136, P5298, DOI 10.1210/en.136.12.5298; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Machide M, 1998, J NEUROCHEM, V71, P592; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Taylor BK, 2000, AM J PHYSIOL-LUNG C, V278, pL1062, DOI 10.1152/ajplung.2000.278.5.L1062; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	72	36	36	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					156	166		10.1038/sj.onc.1204047	http://dx.doi.org/10.1038/sj.onc.1204047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313945				2022-12-28	WOS:000166410900003
J	Chapman, RS; Duff, EK; Lourenco, PC; Tonner, E; Flint, DJ; Clarke, AR; Watson, CJ				Chapman, RS; Duff, EK; Lourenco, PC; Tonner, E; Flint, DJ; Clarke, AR; Watson, CJ			A novel role for IRF-1 as a suppressor of apoptosis	ONCOGENE			English	Article						IRF-1; apoptosis; mammary gland; involution	MAMMARY-GLAND INVOLUTION; TRANSCRIPTION FACTOR IRF-1; CELL-DEATH; MICE; ACTIVATION; PATHWAYS; PROTEINS; BINDING; TISSUE	The tumour suppressor IRF-1 is a transcription factor involved in the induction of apoptosis in several in vitro systems, Post-lactational involution of the mammary gland is characterized by extensive apoptosis of the epithelial cells, We have previously shown that signal transducer and activator of transcription (Stat) 3 drives apoptosis and involution in the mouse mammary gland, Since one of the downstream targets of the Stat signalling pathway is IRF-1, we have used IRF-1 knockout mice to address the potential role of this transcription factor in involution, Surprisingly, in the absence of IRF-1 significantly higher numbers of apoptotic cells were found in involuting glands at 48 h compared to control glands, In addition, the alveolar structure in IRF-1 null mammary glands had collapsed whereas in control glands the alveoli remained intact and distended. However, by 72 h control and null glands were morphologically similar suggesting that IRF-1 suppresses apoptosis only during the early, reversible, stage of involution, This suggests a survival role for IRF-1 in mammary epithelia and demonstrates a novel role for IRF-1 in vivo - suppression of premature epithelial apoptosis during mammary gland involution.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Edinburgh, Sch Med, Dept Pathol, Canc Res Campaign Labs, Edinburgh EH8 9AG, Midlothian, Scotland; Hannah Res Inst, Ayr KA6 5HL, Scotland; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Cambridge; University of Edinburgh; Cardiff University	Watson, CJ (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.		clarke, alan r/P-2820-2014; watson, Christine J/B-1431-2012; Clarke, Alan R/A-6256-2008	Chapman, Rachel/0000-0001-5786-1918; Clarke, Alan/0000-0002-4281-426X				Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Lund LR, 1996, DEVELOPMENT, V122, P181; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Meraro D, 1999, J IMMUNOL, V163, P6468; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; STRANGE R, 1992, DEVELOPMENT, V115, P49; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657	25	36	39	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6386	6391		10.1038/sj.onc.1204016	http://dx.doi.org/10.1038/sj.onc.1204016			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175354				2022-12-28	WOS:000166210500023
J	Mahyar-Roemer, M; Roemer, K				Mahyar-Roemer, M; Roemer, K			p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents	ONCOGENE			English	Article						p21; p53; colon cancer; butyrate; chemotherapy	CHAIN FATTY-ACIDS; NITRIC-OXIDE SYNTHASE; DIETARY FIBER; CYCLE ARREST; CANCER-CELLS; P53; BUTYRATE; GROWTH; P21(WAF1/CIP1); DEATH	The molecular basis for the sensitivity of tumor cells to chemopreventive natural food compounds and commonly used chemotherapeutic agents is not well understood, not least because studies are frequently confounded by the diversity among cell lines or rely on experimental protein overexpression. Here we investigated the effects of n-butyrate, a cancer-preventive short-chain fatty acid produced by anaerobic bacteria in the gastrointestinal tract, on the human wild-type p53 and p21 expressing HCT116 colon carcinoma cell line and on HCT116 cells with either p53 or p21 alleles inactivated by homologous recombination. The effects of n-butyrate were then compared with those elicited by cytotoxic drugs and the natural chemopreventive phytoalexin of wine and grapes, resveratrol. We document that physiological concentrations of n-butyrate stimulate p21 expression and induce apoptosis independently of p53, and that the absence of p21 increases apoptosis drastically. The apoptosis is mediated through the mitochondria and is accompanied by mitochondrial proliferation and membrane potential changes. Adriamycin, etoposide, cisplatinum, colcemid and resveratrol induce distinct cellular responses; however, absence of p21 favors apoptosis-induction by adriamycin, etoposide and colcemid. Thus, control of p21 expression may support chemoprevention and certain tumor therapies.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.							Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Attardi LD, 2000, GENE DEV, V14, P704; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; BARNES PJ, 1994, CL ALLER IM, V4, P501; Barshishat M, 2000, BRIT J CANCER, V82, P195; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BOFFA LC, 1992, CANCER RES, V52, P5906; Brown JM, 1999, CANCER RES, V59, P1391; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; CUPLER EJ, 1995, ACTA NEUROPATHOL, V90, P1; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEERDT BG, 1994, CANCER RES, V54, P3288; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; MIYASHITA T, 1995, CELL, V80, P293; Mortensen K, 1999, J BIOL CHEM, V274, P37679, DOI 10.1074/jbc.274.53.37679; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; REIPERT S, 1995, EXP CELL RES, V221, P281, DOI 10.1006/excr.1995.1376; SCHWARTZ B, 1992, INT J CANCER, V52, P60, DOI 10.1002/ijc.2910520113; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tian H, 2000, CANCER RES, V60, P679; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang H, 1999, J CELL PHYSIOL, V178, P173, DOI 10.1002/(SICI)1097-4652(199902)178:2<173::AID-JCP6>3.3.CO;2-H; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	57	155	161	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3387	3398		10.1038/sj.onc.1204440	http://dx.doi.org/10.1038/sj.onc.1204440			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423989				2022-12-28	WOS:000169248800009
J	Grange, T; Cappabianca, L; Flavin, M; Sassi, H; Thomassin, H				Grange, T; Cappabianca, L; Flavin, M; Sassi, H; Thomassin, H			In vivo analysis of the model tyrosine aminotransferase gene reveals multiple sequential steps in glucocorticoid receptor action	ONCOGENE			English	Review						chromatin; DNA methylation; transcription; liver nuclear receptor	TRANSCRIPTION FACTORS; DNA DEMETHYLATION; RESPONSE ELEMENT; GLYCOSYLASE ACTIVITY; CHROMATIN STRUCTURE; DEPENDENT ENHANCER; STEROID-RECEPTORS; HORMONE-RECEPTOR; NUCLEAR FACTOR; MMTV PROMOTER	We are studying the mechanisms of transcriptional activation by nuclear receptors and we focus our studies on the glucocorticoid regulation of the model tyrosine aminotransferase gene. Rather than using in vitro biochemical approaches, we determine the actual events occurring in the cells, Our experimental approaches include genomic footprinting, chromatin immunoprecipitation, in situ hybridization and transgenic mice. Our results show that the glucocorticoid receptor uses a dynamic multistep mechanism to recruit successively accessory DNA binding proteins that assist in the activation process. Chromatin is first remodelled, DNA is then demethylated, and the synthesis of an accessory factor is induced, Efficient transcription induction is finally achieved upon the formation of a 'stable' multiprotein complex interacting with the regulatory element. We discuss: the relative contribution of histone acetyltransferases and ATP-dependent remodelling machines to the chromatin remodelling event; the nature of the remodelled state; the contribution of regulated DNA demethylation to gene memory during development; the mechanisms of regulated DNA demethylation; the dynamics of protein recruitment at regulatory elements; tbe control of the frequency of transcription pulses and the control levels of the cell-type specificity of the glucocorticoid response.	Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Grange, T (corresponding author), Univ Paris 06, CNRS, Inst Jacques Monod, Tour 43,2 Pl Jussieu, F-75251 Paris 05, France.			cappabianca, lucia/0000-0002-9112-1750; Grange, Thierry/0000-0001-8700-3092; THOMASSIN, Helene/0000-0003-4613-5587				ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BEERMANN F, 1993, MECH DEVELOP, V42, P59, DOI 10.1016/0925-4773(93)90098-I; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen YH, 2000, J BIOL CHEM, V275, P27366; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; ESPINAS ML, 1995, MOL CELL BIOL, V15, P5346; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Glass CK, 2000, GENE DEV, V14, P121; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRANNER DK, 1983, MOL CELL BIOCHEM, V53-4, P113; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Jost J. P., 1996, Epigenetic mechanisms of gene regulation., P109; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LIN ECC, 1957, BIOCHIM BIOPHYS ACTA, V26, P85, DOI 10.1016/0006-3002(57)90057-4; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Newlands S, 1998, GENE DEV, V12, P2748, DOI 10.1101/gad.12.17.2748; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; Sassi H, 1998, P NATL ACAD SCI USA, V95, P5621, DOI 10.1073/pnas.95.10.5621; SASSI H, 1995, P NATL ACAD SCI USA, V92, P7197, DOI 10.1073/pnas.92.16.7197; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHUTZ G, 1986, ANN NY ACAD, V478, P93; Schwarz S, 1997, NUCLEIC ACIDS RES, V25, P5052, DOI 10.1093/nar/25.24.5052; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Swisher JFA, 1998, NUCLEIC ACIDS RES, V26, P5573, DOI 10.1093/nar/26.24.5573; THOMASSIN H, 2001, IN PRESS EMBO J; Tomkins G M, 1971, Adv Cell Biol, V2, P299; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163; Wolffe AP, 1999, P NATL ACAD SCI USA, V96, P5894, DOI 10.1073/pnas.96.11.5894; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157; Zhu B, 2000, P NATL ACAD SCI USA, V97, P5135, DOI 10.1073/pnas.100107597	65	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3028	3038		10.1038/sj.onc.1204327	http://dx.doi.org/10.1038/sj.onc.1204327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420718				2022-12-28	WOS:000169308500006
J	Manos, EJ; Kim, MLH; Kassis, J; Chang, PY; Wells, A; Jones, DA				Manos, EJ; Kim, MLH; Kassis, J; Chang, PY; Wells, A; Jones, DA			Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion	ONCOGENE			English	Article						prostate; invasion; metastasis; phospholipase; EGF receptor; microarray	EPIDERMAL GROWTH-FACTOR; IN-VITRO INVASIVENESS; EGF RECEPTOR; PLASMINOGEN-ACTIVATOR; FIBROBLAST MIGRATION; CARCINOMA-CELLS; CANCER-CELLS; EXPRESSION; MOTILITY; KINASE	The most ominous development in tumor progression is the transition to an invasive and metastatic phenotype, Little is known, however, about the molecular alterations that cause a tumor to become invasive, in view of this, we have used microarray expression analysis to evaluate the expression profiles of a unique panel of human DU145 prostate cancer sublines that vary in their invasive potential, The three DU145 sublines expressed epidermal growth factor (EGF) receptors that differed in their ability to activate phospholipase C-gamma (PLC gamma). Three-way analyses yielded 11 genes out of 4608 genes screened that associated directly or inversely with invasive potential, The gene whose expression correlated most strongly with lack of invasion was identified as a potential invasion suppressor and called prostin-1. Pharmacological inhibition of PLC gamma (U73122) confirmed that PLC gamma, signaling suppressed prostin-1 in that U73122 treatment caused induction of prostin-1 in PLC gamma, competent cells, The prostin-l gene, conserved through phylogeny, is induced by androgen in LNCaP cells acid encodes a 92 amino acid protein, The protein shares no extensive homologies with other known genes, yet was recently identified as a small stabilizer subunit of the dolichol-phosphate-mannose (DPM) synthase complex, That DPM3/prostin-1 might suppress tumor progression was supported by the finding that exogenous expression in COS cells leads to apoptosis, These findings support the use of model cell lines to identify putative tumor suppressors and promoters.	Univ Utah, Huntsman Canc Inst, Div Mol Pharmacol, Salt Lake City, UT 84112 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Pittsburgh VAMC, Pittsburgh, PA 15260 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, Div Mol Pharmacol, 2000 Circle Hope,Rm 5242, Salt Lake City, UT 84112 USA.			Wells, Alan/0000-0002-1637-8150				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Barrack ER, 1997, PROSTATE, V31, P61; BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GORDON SR, 1990, CELL MOTIL CYTOSKEL, V16, P47, DOI 10.1002/cm.970160107; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jacobs W, 1997, J NEURO-ONCOL, V32, P93, DOI 10.1023/A:1005777711567; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; KINDRA V, 1994, ONCOGENE, V9, P1429; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lal A, 1999, CANCER RES, V59, P5403; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Maheshwari G, 1999, BIOPHYS J, V76, P2814, DOI 10.1016/S0006-3495(99)77435-7; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; MOUL JW, 1996, FED PRACT, V13, P3; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Reuning U, 1998, INT J ONCOL, V13, P893; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmitt M, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P151; SHULTZ MJ, 1996, FED PRACT, V13, P14; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Turner T, 1997, CLIN CANCER RES, V3, P2275; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Ware MF, 1998, J CELL SCI, V111, P2423; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITTEMORE AS, 1991, J NATL CANCER I, V83, P1231, DOI 10.1093/jnci/83.17.1231; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; XIE H, 1995, CLIN EXP METASTAS, V13, P407, DOI 10.1007/BF00118180; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	47	24	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2781	2790		10.1038/sj.onc.1204379	http://dx.doi.org/10.1038/sj.onc.1204379			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420690				2022-12-28	WOS:000168712000006
J	Weggen, S; Preuss, U; Pietsch, T; Hilger, N; Klawitz, I; Scheidtmann, KH; Wiestler, OD; Bayer, TA				Weggen, S; Preuss, U; Pietsch, T; Hilger, N; Klawitz, I; Scheidtmann, KH; Wiestler, OD; Bayer, TA			Identification of amplified genes from SV40 large T antigen-induced rat PNET cell lines by subtractive cDNA analysis and radiation hybrid mapping	ONCOGENE			English	Article						SV40 large T antigen; amplification; suppression subtractive hybridization; radiation hybrid mapping; cytosolic branched chain aminotransferase	PRIMITIVE NEUROECTODERMAL TUMORS; C-MYC; BINDING; IMMORTALIZATION; TUMORIGENESIS; EXPRESSION; MODELS; MAPS; UNR	Primitive neuroectodermal tumors (PNETs) such as human medulloblastomas are genetically heterogeneous and therefore poorly understood, In a rat model the SV40 large T antigen was used to induce neoplasms with characteristic features of PNETs, Tumor development requires a latency period of 8-11 months implicating secondary genetic alterations. To identify such secondary alterations we performed comparative analyses of two phenotypically identical PNET-derived eel lines. Indeed, these cell Lines displayed distinct high-level amplification sites. Using a combination of subtractive cDNA analysis and radiation hybrid mapping we have now identified genes in the amplicon regions of the two cell lines. Interestingly, one of these genes encodes the rat homolog of a cytosolic branched chain aminotransferase (BCAT(C)) previously shown to be amplified in a mouse teratocarcinoma cell line. We propose that this simple cloning strategy may serve as a powerful tool for the isolation of genes implicated in known chromosomal aberrations in primary tumors and tumor cell lines.	Univ Bonn, Genet Inst, D-53117 Bonn, Germany; Univ Bonn, Inst Psychol, D-53117 Bonn, Germany; Univ Bonn, Med Ctr, Dept Psychiat, D-53105 Bonn, Germany; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn; University of Bonn	Preuss, U (corresponding author), Univ Bonn, Genet Inst, Roemerstr 164, D-53117 Bonn, Germany.							Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bayer TA, 1999, ACTA NEUROPATHOL, V97, P607, DOI 10.1007/s004010051036; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BenYosef T, 1996, ONCOGENE, V13, P1859; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DESTOPPELAAR JM, 1994, CYTOGENET CELL GENET, V67, P23, DOI 10.1159/000133718; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; EIBL RH, 1994, AM J PATHOL, V144, P556; Ferrer N, 1999, DNA CELL BIOL, V18, P209, DOI 10.1089/104454999315420; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Furth PA, 1998, DEV BIOL STAND, V94, P281; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HALL TR, 1993, J BIOL CHEM, V268, P3092; HELD WA, 1994, CANCER RES, V54, P6489; HELD WA, 1994, CANCER RES, V54, P6496; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; Kappler R, 1999, CARCINOGENESIS, V20, P1433, DOI 10.1093/carcin/20.8.1433; Kholodilov NG, 2000, MOL BRAIN RES, V75, P281, DOI 10.1016/S0169-328X(99)00318-6; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; MORIYAMA T, 1994, FEBS LETT, V353, P305, DOI 10.1016/0014-5793(94)01064-1; NIWA O, 1990, NUCLEIC ACIDS RES, V18, P6709, DOI 10.1093/nar/18.22.6709; Salewski H, 1999, CANCER RES, V59, P1980; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sargent LM, 1997, CANCER RES, V57, P3451; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Steen RG, 1999, GENOME RES, V9, pAP1; Weggen S, 1997, BRAIN PATHOL, V7, P731, DOI 10.1111/j.1750-3639.1997.tb01059.x	33	9	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2023	2031		10.1038/sj.onc.1204287	http://dx.doi.org/10.1038/sj.onc.1204287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360186				2022-12-28	WOS:000168043800010
J	Gschwind, A; Zwick, E; Prenzel, N; Leserer, M; Ullrich, A				Gschwind, A; Zwick, E; Prenzel, N; Leserer, M; Ullrich, A			Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission	ONCOGENE			English	Article						EGFR; GPCR; transactivation; cross-talk; ectodomain shedding; ADAMs	ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; NECROSIS-FACTOR-ALPHA; BETA-GAMMA-SUBUNITS; EGF-RECEPTOR; ANGIOTENSIN-II; LYSOPHOSPHATIDIC ACID; COUPLED RECEPTORS; REGULATED KINASE	Communication between different cellular signaling systems has emerged as a common principle that enables cells to integrate a multitude of signals from its environment. Transactivation of the epidermal growth factor receptor (EGFR) represents the paradigm for cross-talk between G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs), The recent identification of Zn2+-dependent metalloproteinases and transmembrane growth factor precursors as critical elements in GPCR-induced EGFR transactivation pathways has defined new components of a cellular communication network of rapidly increasing complexity. Further elucidation of the molecular details of the EGFR transactivation mechanism will provide new understanding of its relevance for normal physiological processes and their pathophysiological deviations.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.							Adomeit A, 1999, MOL CELL BIOL, V19, P5289; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 2000, SCI STKE        0118; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FAURE M, 1994, J BIOL CHEM, V269, P7851; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KING CR, 1989, ONCOGENE, V4, P13; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Leserer M, 2000, IUBMB LIFE, V49, P405; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; RAO GN, 1995, J BIOL CHEM, V270, P2781; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Slack BE, 2000, BIOCHEM J, V348, P381, DOI 10.1042/0264-6021:3480381; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Tang H, 2000, J BIOL CHEM, V275, P13420, DOI 10.1074/jbc.275.18.13420; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	57	385	396	0	21	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1594	1600		10.1038/sj.onc.1204192	http://dx.doi.org/10.1038/sj.onc.1204192			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313906				2022-12-28	WOS:000168089800009
J	Kranenburg, O; Moolenaar, WH				Kranenburg, O; Moolenaar, WH			Res-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists	ONCOGENE			English	Article						lysophosphatidic acid; sphingosine-1-phosphate; G protein coupled receptors; Ras; Rho; MAP kinase	FACTOR RAS-GRF; EPIDERMAL GROWTH-FACTOR; CELL-CYCLE PROGRESSION; TYROSINE KINASE; EXCHANGE FACTOR; PLASMA-MEMBRANE; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE-3 KINASE; MEDIATED ENDOCYTOSIS	Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are extracellular lipid mediators that signal through distinct members of the Edg/LP subfamily of G protein-coupled receptors (GPCRs), LPA and S1P receptors are expressed in almost every cell type and can couple to multiple G proteins (G(i), G(q) and G(12/13)) to mediate a great variety of responses, ranging from rapid morphological changes to long-term stimulation of cell proliferation. LPA serves as the prototypic GPCR agonist that activates the small GTPases Pas (via G(i)) and RhoA (via G(12/13)), leading to activation of the mitogen-activated protein kinase (MAPK) cascade and reorganization of the actin cytoskeleton, respectively. This review focuses on our current insights into how Ras-MAPK signaling is regulated by GPCR agonists in general, and by LPA in particular.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Alblas J, 1996, EMBO J, V15, P3351, DOI 10.1002/j.1460-2075.1996.tb00700.x; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANDREEV J, 2001, IN PRESS J BIOL CHEM; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Chun J, 1999, CRIT REV NEUROBIOL, V13, P151, DOI 10.1615/CritRevNeurobiol.v13.i2.20; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mattingly RR, 1999, CELL SIGNAL, V11, P603, DOI 10.1016/S0898-6568(99)00034-0; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Razani B, 2000, J CELL SCI, V113, P2103; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAN BT, 1995, NATURE, V376, P781; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xu Y, 1995, CLIN CANCER RES, V1, P1223; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Yuryev A, 1998, Cell Res, V8, P81; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	96	138	142	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1540	1546		10.1038/sj.onc.1204187	http://dx.doi.org/10.1038/sj.onc.1204187			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313900				2022-12-28	WOS:000168089800003
J	Acquaviva, C; Salvat, C; Brockly, F; Bossis, G; Ferrara, P; Piechaczyk, M; Jariel-Encontre, I				Acquaviva, C; Salvat, C; Brockly, F; Bossis, G; Ferrara, P; Piechaczyk, M; Jariel-Encontre, I			Cellular and viral Fos proteins are degraded by different proteolytic systems	ONCOGENE			English	Article						c-Fos; v-Fos; proteasome; protein degradation	OSTEO-SARCOMA VIRUS; DEGRADATION IN-VIVO; FBR V-FOS; C-FOS; TRANSCRIPTION FACTORS; TRANSGENIC MICE; FAMILY MEMBERS; ACTIVE SRC; PROTEASOME; JUN	c-Fos proto-oncoprotein is a short-lived transcription factor degraded by the proteasome in vivo. Its mutated forms expressed by the mouse osteosarcomatogenic retroviruses, FBJ-MSV and FBR-MSV, are stabilized two- and threefold, respectively, To elucidate the mechanisms underlying v-Fos(FBJ) and v-Fos(FBR) protein stabilization, we conducted a genetic analysis in which the half-lives and the sensitivities to various cell-permeable protease inhibitors of a variety of cellular and viral protein mutants were measured. Our data showed that the decreased degradation of v-Fos(FBJ) and v-FOSFBR is not simply explained by the deletion of a c-Fos destabilizing C-terminal domain. Rather, it involves a complex balance between opposing destabilizing and stabilizing mutations which are distinct and which include virally-introduced peptide motifs in both cases. The mutations in viral Fos proteins conferred both total insensitivity to proteasomal degradation and sensitivity to another proteolytic system not naturally operating on c-Fos, explaining the limited stabilization of the two proteins. This observation is consistent with the idea that FBR-MSV and FBJ-MSV expression machineries have evolved to ensure controlled protein levels. Importantly, our data illustrate that the degradation of unstable proteins does not necessarily involve the proteasome and provide support to the notion that highly related proteins can be broken down by different proteolytic systems in living cells.	Inst Genet Mol, CNRS, UMR 5535, IFR24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), Inst Genet Mol, CNRS, UMR 5535, IFR24, 1919 Route Mende, F-34293 Montpellier 05, France.		PIECHACZYK, Marc/E-7896-2013; Acquaviva, Claire/N-4306-2017	PIECHACZYK, Marc/0000-0003-1367-2597; Acquaviva, Claire/0000-0002-0227-9813; bossis, guillaume/0000-0002-3349-8250				Abbott DW, 1997, J BIOL CHEM, V272, P32454, DOI 10.1074/jbc.272.51.32454; Abbott DW, 1997, J BIOL CHEM, V272, P14005, DOI 10.1074/jbc.272.22.14005; AHMED NN, 1993, ONCOGENE, V8, P1957; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CARILLO S, 1994, ONCOGENE, V9, P1679; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Dick LR, 1997, J BIOL CHEM, V272, P182; DIECHANOVER A, 2000, BIOESSAYS, V22, P442; DOHERTY FJ, 1992, INTRACELLULAR PROTEI; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harlow E., 1999, USING ANTIBODIES LAB; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Jotte RM, 1996, J CELL BIOL, V135, P457, DOI 10.1083/jcb.135.2.457; JOTTE RM, 1994, J BIOL CHEM, V269, P16383; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; OLSON EN, 1985, J BIOL CHEM, V260, P3784; Osmulski PA, 1998, CURR BIOL, V8, P1023, DOI 10.1016/S0960-9822(07)00423-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Salvat C, 1999, MOL BIOL REP, V26, P45, DOI 10.1023/A:1006960021281; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; Sambrook J., 1989, MOL CLONING; SCHMIDT J, 1995, VIROLOGY, V206, P85, DOI 10.1016/S0042-6822(95)80022-0; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Steff AM, 1997, BIOCHEM J, V323, P685, DOI 10.1042/bj3230685; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348	55	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					942	950		10.1038/sj.onc.1204155	http://dx.doi.org/10.1038/sj.onc.1204155			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314029				2022-12-28	WOS:000167097000005
J	Hardwick, JCH; van den Brink, GR; Offerhaus, GJ; van Deventer, SJH; Peppelenbosch, MP				Hardwick, JCH; van den Brink, GR; Offerhaus, GJ; van Deventer, SJH; Peppelenbosch, MP			NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps	ONCOGENE			English	Article						polyp; JNK; NF-kappaB; p38 MAPK; COX-2; NSAIDs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TERMINAL KINASE; PROTEIN-KINASE; SODIUM-SALICYLATE; CYCLOOXYGENASE 2; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; B ACTIVATION; CANCER CELLS; INHIBITION	The factors that govern the progression from colonic adenomatous polyp to colon cancer are poorly understood. The observation that NSAIDs act as chemopreventative agents and reduce the size of colonic polyps suggests the involvement of inflammatory signalling, but inflammatory signalling in colonic polyps has not been studied. We investigated the expression of the active forms of NF-kappaB, JNK and p38 MAPK using immunohistochemistry with activation specific antibodies in human colonic adenomas, We show that active NF-kappaB is seen in stromal macrophages that also express COX-2 and TNF-alpha, active JNK is seen in stromal and intraepithelial T-lymphocytes and periendothelial cells of new blood vessels, and active p38 MAPK is most highly expressed in macrophages and other stromal cells. These results demonstrate the presence of active inflammatory signal transduction in colonic polyps and that these are predominantly in the stroma, In the case of NF-kappaB this coincides with the cellular localisation of COX-2. These results support evidence that NSAIDs may act through effects on stromal cells rather than epithelial cells.	Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Hardwick, JCH (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Hardwick, James/J-4862-2013	Hardwick, James/0000-0002-9575-5099; Peppelenbosch, Maikel/0000-0001-9112-6028				Bak AW, 1998, LIFE SCI, V62, pPL367; Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; Chiu CH, 1997, CANCER RES, V57, P4267; DIGIORGIO A, 1992, INT SURG, V77, P256; Gaweco AS, 2000, HEPATOLOGY, V31, P1183, DOI 10.1053/he.2000.6983; Hakansson L, 1997, BRIT J CANCER, V75, P374, DOI 10.1038/bjc.1997.61; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Licato LL, 1998, DIGEST DIS SCI, V43, P1454, DOI 10.1023/A:1018894227169; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piazza GA, 1997, CANCER RES, V57, P2452; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; SANO H, 1995, CANCER RES, V55, P3785; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; SVENNEVIG JL, 1984, BRIT J CANCER, V49, P375, DOI 10.1038/bjc.1984.60; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van den Brink GR, 2000, J IMMUNOL, V164, P3353, DOI 10.4049/jimmunol.164.6.3353; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	44	94	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					819	827		10.1038/sj.onc.1204162	http://dx.doi.org/10.1038/sj.onc.1204162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314016				2022-12-28	WOS:000166924400005
J	Yang, HS; Jansen, AP; Nair, R; Shibahara, K; Verma, AK; Cmarik, JL; Colburn, NH				Yang, HS; Jansen, AP; Nair, R; Shibahara, K; Verma, AK; Cmarik, JL; Colburn, NH			A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappa B or ODC transactivation	ONCOGENE			English	Article						pdcd4; AP-1; NF-kappa B; transformation	MOUSE EPIDERMAL-CELLS; NEOPLASTIC TRANSFORMATION; TUMOR PROMOTION; JB6 CELLS; TRANSCRIPTIONAL REGULATION; ANCHORAGE INDEPENDENCE; HUMAN KERATINOCYTES; TRANSGENIC MICE; EXPRESSION; ACTIVATION	Pdcd4 is a novel transformation suppressor that is highly expressed in promotion-resistant (P-) mouse epidermal JB6 cells but not in susceptible (P+) cells. Overexpression of pdcd4 cDNA in stably transfected P+ cells rendered cells resistant to tumor promoter-induced transformation, indicating that elevated expression of Pdcd4 protein is sufficient to suppress neoplastic transformation. To determine whether Pdcd4 suppresses neoplastic transformation through inhibiting known transformation required events, se examined the possibility that pdcd4 inhibited the activation of AP-1 or NF-kappaB dependent transcription or of ornithine decarboxylase (ODC) activity. Activation of AP-1-dependent transcriptional activity mas inhibited bai pdcd4 expression in a concentration dependent manner. In contrast, Pdcd4 slightly increased NF-kappaB-dependent transcription and did not alter ODC enzymatic activity. Previous studies suggested that activation of AP-1 was required for P+ cell transformation as well as for tumor promotion in vivo. These results indicate that Pdcd4 functions as a transformation suppressor, possibly through inhibiting AP-1 activation in combination with other factors such as enhancing NF-kappaB activation. Pdcd4 may thus constitute a useful molecular target for cancer prevention.	NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD 21702 USA; Univ Wisconsin, Sch Med, Dept Human Oncol, Madison, WI 53792 USA; Kyoto Univ, Sakyo Ku, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison; Kyoto University	Yang, HS (corresponding author), NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD 21702 USA.		Yang, Hsin-Sheng/AAF-6793-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036				AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Azzoni L, 1998, J IMMUNOL, V161, P3493; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang PL, 2000, J CELL BIOCHEM, V78, P8, DOI 10.1002/(SICI)1097-4644(20000701)78:1<8::AID-JCB2>3.3.CO;2-J; Cmarik J.L., 1997, FOOD FACTORS CANC PR, P67, DOI [10.1007/978-4-431-67017-9_13, DOI 10.1007/978-4-431-67017-9_13]; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1980, CARCINOGENESIS, V1, P951, DOI 10.1093/carcin/1.11.951; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DEBENEDETTI F, 1990, PROG LEUC B, V10, P275; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Foo SY, 1999, TRENDS GENET, V15, P229; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Jansen AP, 1999, ONCOGENE, V18, P5806, DOI 10.1038/sj.onc.1202965; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; OBrien TG, 1997, CANCER RES, V57, P2630; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; TAKAHASHI K, 1986, CANCER RES, V46, P5923; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	41	163	169	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					669	676		10.1038/sj.onc.1204137	http://dx.doi.org/10.1038/sj.onc.1204137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314000				2022-12-28	WOS:000166806000002
J	He, W; Cao, TY; Smith, DA; Myers, TE; Wang, XJ				He, W; Cao, TY; Smith, DA; Myers, TE; Wang, XJ			Smads mediate signaling of the TGF beta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis	ONCOGENE			English	Article						keratinocytes; growth inhibition; skin chemical carcinogenesis; transforming growth factor beta; tumor progression	GROWTH-FACTOR-BETA; GROWTH-FACTOR-BETA-1 MESSENGER-RNA; NF-KAPPA-B; TRANSGENIC MICE; MOUSE SKIN; DPC4 GENE; VITAMIN-D; TRANSFORMING GROWTH-FACTOR-BETA-1; TUMOR-SUPPRESSOR; IN-VIVO	The Smads are the signaling mediators of the TGF beta superfamily, In the present study, we examined Smad expression in mouse epidermis and chemically-induced skin tumors. Mutations in Smad2 and -4 genes were also screened. Transcripts of Smad1 through -5 were constantly expressed in the epidermis regardless of changes in TGF beta signaling, state of differentiation and stages of carcinogenesis. Smad7 transcripts were barely detectable in keratinocytes, but were induced by TGF beta1 treatment and in chemically-induced skin tumors. At the protein level, Smad1 was detected throughout the epidermis, whereas Smad2 through -5 exhibited greater levels in suprabasal layers than basal keratinocytes. In cultured keratinocytes, Smad2, -3 and -4 underwent nuclear translocation upon TGF beta1 treatment. Furthermore, nuclear translocation of Smads correlated with decreased BrdU labeling in proliferative keratinocytes. Although no mutations mere detected in the Smad2 and -4 genes in tumors, proteins of Smad1 through -5 were partially or completely lost in carcinomas. These data document that Smads are expressed at high levels in the epidermis and mediate signaling of the TGF beta superfamily. During skin carcinogenesis, loss of Smad1 through -5 and overexpression of Smad7 may contribute to the loss of growth inhibition mediated by TGF beta superfamily members, thus resulting in tumor progression.	Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wang, XJ (corresponding author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA.		Wikramanayake, Tongyu/A-9759-2013		NCI NIH HHS [CA 87849, CA79998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087849, R01CA079998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; Barrett MT, 1996, CANCER RES, V56, P4351; BIKLE DD, 1988, ANN NY ACAD SCI, V548, P27, DOI 10.1111/j.1749-6632.1988.tb18790.x; BLESSING M, 1995, TERATOGEN CARCIN MUT, V15, P11, DOI 10.1002/tcm.1770150103; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Chang H, 1999, DEVELOPMENT, V126, P1631; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Devereux TR, 1997, CARCINOGENESIS, V18, P1751, DOI 10.1093/carcin/18.9.1751; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Go C, 1999, CANCER RES, V59, P2861; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hejlik DP, 1997, CANCER RES, V57, P3779; Heldin CH, 1999, NAT CELL BIOL, V1, pE195, DOI 10.1038/70223; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kong XT, 1997, CANCER RES, V57, P3772; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Ma SH, 1997, GENE EXPRESSION, V6, P361; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Nadeau A, 1997, J HISTOCHEM CYTOCHEM, V45, P107, DOI 10.1177/002215549704500114; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; ROBERTS AB, 1987, NUCL MED BIOL, V14, P435, DOI 10.1016/0883-2897(87)90020-1; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; Rougui Z, 1996, J CELL PHYSIOL, V168, P385, DOI 10.1002/(SICI)1097-4652(199608)168:2<385::AID-JCP17>3.0.CO;2-2; Rozenblum E, 1997, CANCER RES, V57, P1731; Rundhaug JE, 1997, MOL CARCINOGEN, V18, P115, DOI 10.1002/(SICI)1098-2744(199702)18:2<115::AID-MC7>3.0.CO;2-F; Schutte M, 1996, CANCER RES, V56, P2527; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHERMAN JH, 1993, MOL CARCINOGEN, V8, P264, DOI 10.1002/mc.2940080409; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Uchida K, 1996, CANCER RES, V56, P5583; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zavadil J, 1997, LEUKEMIA, V11, P1187, DOI 10.1038/sj.leu.2400750; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	64	68	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					471	483		10.1038/sj.onc.1204117	http://dx.doi.org/10.1038/sj.onc.1204117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313978				2022-12-28	WOS:000166562500007
J	Kim, KW; Chung, HH; Chung, CW; Kim, IK; Miura, M; Wang, SY; Zhu, H; Moon, KD; Rha, GB; Park, JH; Jo, DG; Woo, HN; Song, YH; Kim, BJ; Yuan, JY; Jung, YK				Kim, KW; Chung, HH; Chung, CW; Kim, IK; Miura, M; Wang, SY; Zhu, H; Moon, KD; Rha, GB; Park, JH; Jo, DG; Woo, HN; Song, YH; Kim, BJ; Yuan, JY; Jung, YK			Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: Cleavage of the common alpha subunit during apoptosis	ONCOGENE			English	Article						apoptosis; caspase; farnesyltransferase; geranylgeranyltransferase	FARNESYL TRANSFERASE INHIBITORS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; PROTEIN FARNESYLTRANSFERASE; CELL-DEATH; H-RAS; TRANSFORMED-CELLS; TRANSGENIC MICE; GROWTH-FACTOR; ACTIVATION; SUPPRESSION	Caspase plays an important role in apoptosis. We report here that farnesyltransferase(geranylgeranyltransferase (FTase/GGTase)-alpha, a common subunit of FTase (alpha/beta (FTase)) and GGTase I (alpha/beta (GGTase)), was cleaved by caspase-3 during apoptosis, FTase/GGTase-alpha (49 kDa) was cleaved to 35 kDa (p35) in the Rat-2/H-ras, W4 and Rat-1 cells treated with FTase inhibitor (LB42708), anti-Fas antibody and etoposide, respectively. This cleavage was inhibited by caspase-inhibitors (YVAD-cmk, DEVID-cho), Serial N-terminal deletions and site-directed mutagenesis showed that Asp59 of FTase/GGTase-alpha was cleaved by caspase-3. The common FTase/GGTase-alpha subunit, but not the beta subunits, of the FTase or GGTase I protein complexes purified from baculovirus-infected SF-9 cells was cleaved to be inactivated by purified caspase-3. In contrast, FTase mutant protein complex [(D(59)A)alpha/beta (FTase)] was resistant to caspase-3. Expression of either the cleavage product (60-379) or anti-sense of FTase/GGTase-alpha induced cell death in Rat-2/H-ras cells. Furthermore, expression of (D(59)A)FTase/GCTase-alpha mutant significantly desensitized cells to etoposide-induced death. Taken together, we suggest that cleavage of prenyltransferase by caspase contributes to the progression of apoptosis.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Biotech Res Inst, LG Chem, Taejon, South Korea; Osaka Univ, Sch Med, Dept Neuroanat, Osaka, Japan; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Gwangju Institute of Science & Technology (GIST); LG Chem; Osaka University; Harvard University; Harvard Medical School	Jung, YK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.		Jo, Dong-Gyu/AAN-9278-2021	Jo, Dong-Gyu/0000-0003-2271-1076; Kim, Ki Woo/0000-0002-7790-1515; Zhu, Hong/0000-0002-2575-4031; Jung, Yong-Keun/0000-0002-9686-3120; Woo, Ha-Na/0000-0002-6771-8151				Ahmad M, 1998, CANCER RES, V58, P5201; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, CANCER RES, V59, P4208; Feldkamp MM, 1999, ONCOGENE, V18, P7514, DOI 10.1038/sj.onc.1203105; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; GULBILNS E, 1996, J BIOL CHEM, V271, P26390; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JANSEN B, 1997, CANCER RES, V57, P1846; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lebowitz PF, 1997, CANCER RES, V57, P708; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; McKenna WG, 1996, ONCOGENE, V12, P237; Miquel K, 1997, CANCER RES, V57, P1846; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; O'Reilly LA, 1999, INFLAMM RES, V48, P5, DOI 10.1007/s000110050369; Park HW, 1997, CURR OPIN STRUC BIOL, V7, P873; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; SUMMERS MD, 1998, TEXAS AGR EXP ST B, V1555, P29; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	49	15	16	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					358	366		10.1038/sj.onc.1204099	http://dx.doi.org/10.1038/sj.onc.1204099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313965				2022-12-28	WOS:000166411000010
J	Lim, SJ; Lopez-Berestein, G; Hung, MC; Lupu, R; Tari, AM				Lim, SJ; Lopez-Berestein, G; Hung, MC; Lupu, R; Tari, AM			Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells	ONCOGENE			English	Article						Grb2; heregulin; ErbB2; Akt; breast cancer	PROTEIN-KINASE-B; RECEPTOR TYROSINE KINASES; MAMMARY EPITHELIAL-CELLS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; TUMOR-CELLS; ACTIVATION; RAS	ErbB2 can be activated by its own overexpression or be transactivated by the heregulin polypeptide growth factor. Activation of ErbB2 leads to breast cancer cell proliferation, presumably by inducing the activation of extracellular signal-regulated kinases 1,2 (Erk1,2) and Akt. We have previously reported that the growth factor receptor bound protein-2 (Grb2) is required for the proliferation of ErbB2-overexpressing breast cancer cells. We investigated here whether Grb2 protein plays a role in heregulin-stimulated proliferation. Grb2 protein inhibition led to growth inhibition of heregulin-stimulated breast cancer cells, but not Erk1,2 inactivation. These findings are similar to our earlier observations in ErbB2-overexpressing cells. Since Akt can also be activated by heregulin, the effects of Grb2 inhibition on Akt were examined. Akt was inactivated following Grb2 downregulation in heregulin-stimulated breast cancer cells. We then examined the effects of Grb2 downregulation on Akt in ErbB2-overexpressing cells in the absence of heregulin, Similar to heregulin-stimulated cells, Grb2 inhibition also led to Akt inactivation in ErbB2-over-expressing breast cancer cells. Our results indicate that the activation of ErbB2 by heregulin or by its overexpression requires Grb2 to stimulate the Akt pathway to propagate mitogenic signals.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carriers, Box 60, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HOLMES WE, 1992, SCIENCE, V256, P1206; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Lewis GD, 1996, CANCER RES, V56, P1457; Li J, 1998, CANCER RES, V58, P5667; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Marais R, 1996, CANCER SURV, V27, P101; MARTE BM, 1995, ONCOGENE, V10, P167; MCCANN AH, 1991, CANCER RES, V51, P3296; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TANG C, 1996, CANCER RES, P3350; TANG M, 1999, CANCER RES, V59, P1620; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717	54	34	38	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6271	6276		10.1038/sj.onc.1204014	http://dx.doi.org/10.1038/sj.onc.1204014			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175341				2022-12-28	WOS:000166210500010
J	Zamzami, N; El Hamel, C; Maisse, C; Brenner, C; Munoz-Pinedo, C; Belzacq, AS; Costantini, P; Vieira, H; Loeffler, M; Molle, G; Kroemer, G				Zamzami, N; El Hamel, C; Maisse, C; Brenner, C; Munoz-Pinedo, C; Belzacq, AS; Costantini, P; Vieira, H; Loeffler, M; Molle, G; Kroemer, G			Bid acts on the permeability transition pore complex to induce apoptosis	ONCOGENE			English	Article						apoptosis; Bcl-2; mitochondria; permeability transition; t-Bid	DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; MITOCHONDRIAL CONTROL; BAX; BCL-2; MEMBRANES; PROTEINS; YEAST; PURIFICATION	Similar to most if not all pro-apoptotic members of the Bcl-2 family, Bid land its truncated product t-Bid) triggers cell death via mitochondrial membrane permeabilization (MMP). This effect can be monitored in intact cells, upon microinjection of recombinant Bid protein into the cytoplasm, as well as in purified mitochondria, upon addition of Bid protein. Here we show that Bid-induced MMP can be inhibited, both in cells and in the cell-free system, by three pharmacological inhibitors of the permeability transiton pore complex (PTPC), namely cyclosporin A, N-methyl-4-Val-cyclosporin A, and bongkrekic acid (a ligand of the adenine nucleotide translocase, ANT, one of the PTPC components). Bid effects on synthetic membranes were studied either in proteoliposomes or in synthetic bilayers subjected to electrophysiological measurements. Full length Bid preferentially permeabilizes membranes and induces the formation of large conductance channels at neutral pH, when added to liposomes or bilayers containing both purified ANT and Bax, yet has no or little effect combined with ANT or Bax alone. t-Bid acts on membranes containing ANT alone with the same efficiency as on those containing both ANT and Bax. These results suggest that the proapoptotic effects of Bid are mediated, at least in part, by its functional interaction with ANT, one of the major components of PTPC.	Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Technol Compiegne, UMR 6022, CNRS, F-60205 Compiegne, France; Fac Sci, IFRMP23, UMR 6522, CNRS, F-76821 Mont St Aignan, France; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		KROEMER, Guido/B-4263-2013; brenner, catherine/AAE-8632-2020; Munoz-Pinedo, Cristina/B-6118-2008; Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Vieira, Helena/0000-0001-9415-3742; Maisse, Carine/0000-0003-2848-1638				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	51	164	169	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6342	6350		10.1038/sj.onc.1204030	http://dx.doi.org/10.1038/sj.onc.1204030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175349				2022-12-28	WOS:000166210500018
J	Brandvold, KA; Ewert, DL; Kent, SC; Neiman, P; Ruddell, A				Brandvold, KA; Ewert, DL; Kent, SC; Neiman, P; Ruddell, A			Blocked B cell differentiation and emigration support the early growth of Myc-induced lymphomas	ONCOGENE			English	Article						Myc; lymphoma; retrovirus; B cell differentiation	AVIAN-LEUKOSIS VIRUS; C-MYC; TRANSGENIC MICE; STEM-CELLS; EXPRESSION; APOPTOSIS; FABRICIUS; BURSA; INDUCTION; PROTEIN	Avian leukosis virus induces lymphoma in chickens after proviral integration within the c-Myc gene, and subsequent expansion of Myc-overexpressing lymphocytes within transformed bursal follicles, The clonal expansion of these follicles allowed us to examine how Myc influences cell differentiation, growth, and apoptosis in lymphoid progenitors soon after the onset of Myc overexpression, Immunohistochemical analysis of developmental markers established that Myc overexpression consistently blocks lymphocyte differentiation at a late embryonic stage. Myc-transformed follicles also grow much more rapidly than normal follicles, This rapid growth is not mediated by suppression of apoptosis, as normal and Myc-transformed follicles showed similar rates of cell death by TUNEL immunohistochemical analyis of cells undergoing DNA degradation. Measurements of DNA synthesis and mitotic index showed modest effects of Myc to increase lymphocyte proliferation, as normal lymphocytes already divide rapidly. The major mechanism mediating rapid growth of transformed follicles instead involved failure of myc-overexpressing lymphocytes to emigrate from transformed follicles, while normal lymphocytes actively emigrate after hatching, as measured by BrdU pulse-chase labeling and immunohistochemical measurements. This failure to undergo the normal program of differentiation and subsequent bursal retention of lymphocytes accounts for most of the growth of transformed follicles, while Myc-induced proliferation makes a smaller contribution.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Wistar Inst Anat & Biol, Philadelphia, PA USA; Harvard Univ, Brigham & Womens Hosp, Inst Med, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Washington, Dept Med, Washington, DC USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; The Wistar Institute; Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Mailstop C2-023,POB 19024, Seattle, WA 98109 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA20068, R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brabletz T, 2000, AM J PATHOL, V156, P865, DOI 10.1016/S0002-9440(10)64955-3; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Flenghi L, 1996, AM J PATHOL, V148, P1543; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MASTELLER EL, 1995, DEVELOPMENT, V121, P1657; MASTELLER EL, 1995, J IMMUNOL, V155, P5550; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1988, CURR TOP MICROBIOL, V141, P67; NEIMAN PE, 1994, COLD SPRING HARB SYM, V59, P509, DOI 10.1101/SQB.1994.059.01.056; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PARAMITHIOTIS E, 1995, J EXP MED, V181, P105, DOI 10.1084/jem.181.1.105; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Prasad VS, 1997, MOL CARCINOGEN, V18, P66, DOI 10.1002/(SICI)1098-2744(199702)18:2<66::AID-MC2>3.0.CO;2-O; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RATCLIFFE MJH, 1985, IMMUNOL TODAY, V6, P223, DOI 10.1016/0167-5699(85)90039-8; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCHOENWOLF GC, 1981, J MORPHOL, V167, P35, DOI 10.1002/jmor.1051670104; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3226	3234		10.1038/sj.onc.1204431	http://dx.doi.org/10.1038/sj.onc.1204431			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423972				2022-12-28	WOS:000169163500006
J	Friedrich, K; Wieder, T; Von Haefen, C; Radetzki, S; Janicke, R; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Friedrich, K; Wieder, T; Von Haefen, C; Radetzki, S; Janicke, R; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance	ONCOGENE			English	Article						caspase-3; chemotherapeutics; apoptosis; drug resistance; MCF-7 cells	GENE BAX-ALPHA; CYTOCHROME-C; THYMOCYTE APOPTOSIS; PROTEASE ACTIVITY; ANTICANCER DRUGS; TUMOR-GROWTH; HL-60 CELLS; IN-VIVO; DEATH; EXPRESSION	In this study, we asked whether overexpression of caspase-3, a central downstream executioner of apoptotic pathways, might sensitize breast cancer cells with acquired drug resistance (MT1/ADR) to drug-induced apoptosis, As control, we employed caspase-3 negative and caspase-3-transfected MCF-7 cells, Whereas mock-transfected MCF-7 cells were resistent to epirubicin, etoposide and paclitaxel (taxol), the same drugs led to breakdown of nuclear DNA in caspase-3-transfected MCF-7 cells, MT1/ADR cells express low levels of wild type caspase-3 but show defective caspase activation and apoptosis upon drug exposure. These cells also display a Less efficient activation of the mitochondrial permeability transition. Caspase-3-transfected MT1/ADR clones showed a 2.8-fold increase in the protein level and a 3.7-fold higher specific enzyme activity. Procaspase-3 overexpression was not toxic and did not affect background apoptosis, Interestingly, procaspase-3-transfected MT1/ADR cells were more sensitive to cytotoxic drags as compared with vector-transfected controls and DNA fragmentation nearly reached the levels of the original drug sensitive MT1 cells. Thus, overexpression of caspase-3 enhances chemosensitivity especially in situations where activation of the mitochondrial apoptosome is disturbed.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Lindenberger Weg 80,Campus Berlin Buch, D-13125 Berlin, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hiwasa T, 1998, ANTI-CANCER DRUG, V9, P82, DOI 10.1097/00001813-199801000-00010; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1996, CANCER RES, V56, P4743; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MIYASHITA T, 1993, BLOOD, V81, P151; NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perkins C, 1998, CANCER RES, V58, P4561; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uckert W, 1998, HUM GENE THER, V9, P2619, DOI 10.1089/10430349850019454; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	105	115	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2749	2760		10.1038/sj.onc.1204342	http://dx.doi.org/10.1038/sj.onc.1204342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420687				2022-12-28	WOS:000168712000003
J	Tobias, ES; Hurlstone, AFL; MacKenzie, E; McFarlane, R; Black, DM				Tobias, ES; Hurlstone, AFL; MacKenzie, E; McFarlane, R; Black, DM			The TES gene at 7q31,1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein	ONCOGENE			English	Article						LIM domain; TSG; methylation; chromosome 7	HUMAN GASTRIC CARCINOMAS; PRIMARY BREAST-CANCER; FREQUENT LOSS; LONG ARM; PROMOTER HYPERMETHYLATION; OVARIAN CARCINOMAS; CHROMOSOME 7Q; SQUAMOUS-CELL; ALLELIC LOSS; HETEROZYGOSITY	Many studies suggest that a multi-tissue tumour suppressor gene is located at human chromosome 7q31.1, We have cloned and characterized a novel gene at this locus. The TES gene lies within the minimal region of overlap of several LOH studies and appears to possess the properties of a tumour suppressor. TES is widely expressed and is predicted to encode a protein of 421 amino acids, with three C-terminal LIM domains. Mutation analysis of the coding TES exons in 21 human tumour-derived cell lines revealed the presence of a frameshift mutation in one allele in the breast cancer cell line ZR-75, Methylation of the CpG island at the 5 ' end of TES appears to be a remarkably frequent finding, occurring in seven out of 10 ovarian carcinomas and in each of the 30 tumour-derived cell lines tested, Moreover, forced expression of TES in HeLa or OVCAR5 cells, resulted in a profound reduction in growth potential, as determined by the colony formation assay. We believe that TES is a tumour suppressor gene that is inactivated primarily by transcriptional silencing resulting from CpG island methylation.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands	Beatson Institute; Utrecht University; Utrecht University Medical Center	Black, DM (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Tobias, Edward/D-4246-2009	Tobias, Edward/0000-0003-2649-7695; Hurlstone, Adam/0000-0001-5260-9457				Achille A, 1996, CANCER RES, V56, P3808; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Costanzi-Strauss E, 1998, EXP CELL RES, V238, P51, DOI 10.1006/excr.1997.3810; DIVECHA N, 1995, GENE, V156, P283, DOI 10.1016/0378-1119(95)00088-N; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fleisher AS, 1999, CANCER RES, V59, P1090; HERMAN JG, 1995, CANCER RES, V55, P4525; Hobert O, 2000, TRENDS GENET, V16, P75, DOI 10.1016/S0168-9525(99)01883-1; Hobert O, 1996, ONCOGENE, V12, P1577; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Maniatis T, MOL CLONING LAB MANU; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEDERSEN B, 1994, CANCER GENET CYTOGEN, V78, P181, DOI 10.1016/0165-4608(94)90088-4; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU RY, 1994, J BIOL CHEM, V269, P25085; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 1996, GENOME RES, V6, P1070, DOI 10.1101/gr.6.11.1070	43	81	89	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2844	2853		10.1038/sj.onc.1204433	http://dx.doi.org/10.1038/sj.onc.1204433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420696	Bronze			2022-12-28	WOS:000168712000012
J	Hohenstein, P; Kielman, MF; Breukel, C; Bennett, LM; Wiseman, R; Krimpenfort, P; Cornelisse, G; van Ommen, GJ; Devilee, P; Fodde, R				Hohenstein, P; Kielman, MF; Breukel, C; Bennett, LM; Wiseman, R; Krimpenfort, P; Cornelisse, G; van Ommen, GJ; Devilee, P; Fodde, R			A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage	ONCOGENE			English	Article						Brca1(1700T); mouse model; hereditary breast cancer; p53; genotype-phenotype correlation; DNA damage	DNA-DAMAGE; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; GENETIC INSTABILITY; TUMOR SPECTRUM; MEIOTIC CELLS; MODEL; EXPRESSION; REPAIR; MICE	A mouse model with a targeted mutation in the 3' end of the endogenous Brca1 gene, Brca1(1700T), was generated to compare the phenotypic consequences of truncated SI cal proteins with other mutant Brca1 models reported in the literature to date. Mice heterozygous for the Brca1(1700T) mutation do not show any predisposition to tumorigenesis, Treatment of these mice with ionizing radiation or breeding with Ape, Msh-2 or Tp53 mutant mouse models did not show any change in the tumor phenotype, Like other Brca1 mouse models, the Brca1(1700T) mutation is embryonic lethal in homozygous state, However, homozygous Brca1(1700T) embryos reach the headfold stage but are delayed in their development and fail to turn. Thus, in contrast to Brca1(null) models, the mutant embryos do not undergo growth arrest leading to a developmental block at 6.5 dpc, but continue to proliferate and differentiate until 9.5 dpc. Homozygous embryos die between 9.5-10.5 dpc due to massive apoptosis throughout the embryo. These results indicate that a C-terminal truncating Brca1 mutation removing the last BRCT repeat has a different effect on normal cell function than does the complete absence of Brca1.	Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; NIEHS, Res Triangle Pk, NC 27709 USA; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Netherlands Cancer Institute	Fodde, R (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, POB 9503, NL-2300 RA Leiden, Netherlands.		Fodde, Riccardo/AAW-9394-2021; DEVILEE, PETER/ABR-2140-2022; Hohenstein, Peter/Y-2428-2018	Fodde, Riccardo/0000-0001-9839-4324; Hohenstein, Peter/0000-0001-8548-4734	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Blaszyk H, 2000, INT J CANCER, V89, P32, DOI 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Grade K, 1997, J CANCER RES CLIN, V123, P69, DOI 10.1007/BF01212618; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sobol A, 1996, CANCER RES, V56, P3216; Sobol H, 1997, INT J ONCOL, V10, P349; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197; Wang Y, 2000, GENE DEV, V14, P927; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yu VPCC, 2000, GENE DEV, V14, P1400; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	46	47	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2544	2550		10.1038/sj.onc.1204363	http://dx.doi.org/10.1038/sj.onc.1204363			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420664				2022-12-28	WOS:000168652500005
J	Liu, ML; Shibata, MA; Von Lintig, FC; Wang, WL; Cassenaer, S; Boss, GR; Green, JE				Liu, ML; Shibata, MA; Von Lintig, FC; Wang, WL; Cassenaer, S; Boss, GR; Green, JE			Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice	ONCOGENE			English	Article						Ki-ras; mammary gland tumor; transgenic mice	GROWTH IN-VITRO; MOUSE; GENE; EXPRESSION; CARCINOMA; ADENOCARCINOMA; IDENTIFICATION; AMPLIFICATION; SUPPRESSION; APOPTOSIS	We have previously demonstrated that amplification and overexpression of the Ki-ras gene is associated with mammary tumor progression in C3(1)/SV40Tag transgenic mice (Liu Et al,, 1998), To further evaluate the functional significance of the Ki-vas proto-oncogene in mammary cancer development, in vivo studies were conducted to examine the effect of Ki-vas gene dosage on tumor progression. The lack of one normal Ki-vas allele C3(1)/SV40Tag transgenic mice resulted in significantly delayed mammary intraepithelial neoplasia (MIN) formation as well as in a decreased number of mammary gland carcinomas, However, despite the retardation of tumor development by reduced Ki-ras gene dosage, overall survival was only modestly affected. This appears to be due to several factors including significant mammary tumor growth associated with Ki-ras gene amplification and over-expression that occurs during the advanced stage of oncogenesis in mice carrying either one or two normal Ki-ras alleles, The retardation of tumor progression due to the haploid loss of Ki-ras did not appear to be related to accelerated apoptosis, or a reduced rate of cell proliferation at the tumor stages examined. These data strongly suggest that the gene dosage of Ki-vas affects tumor promotion at an early stage of mammary tumor progression in this SV40 Tag-induced model of mammary oncogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Boss, Gerry/0000-0002-9758-8714				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FILMUS JE, 1985, CANCER RES, V45, P4468; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GARCIA I, 1989, CANCER RES, V49, P6675; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GRAHAM KA, 1985, CANCER RES, V45, P2201; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1999, ONCOGENE, V18, P5435, DOI 10.1038/sj.onc.1202926; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; Sills RC, 1999, IARC SCI PUBL, P55; TANAKA T, 1986, CANCER RES, V46, P1465; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	24	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2044	2049		10.1038/sj.onc.1204280	http://dx.doi.org/10.1038/sj.onc.1204280			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360188				2022-12-28	WOS:000168043800012
J	Maulon, L; Mari, B; Bertolotto, C; Ricci, JE; Luciano, F; Belhacene, N; Deckert, M; Baier, G; Auberger, P				Maulon, L; Mari, B; Bertolotto, C; Ricci, JE; Luciano, F; Belhacene, N; Deckert, M; Baier, G; Auberger, P			Differential requirements for ERK1/2 and p38 MAPK activation by thrombin in T cells. Role of P59Fyn and PKC epsilon	ONCOGENE			English	Article						T lymphocytes; thrombin; Src kinases; PKCs; MAP kinases	PROTEIN-KINASE-C; RECEPTOR AGONIST PEPTIDE; EPIDERMAL-GROWTH-FACTOR; SRC FAMILY KINASES; TYROSINE KINASE; COUPLED RECEPTORS; IL-2 PROMOTER; CROSS-LINKING; RAS; PHOSPHORYLATION	Activation of the mitogen-activated protein kinase (MAPK) cascade is a well documented mechanism for the G-protein-coupled receptors, Here, we have analysed the requirements for ERKs and p38 MAPK activation by thrombin in Jurkat T cells. We show that thrombin-mediated ERKs activation requires both PTK and PKC activities, whereas p38 MAPK activation is dependent only on PTKs, Thrombin-induced ERK and p38 MAPK activation was more pronounced in p56Lck deficient cells indicating that this PTK exerts a negative control on MAPK activity. Accordingly, overexpression of p50 Csk a kinase that inactivates p56Lck induced constitutive activation of ERKs, Requirement for a Src kinase was evidenced by expression of a constitutively active form of p59Fyn in Jurkat cells. Besides its effect on tyrosine phosphorylation events, thrombin also triggered a rapid and robust redistribution of PKC epsilon and delta from the cytosol to the membrane. Expression of constitutively active and dominant negative PKC epsilon demonstrates the pivotal role of this PKC isoform in ERKs activation by thrombin, These data are consistent with a model where thrombin induces ERK activation via both PKC-dependent and independent pathways, whereas p38 MAPK activation requires only PTKs, The PKC-independent pathway requires Src kinases other than p56Lck more likely p59Fyn, while the PKC-dependent mechanism depends on PKC epsilon.	INSERM, U526, F-06107 Nice 2, France; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Hop Archet, INSERM U343, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Innsbruck; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), INSERM, U526, 28 Ave Valombrose, F-06107 Nice 2, France.		Bertolotto, Corine/AAF-6634-2021; Mari, Bernard P/F-8960-2013; Deckert, Marcel/M-4998-2016; RICCI, Jean Ehrland/AAS-4379-2020; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Ricci, Jean Ehrland/I-7117-2016; AUBERGER, Patrick/G-1491-2013; Baier, Gottfried/E-8755-2012; Mari, Bernard P/GVS-3100-2022; luciano, frederic/P-6264-2016; Deckert, Marcel/T-3566-2019; Bertolotto-Ballotti, Corine/O-2155-2016	Bertolotto, Corine/0000-0001-6971-7753; Mari, Bernard P/0000-0002-0422-9182; RICCI, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Ricci, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; luciano, frederic/0000-0001-9253-4998; Deckert, Marcel/0000-0003-2094-559X; Baier, Gottfried/0000-0002-2085-8325				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AUTERO M, 1996, MOL CELL BIOL, V16, P1842; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BRANCH DR, 1995, J IMMUNOL, V154, P3678; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CONWAY AM, 1999, BIOCHEM J, P171; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; DERY O, 1998, AM J PHYSIOL, P1429; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DIKIC I, 1998, J BIOL CHEM, V269, P31706; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; GOLDSCHMITH MA, 1998, P NATL ACAD SCI USA, V84, P6879; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Joyce DE, 1997, BLOOD, V90, P1893, DOI 10.1182/blood.V90.5.1893; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; MARI B, 1994, J BIOL CHEM, V269, P8517; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Satoh K, 1996, BIOCHEM BIOPH RES CO, V225, P1084, DOI 10.1006/bbrc.1996.1299; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	43	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1964	1972		10.1038/sj.onc.1204266	http://dx.doi.org/10.1038/sj.onc.1204266			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360180				2022-12-28	WOS:000168043800004
J	Kim, DH; Nelson, HH; Wiencke, JK; Christiani, DC; Wain, JC; Mark, EJ; Kelsey, KT				Kim, DH; Nelson, HH; Wiencke, JK; Christiani, DC; Wain, JC; Mark, EJ; Kelsey, KT			Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer	ONCOGENE			English	Article						DAP-kinase; k-ras; p53; methylation; nonsmall cell lung cancer	TUMOR-SUPPRESSOR GENES; DNA METHYLATION; CPG ISLAND; SIGNALING PATHWAY; HYPERMETHYLATION; METHYLTRANSFERASE; PROTEIN; DEATH; IDENTIFICATION; APOPTOSIS	Death associated protein (DAP)-kinase is a 16 kDa calmodulin-dependent serine/threonine kinase that carries a death domain at its C-terminus. DAP-kinase functions as a positive mediator of apoptosis that is induced by interferon-gamma. Recent studies suggest that DAP-kinase is involved in tumor metastasis and that it can be inactivated by methylation of CpG islands in the promoter region of the gene in some human tumors. However, little is known about the factors that are associated with the occurrence of DAP-kinase promoter methylation. We investigated both the possible associations of tobacco carcinogen and asbestos exposure with DAP-kinase promoter methylation, and the demographic and clinical factors associated with DAP-kinase promoter methylation in non-small cell lung cancer (NSCLC), One hundred and eighty-five patients diagnosed with NSCLC undergoing surgical resection from June, 1992 through December, 1996 at Massachusetts General Hospital participated in this study, Methylation-Specific PCR (MSP), performed using fresh-frozen tissue, was used to determine the methylation status of the promoter region of the DAP-kinase gene. Forty-seven (25%) of 185 tumors showed DAP-kinase promoter methylation. There was a significant association between methylation and an advanced pathologic stage (P=0.003, Fisher's exact test). Methylation of the DAP-kinase promoter was also associated with an increase in tumor size (P=0.009, Fisher's exact test) and lymph node involvement (P=0.04), No association was found between promoter methylation of DAP-kinase and k-ras or p53 mutation. In addition there was no association with a history of exposure to tobacco or asbestos. Controlling for age, sex, and histology, the odds ratios describing the association of DAP-kinase hypermethylation with stage were 2.70 (1.13-6.45), 3.11 (1.37-7.08) and 7.77 (1.21-50.03) in stages II, III and IV, respectively. Stage I cases with DAP-kinase promoter methylation had worse overall survival, but with the small sample size and limited follow-up this did not reach statistical significance. Our findings suggest that methylation of the promoter region of the DAP-kinase gene is not associated with exposure to tobacco or asbestos. However, they strongly suggest that DAP-kinase may be important in the progression of non-small cell lung cancer from early to late stage disease.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, Lab Mol Epidemiol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Thorac Surg Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Rm 207, Boston, MA 02115 USA.		Kelsey, Karl T/I-1252-2014	Nelson, Heather/0000-0003-1901-9513	NATIONAL CANCER INSTITUTE [R01CA074386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006409, P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA74386, CA08357, CA06717] Funding Source: Medline; NIEHS NIH HHS [ES00002, ES/CA 06409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Eguchi K, 1997, CANCER RES, V57, P4913; ELDEIRY WA, 1990, P NATL ACAD SCI USA, V88, P3470; Esteller M, 1999, CANCER RES, V59, P67; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; NELSON HH, 1999, CANCER RES, V20, P667; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543; WU J, 1990, P NATL ACAD SCI USA, V90, P8891	29	123	133	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1765	1770		10.1038/sj.onc.1204302	http://dx.doi.org/10.1038/sj.onc.1204302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313923				2022-12-28	WOS:000167750900009
J	Richard, DE; Vouret-Craviari, V; Pouyssegur, J				Richard, DE; Vouret-Craviari, V; Pouyssegur, J			Angiogenesis and G-protein-coupled receptors: signals that bridge the gap	ONCOGENE			English	Article						angiogenesis; thrombin; angiotensin II; hypoxia inducible factor 1; p42/p44; MAP kinase; ROS	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; SMOOTH-MUSCLE; THROMBIN RECEPTOR; ANGIOTENSIN-II; ACTIN CYTOSKELETON; TUMOR ANGIOGENESIS; FACTOR EXPRESSION; TYROSINE KINASE; CELL-ACTIVATION	Angiogenesis is a mechanism that has repercussions in a number of physiological and pathological situations. Vascular endothelial growth factor and basic fibroblast growth factor have understandably received enormous research coverage for being the major mediators of new blood vessel growth, often overshadowing other agonist that also have strong angiogenic potential. We wish to put the spotlight on GPCR agonists that undoubtedly have their word to say on the subject of angiogenesis. In this short review, we will discuss our findings along with the work from other groups on the mechanisms by which GPCR agonists, like thrombin and angiotensin II, control a number of angiogenic signals. A complete understanding of these mechanisms could, by the design of new therapeutic strategies, have a strong impact in clinical oncology.	Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Pouyssegur, J (corresponding author), Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.		Richard, Darren E./K-6760-2019	Richard, Darren/0000-0003-2690-0480				Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Biggerstaff JP, 1999, CLIN EXP METASTAS, V17, P723, DOI 10.1023/A:1006763827882; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARNEY DH, 1992, THROMBIN STRUCTURE F, P351; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Feldser D, 1999, CANCER RES, V59, P3915; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gallacher B, 1997, ANN SAUDI MED, V17, P489, DOI 10.5144/0256-4947.1997.489a; GARCIA JGN, 1995, BLOOD COAGUL FIBRIN, V6, P609, DOI 10.1097/00001721-199510000-00001; GARCIA JGN, 1995, J INVEST MED, V43, P117; GRECO NJ, 1992, THROMBIN STRUCTURE F, P275; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Maragoudakis ME, 2000, ADV EXP MED BIOL, V476, P47; MARI B, 1994, J BIOL CHEM, V269, P8517; Martin M, 1996, INT J CANCER, V65, P796, DOI 10.1002/(SICI)1097-0215(19960315)65:6<796::AID-IJC16>3.0.CO;2-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCarthy MJ, 1999, J VASC SURG, V30, P261, DOI 10.1016/S0741-5214(99)70136-9; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nguyen M, 1999, LAB INVEST, V79, P467; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Otani A, 2000, INVEST OPHTH VIS SCI, V41, P1192; PANKONIN G, 1991, BIOMED BIOCHIM ACTA, V50, P1073; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Senger DR, 1996, AM J PATHOL, V149, P293; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sodhi A, 2000, CANCER RES, V60, P4873; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; TSOPANOGLOU NE, 1993, AM J PHYSIOL, V264, pC1302, DOI 10.1152/ajpcell.1993.264.5.C1302; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Vouret-Craviari V, 1999, INFECT IMMUN, V67, P3002, DOI 10.1128/IAI.67.6.3002-3008.1999; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang HS, 1997, J SURG RES, V68, P139, DOI 10.1006/jsre.1997.5044; Wenger RH, 1997, BIOL CHEM, V378, P609; WILLIAMS B, 1995, HYPERTENSION, V25, P913, DOI 10.1161/01.HYP.25.5.913; Zain J, 2000, BLOOD, V95, P3133; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A; Zundel W, 2000, GENE DEV, V14, P391	79	84	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1556	1562		10.1038/sj.onc.1204193	http://dx.doi.org/10.1038/sj.onc.1204193			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313902				2022-12-28	WOS:000168089800005
J	Argentini, M; Barboule, N; Wasylyk, B				Argentini, M; Barboule, N; Wasylyk, B			The contribution of the acidic domain of MDM2 to p53 and MDM2 stability	ONCOGENE			English	Article						ring finger domain; ubiquitylation; nuclear export; p300; NES	RING-FINGER DOMAIN; NUCLEAR EXPORT; IN-VIVO; NUCLEOLAR-LOCALIZATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; UBIQUITIN LIGASE; ONCOPROTEIN MDM2; DNA-DAMAGE; CELL-LINE	p53 and MDM2 are both degraded by the ubiquitin-proteasome pathway, MDM2 binds p53 and promotes its rapid degradation, MDM2 is an E3 ligase that activates self and p53 ubiquitylation, Moreover, MDM2 nuclear-cytoplasmic shuttling contributes to p53 degradation in the cytoplasm, We have identified a new region of MDM2 which regulates the stability of both p53 and MDM2, The first 50 amino-acids of the MDM2 acidic domain (222-272) contribute to MDM2 and MDM2-mediated p53 degradation by a mechanism which is independent of either MDM2 E3-ligase activity or MDM2 nucleo-cytoplasmic shuttling, The transcriptional coactivator p300 could have been involved, since it binds to the MDM2 acidic domain, Howe, er, we found that p300 stabilises MDM2, even in absence of an intact acidic domain, indicating that the MDM2 acidic region contributes to proteolysis independently of p300, We propose that the MDM2 acidic domain is required for unbiquitylated MDM2 and p53 to be degraded by cytoplasmic proteasomes.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Argentini M, 2000, ONCOGENE, V19, P3849, DOI 10.1038/sj.onc.1203737; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haas AL, 1997, FASEB J, V11, P1257; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; KASTAN MB, 1991, CANCER RES, V51, P6304; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSER FG, 1975, J CELL BIOL, V66, P676, DOI 10.1083/jcb.66.3.676; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Pickart CM, 2000, NAT CELL BIOL, V2, pE139, DOI 10.1038/35019610; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STRACK PR, 1992, INT J BIOCHEM, V24, P887, DOI 10.1016/0020-711X(92)90093-G; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	65	69	69	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1267	1275		10.1038/sj.onc.1204241	http://dx.doi.org/10.1038/sj.onc.1204241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313871				2022-12-28	WOS:000167495000001
J	Forgacs, E; Wren, JD; Kamibayashi, C; Kondo, M; Xu, XL; Markowitz, S; Tomlinson, GE; Muller, CY; Gazdar, AF; Garner, HR; Minna, JD				Forgacs, E; Wren, JD; Kamibayashi, C; Kondo, M; Xu, XL; Markowitz, S; Tomlinson, GE; Muller, CY; Gazdar, AF; Garner, HR; Minna, JD			Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers	ONCOGENE			English	Article						microsatellite instability; mutation; repetitive DNA sequences	NONPOLYPOSIS COLON-CANCER; GENETIC INSTABILITY; MUTATOR PHENOTYPE; REPEAT EXPANSION; CELL-LINES; PROTEIN; HMLH1; IDENTIFICATION; TRANSCRIPTION; CONSEQUENCES	RepX represents a new informatics approach to probe the UniGene database for potentially polymorphic repeat sequences in the open reading frame (ORF) of genes, 56% of which were found to be actually polymorphic. We now have performed mutational analysis of 17 such sites in genes not found to be polymorphic (<0.03 frequency) in a large panel of human cancer genomic DNAs derived from 31 lung, 21 breast, seven ovarian, 21 (13 microsatellite instability (MSI)+ and eight MS-) colorectal cancer cell lines. In the lung, breast and ovarian tumor DNAs we found no mutations (<0.03-0.04 rate of tumor associated open reading frame mutations) in these sequences, BS contrast, 18 MSI+ colorectal cancers (13 cancer cell lines and five primary tumors) with mismatch repair defects exhibited six mutations in three of the 17 genes (SREBP-2, TAN-1, GR6) (P<0.000003 compared to all other cancers tested). We conclude that coding region microsatellite alterations are rare in lung, breast, ovarian carcinomas and MSI(-) colorectal cancers, but are relatively frequent in MSI (+) colorectal cancers with mismatch repair deficits.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Program Genet & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Biomed Invent, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Howard Hughes Medical Institute	Minna, JD (corresponding author), Univ Texas, Med Ctr, Hamon Ctr Therapeut Oncol, 6000 Harry Hines Blvd,NB 8-206, Dallas, TX 75390 USA.		Kondo, Masashi/I-7378-2014; Wren, Jonathan D/E-5611-2011	Wren, Jonathan D/0000-0003-2776-3545	NCI NIH HHS [P50 CA70907, CA 67409] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gurin CC, 1999, CANCER RES, V59, P462; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; King BL, 1997, CANCER RES, V57, P209; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Liu T, 1999, HUM GENET, V105, P437, DOI 10.1007/s004390051127; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PARSONS R, 1995, CANCER RES, V55, P5548; Pekarsky Y, 1997, CANCER RES, V57, P3914; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; Wren JD, 2000, AM J HUM GENET, V67, P345, DOI 10.1086/303013; Yamamoto H, 1997, CANCER RES, V57, P4420	26	17	21	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					1005	1009		10.1038/sj.onc.1204211	http://dx.doi.org/10.1038/sj.onc.1204211			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314036				2022-12-28	WOS:000167097000012
J	Fillippovich, I; Sorokina, N; Gatei, M; Haupt, Y; Hobson, K; Moallem, E; Spring, K; Mould, M; McGuckin, MA; Lavin, MF; Khanna, KK				Fillippovich, I; Sorokina, N; Gatei, M; Haupt, Y; Hobson, K; Moallem, E; Spring, K; Mould, M; McGuckin, MA; Lavin, MF; Khanna, KK			Transactivation-deficient p73 alpha (p73 Delta exon2) inhibits apoptosis and competes with p53	ONCOGENE			English	Article						p53; p73; apoptosis; breast cancer; transactivation	APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; KINASE C-ABL; P73 GENE; MEDIATED APOPTOSIS; DNA-DAMAGE; PROTEIN; ACTIVATION; EXPRESSION; INDUCTION	p73 has recently been identified as a structural and functional homolog of the tumor suppressor protein p53. Overexpression of p53 activates transcription of p53 effector genes, causes growth inhibition and induced apoptosis. We describe here the effects of a tumor-derived truncated transcript of p73 alpha (p73 Delta exon2) on p53 function and on cell death. This transcript, which lacks the acidic N-terminus corresponding to the transactivation domain of p53, was initially detected in a neuroblastoma cell line. Overexpression of p73 Delta exon2 partially protects lymphoblastoid cells against apoptosis induced by anti-Fas antibody or cisplatin. By cotransfecting p73 Delta exon2 with wild-type p53 in the p53 null line Saos 2, we found that this truncated transcript reduces the ability of wild-type p53 to promote apoptosis. This anti-apoptotic effect was also observed when p73 Delta exon2 was co-transfected with full-length p73 (p73 alpha). This was further substantiated by suppression of p53 transactivation of the effector gene p21-Waf1 in p73 Delta exon2 transfected cells and by inhibition of expression of a reporter gene under the control of the p53 promoter. Thus, this truncated form of p73 can act as a dominant-negative agent towards transactivation by p53 and p73 alpha, highlighting the potential implications of these findings for p53 signaling pathway. Furthermore, we demonstrate the existence of a p73 Delta exon2 transcript in a very significant proportion (46%) of breast cancer cell lines. However, a large spectrum of normal and malignant tissues need to be surveyed to determine whether this transdominant p73 variant occurs in a tumor-specific manner.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Russian Minist Hlth, Inst Biophys, Lab Mol Radiobiol, Moscow 123182, Russia; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Mater Med Res Inst, Brisbane, Qld 4101, Australia; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Ministry of Health of the Russian Federation; Hebrew University of Jerusalem; Mater Research; Royal Brisbane & Women's Hospital; University of Queensland	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.		Khanna, Kum Kum/I-1747-2013; Hobson, Keith/Q-9306-2019; Lavin, Martin F/F-5961-2014; McGuckin, Michael/G-2310-2010	Lavin, Martin F/0000-0002-5940-4769; McGuckin, Michael/0000-0002-8375-2675; Spring, Kevin/0000-0003-0601-924X; Khanna, Kum Kum/0000-0001-8650-5381				ALLDAY MJ, 1993, J GEN VIROL, V74, P361, DOI 10.1099/0022-1317-74-3-361; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gong JG, 1999, NATURE, V399, P806; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Miyake H, 1998, INT J ONCOL, V12, P469; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; POZNIAK CD, 2000, NATURE, V289, P304; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAMURA T, 1995, ONCOGENE, V11, P1939; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	43	113	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					514	522		10.1038/sj.onc.1204118	http://dx.doi.org/10.1038/sj.onc.1204118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313982				2022-12-28	WOS:000166562500011
J	Thomsen, P; van Deurs, B; Norrild, B; Kayser, L				Thomsen, P; van Deurs, B; Norrild, B; Kayser, L			The HPV16 E5 oncogene inhibits endocytic trafficking	ONCOGENE			English	Article						cytoskeleton; endocytic; human; papillomavirus; trafficking	HUMAN-PAPILLOMAVIRUS; H+-ATPASE; ONCOPROTEIN; ENDOSOMES; ACIDIFICATION; BAFILOMYCINS; EXPRESSION; LYSOSOMES; TRANSPORT; PROTEINS	The small hydrophobic E5 protein of Human Papillomavirus type 16 (HPV16) binds to the 16-kDa subunit of the V-H+-ATPase, This binding has been suggested to interfere with acidification of late endocytic structures. We here used video microscopy, ratio imaging and confocal microscopy of living C127 fibroblasts to study the effects of E5, Various endocytic markers including the pH-sensitive probe DM-NERF coupled to dextran, TransFluoSpheres and TRITC-concanavalin A, were applied. In ES-transfected cells, none of these markers colocalized with the membrane permeable probe Lyso-Tracker Red, which accumulates in acidic, late endocytic structures, or with a green fluorescent version of the small GTPase Rab7 labeling late endocytic structures. Importantly, however, late endocytic structures accumulating LysoTracker were still present in the E5-transfected cells. It is therefore concluded that HPV16 E5 perturbs trafficking from early to late endocytic structures rather than acidification.	Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Inst Mol Pathol, DK-2200 Copenhagen N, Denmark	University of Copenhagen; University of Copenhagen	van Deurs, B (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.							Bar-Ziv R, 1999, P NATL ACAD SCI USA, V96, P10140, DOI 10.1073/pnas.96.18.10140; Barois N, 1998, J CELL SCI, V111, P1791; BERGMAN P, 1988, ONCOGENE, V2, P453; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 1997, J EXP BIOL, V200, P1; Evans LL, 1998, J CELL SCI, V111, P2055; FAGOTTO F, 1994, J CELL SCI, V107, P3325; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; Harada M, 1997, LIVER, V17, P244; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P179, DOI 10.1113/jphysiol.1996.sp021583; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Johnsen CK, 1995, INTERVIROLOGY, V38, P339, DOI 10.1159/000150461; Lee RJ, 1996, BBA-MOL CELL RES, V1312, P237, DOI 10.1016/0167-4889(96)00041-9; Lin HJ, 1999, ANAL BIOCHEM, V269, P162, DOI 10.1006/abio.1999.4011; LYASS LA, 1984, P NATL ACAD SCI-BIOL, V81, P3098, DOI 10.1073/pnas.81.10.3098; Magez S, 1997, J CELL BIOL, V137, P715, DOI 10.1083/jcb.137.3.715; MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303; MCCANCE DJ, 1994, INFECT DIS CLIN N AM, V8, P751; MCCANCE DJ, 1985, BRIT J OBSTET GYNAEC, V92, P1101, DOI 10.1111/j.1471-0528.1985.tb03019.x; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; Venuti A, 1998, VIROLOGY, V248, P1, DOI 10.1006/viro.1998.9227; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; zur Hausen H, 1999, P ASSOC AM PHYSICIAN, V111, P581, DOI 10.1046/j.1525-1381.1999.99723.x	52	58	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6023	6032		10.1038/sj.onc.1204010	http://dx.doi.org/10.1038/sj.onc.1204010			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146554				2022-12-28	WOS:000165827900009
J	Ahrens, T; Sleeman, JP; Schempp, CM; Howells, N; Hofmann, M; Ponta, H; Herrlich, P; Simon, JC				Ahrens, T; Sleeman, JP; Schempp, CM; Howells, N; Hofmann, M; Ponta, H; Herrlich, P; Simon, JC			Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid	ONCOGENE			English	Article						malignant melanoma; hyaluronic acid; CD44; shedding	MAMMARY-CARCINOMA CELLS; HUMAN BREAST-CANCER; MATRIX REORGANIZATION; EXTRACELLULAR DOMAIN; METASTASIS FORMATION; SPLICE VARIANTS; L-SELECTIN; ADHESION; EXPRESSION; MIGRATION	Proteolytic cleavage of the extracellular domain of CD44 from the surface of cells has been observed recently in different cell types, In cell culture supernatants of human melanoma cell lines a 70 kDa soluble CD44 protein (soICD44) was detected at concentrations of 250-300 ng/ml. Protease inhibitor studies revealed that serine proteases and metalloproteases are involved in the cleavage of CD44 from the surface of melanoma cells. To analyse a possible function of soluble CD44 a human malignant melanoma cell line was stably transfected with cDNAs encoding either wild type soluble CD44s or mutated forms with defective HA binding properties (CD44sR41A and CD44sR150A/R154A). Soluble CD44s almost completely inhibited hyaluronic acid binding by melanoma cells, whereas soluble CD44 mutated in the HA binding domain had no effect, When cultivated on hyaluronic acid, melanoma cell proliferation was induced by 30% for both the parental and the control transfected cells. This increase in proliferation was blocked completely in solCD44s-secreting transfectants, whereas solCD44sR41A and solCD44sR150A/R154A-secreting cells again showed hyaluronic acid-induced cell proliferation, These cell lines were subcutaneously injected into MF1 nu/nu mice to compare their growth as tumors in vivo. Compared to tumors derived from parental and control transfected cells, we observed a dramatic reduction of primary tumor growth with solCD44s expressing MM cells. Transfectants expressing solCD44s mutated in the HA binding domain in contrast developed fast-growing primary tumors. These results provide strong evidence that direct solCD44 interactions with hyaluronic acid interfere competively with processes induced by hyaluronic acid binding to surface CD44, Autocrine, or drug-induced secretion of solCD44 by human melanoma cells may thus exert potent antitumoral effects in vivo.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Forschungszentrum Karlsruhe, Genet Inst, D-76021 Karlsruhe, Germany; Lion Biosci AG, D-69120 Heidelberg, Germany	University of Freiburg; Helmholtz Association; Karlsruhe Institute of Technology	Simon, JC (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.		Sleeman, Jonathan P/H-2515-2013; Hofmann-Apitius, Martin/E-6123-2018	Sleeman, Jonathan P/0000-0003-1718-7687; Hofmann-Apitius, Martin/0000-0001-9012-6720				Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1992, J IMMUNOL, V149, P747; BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BAZIL V, 1994, J IMMUNOL, V152, P1314; Champagne B, 1998, J IMMUNOL, V161, P6398; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Dietrich A, 1997, EUR J CANCER, V33, P926, DOI 10.1016/S0959-8049(96)00512-6; Fichtner I, 1997, ANTICANCER RES, V17, P3633; Friedl P, 1997, CANCER RES, V57, P2061; GALANDRINI R, 1994, J IMMUNOL, V153, P21; Goebeler M, 1996, J CELL SCI, V109, P1957; Greco RM, 1998, J CELL PHYSIOL, V177, P465, DOI 10.1002/(SICI)1097-4652(199812)177:3<465::AID-JCP9>3.0.CO;2-5; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; GUO YJ, 1994, CANCER RES, V54, P422; HAMANN KJ, 1995, J IMMUNOL, V154, P4073; Ichikawa T, 1999, J INVEST DERMATOL, V113, P935, DOI 10.1046/j.1523-1747.1999.00804.x; Itano N, 1999, CANCER RES, V59, P2499; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kosaki R, 1999, CANCER RES, V59, P1141; Lackner C, 1998, BREAST CANCER RES TR, V47, P29, DOI 10.1023/A:1005913514376; LECA G, 1995, J IMMUNOL, V154, P1069; LIAO HX, 1995, J IMMUNOL, V155, P3938; Maaser K, 1999, MOL BIOL CELL, V10, P3067, DOI 10.1091/mbc.10.10.3067; Martin S, 1997, INT J CANCER, V74, P443, DOI 10.1002/(SICI)1097-0215(19970822)74:4<443::AID-IJC14>3.3.CO;2-1; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; Rafi A, 1997, BLOOD, V89, P2901, DOI 10.1182/blood.V89.8.2901; Ropponen K, 1998, CANCER RES, V58, P342; Schaider H, 1997, J AM ACAD DERMATOL, V36, P209, DOI 10.1016/S0190-9622(97)70282-2; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Simon JC, 1996, EUR J CANCER, V32A, P1394, DOI 10.1016/0959-8049(96)00196-7; Sleeman JP, 1996, CANCER RES, V56, P3134; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TURLEY EA, 1987, BIOCHEMISTRY-US, V26, P2997, DOI 10.1021/bi00385a007; Victor R, 1999, INT J CANCER, V82, P77, DOI 10.1002/(SICI)1097-0215(19990702)82:1<77::AID-IJC14>3.0.CO;2-Q; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zawadzki V, 1998, INT J CANCER, V75, P919, DOI 10.1002/(SICI)1097-0215(19980316)75:6<919::AID-IJC15>3.3.CO;2-V; Zeimet AG, 1997, BRIT J CANCER, V76, P1646, DOI 10.1038/bjc.1997.611; ZHANG LR, 1995, CANCER RES, V55, P428	51	118	126	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3399	3408		10.1038/sj.onc.1204435	http://dx.doi.org/10.1038/sj.onc.1204435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423990				2022-12-28	WOS:000169248800010
J	Xue, LY; Chiu, SM; Oleinick, NL				Xue, LY; Chiu, SM; Oleinick, NL			Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-2; apoptosis; photodynamic therapy; Pc 4	PROSTATE-CANCER CELLS; CYTOCHROME-C; INDUCED APOPTOSIS; CASPASE ACTIVATION; TYROSINE KINASE; SINGLET OXYGEN; RELEASE; DEATH; MITOCHONDRIA; CLEAVAGE	Photodynamic therapy (PDT), utilizing a photosensitizer and visible light, causes localized oxidative damage. With the mitochondrial photosensitizer Pc 4, PDT induces apoptosis, yet its molecular targets are not known, Here, the anti-apoptotic protein Bcl-2 is shown to be highly sensitive to PDT, as judged on Western blots by the disappearance of anti-Bcl-2-reactive material from the position of the native 26 kDa protein. The loss of Bcl-2 was PDT dose dependent and was observed for both endogenous and overexpressed Bcl-2 in several cell lines, immediately after PDT, and with chilled cells. It was accompanied by a trace of a 23-kDa cleavage product as well as high-molecular weight products that may result from photochemical crosslinking. PDT-induced Bcl-2 loss occurred in MCF-7 cells that do not express caspase-3 or in the presence of protease inhibitors, but was prevented, along with the induction of apoptosis, by the singlet oxygen scavenger L-histidine. Loss of FLAG-Bcl-2 was observed with both anti-FLAG and anti-Bcl-2 antibodies, indicating loss of native protein rather than simple BCL-2-epitope destruction. Photochemical damage was not observed in Bcl-x(L), Bax, Bad, the voltage-dependent anion channel, or the adenine nucleotide translocator. Therefore, Bcl-2 is one target of PDT with Pc 4, and PDT damage to Bcl-2 contributes to its efficient induction of apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, BRB-324,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P01CA048735, P30CA043703, R01CA083917] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48735, R01 CA83917, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL R, 1991, CANCER LETT, V56, P125, DOI 10.1016/0304-3835(91)90086-W; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Carthy CM, 1999, LAB INVEST, V79, P953; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1996, CANCER RES, V56, P1253; HALLIWELL B, 1989, FREE RADICAL BIO MED, P66; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kim HRC, 1999, CANCER RES, V59, P3429; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang WG, 1999, PHOTOCHEM PHOTOBIOL, V69, P582, DOI 10.1562/0031-8655(1999)069<0582:ABRVIT>2.3.CO;2	44	180	198	1	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3420	3427		10.1038/sj.onc.1204441	http://dx.doi.org/10.1038/sj.onc.1204441			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423992				2022-12-28	WOS:000169248800012
J	Chan, TL; Yuen, ST; Ho, JWC; Chan, ASY; Kwan, KD; Chung, LP; Lam, PWY; Tse, CW; Leung, SY				Chan, TL; Yuen, ST; Ho, JWC; Chan, ASY; Kwan, KD; Chung, LP; Lam, PWY; Tse, CW; Leung, SY			A novel germline 1.8-kb deletion of hMLH1 mimicking alternative splicing: a founder mutation in the Chinese population	ONCOGENE			English	Article						hMLH1; germline mutation; intragenic deletion; alternative splicing; HNPCC syndrome	NONPOLYPOSIS COLORECTAL-CANCER; DNA MISMATCH REPAIR; HEREDITARY COLON-CANCER; MLH1 MESSENGER-RNA; MICROSATELLITE INSTABILITY; GENE-MUTATIONS; YOUNG-PATIENTS; HMSH2; MSH2; FAMILIES	We have previously reported that there is a high incidence of microsatellite instability (MSI) and germline mismatch repair gene mutation in colorectal cancer arising from young Hong Kong Chinese, Most of the germline mutations involve hMSH2, which is different from the mutation spectrum in the Western population. It is well known that alternative splicing is common in hMLH1, which complicates RNA based mutation detection methods. In contrast, large deletions in hMLH1, commonly observed in some ethnic groups, tend to escape detection by exon-by-exon direct DNA sequencing. Here we report the detection of a novel germline 1.8 kb deletion involving exon 11 of hMLH1 in a local hereditary non-polyposis colorectal cancer family. This mutation generates a mRNA transcript with deletion of exons 10-11, which is indistinguishable from one of the most common and predominant hMLH1 splice variants, A diagnostic test based on PCR of the breakpoint region led to the identification of an additional young colorectal cancer patient with this mutation. Haplotype analysis suggests that they may share a common ancestral mutation. Our results caution investigators in the interpretation of alternative splicing and have important implications for the design of hMLH1 mutation detection strategy in the Chinese population. Oncogene (2001) 20, 2976-2981.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Leung, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Leung, Suet Yi/C-4340-2009; Chung, Lap Ping/C-4258-2009; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, CANCER RES, V57, P3920; Bapat BV, 1999, HUM GENET, V104, P167, DOI 10.1007/s004390050931; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; Charbonnier F, 2000, CANCER RES, V60, P2760; CHARBONNIER F, 1995, CANCER RES, V55, P1839; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, J MED GENET, V33, P726, DOI 10.1136/jmg.33.9.726; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; Lamberti C, 1999, GUT, V44, P839, DOI 10.1136/gut.44.6.839; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Mauillon JL, 1996, CANCER RES, V56, P5728; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Palmer E, 1998, CHEM BRIT, V34, P27; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; Stelter A, 2000, INT FED INFO PROC, V51, P43; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wijnen J, 1996, AM J HUM GENET, V58, P300; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	41	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2976	2981		10.1038/sj.onc.1204376	http://dx.doi.org/10.1038/sj.onc.1204376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420710				2022-12-28	WOS:000168901800013
J	Nagasawa, M; Gelfand, EW; Lucas, JJ				Nagasawa, M; Gelfand, EW; Lucas, JJ			Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6)	ONCOGENE			English	Article						cyclin-dependent kinase 6; growth control; p53 protein; p130 protein	CDK-ACTIVATING KINASE; DIFFERENTIAL REGULATION; RETINOBLASTOMA-PROTEIN; G1 PHASE; PHOSPHORYLATION; PROGRESSION; POLYMERASE; IDENTIFICATION; MECHANISMS; INHIBITION	Cyclin-dependent kinase 6(cdk6) is present in randomly proliferating cultures of 3T3 cells but has little detectable enzymatic activity, Significant activity is detected only during a short period in early G1 phase. To examine the possible functions of cdk6 in 3T3 cells, lines stably over-expressing cdk6 were constructed and compared to normal 3T3 cells or cell lines with reduced cdk6 levels due to expression of a dominant-negative form of the protein, Over-expression of cdk6 in cells, which led to high levels of activity even in proliferating cultures, had dramatic effects, Cell lines stably over-expressing wild-type cdk6 had a markedly reduced growth rate compared to parental 3T3 cells or lines expressing a dominant-negative form of cdk6. They also over-produced the p53 and p130 proteins and had increased sensitivity to UV-irradiation. Irradiation resulted in accumulation of the Bas protein and rapid cell death, Levels of p53 and p130 proteins were downregulated and the growth rate of the cells was increased by introduction of the dominant-negative form of cdk6 into cells over-expressing cdk6, indicating that cdk6 is involved in the overproduction of p53 and p130. The results suggest that cdk6, through regulation of growth suppressing molecules, may play a role in halting cellular growth when proliferation is inappropriate. Oncogene, (2001) 20, 2889-2899.	Natl Jewish Med& Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Lucas, JJ (corresponding author), Natl Jewish Med& Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Nagasawa, Masayuki/CAI-8101-2022; Nagasawa, Masayuki/AAX-1734-2020	Nagasawa, Masayuki/0000-0002-8085-4940	NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042246, R01AI042246] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-42246] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; BATES S, 1994, ONCOGENE, V9, P71; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; ELDIERY WS, 1993, CELL, V75, P917; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Howard CM, 2000, CANCER RES, V60, P2737; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LeCouter JE, 1996, ONCOGENE, V12, P1433; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; LUCAS JJ, 1995, BLOOD, V86, P2268, DOI 10.1182/blood.V86.6.2268.bloodjournal8662268; LUCAS JJ, 1995, J CELL PHYSIOL, V165, P406, DOI 10.1002/jcp.1041650222; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIYASHITA T, 1995, CELL, V80, P293; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nagasawa M, 1997, J IMMUNOL, V158, P5146; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Ojala PM, 1999, CANCER RES, V59, P4984; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, SEMIN CELL BIOL, V5, P339; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Rickert P, 1996, ONCOGENE, V12, P2631; Sergere JC, 2000, BIOCHEM BIOPH RES CO, V276, P271, DOI 10.1006/bbrc.2000.3395; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SZEPESI A, 1994, BLOOD, V84, P3413; Tang D, 1996, Prog Cell Cycle Res, V2, P205; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TERADA N, 1991, J IMMUNOL, V147, P698; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	76	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2889	2899		10.1038/sj.onc.1204396	http://dx.doi.org/10.1038/sj.onc.1204396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420701				2022-12-28	WOS:000168901800004
J	Herrlich, P				Herrlich, P			Cross-talk between glucocorticoid receptor and AP-1	ONCOGENE			English	Review						immune response; NF-kappa B; tethering; CREB; GR D-loop mutation; genomic footprints	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; THYROID-HORMONE RECEPTOR; DNA-BINDING DOMAIN; RETINOIC ACID RECEPTORS; C-JUN; NUCLEAR FACTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; MEDIATED REPRESSION	Cross-talk between different transcription factors, notably between the glucocorticoid receptor and AP-1, has been discovered more than 10 years ago: a bona fide transcription factor, without apparent need For its own direct DNA contact, influences the activity of another transcription factor. Recent experiments have added interesting aspects: in addition to major insights into the mechanism of cross-talk, it is now clear that the cross-talk ability of glucocorticoid receptor is essential for mouse development, while the activation of target promoters carrying a glucocorticoid response element (GRE), is surprisingly, dispensable for survival under animal house conditions. Interestingly, the cross-talk function is responsible for almost all regulatory actions of cortisol in the immune system. It is possible that the two functions of the glucocorticoid receptor can be activated separately by specific ligands, Future goals will be to define whether adverse effects of long-term corticosteroid treatment, e,g, osteoporosis, joint necroses, metabolic effects, can be ascribed to GRE-target gene activation and thus be dissociated from the desirable actions in the treatment e,g, of autoimmune disease.	Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Forschungszentrum Karlsruhe, Inst Toxicol & Genet, POB 3640, D-76021 Karlsruhe, Germany.							Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baer M, 1999, COLD SPRING HARB SYM, V64, P437, DOI 10.1101/sqb.1999.64.437; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CATO ACB, 1992, J STEROID BIOCHEM, V43, P63, DOI 10.1016/0960-0760(92)90188-O; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cissel DS, 2000, J BIOL CHEM, V275, P7066, DOI 10.1074/jbc.275.10.7066; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DEBOSSCHER K, 2000, THESIS U GHENT; DEKLOET ER, 1993, CELL MOL NEUROBIOL, V13, P433, DOI 10.1007/BF00711582; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DiDomenico M, 1996, CANCER RES, V56, P4516; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEISSE S, 1982, EMBO J, V1, P1613, DOI 10.1002/j.1460-2075.1982.tb01363.x; Gewert K, 2000, BIOCHEM PHARMACOL, V60, P545, DOI 10.1016/S0006-2952(00)00358-0; Godowski P.J., 1989, UCLA S MOL CELLULAR, P197; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gonzalez MV, 1999, FEBS LETT, V459, P272, DOI 10.1016/S0014-5793(99)01257-0; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GutierrezRamos JC, 1997, IMMUNOL TODAY, V18, P329, DOI 10.1016/S0167-5699(97)01085-2; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hirasawa N, 1998, J IMMUNOL, V161, P4939; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONAT C, 1990, THESIS U KARLSRUHE; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; Miller W.L., 1995, ADRENAL CORTEX, P555; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; REICHARDT HM, 2001, IN PRESS P NATL ACAD; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Rider LG, 1996, J IMMUNOL, V157, P2374; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Tak PP, 1996, ARTHRITIS RHEUM, V39, P1077, DOI 10.1002/art.1780390702; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Tumlin JA, 1997, J CLIN INVEST, V99, P1217, DOI 10.1172/JCI119278; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; van Tilborg MAA, 2000, J MOL BIOL, V301, P947, DOI 10.1006/jmbi.2000.4001; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wang YS, 1997, J IMMUNOL, V159, P534; Widen C, 2000, J BIOL CHEM, V275, P39296, DOI 10.1074/jbc.M006943200; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; ZHANG W, 1991, BIOTECHNIQUES, V11, P60	121	173	181	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2465	2475		10.1038/sj.onc.1204388	http://dx.doi.org/10.1038/sj.onc.1204388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402341				2022-12-28	WOS:000168568700012
J	Bouscary, D; Lecoq-Lafon, C; Chretien, S; Zompi, S; Fichelson, S; Muller, O; Porteu, F; Dusanter-Fourt, I; Gisselbrecht, S; Mayeux, P; Lacombe, C				Bouscary, D; Lecoq-Lafon, C; Chretien, S; Zompi, S; Fichelson, S; Muller, O; Porteu, F; Dusanter-Fourt, I; Gisselbrecht, S; Mayeux, P; Lacombe, C			Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo)	ONCOGENE			English	Article						Gab proteins; phosphatidylinositol 3-kinase; Akt; thrombopoietin; cytokines; signal transduction	C-MPL LIGAND; PLECKSTRIN HOMOLOGY DOMAIN; GROWTH-FACTOR RECEPTOR; INDUCED MEGAKARYOCYTIC DIFFERENTIATION; PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; INSULIN-RECEPTOR; EPITHELIAL MORPHOGENESIS; SHC PHOSPHORYLATION	In this study, we show that upon thrombopoietin (Tpo) stimulation the two adapter proteins Gab1 and Gab2 are strongly tyrosine phosphorylated and associated with Shc, SHP2, PI 3-kinase and Grb2 in mpl-expressing UT7 cells. Although Gab1 and Gab2 seem to mediate overlapping biological signals in many cells, only Gab1 is expressed and phosphorylated in response to Tpo in primary human megakaryocytic progenitors; furthermore, it associates with the same proteins. Although a Low level of tyrosine phosphorylated IRS-2 protein is also detected in PI 3-kinase immunoprecipitates, cab proteins are the essential proteins associated with PI 3-kinase after Tpo stimulation. We demonstrate that, albeit no association is detected between the Tpo receptor mpl and Gab proteins, Y112 located in the C-terminal cytoplasmic domain of mpl is required for Gab1/2 tyrosine phosphorylation, Gab proteins are not tyrosine phosphorylated after Tpo stimulation of UT-7 and Ba/F3 cells expressing a mpl mutant lacking Y112. Moreover, no activation of the PI 3-kinase/Akt pathway is observed in cells expressing this mpl mutant. Finally, we show that this mutant does not allow cell proliferation, thereby confirming that PI 3-kinase activation is required for Tpo-induced cell proliferation.	Univ Paris 05, Hop Cochin, ICGM, INSERM,U363, F-75014 Paris, France; AP HP, Hop Cochin, Serv Hematol, Paris, France; Hop Cochin, Lab Rech Hemobiol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Lacombe, C (corresponding author), Univ Paris 05, Hop Cochin, ICGM, INSERM,U363, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018; PORTEU, Françoise/I-8445-2016; Dusanter-Fourt, Isabelle/P-4558-2017	PORTEU, Françoise/0000-0002-2403-4163; Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Bouscary, Didier/0000-0003-3654-5064				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BENIT L, 1994, J VIROL, V68, P5270; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CASE RD, 1994, J BIOL CHEM, V269, P10467; DAMEN JE, 1993, BLOOD, V82, P2296; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Geltz NR, 1998, BLOOD, V91, P930, DOI 10.1182/blood.V91.3.930.930_930_939; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Sattler M, 1997, J CELL PHYSIOL, V171, P28; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	37	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2197	2204		10.1038/sj.onc.1204317	http://dx.doi.org/10.1038/sj.onc.1204317			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402314				2022-12-28	WOS:000168404500001
J	Lindstrom, MS; Klangby, U; Wiman, KG				Lindstrom, MS; Klangby, U; Wiman, KG			p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53	ONCOGENE			English	Article						pl4ARF; MDM2; p53; nucleolus; Bmi-1; burkitt lymphoma	TUMOR-SUPPRESSOR GENE; B-CELL; INK4A/ARF LOCUS; C-MYC; MUTATIONS; ONCOGENE; P19(ARF); ASSOCIATION; METHYLATION; P16(INK4A)	The hallmark of Burkitt lymphoma (BL) is a constitutively activated c-myc gene that drives tumor cell growth. A majority of BL-derived cell lines also carry mutant p53, In addition, the p16INK4a promoter is hypermethylated in most BL biopsies and BL cell lines, leading to silencing of this gene, Activation of c-myc and/or cell cycle dysregulation can induce ARF expression and p53-dependent apoptosis, We therefore investigated the p14ARF-MDM2-p53 pathway in BL cell lines. p14ARF was expressed and localized to nucleoli in all BL carrying mutant p53, Three out of seven BL carrying wt p53 had a homozygous deletion of the CDKN2A locus that encodes both p14ARF and p16INK4a. Three BL carrying wild type p53 retained the CDKN2A locus and overexpressed MDM2, DNA sequencing revealed a point mutation in CDKN2A exon 2 in one of these BL, Seraphine, However, this point mutation did not affect p14ARF's nucleolar localization or ability to induce p53, The Bmi-1 protein that negatively regulates the p14ARF promoter and co-operates with c-myc in tumorigenesis was expressed at low to moderate levels in all BL analysed. Our results indicate that inactivation of the ARF-MDM2-p53 pathway is an essential step during the development of Burkitt lymphoma, presumably as a mechanism to escape c-myc induced apoptosis.	Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, SE-17176 Stockholm, Sweden; AB Sangtec Med, SE-16102 Bromma, Sweden	Karolinska Institutet; Karolinska University Hospital	Wiman, KG (corresponding author), Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, SE-17176 Stockholm, Sweden.		Lindström, Mikael S/AAA-1451-2019; Wiman, Klas/AAB-8399-2021	Lindström, Mikael S/0000-0003-1148-8497; Wiman, Klas/0000-0002-7113-524X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; BHATIA KG, 1992, CANCER RES, V52, P4273; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Cherney BW, 1997, CANCER RES, V57, P2508; CORDONCARDO C, 1994, CANCER RES, V54, P794; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ESTELLER M, 2000, CANCER RES, V60, P29; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Gutierrez MI, 1997, ANN ONCOL, V8, P987, DOI 10.1023/A:1008265304712; Gutierrez MI, 1999, CANCER RES, V59, P696; HAUPT Y, 1993, ONCOGENE, V8, P3161; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; KLEIN G, 1993, GENE, V135, P189, DOI 10.1016/0378-1119(93)90065-B; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRANKS G, 1995, BLOOD, V85, P893, DOI 10.1182/blood.V85.4.893.bloodjournal854893; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Voncken JW, 1999, J CELL SCI, V112, P4627; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WATANABE T, 1994, BLOOD, V84, P3158; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WIMAN KG, 1991, ONCOGENE, V6, P1633; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	48	74	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2171	2177		10.1038/sj.onc.1204303	http://dx.doi.org/10.1038/sj.onc.1204303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360201				2022-12-28	WOS:000168116700012
J	Fukuhara, S; Chikumi, H; Gutkind, JS				Fukuhara, S; Chikumi, H; Gutkind, JS			RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho?	ONCOGENE			English	Article						Rho; G proteins; Ras; signal transduction; G protein-coupled receptors	GUANINE-NUCLEOTIDE EXCHANGE; VAV PROTOONCOGENE PRODUCT; HETEROTRIMERIC G-PROTEINS; CONSTITUTIVELY ACTIVATING MUTATION; SERUM RESPONSE ELEMENT; CELL-SHAPE CHANGES; COUPLED RECEPTORS; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; LYSOPHOSPHATIDIC ACID		Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EN X, 2000, J CELL SCI, V113, P3673; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HEASLEY LE, 2001, IN PRESS ONCOGENE; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Hoff Ana O., 1999, Neoplasia (New York), V1, P485; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; ILLC D, 1995, NATURE, V377, P539; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kotlar TJ, 1997, J CLIN ENDOCR METAB, V82, P1020, DOI 10.1210/jc.82.4.1020; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LANGDON S, 1992, CANCER RES, V52, P4554; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; Offermanns S, 1999, N-S ARCH PHARMACOL, V360, P5, DOI 10.1007/s002109900030; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSENKILDE MM, 2001, IN PRESS ONCOGENE; SETHI T, 1992, CANCER RES, V52, pS2737; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sodhi A, 2000, CANCER RES, V60, P4873; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Teramoto H, 1997, J BIOL CHEM, V272, P10751; THOMAS F, 1992, CANCER RES, V52, P4872; UEDA T, 1990, J BIOL CHEM, V265, P9373; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	80	167	170	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1661	1668		10.1038/sj.onc.1204182	http://dx.doi.org/10.1038/sj.onc.1204182			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313914				2022-12-28	WOS:000168089800017
J	Belsches-Jablonski, AP; Biscardi, JS; Peavy, DR; Tice, DA; Romney, DA; Parsons, SJ				Belsches-Jablonski, AP; Biscardi, JS; Peavy, DR; Tice, DA; Romney, DA; Parsons, SJ			Src family kinases and HER2 interactions in human breast cancer cell growth and survival	ONCOGENE			English	Article						Src family kinases; heregulin; breast cancer; HER2/neu; cell growth; apoptosis	PROTEIN-TYROSINE KINASES; ERBB SIGNALING NETWORK; FACTOR RECEPTOR; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIATION FACTOR; NEU PROTOONCOGENE; EPITHELIAL-CELLS; OVARIAN-CANCER; A431 CELLS	Evidence from murine fibroblast models and human breast cancer cells indicates that c-Src and human EGF receptor (HER1) synergize to enhance neoplastic growth of mammary epithelial cells, To investigate whether interactions between c-Src and other HER members may also play a role in breast tumor progression, we characterized 13 human breast carcinoma cell lines and 13 tumor samples for expression of HER family members and c-Src and examined a subset of the cell lines for Src-dependent, heregulin (HRG)-augmented, anchorage-dependent and independent growth. By immunoblotting, we found that all cell lines overexpressed one or more HER family member, and 60% overexpressed c-Src, Seventy-five per cent of the tumor tissues overexpressed HER2, while 64% overexpressed c-Src, Colony formation in soft agar was enhanced by HRG in three of five cell lines tested, a response that correlated,vith the presence of a c-Src/HER2 heterocomplex, This result suggests that HRG may act through both HER2 and c-Src to facilitate anchorage-independent growth. In contrast, HRG had little effect on anchorage-dependent growth in any of the cell lines tested. PP1, a Src family kinase inhibitor, reduced or ablated HRG-dependent and independent soft agar growth or anchorage dependent growth, and triggered apoptosis in all cell lines tested. The apoptotic effect of PP1 could be partially or completely reversed by HRG, depending on the cell line. These results suggest that while Src family kinases may cooperate with HRG to promote the survival and growth of human breast tumor cells, they also function independently of HER2/HRG in these processes.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Lynchburg Coll, Biol Program, Lynchburg, VA 24501 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NCI NIH HHS [CA71449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; BERCHUCK A, 1990, CANCER RES, V50, P4087; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KAMEDA T, 1990, CANCER RES, V50, P8002; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPERS GJL, 1991, BRIT J CANCER, V64, P469, DOI 10.1038/bjc.1991.333; KERN JA, 1990, CANCER RES, V50, P5184; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; LINSLEY PS, 1980, J SUPRAMOL STR CELL, V14, P441, DOI 10.1002/jss.400140404; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MAGUIRE HC, 1992, PATHOBIOLOGY, V60, P117; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PIERCE JH, 1991, ONCOGENE, V6, P1189; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SAINSBURY JRC, 1987, LANCET, V1, P1398; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VILLANUEVA A, 1984, HISTOCHEMISTRY, V81, P103, DOI 10.1007/BF00495409; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	63	153	157	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1465	1475		10.1038/sj.onc.1204205	http://dx.doi.org/10.1038/sj.onc.1204205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313890				2022-12-28	WOS:000167595200007
J	Suen, TC; Goss, PE				Suen, TC; Goss, PE			Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene	ONCOGENE			English	Article						BRCA1; breast cancer; transcriptional regulation; intron; repressor	SPORADIC BREAST-CANCER; RNA-POLYMERASE-II; OVARIAN-CANCER; CELL-CYCLE; MESSENGER-RNA; NUCLEAR PHOSPHOPROTEIN; GROWTH-RETARDATION; SOMATIC MUTATIONS; EPITHELIAL-CELLS; PROMOTER REGION	Loss or lowered expression of BRCA1 in non-familial breast cancer has been shown in several recent studies. Understanding how BRCA1 expression is regulated should provide new insights into the role of BRCA1 in sporadic breast cancer. We have recently identified a critical 18-base pair (bp) DNA element within the minimal BRCA1 promoter whereupon the formation of a specific protein-DNA complex and transcription of BRCA1 is dependent. We now report a non tissue-specific transcriptional repressor activity, located more than 500 bp into the first intron of BRCA1. Progressive deletions from the 3'-end of intron I and reporter gene assays localized the repressor activity to an 83-bp region. Electrophoretic mobility shift assays with this 83 bp DNA and various sub-fragments of it showed binding of nuclear proteins to a 36 bp BstNI-BseRI fragment. Functional transcriptional repression by this 36 bp DNA could be conferred on a heterologous thymidine kinase promoter. Analysis of multiple reporter gene constructs containing the BRCA1 genomic region driving transcription in both directions suggests that the putative negative regulatory element functions to block transcription only in the BRCA1 direction, although the promoter is shared by the divergently transcribed NBR2 gene.	Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Dept Med Oncol, Breast Grp, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Goss, PE (corresponding author), Toronto Hosp, Oncol Res Labs, Breast Canc Prevent Program, Toronto, ON M5G 2M9, Canada.							Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YM, 1996, CANCER RES, V56, P3168; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobrovic A, 1997, CANCER RES, V57, P3347; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Husain A, 1998, CANCER RES, V58, P1120; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rao VN, 1996, ONCOGENE, V12, P523; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Suen TC, 2000, J BIOL CHEM, V275, P6600, DOI 10.1074/jbc.275.9.6600; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; van der Looij M, 2000, GENE CHROMOSOME CANC, V27, P295, DOI 10.1002/(SICI)1098-2264(200003)27:3<295::AID-GCC10>3.0.CO;2-F; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	64	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					440	450		10.1038/sj.onc.1204078	http://dx.doi.org/10.1038/sj.onc.1204078			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313975				2022-12-28	WOS:000166562500004
J	Tsuiki, H; Nitta, M; Tada, M; Inagaki, M; Ushio, Y; Saya, H				Tsuiki, H; Nitta, M; Tada, M; Inagaki, M; Ushio, Y; Saya, H			Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines	ONCOGENE			English	Article						hyperploidy; spindle assembly checkpoint; glioma; microtubule inhibitor; staurosporine	PROTEIN-KINASE; SPINDLE DISRUPTION; CYCLE CHECKPOINT; MAMMALIAN-CELLS; MITOTIC EXIT; P53; STAUROSPORINE; MITOSIS; PROGRESSION; ARREST	Checkpoint mechanism plays a crucial role in ensuring genomic integrity during cell cycle. Loss of checkpoint function is known to induce genomic instability and to alter ploidy of dividing cells. In this study, we examined mechanisms of hyperploid formation in glioma cells by treatment with nocodazole, which activates spindle assembly checkpoint by inhibiting microtubule polymerization. By prolonged nocodazole treatment, U251MG human glioma cell, which has a p53 mutation, underwent transient arrest at mitosis, and subsequently exited from mitotic arrest (termed 'mitotic slippage') followed by DNA replication without cytokinesis, resulting in hyperploid formation. Additionally, the heterogeneity in the number of centrosomes per cell increased during the hyperploid formation, suggesting that these hyperploid cells have genomic instability. By employing LN382 glioma cell that has a temperature-sensitive p53 mutation, Ne found that the activation of p53 prevents hyperploid formation after the prolonged nocodazole treatment. Furthermore, staurosporine, an inhibitor for a broad range of serine/threonine kinases including cdc2, was found to enhance hyperploid formation in U251MG cells by accelerating the induction of mitotic slippage. Interestingly, inhibitors specific for cdc2 kinase prevented the G2 to M transition but did not accelerate mitotic slippage, suggesting that staurosporine-sensitive kinases other than cdc2 are required for maintenance of spindle assembly checkpoint. Moreover, the enhancement of hyperploid formation by staurosporine was also blocked by p53-dependent G1 checkpoint. These results suggest that abrogation of G1 checkpoint is a critical factor for formation of hyperploid cells after the mitotic slippage.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8600811, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Nagoya, Aichi 4640021, Japan	Kumamoto University; Kumamoto University; Hokkaido University; Aichi Cancer Center	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Hongo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013; Inagaki, Masaki/B-9920-2016					ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BRUNO S, 1992, CANCER RES, V52, P470; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Hall LL, 1996, CANCER RES, V56, P3551; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Khan SH, 1998, CANCER RES, V58, P396; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; RIEDER CL, 1992, J CELL SCI, V102, P387; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tsuiki H, 2000, J CELL BIOCHEM, V76, P254, DOI 10.1002/(SICI)1097-4644(20000201)76:2<254::AID-JCB9>3.0.CO;2-G; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; Verdoodt B, 1999, MUTAGENESIS, V14, P513, DOI 10.1093/mutage/14.5.513; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1	31	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					420	429		10.1038/sj.onc.1204126	http://dx.doi.org/10.1038/sj.onc.1204126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313973				2022-12-28	WOS:000166562500002
J	Scully, R; Puget, N; Vlasakova, K				Scully, R; Puget, N; Vlasakova, K			DNA polymerase stalling, sister chromatid recombination and the BRCA genes	ONCOGENE			English	Article						BRCA1; BRCA2; DNA polymerase; genomic integrity; homologous recombination; sister chromatid	DOUBLE-STRAND BREAKS; WERNERS-SYNDROME GENES; CELL-CYCLE REGULATION; BLOOMS-SYNDROME; MEIOTIC CELLS; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; TARGETED DISRUPTION	Heritable predisposition to breast and/or ovarian cancer is determined, in part, by germline mutation affecting one of two tumor suppressor genes, BRCA1 and BRCA2 (Miki et al., 1994; Wooster et al., 1995). These genes are required for the maintenance of genomic integrity and for control of homologous recombination in somatic and meiotic cells. Here, we explore the hypothesis that a major role of the BRCA gene products in the somatic DNA damage response centers upon the control of recombination between sister chromatids during S phase. By analogy with model organisms, we suggest that stalling of a mammalian DNA polymerase complex by its encounter with abnormal DNA structure calls forth a series of responses that collaborate to enforce appropriate recombinational outcomes, and to suppress inappropriate or 'illegitimate' recombination.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Scully, R (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		PUGET, Nadine/AAB-9689-2020; Scully, Ralph/F-5008-2013	PUGET, Nadine/0000-0003-4046-737X	NATIONAL CANCER INSTITUTE [K01CA079576] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akgun E, 1997, MOL CELL BIOL, V17, P5559, DOI 10.1128/MCB.17.9.5559; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bertwistle D, 1997, CANCER RES, V57, P5485; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boddy Michael N., 1999, Frontiers in Bioscience, V4, pd841, DOI 10.2741/Boddy; Bridges BA, 1999, CURR BIOL, V9, pR475, DOI 10.1016/S0960-9822(99)80299-1; Brown EJ, 2000, GENE DEV, V14, P397; Burgess SM, 1999, GENE DEV, V13, P1871, DOI 10.1101/gad.13.14.1871; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x; FORNACE AJ, 1983, NATURE, V304, P552, DOI 10.1038/304552a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; HAND R, 1977, HUM GENET, V38, P297, DOI 10.1007/BF00402156; HOWARD-FLANDERS P., 1966, Radiation Research, V6, P156, DOI 10.2307/3583555; HUANG CC, 1975, P SOC EXP BIOL MED, V148, P1244; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KADYK LC, 1992, GENETICS, V132, P387; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Merrill BJ, 1998, GENETICS, V148, P611; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MONTEIRO ANA, 2000, IN PRESS TRENDS BIOC; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; SARASIN AR, 1980, J MOL BIOL, V138, P299, DOI 10.1016/0022-2836(80)90288-0; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH KC, 1970, J MOL BIOL, V51, P459, DOI 10.1016/0022-2836(70)90001-X; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Y, 2000, GENE DEV, V14, P927; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WU X, 2000, SCIENCE, V289, pA11; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	80	56	60	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6176	6183		10.1038/sj.onc.1203971	http://dx.doi.org/10.1038/sj.onc.1203971			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156531				2022-12-28	WOS:000166121400011
J	Bessa, M; Saville, MK; Watson, RJ				Bessa, M; Saville, MK; Watson, RJ			Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator	ONCOGENE			English	Article						B-Myb; cyclin A; phosphorylation; CBP; transcriptional regulation	NEGATIVE REGULATORY DOMAIN; TERMINAL CONSERVED DOMAIN; HUMAN C-MYB; CELL-CYCLE; A-MYB; TRANSCRIPTIONAL COACTIVATOR; HEMATOPOIETIC-CELLS; BINDING ACTIVITY; GENE-PRODUCT; ACTIVATION	Expression of the B-Myb transcription factor is directed by an E2F-dependent transcriptional mechanism to late G1 and S phases of the cell cycle, where its transactivation properties are enhanced post-translationally by cyclin A/Cdk2-mediated phosphorylation, Other experiments have shown that removal of the B-Myb C-terminus constitutively activates both transactivation and DNA-binding activities, suggesting that autoregulation by this inhibitory domain is counteracted by phosphorylation. We report here on further experiments to examine this hypothesis. The importance of this We report here on further experiments to examine this hypothesis. The importance of this modification was first emphasized by showing that co-transfected dominant-negative Cdk2 (Cdk2DN) substantially reduced B-Myb transactivation activity. We then attempted to map the autoregulatory domain by analysing a series of progressively deleted C-terminal B-Myb mutants. Removal of just 29 C-terminal aa increased transactivation appreciably, however, maximal activity required removal of 143 amino acids (as in B-Myb+561). Enhanced B-Myb+561 function correlated with the acquisition of DNA binding activity to a single Myb binding site (MBS) oligonucleotide as determined by bandshift assays, however, further assays showed that even wt B-Myb could bind a DNA fragment containing three MBS. Although transactivation by B-Myb was severely dependent on hyperphosphorylation, neither inhibiting this activity by co-transfecting Cdk2DN nor augmenting it with cyclin A resulted in significant effects on DNA-binding. We also found that B-Myb could synergize with the CBP coactivator and that this cooperativity was cyclin A/Cdk2-dependent. Despite this, the physical association between these proteins was not influenced by the B-Myb phosphorylation status. We discuss these findings in relation to the autoregulation of B-Myb by the C-terminal domain.	Imperial Coll Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Imperial Coll Sch Med, Sect Virol & Cell Biol, Norfolk Pl,St Marys Campus, London W2 1PG, England.							Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; GOLAY J, 1991, BLOOD, V77, P149; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; Humbert-Lan G, 1999, J BIOL CHEM, V274, P10293, DOI 10.1074/jbc.274.15.10293; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kamano H, 1995, ONCOGENE, V11, P2575; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Vorbrueggen G, 1996, BIOL CHEM, V377, P721, DOI 10.1515/bchm3.1996.377.11.721; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282	53	35	35	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3376	3386		10.1038/sj.onc.1204439	http://dx.doi.org/10.1038/sj.onc.1204439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423988				2022-12-28	WOS:000169248800008
J	Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Ellis, E; Fisher, PB; Dent, P				Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Ellis, E; Fisher, PB; Dent, P			Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways	ONCOGENE			English	Article						ionizing radiation; MAPK; JNK; AP-1; VEGF; PEG-3; apoptosis	SQUAMOUS CARCINOMA-CELLS; BREAST-CANCER CELLS; FACTOR-ALPHA; GLIOBLASTOMA-MULTIFORME; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; GENE-EXPRESSION; A431 CELLS; FACTOR-I; INHIBITION	We investigated the role of radiation-induced mitogen activated protein kinase (MAPK) pathway activity in the regulation of proliferation, cell survival and vascular endothelial growth factor (VEGF) production in primary astrocytes and in To and RT2 glioblastoma cells derived from Fisher 344 rats, In these cells, ionizing radiation (2 Gy) caused activation of the MAPK pathway which was blocked by specific inhibitor drugs, Blunting of radiation-induced MAPK activity weakly enhanced radiation-induced apoptosis 24 h after exposure in RT2 cells, Furthermore, blunting of MAPK activation weakly enhanced the ability of radiation to reduce RT2 cell growth in clonogenic growth assays, These findings argue that inhibition of MAPK signaling reduces proliferation and enhances cell killing by ionizing radiation in transformed astrocytes, Proliferation and survival of cancer cells has been linked in vivo to enhanced expression of angiogenic growth factors, Recently we demonstrated that the gene product of a novel rodent radiation-responsive gene, progression elevated gene 3 (PEG-3), could enhance vascular endothelial growth factor (VEGF) promoter activity in rodent fibroblasts, leading to increased VEGF protein levels and tumorigenic behavior in vivo. Thus PEG-3 and VEGF expression could be expected to directly correlate with the oncogenic potential of transformed cells, RT2 cells expressed more PEG-3 and VEGF protein than To cells, and were more tumorigenic in vivo than To cells, Radiation activated the PEG-3 promoter via MAPK signaling and ectopic over-expression of PEG-3 enhanced both basal MARK activity and basal VEGF promoter activity, Basal MAPK activity partially correlated with basal VEGF promoter activity and VEGF protein levels in primary astrocytes, T9 and RT2 cells, Radiation increased the activity of the VEGF promoter and VEGF protein levels in primary astrocytes, T9 and RT2 cells which were dependent upon MAPK function, Furthermore, inhibition of AP-1 transcription factor signaling by dominant negative c-Jun (TAM67) also significantly reduced basal, and to a lesser extent radiation-induced, VEGF promoter function in RT2 cells, Collectively, our data demonstrate that radiation-induced MAPK signaling can both protect cells: from radiation-induced cell death as well as enhance protein levels of pro-angiogenic factors such as VEGF, Enhanced VEGF expression in RT2 cells may be mediated via MAPK and JNK pathway signaling which converges upon the AP-1 transcription factor complex.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Dept Urol & Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Columbia University; Columbia University	Dent, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, 401 Coll St, Richmond, VA 23298 USA.				NCI NIH HHS [CA35675] Funding Source: Medline; NIDDK NIH HHS [DK52875] Funding Source: Medline; NIGMS NIH HHS [GM31452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031452] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Cartee L, 2000, INT J ONCOL, V16, P413; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chmura SJ, 1997, CANCER RES, V57, P4340; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hossain MA, 2000, J BIOL CHEM, V275, P27874; Huhn SL, 1999, CLIN CANCER RES, V5, P1435; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kraus JA, 2000, J NEUROL, V247, P455, DOI 10.1007/s004150070175; Levenson AS, 1998, BRIT J CANCER, V77, P1812, DOI 10.1038/bjc.1998.301; Li ZG, 2000, INT J ONCOL, V17, P453; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Park JS, 1999, MOL BIOL CELL, V10, P4231, DOI 10.1091/mbc.10.12.4231; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Putz T, 1999, CANCER RES, V59, P227; Rak J, 2000, CANCER RES, V60, P490; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHMIDTULLRICH RK, 1992, INT J RADIAT BIOL, V61, P405, DOI 10.1080/09553009214551101; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Slevin M, 2000, NEUROREPORT, V11, P2759, DOI 10.1097/00001756-200008210-00030; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zundel W, 2000, GENE DEV, V14, P391	46	114	122	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3266	3280		10.1038/sj.onc.1204258	http://dx.doi.org/10.1038/sj.onc.1204258			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423976				2022-12-28	WOS:000169163500010
J	Tarapore, P; Horn, HF; Tokuyama, Y; Fukasawa, K				Tarapore, P; Horn, HF; Tokuyama, Y; Fukasawa, K			Direct regulation of the centrosome duplication cycle by the p53-p21(Waf1/Cip1) pathway	ONCOGENE			English	Article						centrosome duplication; Waf1; p53; CDK2; cyclin E	CELL-CYCLE; MAMMALIAN-CELLS; CHROMOSOME INSTABILITY; GENOMIC INSTABILITY; DEPENDENT KINASES; PHASE-TRANSITION; PROTEIN-KINASE; P53; EXPRESSION; INHIBITOR	The function of the centrosomes to direct mitotic spindles is critical for accurate chromosome transmission to daughter cells. Since each daughter cell inherits one centrosome, each centrosome must duplicate prior to the next mitosis, and do so only once, Thus, there are control mechanism(s) that ensure the coordinated progression of centrosome duplication and other cell cycle events (i,e, DNA synthesis), and limit centrosome duplication to once per cell cycle, Deregulation of the centrosome duplication cycle results in abnormal amplification of centrosomes, leading to aberrant mitoses and increased chromosome transmission errors, This has been found to be the case for cells lacking functional p53 tumor suppressor protein. However, it had remained to be determined whether the deregulation of the centrosome duplication cycle is the direct or indirect effect of loss/mutational inactivation of p53, Here, we found that the normal centrosome duplication cycle is almost completely restored in p53(-/-) cells by re-introduction of wild-type p53 at a physiologically relevant level, demonstrating that p,53 is directly involved in the regulation of centrosome duplication, Since cyclin dependent kinase 2 (CDK2)/cyclin E triggers DNA synthesis as well as centrosome duplication, we tested whether Waf1, a CDK inhibitor and a major target of p53's transactivation function, is an effector of p,53-mediated regulation of centrosome duplication, We found that induced expression of Waf1 in p53(-/-) cells only partially restored the centrosome duplication control, suggesting that Waf1 comprises one of the multiple effector pathways of the p53-mediated regulation of the centrosome duplication cycle.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Horn, Henning/0000-0002-5885-8996				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BORNENS M, 1992, CENTROSOME, V6, P1; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORO F, 1995, CARCINOGENESIS, V16, P2435, DOI 10.1093/carcin/16.10.2435; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pihan GA, 1998, CANCER RES, V58, P3974; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tournier Frederic, 1994, V13, P303; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Wahl GM, 1997, CANCER SURV, V29, P183; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	52	120	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3173	3184		10.1038/sj.onc.1204424	http://dx.doi.org/10.1038/sj.onc.1204424			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423967				2022-12-28	WOS:000169163500001
J	Fattman, CL; Delach, SM; Dou, QP; Johnson, DE				Fattman, CL; Delach, SM; Dou, QP; Johnson, DE			Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis	ONCOGENE			English	Article						retinoblastoma; caspase; apoptosis; etoposide; cleavage	S-PHASE ENTRY; TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-CYCLE; P53-MEDIATED APOPTOSIS; SUSCEPTIBILITY GENE; CANCER-CELLS; RB; DEPHOSPHORYLATION; E2F-1	During cellular apoptosis, retinoblastoma protein (RB) is subjected to cleavage near the carboxyl terminus by a caspase-3-like protease, In addition, an heretofore unidentified protease cleaves RB internally, generating fragments of 68 and 48 kDa, Internal cleavage abrogates the ability of RB to associate with E2F, To investigate the mechanism of RB internal cleavage, we developed and employed an in vitro cleavage assay. Incubation of in vitro translated S-35-RB with apoptotic cell extracts led to RB cleavage at the C-terminus, followed by internal cleavage. The caspase peptide inhibitors z-VAD-FMK or z-DEVD-FMK blocked both cleavage events. Rapid C-terminal and internal cleavage were also observed when recombinant caspase-3 was added to S-35-RB. Moreover, when caspase-3 was added to nonapoptotic cell extract, efficient internal cleavage of cellular RB was observed. Caspase-mediated internal cleavage occurred following RB residue aspartate(349) in the sequence DSID349. This sequence is consistent with a DXXD recognition motif for caspase-3-like enzymes. Interestingly, ne also observed RB internal cleavage in caspase-3-deficient MCF-7 cells, indicating that other caspases are capable of cleaving RB internally. Indeed, caspase-7, a member of the caspase-3 subfamily, was found to cleave S-35-RB at both the carboxyl terminus, and following aspartate(349). By contrast, caspases that are not members of the caspase-3 subfamily failed to cleave RB. Taken together, our findings demonstrate that during apoptosis, a caspase-3-like protease is responsible for degradation and functional inactivation of RB by cleaving the protein internally following aspartate(349). Oncogene (2001) 20, 2918-2926.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Biochem & Mol Biol, Drug DIscovery Program, Tampa, FL 33612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Johnson, DE (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Div Hematol Oncol, BST E1055,211 Lothrop St, Pittsburgh, PA 15213 USA.			Dou, Qingping/0000-0002-6465-1473	NATIONAL CANCER INSTITUTE [R29CA066044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG013300, R29AG013300] Funding Source: NIH RePORTER; NCI NIH HHS [CA66044] Funding Source: Medline; NIA NIH HHS [AG13300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Berry DE, 1996, ONCOGENE, V12, P1809; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Dou QP, 1997, APOPTOSIS, V2, P5; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Fattman CL, 1998, CANCER LETT, V130, P103, DOI 10.1016/S0304-3835(98)00121-9; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HASSKOGAN DA, 1995, EMBO J, V14, P461; HAUPT Y, 1995, ONCOGENE, V10, P1563; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kurokawa H, 1999, ONCOL REP, V6, P33; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; McConkey DJ, 1996, ONCOGENE, V13, P1693; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	38	46	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2918	2926		10.1038/sj.onc.1204414	http://dx.doi.org/10.1038/sj.onc.1204414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420704				2022-12-28	WOS:000168901800007
J	Rudolph, B; Hueber, AO; Evan, GI				Rudolph, B; Hueber, AO; Evan, GI			Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation	ONCOGENE			English	Article						Myc; Mad; oncogene; cell cycle; lymphocyte; tumor suppressor	MYC-MEDIATED APOPTOSIS; WILD-TYPE P53; C-MYC; CYCLE PROGRESSION; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSORS; MAX; ACTIVATION; MICE; DIFFERENTIATION	To investigate Mad1 function in vivo, transgenic mice were:generated that express a Mad1 transgene in T lineage cells under the control of the proximal lck promoter. Thymus size in lck-Mad1 transgenic mice is drastically reduced although representation of the various thymocyte sub populations appears normal. To investigate more closely any effects of Mad1 expression on thymocytes, we examined thymic selection using MHC class I-restricted H-Y-TCR transgenic mice. Mad1 expression in vivo reduces the efficiency of positive selection. Furthermore, thymocytes and splenic T cells from lck-Mad1 transgenic mice display a profound proliferative defect in response to activation with either PMA/lonomycin or immobilized anti-CD3/CD28 antibody. This proliferative defect is not reversed by addition of exogenous IL-2 and is p53-independent. The growth inhibition caused by Mad1 is overcome by expression of active c-Myc.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Evan, GI (corresponding author), Univ Calif San Francisco, Ctr Canc, 2340 Sutter St, San Francisco, CA 94143 USA.		Anne-Odile, Hueber/P-9860-2019; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BACKWOOD EM, 1992, GENE DEV, V6, P71; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BroussardDiehl C, 1996, J IMMUNOL, V156, P3141; CARDING S, 1987, THYMUS, V10, P219; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EDELHOFF S, 1994, ONCOGENE, V9, P665; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELSON A, 1995, ONCOGENE, V11, P181; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; Kiermaier A, 1997, CURR BIOL, V7, pR505, DOI 10.1016/S0960-9822(06)00249-1; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MOORE JP, 1987, ONCOGENE RES, V2, P65; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Rudolph B, 2000, ONCOGENE, V19, P1891, DOI 10.1038/sj.onc.1203508; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STEWART M, 1993, INT J CANCER, V53, P1023; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	56	17	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1164	1175		10.1038/sj.onc.1204196	http://dx.doi.org/10.1038/sj.onc.1204196			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313860				2022-12-28	WOS:000167570100003
J	Yuen, PH; Ryan, EA; Devroe, E; Wong, PKY				Yuen, PH; Ryan, EA; Devroe, E; Wong, PKY			A single Glu(62)-to-Lys(62) mutation in the Mos residues of the R7 Delta 447Gag-tMos protein causes the mutant virus to induce brain lesions	ONCOGENE			English	Article						Mos mutation; MEK; ERK; brain lesions	MURINE LEUKEMIA-VIRUS; MYELOPROLIFERATIVE SARCOMA-VIRUS; TEMPERATURE-SENSITIVE MUTANTS; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; TRANSFORMING GENE; OOCYTE MATURATION; CYTOSTATIC FACTOR; KINASE CASCADE; C-MOS	We previously reported that R7 Delta 447, a 2954-base-pair (bp) laboratory-generated Moloney murine sarcoma virus, induced subcutaneous tumors in about 14% of infected mice but did not induce brain lesions. We now report that R7 Delta 447K, a spontaneous mutant of R7 Delta 447, induced brain lesions as well as subcutaneous tumors in all injected mice. The genomes of the two viruses differ in a single base pair: the deduced Glu(62) of the Mos residue of the R7 Delta 447 Gag-tMos protein is changed to Lys(62), More R7 Delta 447 than R7 Delta 447K focus-forming units were detected in both NIH3T3 and mouse cerebral vascular endothelial (MCVE) cells. However, R7 Delta 447K transformed NIH3T3 and MCVE: cells more acutely than did R7 Delta 447. A distinctive feature that distinguished the morphologic transformation of R7 Delta 447- and R7 Delta 447K-infected MCVE cells is the markedly prolonged spindle-shaped phase exhibited by R7 Delta 447-infected MCVE cells. In addition, R7 Delta 447K was more efficient in inducting the phosphorylation of ERK1/2 than R7 Delta 447 in both MCVE and NIH3T3 cells. Moreover morphologic transformation was inhibited, and levels of phosphorylated ERK1/2 were reduced when R7 Delta 447- or R7 Delta 447K-infected NIH3T3 or MCVE cells were grown in the presence of the MEK1/2-specific inhibitor PD98095. Thus, ne have identified a key residue in the Gag-tMos protein that profoundly affects activation of the Mos/MEK/ERK pathway, virus and cell replication, morphologic transformation in vitro and pathogenicity in vivo.	Univ Texas, MD Anderson Canc Ctr, Div Res, Dept Carcinogenesis, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Yuen, PH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Res, Dept Carcinogenesis, Sci Pk, Smithville, TX 78957 USA.				NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALROY J, 1987, HISTOCHEMISTRY, V86, P603, DOI 10.1007/BF00489554; BERMAN LD, 1969, INT J CANCER, V4, P820, DOI 10.1002/ijc.2910040611; BOUSSEKERDILES MCL, 1980, EUR J CANCER, V16, P43, DOI 10.1016/0014-2964(80)90106-1; BROW MAD, 1984, J VIROL, V49, P579, DOI 10.1128/JVI.49.2.579-582.1984; CHIRIGOS MA, 1968, INT J CANCER, V3, P223, DOI 10.1002/ijc.2910030207; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; GAZDAR AF, 1972, INT J CANCER, V9, P219; GONZALEZSCARANO F, 1995, RETROVIRIDAE, V4, P409; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HAYASHI Y, 1988, PATHOL RES PRACT, V183, P314, DOI 10.1016/S0344-0338(88)80128-6; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Lim KY, 2000, J NEUROVIROL, V6, P106, DOI 10.3109/13550280009013154; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; OKAZAKI K, 1995, ONCOGENE, V10, P1149; OSTERTAG W, 1980, J VIROL, V33, P573, DOI 10.1128/JVI.33.2.573-582.1980; PERK K, 1966, J NATL CANCER I, V37, P581; PHAM CD, 1995, ONCOGENE, V10, P1683; PROPST F, 1990, P NATL ACAD SCI USA, V87, P9703, DOI 10.1073/pnas.87.24.9703; PROPST F, 1992, J NEUROPATH EXP NEUR, V51, P499, DOI 10.1097/00005072-199209000-00004; PULS A, 1995, ONCOGENE, V10, P623; RIBACCHI RODOLFO, 1966, LAV IST ANAT ISTOL PATOL UNTV STUDI PERUGIA, V26, P149; Robertson SC, 1996, MOL CELL BIOL, V16, P3472; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SIMONS PJ, 1970, J NATL CANCER I, V44, P1289; STACEY A, 1984, J VIROL, V50, P725, DOI 10.1128/JVI.50.3.725-732.1984; STANTON MF, 1968, J NATL CANCER I, V40, P1113; STOICA G, 1990, AM J PATHOL, V136, P933; TOPOL LZ, 1995, CELL GROWTH DIFFER, V6, P1119; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WONG PKY, 1990, CURR TOP MICROBIOL, V160, P29; WONG PKY, 1981, VIROLOGY, V109, P366, DOI 10.1016/0042-6822(81)90507-9; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; Yuen PH, 1998, AM J PATHOL, V152, P1509; YUEN PH, 1989, J VIROL, V63, P471, DOI 10.1128/JVI.63.2.471-480.1989; YUEN PH, 1991, MOL CARCINOGEN, V4, P72, DOI 10.1002/mc.2940040111; Yuen PH, 1997, VIROLOGY, V236, P213, DOI 10.1006/viro.1997.8729; YUEN PH, 1985, J VIROL, V54, P178, DOI 10.1128/JVI.54.1.178-185.1985; Yuen PH, 2000, J NEUROVIROL, V6, P329, DOI 10.3109/13550280009030759	46	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					692	703		10.1038/sj.onc.1204150	http://dx.doi.org/10.1038/sj.onc.1204150			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314003				2022-12-28	WOS:000166806000005
J	Arlt, A; Grobe, O; Sieke, A; Kruse, ML; Folsch, UR; Schmidt, WE; Schafer, H				Arlt, A; Grobe, O; Sieke, A; Kruse, ML; Folsch, UR; Schmidt, WE; Schafer, H			Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells	ONCOGENE			English	Article						programmed cell death; NF-kappa B; early response gene; cell cycle	EARLY-RESPONSE GENE; ALPHA-INDUCED APOPTOSIS; TRANSCRIPTIONAL REGULATION; CYCLIN D1; C-MYC; INHIBITOR; PROTEIN; ACTIVATION; PROMOTER; GROWTH	P22(PRG1/IEX-1) is putative NF-kappaB target gene implicated in the regulation of cellular viability. Here, we show that in HeLa cells TNF alpha induces expression of p22(PRG1/IEX-1) in an NF-kappaB dependent fashion. Blockade of NF-kappaB activation by various NF-kappaB inhibitors abolished TNF alpha -induced p22(PRG1/IEX-1) expression and increased the sensitivity to apoptosis induced by TNF alpha, an activating Fas-antibody or the anti-cancer drug etoposide, Surprisingly, ectopic expression of p22(PRG1/IEX-1) in HeLa cells transfected with an inducible p22(PRG1/IEX-1)-expression vector augments the susceptibility to apoptosis initiated by death-receptor ligands or by etoposide, In addition, p22(PRG1/IEX-1) expressing HeLa cells exhibit an accelerated progression through the cell cycle. Transfection of an antisense hammerhead ribozyme targeted to p22(PRG1/IEX-1) reduced the speed in cell cycle progression and decreased the apoptotic response to death ligands. Our data demonstrate that p22(PRG1/IEX-1) is specifically induced during NF-kappaB activation, but this seems not to be related to the anti-apoptotic actions of NF-kappaB, Instead, NF-kappaB dependent recruitment of p22(PRG1/IEX-1) might be related to a modulation in the cell cycle, and hereby, p22(PRG1/IEX-1) accelerate cell growth on the one hand, but may trigger apoptosis on the other.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, D-4630 Bochum, Germany	University of Kiel; Ruhr University Bochum	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHARLES CH, 1993, ONCOGENE, V8, P797; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang MC, 1996, ONCOGENE, V13, P609; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kroll M, 1999, CHEM BIOL, V6, P689, DOI 10.1016/S1074-5521(00)80016-2; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Usami I, 1998, BIOCHEM PHARMACOL, V55, P185, DOI 10.1016/S0006-2952(97)00429-2; VAN AD, 1996, SCIENCE, V274, P787; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	43	72	76	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					69	76		10.1038/sj.onc.1204061	http://dx.doi.org/10.1038/sj.onc.1204061			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244505				2022-12-28	WOS:000166361400008
J	Crooke, ST				Crooke, ST			Potential roles of antisense technology in cancer chemotherapy	ONCOGENE			English	Article						antisense; mechanisms of action; gene functionalization; anticancer activity	INTERCELLULAR-ADHESION MOLECULE-1; COLI RNASE H1; C-14-LABELED PHOSPHOROTHIOATE OLIGONUCLEOTIDE; KINASE-C-ALPHA; MESSENGER-RNA; PHARMACOKINETIC PROPERTIES; THERAPEUTIC APPLICATIONS; RAT-LIVER; INHIBITION; EXPRESSION	Antisense technology may play a major role in cancer chemotherapy. It is clearly a tool of exceptional value in the functionalization of genes and their validation as potential targets for cancer chemotherapy. Additionally, there is now substantial evidence that antisense drugs are safe, and a growing body of data showing activity in animal models of human disease including cancer, and suggesting efficacy in patients with cancer. In this article, I review the progress in the technology, the anticancer antisense drugs in development and potential roles that antisense technology might play.	ISIS Pharmaceut Inc, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut Inc, 2292 Faraday Ave, Carlsbad, CA 92008 USA.							AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Baker BF, 1999, BBA-GENE STRUCT EXPR, V1489, P3, DOI 10.1016/S0167-4781(99)00146-3; Bennett CF, 1999, BBA-GENE STRUCT EXPR, V1489, P19, DOI 10.1016/S0167-4781(99)00144-X; Bennett CF, 1998, HANDB EXP PHARM, V131, P371; Bost F, 1999, MOL CELL BIOL, V19, P1938; Butler M, 1997, LAB INVEST, V77, P379; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; Chen HX, 2000, CLIN CANCER RES, V6, P1259; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COHEN JS, 1993, ANTISENSE RES APPL, P205; Cook PD, 1998, HANDB EXP PHARM, V131, P51; COSSUM PA, 1994, J PHARMACOL EXP THER, V269, P89; COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1181; Cotter F E, 1999, Haematologica, V84 Suppl EHA-4, P19; Cotter FE, 1999, BBA-GENE STRUCT EXPR, V1489, P97, DOI 10.1016/S0167-4781(99)00139-6; Crooke R.M., 1993, ANTISENSE RES APPL, P427; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; CROOKE ST, 1992, BIO-TECHNOL, V10, P882, DOI 10.1038/nbt0892-882; Crooke ST, 2000, ANTISENSE NUCLEIC A, V10, P123, DOI 10.1089/oli.1.2000.10.123; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Crooke ST, 1996, J PHARMACOL EXP THER, V277, P923; CROOKE ST, 1994, CLIN PHARMACOL THER, V56, P641, DOI 10.1038/clpt.1994.189; CROOKE ST, 1998, ANTISENSE RES APPL; Crouch RJ, 1985, NUCLEASES, P211; CRUM C, 1988, NUCLEIC ACIDS RES, V16, P4569, DOI 10.1093/nar/16.10.4569; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DECLERCQ E, 1969, SCIENCE, V165, P1137; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DORR A, 1999, 35 ANN M AM SOC CLIN, V18, P157; DORR A, IN PRESS ANTISENSE D; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRANK P, 1994, NUCLEIC ACIDS RES, V22, P5247, DOI 10.1093/nar/22.24.5247; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; FREIER SM, 1993, ANTISENSE RES APPL, P67; FURDON PJ, 1989, NUCLEIC ACIDS RES, V17, P9193, DOI 10.1093/nar/17.22.9193; GAGNOR C, 1989, NUCLEIC ACIDS RES, V17, P5107, DOI 10.1093/nar/17.13.5107; GEWIRTZ A, IN PRESS ANTISENSE D; GORDON MS, 1999, 35 ANN M AM SOC CLIN, V18, P157; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; Hartmann G, 1996, MOL MED, V2, P429, DOI 10.1007/BF03401902; HENRY S, 2000, UNPUB MOL IMMUNOLOGY; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; Herdewijn P, 1999, BBA-GENE STRUCT EXPR, V1489, P167, DOI 10.1016/S0167-4781(99)00152-9; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOLMLUND J, IN PRESS ANTISENSE D; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; JOOS RW, 1969, J PHARMACOL EXP THER, V166, P113; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; Larsen HJ, 1999, BBA-GENE STRUCT EXPR, V1489, P159, DOI 10.1016/S0167-4781(99)00145-1; Lebleu B., 1993, ANTISENSE RES APPL; Leeds JM, 1998, HANDB EXP PHARM, V131, P217; Levin AA, 1999, BBA-GENE STRUCT EXPR, V1489, P69, DOI 10.1016/S0167-4781(99)00140-2; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 1997, J BIOL CHEM, V272, P27513, DOI 10.1074/jbc.272.44.27513; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; Manoharan M, 1999, BBA-GENE STRUCT EXPR, V1489, P117, DOI 10.1016/S0167-4781(99)00138-4; MILLER D, 1989, J LOGIC PROGRAM, V6, P79, DOI 10.1016/0743-1066(89)90031-9; MIRABELLI CK, 1991, ANTI-CANCER DRUG DES, V6, P647; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Monia BP, 1998, HANDB EXP PHARM, V131, P427; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MORVAN F, 1991, ANTI-CANCER DRUG DES, V6, P521; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; QUARTIN RS, 1989, NUCLEIC ACIDS RES, V17, P7253, DOI 10.1093/nar/17.18.7253; RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205; Shanahan WR, 1998, HANDB EXP PHARM, V131, P499; SIU LL, 2000, 36 ANN M AM SOC CLIN, V19, pA189; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; SRINIVASAN SK, 1995, ANTISENSE RES DEV, V5, P131, DOI 10.1089/ard.1995.5.131; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; Stevenson JP, 1999, J CLIN ONCOL, V17, P2227, DOI 10.1200/JCO.1999.17.7.2227; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Takakura Y, 1996, ANTISENSE NUCLEIC A, V6, P177, DOI 10.1089/oli.1.1996.6.177; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YUEN A, 1999, AACR NCI EORTC INT C	85	67	79	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6651	6659		10.1038/sj.onc.1204093	http://dx.doi.org/10.1038/sj.onc.1204093			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426651				2022-12-28	WOS:000167704000012
J	Gershenwald, JE; Sumner, W; Calderone, T; Wang, Z; Huang, SY; Bar-Eli, M				Gershenwald, JE; Sumner, W; Calderone, T; Wang, Z; Huang, SY; Bar-Eli, M			Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo	ONCOGENE			English	Article						melanoma; angiogenesis; metastasis; matrix metallaproteinase-2; transcriptional regulation	HUMAN-MALIGNANT MELANOMA; MMP-2 IMMUNOREACTIVE PROTEIN; PRIMARY CUTANEOUS MELANOMA; IV COLLAGENASE GENE; C-KIT EXPRESSION; DNA-BINDING; E-CADHERIN; MATRIX METALLOPROTEINASES; SIGNAL-TRANSDUCTION; RELATIVE EXPRESSION	We have previously demonstrated that the transition of melanoma to the metastatic phenotype is associated with a loss of expression of the transcription factor AP-2. To further investigate the role of AP-2 in the progression of human melanoma, we attempted to inactivate AP-2 in primary cutaneous SB-2 melanoma cells by using a dominant-negative AP-2, or AP-2B, gene, AP-2B is an alternatively spliced AP-2 variant capable of inhibiting AP-2 trans-activator function, Stable transfection of primary cutaneous melanoma SB-2 cells with the dominant-negative AP-2B gene was confirmed by RT-PCR and Northern blot analyses, Electromobility shift assay using nuclear extracts from these cell lines demonstrated decreased functional binding of AP-2B-transfected cells to the AP-2 consensus binding sequence compared with neo-transfected controls. In addition, CAT activity driven by a construct containing the AP-2 consensus binding sequence was downregulated in the AP-2B transfected cells, indicating AP-2 activity was quenched in the transfected cells, Orthotopic (subcutaneous) injection of the dominant-negative (AP-2B)-transfected cell lines into nude mice increased their tumorigenicity compared to control neo-transfected cells, The AP-2B-transfected cells displayed an increase in MMP-2 expression (by Northern blot) and MMP-2 activity (by zymography), which resulted in an increase in invasiveness through Matrigel-coated filters. The AP-2B-transfected tumors also displayed an increase in MMP-2 expression, microvessel density, and angiogenesis in vivo. These results demonstrate that inactivation of AP-2 contributes to the progression of melanoma, at least partially via deregulation of the MMP-2 gene.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Gershenwald, Jeff/AAX-4367-2020	Gershenwald, Jeff/0000-0003-4519-5369	NATIONAL CANCER INSTITUTE [R01CA076098, T32CA009599] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA09599, CA76098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COPEMAN MC, 1992, PATHOLOGY, V24, P307, DOI 10.3109/00313029209068886; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; Fang D, 1999, BIOCHEM BIOPH RES CO, V256, P657, DOI 10.1006/bbrc.1999.0400; FIDLER IJ, 1990, CANCER RES, V50, P6130; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Goding CR, 2000, GENE DEV, V14, P1712; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Herbst RS, 2000, CLIN CANCER RES, V6, P790; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; HOLMAN CDJ, 1980, INT J CANCER, V25, P317, DOI 10.1002/ijc.2910250303; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang SY, 1996, ONCOGENE, V13, P2339; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jean D, 2000, MOL CELL BIOCHEM, V212, P19, DOI 10.1023/A:1007128101751; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KARELINA TV, 1995, J INVEST DERMATOL, V105, P411, DOI 10.1111/1523-1747.ep12321097; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kuniyasu H, 1999, CLIN CANCER RES, V5, P25; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; LASSAM N, 1992, ONCOGENE, V7, P51; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Real LM, 1998, INT J CANCER, V75, P317, DOI 10.1002/(SICI)1097-0215(19980119)75:2<317::AID-IJC23>3.0.CO;2-8; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHIH IM, 1994, CANCER RES, V54, P2514; SINGH RK, 1995, CANCER RES, V55, P3669; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; TRENT JM, 1989, CANCER RES, V49, P420; Vaisanen A, 1999, J PATHOL, V188, P56; Vaisanen A, 1998, J PATHOL, V186, P51; VERSCHRAEGEN CF, 1991, ANTICANCER RES, V11, P529; WELCH DR, 1994, ONCOGENE, V9, P255; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; ZAKUT R, 1993, ONCOGENE, V8, P2221; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG J, 1995, CANCER RES, V55, P4640; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	85	69	71	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3363	3375		10.1038/sj.onc.1204450	http://dx.doi.org/10.1038/sj.onc.1204450			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423987				2022-12-28	WOS:000169248800007
J	Cobellis, G; Missero, C; Simionati, B; Valle, G; Di Lauro, R				Cobellis, G; Missero, C; Simionati, B; Valle, G; Di Lauro, R			Immediate early genes induced by H-Ras in thyroid cells	ONCOGENE			English	Article						thyroid; tumorigenicity; differentiation; subtraction library; adenovirus	ACTIN STRESS FIBERS; MAP KINASE KINASE; E2F FAMILY; EPITHELIAL-CELLS; TRANSFORMATION; DIFFERENTIATION; EXPRESSION; ACTIVATION; MEMBER; RHO	Expression of oncogenic v-H-Ras in the thyroid cell line FRTL-5 (FRTL-5(Ras)) results in uncontrolled proliferation, loss of thyroid-specific gene expression and tumorigenicity. Concomitant expression of constitutively activated MEK and pac, two major H-Ras downstream effecters, in FRTL-5 (FRTL-5(MEK/Rac)) recapitulates H-Ras effects on proliferation and morphology, In contrast to FRTL-5(Ras), however, FRTL-5(MEK/Rac) cells remain differentiated and are not tumorigenic, To find H-Ras induced genes potentially responsible for tumorigenicity and loss of differentiation, we have used subtractive suppression hybridization (SSH), a PCR-based cDNA subtraction technique, between de-differentiated and tumorigenic FRTL-5(Ras) cells and differentiated and nontumorigenic FRTL-5(MEK/Rac) cells. We examined 800 of the cDNA clones obtained after subtraction and verified their levels of expression in the two cell lines by reverse northern, identifying 337 H-Ras induced genes. By sequence analysis, we clustered 57 different genes. Among these, 39 were known genes (involved in diverse signal transduction processes regulating mitogenic activity, cell survival, cytoskeletal reorganization, stress response and invasion) while the remaining 18 clones were novel genes. Among the 57 H-Ras specific clones, we identified those genes whose expression is induced early by H-Ras, We suggest that these immediate-early genes may play a crucial role in H-Ras-mediated transformation in thyroid epithelial cells.	Staz Zool Anton Dohrn, Lab Biochim & Biol Mol, I-80121 Naples, Italy; Univ Padua, Dipartimento Biol, CRIBI Biotechnol Ctr, I-35121 Padua, Italy	Stazione Zoologica Anton Dohrn di Napoli; University of Padua	Di Lauro, R (corresponding author), Staz Zool Anton Dohrn, Lab Biochim & Biol Mol, Villa Comunale, I-80121 Naples, Italy.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; VALLE, GIORGIO/0000-0003-4377-5685; simionati, barbara/0000-0002-0522-0737; Cobellis, Gilda/0000-0003-2687-2272; Missero, Caterina/0000-0003-0905-5123	Telethon [TGM06S01, D.067] Funding Source: Medline	Telethon(Fondazione Telethon)		AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BOS JL, 1989, CANCER RES, V49, P4682; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ciccarelli FD, 2000, HUM MOL GENET, V9, P1001, DOI 10.1093/hmg/9.6.1001; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Langnaese K, 1997, J BIOL CHEM, V272, P821, DOI 10.1074/jbc.272.2.821; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Uwabe K, 1997, NEUROSCIENCE, V80, P501, DOI 10.1016/S0306-4522(97)00112-7; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	37	3	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2281	2290		10.1038/sj.onc.1204320	http://dx.doi.org/10.1038/sj.onc.1204320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402323				2022-12-28	WOS:000168404500010
J	Gagliardi, M; Maynard, S; Bojovic, B; Bedard, PA				Gagliardi, M; Maynard, S; Bojovic, B; Bedard, PA			The constitutive activation of the CEF-4/9E3 chemokine gene depends on C/EBP beta in v-src transformed chicken embryo fibroblasts	ONCOGENE			English	Article						CEF-4/9E3 chemokine; C/EBP beta; pp60(v-src)	ROUS-SARCOMA VIRUS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; EFII ENHANCER SEQUENCE; BINDING-PROTEIN-BETA; LONG TERMINAL REPEAT; KINASE-C SUBSTRATE; TRANSCRIPTION FACTOR; CELLULAR-TRANSFORMATION	The CEF-4/9E3 chemokine gene is expressed constitutively in chicken embryo fibroblasts (CEF) transformed by the Rous sarcoma virus (RSV), This aberrant induction is controlled at the transcriptional and posttranscriptional Levels. Transcriptional activation depends on multiple elements of the CEF-4 promoter composing a Src-responsive-Unit or SRU, The SRU includes a TPA responsive element, a PRDII/kappaB domain and a CAAT box. In this report, we identify C/EBP beta as a component of the trans-acting factor interacting with the CAAT box of the CEF-4 promoter. In addition, we show that CI EBP beta binds to a second element located in proximity of the TRE, A mutation of this distal CAAT box impaired the activation of the CEF-4 promoter by pp60(v-src) indicating that this element is also part of the SRU, Using the RCASBP retroviral vector, we expressed a dominant negative mutant of C/EBP beta (designated Delta 184-C/EBP beta) in RSV-transformed CEF, Delta 184-C/EBP beta decreased the accumulation of the CEF-4 mRNA and activation of the CEF-4 promoter by pp60(v-src). The induction of the Cox-2 gene (CEF-147) was also reduced by Delta 184-C/EBP beta. The effect of the dominant negative mutant was observed within 1 h of the activation of a thermolabile pp60(v-src) suggesting that C/EBP beta is an early target of v-src transformation. The dominant negative mutant did not inhibit the transformation of CEF by RSV and in fact accentuated the transformed cell phenotype, Therefore, the activation of C/EBP beta is important for the expression of v-src regulated genes but is not required for the in vitro transformation of CEF by pp60(v-src).	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	York University - Canada; McMaster University	Bedard, PA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.			Maynard, Scott/0000-0001-5625-936X				Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lin X, 1997, CANCER RES, V57, P3068; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Lin XY, 1998, CANCER RES, V58, P1770; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Mangeney M, 1996, ONCOGENE, V13, P1441; MAO PL, 1993, J BIOL CHEM, V268, P8131; Martins-Green M., 1997, Cytokine and Growth Factor Reviews, V8, P221, DOI 10.1016/S1359-6101(97)00016-6; Martins-Green M, 1998, CYTOKINE, V10, P522, DOI 10.1006/cyto.1997.0311; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Raught B, 1996, CANCER RES, V56, P4382; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCHADENDORF, 1994, J IMMUNOL, V153, P3360; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SEARS RC, 1994, MOL CELL BIOL, V14, P5617; SEARS RC, 1992, J VIROL, V66, P6338, DOI 10.1128/JVI.66.11.6338-6352.1992; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wakabayashi Y, 1995, JPN J CANCER RES, V86, P1189, DOI 10.1111/j.1349-7006.1995.tb03314.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	71	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2301	2313		10.1038/sj.onc.1204354	http://dx.doi.org/10.1038/sj.onc.1204354			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402325				2022-12-28	WOS:000168404500012
J	Lin, J; Jinno, S; Okayama, H				Lin, J; Jinno, S; Okayama, H			Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell's proliferation competence	ONCOGENE			English	Article						Cdk6; cyclin D3; CKI; proliferation competence	CYCLIN-DEPENDENT KINASE-6; CDK INHIBITORS; TYROSINE PHOSPHORYLATION; VIRAL CYCLIN; PROGRESSION; EXPRESSION; P27(KIP1); ANCHORAGE; FAMILY; GROWTH	Mammalian cells require a cyclin D-dependent kinase for the cell cycle start, yet many mesenchymal cells express three seemingly redundant D cyclins and similarly, seemingly redundant Cdk4 and Cdk6 as their kinase partners, We have found that the Cdk6-cyclin D3 complex is unique among the D cyclin and kinase combinations in the ability to promote the cell cycle start. In an anchorage-minus G(1)-arrested rat fibroblast, only Cdk6-D3 retains kinase activity due mainly to its ability to evade inhibition by p27(KIPI) and p21(CIPI) with a resemblance to viral cyclin-bound Cdk6, Rodent fibroblasts engineered to overexpress both Cdk6 and cyclin D3 highly resist serum starvation- or cell-cell contact-imposed G(1)-arrest, In BALB/c 3T3 cells, D3 is constitutively expressed, but Cdk6 is markedly induced with concomitant activation upon stimulation with a growth-promoting factor. These results suggest a role for the Cdk6-D3 complex in regulating cell's proliferation ability in response to external stimuli.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.							Belyavskyi M, 1998, P NATL ACAD SCI USA, V95, P11205, DOI 10.1073/pnas.95.19.11205; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chilosi M, 1998, AM J PATHOL, V152, P209; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KUME K, 1992, NEW BIOL, V4, P504; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Schulze-Gahmen U, 1999, STRUCTURE, V7, P245, DOI 10.1016/S0969-2126(99)80035-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Van Dyk LF, 1999, J VIROL, V73, P5110, DOI 10.1128/JVI.73.6.5110-5122.1999; Wagner EF, 1998, J IMMUNOL, V161, P1123	27	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2000	2009		10.1038/sj.onc.1204375	http://dx.doi.org/10.1038/sj.onc.1204375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360184				2022-12-28	WOS:000168043800008
J	Graves, PR; Lovly, CM; Uy, GL; Piwnica-Worms, H				Graves, PR; Lovly, CM; Uy, GL; Piwnica-Worms, H			Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding	ONCOGENE			English	Article						cell cycle; Cdc25C; 14-3-3; nuclear import; nuclear export	CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; TYROSINE KINASE; DNA-DAMAGE; HUMAN WEE1; 7-HYDROXYSTAUROSPORINE UCN-01; PHOSPHORYLATION SITES; MOLECULAR-CLONING; DEPENDENT KINASES; G(2) CHECKPOINT	Entry into mitosis requires activation of the Cdc2 protein kinase by the Cdc25C protein phosphatase, The interactions between Cdc2 and Cdc25C are negatively regulated throughout interphase and in response to G2 checkpoint activation. This is accomplished in part by maintaining the Cdc25 phosphatase in a phosphorylated form that binds 14-3-3 proteins. Here we report that 14-3-3 binding regulates the intracellular trafficking of Cdc25C, Although primarily cytoplasmic, Cdc25C accumulated in the nuclei of leptomycin B (LMB)-treated cells, indicating that Cdc25C is actively exported out of the nucleus. A mutant of Cdc25C that is unable to bind 14-3-3 was partially nuclear in the absence of LMB and its nuclear accumulation was greatly enhanced by LMB-treatment, A nuclear export signal (NES) was identified within the amino terminus of Cdc25C, Although mutation of the NES did not effect 14-3-3 binding, it did cause nuclear accumulation of Cdc25C, These results demonstrate that 14-3-3 binding is dispensable for the nuclear export of Cdc25C, However, complete nuclear accumulation of Cdc25C required loss of both NES function and 14-3-3 binding and this was accomplished both pharmacologically and by mutation. These findings suggest that the nuclear export of Cdc25C is mediated by an intrinsic NES and that 14-3-3 binding negatively regulates nuclear import.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Piwnica-Worms, Helen/C-5214-2012; Uy, Geoffrey/A-2058-2010; Uy, Geoffrey/AAD-9815-2021	Uy, Geoffrey/0000-0002-7809-0996; Lovly, Christine/0000-0002-3641-6361				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Busby EC, 2000, CANCER RES, V60, P2108; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NISHI K, 1994, J BIOL CHEM, V269, P6320; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OGG S, 1994, J BIOL CHEM, V269, P30461; OUYANG B, 1997, J BIOL CHEM, P28646; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	71	168	175	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1839	1851		10.1038/sj.onc.1204259	http://dx.doi.org/10.1038/sj.onc.1204259			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313932				2022-12-28	WOS:000167908400005
J	Beadling, C; Cereseto, A; Fan, W; Naramura, M; Smith, KA				Beadling, C; Cereseto, A; Fan, W; Naramura, M; Smith, KA			Cytokine response gene 8 (CR8) regulates the cell cycle G1-S phase transition and promotes cellular survival	ONCOGENE			English	Article						basic helix-loop-helix; G1 progression; survival	LOOP-HELIX PROTEINS; ID PROTEINS; EXPRESSION; GROWTH; TRANSCRIPTION; PROGRESSION; APOPTOSIS; DIFFERENTIATION; ENHANCER; ARREST	Cellular proliferation and survival are modulated by the expression of specific genes. Cytokine response gene 8 (CR8), which was originally cloned as an IL-2-induced gene in human T lymphocytes, encodes a basic helix-loop-helix (bHLH) transcription factor, The CR8 gene product is highly conserved among human, mouse and rat, and contains sequence motifs that distinguish it from other bHLH families, The CR8 gene is ubiquitously expressed, and CR8 gene expression is induced by both growth-promoting as well as growth-inhibitory stimuli. As bHLH proteins have been found to regulate both the G1-S phase cell cycle transition, as well as cellular survival, the effects of CR8 on these processes were investigated. Ectopic CR8 expression in asynchronous U2OS cell cultures reduces the percentage of cells in the cell cycle S phase, and also slows the entry of G1-synchronized cells into S phase. The prolonged G1 interval correlates with impaired elevation of cyclin E protein and prolonged p21 protein expression in G1, CR8 expression also protects U2OS cells from serum-withdrawal induced apoptosis, These results indicate that CR8 is an important modulator of both the G1-S phase cell cycle transition, and cellular survival.	New York Presbyterian Cornell Med Ctr, Div Immunol, Dept Med, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Weill Med Coll, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Grad Sch Med Sci, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), New York Presbyterian Cornell Med Ctr, Div Immunol, Dept Med, 1300 York Ave, New York, NY 10021 USA.			Cereseto, Anna/0000-0003-4453-2597; Naramura, Mayumi/0000-0003-3658-0767	NIAID NIH HHS [1RO1 AI44207-O1A1, R01 AI 32031-24] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032031, R01AI044207] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; GONG J, 1994, CELL PROLIFERAT, V27, P357, DOI 10.1111/j.1365-2184.1994.tb01469.x; GONG JP, 1993, INT J ONCOL, V3, P1037; GULLBERG M, 1986, J EXP MED, V163, P270, DOI 10.1084/jem.163.2.270; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297	34	6	6	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1771	1783		10.1038/sj.onc.1204212	http://dx.doi.org/10.1038/sj.onc.1204212			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313924				2022-12-28	WOS:000167750900010
J	Bean, LJH; Stark, GR				Bean, LJH; Stark, GR			Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV	ONCOGENE			English	Article						HDM; p21; adriamycin; DNA damage; Li-Fraumeni syndrome	DEPENDENT PROTEIN-KINASE; CELL-CYCLE ARREST; DAMAGE-INDUCED PHOSPHORYLATION; P53-DEPENDENT G(1) ARREST; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; WILD-TYPE P53; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; GENE AMPLIFICATION	Changes in the phosphorylation state of p53 are important in increasing its half-life and potency as a transcription factor. To investigate their roles, serine residues 15 and 37 were mutated to alanines and the mutated proteins were expressed stably at low basal levels in Li-Fraumeni-derived p53-null human fibroblasts, The accumulation of p53 after DNA damage was analysed quantitatively in multiple clones. Mutation of serine 15, serine 37 or both impaired the accumulation of the protein after exposing the cells to ultraviolet radiation (50-100% increase for the mutant proteins, 500% increase for wild-type p53) but not after treatment with adriamycin. The diminished accumulation of mutant p53 protein is due to a reduction of basal HDM association. Analysis of p53-dependent transcription revealed that phosphorylation of serine 15 is required to maintain basal levels of p21 mRNA. These results provide new evidence for an important function of serine 37 phosphorylation, dearly distinguish the pathways of p53 activation in response to ultraviolet radiation or DNA damage inflicted by adriamycin, and reveal that serine 15 is crucial to support the p53-mediated basal expression of p21.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Stark, GR (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008613, R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49345, 5-T32-GM08613] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen CYM, 1996, CANCER RES, V56, P3659; CHEN J, 1993, MOL CELL BIOL, V7, P2353; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mayo LD, 1997, CANCER RES, V57, P5013; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Prives C, 1999, J PATHOL, V187, P112; Robinson G.K., 1991, STAT SCI, P15, DOI DOI 10.1214/SS/1177011926; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1995, ONCOGENE, V10, P1053; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; VANLAAR T, 1994, ONCOGENE, V9, P981; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; [No title captured]	72	54	54	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1076	1084		10.1038/sj.onc.1204204	http://dx.doi.org/10.1038/sj.onc.1204204			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314044				2022-12-28	WOS:000167232100007
J	Kobrinsky, EM; Kirchberger, MA				Kobrinsky, EM; Kirchberger, MA			Evidence for a role of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in thapsigargin and Bcl-2 induced changes in Xenopus laevis oocyte maturation	ONCOGENE			English	Article						SERCA; Xenopus laevis; meiotic maturation; Bcl-2 thapsigargin; capacitative Ca2+ entry	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CA2+ STORES; ENDOPLASMIC-RETICULUM; CELL-LINE; CALCIUM-PUMP; PROTEIN; APOPTOSIS; ATPASE; PHOSPHOLAMBAN; INHIBITION	Thapsigargin (Tg), a selective inhibitor of sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (SERCA), causes depiction of intracellular Ca2+ stores, hence activation of capacitative Ca2+ entry (CCE). Incubation of Xenopus laevis oocytes with Tg resulted in an increased rate of progesterone-induced meiotic maturation. Non-mitochondrial Ca-45(2+) uptake by SERCA-containing microsomes prepared from control wild-type oocytes microinjected with sterile water was inhibited essentially 100% by Tg. However, overexpression of Bcl-2, an oncogene known to protect against Tg-induced apoptosis in certain cell types, resulted in only 40% inhibition of microsomal Ca-45(2+) uptake by Tg while non-inhibited Ca-45(2+) uptake remained unchanged, Moreover Bcl-2 overexpression also protected against inhibition of CCE. I-Cl(Ca) was similar in Bcl-2-overexpressing and control oocytes when intracellular Ca2+ store depletion was induced by microinjection of inositol 1,4,5-trisphosphate (InsP(3)) and other means and when CCE was induced by means independent of SERCA inhibition. Our data indicate that Bcl-2 affects neither the InsP(3) receptor nor Ca2+ entry itself. At the end of a 24-h period after progesterone addition to the medium, only 25% of Bcl-2-overexpressing oocytes had matured compared to 85% of control oocytes. Our data suggest that SERCA participates in Xenopus oocyte maturation by controlling cytosolic Ca2+ and/or intracellular Ca2+ stores, hence CCE. An observed progesterone-dependent protein kinase-catalysed phosphorylation of SERCA is further indication of its role in oocyte maturation.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Kirchberger, MA (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.				NHLBI NIH HHS [HL15764] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015764] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; Antipenko AY, 1997, CARDIOVASC RES, V36, P67, DOI 10.1016/S0008-6363(97)00183-1; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BOYER J, 1983, BIOCHIMIE, V65, P15, DOI 10.1016/S0300-9084(83)80024-8; CHOI OH, 1993, J IMMUNOL, V151, P5586; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; ENOUF J, 1987, J BIOL CHEM, V262, P9293; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Han JK, 1995, BIOCHEM BIOPH RES CO, V217, P931, DOI 10.1006/bbrc.1995.2860; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; Kobrinsky E, 1995, DEV BIOL, V172, P531, DOI 10.1006/dbio.1995.8058; Kobrinsky E, 1999, AM J PHYSIOL-CELL PH, V277, pC665, DOI 10.1152/ajpcell.1999.277.4.C665; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAMB M, 1994, P NATL ACAD SCI USA, V91, P6569; Lechleiter JD, 1998, BIOPHYS CHEM, V72, P123, DOI 10.1016/S0301-4622(98)00128-8; Mahaney J, 1999, ARCH BIOCHEM BIOPHYS, V372, P408, DOI 10.1006/abbi.1999.1524; Matten Wayne T., 1994, Seminars in Developmental Biology, V5, P173, DOI 10.1006/sedb.1994.1023; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Vairo G, 1996, ONCOGENE, V13, P1511; VILAIN JP, 1989, J EXP ZOOL, V250, P100, DOI 10.1002/jez.1402500114; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Wei HF, 1998, J NEUROCHEM, V70, P2305; Xu AD, 2000, J BIOL CHEM, V275, P4407, DOI 10.1074/jbc.275.6.4407; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T	44	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					933	941		10.1038/sj.onc.1204153	http://dx.doi.org/10.1038/sj.onc.1204153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314028				2022-12-28	WOS:000167097000004
J	Bradley, G; Irish, J; MacMillan, C; Mancer, K; Witterick, I; Hartwick, W; Gullane, P; Kamel-Reid, S; Benchimol, S				Bradley, G; Irish, J; MacMillan, C; Mancer, K; Witterick, I; Hartwick, W; Gullane, P; Kamel-Reid, S; Benchimol, S			Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma	ONCOGENE			English	Article						p53; mutation; immunohistochemistry; p14ARF; homozygous deletion; oral squamous carcinoma	NECK-CANCER; TUMOR-SUPPRESSOR; P53 ALTERATIONS; HEAD; MUTATIONS; SMOKING; GENE; OVEREXPRESSION; INACTIVATION; PROGRESSION	Oral squamous cell carcinoma (OSCC) is associated with heavy smoking and drinking, but the molecular pathway of tumorigenesis is not understood. Inactivation of the p53 tumor suppressor gene is likely to play an important role since p53 mutation is frequently found. The p14ARF tumor suppressor gene is functionally linked to p53, because it is activated by oncogenes and causes p53-dependent growth arrest and apoptosis, The relationship between p14ARF and p53 inactivation has not been described for OSCC, We studied 25 cases of OSCC to determine if there is an inverse correlation between p53 mutation and p14ARF inactivation by homozygous deletion or mutation. p53 mutation was found in 16 of 25 cases (64%), including nine missense and seven truncating mutations, While all cases with missense mutations showed abnormal accumulation of p53 protein, there were also five carcinomas which showed increased p53 staining in the absence of mutation. p14ARF deletion or mutation was found in eight cases (32%), six of which also demonstrated p53 mutation. Our findings indicate that OSCC often involves loss of both p14ARF and p53 function and suggest that inactivation of these two tumor suppressor genes are not functionally equivalent during tumorigenesis.	Univ Toronto, Fac Dent, Toronto, ON M5G 1G6, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Dept Otolaryngol Surg Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Toronto Gen Hosp, Dept Pathol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Mt Sinai Hosp, Dept Otolaryngol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Bradley, G (corresponding author), Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G6, Canada.			Kamel-Reid, Suzanne/0000-0002-4386-0292; Benchimol, Samuel/0000-0003-3433-890X				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BLOT WJ, 1988, CANCER RES, V48, P3282; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; Califano J, 1996, CANCER RES, V56, P2488; Casey G, 1996, ONCOGENE, V13, P1971; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Ichimura K, 2000, CANCER RES, V60, P417; Koch WM, 1999, LARYNGOSCOPE, V109, P1544, DOI 10.1097/00005537-199910000-00002; Liloglou T, 1997, CANCER RES, V57, P4070; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Markl IDC, 1998, CANCER RES, V58, P5348; MASHBERG A, 1993, CANCER-AM CANCER SOC, V72, P1369, DOI 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L; Prives C, 1999, J PATHOL, V187, P112; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Shahnavaz SA, 2000, J PATHOL, V190, P417; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; XU L, 1994, DIAGN MOL PATHOL, V3, P83, DOI 10.1097/00019606-199406000-00004; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	29	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					654	658		10.1038/sj.onc.1204131	http://dx.doi.org/10.1038/sj.onc.1204131			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313998				2022-12-28	WOS:000166755000013
J	Melillo, RM; Carlomagno, F; De Vita, G; Formisano, P; Vecchio, G; Fusco, A; Billaud, M; Santoro, M				Melillo, RM; Carlomagno, F; De Vita, G; Formisano, P; Vecchio, G; Fusco, A; Billaud, M; Santoro, M			The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret	ONCOGENE			English	Article						Ret; tyrosine kinase; IRS-1; P13-K	PROTEIN-KINASE B; TYROSINE PHOSPHORYLATION; NEUROTROPHIC FACTOR; DOCKING SITE; PTB DOMAINS; ACTIVATION; MUTATIONS; SURVIVAL; INTERLEUKIN-4; PROLIFERATION	Tyrosine 1062 of Ret, which represents an intracytoplasmic docking site for multiple signaling molecules, is essential for Ret-mediated activation of phosphatidylinositol 3-Kinase (PI3-K), PI3-K, in turn, has been implicated in inducing cell survival and neoplastic transformation mediated by Ret, We have examined the mechanisms by which Ret stimulates PD-K. Here me show that the Insulin Receptor Substrate-1 (IRS-1) is tyrosine phosphorylated and associated with the p85 regulatory subunit of PI3-K in response to Ret activation. IRS-1 coimmunoprecipitates with Ret and co-expression of IRS-1 results in the potentiation of Ret-mediated activation of Akt(PKB), a bona fide effector of PI3-K, The association with the PTB domain of IRS-1 depends on the phosphorylation of tyrosine 1062 of Ret, The deletion of asparagine 1059 (delN1059) and the substitution of leucine 1061 (L1061P), two Ret mutations identified in families affected by congenital megacolon (Hirscbsprungs disease), impair the binding of IRS-1 to Ret as well as Ret-mediated Akt(PKB) stimulation. Finally, me show that Shc, which was previously identified as another ligand of Y1062 of Ret, competes with IRS-1 for the binding to Ret pY1062. All together, these findings suggest that IRS-1 is a component of the signaling pathway which leads to Ret-mediated PI3-K activation, a pathway which can be targeted by Hirschsprung-associated Ret mutations. The alternative binding of Shc and IRS-1 to Ret pY1062 can be a system to modulate the activation of different intracellular signaling pathways and to elicit different biological responses following net activation.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; CNRS, UMR5641, Genet Lab, F-69373 Lyon 08, France	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Centre National de la Recherche Scientifique (CNRS)	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		melillo, rosa marina/O-5255-2015; De Vita, Gabriella/H-4422-2011; Billaud, Marc N/M-6954-2013; Formisano, Pietro/J-4237-2018	De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197; Formisano, Pietro/0000-0001-7020-6870; MELILLO, Rosa Marina/0000-0002-9233-5275				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BESSET V, 2000, IN PRESS J BIOL CHEM; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Vita G, 2000, CANCER RES, V60, P3916; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Melillo RM, 1999, CANCER RES, V59, P1120; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Siegal G, 1999, NAT STRUCT BIOL, V6, P7, DOI 10.1038/4873; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; van der Geer P, 1999, ONCOGENE, V18, P3071, DOI 10.1038/sj.onc.1202879; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, RECENT PROG HORM RES, V53, P119; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	55	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					209	218		10.1038/sj.onc.1204049	http://dx.doi.org/10.1038/sj.onc.1204049			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313948				2022-12-28	WOS:000166410900008
J	Blair, DG; Athanasiou, M				Blair, DG; Athanasiou, M			Ets and retroviruses - transduction and activation of members of the Ets oncogene family in viral oncogenesis	ONCOGENE			English	Review						ETS; retrovirus; oncogenesis; E26; F-MuLV; SFFV	MURINE LEUKEMIA-VIRUS; NON-T-CELL; AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN ERYTHROID-CELLS; V-ETS; TRANSCRIPTION FACTOR; DNA-BINDING; PROVIRAL INTEGRATION; FRIEND-VIRUS; PUTATIVE ONCOGENE	Studies of retroviral-induced oncogenesis in animal systems led to the initial discovery of viral oncogenes and their cellular homologs, and provided critical insights into their role in the neoplastic process. V-ets, the founding member of the ETS oncogene family, was originally identified as part of the fusion oncogene encoded by the avian acute leukemia virus E26 and subsequent analysis of virus induced leukemias led to the initial isolation of two other members of the ETS gene family. PU.1 was identified as a target of insertional activation in the majority of tumors induced by the murine Spleen Focus Forming virus (SFFV), while fli-1 proved to be the target of Friend murine leukemia virus (F-MuLV) in F-MuLV induced erythroleukemia, as well as that of the 10A1 and Graffi viruses. The common features of the erythroid and myeloid diseases induced by these viruses provided the initial demonstration that these and other members of the ETS family play important roles in hematopoietic development as well as disease. This review provides an overview of the role of ETS genes in retrovirally induced neoplasia, their possible mechanisms of action, and how these viral studies relate to current knowledge of the functions of these genes in hematopoiesis.	NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Res Lab,Oncogene Mechanisms Sect, Frederick, MD 21702 USA; SAIC, Intramural Res Support Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick	Blair, DG (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Res Lab,Oncogene Mechanisms Sect, Bld 469,Room 102, Frederick, MD 21702 USA.				NCI NIH HHS [N01-CO56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Athanasiou M, 1996, ONCOGENE, V12, P337; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; AURIGEMMA RE, 1994, MOL BIOL HAEMATOPOIE, V3, P669; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BEAR SE, 1989, P NATL ACAD SCI USA, V86, P7495, DOI 10.1073/pnas.86.19.7495; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1993, LEUKEMIA, V7, P954; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Coffin J, 1997, RETROVIRUSES; DAVID YB, 1988, ONCOGENE, V3, P179; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Delgado MD, 1998, BIOCHEM BIOPH RES CO, V252, P383, DOI 10.1006/bbrc.1998.9587; DELGADO MD, 1994, ONCOGENE, V9, P1723; Denicourt C, 1999, J VIROL, V73, P4439, DOI 10.1128/JVI.73.5.4439-4442.1999; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DOMENGET C, 1992, ONCOGENE, V7, P2231; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; Frykberg L, 1988, Oncogene Res, V3, P313; GARDNER MB, 1978, TUMORS EARLY LIFE MA, P343; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEGONNE A, 1987, VIROLOGY, V156, P177, DOI 10.1016/0042-6822(87)90450-8; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; Graf T, 1978, DIFFERENTIATION NORM, P625; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Hu NP, 1997, CANCER RES, V57, P4123; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KRAUT N, 1995, ONCOGENE, V10, P1027; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; OTT D, 1990, J VIROL, V64, P757, DOI 10.1128/JVI.64.2.757-766.1990; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; OTT DE, 1992, J VIROL, V66, P6107, DOI 10.1128/JVI.66.10.6107-6116.1992; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Rascle A, 1996, MOL CELL BIOL, V16, P6338; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; Rossi F, 1996, CURR BIOL, V6, P866, DOI 10.1016/S0960-9822(02)00610-3; RU M, 1993, J VIROL, V67, P4722, DOI 10.1128/JVI.67.8.4722-4731.1993; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SETH A, 1990, ONCOGENE, V5, P1761; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; SPIRO C, 1988, J VIROL, V62, P4129, DOI 10.1128/JVI.62.11.4129-4135.1988; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; WATSON DK, 1988, ADV GENE TECHNOLOGY, P158; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	101	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6472	6481		10.1038/sj.onc.1204046	http://dx.doi.org/10.1038/sj.onc.1204046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175363				2022-12-28	WOS:000166595000009
J	Nishioka, M; Kohno, T; Takahashi, M; Niki, T; Yamada, T; Sone, S; Yokota, J				Nishioka, M; Kohno, T; Takahashi, M; Niki, T; Yamada, T; Sone, S; Yokota, J			Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line	ONCOGENE			English	Article						lung cancer; tumor suppressor gene; chromosomal deletion; chromosome 22q; SEZ6L	TUMOR-SUPPRESSOR GENE; NEUROFIBROMATOSIS TYPE-2; POLYPYRIMIDINE TRACT; CARCINOMA; DNA; SEQUENCE; FREQUENT; METHYLATION; PREDICTION; EXPRESSION	Frequent allelic losses on chromosome 22q in small cell lung carcinomas (SCLCs) and advanced non-small cell lung carcinomas indicate the presence of tumor suppressor gene(s) on this chromosome arm. We detected a homozygous deletion at 22q12.1 in a SCLC cell line, Lu24. Cloning of the breakpoints of the Lu24 deletion revealed that the deletion was interstitial and 428, 131 bp in size. The deleted region contained the SEZ6L (Seizure 6-like) gene, whose structure had been partially determined by the chromosome 22 sequencing project, We determined the full length cDNA sequence for the SEZ6L gene based on the genomic sequence for the SEZ6L locus using the GENSCAN program and the RT-PCR method. The deduced SEZ6L protein was a transmembrane protein of 1024 amino acids with multiple domains involved in protein-protein interaction and signal transduction, SEZ6L expression was detected in a variety of human tissues, including lung, while its expression was detected in 14 (30%) of 46 lung cancer cell lines examined, Missense mutations were detected in three (7%) of the 46 cell lines, and a 1 bp deletion in the polypyrimidine tract preceding exon 4 was detected in one (2%) of 46 primary lung cancers. Therefore, it is possible that genetic and/or epigenetic SEZ6L alterations are involved in the development and/or progression in a subset of lung cancer, although functional analysis of the SEZ6L gene as well as molecular analysis of other genes in the homozygously deleted region is necessary to understand the pathogenetic significance of 220 deletions in human lung carcinogenesis.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Univ Tokushima, Sch Med, Dept Internal Med 3, Tokushima 7708503, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tokushima University	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.		niki, toshiro/K-8917-2012					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anami Y, 2000, INT J CANCER, V89, P19, DOI 10.1002/(SICI)1097-0215(20000120)89:1<19::AID-IJC4>3.0.CO;2-3; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Castells A, 2000, CANCER RES, V60, P2836; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Herbst R, 1997, MOL BRAIN RES, V44, P309, DOI 10.1016/S0169-328X(96)00274-4; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Kawanishi M, 1997, CARCINOGENESIS, V18, P2057, DOI 10.1093/carcin/18.11.2057; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kohno T, 1999, CANCER RES, V59, P4170; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; LEVIN NA, 1994, CANCER RES, V54, P5086; Magnusson KP, 2000, GENE, V246, P247, DOI 10.1016/S0378-1119(00)00068-8; Manda R, 2000, CANCER LETT, V153, P57, DOI 10.1016/S0304-3835(00)00342-6; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1995, CANCER RES, V55, P1227; SHIMIZUNISHIKAWA K, 1995, MOL BRAIN RES, V28, P201, DOI 10.1016/0169-328X(94)00203-Q; SHISEKI M, 1994, CANCER RES, V54, P5643; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Ueda T, 1999, CANCER RES, V59, P6080; Ueki K, 1999, CANCER RES, V59, P5995; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wilmotte R, 1999, BRIT J HAEMATOL, V104, P855, DOI 10.1046/j.1365-2141.1999.01271.x; Yamada T, 2000, CANCER GENET CYTOGEN, V120, P11, DOI 10.1016/S0165-4608(99)00240-X	43	43	46	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6251	6260		10.1038/sj.onc.1204031	http://dx.doi.org/10.1038/sj.onc.1204031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175339				2022-12-28	WOS:000166210500008
J	Mercalli, E; Ghizzoni, S; Arighi, E; Alberti, L; Sangregorio, R; Radice, MT; Gishizky, ML; Pierotti, MA; Borrello, MG				Mercalli, E; Ghizzoni, S; Arighi, E; Alberti, L; Sangregorio, R; Radice, MT; Gishizky, ML; Pierotti, MA; Borrello, MG			Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein	ONCOGENE			English	Article						Ret; Shc; oncogene; thyroid carcinoma	RECEPTOR TYROSINE KINASES; NEUROTROPHIC FACTOR; TRANSDUCTION PATHWAYS; PHOSPHORYLATION SITES; RET MUTATIONS; DOCKING SITE; PROTEIN; ACTIVATION; BINDING; DOMAIN	The RET/PTC oncogenes, generated by chromosomal rearrangements in papillary thyroid carcinomas, are constitutively activated versions of protoRET, a gene encoding two protein isoforms of a transmembrane tyrosine kinase receptor, By using Ret/ptc2 short isoform (iso9), we have previously demonstrated that Tyr586 (Tyr1062 of protoRet) is the docking site for both the PTB and the SH2 domains of Shc. To determine the relevance of this interaction for the transforming activity of Ret/ptc oncogenes, we have generated and characterized novel Ret/ptc mutants unable to activate Shc: Ret/ptc2 long isoform (iso51)-Y586F and both isoforms of Ret/ptc2-N583A, These mutants neither activate Shc nor transform NIH3T3 cells. Since Tyr1062 shows features of a multifunctional docking site, we have used a Shc mutant (Shc Y317F) to directly assess Shc role, We have demonstrated that in our cell syst-ern Shc Y317F behaves like a dominant interfering mutant on the activation of the Grb2-Sos pathway by endogenous Shc triggered by Ret/ptc2, A strong reduction of the transforming activity of Ret/ptc2 in presence of this mutant was also demonstrated. Our data suggest that Shc activation play a key role in the transforming pathways triggered by Ret/ptc oncoproteins. Moreover, we have shown that coexpression of the Shc-Y317F mutant with Ret/ptc2 specifically causes apoptosis, and that the surviving cells lose the long-term expression of one of the two genes.	Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, I-20133 Milan, Italy; SUGEN, San Francisco, CA 94080 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Pfizer	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, Via G Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fischer AH, 1998, AM J PATHOL, V153, P1443, DOI 10.1016/S0002-9440(10)65731-8; FIXMAN ED, 1995, ONCOGENE, V10, P237; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hennige AM, 2000, MOL CELL ENDOCRINOL, V167, P69, DOI 10.1016/S0303-7207(00)00283-5; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	50	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3475	3485		10.1038/sj.onc.1204462	http://dx.doi.org/10.1038/sj.onc.1204462			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429694				2022-12-28	WOS:000169478300003
J	Yamane, K; Katayama, E; Tsuruo, T				Yamane, K; Katayama, E; Tsuruo, T			p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb	ONCOGENE			English	Article						DNA damage; tumor suppressor; Nijmegen breakage syndrome; DNA double-strand breaks; DNA end binding	C-TERMINAL DOMAIN; OLIGOMERIZATION DOMAIN; LI-FRAUMENI; PROTEIN; CHECKPOINT; APOPTOSIS; DAMAGE; REPAIR; TRANSFORMATION; LOCALIZATION	The BRCT regions are two repeating structures at BRCA1 carboxyl-terminus and are ubiquitous in some proteins involved in DNA repair and cell cycle checkpoints. It was shown that BRCTs of TopBP1, BRCA1, and BRCT-Ws of Rb hound DNA ends and breaks. We indicate here that the C-terminus of p53 tumor suppressor contains a DNA binding motif (residues 327-333 in human), whose features are similar to those of the part of BRCT-W in Rb with DNA binding activity. The short motif was required for the gel retardation activity of DNA fragments, since residues 311-333 show cd the activity while residues 311-326 showed no activity. Significant numbers of total p53 and its fragments with the motif formed multimerizing complexes and associated with DNA ends and breaks, These results suggest the common presence of DNA binding motifs that can recognize DNA ends or damages in major tumor suppressors, Rb, BRCA1 and p53. The oncogenic activity of p53 C-terminus (residues 311-393) required both the DNA damage recognition motif and the repair enzyme-associating domain. Oncogene (2001) 20, 2859-2867.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Japan Sci & Technol Corp, Div Biomol Imaging, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japanese Foundation for Cancer Research; Japan Science & Technology Agency (JST); University of Tokyo	Yamane, K (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Guggenheim Bldg,Room 1306,200 1st St SW, Rochester, MN 55905 USA.							Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIMORI T, 1986, J BIOL CHEM, V261, P375; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamane K, 2000, ONCOGENE, V19, P1982, DOI 10.1038/sj.onc.1203528; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	38	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2859	2867		10.1038/sj.onc.1204408	http://dx.doi.org/10.1038/sj.onc.1204408			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420698				2022-12-28	WOS:000168901800001
J	Frost, V; Al-Mehairi, S; Sinclair, AJ				Frost, V; Al-Mehairi, S; Sinclair, AJ			Exploitation of a non-apoptotic caspase to regulate the abundance of the cdkI p27(KIP1) in transformed lymphoid cells	ONCOGENE			English	Article						cell cycle; apoptosis; lymphoma; protease	DEPENDENT KINASE INHIBITOR; EPSTEIN-BARR-VIRUS; BREAST-CANCER CELLS; CYCLE ARREST; GROWTH ARREST; T-CELLS; MDM2 ONCOPROTEIN; GENE P27(KIP1); B-LYMPHOCYTES; MICE LACKING	Expression of the cyclin dependent kinase inhibitor p27(KIP1) is intimately linked to the control of proliferation, and is itself regulated by transcription, translation, phosphorylation, protein stability or sequestration, p27(KIP1) is also regulated during apoptosis; cleavage occurs at (DPSDS)-S-139 and ESQD(108)V, by a sub-set of z-VAD-fmk-sensitive caspases, We have identified related but distinct mechanism that regulates p27(KIP1) in proliferating lymphoid cell lines. In a B-lymphoid cell line (BJAB), the abundance of p27(KIP1) oscillates inversely to proliferation; loss of full-length p27(KIP1) correlates with the appearance of a truncated version corresponding to cleavage at (DPSDS)-S-139, A direct correlation exists between the appearance of truncated p27(KIP1) and the presence of an activity able to cleave peptides representing (DPSDS)-S-139 and a caspase-8 substrate (Ac-IETD-AMC) in vitro. This activity is inhibited by Ac-IETD-CHO but not Z-VAD-fmk in vitro, Furthermore a requirement for caspase-8 has been excluded. The activity differs from the apoptosis related p27(KIP1)-cleaving activity; indeed few cells undergoing apoptosis are present in the population of proliferating cells, The activity is further distinguished by its inability to cleave a peptide based on ESQD(108)V in vitro, together with the lack of a corresponding cleavage product in vivo. Inhibition of the caspase activity in vivo promotes an accumulation of full length p27(KIP1), as well as a decrease in cell proliferation. Together these studies highlight the importance of non-apoptotic caspases in regulating p27(KIP1) in transformed lymphoid cells.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Sinclair, AJ (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.			Sinclair, Alison/0000-0001-8510-8691				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Barnouin K, 1999, ONCOGENE, V18, P6388, DOI 10.1038/sj.onc.1203162; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Cannell EJ, 1996, ONCOGENE, V13, P1413; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Frost V, 2000, ONCOGENE, V19, P3115, DOI 10.1038/sj.onc.1203657; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1997, J IMMUNOL, V158, P5642; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Wu DMH, 1999, J IMMUNOL, V162, P1287; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	66	26	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2737	2748		10.1038/sj.onc.1204367	http://dx.doi.org/10.1038/sj.onc.1204367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420686				2022-12-28	WOS:000168712000002
J	Sutherland, LC; Lerman, M; Williams, GT; Miller, BA				Sutherland, LC; Lerman, M; Williams, GT; Miller, BA			LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells	ONCOGENE			English	Article						LUCA-15; 3p21.3; apoptosis; CD95; staurosporine; Jurkat	CHEMOTHERAPY-INDUCED APOPTOSIS; MOLECULAR-GENETIC CHANGES; CYTOCHROME-C RELEASE; RNA-BINDING PROTEIN; LUNG-CANCER; HOMOZYGOUS DELETION; CHROMOSOME 3P21.3; TUMOR-GROWTH; EXPRESSION PATTERNS; MICROCELL HYBRIDS	The candidate tumour suppressor gene, LUCA-15, maps to the lung cancer tumour suppressor locus 3p21.3. Overexpression of an alternative RNA splice variant of LUCA-15 has been shown to retard human Jurkat T cell proliferation and to accelerate CD95-mediated apoptosis, An antisense cDNA to the 3'-UTR of this splice variant was able to suppress CD95-mediated apoptosis, Here, we report that overexpression of LUCA-15 itself suppresses CD95-mediated apoptosis in Jurkat cells. This suppression occurs Drier to the final execution stage of the CD95 signalling pathway, and is associated with upregulation of the apoptosis inhibitory protein Bcl-2, LUCA-15 overexpression is also able to inhibit apoptosis induced by the protein kinase inhibitor staurosporine, but is not able to significantly suppress apoptosis mediated by the topoisomerase II inhibitor etoposide, These findings suggest that LUCA-15 is a selective inhibitor of cell death, and confirm the importance of the LUCA-15 genetic locus in the control of apoptosis.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA; NCI, Immunobiol Lab, FCRDC, Frederick, MD 21702 USA; Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Keele University	Sutherland, LC (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NCRR NIH HHS [M01RR10732] Funding Source: Medline; NIDDK NIH HHS [DK46778] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chung GTY, 1995, ONCOGENE, V11, P2591; Daigo Y, 1999, CANCER RES, V59, P1966; DALY MC, 1993, ONCOGENE, V8, P1721; DOLE M, 1994, CANCER RES, V54, P3253; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GRAY DA, 1995, ONCOGENE, V10, P2179; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Imreh S, 1997, GENE CHROMOSOME CANC, V20, P224; Inoue A, 1996, NUCLEIC ACIDS RES, V24, P2990, DOI 10.1093/nar/24.15.2990; Jackers P, 1996, ONCOGENE, V13, P495; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johnson DE, 2000, CANCER RES, V60, P1818; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X; Kholodnyuk I, 1997, GENE CHROMOSOME CANC, V18, P200, DOI 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.0.CO;2-5; KOK K, 1994, CANCER RES, V54, P4183; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lock RB, 1996, CANCER RES, V56, P4006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1993, BLOOD, V81, P151; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shriver SP, 1998, MUTAT RES-GENOMICS, V406, P9, DOI 10.1016/S1383-5726(98)00006-5; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Sutherland LC, 1997, J IMMUNOL METHODS, V207, P179, DOI 10.1016/S0022-1759(97)00118-X; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Timmer T, 1999, EUR J HUM GENET, V7, P478, DOI 10.1038/sj.ejhg.5200334; Todd MC, 1996, ONCOGENE, V13, P2387; Uchida K, 1997, CYTOGENET CELL GENET, V78, P209, DOI 10.1159/000134658; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wei MH, 1996, CANCER RES, V56, P1487; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	50	33	34	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2713	2719		10.1038/sj.onc.1204371	http://dx.doi.org/10.1038/sj.onc.1204371			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420683				2022-12-28	WOS:000168652600012
J	Nozaki, S; Sledge, GW; Nakshatri, H				Nozaki, S; Sledge, GW; Nakshatri, H			Repression of GADD153/CHOP by NF-kappa B: a possible cellular defense against endoplasmic reticulum stress-induced cell death	ONCOGENE			English	Article						NF-kappa B; GADD153/CHOP; apoptosis; transcription repression; endoplasmic reticulum stress	HUMAN BREAST-CANCER; DAMAGE-INDUCIBLE GENES; INDUCED APOPTOSIS; MESSENGER-RNA; C/EBP-BETA; GROWTH ARREST; MAMMARY-GLAND; BINDING-SITE; DNA-BINDING; NUDE-MICE	Exposure of mammalian cells to ultraviolet light, nutrient deprived culture media, hypoxia, environmental toxicants such as methyl mercury, methyl methanesulfonate, crocodilite asbestos or the agents that disrupt the function of endoplasmic reticulum (ER) leads to activation of the pro-apoptotic transcription factor GADD153/CHOP. Paradoxically, several of these agents also induce the anti-apoptotic transcription factor NF-kappaB. In this report, we demonstrate that NF-kappaB inhibits GADD153 activation in breast cancer cells exposed to nutrient deprived media, tunicamycin (which blocks protein folding in ER) or calcium ionopore (which depletes calcium stores in ER), Basal and calcium ionopore-induced GADD153 expression was more pronounced in fibroblasts obtained from mouse embryos lacking in p65 subunit of NF-kappaB compared to fibroblasts from wild type Littermate embryos. Moreover, p65-/-fibroblasts were killed more efficiently by calcium ionopore and tunicamycin but not hydrogen peroxide compared to wild type fibroblasts, We also show that parthenolide, a NF-kappaB inhibitor, sensitizes breast cancer tells to tunicamycin, Transient transfection assay revealed that the p65 subunit but not the p50 subunit of NF-kappaB represses GADD153 promoter activity, These results establish a correlation between repression of proapoptotic genes by NF-kappaB and increased cell survival during ER stress as well as identify a distinct NF-kappaB regulated cell survival pathway.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.			Nakshatri, Harikrishna/0000-0001-8876-0052				Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARTEK J, 1990, ONCOGENE, V5, P893; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; CORNETTA K, 1994, CLIN EXP METASTAS, V12, P3, DOI 10.1007/BF01784328; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, J BIOL CHEM, V271, P20588, DOI 10.1074/jbc.271.34.20588; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; Johnson NF, 1997, ENVIRON HEALTH PERSP, V105, P913, DOI 10.2307/3433303; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim R, 1999, ANTICANCER RES, V19, P1779; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Los G, 1999, CLIN CANCER RES, V5, P1610; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; Ou YC, 1997, TOXICOL APPL PHARM, V147, P31, DOI 10.1006/taap.1997.8235; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Ravi R, 1998, CANCER RES, V58, P4531; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Schmitt-Ney M, 2000, J BIOL CHEM, V275, P40839, DOI 10.1074/jbc.M007440200; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	97	108	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2178	2185		10.1038/sj.onc.1204292	http://dx.doi.org/10.1038/sj.onc.1204292			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360202				2022-12-28	WOS:000168116700013
J	Ruediger, R; Pham, HT; Walter, G				Ruediger, R; Pham, HT; Walter, G			Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene	ONCOGENE			English	Article						PP2A; A beta subunit; mutation; lung and colon cancer; tumor suppressor	ADENOVIRUS E4ORF4 PROTEIN; SERINE THREONINE PHOSPHATASES; REGULATORY B-SUBUNITS; PP2A CORE ENZYME; CATALYTIC SUBUNIT; MOLECULAR-CLONING; TUMOR-ANTIGENS; PPP2R1B GENE; SEQUENCE-ANALYSIS; DNA-REPLICATION	Protein phosphatase 2A (PP2A) consists of three subunits, A, B and C, The A and B subunits have regulatory functions while C is the catalytic subunit, PP2A core enzyme is composed of subunits A and C, and the holoenzyme of subunits A, B and C, All subunits exist as multiple isoforms or splice variants. The A subunit exists as two isoforms, A alpha and A beta. Here we report about the properties of eight A beta mutants, which were found in human lung and colon cancer. These mutants were reconstructed by site-directed mutagenesis and assayed for their ability to bind B and C subunits, Two mutants showed decreased binding of PR72, a member of the B " family of B subunits, but normal C subunit binding; two mutants exhibited decreased binding of the C subunit and of B " /PR72; and one mutant showed increased binding of both the C subunit and B " /PR72, Of three mutants that behaved like the wildtype A beta subunit, one is a polymorphic variant and another one is altered outside the binding region for B and C subunits, Importantly, we also found that the wildtype A alpha and A beta isoforms, although 85% identical, are remarkably different in their ability to bind B and C subunits, Our findings may have important implications in regard to the role of PP2A as a tumor suppressor.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Walter, G (corresponding author), Univ Calif San Diego, Dept Pathol, 0612,9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [CA-36111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOSCH M, 1995, EUR J BIOCHEM, V230, P1037, DOI 10.1111/j.1432-1033.1995.tb20653.x; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, J BIOL CHEM, V264, P21435; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hong YL, 2000, BIOCHEM BIOPH RES CO, V272, P84, DOI 10.1006/bbrc.2000.2733; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagase T, 1997, J BIOCHEM, V122, P178; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	65	108	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1892	1899		10.1038/sj.onc.1204279	http://dx.doi.org/10.1038/sj.onc.1204279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313937				2022-12-28	WOS:000167908400010
J	Galy, B; Creancier, L; Zanibellato, C; Prats, AC; Prats, H				Galy, B; Creancier, L; Zanibellato, C; Prats, AC; Prats, H			Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism	ONCOGENE			English	Article						FGF; p53; p73; post-transcriptional control; growth factor; tumour suppressor	INTERNAL RIBOSOME ENTRY; FACTOR MESSENGER-RNA; ALTERNATIVE TRANSLATION; HUMAN CANCERS; FIBROBLAST-GROWTH-FACTOR-2; INITIATION; PROTEIN; CELLS; GROWTH-FACTOR-2; LOCALIZATION	Fibroblast growth factor-2 (FGF-2) is a powerful mitogen and angiogenic factor whose expression is strongly regulated at the translational level. The constitutive upregulation of FGF-2 isoforms in transformed cells prompted us to investigate the posttranscriptional effects of a tumour suppressor, p53, on FGF-2 expression. We show here in human primary skin fibroblasts that the cell density-dependent variation of FGF-2 mRNA translatability was inversely correlated with endogenous p53 expression. Transient cell transfection revealed an inhibitory effect of wild-type p53 on the expression of chimeric FGF-CAT proteins. RNAse mapping experiments ruled out any effect of p53 on FGF-CAT mRNA accumulation, suggesting a translational inhibition. This inhibition was mediated by the FGF-2 mRNA leader, but not by vascular endothelial growth factor or platelet derived growth factor mRNA leaders. Neither p53-like protein p73, nor p21/waf had any inhibitory activity. Furthermore a set of hot spot mutants of p53 bearing mutations in the DNA binding domain had no post-transcriptional inhibitory effect. In contrast a p53 mutant of the transactivating domain was still able to block FGF - CAT expression, indicating that the post-transcriptional activity of p53 described here was independent of the trans-activation of target genes. Such data reveal a novel mechanism by which p53 efficiently blocks the expression of a major proliferating, anti-apoptotic and angiogenic gene.	CHU Rangueil, Inst Federat Rech Louis Bugnard, INSERM U397, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, H (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Prats, Herve/0000-0002-4861-2167; Galy, Bruno/0000-0002-0501-6357				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FUKS Z, 1994, CANCER RES, V54, P2582; Galy B, 1999, CANCER RES, V59, P165; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696	33	45	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1669	1677		10.1038/sj.onc.1204271	http://dx.doi.org/10.1038/sj.onc.1204271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313915				2022-12-28	WOS:000167750900001
J	Pianetti, S; Arsura, M; Romieu-Mourez, R; Coffey, RJ; Sonenshein, GE				Pianetti, S; Arsura, M; Romieu-Mourez, R; Coffey, RJ; Sonenshein, GE			Her-2/neu overexpression induces NF-kappa B via a PI3-kinase/Akt pathway involving calpain-mediated degradation of I kappa-B-alpha that can be inhibited by the tumor suppressor PTEN	ONCOGENE			English	Article						breast cancer; EGF receptor; transgenic mice; NF-kappa B; I kappa B-alpha; calpain	GROWTH-FACTOR-ALPHA; BREAST-CANCER; TRANSCRIPTION FACTOR; C-MYC; CONSTITUTIVE ACTIVATION; NECROSIS-FACTOR; PHOSPHOINOSITIDE 3-KINASE; MAMMARY EPITHELIUM; NEU PROTOONCOGENE; INDUCED APOPTOSIS	The Nuclear Factor (NF)-kappaB family of transcription factors controls expression of genes which promote cell growth, survival, and neoplastic transformation, Recently we demonstrated aberrant constitutive activation of NF-kappaB in primary human and rat breast cancer specimens and in cell lines. Overexpression of the epidermal growth factor receptor (EGFR) family member Her-2/neu, seen in approximately 30% of breast cancers, is associated with poor prognosis. Previously, Her-2/neu has been shown to signal via a phosphatidylinositol 3 (PI3)-kinase to Akt/protein kinase B (PKB) pathway. Since this signaling pathway was recently shown to activate NF-kappaB, here we have tested the hypothesis that Her-2/neu can activate TF-kappaB in breast cancer, Overexpression of Her-2/neu and EGFR-4 in Ba/F3 cells led to constitutive PI3- and Akt kinase activities, and induction of classical NF-kappaB (p50/p65). Similarly, a tumor cell line and tumors derived from MMTV-Her-2/neu transgenic mice displayed elevated levels of classical NF-kappaB, Engagement of Her-2/neu receptor downregulated the level of NF-kappaB. NF-kappaB binding and activity in the cultured cells was reduced upon inhibition of the PI3- to Akt kinase signaling pathway via ectopic expression of kinase inactive mutants, incubation with wortmannin, or expression of the tumor suppressor phosphatase PTEN, Inhibitors of calpain, but not the proteasome, blocked I kappaB-alpha degradation. Inhibition of Akt did not affect IKK activity, These results indicate that Her-2/neu activates NF-kappaB via a P13- to Akt kinase signaling pathway that can be inhibited via the tumor suppressor PTEN, and is mediated by calpain rather than the I kappaB kinase complex.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Program Res Womens Hlth, Boston, MA 02118 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA	Boston University; Boston University; Vanderbilt University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.				NCI NIH HHS [CA 82742, CA78616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078616, R01CA082742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BROWN K, 1995, CELL, V84, P853; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; CHEN ZJ, 1996, MOL CELL BIOL, V16, P1295; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Duffey DC, 1999, CANCER RES, V59, P3468; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Fields ER, 2000, J IMMUNOL, V164, P4762, DOI 10.4049/jimmunol.164.9.4762; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hortobagyi GN, 1999, SEMIN ONCOL, V26, P11; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Jeay S, 2000, MOL ENDOCRINOL, V14, P650, DOI 10.1210/me.14.5.650; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Miyajima A, 1999, INT J HEMATOL, V69, P137; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Mori N, 1999, BLOOD, V93, P2360; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ozes ON, 1999, NATURE, V401, P82; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Rawadi G, 1999, J BIOL CHEM, V274, P30794, DOI 10.1074/jbc.274.43.30794; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REGNIER CH, 1997, SCIENCE, V278, P866; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ross, 1998, Oncologist, V3, P237; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Tam S. W., 1997, Leukemia (Basingstoke), V11, P363; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	70	232	243	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1287	1299		10.1038/sj.onc.1204257	http://dx.doi.org/10.1038/sj.onc.1204257			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313873				2022-12-28	WOS:000167495000003
J	Bilanges, B; Varrault, A; Mazumdar, A; Pantaloni, C; Hoffmann, A; Bockaert, J; Spengler, D; Journot, L				Bilanges, B; Varrault, A; Mazumdar, A; Pantaloni, C; Hoffmann, A; Bockaert, J; Spengler, D; Journot, L			Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities	ONCOGENE			English	Article						ZAC; cell cycle; apoptosis; breast cancer; transient neonatal diabetes; imprinting	ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR-I; BREAST-CANCER; CHROMOSOME 6Q; CELLS; HETEROZYGOSITY; IDENTIFICATION; SPECIFICITY; EXPRESSION; CARCINOMAS	ZAC encodes a zinc finger protein with antiproliferative activity, is maternally imprinted and is a candidate for the tumor suppressor gene on 6q24, ZAC expression is frequently lost in breast and ovary tumor-derived cell lines and down-regulated in breast primary tumors. In this report, we describe ZAC Delta2, an alternatively spliced variant of ZAC lacking the sequence encoding the two IV-terminal zinc fingers. Messenger RNAs encoding ZAC or ZAC Delta2 mere equally abundant and both proteins were nuclear. ZAC Delta2 displayed an improved transactivation activity and an enhanced affinity for a ZAC binding site, suggesting that the two N-terminal zinc fingers negatively regulated ZAC binding to its target DNA sequences. Both proteins were equally efficient in preventing colony formation, indicating similar overall antiproliferative activities. However, these activities resulted from a differential regulation of apoptosis vs cell cycle progression since ZAC Delta2 was more efficient at induction of cell cycle arrest than ZAC, whereas it was the reverse for apoptosis induction. Hence, these data further underline that ZAC gene is critically controlled, both at the transcriptional level through imprinting and at the functional level through alternative splicing.	CNRS, UPR 9023, F-34094 Montpellier 05, France; Max Planck Inst Psychiat, D-80804 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Journot, L (corresponding author), CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Journot, Laurent/T-9652-2018; Bilanges, Benoit/AAP-6078-2020	Journot, Laurent/0000-0003-3499-8887; Bilanges, Benoit/0000-0003-4400-3716				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Cabanillas AM, 1996, DNA CELL BIOL, V15, P643, DOI 10.1089/dna.1996.15.643; Cave H, 2000, DIABETES, V49, P108, DOI 10.2337/diabetes.49.1.108; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVILEE P, 1991, ONCOGENE, V6, P1705; FERGUSON AW, 1970, ARCH DIS CHILD, V45, P80, DOI 10.1136/adc.45.239.80; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NEGRINI M, 1994, CANCER RES, V54, P1331; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Noviello C, 1996, CLIN CANCER RES, V2, P1601; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Queimado L, 1999, LAB INVEST, V79, P583; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Theile M, 1996, ONCOGENE, V13, P677; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835	39	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1246	1253		10.1038/sj.onc.1204237	http://dx.doi.org/10.1038/sj.onc.1204237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313869				2022-12-28	WOS:000167570100012
J	Jaks, V; Joers, A; Kristjuhan, A; Maimets, T				Jaks, V; Joers, A; Kristjuhan, A; Maimets, T			p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin	ONCOGENE			English	Article						p53; DNA damage; cell cycle; apoptosis	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; UV-LIGHT; TRANSCRIPTIONAL ACTIVITY; DEPENDENT KINASES; HUMAN FIBROBLASTS; GENE-EXPRESSION; STRAND BREAKS; APOPTOSIS; RADIATION	In this studyw we characterize the connections between p53-dependent G1 cell cycle arrest, transcriptional activation of the protein and the increase of its intracellular steady-state concentration, Several cell lines expressing wild-type p53 protein were treated with increasing concentrations of DNA-damaging drug camptothecin, Lower doses of the drug caused transcriptional activation of p53, but no accumulation of the protein was detected. Only after a certain threshold dose of camptothecin does the amount of the protein rapidly increase and reach its plateau levels. The threshold dose was different for different cell lines, but the general non-linear profile was similar, Increase of p53 level was accompanied by additional transcriptional activation of some p53 target genes (i,e, waf1), but not the others (mdm2), We demonstrate here that transcriptional activation of p53 after the treatment of camptothecin is not sufficient to cause p53-dependent G1 cell cycle arrest. The latter is observable only after the inrease of steady-state level of p53, Low drug concentrations, although accompanied by transcriptional activation of p53, do not cause either p53 protein accumulation nor cell cycle arrest at G1, We propose a model for p53 acting as a part of cellular sensor system detecting the severity of DNA damage.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia	University of Tartu	Maimets, T (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-51010 Tartu, Estonia.		Jaks, Viljar/H-2467-2012; Maimets, Toivo/E-9268-2017	Jaks, Viljar/0000-0002-2221-6262; Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952; Joers, Arvi/0000-0003-2083-3977				AVEMANN K, 1998, MOL CELL BIOL, V8, P3206; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN C, 1995, GENE DEV, V12, P600; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DEIRY WS, 1993, CELL, V75, P817; Deptala A, 1999, INT J ONCOL, V15, P861; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Ewen ME, 1996, J LAB CLIN MED, V128, P355, DOI 10.1016/S0022-2143(96)80006-0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P291; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P295; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; Kristjuhan A, 1998, ONCOGENE, V16, P2413, DOI 10.1038/sj.onc.1201749; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li G, 1998, BRIT J DERMATOL, V139, P3; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Selkirk JK, 1996, ELECTROPHORESIS, V17, P1764, DOI 10.1002/elps.1150171114; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shieh SY, 2000, GENE DEV, V14, P289; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P704; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	55	15	15	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1212	1219		10.1038/sj.onc.1204232	http://dx.doi.org/10.1038/sj.onc.1204232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313865				2022-12-28	WOS:000167570100008
J	Labuhn, M; Jones, G; Speel, EJM; Maier, D; Zweifel, C; Gratzl, O; Van Meir, EG; Hegi, ME; Merlo, A				Labuhn, M; Jones, G; Speel, EJM; Maier, D; Zweifel, C; Gratzl, O; Van Meir, EG; Hegi, ME; Merlo, A			Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas	ONCOGENE			English	Article						INK4A locus; P16(INK4A); p14(ARF); co-deletions; quantitative real-time PCR	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; HOMOZYGOUS DELETION; INK4A LOCUS; P15(INK4B) GENE; HUMAN CANCERS; BRAIN-TUMORS; CPG ISLAND; LOW-GRADE; P53	In many human cancers, the INK4A locus is frequently mutated by homozygous deletions, By alternative splicing this locus encodes two non-related tumor suppressor genes, p16(INK4A) and p14(ARF) (p19(ARF) in mice), which regulate cell cycle and cell survival in the retinoblastoma protein (pRb) and p53 pathways, respectively, In mice, the role of p16(INK4A) as th, critical tumor suppressor gene at the INK4A locus was challenged when it was found that p19(ARF) only knock-out mice developed tumors, including gliomas, We have analysed the genetic status of the INK4A locus in 105 primary gliomas using both microsatellite mapping (MSM) and quantitative realtime PCR (QRT-PCR). Comparison of the results of the two methods revealed agreement in 67% of the tumors examined, In discordant cases, fluorescence in situ hybridization (FISH) analysis was always found to support QRT-PCR classification, Direct assessment of p14(ARF) exon 1 beta, p16(INK4A) exon 1 alpha and exon 2 by QRT-PCR revealed 43 (41%) homozygous and eight (7%) hemizygous deletions at the INK4A locus. In 49 (47%) gliomas, both alleles were retained, In addition, QRT-PCR, but not MSM, detected hyperploidy in five (5%) tumors, Deletion of p14(ARF) was always associated with co-deletion of p16(INK4A) and increased in frequency upon progression from low to high grade gliomas, Shorter survival was associated with homozygous deletions of INK4A in the subgroup of glioblastoma patients older than 50 years of age (P = 0.025, Anova test single factor, alpha =0.05).	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; CHU Vaudois, Lab Tumor Biol & Genet, CH-1101 Lausanne, Switzerland; Emory Univ, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Univ Maastricht, Dept Mol Cell Biol & Genet, NL-6200 MD Maastricht, Netherlands	University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Maastricht University	Merlo, A (corresponding author), Univ Basel Hosp, Dept Res, Schanzenstr 46, CH-4031 Basel, Switzerland.		Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DURO D, 1995, ONCOGENE, V11, P21; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; GLENDENING JM, 1995, CANCER RES, V55, P5531; Gortz B, 1999, INT J CANCER, V80, P373, DOI 10.1002/(SICI)1097-0215(19990129)80:3<373::AID-IJC7>3.0.CO;2-B; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; LI YJ, 1995, ONCOGENE, V11, P597; Lloyd AC, 2000, NAT CELL BIOL, V2, pE48, DOI 10.1038/35004078; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; Newcomb EW, 1998, BRAIN PATHOL, V8, P655, DOI 10.1111/j.1750-3639.1998.tb00191.x; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; ROCCHI M, 1991, GENOMICS, V9, P517, DOI 10.1016/0888-7543(91)90419-F; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Speel EJM, 1997, J HISTOCHEM CYTOCHEM, V45, P1439, DOI 10.1177/002215549704501013; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wang YW, 1997, ELECTROPHORESIS, V18, P1742, DOI 10.1002/elps.1150181007; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhuang ZP, 1997, CANCER RES, V57, P4682	42	54	58	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1103	1109		10.1038/sj.onc.1204197	http://dx.doi.org/10.1038/sj.onc.1204197			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314047				2022-12-28	WOS:000167232100010
J	Ozbek, S; Peters, M; Breuhahn, K; Mann, A; Blessing, M; Fischer, M; Schirmacher, P; Mackiewicz, A; Rose-John, S				Ozbek, S; Peters, M; Breuhahn, K; Mann, A; Blessing, M; Fischer, M; Schirmacher, P; Mackiewicz, A; Rose-John, S			The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells	ONCOGENE			English	Article						designer cytokine; GM-CSF; interleukin-6; melanoma; soluble receptor; tumor rejection	SOLUBLE IL-6 RECEPTOR; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; HEMATOPOIETIC PROGENITOR CELLS; DOUBLE-TRANSGENIC MICE; TUMOR-CELLS; IN-VIVO; INTERLEUKIN-6 RECEPTOR; ANTITUMOR-ACTIVITY; GENE-TRANSFER	The low immunogenic B16 melanoma cell line was transfected with a mammalian expression vector containing the complementary DNA for a sIL-6R/IL-6 fusion protein, termed Hyper-IL-6 (H-IL-6), which was shown to have biological activities at 100-1000-fold lower concentrations than IL-6 in combination with sIL-6R. The secreted p84 glycoprotein was detected in the supernatant of transfected cells and was fully active on BAF3/gp130 cells, which respond to IL-6/sIL-6R but not to IL-6 alone. Administration of recombinant H-IL-6 to C57BL/6 mice resulted in a prolonged acute phase protein gene expression indicating long systemic persistence of the fusion protein. Transfected B16 cells (B16/ H-IL6 cells) showed morphological alterations in combination with a dramatic growth inhibition in vitro. Subcutaneous injection in C57BL/6 mice resulted in an almost complete rejection of B16/H-IL6 cells. This effect was partially abolished in FVB/BL/6 mice transgenic for a GM-CSF receptor antagonist, indicating a GM-CSF-deependent rejection of H-IL-6 transfected B16 cells. These results demonstrate that the anti-tumor effect of cytokines like IL-6 which are secreted by transfected melanoma cells at least in part depends on GM-CSF activity.	Univ Kiel, Inst Biochem, Dept Biochem, D-24098 Kiel, Germany; Univ Mainz, Dept Med, Sect Pathophysiol, D-55101 Mainz, Germany; Univ Cologne, Inst Pathol, D-5000 Cologne, Germany; Great Poland Canc Ctr, Dept Canc Immunol, Poznan, Poland	University of Kiel; Johannes Gutenberg University of Mainz; University of Cologne; Wielkopolskie Centrum Onkologii	Rose-John, S (corresponding author), Univ Kiel, Inst Biochem, Dept Biochem, Olshausenstr 40, D-24098 Kiel, Germany.		Rose-John, Stefan/A-7998-2010; Özbek, Suat/D-3701-2014	Rose-John, Stefan/0000-0002-7519-3279; Breuhahn, Kai/0000-0002-2462-1229; Ozbek, Suat/0000-0003-2569-3942				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; Bernhard H, 2000, EXP HEMATOL, V28, P365, DOI 10.1016/S0301-472X(00)00126-0; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Englaro W, 1999, ONCOGENE, V18, P1553, DOI 10.1038/sj.onc.1202446; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; Greene AL, 1997, J INTERF CYTOK RES, V17, P727, DOI 10.1089/jir.1997.17.727; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HERMANN E, 1989, CLIN EXP RHEUMATOL, V7, P411; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HOGAN BF, 1986, MANIPULATING MOUSE M; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; Klouche M, 1999, J IMMUNOL, V163, P4583; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; MACKIEWICZ A, 1995, HUM GENE THER, V6, P805, DOI 10.1089/hum.1995.6.6-805; MACKIEWICZ A, 1995, CYTOKINE, V7, P142, DOI 10.1006/cyto.1995.1019; MCINTOSH JK, 1989, J IMMUNOL, V143, P162; MULE JJ, 1990, J EXP MED, V171, P629, DOI 10.1084/jem.171.3.629; MULE JJ, 1992, J IMMUNOL, V148, P2622; MULE JJ, 1992, RES IMMUNOL, V143, P777, DOI 10.1016/0923-2494(92)80023-E; MULLEN CA, 1992, CANCER RES, V52, P6020; Nawrocki S, 2000, IMMUNOL LETT, V74, P81, DOI 10.1016/S0165-2478(00)00253-4; NOVICK D, 1992, CYTOKINE, V4, P6, DOI 10.1016/1043-4666(92)90029-Q; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; Peters M, 1996, IMMUNOL LETT, V54, P177, DOI 10.1016/S0165-2478(96)02669-7; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Peters M, 1998, J IMMUNOL, V161, P3575; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; PORGADOR A, 1992, CANCER RES, V52, P3679; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUN WH, 1992, CANCER RES, V52, P5412; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; Wu TY, 1998, J INTERF CYTOK RES, V18, P829, DOI 10.1089/jir.1998.18.829	47	25	32	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					972	979		10.1038/sj.onc.1204180	http://dx.doi.org/10.1038/sj.onc.1204180			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314032				2022-12-28	WOS:000167097000008
J	Baross-Francis, A; Makhani, N; Liskay, RM; Jirik, FR				Baross-Francis, A; Makhani, N; Liskay, RM; Jirik, FR			Elevated mutant frequencies and increased C : G -> T : A transitions in Mlh1(-/-) versus Pms2(-/-) murine small intestinal epithelial cells	ONCOGENE			English	Article						DNA mismatch repair; Mlh1; Pms2; transgenic; lacI	DNA MISMATCH REPAIR; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PROMOTER METHYLATION; TRANSGENIC MICE; GENE PMS2; LACI GENE; MUTATIONS; MLH1; HMLH1	Mutations in DNA mismatch repair (MMR) genes are associated with increased genomic instability and susceptibility to cancer. Mice rendered deficient in either Mlh1 or Pms2 as a result of gene targeting are prone to tumorigenesis, particularly, lymphomas, In addition, although Mlh1(-/-) mice also develop small intestinal adenomas and adenocarcinomas, Pms2(-/-) animals remain free of such tumors. To establish whether this phenotypic dichotomy might he associated with quantitative and/or qualitative difference in genomic instability in these mice, we determined small intestinal epithelial cell DNA mutant frequency and mutation using a transgenic lambda -phage lacI reporter Mutant frequencies obtained from both Mlh1(-/-) and Pms2(-/-) mice revealed elevations of 18 and 13-fold, respectively, as compared to their wild-type littermates. interestingly, we found that C:G-->T:A transitions, were significantly elevated in MlH1 (/-) mice, accounting in large measure for the 1.5-fold lacI mutant frequency increase seen in these animals, We hypothesize that the increased level of C:G-->T:A mutations may explain, in part, why Mlh1(-/) mice, but not Pms2(-/-) mice, develop small intestinal tumors, Furthermore, the difference in the lacI mutational spectrum of Mlh1 and Pms2(-/-) mice suggests that other MutL-like heterodimers may play important roles in the repair of G : T mispairs arising within murine small intestinal epithelial cells.	Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 4H4, Canada; Oregon Hlth Sci Univ, Dept Med & Mol Genet, Portland, OR 97201 USA	University of British Columbia; University of British Columbia; Oregon Health & Science University	Jirik, FR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032741] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM32741] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; de Boer JG, 1998, GENETICS, V148, P1441; DEBOER J, 1999, BIG BLUE WEBSITE; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dogliotti E, 1996, CARCINOGENESIS, V17, P2113, DOI 10.1093/carcin/17.10.2113; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, GENET ANAL-BIOMOL E, V7, P212, DOI 10.1016/0735-0651(90)90003-X; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; Leung SY, 1999, CANCER RES, V59, P159; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Ricciardone MD, 1999, CANCER RES, V59, P290; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Toft NJ, 1998, J PATHOL, V185, P123; Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067; Wang Q, 1999, CANCER RES, V59, P294; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yang Y, 1999, MOL GEN GENET, V261, P777, DOI 10.1007/s004380050021; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	41	32	32	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					619	625		10.1038/sj.onc.1204138	http://dx.doi.org/10.1038/sj.onc.1204138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313994				2022-12-28	WOS:000166755000009
J	Zwerner, JP; May, WA				Zwerner, JP; May, WA			PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors	ONCOGENE			English	Article						Ewing's sarcoma; Ewing family tumors; PDGF-C; EWS/FLI	FUSION GENE; SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR; EXPRESSION CLONING; EWS GENE; CELLS; ONCOGENE; RECEPTOR; PROTEIN; BINDING	The aberrant transcription factors associated with many human malignancies function by deregulation of tumorigenic pathways, However, identification of these pathways has come slowly . Virtually all cases of Ewing's Sa;coma and peripheral Primitive, Neuroectodermal Tumor (PNET) are associated with aberrant transcription factors which fuse amino-terminal EWS with the DNA binding moiety of an ETS transcription factor (FLI-1 in 90% of cases), Attempts to identify the downstream targets of these chimeras in the Ewing Family Tumors (EFT) on the basis of differential gene regulation have produced little association with tumor biology, As an alternative approach, we have used highly efficient retroviral systems to biologically screen cDNA derived from cells transformed by EWS/FLI-1. We have identified the recently described PDGF-C as target of EWS/ETS transcriptional deregulation, This transcriptional deregulation is specific to EWS/FLI, PDGF-C possesses substantial biologic activity in vitro and in vivo. It is expressed in EFT cell lines and in primary tumors, Within these EFT cell lines, PDGF-C expression is dependent upon EWS/FLI activity. These results suggest that PDGF-C may be a significant mediator of EWS/FLI driven oncogenesis.	Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	May, WA (corresponding author), Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ding H, 2000, MECH DEVELOP, V96, P209, DOI 10.1016/S0925-4773(00)00425-1; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HELDIN CH, 1992, KIDNEY INT, V41, P571, DOI 10.1038/ki.1992.84; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Im YH, 2000, CANCER RES, V60, P1536; JEON IS, 1995, ONCOGENE, V10, P1229; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; Lawlor ER, 1998, CANCER RES, V58, P2469; LESSNICK SL, 1995, ONCOGENE, V10, P423; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thompson AD, 1996, ONCOGENE, V13, P2649; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vukmirovic OG, 2000, NATURE, V405, P820, DOI 10.1038/35015690; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	40	97	105	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					626	633		10.1038/sj.onc.1204133	http://dx.doi.org/10.1038/sj.onc.1204133			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313995	Green Accepted			2022-12-28	WOS:000166755000010
J	Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Montalvo, EA; Gao, SJ				Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Montalvo, EA; Gao, SJ			Characterization of the promoter region of the viral interferon regulatory factor encoded by Kaposi's sarcoma-associated herpesvirus	ONCOGENE			English	Article						Kaposi's sarcoma-associated herpesvirus; viral interferon regulatory factor; oncogene; promoter; TPA induction	MULTICENTRIC CASTLEMANS DISEASE; CAVITY-BASED LYMPHOMA; DNA-SEQUENCES; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION; GENES; KSHV; IRF-1; IDENTIFICATION; PATHWAY	Viral interferon regulatory factor (vIRF) encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) inhibits the expression of interferon-responsive genes, causes cellular transformation and transactivates KSHV genes. In the present study, we characterized the mRNA expression pattern of the vIRF gene and its promoter, A vIRF transcript of 1.7 kb in size was detected in low level in uninduced KSHV-infected cells and its expression was inducible by 12-O-tetradecanoylphorbol-13-acetate (TPA), sensitive to cycloheximide and resistant to phosphonoacetic acid. The transcription start site was mapped to 79 nt upstream of the ATG initiation site by 5'-RACE. Mutagenesis analysis identified a region between -56 and the transcription start site (+1) as the minimal promoter region that contains a functional TATA box at -27. A region between -337 and -125 contains a repressor domain negated by sequence from -991 to -499 in BCBL-1 cells, a region which was also identified to be responsive to TPA induction. These results demonstrate vIRF as st KSHV early gene, identify its promoter and define the promoter regions that contain regulatory elements controlling vIRF transcription.	Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Gao, SJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA.		Gao, Shou-Jiang/B-8641-2012	Gao, Shou-Jiang/0000-0001-6194-1742	NHLBI NIH HHS [HL60604-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060604] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASUBEL FM, 1995, CURRENT PROTOCOLS MO; BOSHOFF C, 1995, LANCET, V345, P1043; Burysek L, 1999, J VIROL, V73, P7334; Carbone A, 1996, BRIT J HAEMATOL, V94, P533, DOI 10.1046/j.1365-2141.1996.d01-1826.x; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHADBURN A, 1996, LAB INVEST, V74, pA109; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chen JG, 2000, J VIROL, V74, P8623, DOI 10.1128/JVI.74.18.8623-8634.2000; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gessain A, 1996, BLOOD, V87, P414; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; Inagi R, 1999, J HUMAN VIROL, V2, P63; KARCHER DS, 1995, NEW ENGL J MED, V333, P797; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; PASTORE C, 1995, BRIT J HAEMATOL, V91, P918, DOI 10.1111/j.1365-2141.1995.tb05410.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Roan F, 1999, J GEN VIROL, V80, P2205, DOI 10.1099/0022-1317-80-8-2205; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	35	17	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					523	530		10.1038/sj.onc.1204115	http://dx.doi.org/10.1038/sj.onc.1204115			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313983				2022-12-28	WOS:000166562500012
J	Adams, J; Elliott, PJ				Adams, J; Elliott, PJ			New agents in cancer clinical trials	ONCOGENE			English	Article						proteasome; tubulin; heat shock proteins; histone; antifolates; protein tyrosine kinase	TRANSFORMED-CELL DIFFERENTIATION; COMBRETASTATIN A-4 PHOSPHATE; ABL TYROSINE KINASE; NF-KAPPA-B; ANTITUMOR AGENTS; HISTONE DEACETYLASE; IN-VIVO; FORMYLTRANSFERASE INHIBITORS; PROTEASOME INHIBITORS; ANTINEOPLASTIC AGENTS		Millennium Pharmaceut Inc, Res & Dev, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Adams, J (corresponding author), Millennium Pharmaceut Inc, Res & Dev, 38 Sidney St, Cambridge, MA 02139 USA.							Adams J, 1999, CANCER RES, V59, P2615; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Akagi T, 1996, ONCOGENE, V13, P399; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; BROGGINI M, 1989, NUCLEIC ACIDS RES, V17, P1051, DOI 10.1093/nar/17.3.1051; BROGGINI M, 1994, ANTI-CANCER DRUG DES, V9, P373; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; Buchdunger E, 1996, CANCER RES, V56, P100; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DINCALCI M, 1999, P 1999 AACR NCI EORT, V5, P144; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p368A; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GarciaRocha M, 1996, BRIT J CANCER, V73, P875, DOI 10.1038/bjc.1996.176; GLICK RD, 1999, P AM ASS CANC RES, V40; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grosios K, 2000, ANTICANCER RES, V20, P229; Grosios K, 1999, BRIT J CANCER, V81, P1318, DOI 10.1038/sj.bjc.6692174; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Habeck Lillian L., 1994, Cancer Research, V54, P1021; Habeck LL, 1998, CANCER CHEMOTH PHARM, V41, P201; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Hori K, 1999, JPN J CANCER RES, V90, P1026, DOI 10.1111/j.1349-7006.1999.tb00851.x; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Jimeno Jose M., 1996, Drugs of the Future, V21, P1155; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Kamen B, 1997, SEMIN ONCOL, V24, P30; Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; KWON HJ, 1999, P AM ASS CANC RES, V40; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LIN CM, 1989, BIOCHEMISTRY-US, V28, P6984, DOI 10.1021/bi00443a031; Martinez EJ, 2000, ORG LETT, V2, P993, DOI 10.1021/ol0056729; Mendelsohn LG, 1996, INVEST NEW DRUG, V14, P287, DOI 10.1007/BF00194532; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Nguyen D., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P485; Nihei Y, 1999, JPN J CANCER RES, V90, P1016, DOI 10.1111/j.1349-7006.1999.tb00850.x; NOWELL PC, 1960, SCIENCE, V132, P1497; Ochel HJ, 1999, MOL GENET METAB, V66, P24, DOI 10.1006/mgme.1998.2774; Orlowski RZ, 1998, CANCER RES, V58, P4342; PETERS JM, 1998, UBIQUITIN BIOL CELL, pCH1; Pettit GR, 1998, ANTI-CANCER DRUG DES, V13, P183; PETTIT GR, 1989, EXPERIENTIA, V45, P209, DOI 10.1007/BF01954881; PIZZORNO G, 1993, J BIOL CHEM, V268, P1017; Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b; RAY MS, 1993, J NATL CANCER I, V85, P1154, DOI 10.1093/jnci/85.14.1154; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; RINEHART KL, 1990, J ORG CHEM, V55, P4512, DOI 10.1021/jo00302a007; Rosing H, 1998, J CHROMATOGR B, V710, P183, DOI 10.1016/S0378-4347(98)00143-1; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Taamma A, 1999, CLIN CANCER RES, V5, p3791S; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Takimoto C H, 1995, Oncology (Williston Park), V9, P649; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tozer GM, 1999, CANCER RES, V59, P1626; VAN AD, 1996, SCIENCE, V274, P787; VILLALONACALERO M, 1999, ASCO, V18, P180; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	75	76	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6687	6692		10.1038/sj.onc.1204088	http://dx.doi.org/10.1038/sj.onc.1204088			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426656				2022-12-28	WOS:000167704000017
J	Hidalgo, M; Rowinsky, EK				Hidalgo, M; Rowinsky, EK			The rapamycin-sensitive signal transduction pathway as a target for cancer therapy	ONCOGENE			English	Article						rapamycin; CCI-779; signal transduction; clinical development	PROTEIN-KINASE-B; MAMMALIAN TARGET; MESSENGER-RNA; CYCLIN D1; PHOSPHOINOSITIDE 3-KINASE; CELL-PROLIFERATION; UP-REGULATION; IN-VITRO; INHIBITION; ACTIVATION	The high frequency of mutations in cancer cells which result in altered cell cycle regulation and growth signal transduction, conferring a proliferative advantage, indicates that many of these aberrant mechanisms may be strategic targets for cancer therapy. The macrolide fungicide rapamycin, a natural product with potent antimicrobial, immunosuppressant, and anti-tumor properties, inhibits the translation of key mRNAs of proteins required for cell cycle progression from G(1) to S phase. Rapamycin binds intracellularly to the immunophilin FK506 binding protein 12 (FKBP12), and the resultant complex inhibits the protein kinase activity of a protein kinase termed mammalian target of rapamycin (mTOR), The inhibition of mTOR, in turn, blocks signals to two separate downstream pathways which control the translation of specific mRNAs required for cell cycle traverse from G(1) to S phase. Blocking mTOR affects the activity of the 40S ribosomal protein S6 kinase (p70(s6k)) and the function of the eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), leading to growth arrest in the the G(1) phase of the cell cycle. In addition to its actions on p70(s6k) and 4E-BP1, rapamycin prevents cyclin-dependent kinase activation, inhibits retinoblastoma protein (pRb) phosphorylation, and accelerates the turnover of cyclin D1 that leads to a deficiency of active cdk4/cyclin D1 complexes, all of which can inhibit cell cycle traverse at the G(1)/S phase transition. Both rapamycin and CCI-779, an ester analog of rapamycin with improved pharmaceutical properties and aqueous solubility, have demonstrated impressive activity against a broad range of human cancers growing in tissue culture and in human tumor xenograft models, which has supported the development of compounds targeting rapamycin-sensitive signal-transduction pathways. CCI-779 has completed several phase I clinical evaluations and is currently undergoing broad disease-directed efficacy studies. The agent appears to be well tolerated at doses that have resulted in impressive anti-tumor activity in several types of refractory neoplasms. Important challenges during clinical development include the definition of a recommended dose range associated with optimal biological activity and maximal therapeutic indices, as well as the ability to predict which tumors will be sensitive or resistant to CCI-779.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol,Inst Drug Dev,Canc Therapy & Res Ct, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Hidalgo, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol,Inst Drug Dev,Canc Therapy & Res Ct, 7703 Floyd Curl Dr,Mail Code 7884, San Antonio, TX 78229 USA.							Adjei AA, 2000, CANCER RES, V60, P1871; BAKER H, 1978, J ANTIBIOT, V31, P539, DOI 10.7164/antibiotics.31.539; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; FERRY D, 2000, P AN M AM SOC CLIN, V19, P30; FRUMAN DA, 1995, EUR J IMMUNOL, V25, P563, DOI 10.1002/eji.1830250239; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; GIBBONS JJ, 2000, P AM ASSOC CANC RES, V40, P301; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Grewe M, 1999, CANCER RES, V59, P3581; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HIDALGO M, 2000, P AN M AM SOC CLIN, V19, P187; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; Hu LM, 2000, CLIN CANCER RES, V6, P880; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; RAYMOND E, 2000, P AM SOC CLIN ONCO, V40, P187; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sausville EA, 1999, PHARMACOL THERAPEUT, V82, P285, DOI 10.1016/S0163-7258(98)00062-X; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SEHGAL SN, 1995, THER DRUG MONIT, V17, P660, DOI 10.1097/00007691-199512000-00019; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Sekulic A, 2000, CANCER RES, V60, P3504; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Seufferlein T, 1996, CANCER RES, V56, P3895; SHANTZ LM, 1995, CANCER RES, V58, P2748; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sherr CJ, 2000, CANCER RES, V60, P3689; SHI YF, 1995, CANCER RES, V55, P1982; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Teng DHF, 1997, CANCER RES, V57, P5221; Thomas JE, 1997, J CELL BIOCHEM, V64, P182, DOI 10.1002/(SICI)1097-4644(199702)64:2<182::AID-JCB2>3.0.CO;2-T; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yatscoff RW, 1998, THER DRUG MONIT, V20, P459, DOI 10.1097/00007691-199810000-00002	61	489	544	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6680	6686		10.1038/sj.onc.1204091	http://dx.doi.org/10.1038/sj.onc.1204091			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426655				2022-12-28	WOS:000167704000016
J	Kirn, D				Kirn, D			Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer	ONCOGENE			English	Article						gene therapy; adenovirus; oncolytic; replication-selective	TUMOR-NECROSIS-FACTOR; HERPES-SIMPLEX VIRUS; COMPETENT ADENOVIRUS; NECK-CANCER; P53 STATUS; IN-VIVO; ATTENUATED ADENOVIRUS; ANTITUMORAL EFFICACY; RECURRENT HEAD; DEATH PROTEIN		Hammersmith Hosp, Imperial Coll, Sch Med, Imperial Canc Res Fund,Program Viral & Genet Ther, London W12 0NN, England	Cancer Research UK; Imperial College London	Kirn, D (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Imperial Canc Res Fund,Program Viral & Genet Ther, DuCane Rd, London W12 0NN, England.							Agha-Mohammadi S, 2000, J CLIN INVEST, V105, P1173, DOI 10.1172/JCI10026; ASADA T, 1974, CANCER, V34, P1907, DOI 10.1002/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dimitrov T, 1997, J VIROL, V71, P2830, DOI 10.1128/JVI.71.4.2830-2837.1997; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Ganly I, 2000, CLIN CANCER RES, V6, P798; GOODING LR, 1994, INFECT AGENT DIS, V3, P106; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Hawkins L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P476; HECHT R, 2000, P AN M AM SOC CLIN, V19, P1039; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Heise C, 2000, J CLIN INVEST, V105, P847, DOI 10.1172/JCI9762; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HEISE C, 2000, IN PRESS CLIN CANC R; HEISE C, 1999, CANC GENE THERAPY, V6; Heise CC, 1999, CANCER RES, V59, P2623; Hermiston T, 2000, J CLIN INVEST, V105, P1169, DOI 10.1172/JCI9973; HERMISTON TW, 1993, J VIROL, V67, P5289, DOI 10.1128/JVI.67.9.5289-5298.1993; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kim DH, 2000, GENE THER, V7, P815, DOI 10.1038/sj.gt.3301213; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; KIRN D, 1998, CANC GENE THERAPY; Kirn DH, 2000, J CLIN INVEST, V105, P837, DOI 10.1172/JCI9761; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Lattime EC, 1996, SEMIN ONCOL, V23, P88; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Mastrangelo MJ, 2000, J CLIN INVEST, V105, P1031, DOI 10.1172/JCI9819; Medina DJ, 1999, BLOOD, V94, P3499; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Nemunaitis J, 2000, CANCER RES, V60, P6359; NEMUNAITIS J, 1999, P CANC GENE THER M, V18, P714; NEMUNAITIS J, 2000, P AN M AM SOC CLIN, V19, P724; NIELSCH U, 1991, ONCOGENE, V6, P1031; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Reid T, 2000, P AN M AM SOC CLIN, V19, P953; RIED A, 1999, EORTC NCI AACR M MOL; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rodriguez R, 1997, CANCER RES, V57, P2559; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Rogulski KR, 2000, CANCER RES, V60, P1193; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Sauthoff H, 2000, HUM GENE THER, V11, P379, DOI 10.1089/10430340050015851; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHENK T, 1996, FIELDS VIROLOGY, P2135; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SMITH RR, 1956, CANCER, V9, P1211, DOI 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7; SOUTHAM CM, 1952, CANCER, V5, P1025, DOI 10.1002/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q; Sparer TE, 1996, J VIROL, V70, P2431, DOI 10.1128/JVI.70.4.2431-2439.1996; Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818; Toda M, 1999, HUM GENE THER, V10, P385, DOI 10.1089/10430349950018832; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; VASEY P, 2000, P AN M AM SOC CLIN, V19, P1512; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wildner O, 1999, CANCER RES, V59, P410; Wold W S, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P237; Wold William S. M., 1994, Trends in Microbiology, V2, P437, DOI 10.1016/0966-842X(94)90801-X; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yu DC, 1999, CANCER RES, V59, P1498; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	77	102	120	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6660	6669		10.1038/sj.onc.1204094	http://dx.doi.org/10.1038/sj.onc.1204094			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426652				2022-12-28	WOS:000167704000013
J	Scott, GK; Chang, CH; Erny, KM; Xu, F; Fredericks, WJ; Rauscher, FJ; Thor, AD; Benz, CC				Scott, GK; Chang, CH; Erny, KM; Xu, F; Fredericks, WJ; Rauscher, FJ; Thor, AD; Benz, CC			Ets regulation of the erbB2 promoter	ONCOGENE			English	Article						erbB2(HER2/neu) promoter; Ets binding site; Ets candidates	TRANSCRIPTION FACTOR; HER2/NEU PROMOTER; DOWN-REGULATION; DNA; PROTEIN; C-ERBB-2; EXPRESSION; BINDING; OVEREXPRESSION; INHIBITION	Evaluating the chromatinized erbB2 gene in nuclei from breast cancer cells expressing varying levels of ErbB2 transcripts, we identified a nuclease-sensitive site within a 0.22 kb region of maximum enhancer activity centered over a conserved 28 bp polypurine(GGA)-polypyrimidine(TCC) mirror-repeat and an adjacent essential Ets binding site (EBS), Promoter footprinting with nuclear extracts reveals an intense Ets hypersensitivity site at the EBS whose degree of intensity correlates with the Level of cellular ErbB2 expression. In vitro mapping assays show that the supercoiled erbB2 promoter forms an internal tripler structure (Hr-DNA) at the mirror-repeat element. Mutations preventing Hr-DNA formation can enhance erbB2 promoter activity in human breast cancer cells, a result consistent with previous demonstration that Ets-erbB2 promoter complexes cannot form when the mirror-repeat is engaged in tripler binding, and new results suggesting that Ets binding induces severe promoter bending that may restrict local tripler formation. In addition to previously described erbB2-regulating breast cancer Ets factors (PEA3, ESX/Elf-3), Elf-1 is now shown to be another endogenously expressed Ets candidate capable of binding to and upregulating the erbB2 promoter. Given current strategies to transcriptionally inhibit ErbB2 overexpression, including development of novel erbB2 promoter-targeted therapeutics, an EBS-targeted approach is presented using chimeric Ets proteins that strongly repress erbB2 promoter activity.	Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; Wistar Inst Anat & Biol, Mol Genet Program, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Ctr Canc, Philadelphia, PA 19104 USA; Northwestern Univ, Evanston Hosp, Dept Pathol, Evanston, IL 60201 USA	University of California System; University of California San Francisco; The Wistar Institute; The Wistar Institute; NorthShore University Health System; Northwestern University	Benz, CC (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.			Erny-Albrecht, Katrina/0000-0003-3538-1475	NATIONAL CANCER INSTITUTE [P50CA058207, R01CA036773, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA44768, R01-CA36773, P50-CA58207, R01 CA036773, P50 CA058207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; BENZ C, 2000, J WOMENS CANC, V2, P33; Benz CC, 1998, ENDOCR-RELAT CANCER, V5, P271, DOI 10.1677/erc.0.0050271; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Chen YY, 1996, J BIOL CHEM, V271, P5183; CHEN YY, 1994, ONCOGENE, V9, P2269; Chiang SY, 2000, J BIOL CHEM, V275, P24246, DOI 10.1074/jbc.M000820200; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Czubayko F, 1997, GENE THER, V4, P943, DOI 10.1038/sj.gt.3300483; EBBINGHAUS SW, 1993, J CLIN INVEST, V92, P2433, DOI 10.1172/JCI116850; EBBINGHAUS SW, 1999, PERSPECT ANTISEN SCI, P117; GROOTECLAES M, 1994, CANCER RES, V54, P4193; GUIEYSSE AL, 1999, PERSPECT ANTISEN SCI, P223; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HOLLYWOOD DP, 1995, BRIT J CANCER, V71, P753, DOI 10.1038/bjc.1995.146; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; Hung M C, 2000, Breast Dis, V11, P133; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Krauss W C, 2000, Breast Dis, V11, P113; MARDEN C, 2000, IN PRESS ENCY MOL ME; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; McCormick RJ, 1996, P NATL ACAD SCI USA, V93, P14434, DOI 10.1073/pnas.93.25.14434; MIRKIN SM, 1999, PERSPECT ANTISEN SCI, P193; MIZUGUCHI G, 1994, FEBS LETT, V348, P80, DOI 10.1016/0014-5793(94)00578-8; NOONBERG SB, 1994, GENE, V149, P123, DOI 10.1016/0378-1119(94)90420-0; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; Porumb H, 1996, CANCER RES, V56, P515; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Roh H, 2000, CANCER RES, V60, P560; Sacco MG, 1998, GENE THER, V5, P388, DOI 10.1038/sj.gt.3300592; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Suzuki T, 2000, GENE THER, V7, P241, DOI 10.1038/sj.gt.3301065; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294	53	67	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6490	6502		10.1038/sj.onc.1204041	http://dx.doi.org/10.1038/sj.onc.1204041			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175365				2022-12-28	WOS:000166595000011
J	Ogawa, K; Pasqualini, R; Lindberg, RA; Kain, R; Freeman, AL; Pasquale, EB				Ogawa, K; Pasqualini, R; Lindberg, RA; Kain, R; Freeman, AL; Pasquale, EB			The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization	ONCOGENE			English	Article						Eph receptor tyrosine kinases; angiogenesis; endothelial cells	PROTEIN-TYROSINE KINASE; BLOOD-VESSEL FORMATION; VASCULAR DEVELOPMENT; CARDIOVASCULAR DEVELOPMENT; MELANOMA PROGRESSION; RESPONSE GENE; CELL-LINES; ANGIOGENESIS; B61; ECK	Eph receptor tyrosine kinases and their ephrin ligands have been implicated in embryonic vascular development and in in vivo models of angiogenesis. Eph proteins may also regulate tumor neovascularization, but this role has not been previously investigated. To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells, By immunohistochemistry, the ephrin-A1 ligand and one of its receptors, EphA2, were detected throughout tumor vasculature. Double-labeling with anti-CD34 antibodies demonstrated that both ephrin-A1 and EphA2 were expressed in xenograft endothelial cells and also tumor cells. Furthermore, EphA2 was tyrosine-phosphorylated in the xenograft tumors, indicating that it was activated, presumably by interacting with ephrin-A1. Ephrin-A1 and EphA2 were also detected in both the vasculature and tumor cells of surgically removed human cancers. In an in vitro angiogenesis model, a dominant negative form of EphA2 inhibited capillary tube-like formation by human umbilical vein endothelial cells (HUVECs), demonstrating a requirement for EphA receptor signaling, These data suggest that ephrin-A1 and EphA2 play a role in human cancers, at least in part by influencing tumor neovascularization. Eph proteins may represent promising new targets for antiangiogenic cancer treatments.	Burnham Inst, La Jolla, CA 92037 USA; Iwate Univ, Fac Agr, Dept Vet Anat, Morioka, Iwate 2028550, Japan; Amgen Inc, Amgen Ctr, Thousand Oaks, CA 91320 USA; Univ Vienna, AK Hosp, Inst Clin Pathol, A-1090 Vienna, Austria	Sanford Burnham Prebys Medical Discovery Institute; Iwate University; Amgen; University of Vienna	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, R01HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA082713] Funding Source: NIH RePORTER; NCI NIH HHS [CA82713] Funding Source: Medline; NICHD NIH HHS [HD26351] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1994, ONCOGENE, V9, P1461; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Bobik A, 1997, TUMOUR ANGIOGENESIS, P169; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DANIEL TO, 1996, KIDNEY INT S, V57, P73; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; DODELET VC, 2000, IN PRESS ONCOGENE; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Eberhart J, 2000, DEV NEUROSCI-BASEL, V22, P237, DOI 10.1159/000017446; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FOX SB, 1995, J PATHOL, V177, P369, DOI 10.1002/path.1711770407; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gasparini G, 1997, TUMOUR ANGIOGENESIS, P29; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; KIYOKAWA E, 1994, CANCER RES, V54, P3645; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PRICE JE, 1990, CANCER RES, V50, P717; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SARMA V, 1992, J IMMUNOL, V148, P3302; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SOANS C, 1994, ONCOGENE, V9, P3353; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKAHASHI H, 1995, ONCOGENE, V11, P879; UICC/AJCC, 1997, TNM CLASS MAL TUM; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	59	309	344	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6043	6052		10.1038/sj.onc.1204004	http://dx.doi.org/10.1038/sj.onc.1204004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146556				2022-12-28	WOS:000165827900011
J	Inga, A; Resnick, MA				Inga, A; Resnick, MA			Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants	ONCOGENE			English	Article						p53; yeast functional assays; p53 toxic mutants; enhanced transactivation; p53 mutants reactivation	CELL-CYCLE ARREST; DNA-BINDING SITES; FUNCTIONAL ASSAY; GENE-EXPRESSION; SEQUENCE-SPECIFICITY; SUPPRESSOR PROTEIN; TERMINAL DOMAIN; GROWTH ARREST; CANCER-CELLS; TARGET GENE	Since highly expressed human p53 can inhibit human and yeast cell growth, we predicted that p53 mutants could be generated with increased growth inhibition of the yeast Saccharomyces cerevisiae and that these would be useful for characterizing p53 functions and tumor p53 mutants. A random mutagenesis screen led to the isolation of mutations in the DIVA binding domain that result in p53 being lethal even at moderate expression levels in yeast. Three independent mutants had an alanine change at the evolutionary invariant V122 in the L1 loop. The other toxic mutations affected codons 277 (C277R, C277W) and 279 (G279R). This latter amino acid change was also reported in tumors, while all the other mutations are novel. A recently developed rheostatable GALI promoter system that provides graded increases in expression of p53 was used to examine the transactivation function of the toxic mutations when expression was greatly reduced and cells were viable. At low expression levels the toxic mutants lacked transactivation from a 3xRGC responsive element (RE). Surprisingly some exhibited enhanced transactivation with p21 and bax REs. The V122A mutant was able to re-activate transactivation of various p53 tumor mutants and retained growth inhibition when co-expressed with dominant-negative tumor mutations. Upon expression in human Saos-2 cells the V122A p53 mutant caused growth suppression, was capable of transactivation and exhibited higher than wild type activity with the bax promoter in luciferase assays. A non-functional p53 tumor mutant was partially reactivated by V122A for both transactivation and growth suppression. Thus, the screen for toxic p53 mutants in yeast can identify novel p53 variants that may be useful in dissecting p53 regulated cellular responses and in developing p53-based cancer therapies.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Inga, Alberto/AAC-3815-2022; resnick, Michael/F-1668-2019	Inga, Alberto/0000-0002-8767-1637; resnick, Michael/0000-0002-8473-7506	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; Chene P, 1999, BIOCHEM BIOPH RES CO, V263, P1, DOI 10.1006/bbrc.1999.1294; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LIN JY, 1995, ONCOGENE, V10, P2387; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; ROLLEY N, 1995, ONCOGENE, V11, P763; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wolf JK, 1999, GYNECOL ONCOL, V75, P261, DOI 10.1006/gyno.1999.5565; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	62	42	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3409	3419		10.1038/sj.onc.1204457	http://dx.doi.org/10.1038/sj.onc.1204457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423991				2022-12-28	WOS:000169248800011
J	Kwek, SSS; Derry, J; Tyner, AL; Shen, ZY; Gudkov, AV				Kwek, SSS; Derry, J; Tyner, AL; Shen, ZY; Gudkov, AV			Functional analysis and intracellular localization of p53 modified by SUMO-1	ONCOGENE			English	Article						SUMO-1; p53; transactivation; cellular localization	UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; CELL-CYCLE PROGRESSION; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; COVALENT MODIFICATION; ADENOVIRUS TYPE-5; IN-VITRO; MDM2; CONJUGATION	p53 tumor suppressor is a subject of several posttranslational modifications, including phosphorylation, ubiquitination and acetylation, which regulate p53 function. A new covalent modification of p53 at lysine 386 by SUMO-1 was recently identified. To elucidate the function of sumoylated p53, we compared the properties of wild type p53 and sumoylation-deficient p53 mutant, K386R, No differences were found between wild type p53 and K386R mutant of p53 in transactivation or growth suppression assays. Moreover, overexpression of SUMO-1 has no effect on p53-regulated transcription. Biochemical fractionation showed that sumoylated p53 is localized in the nucleus and is tightly bound to chromatin structures. p53 and SUMO-1 colocalized in PML nuclear bodies in 293 cells and the nucleoli in MCF7 and HT1080 cells. However, sumoylation-deficient p53 mutant showed a similar pattern of intranuclear localization, suggesting that SUMO-1 does not target p53 to subnuclear structures. These data indicate that SUMO-1 modification of p53 at lysine 386 may not be essential for p53's cellular localization, transcriptional activation, or growth regulation.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Shen, Zhiyuan/0000-0003-2834-0309; Gudkov, Andrei/0000-0003-2548-0154; Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008353, R29ES008353] Funding Source: NIH RePORTER; NCI NIH HHS [CA75179] Funding Source: Medline; NIDDK NIH HHS [R01 DK056283] Funding Source: Medline; NIEHS NIH HHS [ES08353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Boddy MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CARTER T, 1987, CANCER RES, V47, P803; Chehab NH, 2000, GENE DEV, V14, P278; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM JM, 1997, SUBCELLULAR FRACTION, P71; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAY RR, 1972, EUR J BIOCHEM, V30, P145, DOI 10.1111/j.1432-1033.1972.tb02081.x; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Kondratov R. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P613; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shieh SY, 2000, GENE DEV, V14, P289; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	69	110	116	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2587	2599		10.1038/sj.onc.1204362	http://dx.doi.org/10.1038/sj.onc.1204362			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420669				2022-12-28	WOS:000168652500010
J	Shaulian, E; Karin, M				Shaulian, E; Karin, M			AP-1 in cell proliferation and survival	ONCOGENE			English	Review						AP-1; Jun; Fos; target-genes; apoptosis; proliferation	C-FOS PROTEIN; MAMMALIAN UV RESPONSE; TRANSFORMING GROWTH FACTOR-BETA-1; TRANSCRIPTION FACTOR AP-1; STRESS-INDUCED APOPTOSIS; DNA-BINDING PROTEIN; RAT EMBRYO CELLS; CYCLIN D1; TUMOR-SUPPRESSOR; GENE-EXPRESSION	A plethora of physiological and pathological stimuli induce and activate a group of DNA binding proteins that form AP-1 dimers, These proteins include the Jun, Fos and ATF subgroups of transcription factors. Recent studies using cells and mice deficient in individual AP-1 proteins have begun to shed light on their physiological functions in the control of cell proliferation, neoplastic transformation and apoptosis, Above all such studies have identified some of the target genes that mediate the effects of AP-1 proteins on cell proliferation and death. There is evidence that AP-1 proteins, mostly those that belong to the Jun group, control cell life and death through their ability to regulate the expression and function of cell cycle regulators such as Cyclin D1, p53, p21(cip1/waf1), p19(ARF) and p16, Amongst the Jun proteins, c-Jun is unique in its ability to positively regulate cell proliferation through the repression of tumor suppressor gene expression and function, and induction of cyclin D1 transcription. These actions are antagonized by JunB, which upregulates tumor suppressor genes and represses cyclin D1, An especially important target for AP-1 effects on cell life and death is the tumor suppressor p53, whose expression as well as transcriptional activity, are modulated by AP-1 proteins.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Shaulian, Eitan/0000-0001-6242-6849				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DENT T, 1993, GENE DEV, V7, P479; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERBER B, 1994, ONCOGENE, V9, P1295; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Herrlich P, 1997, BIOL CHEM, V378, P1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kenney AM, 1998, J NEUROSCI, V18, P1318; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Liebermann DA, 1998, INT J ONCOL, V12, P685; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MILLER AD, 1984, CELL, V36, P51; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Preston GA, 1996, MOL CELL BIOL, V16, P211; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; QUELLE DE, 1995, CELL, V83, P993; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1991, ONCOGENE, V6, P533; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH MJ, 1992, BLOOD, V79, P2107; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Thepot D, 2000, DEVELOPMENT, V127, P143; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Watson A, 1998, J NEUROSCI, V18, P751; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; WU BY, 1989, J BIOL CHEM, V264, P9000; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	134	1323	1381	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2390	2400		10.1038/sj.onc.1204383	http://dx.doi.org/10.1038/sj.onc.1204383			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402335				2022-12-28	WOS:000168568700006
J	Degryse, B; Orlando, S; Resnati, M; Rabbani, SA; Blasi, F				Degryse, B; Orlando, S; Resnati, M; Rabbani, SA; Blasi, F			Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways	ONCOGENE			English	Article						urokinase; integrins; chemotaxis; cytoskeleton	SMOOTH-MUSCLE CELLS; UROKINASE RECEPTOR; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; KINASE FUNCTIONS; GROWTH-FACTORS; MIGRATION; VITRONECTIN; ADHESION	Vitronectin (VN) and pro-urokinase (pro-uPA) stimulated migration of rat smooth muscle cells in a dose-dependent and additive way, and induced motile-type changes in cell morphology together with a complete reorganization of the actin filaments and of the microtubules, All these effects were inhibited by pertussis toxin, or by antibodies directed against the urokinase receptor (uPAR) or against the VN receptor alpha (v)beta (3) suggesting that an association between the two receptors is required to mediate both signals. Investigation of the signaling pathways showed that increasing the intracellular cAMP resulted in a selective inhibition of VN-induced cell migration. On the other hand, PD 98059, an inhibitor of MEK, differentially inhibited the pro-uPA but not the VN-induced cell migration. Phosphorylation and nuclear translocation of Erk by pro-uPA was directly observed. We conclude that the signaling pathways of pro-uPA and VN must be at least in part different.	Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, I-20132 Milan, Italy; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal, PQ H3A 1A1, Canada	Vita-Salute San Raffaele University; McGill University; Royal Victoria Hospital; McGill University	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Via Olgettina 58, I-20132 Milan, Italy.		Massimo, Resnati/AAN-5854-2020	Massimo, Resnati/0000-0002-4804-4569; rabbani, shafaat/0000-0001-5594-3899; Blasi, Francesco/0000-0001-9406-1784				BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOYLE MDP, 1987, J IMMUNOL, V139, P169; BROWN SL, 1994, CARDIOVASC RES, V28, P1815, DOI 10.1093/cvr/28.12.1815; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Carriero MV, 1999, CANCER RES, V59, P5307; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DELROSSO M, 1992, EXP CELL RES, V203, P427; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KJOELLER L, 1997, EXP CELL RES, V232, P420; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lin TH, 1997, J BIOL CHEM, V272, P8849; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Slepian MJ, 1998, CIRCULATION, V97, P1818, DOI 10.1161/01.CIR.97.18.1818; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; TARUI T, 2000, J BIOL CHEM, V276, P3938; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Webb DJ, 2000, J CELL SCI, V113, P123; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	58	91	97	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2032	2043		10.1038/sj.onc.1204261	http://dx.doi.org/10.1038/sj.onc.1204261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360187	Bronze			2022-12-28	WOS:000168043800011
J	Rashid, SF; Moore, JS; Walker, E; Driver, PM; Engel, J; Edwards, CE; Brown, G; Uskokovic, MR; Campbell, MJ				Rashid, SF; Moore, JS; Walker, E; Driver, PM; Engel, J; Edwards, CE; Brown, G; Uskokovic, MR; Campbell, MJ			Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D-3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A	ONCOGENE			English	Article; Proceedings Paper	91st Annual Meeting of the American-Association-for-Cancer-Research	APR 01-05, 2000	SAN FRANCISCO, CALIFORNIA	Amer Assoc Canc Res		histone deacetylation inhibitors; 1 alpha,25 Dihydroxyvitamin D-3; prostate cancer; growth inhibition; apoptosis	VITAMIN-D-RECEPTOR; D-RESPONSIVE ELEMENTS; HISTONE DEACETYLASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; INDUCED-DIFFERENTIATION; 24-HYDROXYLASE ACTIVITY; PROMYELOCYTIC LEUKEMIA; PROMOTER SELECTIVITY; GENE POLYMORPHISM	Prostate cancer is a major cause of male cancer death. In vitro and in vivo data support a role for 1 alpha ,25 Dihydroxyvitamin D-3 (1 alpha ,25(OH)(2)D-3) in regulating the growth and differentiation of the normal prostate gland yet prostate cancer cells appear significantly less sensitive to this action. Vitamin D-3 receptor (VDR) content or mutational status do not correlate clearly with the antiproliferative effects of 1 alpha ,25(OH)(2)D-3 and therefore it is unclear why prostate cancer cell lines are significantly less sensitive to this action. We hypothesized that the antiproliferative responses of prostate cancer cells to 1 alpha ,25(OH)(2)D-3 are suppressed by a process involving histone deacetylation, Sodium butyrate (NaB) and trichostatin A (TSA) are inhibitors of histone deacetylase (HDAC) activity. Low doses of NaB or TSA (300 muM and 15 nM respectively), which alone were relatively inactive, synergized with 1 alpha ,25(OH)(2)D-3 in liquid and semi-solid agar to inhibit the growth of LNCaP, PC-3 and DU-145 prostate cancer cells. Still greater synergy was observed between vitamin D-3 hexafluoride analogs and either NaB or TSA, The mechanism appeared to involve neither the cyclin-dependent kinase inhibitor, p21((waf1/cip1)) nor cell cycle arrest, but rather induction of apoptosis, These data suggest that cells dysregulate the normal pro-apoptotic signals of 1 alpha ,25(OH)(2)D-3 during prostate cancer development by a mechanism involving histone deacetylation, Combination therapy with potent vitamin D-3 analogs and clinically approved HDAC inhibitors may overcome this lesion and improve the treatment of both androgen-dependent and independent prostate cancer.	Univ Birmingham, Sch Med, Div Med Sci, Dept Med, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TH, W Midlands, England; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	University of Birmingham; University of Birmingham; Roche Holding	Campbell, MJ (corresponding author), Univ Birmingham, Sch Med, Div Med Sci, Dept Med, Birmingham B15 2TH, W Midlands, England.		FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Campbell, Moray/ABF-1264-2021; Campbell, Moray J/A-1311-2013	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Campbell, Moray/0000-0002-3355-0928; Brown, Geoffrey/0000-0003-0821-0275				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; ANZANO MA, 1994, CANCER RES, V54, P1653; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Campbell MJ, 1999, BRIT J CANCER, V79, P101, DOI 10.1038/sj.bjc.6690018; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 1999, MOL CELL ENDOCRINOL, V149, P169, DOI 10.1016/S0303-7207(98)00245-7; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; deVos S, 1997, PROSTATE, V32, P115; Ellerhorst J, 1999, INT J ONCOL, V14, P225; Evans SRT, 1999, INT J ONCOL, V14, P979; EWING CM, 1995, CANCER RES, V55, P4813; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Habuchi T, 2000, CANCER RES, V60, P305; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Hedlund TE, 1996, J STEROID BIOCHEM, V58, P277, DOI 10.1016/0960-0760(96)00030-1; Hedlund TE, 1997, CLIN CANCER RES, V3, P1331; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; IOWA Y, 1999, CANCER RES, V59, P4266; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Koike M, 1997, CANCER RES, V57, P4545; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krill D, 1999, UROLOGY, V54, P171, DOI 10.1016/S0090-4295(99)00103-X; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lea MA, 1998, ANTICANCER RES, V18, P2717; Li X, 1995, CELL PROLIFERAT, V28, P571, DOI 10.1111/j.1365-2184.1995.tb00045.x; Liang JY, 1999, PROSTATE, V38, P228; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; MAIYAR AC, 1992, MOL CELL ENDOCRINOL, V84, P99, DOI 10.1016/0303-7207(92)90076-I; Medina V, 1997, CANCER RES, V57, P3697; Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; Nayeri S, 1997, BIOCHEM J, V327, P561, DOI 10.1042/bj3270561; Pace BS, 2000, EXP HEMATOL, V28, P283, DOI 10.1016/S0301-472X(99)00153-8; PEEHL DM, 1994, CANCER RES, V54, P805; PEEHL DM, 1993, ENDOC J, V132, P1952; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rashid SF, 2001, STEROIDS, V66, P433, DOI 10.1016/S0039-128X(00)00203-8; Rosenthal DS, 1998, CA-CANCER J CLIN, V48, P3, DOI 10.3322/canjclin.48.1.3; Schwartz GG, 1998, CANCER EPIDEM BIOMAR, V7, P391; SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; TANAKA Y, 1989, BIOCHEM PHARMACOL, V38, P3859, DOI 10.1016/0006-2952(89)90596-0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Watanabe M, 1999, ANTICANCER RES, V19, P4511; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YONEDA T, 1984, BIOCHEM BIOPH RES CO, V121, P796, DOI 10.1016/0006-291X(84)90748-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1992, ANTICANCER RES, V12, P1947; ZHANG SH, 1997, MOL CELL ENDOCRINOL, V126, P83; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	66	107	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1860	1872		10.1038/sj.onc.1204269	http://dx.doi.org/10.1038/sj.onc.1204269			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313934				2022-12-28	WOS:000167908400007
J	Olsen, RJ; Hinrichs, SH				Olsen, RJ; Hinrichs, SH			Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins	ONCOGENE			English	Article						sarcoma; fusion protein; phosphorylation; IQ domain; EWS/ATF1; EWS/FLI1	CLEAR-CELL-SARCOMA; DNA-BINDING; CHIMERIC TRANSCRIPTS; MALIGNANT-MELANOMA; KINASE-C; TRANSLOCATION; INHIBITION; REQUIRES; TRANSACTIVATION; EWS-FLI-1	Specific chromosomal translocations are commonly present in mesenchymal tumors and frequently involve genes encoding transcription factors, The combination of different domains from unrelated genes results in chimeric proteins belie, ed to play a key role in the neoplastic process. The EWS/ATF1 and EWS/FLI1 fusion proteins associated with Clear Cell Sarcoma and Ewing's Sarcoma, respectively, were utilized to study the comparative effect of the EWS component on two different DNA binding partners. A potential regulatory site within the EWS IQ domain at serine266 was identified, and studies were performed to demonstrate that EWS is phosphorylated in cells and phosphorylation of serine266 regulates transcriptional activity. Mutational analysis showed that elimination of phosphorylation significantly reduced DNA binding activity by EMSA and reporter activation in luciferase assays, whereas phosphorylation mimicry resulted in a partial restoration to wild-type levels. Phosphorylation was also observed to mediate cellular compartmentalization. These studies confirm that IQ domain phosphorylation regulates the transcriptional activity of exogenous EWS/ATF1 and EWS/FLI1 and suggests that post-translational modifications may potentiate the neoplastic behavior of fusion proteins in general. Since the IQ domain is incorporated into only a subset of fusion transcripts, these findings may provide insight into the molecular mechanism underlying clinical heterogeneity observed in Ewing's sarcoma.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 69198 USA	University of Nebraska System; University of Nebraska Medical Center	Hinrichs, SH (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 69198 USA.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bosilevac JM, 1998, J BIOL CHEM, V273, P16874, DOI 10.1074/jbc.273.27.16874; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; BRIDGE JA, 1991, CANCER GENET CYTOGEN, V52, P101, DOI 10.1016/0165-4608(91)90059-4; BRIDGE JA, 1990, AM J CLIN PATHOL, V93, P26, DOI 10.1093/ajcp/93.1.26; Bridge Julia A., 1996, Current Opinion in Oncology, V8, P284; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Dohjima T, 2000, BRIT J CANCER, V82, P16, DOI 10.1054/bjoc.1998.0870; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Fujimura Y, 1996, ONCOGENE, V12, P159; GILCHRIST C, 1995, J BIOCH SCI, V3, P96; Gilchrist CA, 1995, ANTIBODY IMMUNOCONJ, V8, P281; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Li KKC, 1998, ONCOGENE, V16, P1325, DOI 10.1038/sj.onc.1201649; Lin PP, 1999, CANCER RES, V59, P1428; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419	32	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1756	1764		10.1038/sj.onc.1204268	http://dx.doi.org/10.1038/sj.onc.1204268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313922				2022-12-28	WOS:000167750900008
J	Pierce, KL; Luttrell, LM; Lefkowitz, RJ				Pierce, KL; Luttrell, LM; Lefkowitz, RJ			New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades	ONCOGENE			English	Article						GPCR; ERK; JNK; beta-arrestin; scaffold; internalization	GROWTH-FACTOR RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; COUPLED RECEPTORS; EGF RECEPTOR; MAP KINASE; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; TYROSINE KINASE; T-84 CELLS; C-SRC	Activation of classical second messenger cascades cannot fully explain the recently appreciated roles of heptahelical, or G-protein coupled receptors (GPCRs), in stimulation of mitogen activated protein kinase (MAPK) cascades. Rather, several distinct signaling mechanisms appear to contribute to GPCR-mediated MAPK activation. These include transactivation of the Epidermal Growth Factor Receptor (EGFR) via the autocrine/paracrine release of EGF-like ligands at the cell surface and scaffolding of MARK cascades, A significant advance in the understanding of how GPCRs activate MAPK cascades is the discovery that p-arrestin, a protein well known for its roles in both receptor desensitization and internalization, serves as a scaffolding protein for at least two GPCR stimulated MARK cascades, the extracellular signal regulated kinase (ERK) cascade and the c-jun N-terminal kinase 3 (JNK3) cascade, Together, these novel mechanisms of GPCR-mediated MAPK regulation may permit GPCRs in specific situations to control the temporal and spatial activity of MAPKs and thereby determine the consequences of GPCR stimulation with respect to transcriptional activation, cell proliferation and apoptosis.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055524, R56DK055524] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK55524] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Blaukat A, 1999, FEBS LETT, V451, P337, DOI 10.1016/S0014-5793(99)00613-4; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHOI KY, 1994, CELL, V78, P499; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; GOODMAN BO, 1996, NATURE, V383, P447; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; Roche JP, 1999, MOL PHARMACOL, V56, P611, DOI 10.1124/mol.56.3.611; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VAN BT, 1995, NATURE, V376, P781; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	51	347	354	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1532	1539		10.1038/sj.onc.1204184	http://dx.doi.org/10.1038/sj.onc.1204184			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313899				2022-12-28	WOS:000168089800002
J	Nishimoto, A; Miura, N; Horikawa, I; Kugoh, H; Murakami, Y; Hirohashi, S; Kawasaki, H; Gazdar, AF; Shay, JW; Barrett, JC; Oshimura, M				Nishimoto, A; Miura, N; Horikawa, I; Kugoh, H; Murakami, Y; Hirohashi, S; Kawasaki, H; Gazdar, AF; Shay, JW; Barrett, JC; Oshimura, M			Functional evidence for a telomerase repressor gene on human chromosome 10p15.1	ONCOGENE			English	Article						microcell-mediated chromosome transfer; telomerase; chromosome 10p; telomerase repressor gene; hTERT	HUMAN PROSTATE-CANCER; CATALYTIC SUBUNIT HTERT; TUMOR-SUPPRESSOR GENES; CELLULAR SENESCENCE; EFFICIENT MODIFICATION; INSITU HYBRIDIZATION; MAMMALIAN TELOMERASE; IMMORTAL CELLS; HUMAN GLIOMAS; ALLELIC LOSS	Based on the sites of frequent allelic loss in hepatocellular carcinoma, five normal human chromosomes (2, 4, 5, 10 and 16) were transferred individually into a telomerase-positive human hepatocellular carcinoma cell line, Li7HM, by microcell-mediated chromosome transfer (MMCT). Chromosome 10, but not the others, repressed telomerase activity immediately and stopped cell growth after 50 population doublings (PDs), Loss of the transferred 10p loci resulted in the emergence of revertant cells that continued to proliferate and expressed telomerase activity, suggesting the presence of a telomerase repressor gene on this chromosomal arm. Transfer of a series of defined fragments from chromosome 10p successfully narrowed down the responsible region: a 28.9-cM region on 10p15 (between WI-4752 and D10S249), but not a 26.2-cM region (between D10S1728 and D10S249), caused repression of telomerase activity and progressive telomere shortening. A strong correlation between the expression level of telomerase catalytic subunit gene (hTERT) and telomerase activity was observed. These findings suggest that a novel telomerase repressor gene which controls the expression of hTERT is located on the 2.7-cM region (between WI-4752 and D10S1728) on chromosome 10p15.1.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Tottori 6838503, Japan; NCI, Lab Biosyst & Canc, Canc & Aging Sect, Bethesda, MD 20892 USA; Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Tottori Univ, Dept Internal Med 2, Tottori 6838503, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Tottori University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan; National Cancer Center - Japan; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Tottori 6838503, Japan.		Shay, Jerry W/F-7878-2011					CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIROHASHI S, 1979, CANCER RES, V39, P1819; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; Ittmann M, 1996, CANCER RES, V56, P2143; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Kuroiwa Y, 1998, NUCLEIC ACIDS RES, V26, P3447, DOI 10.1093/nar/26.14.3447; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; Murakami Y, 2000, J HUM GENET, V45, P370, DOI 10.1007/s100380070011; Murakami YS, 1996, CANCER RES, V56, P2157; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Robertson GP, 1999, CANCER RES, V59, P3596; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; TAHARA H, 1995, CANCER RES, V55, P2734; Takakura M, 1999, CANCER RES, V59, P551; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Trybus TM, 1996, CANCER RES, V56, P2263; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Voesten AMJ, 1997, GENE CHROMOSOME CANC, V20, P167, DOI 10.1002/(SICI)1098-2264(199710)20:2<167::AID-GCC7>3.0.CO;2-1; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	41	44	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					828	835		10.1038/sj.onc.1204165	http://dx.doi.org/10.1038/sj.onc.1204165			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314017				2022-12-28	WOS:000166924400006
J	Li, Y; DeFatta, R; Anthony, C; Sunavala, G; De Benedetti, A				Li, Y; DeFatta, R; Anthony, C; Sunavala, G; De Benedetti, A			A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed	ONCOGENE			English	Article						eIF4E; translational regulation; histone H3 kinase; Tousled-like kinase; radioresistance	INITIATION-FACTOR 4E; PROTEIN-KINASE; MESSENGER-RNA; DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; GROWTH; GENE; FIBROBLASTS; EXPRESSION	The gene Tousled of Arabidopsis Thaliana encodes a protein kinase which, when mutated, results in abnormal flower development, From a library of mRNAs that are translationally upregulated by overexpression of the translation initiation factor 4E, we identified a mammalian Tousled Like kinase (TLK1B), The human TLK1B mRNA contains a 5'UTR 1088-nt-long with two upstream AUG codons, and was found to be very inhibitory for translation, The TLK1B protein localizes almost exclusively mammalian cells rendered them more resistant to ionizing radiation OR). Purified TLK1S phosphorylated histone H3 at S-10 with high specificity both in a mis of core histones and in isolated chromatin, suggesting that histone H3 is a physiological substrate for TLK1B, Moreover, overexpression of TLK1B in transfected cells resulted in a higher degree of H3 phosphorylation. Expression of TLK1B in a yeast strain that harbors a temperature-sensitive mutation of the major H3 kinase, IpI1, complemented the growth defect; restored normal levels of histone H3 phosphorylation; and increased their resistance to IR. Phosphorylation of H3 has been linked to the activation of the immediate-early gems upon mitogenic stimulation, and to chromatin condensation during mitotic/meiotic events, A possible role for TLK1B in radioprotection is discussed.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	De Benedetti, A (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.				NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHAN CSM, 1993, GENETICS, V135, P677; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; DEBENEDETTI A, 1991, NUCLEIC ACIDS RES, V19, P1925, DOI 10.1093/nar/19.8.1925; GEBALLE AP, 1994, TIBS, V19, P150; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; GROSS DS, 1985, J MOL BIOL, V183, P251, DOI 10.1016/0022-2836(85)90218-9; Howard EL, 1999, MOL CELL BIOL, V19, P1990; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MOORE SA, 1988, J BIOL CHEM, V263, P9674; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Newton GL, 1996, RADIAT RES, V145, P776, DOI 10.2307/3579370; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Shalom S, 1999, MOL REPROD DEV, V52, P392, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;392::AID-MRD8&gt;3.0.CO;2-Y; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yamakawa A, 1997, GENE, V202, P193, DOI 10.1016/S0378-1119(97)00495-2	36	71	72	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					726	738		10.1038/sj.onc.1204147	http://dx.doi.org/10.1038/sj.onc.1204147			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314006				2022-12-28	WOS:000166806000008
J	Garcia-Cuellar, MP; Zilles, O; Schreiner, SA; Birke, M; Winkler, TH; Slany, RK				Garcia-Cuellar, MP; Zilles, O; Schreiner, SA; Birke, M; Winkler, TH; Slany, RK			The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3	ONCOGENE			English	Article						leukemia; MLL; translocation; ENL; polycomb	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTORS; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MUTANT MICE; ALL-1 GENE; HRX-ENL; PROTEIN; FUSION; TRANSFORMATION	The translocation t(11;19) is frequently found in acute leukemia in infants. This event truncates the protooncogene MLL and fuses the 5' end of MLL in frame with the ENL gene. ENL contributes a crucial protein-protein interaction domain to the resulting oncoprotein MLL-ENL. Here we show by yeast two-hybrid assays, GST-pull-down experiments and in a far western blot analysis that this domain is necessary and sufficient to recruit a novel member of the human Polycomb protein family (hPc3), hPc3 RNA was detected throughout the human hematopoietic system. Similar to other Polycomb proteins hPc3 acts as a transcriptional repressor. The ENL-hPc3 interaction was verified by mutual coprecipitation of the proteins from cell extracts. ENL and hPc3 tagged with fluorescent proteins co-localized in living cells in a nuclear dot pattern. An internal region of hPc3 was responsible for binding to ENL. Finally, hPc3 binds to the C-terminus of AF9, another common MLL fusion partner. The recruitment of a repressive function by ENL opens up a new insight into a possible mechanism of leukemogenesis by the fusion protein MLL-ENL.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Internal Med 3, Div Mol Immunol, D-91056 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Fidanza V, 1996, CANCER RES, V56, P1179; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hemenway CS, 2000, GENE, V242, P31, DOI 10.1016/S0378-1119(99)00540-5; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; IIDA S, 1993, ONCOGENE, V8, P3085; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; James P, 1996, GENETICS, V144, P1425; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Slack JL, 1999, CANC TREAT, V99, P75; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	39	56	59	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					411	419		10.1038/sj.onc.1204108	http://dx.doi.org/10.1038/sj.onc.1204108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313972				2022-12-28	WOS:000166562500001
J	Ladanyi, M; Lui, MY; Antonescu, CR; Krause-Boehm, A; Meindl, A; Argani, P; Healey, JH; Ueda, T; Yoshikawa, H; Meloni-Ehrig, A; Sorensen, PHB; Mertens, F; Mandahl, N; van den Berghe, H; Sciot, R; Dal Cin, P; Bridge, J				Ladanyi, M; Lui, MY; Antonescu, CR; Krause-Boehm, A; Meindl, A; Argani, P; Healey, JH; Ueda, T; Yoshikawa, H; Meloni-Ehrig, A; Sorensen, PHB; Mertens, F; Mandahl, N; van den Berghe, H; Sciot, R; Dal Cin, P; Bridge, J			The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25	ONCOGENE			English	Article						chromosomal translocation; gene fusion; molecular diagnosis; UBX domain; soft tissue sarcoma	RENAL-CELL CARCINOMA; SKELETAL-MUSCLE DIFFERENTIATION; REGULATORY PROTEIN EXPRESSION; ACTIVATOR INHIBITOR-1 GENE; BETA-INDUCED TRANSCRIPTION; CRYPTIC INTRON; SMAD PROTEINS; DOMAIN; ORGANIZATION; INVOLVEMENT	Alveolar soft part sarcoma (ASPS) is an unusual tumor with highly characteristic histopathology and ultrastructure, controversial histogenesis, and enigmatic clinical behavior. Recent cytogenetic studies have identified a recurrent der(17) due to non-reciprocal t(X;17)(p11.2;q25) in this sarcoma, To define the interval containing the Xp11,2 break, we first performed FISH on ASPS cases using YAC probes for OA TLI (Xp11,23) and OATL2 (Xp11,21), and cosmid probes from the intervening genomic region. This localized the breakpoint to a 160 kb interval. The prime candidate within this previously fully sequenced region was TFE3, a transcription factor gene known to be fused to translocation partners on 1 and X in some papillary renal cell carcinomas. Southern blotting using a TFE3 genomic probe identified non-germline bands in several ASPS cases, consistent with rearrangement and possible fusion of TFE3 with a gene on 17q25, Amplification of the 5' portion of cDNAs containing the 3' portion of TFE3 in two different ASPS cases identified a novel sequence, designated ASPL, fused in-frame to TFE3 exon 4 (type 1 fusion) or exon 3 (type 2 fusion), Reverse transcriptase PCR using a forward primer from ASPL and a TFE3 exon 4 reverse primer detected an ASPL-TFE3 fusion transcript in all ASPS cases (12/12: 9 type 1, 3 type 2), establishing the utility of this assay in the diagnosis of ASPS. Using appropriate primers, the reciprocal fusion transcript, TFE3-ASPL, was detected in only one of 12 cases, consistent with the non-reciprocal nature of the translocation in most cases, and supporting ASPL-TFE3 as its oncogenically significant fusion product. ASPL maps to chromosome 17, is ubiquitously expressed, and matches numerous ESTs (Unigene cluster Hs.84128) but no named genes. The ASPL cDNA open reading frame encodes a predicted protein of 476 amino acids that contains within its carboxy-terminal portion of a UBX-like domain that shows significant similarity to predicted proteins of unknown function in several model organisms. The ASPL-TFE3 fusion replaces the N-terminal portion of TFE3 by the fused ASPL sequences, while retaining the TFE3 DNA-binding domain, implicating transcriptional deregulation in the pathogenesis of this tumor, consistent with the biology of several other translocation-associated sarcomas.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Univ Nebraska, Med Ctr, Dept Pathol, CGMG MMI, Omaha, NE USA; Univ Munich, Dept Med Genet, Munich, Germany; Johns Hopkins Hosp, Dept Pathol, Baltimore, MD 21287 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Orthoped Surg, Osaka, Japan; Univ Utah, Med Ctr, Huntsman Canc Inst, Dept Human Genet, Salt Lake City, UT USA; British Columbia Childrens Hosp, Dept Pathol, Vancouver, BC V6H 3V4, Canada; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Univ Leuven, Ctr Human Genet, Louvain, Belgium; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Dept Pediat, CHMG MMI, Omaha, NE USA; Univ Nebraska, Med Ctr, Dept Orthoped Surg, CHMG MMI, Omaha, NE USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Nebraska System; University of Nebraska Medical Center; University of Munich; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Osaka Medical Center for Cancer & Cardiovascular Diseases; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; BC Childrens Hospital; University of British Columbia; Lund University; Skane University Hospital; KU Leuven; Harvard University; Brigham & Women's Hospital; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.		Ladanyi, Marc/AAG-8585-2019; Meloni-Ehrig, Aurelia/AAF-9248-2020	sciot, raf/0000-0003-2244-5839; Mertens, Fredrik/0000-0002-6278-5232; Healey, John/0000-0002-0802-1186	NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA47179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Bruce SR, 1999, NUCLEIC ACIDS RES, V27, P3446, DOI 10.1093/nar/27.17.3446; CHRISTOPHERSON WM, 1952, CANCER, V5, P100, DOI 10.1002/1097-0142(195201)5:1<100::AID-CNCR2820050112>3.0.CO;2-K; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Golub TR, 1997, CURR TOP MICROBIOL, V220, P67; Gomez JA, 1999, ARCH PATHOL LAB MED, V123, P503; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Heimann P, 1998, GENE CHROMOSOME CANC, V23, P194, DOI 10.1002/(SICI)1098-2264(199810)23:2<194::AID-GCC14>3.3.CO;2-O; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERNANDEZMARTI MJ, 1995, CANCER GENET CYTOGEN, V83, P82, DOI 10.1016/0165-4608(94)00184-7; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Joyama S, 1999, CANCER, V86, P1246, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1246::AID-CNCR20>3.3.CO;2-W; Kiuru-Kuhlefelt S, 1998, MODERN PATHOL, V11, P227; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Ladanyi M, 2000, HUM PATHOL, V31, P532, DOI 10.1053/hp.2000.6706; LIEBERMAN PH, 1989, CANCER-AM CANCER SOC, V63, P1, DOI 10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E; MACCHI P, 1995, GENOMICS, V28, P491, DOI 10.1006/geno.1995.1179; Ordonez NG, 1999, ADV ANAT PATHOL, V6, P125, DOI 10.1097/00125480-199905000-00001; Rehli M, 1999, GENOMICS, V56, P111, DOI 10.1006/geno.1998.5588; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROSAI J, 1991, AM J SURG PATHOL, V15, P974, DOI 10.1097/00000478-199110000-00008; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; SCIOT R, 1993, HISTOPATHOLOGY, V23, P439, DOI 10.1111/j.1365-2559.1993.tb00492.x; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; TALLINI G, 1994, AM J PATHOL, V144, P693; Tian G, 1999, MOL CELL BIOL, V19, P2946; TOMLINSON GE, 1991, CANCER GENET CYTOGEN, V57, P11, DOI 10.1016/0165-4608(91)90184-V; Verastegui C, 2000, MOL ENDOCRINOL, V14, P449, DOI 10.1210/me.14.3.449; Wang NP, 1996, MODERN PATHOL, V9, P496; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; WONG SC, 1995, J NEUROCHEM, V65, P23	35	393	426	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					48	57		10.1038/sj.onc.1204074	http://dx.doi.org/10.1038/sj.onc.1204074			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244503	Green Published			2022-12-28	WOS:000166361400006
J	Ladendorff, NE; Wu, S; Lipsick, JS				Ladendorff, NE; Wu, S; Lipsick, JS			BS69, an adenovirus E1A-associated protein, inhibits the transcriptional activity of c-Myb	ONCOGENE			English	Article						Myb; BS69; corepressor; MYND domain	DNA-BINDING DOMAIN; ACUTE MYELOID-LEUKEMIA; V-MYB; B-MYB; 2-HYBRID SYSTEM; A-MYB; HISTONE DEACETYLASE; COACTIVATOR CBP; GENE-EXPRESSION; FUSION PARTNER	The carboxyl terminus of c-Myb contains a negative regulatory domain that is absent in the v-Myb oncoprotein, but conserved among all the known Myb proteins of animals. This domain inhibits transcriptional activation by c-Myb in animal cells, but not in budding yeast, suggesting that additional protein(s) present in animal cells but not yeast are required for this negative regulatory function. A yeast two-hybrid screen identified BS69, an adenovirus E1A-associated protein, as interacting with the carboxy-terminal region of c-Myb, BS69 contains regions of similarity to the PHD finger, the bromodomain, and the MYND domain, all of which are found in other proteins present in high molecular weight complexes that regulate transcription and/or modify chromatin structure. Further study showed that BS69 inhibited the transcriptional activity of c-Myb, that this inhibition was specific, that it mapped to the carboxyl termini of the two proteins and that it was dose-dependent. A direct interaction between these two proteins was observed in vitro, Furthermore, the 289R E1A protein could inhibit the BS69-mediated decrease in transcriptional activation by c-Myb, By analogy with the inhibition of the Rb/E2F regulatory axis by EIA, we propose that a BS69/Myb regulatory circuit may also be a target of disruption during oncogenesis.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA65609] Funding Source: Medline; NIAID NIH HHS [T32 AI07290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Coffman JA, 1997, DEVELOPMENT, V124, P4717; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Dubendorff JW, 1999, ONCOGENE, V18, P3452, DOI 10.1038/sj.onc.1202679; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lipsick JS, 1996, ONCOGENE, V13, P223; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Saville MK, 1998, ADV CANCER RES, V72, P109; SENECA S, 1993, ONCOGENE, V8, P2335; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	53	49	52	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					125	132		10.1038/sj.onc.1204048	http://dx.doi.org/10.1038/sj.onc.1204048			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244510				2022-12-28	WOS:000166361400014
J	Tan, C; Costello, P; Sanghera, J; Dominguez, D; Baulida, J; de Herreros, AG; Dedhar, S				Tan, C; Costello, P; Sanghera, J; Dominguez, D; Baulida, J; de Herreros, AG; Dedhar, S			Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells	ONCOGENE			English	Article						cyclin D1; E-cadherin; GSK-3; colon cancer	GLYCOGEN-SYNTHASE KINASE; CYCLIN D1; ADHESION; ACTIVATION; TARGET; CANCER; B/AKT; GENE	Loss of functional adenomatous polyposis coli (APC) protein results in the stabilization of cytosolic beta -catenin and activation of genes that are responsive to Lef/Tcf family transcription factors. We have recently shown that an independent cell adhesion and integrin linked kinase (ILK)-dependent pathway can also activate beta -catenin/LEF mediated gene transcription and downregulate E-cadherin expression. In addition, ILK activity and expression are elevated in adenomatous polyposis and colon carcinomas. To examine the role of this pathway in the background of APC mutations we inhibited ILK activity in APC-/- human colon carcinoma cell lines. In all cases, inhibition of ILK resulted in substantial inhibition of TCF mediated gene transcription and inhibition of transcription and expression of the TCF regulated gene, cyclin D1, Inhibition of ILK resulted in decreased nuclear beta-catenin expression, and in the inhibition of phosphorylation of GSK-3 and stimulation of its activity, leading to accelerated degradation of beta -catenin. In addition, inhibition of ILK suppressed cell growth in culture as well as growth of human colon carcinoma cells in SCID mice. Strikingly, inhibition of ILK also resulted in the transcriptional stimulation of E-cadherin expression and correlated with the inhibition of gene transcription of snail, a repressor of E-cadherin gene expression. Overexpression of ILK caused a stimulation of expression of snail, but snail expression was found not to be regulated by beta -catenin/ Tcf, These data demonstrate that ILK can regulate beta -catenin/TCF and snail transcription factors by distinct pathways. We propose that inhibition of ILK may be a useful strategy in the control of progression of colon as well as other carcinomas.	British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Kinetek Pharmceut Inc, Vancouver, BC V6P 6P2, Canada; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Pompeu Fabra University	Dedhar, S (corresponding author), British Columbia Canc Agcy, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808; Dominguez-Sola, David/0000-0001-9569-8402; Dedhar, Shoukat/0000-0003-4355-1657				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baulida J, 1999, BIOCHEM J, V344, P565, DOI 10.1042/0264-6021:3440565; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li FG, 1999, J CELL SCI, V112, P4589; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Popov Z, 2000, BRIT J CANCER, V83, P209; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	27	208	230	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					133	140		10.1038/sj.onc.1204052	http://dx.doi.org/10.1038/sj.onc.1204052			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244511				2022-12-28	WOS:000166361400015
J	Chiu, IM; Touhalisky, K; Liu, Y; Yates, A; Frostholm, A				Chiu, IM; Touhalisky, K; Liu, Y; Yates, A; Frostholm, A			Tumorigenesis in transgenic mice in which the SV40 T antigen is driven by the brain-specific FGF1 promoter	ONCOGENE			English	Article						FGF1; brain tumor; gene expression; promoter regulation; neural stem cells	FIBROBLAST-GROWTH-FACTOR; PRIMITIVE NEUROECTODERMAL TUMORS; STEM-CELL; DIFFERENTIAL EXPRESSION; HEPARAN-SULFATE; MESSENGER-RNA; FIBROBLAST-GROWTH-FACTOR-1; ADULT; PROTEIN; IDENTIFICATION	Gene expression can be manipulated by the introduction of a hybrid gene formed by linking a highly tissue-specific regulatory element to a gene whose expression might be expected to alter cellular function. Previously, we have shown that the human FGF1 gene contains four distinct tissue-specific promoters. In an effort to perturb the programming of proliferation and differentiation in a subset of neural cells, we have produced transgenic mice bearing the brain-specific promoter of the human FGF1 gene joined to the SV40 immediate early gene, which encodes the large T antigen. The resulting mice, and offspring from four individual lines, developed brain tumors that originated in the pontine gray, just rostral to the fourth ventricle, Tumors were moderately vascularized, as demonstrated by staining with both hematoxylin and eosin and antibodies to three different endothelial cell markers, but vessels were histologically normal. Scattered tumor foci were present as early as postnatal day 26; and affected animals died between 5-8 months of age. In mature animals, tumors lacked terminal differentiation markers for astrocytes (glial fibrillary acidic protein) or neurons (synaptophysin and neuron-specific enolase). However, they expressed high levels of proliferating cell nuclear antigen and vimentin, markers for proliferating cells. This immunophenotype iis consistent with the tumor being at an early stage of differentiation. Therefore, these mice may provide a valuable tool for the study of tumorigenesis, replenishment and differentiation of neural stem cells.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.		Chiu, Ing-Ming/B-1534-2008					Alam KY, 1996, J BIOL CHEM, V271, P30263, DOI 10.1074/jbc.271.47.30263; Anderson DJ, 1999, CURR OPIN NEUROBIOL, V9, P517, DOI 10.1016/S0959-4388(99)00015-X; Barres BA, 1999, CELL, V97, P667, DOI 10.1016/S0092-8674(00)80777-1; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CHIU IM, 1990, ONCOGENE, V5, P755; Cho JY, 2000, GENE THER, V7, P740, DOI 10.1038/sj.gt.3301170; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; FUNG KM, 1994, LAB INVEST, V70, P114; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; Madiai F, 1999, J BIOL CHEM, V274, P11937, DOI 10.1074/jbc.274.17.11937; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; ORAITZ DM, 1996, J BIOL CHEM, V271, P15292; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; REIFENBERGER G, 1987, ACTA NEUROPATHOL, V74, P105, DOI 10.1007/BF00692841; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TABERPIERCE E, 1966, J COMP NEUROL, V126, P219; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; YACHNIS AT, 1994, J NEUROPATH EXP NEUR, V53, P61, DOI 10.1097/00005072-199401000-00008	44	30	32	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6229	6239		10.1038/sj.onc.1204021	http://dx.doi.org/10.1038/sj.onc.1204021			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175337				2022-12-28	WOS:000166210500006
J	Simoneau, M; LaRue, H; Aboulkassim, TO; Meyer, F; Moore, L; Fradet, Y				Simoneau, M; LaRue, H; Aboulkassim, TO; Meyer, F; Moore, L; Fradet, Y			Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest	ONCOGENE			English	Article						bladder cancer; LOH; recurrence; prognostic; chromosome 9	TRANSITIONAL-CELL CARCINOMA; TUMOR-SUPPRESSOR LOCI; URINARY-BLADDER; HUMAN HOMOLOG; GENE; PROGRESSION; MUTATIONS; ANTIGENS; SMOKING; MARKERS	In a previous study, loss of heterozygosity (LOH) of 28 chromosome 9 microsatellite markers was assessed on 139 Ta/T1 bladder tumors. LOH at one or more loci was detected in 67 tumors, 62 presenting subchromosomal deletions. One hundred and thirty-three of these patients have now been followed for up to 8 years. The purpose of the present study was to evaluate the potential biological significance of chromosome 9 deletions in superficial bladder tumors at initial diagnosis. High grade was associated with LOH (P=0.004). Large tumors carried more frequently 9p deletions (P = 0.022). Female patients had more chromosome 9q LOH than male patients did (P = 0.010), Chromosome 9 LOH at all loci was associated with an elevated risk of recurrence but four regions were associated with a particularly high risk of recurrence. Multivariate analysis taking into account grade, stage, size and number of tumors showed that tumors deleted in the regions 9ptr-p22, 9q22.3, 9q33, and 9q34 recurred significantly more rapidly than those without deletions (Recurrence rate ratio=2.32, 2.53, 2.52 and 2.43 respectively). Log-rank statistics comparing Kaplan-Meier survival curves for the same chromosomal regions confirmed the correlation (P = 0.0002, 0.010, 0.002 and 0.009 respectively). Only four patients progressed to muscle-invasive disease. They all had extensive deletions on 9q but none had deletions at 9ptr-p22. This study suggests a link between chromosome 9 anomalies and recurrence of superficial bladder cancer.	Univ Laval, Ctr Hosp Univ Quebec, Ctr Rech Cancerol, Quebec City, PQ, Canada	Laval University	Fradet, Y (corresponding author), CHUQ LHotel Dieu Quebec, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.			Fradet, Yves/0000-0002-7581-2500	NATIONAL CANCER INSTITUTE [R01CA047526, U01CA047526] Funding Source: NIH RePORTER; NCI NIH HHS [CA47526] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard P, 1998, BRIT J UROL, V81, P692; Allard P, 1995, CLIN CANCER RES, V1, P1195; Bartlett JMS, 1998, BRIT J CANCER, V77, P2193, DOI 10.1038/bjc.1998.365; Bartlett JMS, 1997, ANN HUM GENET, V61, P207; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Erbersdobler A, 1998, ONCOL RES, V10, P415; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hills, 1993, STAT MODELS EPIDEMIO; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KEEN AJ, 1994, ONCOGENE, V9, P2083; Kleinbaum DG, 1987, APPL REGRESSION ANAL; LaRue H, 2000, CARCINOGENESIS, V21, P101, DOI 10.1093/carcin/21.1.101; Lee E, 1997, J UROLOGY, V157, P1070, DOI 10.1016/S0022-5347(01)65143-7; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Micheli A, 1998, EUR J CANCER, V34, P2271, DOI 10.1016/S0959-8049(98)00324-4; Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X; POWELL I, 1990, CANCER GENET CYTOGEN, V50, P97, DOI 10.1016/0165-4608(90)90242-3; RAO JY, 1993, P NATL ACAD SCI USA, V90, P8287, DOI 10.1073/pnas.90.17.8287; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Simoneau AR, 1996, CANCER RES, V56, P5039; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; SPRUCK CH, 1994, CANCER RES, V54, P784; TSAI YC, 1990, CANCER RES, V50, P44; Uchida T, 1996, INT J CANCER, V69, P142, DOI 10.1002/(SICI)1097-0215(19960422)69:2<142::AID-IJC13>3.3.CO;2-N; Van Tilborg AAG, 1998, INT J CANCER, V75, P9, DOI 10.1002/(SICI)1097-0215(19980105)75:1<9::AID-IJC2>3.3.CO;2-I; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zhang ZF, 1997, CANCER EPIDEM BIOMAR, V6, P321; Zhang Zuo-Feng, 1997, P215; Zhao JM, 1999, CANCER RES, V59, P4658	34	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6317	6323		10.1038/sj.onc.1204022	http://dx.doi.org/10.1038/sj.onc.1204022			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175346				2022-12-28	WOS:000166210500015
J	Wykoff, CC; Pugh, CW; Maxwell, PH; Harris, AL; Ratcliffe, PJ				Wykoff, CC; Pugh, CW; Maxwell, PH; Harris, AL; Ratcliffe, PJ			Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling	ONCOGENE			English	Article						VHL; hypoxia; HIF-1 alpha	RECEPTOR-RELATED PROTEIN; RENAL-CELL CARCINOMA; TISSUE TRANSGLUTAMINASE; INDUCIBLE GENES; DOWN-REGULATION; CYCLIN G2; C-FOS; ENDOTHELIN-1; ANGIOGENESIS; HIF-1-ALPHA	The von Hippel-Lindau tumour suppressor gene (VHL) targets hypoxia inducible factor (HIF)-alpha subunits for ubiquitin dependent proteolysis, To better understand the role of this and other putative pathways of gene regulation in VHL function we subjected mRNA from VHL defective renal carcinoma cells and transfectants re-expressing a wild type VHL allele to differential expression profiling, and analysed VHL target genes for oxygen regulated expression, Among a group of newly identified VHL target genes the majority but not all were regulated by oxygen, indicating that whilst dysregulation of the HIF system makes a dominant contribution to alterations in transcription, VHL has other influences on patterns of gene expression. Genes newly defined as targets of the VHL/hypoxia pathway (conditionally downregulated by VHL in normoxic cells) include aminopeptidase A, collagen type V, alpha 1, cyclin G2, DEC1/Stra13, endothelin 1, low density lipoprotein receptor-related protein 1, MIC2/CD99, and transglutaminase 2. These genes have a variety of functions relevant to tumour biology. However, not all are connected with the promotion of tumour growth, some being pro-apoptotic or growth inhibitory. We postulate that co-ordinate regulation as part of the HIF pathway may explain this paradox, and that evolution of anti; apoptotic pathways may be required for tumour growth under VHL-dysregulation, Our results indicate that it will be necessary to consider the effects of abnormal activity in integral regulatory pathways, as well as the effects of individual genes to understand the role of abnormal patterns of gene expression in cancer.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Ratcliffe, PJ (corresponding author), Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.		Harris, Adrian L/ABA-3343-2020; Maxwell, Patrick H/C-5557-2008	Harris, Adrian L/0000-0003-1376-8409; Maxwell, Patrick H/0000-0002-0338-2679; Pugh, Chris/0000-0002-5170-1662; Ratcliffe, Peter/0000-0002-2853-806X				Bates S, 1996, ONCOGENE, V13, P1103; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chazaud B, 2000, EXP CELL RES, V258, P237, DOI 10.1006/excr.2000.4934; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Fujimura H, 2000, ONCOLOGY-BASEL, V58, P342, DOI 10.1159/000012122; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hahn JH, 1997, J IMMUNOL, V159, P2250; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HIEDA HS, 1990, LIFE SCI, V47, P247, DOI 10.1016/0024-3205(90)90327-N; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Koong AC, 2000, CANCER RES, V60, P883; Kozawa O, 2000, CELL SIGNAL, V12, P375, DOI 10.1016/S0898-6568(00)00061-9; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Okuda Y, 1998, LIFE SCI, V63, P477, DOI 10.1016/S0024-3205(98)00296-3; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Pasqualini R, 2000, CANCER RES, V60, P722; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soslow RA, 1997, HUM PATHOL, V28, P1158, DOI 10.1016/S0046-8177(97)90254-9; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; YIN J, 1992, MOL BRAIN RES, V14, P213, DOI 10.1016/0169-328X(92)90176-C; Zhang PJ, 2000, MODERN PATHOL, V13, P452, DOI 10.1038/modpathol.3880077; ZOUBEK A, 1995, KLIN PADIATR, V207, P242, DOI 10.1055/s-2008-1046548	47	223	234	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6297	6305		10.1038/sj.onc.1204012	http://dx.doi.org/10.1038/sj.onc.1204012			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175344				2022-12-28	WOS:000166210500013
J	Saaristo, A; Karpanen, T; Alitalo, K				Saaristo, A; Karpanen, T; Alitalo, K			Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis	ONCOGENE			English	Review						breast cancer; metastasis; lymphatic vessels; VEGF; VEGF-C	RECEPTOR TYROSINE KINASE; FACTOR-C EXPRESSION; IN-VIVO; VEGF-C; INTEGRIN ALPHA(V)BETA(3); MONOCLONAL-ANTIBODY; BLOOD-VESSELS; MESSENGER-RNA; UP-REGULATION; CELL GROWTH	There is a constant requirement for vascular supply in solid tumors. Tumor-associated neovascularization allows the tumor cells to express their critical growth advantage. Axillary lymph node status is the most important prognostic factor in operable breast cancer, and experimental and clinical evidence suggests that the process of metastasis is also angiogenesis-dependent. Various angiogenic growth factors and cytokines induce neovascularization in tumors, namely members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) gene families. A strong correlation has been found between VEGF expression and increased tumor microvasculature, malignancy, and metastasis in breast cancer, Anti-angiogenic therapy approaches offer a new promising anti-cancer strategy and a remarkably diverse group of over 20 such drugs is currently undergoing evaluation in clinical trials.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Karpanen, Terhi/0000-0002-2803-083X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; APRELIKOVA O, 1992, CANCER RES, V52, P746; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Brekken RA, 1998, CANCER RES, V58, P1952; BREM SS, 1978, CANCER, V41, P239, DOI 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO;2-X; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Browder T, 2000, CANCER RES, V60, P1878; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; DVORAK HF, 1989, J NATL CANCER I, V81, P497, DOI 10.1093/jnci/81.7.497; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fukumura D, 1997, AM J PATHOL, V151, P679; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Grunstein J, 1999, CANCER RES, V59, P1592; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holder N, 1999, DEVELOPMENT, V126, P2033; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; Hyder SM, 2000, CANCER RES, V60, P3183; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Kaban LB, 1999, PEDIATRICS, V103, P1145, DOI 10.1542/peds.103.6.1145; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823; Kremer C, 1997, CANCER RES, V57, P3852; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEU AJ, 2000, IN PRESS CANC RES; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NAGY JA, 1989, BIOCHIM BIOPHYS ACTA, V948, P305, DOI 10.1016/0304-419X(89)90004-8; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Presta LG, 1997, CANCER RES, V57, P4593; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Saaristo A, 2000, AM J PATHOL, V157, P7, DOI 10.1016/S0002-9440(10)64510-5; Senger DR, 1996, AM J PATHOL, V149, P1; Shutter JR, 2000, GENE DEV, V14, P1313; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1996, CANCER RES, V56, P2299; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SURI C, 1997, CELL, V87, P1161; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2000, CANCER RES, V60, P203; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Witte M H, 1997, EXS, V79, P65; YlaHerttuala S, 1997, CURR OPIN LIPIDOL, V8, P72; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823	113	237	269	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6122	6129		10.1038/sj.onc.1203969	http://dx.doi.org/10.1038/sj.onc.1203969			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156525				2022-12-28	WOS:000166121400005
J	Zheng, L; Li, S; Boyer, TG; Lee, WH				Zheng, L; Li, S; Boyer, TG; Lee, WH			Lessons learned from BRCA1 and BRCA2	ONCOGENE			English	Review						BRCA1; BRCA2; breast cancer; tumor suppressor; transcription regulation; DNA damage repair	CANCER SUSCEPTIBILITY GENE; DOUBLE-STRAND BREAKS; CELL-CYCLE CHECKPOINT; DNA-DAMAGE RESPONSE; HUMAN RAD51 PROTEIN; EARLY EMBRYONIC LETHALITY; POLYMERASE-II HOLOENZYME; MAMMARY EPITHELIAL-CELLS; C-TERMINAL REGION; INTERACT IN-VIVO	BRCA1 and BRCA2 are breast cancer susceptibility genes. Mutations within BRCA1 and BRCA1 are responsible for most familial breast cancer cases. Targeted deletion of Brca1 or Brca2 in mice has revealed an essential function for their encoded products, BRCA1 and BRCA2, in cell proliferation during embryogenesis. Mouse models established from conditional expression of mutant Brca1 alleles develop mammary gland tumors, providing compelling evidence that BRCA1 functions as a breast cancer suppressor. Human cancer cells and mouse cells deficient in BRCA1 or BRCA2 exhibit radiation hypersensitivity and chromosomal abnormalities, thus revealing a potential role for both BRCA1 and BRCA2 in the maintenance of genetic stability through participation in the cellular response to DIVA damage. Functional analyses of the BRCA1 and BRCA2 gene products have established their dual participation in transcription regulation and DNA damage repair. Potential insight into the molecular basis for these functions of BRCA1 and BRCA2 has been provided by studies that implicate these two tumor suppressors in both the maintenance of genetic stability and the regulation of cell growth and differentiation.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.		LI, SHANG/HII-4989-2022	LI, SHANG/0000-0002-6226-3362				ALANI E, 1989, GENETICS, V122, P47; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertwistle D, 1997, CANCER RES, V57, P5485; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chamankhah M, 1999, NUCLEIC ACIDS RES, V27, P2072, DOI 10.1093/nar/27.10.2072; Chamankhah M, 2000, GENETICS, V155, P569; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; Clark AJ, 1996, BIOESSAYS, V18, P767, DOI 10.1002/bies.950180912; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; EASTON DF, 1993, AM J HUM GENET, V52, P678; Eisinger F, 1997, LANCET, V350, P1101, DOI 10.1016/S0140-6736(05)70461-X; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Friedman LS, 1998, CANCER RES, V58, P1338; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gerecke EE, 2000, GENETICS, V154, P1125; Glass CK, 2000, GENE DEV, V14, P121; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; IVANOV EL, 1992, GENETICS, V132, P651; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; JOHZUKA K, 1995, GENETICS, V139, P1521; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; KOIPALLY J, 2000, J BIOL CHEM, V13, P13; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li L, 1999, MOL CELL BIOL, V19, P5619; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lu KP, 1996, NATURE, V380, P544; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCKEE RH, 1980, MUTAT RES, V70, P37, DOI 10.1016/0027-5107(80)90056-1; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nordling M, 1998, CANCER RES, V58, P1372; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1987, J CELL SCI, P207; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Prives C, 1999, J PATHOL, V187, P112; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Su TT, 2000, NAT CELL BIOL, V2, pE28; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Suzuki M, 1997, FASEB J, V11, pA1155; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang Y, 2000, GENE DEV, V14, P927; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu VPCC, 2000, GENE DEV, V14, P1400; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	164	130	139	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6159	6175		10.1038/sj.onc.1203968	http://dx.doi.org/10.1038/sj.onc.1203968			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156530				2022-12-28	WOS:000166121400010
J	Abe, K; Hirai, M; Mizuno, K; Higashi, N; Sekimoto, T; Miki, T; Hirano, T; Nakajima, K				Abe, K; Hirai, M; Mizuno, K; Higashi, N; Sekimoto, T; Miki, T; Hirano, T; Nakajima, K			The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway	ONCOGENE			English	Article						STAT3; ser phosphorylation; IL-6; gp 130; YXXQ motif; transcription	TRANSCRIPTIONALLY ACTIVE STAT1; CYTOKINE RECEPTOR GP130; IL-6 RESPONSE ELEMENT; CRE-LIKE SITE; SERINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; JUNB PROMOTER; GROWTH ARREST	The signal transducer and activator of transcription (STAT) 3 is essential for mediating signals from the receptors for a variety of cytokines and growth factors, including IL-6 and EGF, and from cytoplasmic tyrosine kinases, Upon stimulation, STAT3 is phosphorylated at Ser727 and Tyr705, However, the role of phosphorylation at Ser727, and the kinase pathways responsible for this phosphorylation in IL-6 signaling remain obscure. Here we show that IL-6 activates at least two distinct STAT3 serine kinase pathways and that an H7-sensitive pathway is dominant over a PD98059-sensitive one in HepG2 cells stimulated with a low concentration of IL-6, The analysis, using a series of chimeric receptors containing the extracellular domain of the G-CSF receptor, the truncated form of gp 130, and additional short peptides at the gp 130 carboxy-terminus, shelved that the YXXQ motif of gp 130 was sufficient for the H7-sensitive STAT3 Ser727 phosphorylation, This YXXQ-mediated pathway does not involve Erk, p38, JNK, or PKC delta, and requires a site in the region from 533 to 711 of STAT3 for phosphorylation in vivo. Moreover, we show that Ser727 is required for full transcriptional activity of STAT3 for two different response elements, Thus, the YXXQ motif regulates STAT3 activities in two ways in response to even a low concentration of IL-6: it recruits STAT3 to the receptor for tyrosine phosphorylation, and activates an unidentified H7-sensitive pathway leading to the serine phosphorylation of STAT3.	Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Oncol, Osaka 5458585, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University	Nakajima, K (corresponding author), Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.		Hirano, Toshio/C-8194-2009					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Cho SS, 1996, J IMMUNOL, V157, P4781; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; COFFER P, 1995, ONCOGENE, V10, P985; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kojima H, 1996, ONCOGENE, V12, P547; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STAHL N, 1994, SCIENCE, V263, P91; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 1997, J IMMUNOL, V158, P2390; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	55	56	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3464	3474		10.1038/sj.onc.1204461	http://dx.doi.org/10.1038/sj.onc.1204461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429693				2022-12-28	WOS:000169478300002
J	Jimenez, B; Volpert, OV; Reiher, F; Chang, LF; Munoz, A; Karin, M; Bouck, N				Jimenez, B; Volpert, OV; Reiher, F; Chang, LF; Munoz, A; Karin, M; Bouck, N			c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1	ONCOGENE			English	Article						thrombospondin; anti-angiogenic signalling; CD36; tumor angiogenesis; JNK	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE; IN-VITRO; ANGIOGENESIS; APOPTOSIS; CELLS; JNK2; MECHANISMS; INDUCTION; SURVIVIN	Thrombospondin-1 (TSP-1) is a potent inhibitor of angiogenesis that acts directly on endothelial cells via the CD36 surface receptor molecule to halt their migration, proliferation, and morphogenesis in vitro and to block neovascularization in vivo. Here we show that inhibitory signals elicited by TSP-1 did not alter the ability of inducers of angiogenesis to activate p42 and p44 mitogen-activated protein kinase (MAPK). Rather, TSP-1 induced a rapid and transient activation of c-Jun N-terminal kinases (JNK). JNK activation by TSP-1 required engagement of CD36, as it was blocked by antagonistic CD36 antibodies and stimulated by short anti-angiogenic peptides derived from TSP-1 that act exclusively via CD36. TSP-1 inhibition of corneal neovascularization induced by bFGF was severely impaired in mice null for JNK-1, pointing to a critical role for this stress-activated kinase in the inhibition of neovascularization by TSP-1.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Madrid 28029, Spain; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid, Spain; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Autonomous University of Madrid; University of California System; University of California San Diego	Jimenez, B (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.		Munoz, Alberto/O-6393-2014; Cuenca, Benilde Jimenez/K-9959-2014	Munoz, Alberto/0000-0003-3890-4251; Volpert, Olga/0000-0003-1381-5543; Jimenez Cuenca, Benilde/0000-0002-1806-6636	NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LOO D, 1994, CELL BIOL LAB HDB, P45; Lucas R, 1998, BLOOD, V92, P4730; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yeh CH, 1998, BLOOD, V92, P3268, DOI 10.1182/blood.V92.9.3268.421k41_3268_3276; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	33	65	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3443	3448		10.1038/sj.onc.1204464	http://dx.doi.org/10.1038/sj.onc.1204464			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423995				2022-12-28	WOS:000169248800015
J	Yount, GL; Afshar, G; Ries, S; Korn, M; Shalev, N; Basila, D; McCormick, F; Haas-Kogan, DA				Yount, GL; Afshar, G; Ries, S; Korn, M; Shalev, N; Basila, D; McCormick, F; Haas-Kogan, DA			Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells	ONCOGENE			English	Article						TRADD; glioma; radiation; apoptosis; cDNA array; gene therapy	DRUG-INDUCED APOPTOSIS; NF-KAPPA-B; APO-1/FAS RECEPTOR/LIGAND SYSTEM; MYC-INDUCED APOPTOSIS; IONIZING-RADIATION; BRAIN-TUMORS; C-MYC; CYCLIN-A; DEATH; EXPRESSION	Survival of patients with Glioblastoma Multiforme (GM), a highly malignant brain tumor, remains poor despite concerted efforts to improve therapy. The median survival of patients with GM has remained approximately 1 year regardless of the therapeutic approach, Since radiation therapy is the most effective adjuvant therapy for GM and nearly half of GM tumors harbor p53 mutations, we sought to identify genes that mediate p53-independent apoptosis of GM cells in response to ionizing radiation. Using broad-scale gene expression analysis we found that following radiation treatment, TRADD expression was induced in a uniquely radiosensitive GM cell line but not in radioresistant GM cell lines. TRADD over-expression killed GM cells and activated NF-kappaB, We found that blocking the TRADD-mediated pathway using a dominant-negative mutant of FADD (FADD-DN) enhanced radiation resistance of GM cells, as reflected in both susceptibility to apoptosis and clonogenic survival following irradiation, Conversely stable expression of exogenous TRADD enhanced radiation-induced apoptosis of GM cell lines, reflecting the biological significance of TRADD regulation in p53-independent apoptosis, These findings generate interest in utilizing TRADD in gene therapy for GM tumors, particularly in light of its dual function of directly inducing rapid apoptosis and sensitizing GM cells to standard anti-neoplastic therapy.	Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Complementary Med Res Inst, San Francisco, CA 94115 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco	Haas-Kogan, DA (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, 505 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR01271] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; Baumler CB, 1996, BLOOD, V88, P1741; Brown JM, 1999, CANCER RES, V59, P1391; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DeNardo GL, 1999, CLIN CANCER RES, V5, p3219S; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; FERRER I, 1992, BRAIN RES, V588, P351, DOI 10.1016/0006-8993(92)91599-A; FERRER I, 1995, INT J DEV NEUROSCI, V13, P21, DOI 10.1016/0736-5748(94)00064-A; FERTIL B, 1985, INT J RADIAT ONCOL, V11, P1699, DOI 10.1016/0360-3016(85)90223-8; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Haas-Kogan D A, 1996, Cancer J Sci Am, V2, P114; HaasKogan DA, 1996, INT J RADIAT ONCOL, V36, P95, DOI 10.1016/S0360-3016(96)00244-1; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LUDGATE CM, 1988, INT J RADIAT ONCOL, V15, P1091, DOI 10.1016/0360-3016(88)90189-7; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Murphy S, 1990, METHODS NEUROSCIENCE, V2, P33; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prados MD, 1998, INT J RADIAT ONCOL, V40, P57, DOI 10.1016/S0360-3016(97)00566-X; SARKAR A, 1993, CANCER CHEMOTH PHARM, V32, P477, DOI 10.1007/BF00685893; SHELINE GE, 1977, CANCER, V39, P873, DOI 10.1002/1097-0142(197702)39:2+<873::AID-CNCR2820390725>3.0.CO;2-Y; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; TAGHIAN A, 1992, INT J RADIAT ONCOL, V23, P55, DOI 10.1016/0360-3016(92)90543-Q; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Uberti D, 1999, EXP CELL RES, V252, P123, DOI 10.1006/excr.1999.4606; Villa R, 1996, INT J CANCER, V66, P104, DOI 10.1002/(SICI)1097-0215(19960328)66:1<104::AID-IJC18>3.0.CO;2-D; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	59	26	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2826	2835		10.1038/sj.onc.1204393	http://dx.doi.org/10.1038/sj.onc.1204393			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420694				2022-12-28	WOS:000168712000010
J	Verrecchia, F; Tacheau, C; Schorpp-Kistner, M; Angel, P; Mauviel, A				Verrecchia, F; Tacheau, C; Schorpp-Kistner, M; Angel, P; Mauviel, A			Induction of the AP-1 members c-Jun and JunB by TGF-beta/Smad suppresses early Smad-driven gene activation	ONCOGENE			English	Article						TGF-zeta; signaling; Smad; AP-1; Jun; gene expression	GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR P300; BINDING SEQUENCE; COL7A1 PROMOTER; DNA-BINDING; FOS; EXPRESSION; COMPLEX; IDENTIFICATION	Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes, Among the latter are c-jun and junB, which encode members of the AP-I family of transcription factors. In this study, we have investigated the functional interactions of the Smad and AP-1 transcription factors in the context of Smad-specific gene transactivation in both fibroblasts and keratinocytes. We demonstrate that overexpression of either junB or c-jun prevents TGF-beta- or Smad3-induced transactivation of the Smad-specific promoter construct (SBE)(4)-Lux. Inversely, Smad-driven promoter transactivation by TGF-beta /Smad is significantly enhanced when c-jun expression is abolished in HaCaT keratinocytes, and when junB expression is prevented in fibroblasts, consistent with the cell-type specific induction of jun members by TGF-beta, We also demonstrate that Smad-specific gene transactivation in junB(-/-) mouse embryonic fibroblasts is significantly higher than in embryonic fibroblasts from the control parental mouse line, and that this difference is abolished by rescuing junB expression in junB(-/-) cells. Finally, we have determined that off-DNA interactions between Smad3 and both c-jun and JunB result in the reduction of Smad3/ DNA interactions, From these results, we provide a model in which jun expression in response to the initial Smad cascade represents a negative feed-back mechanism counteracting Smad-driven gene transactivation.	Hop St Louis, INSERM, U532, F-75010 Paris, France; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Helmholtz Association; German Cancer Research Center (DKFZ)	Mauviel, A (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U532, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	39	85	87	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2205	2211		10.1038/sj.onc.1204347	http://dx.doi.org/10.1038/sj.onc.1204347			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402315				2022-12-28	WOS:000168404500002
J	Wong, AST; Pelech, SL; Woo, MMM; Yim, G; Rosen, B; Ehlen, T; Leung, PCK; Auersperg, N				Wong, AST; Pelech, SL; Woo, MMM; Yim, G; Rosen, B; Ehlen, T; Leung, PCK; Auersperg, N			Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?	ONCOGENE			English	Article						hepatocyte growth factor; Met; ovarian surface epithelial cells; cell signaling; familial ovarian cancer; ovarian cancer	FACTOR SCATTER FACTOR; SURFACE EPITHELIAL-CELLS; C-MET; EXTRACELLULAR-MATRIX; CARCINOMA CELLS; FAMILY HISTORY; HGF RECEPTOR; CANCER; EXPRESSION; KINASE	Since autocrine regulation of HGF-Met is implicated in many forms of human cancer, we investigated whether the predisposition to develop ovarian cancer in women with hereditary ovarian cancer syndromes involves changes in the expression of HGF-Met by the tissue of origin of epithelial ovarian cancers, the ovarian surface epithelium (OSE), We compared cultures of normal OSE from women with (FH-OSE) (n = 20) and with no (NFH-OSE) (n = 48) family histories of ovarian cancer, SV40 Tag immortalized OSE lines (IOSE, n = 5) and ovarian cancer cell lines (n = 3), Cultures derived from 21/22 women with NFH-OSE and 13/13 women with FH-OSE expressed Met mRNA initially. After two to three passages, Met was downregulated in 37% of NFH-OSE cultures but persisted in 100% of FH-OSE cultures and ovarian cancer lines, like other epithelial differentiation markers that are stabilized in FH-OSE and neoplasia, HGF and Met mRNA were concomitantly expressed by NFH-OSE from only three of 32 women but in FH-OSE from eight of 13 women, and also in five of five IOSE and two of three ovarian cancer lines. Conditioned media from FH-OSE, but not NFH-OSE, contained immunoreactive HGF and induced cohort migration which was inhibited by neutralizing HGF antibody. Several signaling molecules of the PI3K pathway, including Akt2 and p70 S6K, were constitutively activated in FH-OSE from six of six women but in NFH-OSE from only four of eight women. Exogenous HGF was mitogenic in OSE, and that effect was regulated through the MAP kinase (ERK1/ERK2) and FRAP/p70 S6K pathways. The proliferative response to HGF was greater in NFH-OSE than in FH-OSE cultures. The results show that FH-OSE cultures differ from NFH-OSE by increased stability of Met expression and by HGF secretion. Constitutive phosphorylation of kinases and a diminished growth response to HGF suggest the presence of autocrine regulation in FH-OSE. In analogy with other cell types where an autocrine HGF-R let loop has been implicated in tumorigenic transformation, this change in FH-OSE may play a role in the enhanced susceptibility to ovarian carcinogenesis in women with hereditary ovarian cancer syndromes.	Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V6H 3V5, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6H 3V5, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada	University of British Columbia; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Auersperg, N (corresponding author), Univ British Columbia, British Columbia Childrens Hosp, Dept Obstet & Gynecol, 2H30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.		Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475; Leung, Peter/0000-0003-3152-3800				AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 1998, SEMIN ONCOL, V25, P281; AUERSPERG N, 1995, AM J OBSTET GYNECOL, V173, P558, DOI 10.1016/0002-9378(95)90282-1; Aunoble B, 2000, INT J ONCOL, V16, P567; Balkovetz DF, 1999, LIFE SCI, V64, P1393, DOI 10.1016/S0024-3205(99)00073-9; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; ELLIOTT WM, 1993, BIOTECH HISTOCHEM, V68, P29, DOI 10.3109/10520299309105573; Gulati R, 1997, ENDOCRINOLOGY, V138, P1847, DOI 10.1210/en.138.5.1847; Hess S, 1999, ENDOCRINOLOGY, V140, P2908, DOI 10.1210/en.140.6.2908; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; Huntsman D, 1999, AM J PATHOL, V155, P343, DOI 10.1016/S0002-9440(10)65130-9; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim SO, 1998, J CELL BIOCHEM, V71, P328, DOI 10.1002/(SICI)1097-4644(19981201)71:3<328::AID-JCB2>3.0.CO;2-U; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Nabeshima K, 1998, INT J CANCER, V78, P750, DOI 10.1002/(SICI)1097-0215(19981209)78:6<750::AID-IJC13>3.0.CO;2-#; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; Parrott JA, 2000, BIOL REPROD, V62, P491, DOI 10.1095/biolreprod62.3.491; PARROTT JA, 1994, ENDOCRINOLOGY, V135, P569, DOI 10.1210/en.135.2.569; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Sato N, 1997, Respirology, V2, P185, DOI 10.1111/j.1440-1843.1997.tb00077.x; Scully RE, 1995, J CELL BIOCHEM, P208; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; STOKER M, 1985, J CELL SCI, V77, P209; To CTT, 1998, ONCOL REP, V5, P1013; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wong AST, 1999, INT J CANCER, V81, P180; Wong AST, 2000, GYNECOL ONCOL, V78, P158, DOI 10.1006/gyno.2000.5877; ZILTENER HJ, 1993, BIOL REPROD, V49, P635, DOI 10.1095/biolreprod49.3.635	44	65	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1318	1328		10.1038/sj.onc.1204253	http://dx.doi.org/10.1038/sj.onc.1204253			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313876				2022-12-28	WOS:000167495000006
J	Berry, DM; Benn, SJ; Cheng, AM; McGlade, CJ				Berry, DM; Benn, SJ; Cheng, AM; McGlade, CJ			Caspase-dependent cleavage of the hematopoietic specific adaptor protein Gads alters signalling from the T cell receptor	ONCOGENE			English	Article						Gads; caspase; T cell receptor; SH2 domain; SH3 domain	PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHOPROTEIN; MAMMALIAN CASPASES; MOLECULAR-CLONING; ACTIVATION; SLP-76; LAT; APOPTOSIS; GRB2; DEATH	Gads is a SH2 and SH3 domain-containing, hematopoietic-specific adaptor protein that functions in signalling from the T cell receptor. Gads acts by linking SLP-76, bound by the carboxy-terminal Gads SH3 domain, to tyrosine phosphorylated LAT which contains binding sites for the Gads SH2 domain. Gads is distinguished from Grb2 and the closely related Grap protein by the presence of a 120 amino acid unique region between the SH2 domain and the carboxy terminal SH3 domain. Here we demonstrate that the unique region of Gads contains a capase cleavage site. Induction of apoptosis in lymphocytes results in detectable Gads cleavage by 60 min. Gads cleavage is blocked in vivo by treating cells with a caspase 3 inhibitor. A putative caspase 3 cleavage site was identified within the unique region and mutation of this site prevented Gads cleavage in vitro, and in vivo. The Gads cleavage products retained the predicted binding specificity for SLP-76 and LAT, Expression of the Gads cleavage products in Jurkat T cells inhibited NFAT activation following TCR cross linking. These findings indicate that cleavage of Gads in vivo could function to alter signalling downstream of the T cell receptor by disrupting cross talk between SLP-76 and LAT.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Washington University (WUSTL)	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	39	23	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1203	1211		10.1038/sj.onc.1204218	http://dx.doi.org/10.1038/sj.onc.1204218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313864				2022-12-28	WOS:000167570100007
J	Imamura, O; Fujita, K; Shimamoto, A; Tanabe, H; Takeda, S; Furuichi, Y; Matsumoto, T				Imamura, O; Fujita, K; Shimamoto, A; Tanabe, H; Takeda, S; Furuichi, Y; Matsumoto, T			Bloom helicase is involved in DNA surveillance in early S phase in vertebrate cells	ONCOGENE			English	Article						Bloom helicase; Bloom syndrome; DT40; chromosomal instability	SISTER-CHROMATID EXCHANGE; SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SYNDROME FIBROBLASTS; ULTRAVIOLET-LIGHT; MOLECULAR-CLONING; MAMMALIAN-CELLS	Bloom syndrome (BS) is a recessive human genetic disorder characterized by short stature, immunodeficiency and an elevated risk of malignancy. The gene mutated in BS, BLM, encodes a RecQ-type DNA helicase. BS cells have mutator phenotypes such as hyper-recombination, chromosome instability and an increased frequency of sister chromatid exchange (SCE). To define the primary role of BLM, we generated BLM-/- mutants of the chicken B-cell line DT40. In addition to characteristics of BLM-/- cells reported previously by the other group, they are hypersensitive to genotoxic agents such as etoposide, bleomycin and 4-nitroquinoline-1-oxide and irradiation with the short wave length of UV (UVC) light, whereas they exhibit normal sensitivity to X-ray irradiation and hydroxyurea. UVC irradiation to BLM-/- cells during G(1) to early S phase caused chromosomal instability such as chromatid breaks and chromosomal quadriradials, leading to eventual cell death. These results suggest that BLM is involved in surveillance of base abnormalities in genomic DNA that may be encountered by replication forks in early S phase. Such surveillance would maintain genomic stability in vertebrate cells, resulting in the prevention of cellular tumorigenesis.	AGENE REs Inst, Kanagawa 2470063, Japan; Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, Tokyo 1588501, Japan; Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan	National Institute of Health Sciences - Japan; Kyoto University	Matsumoto, T (corresponding author), AGENE REs Inst, 200 Kajiwara, Kanagawa 2470063, Japan.			Takeda, Shunichi/0000-0002-7924-7991				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Dedon PC, 1998, P NATL ACAD SCI USA, V95, P11113, DOI 10.1073/pnas.95.19.11113; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GALIEGUEZOUITINA S, 1984, ANAL BIOCHEM, V138, P454, DOI 10.1016/0003-2697(84)90839-X; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; HENSON P, 1981, CANCER RES, V41, P760; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; KADYK LC, 1993, GENETICS, V133, P469; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; Kusano K, 1999, GENETICS, V151, P1027; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Matsumoto L, 1999, MUTAT RES-FUND MOL M, V426, P79, DOI 10.1016/S0027-5107(99)00042-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; RAY JH, 1984, CHROMOSOMA, V90, P383, DOI 10.1007/BF00294165; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; SHIRAISHI Y, 1985, EMBO J, V4, P2553, DOI 10.1002/j.1460-2075.1985.tb03970.x; SMITH GJ, 1983, MUTAT RES, V111, P405, DOI 10.1016/0027-5107(83)90036-2; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WERNERFAVRE C, 1984, AM J MED GENET, V18, P215, DOI 10.1002/ajmg.1320180205; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	34	35	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1143	1151		10.1038/sj.onc.1204195	http://dx.doi.org/10.1038/sj.onc.1204195			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313858				2022-12-28	WOS:000167570100001
J	McGarvey, TW; Nguyen, T; Tomaszewski, JE; Monson, FC; Malkowicz, SB				McGarvey, TW; Nguyen, T; Tomaszewski, JE; Monson, FC; Malkowicz, SB			Isolation and characterization of the TERE1 gene, a gene down-regulated in transitional cell carcinoma of the bladder	ONCOGENE			English	Article						tumor related gene; bladder neoplasms; TERE1 gene	TUMOR-SUPPRESSOR REGION; CHROMOSOME 1P; GENOMIC INSTABILITY; DELETION; LOCALIZATION; ABERRATIONS; FREQUENT; DNA; HETEROZYGOSITY; METHYLATION	We have identified a novel cDNA product designated transitional epithelial response gene (TERE1), which was localized to chromosome 1p36. The TERE1 transcript (1.5 and 3.5 kb) is present in most normal human tissues including urothelium, but was reduced or absent in the majority of muscle invasive TCC tumors (22 out of 29 cases). The open reading frame encodes a protein of 338 amino acids (MW 36.8 KD). This protein is 57% homologous to a Drosophila protein called heir. We have shown by Western blotting and immuno-histochemistry with a polyclonal antibody to a specific TERE1 peptide, reduced or absent staining in muscle invasive tumors. Transfection of a sense TERE1 construct resulted in an 80-90% inhibition of cellular proliferation in two TCC cell lines and a lack of aneuploidy in the TERE1-transduced J82 cell line, These data suggest a potential role for this gene product in the progression of bladder cancer.	Dept Surg, Div Urol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania	Malkowicz, SB (corresponding author), Dept Surg, Div Urol, 1 Rhoads,3400 Spruce St, Philadelphia, PA 19104 USA.							*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; Ashburner M, 1999, GENETICS, V153, P179; Bieche I, 1998, ONCOL REP, V5, P267; Boni R, 1998, J INVEST DERMATOL, V110, P215, DOI 10.1046/j.1523-1747.1998.00109.x; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; CAIRNS P, 1991, ONCOGENE, V6, P2305; CHANG WYH, 1995, CANCER RES, V55, P3246; Chen HL, 1996, CANCER GENET CYTOGEN, V86, P102, DOI 10.1016/0165-4608(95)00186-7; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Ebrahimi SA, 1999, CANCER RES, V59, P311; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gasparian AV, 1998, BRIT J CANCER, V77, P1604, DOI 10.1038/bjc.1998.263; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hayashi K, 1991, PCR Methods Appl, V1, P34; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HONG L, 1998, A DROS RES C, V39, pB373; KNOWLES MA, 1994, CANCER RES, V54, P531; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Malkowicz S B, 1997, Semin Urol Oncol, V15, P169; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Monteiro ANA, 2000, HISTOL HISTOPATHOL, V15, P299, DOI 10.14670/HH-15.299; NAGAI H, 1995, CANCER RES, V55, P1752; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PRAML C, 1995, ONCOGENE, V11, P1357; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; ROSIN MP, 1995, CANCER RES, V55, P5213; Salem C, 2000, CANCER RES, V60, P2473; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Sattler HP, 1999, PROSTATE, V39, P79; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Simon R, 1998, J PATHOL, V185, P345; SPRUCK CH, 1994, CANCER RES, V54, P784; Steenman M, 1997, CYTOGENET CELL GENET, V77, P296, DOI 10.1159/000134602; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Wagner U, 1997, AM J PATHOL, V151, P753; White RWD, 1998, ONCOLOGY-NY, V12, P1717; Williamson C, 1997, J MED GENET, V34, P617, DOI 10.1136/jmg.34.8.617; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206	43	35	42	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1042	1051		10.1038/sj.onc.1204143	http://dx.doi.org/10.1038/sj.onc.1204143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314041				2022-12-28	WOS:000167232100004
J	Lallemand, F; Mazars, A; Prunier, C; Bertrand, F; Kornprost, M; Gallea, S; Roman-Roman, S; Cherqui, G; Atfi, A				Lallemand, F; Mazars, A; Prunier, C; Bertrand, F; Kornprost, M; Gallea, S; Roman-Roman, S; Cherqui, G; Atfi, A			Smad7 inhibits the survival nuclear factor kappa B and potentiates apoptosis in epithelial cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; Smad7	PROTEIN-KINASE B/AKT; ACTIVATION; RAS; INSULIN; PATHWAY; GENES; DEATH	In this study, we examined the effect of the stable expression of Smad7 in two different cell lines on apoptosis induced by various stimuli including TGF-beta, serum withdrawal, loss of cell adhesion (anoikis) and TNF-alpha. Smad7 increased TGF-beta -mediated apoptosis in Mv1Lu cells as well as anoikis and/or serum withdrawal-induced apoptosis in Mv1Lu and MDCK cells. Smad7 markedly decreased the activity of the survival NF-kappaB transcription factor in MDCK cells, Interestingly, the stable expression of oncogenic Ras in MDCK cells which suppressed Smad7 inhibition of NF-kappaB also suppressed Smad7 potentiation of serum withdrawal-induced apoptosis and anoikis, In addition, Smad7 inhibited TNF-alpha stimulation of NF-kappaB and increased TNF-alpha -mediated apoptosis in MDCK cells. Our results provide the first evidence that Smad7 induces sensitization of cells to different forms of cell death. They moreover demonstrate that Smad7 inhibits the survival NF-kappaB factor, providing a potential mechanism whereby Smad7 potentiates cell death.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U402, F-75571 Paris, France; Hoechst Marion Roussel, Romainville, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis; Sanofi France	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Roman-Roman, Sergio/K-9993-2014; Frottier, Celine Prunier/G-8259-2017	Roman-Roman, Sergio/0000-0001-6459-2613; Frottier, Celine Prunier/0000-0002-7784-0273				Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Bitzer M, 2000, GENE DEV, V14, P187; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200	25	92	99	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					879	884		10.1038/sj.onc.1204167	http://dx.doi.org/10.1038/sj.onc.1204167			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314022				2022-12-28	WOS:000166924400012
J	Katich, SC; Zerfass-Thome, K; Hoffmann, I				Katich, SC; Zerfass-Thome, K; Hoffmann, I			Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene	ONCOGENE			English	Article						Cdc25; cell cycle; human papillomavirus type 16; E7 oncoprotein	CELL-CYCLE REGULATION; S-PHASE; G(1)/S TRANSITION; EXPRESSION; ACTIVATION; E2F; PHOSPHATASE; PHOSPHORYLATION; ONCOPROTEIN; REPRESSION	Cdc25A is a tyrosine phosphatase that is involved in the regulation of the G1/S phase transition by activating cyclin E/Cdk2 and cyclin A/Cdk2 complexes through removal of inhibitory phosphorylations. The E6 and E7 oncoproteins of the high-risk human papillomaviruses (HPV) interact with and functionally abrogate the p53 and pRB proteins, respectively. In the present study we have investigated the regulation of the Cdc25A promoter during G1 and S-phases of the cell cycle and by the HPV-16 E7 oncoprotein. Serum induction leads to a derepression of the Cdc25A promoter and can be mediated through two E2F binding sites, E2F-A and E2F-C, While E2F-A is by both E2F1 and E2F4, E2F-C is regulated only by E2F1, The Cdc25A promoter is transactivated by the E7 oncogene of HPV-16. Furthermore, Cdc25A levels art highly increased in E7-expressing cell lines, Inducible expression of E7 leads to an immediate increase in Cdc25A protein levels. These data suggest that Cdc25A may be a critical target of HPV-16 E7 in the disruption of the G1/S phase transition.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoffmann, I (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; Chen X, 1999, MOL CELL BIOL, V19, P4695; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; Iavarone A, 1999, MOL CELL BIOL, V19, P916; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Lammer C, 1998, J CELL SCI, V111, P2445; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Spitkovsky D, 1996, ONCOGENE, V12, P2549; Vigo E, 1999, MOL CELL BIOL, V19, P6379; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	32	33	38	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					543	550		10.1038/sj.onc.1204130	http://dx.doi.org/10.1038/sj.onc.1204130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313986				2022-12-28	WOS:000166755000001
J	Han, DC; Rodriguez, LG; Guan, JL				Han, DC; Rodriguez, LG; Guan, JL			Identification of a novel interaction between integrin beta 1 and 14-3-3 beta	ONCOGENE			English	Article						integrins; 14-3-3 proteins; cell migration; protein-protein interaction	FOCAL ADHESION KINASE; PROTEIN-KINASE; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; CELL-MIGRATION; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; FIBRONECTIN RECEPTOR; 14-3-3-PROTEINS	Integrins are cell surface receptors for extracellular matrix, which play important roles ina a variety of biological processes. 14-3-3 proteins are a highly conserved family of cytoplasmic proteins that associate with several intracellular signaling molecules in regulation of various cellular functions. Here, we report identification of an interaction between the integrin beta1 cytoplasmic domain and 14-3-3 beta by using the yeast two-hybrid screen, Like several other proteins, the integrin beta1 cytoplasmic domain associated with 14-3-3 beta by a non-phosphoserine mechanism. The 14-3-3 beta /integrin beta1 interaction was confirmed by iir vitro binding assays as well as to-precipitation in vivo. Furthermore, we found that 14-3-3 beta co-localized with integrin beta1 during the early stage of cell spreading on fibronectin, suggesting a potential role of the 14-3-3 beta /integrin beta1 interaction in the regulation of cell adhesion. Using tetracycline-regulated expression system, we showed that overexpression of 14-3-3 beta stimulated cell spreading and migration on fibronectin but not on poly-L-lysine. However, the induced expression of 14-3-3 beta did not affect tyrosine phosphorylation of FAK or its substrates, p130(cas) and paxillin, suggesting that 14-3-3 beta regulated integrin-mediated cell spreading and migration by FAK-independent mechanisms. Taken together, these results identify an interaction between integrin and 14-3-3 proteins and suggest a potentially novel cellular function for 14-3-3 proteins in the regulation of integrin-mediated cell adhesion and signaling events.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Aplin AE, 1998, PHARMACOL REV, V50, P197; Autieri MV, 1996, CELL GROWTH DIFFER, V7, P1453; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHUN JS, 1993, MOL BIOL CELL, V4, P271; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Loftus JC, 1997, J CLIN INVEST, V100, pS77; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Meller N, 1996, MOL CELL BIOL, V16, P5782; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORGAN A, 1992, BIOCHEM J, V286, P807, DOI 10.1042/bj2860807; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	75	79	83	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					346	357		10.1038/sj.onc.1204068	http://dx.doi.org/10.1038/sj.onc.1204068			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313964				2022-12-28	WOS:000166411000009
J	Jee, SH; Shen, SC; Chiu, HC; Tsai, WL; Kuo, ML				Jee, SH; Shen, SC; Chiu, HC; Tsai, WL; Kuo, ML			Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency	ONCOGENE			English	Article						interleukin-6; anti-apoptosis; basal cell carcinoma cells; Mcl-1; cyclooxygenase; vascular endothelial growth factor	GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; HUMAN KERATINOCYTES; TNF-ALPHA; IN-VITRO; BCL-2; IL-6; EXPRESSION; TRANSCRIPTION; ANGIOGENESIS	Interleukin-6 (IL-6) is a pleiotropic cytokine that is capable of modulating the diverse functions of cells such as acute phase responses and inflammation. Excessive or insufficient production of IL-6 may contribute to certain diseases of the skin. The aim of this study was to investigate the possible role of IL-6 in the tumorigenesis of basal cell carcinoma (BCC), Initially, ffe transfected IL-6 expression vector, under the control of a CMV promoter, into human BCC cells and successfully obtained IL-6-overespressing clones (BCC/IL-6-c1 and BCC/IL-6-c2) and a mixture (BCC/IL-6). DNA synthesis assay determined using H-3-thymidine pulse incorporation revealed that IL-6-expressing BCC cells exhibited a much higher DNA synthesis rate than the neo control or parental BCC cells. Ne also detected a greater abundance of IL-6-expressing cell colonies formed in soft agar than in the vector control cells. Furthermore, BCC/IL-6 cells, but not vector control cells, were resistant to UV and photodynamic therapy (PDT)-induced apoptosis, as confirmed using DNA fragmentation and morphologic change analyses. Immunoblot analysis showed that Mcl-1, an anti-apoptotic protein, was specifically up-regulated IL-6 transfectants but not in the control cells, Transient transfection of IL-6 transfectants with antisense mcl-1 greatly enhanced their apoptosis frequency by UV treatment, In tumorigenesis assay, IL-6 transfected clones formed tumors in nude mice more rapidly than the control cells. These tumors appeared to be highly vascularized using pathological examination, Supportive of this finding, ffe found that IL-6 transfected cells expressed elevated levels of two angiogenic factors, cycloosygenase (Cos)-2 and vascular endothelial growth factor (VEGF). These results suggest that overexpression of IL-6 enhances the tumorigenic activity of BCC cells by both suppressing apoptosis and actively promoting angiogenesis.	Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol,Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan; Taipei Med Univ, Sch Med, Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; National Taiwan University	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol,Dept Dermatol, 1 Sec,1 Jen Ai Rd, Taipei, Taiwan.		Kuo, Min-Liang/C-4872-2009	CHIU, HSIEN-CHING/0000-0002-1409-8470; KUO, MIN-LIANG/0000-0002-7139-0144; JEE, SHIOU-HWA/0000-0001-6737-6297				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akira S, 1992, Semin Cancer Biol, V3, P17; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Ando T, 1998, ENDOCR RES, V24, P955, DOI 10.3109/07435809809032715; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoyagi T, 1996, Int J Urol, V3, P392, DOI 10.1111/j.1442-2042.1996.tb00560.x; Avalos-Diaz E, 1999, REV RHUM, V66, P13; Barton BE, 1997, CLIN IMMUNOL IMMUNOP, V85, P16, DOI 10.1006/clin.1997.4420; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; CALLERY MP, 1990, J SURG RES, V48, P523, DOI 10.1016/0022-4804(90)90224-P; Cassell GH, 1998, EMERG INFECT DIS, V4, P475, DOI 10.3201/eid0403.980339; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Dietrich JB, 1997, ARCH PHYSIOL BIOCHEM, V105, P125, DOI 10.1076/apab.105.2.125.12927; Eberlein-Konig B, 1998, BRIT J DERMATOL, V139, P415; Elder DJE, 1996, CANCER RES, V56, P2273; Gniadecki R, 1998, ARCH DERMATOL RES, V290, P528, DOI 10.1007/s004030050347; HANADA N, 1995, NUCL ACID ENZYME, V40, P1713; HORII Y, 1993, KIDNEY INT, V43, pS71; HOUSSIAU F, 1992, RES IMMUNOL, V143, P740, DOI 10.1016/0923-2494(92)80014-C; Kinoshita T, 1999, CANCER, V85, P2526, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3; Kondo S, 1998, J CELL PHYSIOL, V177, P493, DOI 10.1002/(SICI)1097-4652(199812)177:3<493::AID-JCP12>3.0.CO;2-B; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Kuo ML, 1998, ONCOGENE, V17, P2225, DOI 10.1038/sj.onc.1202133; Lear JT, 1998, J ROY SOC MED, V91, P585, DOI 10.1177/014107689809101110; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; Lu C, 1996, CLIN CANCER RES, V2, P1417; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Okamoto M, 1997, INT J CANCER, V72, P149, DOI 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D; OTAKE S, 1996, J BONE MINER RES, V11, P88; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; REZAI AR, 1994, J NEURO-ONCOL, V19, P131, DOI 10.1007/BF01306454; Rifas L, 1999, J BONE MINER RES, V14, P1096, DOI 10.1359/jbmr.1999.14.7.1096; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; SCHLAG P, 1984, CANCER TREAT REV, V11, P131, DOI 10.1016/0305-7372(84)90052-5; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Seymour J F, 1996, Cancer Treat Res, V84, P167; SKELLY SM, 1994, J BIOTECHNOL, V34, P79, DOI 10.1016/0168-1656(94)90168-6; Soriani M, 1999, CARCINOGENESIS, V20, P727, DOI 10.1093/carcin/20.4.727; Swiergiel AH, 1999, BRAIN BEHAV IMMUN, V13, P252, DOI 10.1006/brbi.1999.0565; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Tseng JF, 1996, J CLIN ENDOCR METAB, V81, P1118, DOI 10.1210/jc.81.3.1118; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Wang JM, 1999, MOL CELL BIOL, V19, P6195; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yen HT, 1996, ARCH DERMATOL RES, V288, P157, DOI 10.1007/BF02505826	54	109	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					198	208		10.1038/sj.onc.1204076	http://dx.doi.org/10.1038/sj.onc.1204076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313947				2022-12-28	WOS:000166410900007
J	Yam, JWP; Chan, KW; Hsiao, WLW				Yam, JWP; Chan, KW; Hsiao, WLW			Suppression of the tumorigenicity of mutant p53-transformed rat embryo fibroblasts through expression of a newly cloned rat nonmuscle myosin heavy chain-B	ONCOGENE			English	Article						nmMHC; cytoskeletal protein; tumor suppression; Rat 6; mutant p53	PROTEIN KINASE-C; SMOOTH-MUSCLE; II-B; CELLS; CDNA; CLONING; ISOFORM; DISRUPTION; ANTIBODIES; TISSUES	In our previous study, a rat homolog of human nonmuscle myosin heavy chain-B (nmMHC-B) was identified by mRNA differential display comparing of transformed against nontransformed Rat 6 cells overexpressing mutant p53(val135) gene. The nmMHC-B was found to be expressed in normal Rat 6 embryo fibroblast cell line, but markedly suppressed in the mutant p53(val135) transformed Rat 6 cells. To examine the possible involvement of nmMHC-B in cell transformation, we first cloned and sequenced the full length cDNA of rat nmMHC-B, which was then cloned into an ecdysone-expression vector. The resulting construct was introduced into the T2 cell line, a mutant p53(val135)-transformed Rat 6 cells lacking the expression of the endogenous nmMHC-B, The clonal transfectants, expressing muristerone A-induced nmMHC-B, displayed a slightly flatter morphology and reached to a lower saturation density compared to the parental transformed cells. Reconstitution of actin filamental bundles was also clearly seen in cells overexpressing the nmMHC-B, In soft agar assays, nmMHC-B transfectants formed fewer and substantially smaller colonies than the parental cells in response to muristerone A induction. Moreover, it was strikingly effective in suppressing the tumorigenicity of the T2 cells when tested in nude mice. Thus, the nmMHC-B, known as a component of the cytoskeletal network, may act as a tumor suppressor gene. Our current finding may reveal a novel role of nmMHC-B in regulating cell growth and cell signaling in nonmuscle cells.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Hsiao, WLW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Yam, Judy Wai Ping/C-4454-2009	Yam, Judy Wai Ping/0000-0002-5637-121X				BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FREEMAN AE, 1967, P NATL ACAD SCI USA, V58, P1205, DOI 10.1073/pnas.58.3.1205; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HONER B, 1988, J CELL BIOL, V107, P2181, DOI 10.1083/jcb.107.6.2181; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mummert CM, 1997, J NEUROCHEM, V68, P596; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; STANBRIDGE EJ, 1980, INT J CANCER, V26, P1, DOI 10.1002/ijc.2910260102; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Weir L, 1996, GENE EXPRESSION, V6, P45; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852	41	15	15	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					58	68		10.1038/sj.onc.1203982	http://dx.doi.org/10.1038/sj.onc.1203982			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244504				2022-12-28	WOS:000166361400007
J	Sebti, SM; Hamilton, AD				Sebti, SM; Hamilton, AD			Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies	ONCOGENE			English	Article						farnesyltransferase; geranylgeranyltransferase I; FTI; GGTI; Ras; cancer therapy; hypothesis-driven clinical trials	PROTEIN TRANSFERASE INHIBITOR; TUMOR-CELL LINES; MALIGNANT GLIOMA GROWTH; RAS-TRANSFORMED CELLS; K-RAS; PEPTIDOMIMETIC INHIBITORS; ACTIVATE RAF-1; PHASE-I; CENP-E; H-RAS	In 1990, more than 10 years after the discovery that the low molecular weight GTPase Pas is a major contributor to human cancer, farnesylation, a lipid posttranslational modification required for the cancer-causing activity of Ras, emerged as a major target for the development of novel anticancer agents. However, it took only 5 years from 1993, when the first farnesyltransferase inhibitors (FTIs) were reported, to 1998 when results from the first phase I clinical trials were described. This rapid progress was due to the demonstration of outstanding antitumor activity and lack of toxicity of FTls in preclinical models. Although, many FTIs are currently in phase II and at least one is in phase III clinical trial, the mechanism of FTI antitumor activity is not known, In this review a brief summary of the development of FTIs as antitumor agents mill be given. The focus of the review will be on important mechanistic and bench-to-bedside translational issues. Among the issues that will be addressed are: evidence for and against inhibition of the prenylation of Pas and RhoB proteins in the mechanism of action of FTIs; implications of the alternative prenylation of K-Ras by geranylgeranyl-transferase I (when FTase is inhibited) in cancer therapy; GGTase I inhibitors (GGTIs) as antitumor agents; effects of FTIs and GGTIs on cell cycle machinery and progression and potential mechanisms by which FTIs and GGTIs induce apoptosis in human cancer cells. A thorough discussion about bench-to-bedside issues relating to hypothesis-driven clinical trials with proof-of-principle in man will also be included. This section will cover issues relating to whether the biochemical target (FTase) is inhibited and the level of inhibition of FTase required for clinical response; are signaling pathways such as H-Ras/PI3K/ Akt and/or K-Ras/Raf/MEK/Erk relevant biological readouts?; is Ras (particularly N-Ras and H-Ras) mutation status a good predictor of clinical response?; in phase I trials should effective biological dose, not maximally tolerated dose, be used to determine phase II dose?; and finally, in phase II/III trials what are the most appropriate clinical end points for anti-signaling molecules such as FTIs? Parts of this topic have been recently reviewed (Sebti and Hamilton, 2000c).	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adjei AA, 2000, CANCER RES, V60, P1871; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Barbacid M, 1986, Important Adv Oncol, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bredel M, 1998, NEUROSURGERY, V43, P124, DOI 10.1097/00006123-199807000-00081; BRITTEN CD, 1999, P AN M AM SOC CLIN, V18, pA155; CASEY PJ, 1992, J LIPID RES, V33, P1731; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; CRESPO NC, 2001, IN PRESS J BIOL CHEM; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, CANCER RES, V59, P4208; ESKENS F, 1999, P AN M AM SOC CLIN, V18, pA156; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIBBS JB, 2000, FARNESYLTRANSFERASE, P65; HAHN SM, 2000, P AN M AM SOC CLIN, V19, pA231; HUDES G, 1999, P AN M AM SOC CLIN, V18, pA156; HURWITZ HI, 2000, P AN M AM SOC CLIN, V19, pA185; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KAUFFMANN RC, 1995, P NATL ACAD SCI USA, V92, P10919, DOI 10.1073/pnas.92.24.10919; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KHURI FR, 2000, P AN M AM SOC CLIN, V19, pA205; LANCET J, 2000, P AN M AM SOC CLIN, V19, pA3; Lantry LE, 2000, CARCINOGENESIS, V21, P113, DOI 10.1093/carcin/21.1.113; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lee J, 2000, MOL REPROD DEV, V56, P51, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;51::AID-MRD7&gt;3.0.CO;2-N; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; NAGASU T, 1995, CANCER RES, V55, P5310; NIGAM M, 1993, J BIOL CHEM, V268, P20695; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Omer CA, 2000, CANCER RES, V60, P2680; PATNAIK A, 2000, FARNESYLTRANSFERASE, P233; Pollack IF, 1999, NEUROSURGERY, V45, P1208, DOI 10.1097/00006123-199911000-00039; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIAN YM, 1994, BIOORG MED CHEM LETT, V4, P2579, DOI 10.1016/S0960-894X(01)80287-0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Robinet G, 2000, B CANCER, V87, P253; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; RYAN DP, 2000, ASCO ANN M NEW ORL L; Sebti S M, 1997, Expert Opin Investig Drugs, V6, P1711, DOI 10.1517/13543784.6.11.1711; Sebti S. M., 2000, FARNESYLTRANSFERASE, P197; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHIH TY, 1982, J BIOL CHEM, V257, P1767; Soignet S., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P517; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1999, CANCER RES, V59, P4919; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	73	251	262	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6584	6593		10.1038/sj.onc.1204146	http://dx.doi.org/10.1038/sj.onc.1204146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426643				2022-12-28	WOS:000167704000004
J	Rodier, F; Bertrand, R; Bossolasco, M; Mes-Masson, AM				Rodier, F; Bertrand, R; Bossolasco, M; Mes-Masson, AM			Polyomavirus large T-antigen protects mouse cells from Fas-, TNF-alpha- and taxol-induced apoptosis	ONCOGENE			English	Review						apoptosis; polyomavirus large T-antigen; Fas receptor; caspase-8; caspase-3	CHEMOTHERAPY-INDUCED APOPTOSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; HEAT-SHOCK PROTEINS; RETINOBLASTOMA PROTEIN; MEDIATED APOPTOSIS; EXPRESSING MYOBLASTS; INTERACTING PROTEIN; TRANSGENIC MICE; DEATH RECEPTORS; MAMMALIAN-CELL	Polyomavirus large T-antigen (PyLT-Ag), a nucleophosphoprotein essential for regulating viral gene expression, modulates the cell cycle by binding to the Rb tumor suppressor gene product. PyLT-Ag/Rb binding is essential for in vitro immortalization. However, the effect of PyLT-Ag on apoptosis has not been extensively studied, We have previously reported that FasR agonist antibodies (FasR(Ab)) treatment of Sertoli cells derived from transgenic mice expressing PyLT-Ag induces the cells without concomitant apoptosis, Here we show that stable expression of PyLT-Ag in murine Sertoli TM4 and hybridoma NSO cell lines confers protection from FasR(Ab)-induced apoptosis, The protection was maintained up to 48 h when cells were grown continuously in the presence of FasR(Ab), Removal of the death stimulus after 24 h exposure was sufficient to allow full recovery of the PyLT-Ag expressing cells. The protective effect conferred by PyLT-Ag was associated with a delay in the sequential activation of caspase-8 and -3 after FasR(Ab) treatment. PyLT-Ag co-precipitated following immunoprecipitation of caspase-8 or FADD, both components of; the DISC, Based on these results we suggest that PyLT-Ag directly impedes the recruitment or activation of caspase-8 by the FasR, PyLT-Ag expression in TM4 cells was also associated with protection from TNF-chi -and taxol-induced apoptosis, In contrast, PyLT-Ag expression was not sufficient to confer protection from captothecin-induced apoptosis, Taken together, these results indicate that PyLT-Ag can be a potent inhibitor of Fas(R)(Ab)-, TNF-chi- and taxol-induced apoptosis.	CHUM, Ctr Rech, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada; Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, Ctr Rech, Hop Notre Dame, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.			Rodier, Francis/0000-0003-2523-309X; Mes-Masson, Anne-Marie/0000-0002-6498-266X				Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Arrigo AP, 1998, BIOL CHEM, V379, P19; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Decaudin D, 1998, INT J ONCOL, V12, P141; DOLE MG, 1995, CANCER RES, V55, P2576; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Endo T, 1998, J CELL SCI, V111, P1081; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fimia GM, 1998, MOL BIOL CELL, V9, P1449, DOI 10.1091/mbc.9.6.1449; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Gottifredi V, 1999, J CELL SCI, V112, P2397; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hohfeld J, 1998, BIOL CHEM, V379, P269; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lebel M, 1996, ONCOGENE, V12, P1127; LEBEL M, 1994, EXP CELL RES, V213, P12, DOI 10.1006/excr.1994.1167; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mountz JD, 1997, IMMUNOL REV, V160, P19, DOI 10.1111/j.1600-065X.1997.tb01024.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Perkins CL, 2000, CANCER RES, V60, P1645; Pilon AA, 1996, J VIROL, V70, P4457, DOI 10.1128/JVI.70.7.4457-4465.1996; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RASSSOULZADEGAN M, 1983, P NATL ACAD SCI USA, V82, P4354; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Reed JC, 1997, SEMIN HEMATOL, V34, P9; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; ROUQUET N, 1995, ONCOGENE, V11, P1061; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1379/1466-1268(1998)003<0228:HSPROS>2.3.CO;2; Sambrook J., 2002, MOL CLONING LAB MANU; Sane AT, 1999, CANCER RES, V59, P3565; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schett G, 1999, FASEB J, V13, P833, DOI 10.1096/fasebj.13.8.833; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 1999, DRUG RESIST UPDATE, V2, P21, DOI 10.1054/drup.1999.0065; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Siegel RM, 1999, J ALLERGY CLIN IMMUN, V103, P729, DOI 10.1016/S0091-6749(99)70412-4; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Slinskey A, 1999, J VIROL, V73, P6791, DOI 10.1128/JVI.73.8.6791-6799.1999; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vayssier M, 1998, CELL STRESS CHAPERON, V3, P221, DOI 10.1054/csac.1998.0125; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weigel TL, 2000, J THORAC CARDIOV SUR, V119, P795, DOI 10.1016/S0022-5223(00)70016-X; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Young LS, 1997, BRIT MED BULL, V53, P509; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	92	6	7	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6261	6270		10.1038/sj.onc.1204015	http://dx.doi.org/10.1038/sj.onc.1204015			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175340				2022-12-28	WOS:000166210500009
J	Montpetit, A; Sinnett, D				Montpetit, A; Sinnett, D			Comparative analysis of the ETV6 gene in vertebrate genomes from pufferfish to human	ONCOGENE			English	Article						ETV6; transcription factor; comparative genetics; vertebrate genomes; Fugu rubripes	CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FUGU RUBRIPES; TYROSINE KINASE; FUSION GENES; TEL; SEQUENCE; PROTEIN; MICE; TRANSFORMATION	The ETV6 gene encodes an Ets-like transcription factor that is frequently rearranged in leukemias. While some of the functions of ETV6 have been uncovered recently, little is known about the key structural elements involved. Comparative genome analysis may provide novel insights into gene evolution and functions. In this study, me cloned and sequenced the homologue of ETV6 from the compact genome of the pufferfish Fugu rubripes (fETV6). The genomic structure of the fETV6 gene was investigated by sequence analysis of a contig of genomic clones. The fETV6 gene, composed of eight exons, spans about 15 kb and is 16 times smaller than its human counterpart mainly because of the reduced intron size. Three of the seven introns of fETV are unusually large (more than 2 kb), including the 8.2 kb intron 2. The gene codes for a protein of 465 amino acids that is highly related to its human homologue, exhibiting an overall identity of 58% (72% similarity). To investigate the functional and evolutionary aspects of ETV6, we undertook a comparative analysis of this gene from various vertebrates (human, mouse, chicken, zebrafish and Fugu). As expected, the PNT and ETS domains were highly conserved, with on average 81 and 95% peptide sequence identity, respectively. In addition, we found several new highly conserved regions within the central section of the protein that are likely to represent further functional or structural domains, which may be associated with the transcription repression capacity of this protein. We also found conserved putative regulatory elements in the promoter as well as in the large intron 2 of fETV6. The information derived from this comparative analysis will serve as the basis for more precise functional studies of ETV6 gene regulation and function.	Hop St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Sinnett, D (corresponding author), Hop St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.		sinnett, daniel/S-4589-2017	sinnett, daniel/0000-0003-3625-6676				Aissani B, 1999, LEUKEMIA LYMPHOMA, V34, P231, DOI 10.3109/10428199909050948; APARICIO S, 1995, P NATL ACAD SCI USA, V92, P1684, DOI 10.1073/pnas.92.5.1684; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; BAXENDALE S, 1995, NAT GENET, V10, P67, DOI 10.1038/ng0595-67; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Caldas C, 1998, ONCOGENE, V16, P3233, DOI 10.1038/sj.onc.1201873; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carron C, 2000, BLOOD, V95, P3891; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Elgar G, 1996, TRENDS GENET, V12, P145, DOI 10.1016/0168-9525(96)10018-4; Gellner K, 1999, GENOME RES, V9, P251; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; How GF, 1996, GENOME RES, V6, P1185, DOI 10.1101/gr.6.12.1185; Kimura C, 1997, DEVELOPMENT, V124, P3929; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MASON PJ, 1995, GENOMICS, V26, P587, DOI 10.1016/0888-7543(95)80179-P; Miles C, 1998, P NATL ACAD SCI USA, V95, P13068, DOI 10.1073/pnas.95.22.13068; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowitch DH, 1998, DEVELOPMENT, V125, P2735; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Venkatesh B, 2000, FEBS LETT, V476, P3, DOI 10.1016/S0014-5793(00)01659-8; Villard L, 1998, GENE, V210, P17, DOI 10.1016/S0378-1119(98)00032-8; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0	41	10	10	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3437	3442		10.1038/sj.onc.1204444	http://dx.doi.org/10.1038/sj.onc.1204444			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423994				2022-12-28	WOS:000169248800014
J	Jopling, CL; Willis, AE				Jopling, CL; Willis, AE			N-myc translation is initiated via an internal ribosome entry segment that displays enhanced activity in neuronal cells	ONCOGENE			English	Article						N-myc; translation initiation; IRES; neuronal	FACTOR MESSENGER-RNA; HUMAN NEUROBLASTOMA-CELLS; C-MYC; ALTERNATIVE TRANSLATION; MURINE DEVELOPMENT; RETINOIC ACID; SITE; EXPRESSION; GROWTH; PROTEIN	Eukaryotic translation can be initiated either by a cap-dependent mechanism or by internal ribosome entry, a process by which ribosomes are directly recruited to structured regions of mRNA upstream of the initiation codon, We analysed the 5' untranslated region (UTR) of the proto-oncogene N-myc, and demonstrated by transfections in a dicistronic vector system that it contains a potent internal ribosome entry segment (IRES), The IRES is similar in length to the c-myc [RES and the activities of these IRESs are comparable in non-neuronal cells. Transfections were also carried out in cell lines derived from neuroblastomas, in which N-myc is expressed, and in a neuronal precursor cell line. In these cells the N-myc IRES is up to seven times more active than that of c-myc, suggesting that neuronal-specific non-canonical trans-acting factors are used by the N-myc but not the c-myc IRES, N-myc expression is increased by gene amplification in many neuroblastomas, but this is the first example of a translational mechanism by which N-myc expression could be further increased. The discovery of an IRES that displays enhanced activity in neuronal cell lines has important potential as a tool for protein expression in neural tissue.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Jopling, Catherine/0000-0001-6046-1456; Willis, Anne/0000-0002-1470-8531				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Dang CV, 1999, MOL CELL BIOL, V19, P1; Derrington EA, 1999, HUM GENE THER, V10, P1129, DOI 10.1089/10430349950018120; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IBSON JM, 1988, ONCOGENE, V2, P399; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; KATOH K, 1988, NUCLEIC ACIDS RES, V16, P3589, DOI 10.1093/nar/16.8.3589; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pilipenko EV, 2000, GENE DEV, V14, P2028; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHEA TB, 1994, NEUROREPORT, V5, P797, DOI 10.1097/00001756-199403000-00015; Sivak LE, 1999, MOL CELL BIOL, V19, P155; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUGIYAMA A, 1991, ONCOGENE, V6, P2027; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	56	57	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2664	2670		10.1038/sj.onc.1204404	http://dx.doi.org/10.1038/sj.onc.1204404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420678				2022-12-28	WOS:000168652600007
J	Nielsen, KH; Gredsted, L; Broach, JR; Willumsen, BM				Nielsen, KH; Gredsted, L; Broach, JR; Willumsen, BM			Sensitivity of wild type and mutant ras alleles to Ras specific exchange factors: Identification of factor specific requirements	ONCOGENE			English	Article						Ras exchange; Ras V103E; Sos1; GRF; GRP; S. cerevisiae	MURINE SARCOMA-VIRUS; NUCLEOTIDE-RELEASING FACTOR; SACCHAROMYCES-CEREVISIAE CDC25; GTPASE ACTIVATING PROTEIN; P21 TRANSFORMING PROTEIN; MOLECULAR-CLONING; MAMMALIAN RAS; R-RAS; N-RAS; FUNCTIONAL INTERACTION	We have investigated the productive interaction between the four mammalian Ras proteins (H-, N-, KA- and KB-Ras) and their activators, the mammalian exchange factors mSos1, GRF1 and GRP, by using a modified Saccharomyces cerevisiae whose growth is dependent on activation of a mammalian Ras protein by its activator. All four mammalian Ras proteins were activated with similar efficiencies by the individual exchange factors. The H-Ras mutant V103E, which is competent for membrane localization, nucleotide binding, intrinsic and stimulated GTPase activity as well as intrinsic exchange, was defective for activation by all factors tested, suggesting that the integrity of this residue is necessary for catalyzed exchange. However, when other H-Ras mutants were studied, some distinct sensitivities to the exchange factors were observed. GRP-mediated, but not mSos1-mediated, exchange was blocked in additional mutants, suggesting different structural requirements for GRP, Analysis of Ras-mediated gene activation in murine fibroblasts confirmed these results.	Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; Princeton Univ, Lewis Thomas Lab 303, Princeton, NJ 08544 USA	University of Copenhagen; Princeton University	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Mol Cell Biol, Oester Farimagsgade 2A, DK-1353 Copenhagen, Denmark.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Broach, James/0000-0003-1197-0312	NCI NIH HHS [CA41086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COX AD, 1994, ONCOGENE, V9, P3281; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOWE LR, 1993, ONCOGENE, V8, P2583; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leonardsen L, 1996, ONCOGENE, V13, P2177; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; ORITA S, 1993, J BIOL CHEM, V268, P25542; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PILZ RB, 1984, J BIOL CHEM, V259, P2927; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rose MD., 1990, METHODS YEAST GENETI; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1992, J BIOL CHEM, V267, P22747; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269	61	9	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2091	2100		10.1038/sj.onc.1204306	http://dx.doi.org/10.1038/sj.onc.1204306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360193	Bronze			2022-12-28	WOS:000168116700004
J	Offermanns, S				Offermanns, S			In vivo functions of heterotrimeric G-proteins: studies in G alpha-deficient mice	ONCOGENE			English	Article						G-protein; knock-out; transgenic mouse; signal transduction	CEREBELLAR PURKINJE-CELLS; CLIMBING FIBER INNERVATION; PERTUSSIS-TOXIN; SIGNAL-TRANSDUCTION; NEURAL CREST; G-ALPHA-I2-DEFICIENT MICE; PHOSPHOLIPASE C-BETA-4; BIOCHEMICAL-PROPERTIES; MOLECULAR MECHANISMS; PLATELET ACTIVATION	Heterotrimeric guanine nucleotide binding proteins (G-proteins) mediate the effects of numerous hormones, neurotransmitters or sensory stimuli by coupling their transmembranous receptors to various effecters like enzymes and ion channels. Changes in the activity of these effector molecules eventually lead to the regulation of multiple cellular functions ranging from short term regulatory processes like the control of secretion rates, muscle tonus or metabolic processes to long term effects like regulation of growth and differentiation. Heterotrimeric G-proteins play a pivotal role in this transmembrane signaling process as they take part in processing and sorting of incoming signals as well as in adjusting the sensitivity of the system, This review describes some of the new insights into the biological role of G-protein mediated signaling processes provided by the analysis of mice genetically engineered to lack distinct G-protein alpha -subunits.	Heidelberg Univ, Inst Pharmakol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Offermanns, S (corresponding author), Heidelberg Univ, Inst Pharmakol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Broaddus R, 1998, FASEB J, V12, pA736; BRONNERFRASER M, 1995, EXP CELL RES, V218, P405, DOI 10.1006/excr.1995.1173; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Choi DS, 1997, DEVELOPMENT, V124, P1745; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Clouthier DE, 1998, DEVELOPMENT, V125, P813; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Davignon I, 2000, MOL CELL BIOL, V20, P797, DOI 10.1128/MCB.20.3.797-804.2000; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hendry IA, 2000, BRAIN RES, V870, P10, DOI 10.1016/S0006-8993(00)02387-8; HERVE D, 1993, J NEUROSCI, V13, P2237, DOI 10.1523/jneurosci.13-05-02237.1993; HERVE D, 1995, MOL BRAIN RES, V32, P125, DOI 10.1016/0169-328X(95)00070-9; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Ho MKC, 1998, BIOL SIGNAL RECEPT, V7, P80; Hornquist CE, 1997, J IMMUNOL, V158, P1068; Jantzen HM, 1999, BLOOD, V94, p618A; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Johnson GJ, 1996, BIOCHEM J, V318, P1023, DOI 10.1042/bj3181023; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; Kano M, 1998, P NATL ACAD SCI USA, V95, P15724, DOI 10.1073/pnas.95.26.15724; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Knall C, 1998, J CELL BIOCHEM, P137; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; Lem J., 1998, IOVS, V39, pS644; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lindemann B, 1996, CURR BIOL, V6, P1234, DOI 10.1016/S0960-9822(96)00704-X; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Ohman L, 2000, SCAND J IMMUNOL, V52, P80; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; ROUSTAN P, 1995, NEUROREPORT, V6, P1837, DOI 10.1097/00001756-199510020-00004; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sasaki T, 2000, NATURE, V406, P897, DOI 10.1038/35022585; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; SPANGRUDE GJ, 1984, J IMMUNOL, V132, P354; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Tanaka J, 2000, EUR J NEUROSCI, V12, P781, DOI 10.1046/j.1460-9568.2000.00959.x; Valenzuela D, 1997, P NATL ACAD SCI USA, V94, P1727, DOI 10.1073/pnas.94.5.1727; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Watanabe M, 1998, EUR J NEUROSCI, V10, P2016, DOI 10.1046/j.1460-9568.1998.00213.x; Weinstein LS, 1999, TRENDS ENDOCRIN MET, V10, P81, DOI 10.1016/S1043-2760(98)00124-6; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Ye CP, 1999, J MOL CELL CARDIOL, V31, P1771, DOI 10.1006/jmcc.1999.1015; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zhuang XX, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-16-j0001.2000	89	63	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1635	1642		10.1038/sj.onc.1204189	http://dx.doi.org/10.1038/sj.onc.1204189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313911				2022-12-28	WOS:000168089800014
J	Whitehead, IP; Zohn, IE; Der, CJ				Whitehead, IP; Zohn, IE; Der, CJ			Rho GTPase-dependent transformation by G protein-coupled receptors	ONCOGENE			English	Article						gene transfer assays; Dbl family proteins	NUCLEOTIDE EXCHANGE FACTOR; CONSTITUTIVELY ACTIVATING MUTATION; HETEROTRIMERIC G-PROTEINS; SERUM RESPONSE FACTOR; MUTANT ALPHA-SUBUNIT; CELL LUNG-CANCER; SWISS 3T3 CELLS; RAS TRANSFORMATION; BINDING PROTEIN; THROMBIN RECEPTOR	G protein coupled receptors (GPCRs) constitute the largest family of cell surface receptors, with more than 1000 members, and are responsible for converting a diverse array of extracellular stimuli into intracellular signaling events. Most members of the family have defined roles in intermediary metabolism and generally perform these functions in well-differentiated cells. However, there is an increasing awareness that some GPCRs can also regulate proliferative signaling pathways and that chronic stimulation or mutational activation of receptors can lead to oncogenic transformation. Activating mutations in GPCRs are associated with several types of human tumors and some receptors exhibit potent oncogenic activity due to agonist overexpression, Additionally, expression screening analyses for novel oncogenes identified GPCRs whose expression causes the oncogenic transformation of NIH3T3 mouse fibroblasts, These include Mas, G2A, and the PAR-1 thrombin receptor. In this review we summarize the signaling and transforming properties of these GPCR oncoproteins. What has emerged from these studies is the delineation of a GTPase cascade where transforming GPCRs cause aberrant growth regulation via activation of Rho family small GTPases.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; Rockefeller Univ, Mol Embryol Lab, New York, NY 10021 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rockefeller University; University of North Carolina; University of North Carolina Chapel Hill	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.			Zohn, Irene/0000-0001-7688-682X; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA55008, CA77493, CA63071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071, R01CA055008, R29CA077493, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRASS LF, 1998, ANN NEW YORK ACAD SC; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHARDIN P, 1993, GTPASES BIOL, V1, pCH12; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V66, P184; CRESPO P, 1994, NATURE, V379, P557; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; del Peso L, 1997, ONCOGENE, V15, P3047; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2664; Ellis S, 2000, CURR BIOL, V10, P1387, DOI 10.1016/S0960-9822(00)00777-6; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAHMOUD S, 1991, CANCER RES, V51, P1798; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; MARTIN CB, 2001, IN PRESS ONCOGENE; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MONNOT C, 1991, MOL ENDOCRINOL, V5, P1477, DOI 10.1210/mend-5-10-1477; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; POYNER DR, 1990, BIOCHEM J, V271, P605, DOI 10.1042/bj2710605; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROSS PC, 1990, P NATL ACAD SCI USA, V87, P3052, DOI 10.1073/pnas.87.8.3052; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; SEITZ JF, 1991, J CLIN GASTROENTEROL, V13, P1541; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANOBBERGHENSCHILLING E, 1993, THROMB HAEMOSTASIS, V70, P163; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	88	72	77	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1547	1555		10.1038/sj.onc.1204188	http://dx.doi.org/10.1038/sj.onc.1204188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313901				2022-12-28	WOS:000168089800004
J	Sawada, M; Nakashima, S; Kiyono, T; Nakagawa, M; Yamada, J; Yamakawa, H; Banno, Y; Shinoda, J; Nishimura, Y; Nozawa, Y; Sakai, N				Sawada, M; Nakashima, S; Kiyono, T; Nakagawa, M; Yamada, J; Yamakawa, H; Banno, Y; Shinoda, J; Nishimura, Y; Nozawa, Y; Sakai, N			p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells	ONCOGENE			English	Article						ceramide; glioma; neutral sphingomyelinase; p53; reactive oxygen species	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; INDUCED APOPTOSIS; HYDROGEN-PEROXIDE; P53-INDUCED APOPTOSIS; CASPASE ACTIVATION; GROWTH ARREST; DEATH; INHIBITION	The present study was designed to elucidate the relationship between p53 and ceramide, both of which are involved in apoptotic signaling, Treatment of human glioma cells with etoposide caused apoptosis only in cells expressing functional p53. p53 activation was followed by the formation of reactive oxygen species (ROS), superoxide anion (O-2(-.)) measured by hydroethidium oxidation into ethidium and hydrogen peroxide (H2O2) measured by oxidation of 2',7'-dichlorofluorescin (DCFH) into 2',7'-dichlorofluorescein (DCF), which was accompanied with ceramide generation through the activation of neutral, but not acid, sphingomyelinase. Superoxide dismutase (SOD), a selective antioxidant for O-2(-.) had no effects on p53 expression but inhibited ceramide generation and apoptotic cell death caused by etoposide, However, catalase, a specific antioxidant for H2O2, only weakly inhibited and sodium formate, a hydroxyl radical ((OH)-O-.) scavenger, unaffected etoposide-induced apoptosis, Like etoposide-induced cell death, treatment of glioma cells with the O-2(-.)-releasing agent, pyrogallol, induced typical apoptosis and ceramide generation even in the presence of catalase, In contrast, human glioma cells lacking functional p53, either due to mutation or the expression of E6 protein of human papillomavirus, were highly resistant to etoposide and exhibited no significant change in the ceramide level. Moreover, expression of functional p53 protein in glioma cells expressing mutant p53 using a temperature-sensitive human p53(Val138) induced ceramide accumulation by the activation of neutral sphingomyelinase which was dependent on the generation of O-2(-.), Taken together, these results suggest that p53 may modulate ceramide generation by activation of neutral sphingomyelinase through the formation of O-2(-.), but not its downstream compounds H2O2 or (OH)-O-..	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Aichi Canc Ctr, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Int Inst Biotechnol, Mitake, Gifu 5050116, Japan	Gifu University; Gifu University; Aichi Cancer Center	Sawada, M (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, Tsukasamachi 40, Gifu 5008705, Japan.		Kiyono, Tohru/H-5834-2011					BOREK C, 1987, British Journal of Cancer, V55, P74; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKEL RH, 1992, CANCER RES, V52, P1427; GomezManzano C, 1996, CANCER RES, V56, P694; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Jacobs S, 1996, IN SESSION-PSYCHOTH, V2, P21; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Narayanan PK, 1997, CANCER RES, V57, P3963; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAMAKRISHNAN N, 1992, J IMMUNOL, V148, P1817; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; VAVSSIARE JL, 1994, P NATL ACAD SCI USA, V91, P11752; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WALKER PR, 1991, CANCER RES, V51, P1078; Xie YW, 1998, CIRC RES, V82, P891; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zhang P, 1997, J BIOL CHEM, V272, P9609	53	89	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1368	1378		10.1038/sj.onc.1204207	http://dx.doi.org/10.1038/sj.onc.1204207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313880				2022-12-28	WOS:000167495000010
J	Yan, W; Kero, J; Suominen, J; Toppari, J				Yan, W; Kero, J; Suominen, J; Toppari, J			Differential expression and regulation of the retinoblastoma family of proteins during testicular development and spermatogenesis: roles in the control of germ cell proliferation, differentiation and apoptosis	ONCOGENE			English	Article						retinoblastoma protein family; spermatogenesis; cell cycle; apoptosis; differentiation	MESSENGER-RIBONUCLEIC-ACID; STAGE-SPECIFIC EXPRESSION; KIT RECEPTOR; ANDROGEN RECEPTOR; MOLECULAR-CLONING; SURVIVAL FACTOR; LEYDIG-CELLS; MICE LACKING; GENE FAMILY; C-KIT	Normal spermatogenesis is highly dependent on well-balanced germ cell proliferation, differentiation, and apoptosis, However, the molecular mechanisms that govern these processes are largely unknown. Retinoblastoma family proteins (pRb, p107 and p130) are potentially important regulators of cell growth, differentiation and apoptosis, pRb has been shown to be expressed in the rat testis and involved in the regulation of spermatogenesis, In the present study, the expression and localization of the other two pRb family members, p107 and p130, were analysed at both mRNA and protein levels during testicular development and spermatogenesis using Northern, Western blotting, immunohistochemistry, and in situ hybridization, Furthermore, changes of levels and phosphorylation status of pRb family proteins in response to growth suppression and/or apoptosis induction were investigated using a seminiferous tubule culture system and three animal models, Our data suggest that: (1) pRb family proteins are differentially expressed in the rat testis and they function in a cell-type-specific manner during testicular development and spermatogenesis; (2) they participate in the control of germ cell cycle and act in a cell cycle-phase-specific fashion during germ cell proliferation, and (3) they are also involved in the regulation of apoptosis of germ cells and Leydig cells.	Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland	University of Turku; University of Turku	Toppari, J (corresponding author), Univ Turku, Dept Physiol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.		Yan, Wei/G-1618-2011; kero, jukka/G-3448-2014	kero, jukka/0000-0001-8767-7222				Beumer TL, 1999, ENDOCRINOLOGY, V140, P1834, DOI 10.1210/en.140.4.1834; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hakovirta H, 1999, ENDOCRINOLOGY, V140, P1492, DOI 10.1210/en.140.3.1492; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARDY MP, 1989, ENDOCRINOLOGY, V124, P762, DOI 10.1210/endo-124-2-762; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; Huppi K, 1996, MAMM GENOME, V7, P353, DOI 10.1007/s003359900102; JACKSON CM, 1984, J REPROD FERTIL, V71, P393; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Krishnamurthy H, 1998, J ANDROL, V19, P710; LeCouter JE, 1996, ONCOGENE, V12, P1433; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; McKinnell C, 1997, INT J ANDROL, V20, P171; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PARVINEN M, 1986, INT REV CYTOL, V104, P115, DOI 10.1016/S0074-7696(08)61925-7; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Stiegler P, 1998, J CELL BIOCHEM, P30; Suter L, 1998, ARCH TOXICOL, V72, P791, DOI 10.1007/s002040050575; TAJIMA Y, 1994, J REPROD FERTIL, V102, P117, DOI 10.1530/jrf.0.1020117; Teerds K. J., 1996, LEYDIG CELL, P203; TENASEMPERE M, 1994, ENDOCRINOLOGY, V135, P1018, DOI 10.1210/en.135.3.1018; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Vincent S, 1998, DEVELOPMENT, V125, P4585; Yan W, 2000, DEV BIOL, V227, P169, DOI 10.1006/dbio.2000.9885; Yan W, 1997, MOL CELL ENDOCRINOL, V132, P137, DOI 10.1016/S0303-7207(97)00129-9; Yan W, 2000, MOL ENDOCRINOL, V14, P682, DOI 10.1210/me.14.5.682; Yan W, 2000, J CELL SCI, V113, P161; Yan W, 1999, ENDOCRINOLOGY, V140, P1499, DOI 10.1210/en.140.3.1499; Yan W, 2000, MOL CELL ENDOCRINOL, V165, P115, DOI 10.1016/S0303-7207(00)00257-4; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	48	36	37	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1343	1356		10.1038/sj.onc.1204254	http://dx.doi.org/10.1038/sj.onc.1204254			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313878				2022-12-28	WOS:000167495000008
J	Chen, XB; Zheng, YM; Zhu, JH; Jiang, JY; Wang, J				Chen, XB; Zheng, YM; Zhu, JH; Jiang, JY; Wang, J			p73 is transcriptionally regulated by DNA damage, p53, and p73	ONCOGENE			English	Article						p53; p73; DNA damage; transcriptional regulation	KINASE C-ABL; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; IDENTIFICATION; PROTEIN; DOMAIN; CELLS; GENES	p73 is a member of the p53 family, Recent studies have shown that DNA damage can stabilize p73 protein and enhance p73-mediated apoptosis in a c-Abl dependent manner. To determine what regulates p73 transcriptionally, we analysed the expression of p73 in several cell lines following genotoxic stresses. We found that p73 is induced in certain cell lines when treated with therapeutic DNA damaging agents. We also found that p53 and p73, but not mutant p53(R249S) and p73 beta 292, directly induce the expression of the p73 gene. In addition, we found one potential p53-binding site in the promoter of the p73 gene. This binding site is responsive to p53, p73, and DIVA damage. Taken together, these data suggest that p73 is transcriptionally regulated by DNA damage and p53, and is autoregulated.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [R01 CA81237, CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069, R01CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	23	84	86	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					769	774		10.1038/sj.onc.1204149	http://dx.doi.org/10.1038/sj.onc.1204149			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314010				2022-12-28	WOS:000166806000012
J	Pucci, S; Mazzarelli, P; Rabitti, C; Giai, M; Gallucci, M; Flammia, G; Alcini, A; Altomare, V; Fazio, VM				Pucci, S; Mazzarelli, P; Rabitti, C; Giai, M; Gallucci, M; Flammia, G; Alcini, A; Altomare, V; Fazio, VM			Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies	ONCOGENE			English	Article						Ku70/80 heterodimer; DNA repair; DNA double-strand breaks; DNA-PK; human tumors	DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; KU-PROTEIN; V(D)J RECOMBINATION; PROGNOSTIC MARKERS; CELL-SURFACE; ANTIGEN-KU; CANCER; AUTOANTIGEN; REPAIR	The Ku70/80 heterodimer is the regulatory subunit of the DNA-dependent protein kinase (DNA-PK) and its DNA-binding activity mediates DNA double-strand breaks repair. Although Ku80 was recently proposed as a caretaker gene involved in the control of genome integrity, no data are available on Ku70/80 DNA-binding activity in human tumors. Heterodimer DNA-binding activity and protein expression were assayed by electrophoretic-mobility-shift-assay (EMSA) and Western blot analysis, in nuclear and cytoplasmic extracts from eight breast, seven bladder primary tumors and three metastatic nodes from breast cancers. Corresponding normal tissues of the same patients were used as controls. Ten out of 15 tumors showed nuclear Ku-binding activity 3-10 times higher than in the normal tissues, irrespective of bladder or breast origin. Conversely, in 5/15 primary tumors and in all the metastatic nodes analysed, nuclear Ku-activity was 1.5-4.5-fold lower than in the corresponding normal tissues. Cytoplasmic heterodimer activity significantly differed between tumor and normal tissues, displaying a 2-10-fold increase in neoplastic tissues. Three different patterns combining both Ku expression and activity with tumor characteristics were identified. In low aggressive breast tumors p70/p80 proteins were expressed in tumor but not in normal tissues. The heterodimer binding-activity matched the protein levels. In non-invasive bladder carcinomas no significant differences in protein expression between tumor and the corresponding normal tissues were found, however heterodimer binding-activity was increased in tumor samples. In breast and bladder tumors, at the advanced stage and in node metastases, the binding activity was strongly reduced in tumor biopsies, however no differences mere demonstrated between normal and tumor protein levels, Our results suggest a different modulation of Ku70/80 DNA-binding activity in human neoplastic tissues, possibly related to tumor progression. Findings provide further data on tissue-specific protein expression and post-translational regulation of heterodimer activity.	CNR, Inst Expt Med, I-00133 Rome, Italy; Lab Mol Med & Biotechnol, I-00155 Rome, Italy; Lab Histopathol, I-00155 Rome, Italy; Dept Urol, I-00155 Rome, Italy; Dept Gen Surg, I-00155 Rome, Italy; IRCCS H Casa Sollievo Sofferenza, Lab Mol Pathol, I-71013 San Giovanni Rotondo, FG, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Casa Sollievo Della Sofferenza	Fazio, VM (corresponding author), CNR, Inst Expt Med, Via Fosso Cavaliere 100, I-00133 Rome, Italy.		Pucci, Sabina/J-2542-2012; Fazio, Vito Michele VMF/H-3007-2016; Gallucci, Michele/K-9600-2016	Fazio, Vito Michele VMF/0000-0002-7751-1867; Altomare, Vittorio/0000-0002-9839-4129; Gallucci, Michele/0000-0002-3637-6531; Pucci, Sabina/0000-0002-2418-6482				Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; Dahiya R, 1998, BREAST CANCER RES TR, V52, P185, DOI 10.1023/A:1006101729631; DALZIEL RG, 1992, AUTOIMMUNITY, V13, P265, DOI 10.3109/08916939209112334; DEVITA R, 1991, EUR UROL, V19, P65; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frasca D, 1998, MECH AGEING DEV, V100, P197, DOI 10.1016/S0047-6374(97)00137-1; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hwang BJ, 1999, METH MOL B, V113, P103; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Kessel David, 1994, In Vivo (Attiki), V8, P829; Kinsella AR, 1997, BRIT J CANCER, V75, P935, DOI 10.1038/bjc.1997.164; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Koike M, 1999, J CELL SCI, V112, P4031; Korkolopoulou P, 1997, PATHOL RES PRACT, V193, P767, DOI 10.1016/S0344-0338(97)80055-6; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Moll U, 1999, ONCOGENE, V18, P3114, DOI 10.1038/sj.onc.1202640; MORGAN WF, 1995, CANCER METAST REV, V14, P49, DOI 10.1007/BF00690211; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; ONEILL KL, 1992, MED LAB SCI, V49, P244; POWELL SN, 1993, CYTOTECHNOLOGY, V12, P325, DOI 10.1007/BF00744671; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; SATO T, 1991, CANCER RES, V51, P5794; Sekowski JW, 1998, CANCER RES, V58, P3259; Teoh G, 1998, J CLIN INVEST, V101, P1379; Tovari J, 1998, CELL SIGNAL, V10, P277, DOI 10.1016/S0898-6568(97)00128-9; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Wong SWJ, 1999, PATHOLOGY, V31, P90, DOI 10.1080/003130299105241; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yoo S, 1998, BIOCHEMISTRY-US, V37, P1336, DOI 10.1021/bi972100w; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	43	83	84	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					739	747		10.1038/sj.onc.1204148	http://dx.doi.org/10.1038/sj.onc.1204148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314007				2022-12-28	WOS:000166806000009
J	Komatsu, M; Jepson, S; Arango, ME; Carraway, CAC; Carraway, KL				Komatsu, M; Jepson, S; Arango, ME; Carraway, CAC; Carraway, KL			Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor	ONCOGENE			English	Article						Muc4; apoptosis; ErbB2; xenotransplanted tumor; tumor growth; sialomucin complex	SURFACE GLYCOPROTEIN COMPLEX; MAMMARY ADENOCARCINOMA CELLS; SIALOMUCIN COMPLEX; EXTRACELLULAR-MATRIX; RAT MUC4; MOLECULAR-CLONING; EPITHELIAL-CELLS; FACTOR-BETA; EXPRESSION; MEMBRANE	Overexpression of the membrane mucin MUC4/Sialo-mucin complex (SMC) has been observed during malignant progression of mammary tumors in both humans and rats, suggesting that deregulation of MUC4/SMC expression might facilitate development of these malignancies, As previously reported, overexpression of SMC results in suppression of both cell adhesion and immune killing of tumor cells, SMC also acts as a ligand for ErbB2/Neu, modulating phosphorylation of the receptor tyrosine kinase in the presence and absence of heregulin. The present studies investigated the effect of Muc4/SMC up-regulation on primary tumor growth using a tetracycline-inducible SMC expression system in a xenotransplanted tumor model. SMC upregulation provoked rapid growth of transfected A375 melanoma in nude mice. Up-regulation of SMC, however, did not significantly increase proliferation of A375 cells in vitro, Instead, a strong suppression of apoptosis was observed in situ in SMC-overexpressing tumors, These data suggest that Muc4/SMC expression promotes tumor growth in vivo at least in part via suppression of tumor cell apoptosis, Importantly, reduction of apoptosis was also observed in vitro, indicating that anti-apoptotic effect of SMC is independent of tumor-host interactions, These findings strongly suggest that SMC up-regulation alters intracellular signaling to favor cell survival, providing for the first time evidence for the regulation of programmed cell death by a gene of the MUC family.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA.			Komatsu, Masanobu/0000-0001-7548-137X	NCI NIH HHS [CA52498, CA74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498, R01CA074072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 1996, BREAST CANCER RES TR, V38, P49, DOI 10.1007/BF01803783; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CARRAWAY KL, 1992, J CELL SCI, V103, P299; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; DHAWAN J, 1995, SOMAT CELL MOLEC GEN, V21, P233, DOI 10.1007/BF02255778; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; HUGGINS JW, 1980, CANCER RES, V40, P1873; Idris N, 2000, J CELL PHYSIOL, V185, P310, DOI 10.1002/1097-4652(200011)185:2<310::AID-JCP16>3.0.CO;2-W; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; PANDEY P, 1995, CANCER RES, V55, P4000; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WU K, 1994, J BIOL CHEM, V269, P11950; WU K, 1994, ONCOGENE, V9, P3139; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	39	106	115	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					461	470		10.1038/sj.onc.1204106	http://dx.doi.org/10.1038/sj.onc.1204106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313977				2022-12-28	WOS:000166562500006
J	Jabbur, JR; Huang, P; Zhang, W				Jabbur, JR; Huang, P; Zhang, W			DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo	ONCOGENE			English	Article						phosphorylation; ionizing radiation; p53; p21	TUMOR-SUPPRESSOR PROTEIN; ONCOPROTEIN MDM2; KINASE; ACTIVATION; STABILITY; APOPTOSIS; RADIATION; DEGRADATION; TERMINUS; DOMAIN	We investigated the induction and physiological role of Ser20 phosphorylation of p53 in response to DNA damage caused by ionizing radiation (IR) or ultraviolet radiation (UV), A polyclonal antibody that specifically recognizes a p53 peptide containing phosphorylated Ser20 was generated and used to detect p53 phosphorylation at Ser20, Western blot analyses of p53 in four cell lines with this antibody revealed that the p53 protein was phosphorylated at Ser20 to a different extent after treatment with IR or UV, The phosphorylation of Ser20 of wild-type p53 correlated with enhanced induction of the p53 downstream target genes p21(WAF1/Cip1) (p21) and mdm-2. These results suggest that DNA damage-induced phosphorylation of p53 at Ser20 enhances the transactivation function of p53 for p21 and mdm-2 in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA55164, CA16672, CA77339, CA67987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R29CA077339, P01CA055164, R29CA067987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WATTHEW JF, 1998, NAT GENET, V19, P175; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	48	46	46	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6203	6208		10.1038/sj.onc.1204017	http://dx.doi.org/10.1038/sj.onc.1204017			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175334				2022-12-28	WOS:000166210500003
J	Varga-Weisz, P				Varga-Weisz, P			ATP-dependent chromatin remodeling factors: Nucleosome shufflers with many missions	ONCOGENE			English	Review						DNA superhelical torsion; chromatin domain; Bromodomain; histone code; DNA repair	YEAST SWI/SNF COMPLEX; SWI-SNF COMPLEX; HISTONE ACETYLATION; IN-VITRO; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; ACTIVATOR BINDING; OCTAMER TRANSFER; GENE-EXPRESSION; ERYTHROID-CELLS	This review addresses recent developments in the field of ATP-dependent chromatin remodeling factors. These factors use the energy of ATP hydrolysis to introduce superhelical torsion into DNA, which suggests a common mechanistic basis of action. Chromatin remodeling factors function both in transcriptional activation and repression, but they may hale roles outside of transcriptional regulation such as DNA repair. A study of the nucleosome dependent ATPase ISWI in yeast illustrates the involvement of ATP-dependent chromatin remodeling in transcriptional repression by setting up inaccessible chromatin structures at promoters. However, factors such as ISWI are also involved in the restructuring of large chromatin domains and even whole chromosomes. Transcriptional regulation by ATP-dependent chromatin remodeling factors occurs in concert with histone modifying enzymes such as histone acetyltransferases and histone deacetylases: In yeast, SWI/SNF targeting is a requirement for histone acetyltransferases activity at promoters that are active at late stages of mitosis, when the chromatin is still condensed, This demonstrates that ATP-dependent remodeling factors facilitate covalent histone modifications. However, they are also regulated by histone modifications and in some circumstances they function in parallel with histone modifications towards the same goal.	Marie Curie Res Inst, Surrey RH8 0TL, England		Varga-Weisz, P (corresponding author), Marie Curie Res Inst, Surrey RH8 0TL, England.			Varga-Weisz, Patrick/0000-0001-7409-8686				Amedeo P, 2000, NATURE, V405, P203, DOI 10.1038/35012108; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brown SA, 1997, GENE DEV, V11, P3116, DOI 10.1101/gad.11.23.3116; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Guschin D, 2000, J BIOL CHEM, V275, P35248, DOI 10.1074/jbc.M006041200; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Janscak P, 2000, J MOL BIOL, V295, P1089, DOI 10.1006/jmbi.1999.3414; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kal AJ, 2000, GENE DEV, V14, P1058; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; Perez-Martin J, 1998, MOL CELL BIOL, V18, P4157, DOI 10.1128/MCB.18.7.4157; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Picketts DJ, 1996, HUM MOL GENET, V5, P1899, DOI 10.1093/hmg/5.12.1899; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	94	102	105	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3076	3085		10.1038/sj.onc.1204332	http://dx.doi.org/10.1038/sj.onc.1204332			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420723				2022-12-28	WOS:000169308500011
J	Reichel, M; Gillert, E; Angermuller, S; Hensel, JP; Heidel, F; Lode, M; Leis, T; Biondi, A; Haas, OA; Strehl, S; Panzer-Grumayer, ER; Griesinger, F; Beck, JD; Greil, J; Fey, GH; Uckun, FM; Marschalek, R				Reichel, M; Gillert, E; Angermuller, S; Hensel, JP; Heidel, F; Lode, M; Leis, T; Biondi, A; Haas, OA; Strehl, S; Panzer-Grumayer, ER; Griesinger, F; Beck, JD; Greil, J; Fey, GH; Uckun, FM; Marschalek, R			Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL	ONCOGENE			English	Article						chromosomal translocation t(4;11); ALL-1/MLL/HRX gene; AF4 gene	ACUTE-LEUKEMIA; CLUSTER REGION; TRANSLOCATION T(4-11); EXON/INTRON STRUCTURE; SEQUENCE-ANALYSIS; 11Q23; IDENTIFICATION; CLEAVAGE	Derivative chromosomes of 40 patients diagnosed with t(4;11) acute lymphoblastic leukemia (ALL),were analysed on the genomic DNA level. Chromosomal breakpoints were identified in most cases within the known breakpoint cluster regions of the involved MLL and AF4 genes, Due to our current knowledge of the primary DNA sequences of both breakpoint cluster regions, specific features were identified at the chromosomal fusion sites, including deletions, inversions and duplications of parental DNA sequences, After separation of all t(4;11) leukemia patients into two age classes (below and above 1 year of age), the analysis of chromosomal fusion sites revealed significant differences in the distribution of chromosomal breakpoints and led to the definition of two hotspot areas within the MLL breakpoint cluster region, This may point to the possibility of different age-linked mechanisms that sere leading to t(4;11) chromosomal translocations. Oncogene (2001) 20, 2900-2907.	Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany; Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Pediat, D-91054 Erlangen, Germany; Osped S Gerardo, Ctr Ric M Tettamanti, I-20052 Monza, MI, Italy; St Anna Kinderspital, CCRI, A-1090 Vienna, Austria; Univ Hosp Gottingen, Div Haematol Oncol, D-37075 Gottingen, Germany; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Childrens Canc Grp, ALL Biol Reference Lab, St Paul, MN 55113 USA	Goethe University Frankfurt; University of Erlangen Nuremberg; University of Erlangen Nuremberg; San Gerardo Hospital; Saint Anna Children's Hospital; University of Gottingen	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, N230,303 Marie-Curie Str 9, D-60439 Frankfurt, Germany.		Biondi, Andrea/AAX-1865-2020; Haas, Oskar/AAM-5794-2020; Biondi, Andrea/K-9997-2016; Marschalek, Rolf/D-3404-2011	Biondi, Andrea/0000-0002-6757-6173; Marschalek, Rolf/0000-0003-4870-3445; Heidel, Florian/0000-0003-2438-1955; Reichel, Martin/0000-0001-7886-2784; Strehl, Sabine/0000-0002-0179-0628; Uckun, Fatih M./0000-0001-9334-183X				BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; Cimino G, 1997, CANCER RES, V57, P2879; Cimino G, 1998, HAEMATOLOGICA, V83, P350; Felix CA, 1997, BLOOD, V90, P4679, DOI 10.1182/blood.V90.12.4679.4679_4679_4686; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GU Y, 1994, CANCER RES, V54, P2327; Leis T, 1998, LEUKEMIA, V12, P758, DOI 10.1038/sj.leu.2401006; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reichel M, 1999, CANCER RES, V59, P3357; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strissel Gbroeker Pamela L., 1996, Blood, V87, P1912; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	19	64	68	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2900	2907		10.1038/sj.onc.1204401	http://dx.doi.org/10.1038/sj.onc.1204401			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420702				2022-12-28	WOS:000168901800005
J	Rodier, A; Rochard, P; Berthet, C; Rouault, JP; Casas, F; Daury, L; Busson, M; Magaud, JP; Wrutniak-Cabello, C; Cabello, G				Rodier, A; Rochard, P; Berthet, C; Rouault, JP; Casas, F; Daury, L; Busson, M; Magaud, JP; Wrutniak-Cabello, C; Cabello, G			Identification of functional domains involved in BTG1 cell localization	ONCOGENE			English	Article						BTG1; NLS; NES; myoblast; cell localization	TRANSCRIPTIONAL REGULATORY COMPLEX; NUCLEAR EXPORT SIGNAL; ARGININE N-METHYLTRANSFERASE; MOLECULAR-CLONING; MESSENGER-RNA; PROTEIN BTG1; LEPTOMYCIN-B; GENE; CRM1; TRANSLOCATION	We have previously shown that BTG1 stimulates myoblast differentiation, In addition, this protein displays a major nuclear localization in confluent myoblasts, decreasing during the early steps of differentiation, and is essentially detected in the cytoplasm of mature myotubes. To identify the domains involved in the cellular trafficking of BTG1, we observed the localization of several BTG1 sequences fused to beta Galactosidase. The highly conserved B box among all members of the BTG family induces a significant nuclear localization of the beta Gal moiety, enhanced by presence of the BTG1 carboxy-terminal sequence. In addition, a functional Nuclear Export Signal (NES) overlaps the B box. Moreover, presence of the first 43 NH2-terminal amino acids reduced the nuclear localization of each chimeric protein tested. Last, the BTG1 amino-terminal domain hears an LxxLL, motif favouring nuclear accumulation, and another region encompassing the A box inhibiting nuclear localization. In contrast to a BTG1 mutant exclusively localized in the cytoplasm, transient expression of a mutant displaying a nuclear Localization enhanced myoblasts withdrawal from the cell cycle and terminal differentiation, thus mimicking the myogenic influence of BTG1, In conclusion, several regions of BTG1 are implicated in its cellular localization, and BTG1 myogenic activity is induced at the nuclear level.	Univ Montpellier 2, ENSAM, INRA,Unite Endocrinol Cellulaire, UMR Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France	Arts et Metiers Institute of Technology; INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Cabello, G (corresponding author), Univ Montpellier 2, ENSAM, INRA,Unite Endocrinol Cellulaire, UMR Differenciat Cellulaire & Croissance, 2 Pl Viala, F-34060 Montpellier 1, France.		berthet, cyril/T-4842-2017	berthet, cyril/0000-0003-3166-3141; Daury, Laetitia/0000-0002-1296-7150; Francois, Casas/0000-0002-5535-8195				ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen PJ, 2000, DEV BIOL, V217, P77, DOI 10.1006/dbio.1999.9521; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Saka Y, 2000, MECH DEVELOP, V93, P27, DOI 10.1016/S0925-4773(00)00260-4; Snedecor G.W., 1961, STAT METHODS; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	41	22	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2691	2703		10.1038/sj.onc.1204398	http://dx.doi.org/10.1038/sj.onc.1204398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420681				2022-12-28	WOS:000168652600010
J	Giambartolomei, S; Covone, F; Levrero, M; Balsano, C				Giambartolomei, S; Covone, F; Levrero, M; Balsano, C			Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein	ONCOGENE			English	Article						HCV; core; Raf; Erk1/2; EGF; HCC	HUMAN HEPATOCELLULAR-CARCINOMA; B VIRUS; TRANSCRIPTION FACTORS; RNA HELICASE; HBX PROTEIN; KINASES; RAS; HEPATOCARCINOGENESIS; INTERACTS; CIRRHOSIS	Chronic hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The HCV capside core is a multifunctional protein with regulatory functions that affects transcription and cell growth in vitro and in vivo. Here, we show that both HCV genotype 1a and 3 core proteins activate MEK1 and Erk1/2 MAP kinases and that the costitutive expression of the HCV core results in a high basal activity of Raf1 and MAP/kinase/ kinase, as determined by endogenous Raf1 in vitro kinase assay and immunodetection of hyperphosphorylated Erk1 and Erk2 even after a serum starvation. Moreover, the activation of both Erk1/2 and the downstream transcription factor Elk-l in response to the mitogenic stimulus EGF is significantly prolonged. The sustained response to EGF in cells expressing the HCV core occurs despite a normal induction of the MAP phosphatases MKP regulatory feedback and is likely due to the costitutive activation of Raf-l activity. The ability of HCV core proteins to directly activate the MAP kinase cascade and to prolong its activity in response to mitogenic stimuli may contribute to the neoplastic transformation of HCV infected liver cells.	Univ Rome La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy; Univ Aquila, Dept Internal Med, I-67100 Laquila, Italy; Univ Cagliari, Dept Internal Med, Cagliari, Italy	Sapienza University Rome; University of L'Aquila; University of Cagliari	Balsano, C (corresponding author), Policlin Umberto I, Med Clin 1, Fdn A Cesalpino, Viale Policlin 155, I-001612 Rome, Italy.		Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875				Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; Colombo M, 1999, J HEPATOL, V31, P25, DOI 10.1016/S0168-8278(99)80370-5; De Francesco R, 1999, J HEPATOL, V31, P47, DOI 10.1016/S0168-8278(99)80374-2; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kalkuhl A, 1998, HEPATOLOGY, V27, P1081, DOI 10.1002/hep.510270425; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; McKillop IH, 1997, HEPATOLOGY, V26, P1484; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NATOLI G, 1994, ONCOGENE, V9, P2837; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Shibata Y, 1999, INT J ONCOL, V14, P1153; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Tamori A, 1999, HEPATOLOGY, V29, P1429, DOI 10.1002/hep.510290520; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999	31	117	122	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2606	2610		10.1038/sj.onc.1204372	http://dx.doi.org/10.1038/sj.onc.1204372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420671				2022-12-28	WOS:000168652500012
J	Ahmad, N; Kalka, K; Mukhtar, H				Ahmad, N; Kalka, K; Mukhtar, H			In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy	ONCOGENE			English	Article						PDT; EGFR; Shc; cell cycle; apoptosis	ACTIVATED PROTEIN-KINASE; MEDIATED APOPTOSIS; INDUCED ABLATION; CARCINOMA-CELLS; MOUSE SKIN; HELA-CELLS; TUMORS; A431; INVOLVEMENT; PROGRESSION	PDT, a new therapeutic procedure for the management of many malignant conditions including skin cancer, involves the administration of a photosensitizing compound followed by illumination of the lesion with visible light, We earlier showed an involvement of: (i) WAF1/ p21-cyclins (D1 and E)-cdk (2 and 6) network; and (ii) Rb/E2F-DP machinery during silicon phthalocyanine (Pc4)-PDT-mediated cell cycle dysregulation and apoptosis of human epidermoid carcinoma (A431) cells, Here, we investigated the involvement of EGFR-pathway during antiproliferative responses of Pc4-PDT in A431 cells and during ablation of murine skin papillomas. Pc4-PDT of A431 cells was found to result in a time-dependent down-modulation of the protein expression and phosphorylation of EGFR and Shc (an immediate downstream molecule in EGFR-pathway), during progressive increase in apoptotic response. To establish the relevance of these in vitro findings to in vivo situations, we subjected chemically- as well as ultraviolet B radiation-induced squamous papillomas in SENCAR and SKH-1 hairless mice, respectively, to Pc4-PDT, and assessed its effect on EGFR-pathway during ablation of these tumors. Pc4-PDT was found to result in a time-dependent: (i) inhibition of protein expressions of EGFR; and (ii) tyrosine phosphorylation of EGFR and Shc; and (iii) induction of apoptosis, during the regression of these tumors, These data suggest the involvement of EGFR-pathway during the antiproliferative effects of PDT, It is tempting to speculate that inhibitors of EGFR could enhance the therapeutic efficacy of PDT.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA051802, P30CA043703, P01CA048735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 48735, P30 CA 43703, R01 CA 51802] Funding Source: Medline; NIAMS NIH HHS [P30 AR 39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Chiu SM, 2000, INT J ONCOL, V16, P423; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Engbrecht BW, 1999, CANCER RES, V59, P4334; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1998, FEBS LETT, V422, P151, DOI 10.1016/S0014-5793(97)01616-5; Gupta S, 1998, CANCER RES, V58, P1785; Hansen LA, 2000, CANCER RES, V60, P3328; Kalka K, 2000, CANCER RES, V60, P5984; Kalka K, 2000, J AM ACAD DERMATOL, V42, P389, DOI 10.1016/S0190-9622(00)90209-3; Kawaguchi T, 2000, BRIT J CANCER, V82, P418; Kessler JJ, 1998, LAND DEGRAD DEV, V9, P95, DOI 10.1002/(SICI)1099-145X(199803/04)9:2<95::AID-LDR289>3.0.CO;2-Y; Kim HRC, 1999, CANCER RES, V59, P3429; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nakamura T, 1996, ONCOGENE, V13, P1111; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Whitacre CM, 2000, CLIN CANCER RES, V6, P2021; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x; Zhang WG, 1999, CANCER LETT, V138, P189, DOI 10.1016/S0304-3835(99)00013-0	33	54	57	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2314	2317		10.1038/sj.onc.1204313	http://dx.doi.org/10.1038/sj.onc.1204313			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402326				2022-12-28	WOS:000168404500013
J	Goetz, F; Tzeng, YJ; Guhl, E; Merker, J; Graessmann, M; Graessmann, A				Goetz, F; Tzeng, YJ; Guhl, E; Merker, J; Graessmann, M; Graessmann, A			The SV40 small t-antigen prevents mammary gland differentiation and induces breast cancer formation in transgenic mice; truncated large T-antigen molecules harboring the intact p53 and pRb binding region do not have this effect	ONCOGENE			English	Article						SV40 small t-antigen; transgenic animals; cyclin D1; mammary gland differentiation; breast cancer	PROTEIN PHOSPHATASE 2A; CELL-GROWTH; TRANSFORMATION; P21(WAF1/CIP1); INVOLUTION; APOPTOSIS; CARCINOMA; MUTATION; ANIMALS	We report here for the first time, that the SV40 small t-antigen inhibits mammary gland differentiation during mid-pregnancy and that about. 10% of multiparous WAP-SVt transgenic animals develop breast tumors with latencies ranging from 10-17 months, Cyclin D1 is deregulated and over expressed in the small t-antigen positive mammary gland epithelial cells (ME-cells) and in the breast tumor cells, SV40 small t-antigen immortalized ME-cells (t-ME-cells) exhibit a strong intranuclear cyclin D1 staining, also in the absence of external growth factors and the cells continue to divide for several days without serum. In addition, the expression rate of cyclin E acid p21(Waf1) but not of p53 is increased, Coimmunoprecipitation experiments revealed that p21(Waf1) is mainly associated with the cyclin D/CDK4 but not with the cyclin E/CDK2 complex, WAP-SVT transgenic animals exhibit an almost regular mammary gland development until late pregnancy but the majority of the ME-cells are eliminated by apoptosis during the early lactation period. Tumor formation is delayed and less efficient than in T/t-antigen positive animals, Sequestration of p53 and pRb by the N-terminal truncated T-antigen molecules (T1-antigen and T2-antigen) does not affect mammary gland differentiation and the transgenic animals (WAP-SVBst-Bam) do not develop breast tumors.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Free Univ Berlin, Inst Anat, D-14195 Berlin, Germany	Free University of Berlin; Tzu Chi University; Free University of Berlin	Graessmann, A (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.							CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Garcia A, 2000, J BIOL CHEM, V275, P9385, DOI 10.1074/jbc.275.13.9385; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; MARTIN RG, 1979, J VIROL, V31, P596, DOI 10.1128/JVI.31.3.596-607.1979; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; Santarelli R, 1996, ONCOGENE, V12, P495; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; SENKITI S, 1979, BIOCHIM BIOPHYS ACTA, V582, P79; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0	26	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2325	2332		10.1038/sj.onc.1204355	http://dx.doi.org/10.1038/sj.onc.1204355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402328				2022-12-28	WOS:000168404500015
J	Santos, J; Herranz, M; Fernandez, M; Vaquero, C; Lopez, P; Fernandez-Piqueras, J				Santos, J; Herranz, M; Fernandez, M; Vaquero, C; Lopez, P; Fernandez-Piqueras, J			Evidence of a possible epigenetic inactivation mechanism operating on a region of mouse chromosome 19 in gamma-radiation-induced thymic lymphomas	ONCOGENE			English	Article						Pten; Cd95; Jak2; epigenetic inactivation; gamma-irradiation; mouse thymic lymphomas; chromosome 19	TUMOR-SUPPRESSOR GENE; T-CELL LYMPHOMAS; INHIBITOR P15(INK4B); PROSTATE-CANCER; FREQUENT LOSS; DISTAL PART; PTEN/MMAC1; MUTATION; PTEN; MICE	Loss of heterozygosity (LOH) analysis, performed in 68 gamma -radiation-induced primary thymic lymphomas of F1 hybrid mice, provided evidence of significant LOH on chromosome 19 in a region defined by the D19Mit106 (22 cM) and D19Mit100 (27 cM) markers (Thymic Lymphoma Suppressor Region 8, TLSR8), Cd95 and Pten, two genes mapped at this region, were inactivated in a vast majority of these tumors (85.3% for Cd95 and 61.8% for Pten), Moreover, altered expression of Cd95 and Pten occurred concomitantly in 34 of 68 (50%) thymic lymphomas suggesting a coordinated mechanism of inactivation of these genes. Surprisingly, we also found that Jak2, a proto-oncogene located between Cd95 and Pten, was simultaneously inactivated in a significant fraction of the tumors analysed (24 of 34, 70.6%). Taken together these findings and the lack of mutations in the coding sequences of the mentioned genes clearly suggest a possible regional epigenetic inactivation mechanism on mouse chromosome 19 operating during the development of these tumors.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		LORENZO, CONCEPCION VAQUERO/L-2827-2017; Herranz, Michel/L-2561-2016; Santos, Javier/ABF-5755-2021	Santos, Javier/0000-0002-4168-6251				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Butler LM, 2000, BRIT J CANCER, V82, P131; Cairns P, 1997, CANCER RES, V57, P4997; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FEINBERG AP, 1995, J NATL CANC I MONOGR, V17, P21; Herranz M, 1999, CANCER RES, V59, P2068; Liu R, 2000, ONCOGENE, V19, P571, DOI 10.1038/sj.onc.1203364; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Melendez B, 1999, ONCOGENE, V18, P4166, DOI 10.1038/sj.onc.1202826; Okumoto M, 1999, CANCER LETT, V135, P223, DOI 10.1016/S0304-3835(98)00305-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Sachs RK, 2000, TRENDS GENET, V16, P143, DOI 10.1016/S0168-9525(99)01960-5; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yu CL, 1997, J IMMUNOL, V159, P5206	24	23	23	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2186	2189		10.1038/sj.onc.1204297	http://dx.doi.org/10.1038/sj.onc.1204297			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360203				2022-12-28	WOS:000168116700014
J	Munoz, P; Baus, F; Piette, J				Munoz, P; Baus, F; Piette, J			Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193	ONCOGENE			English	Article						cell cycle; DNA topoisomerase II; Ku antigen; DNA replication	DEPENDENT PROTEIN-KINASE; CELL-CYCLE; MAMMALIAN-CELLS; V(D)J RECOMBINATION; M-PHASE; CHROMOSOME STRUCTURE; ENZYME; SEGREGATION; CHECKPOINT; MECHANISM	Ku antigen is necessary for DNA double-strand break (DSB) repair through its ability to bind DNA ends with high affinity and to recruit the catalytic subunit of DNA-PK to the DSBs, Ku-deficient cells are hypersensitive to agents causing DSBs in DNA but also to the DNA topoisomerase II (topo II) inhibitor ICRF-193, which does not induce DSBs, This suggests a new role of Ku antigen, that is independent of DSB repair by DNA-PK. Here we characterize the basis for the hypersensitivity of Ku-deficient cells to ICRF-193, Chromosome condensation and segregation, which are dependent on topo II, but also the catalytic activity of topo II in Late S-G2 were inhibited to a comparable extent when ICRF-193 was applied to Ku-deficient cells or wild-type cells. However, mutant cells arrested in G2 by ICRF-193 treatment were unable to progress into M phase upon drug removal, although drug-trapped topo II complexes were removed from DNA and the two isoforms of topo II recovered their catalytic activity as in wild-type cells, The reversibility of G2 arrest was recovered by complementation of mutant cells with a human Ku86 cDNA, Notably, chromosome condensation was abnormal in Ku-deficient cells after suppression of the G2 arrest by caffeine, even in the absence of ICRF-193, These results reflect the involvement of Ku-antigen in the cellular response to topo II inhibition, more particularly in relieving G2 arrest caused by topo II inhibition in late S/G2 and the subsequent recovery of chromosome condensation.	Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piette, J (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 24,1919 Route Mende, F-34293 Montpellier 5, France.							Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; ANDOH T, 1993, BIOTECHNOL APPL BIOC, V18, P165; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Andreassen PR, 1997, J CELL BIOL, V136, P29, DOI 10.1083/jcb.136.1.29; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CLARKE DJ, 1993, J CELL SCI, V105, P563; Cooper MP, 2000, GENE DEV, V14, P907; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Duguet M, 1997, J CELL SCI, V110, P1345; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Errami A, 1996, MOL CELL BIOL, V16, P1519; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GORBSKY GJ, 1994, CANCER RES, V54, P1042; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Patel S, 2000, MOL PHARMACOL, V58, P560, DOI 10.1124/mol.58.3.560; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; TANABE K, 1991, CANCER RES, V51, P4903; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Wu L, 1999, CURR BIOL, V9, pR518, DOI 10.1016/S0960-9822(99)80325-X; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239	47	7	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					1990	1999		10.1038/sj.onc.1204262	http://dx.doi.org/10.1038/sj.onc.1204262			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360183				2022-12-28	WOS:000168043800007
J	Shao, RG; Cao, CX; Nieves-Neira, W; Dimanche-Boitrel, MT; Solary, E; Pommier, Y				Shao, RG; Cao, CX; Nieves-Neira, W; Dimanche-Boitrel, MT; Solary, E; Pommier, Y			Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells	ONCOGENE			English	Article						Bar; caspase; FADD; z-VAD; nuclease; programmed cell death	DRUG-INDUCED APOPTOSIS; CANCER-CELLS; TOPOISOMERASE-I; CUTTING EDGE; DNA-DAMAGE; WILD-TYPE; DEATH; CD95; CYTOTOXICITY; EXPRESSION	The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line. CPT-induced apoptosis was associated with high molecular weight DNA fragmentation as measured by filter elution, This fragmentation was inhibited by the caspase inhibitor, z-VAD-fmk and by cycloheximide, which also prevented proteolytic activation of caspase-3 and poly(ADP-ribose)polymerase cleavage. Under such conditions, Fas, Fas ligand, Bar, and p21 expression were increased and Fas recruited the FADD adaptor. Fas expression increase was blocked by cycloheximide but not by z-VAD-fmk, consistent with caspase activation downstream from Fas, Treatment of HT29 cells with Fast or with the CH-11 agonistic anti-Fas antibody potentiated the apoptotic response of cells treated with CPT, The anti-Fas blocking antibody ZB4 and the Fas-ligand inhibitor failed to protect HT29 cells from CPT-induced apoptosis, Such a protection was obtained by transient expression of constructs encoding a dominant-negative mutant of FADD, FADD in an antisense orientation and E8 or MC159 viral proteins that inhibit Fas-induced apoptosis at the level of FADD and procaspase-8, respectively. Together, these data show that topoisomerase I-mediated DNA damage-induced apoptosis involves activation of the Fas pathway without detectable Fas-ligand requirement in CPT-treated cells.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Fac Med & Pharm Dijon, INSERM U517, Dept Biol & Therapy Canc, Dijon, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 4E28, Bethesda, MD 20892 USA.		Dimanche-Boitrel, Marie-Therese M/I-4642-2015	Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Favre-Felix N, 2000, J IMMUNOL, V164, P5023, DOI 10.4049/jimmunol.164.10.5023; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Goldwasser F, 1996, CANCER RES, V56, P4430; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Khodarev NN, 1998, INT J RADIAT BIOL, V73, P455; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Memon SA, 1998, J IMMUNOL, V160, P2046; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MIYASHITA T, 1995, CELL, V80, P293; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OConnor PM, 1997, CANCER RES, V57, P4285; OCONNOR PM, 1991, CANCER COMMUN, V3, P233, DOI 10.3727/095535491820873083; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Rusnak JM, 1996, MOL PHARMACOL, V49, P244; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SHIMIZU T, 1995, CANCER RES, V55, P228; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Villunger A, 1997, CANCER RES, V57, P3331; ZHAN QM, 1995, INT J ONCOL, V6, P937	44	70	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1852	1859		10.1038/sj.onc.1204264	http://dx.doi.org/10.1038/sj.onc.1204264			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313933				2022-12-28	WOS:000167908400006
J	Cures, A; House, C; Kanei-Ishii, C; Kemp, B; Ramsay, RG				Cures, A; House, C; Kanei-Ishii, C; Kemp, B; Ramsay, RG			Constitutive c-Myb amino-terminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle	ONCOGENE			English	Article						c-Myb; casein kinase 2; DNA binding; phosphorylation	PROTO-ONCOGENE; LEUCINE-ZIPPER; MESSENGER-RNA; EXPRESSION; PROLIFERATION; ACTIVATION; PROTEINS; GENE; DIFFERENTIATION; INHIBITION	The c-myb gene encodes a transcription factor that is central to hematopoietic cell growth, Phosphorylation of c-Myb by casein kinase 2 (CK2) at serines 11 and 12 has been variously implicated in the regulation of DNA binding. However, it is unclear when c-Myb phosphorylation at serines II and 12 occurs during the cell cycle and how this is regulated, We generated specific antisera that recognize phosphoserines II and 12 of c-Myb, C-Myb protein levels, extent of CK2 phosphorylation and DNA binding were then monitored following mitogenic stimulus and passage through the cell cycle in normal peripheral T-cells and the T leukemia cell line CCRF-CEM, We found that endogenous c-Myb is constitutively phosphorylated at serines 11 and 12, The amount of phosphorylated c-Myb correlates with DNA binding activity in cycling CEM cells but not upon entry of T-cells into the cell cycle, Exogenous expression of c-Myb with substitutions of serines 11 and 12 with glutamic acid or alanine had no effect on the transactivation of a c-Myb responsive reporter. These data strongly suggest that c-Myb is constitutively phosphorylated on serines 11 and 12 by CK2 or like activity and is not regulated during the cell cycle.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3000, Australia; RIKEN, Tsukuba Inst, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan	Peter Maccallum Cancer Center; RIKEN	Ramsay, RG (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, 481 Little Lonsdale St, Melbourne, Vic 3000, Australia.		Ramsay, Robert G/C-3291-2015; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Ramsay, Robert G/0000-0001-5003-0433; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1991, BLOOD, V77, P149; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCARTHY RE, 1965, EXP CELL RES, V40, P197, DOI 10.1016/0014-4827(65)90316-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NORMAN MR, 1977, CANCER RES, V37, P3785; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; Ramsay R G, 1995, Methods Mol Biol, V37, P369; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1995, ONCOGENE, V11, P2113; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sala A, 1996, CANCER RES, V56, P1991; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TIGANIS T, 1993, BIOCHIM BIOPHYS ACTA, V1203, P282, DOI 10.1016/0167-4838(93)90095-9; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Zorbas M, 1999, ONCOGENE, V18, P5821, DOI 10.1038/sj.onc.1202971	38	14	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1784	1792		10.1038/sj.onc.1204345	http://dx.doi.org/10.1038/sj.onc.1204345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313925				2022-12-28	WOS:000167750900011
J	Turton, NJ; Judah, DJ; Riley, J; Davies, R; Lipson, D; Styles, JA; Smith, AG; Gant, TW				Turton, NJ; Judah, DJ; Riley, J; Davies, R; Lipson, D; Styles, JA; Smith, AG; Gant, TW			Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance	ONCOGENE			English	Article						multidrug resistance; cDNA microarrays; differential gene expression; genomic amplification; doxorubicin resistance; breast cancer	CANCER-CELLS; P-GLYCOPROTEIN; PATTERNS; OVEREXPRESSION; METASTASIS; INVASION; ANTIGEN; DISPLAY; LINES	The multidrug resistance (MDR) phenotype is a major cause of cancer treatment failure. Here the expressions of 4224 genes were analysed for association with intrinsic or acquired doxorubicin (DOX) resistance. A cluster of overexpressed genes related to DOX resistance was observed. Included in this cluster was ABCB1 the P-glycoprotein transporter protein gene and MMPI (Matrix Metalloproteinase 1), indicative of the invasive nature of resistant cells, and the oxytocin receptor (OXTR), a potential new therapeutic target. Overexpression of genes associated with xenobiotic transformation, cell transformation, cell signalling and lymphocyte activation was also associated with DOX resistance as was estrogen receptor negativity, In all carcinoma cells, compared with HBL100 a putatively normal breast epithelial cell line, a cluster of overexpressed genes was identified which included several keratins, in particular keratins 8 and 18 which are regulated through the ras signalling pathway. Analysis of genomic amplifications and deletions revealed specific genetic alterations common to both intrinsic and acquired DOX resistance including ABCB1, PGY3 (ABCB4) and BAK, The findings shown here indicate new possibilities for the diagnosis of DOX resistance using gene expression, and potential novel therapeutic targets for pharmacological intervention.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Technion Israel Inst Technol, IL-32000 Haifa, Israel	University of Leicester; Technion Israel Institute of Technology	Gant, TW (corresponding author), Univ Leicester, MRC, Toxicol Unit, Lancaster Rd, Leicester LE1 9HN, Leics, England.			Gant, Timothy/0000-0001-9057-4937				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BATIST G, 1986, J BIOL CHEM, V261, P5544; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Blatchford DR, 1999, J CELL PHYSIOL, V181, P304, DOI 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 2000, J PATHOL, V190, P470, DOI 10.1002/(SICI)1096-9896(200003)190:4<470::AID-PATH550>3.0.CO;2-G; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHEN G, 1994, CANCER RES, V54, P4980; Davies R, 1996, BRIT J CANCER, V73, P307, DOI 10.1038/bjc.1996.54; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EISEN MB, 1999, DNA ARRAYS ANAL GENE, P179; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones JL, 1997, INT J ONCOL, V11, P609; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Martin K, 2000, CANCER RES, V60, P2232; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Stephen R, 1998, J MOL ENDOCRINOL, V20, P375, DOI 10.1677/jme.0.0200375; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; Vasudevan S, 1998, J BIOL CHEM, V273, P25413, DOI 10.1074/jbc.273.39.25413; WEINSTEIN RS, 1991, CANCER RES, V51, P2720	31	95	106	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1300	1306		10.1038/sj.onc.1204235	http://dx.doi.org/10.1038/sj.onc.1204235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313874				2022-12-28	WOS:000167495000004
J	Sugibayashi, R; Shimizu, T; Suzuki, T; Yamamoto, N; Hamada, H; Takeda, K				Sugibayashi, R; Shimizu, T; Suzuki, T; Yamamoto, N; Hamada, H; Takeda, K			Upregulation of p21(WAF1/CIP1) leads to morphologic changes and esterase activity in TPA-mediated differentiation of human prostate cancer cell line TSU-Pr1	ONCOGENE			English	Article						prostate cancer; TSU-Prl; differentiation; TPA; p21(WAF1/CIF1)	PROTEIN-KINASE-C; LEUKEMIA-CELLS; DOWN-REGULATION; PHORBOL ESTERS; CYCLE ARREST; MAP KINASE; EXPRESSION; GROWTH; P21; INHIBITOR	We reported previously that human prostate cancer cell line TSU-Pr1 can differentiate into microglia-like cells by 12-O-tetra-decanoylphorbol-13-acetate (TPA) treatment. In this study, we identified a signal transduction pathway involved in TPA-induced TSU-Pr1 cell differentiation and investigated the mechanism of growth arrest that accompanies this differentiation. TPA-induced differentiation and growth arrest of TSU-Pr1 cells were inhibited by treatment with Protein kinase C (PKC) inhibitor GF109203X and mitogen-activated protein (MAP) kinase inhibitor PD98059, Treatment of TSU-Pr1 cells with TPA for 15 min or longer resulted in translocation of PKC alpha, PKC gamma, and PKC epsilon from cytosolic to membrane fraction. Our results suggest that TPA-induced TSU-Pr1 cell differentiation is associated with activation of MAP kinase and PKC alpha, PKC gamma, and PKC epsilon, The mechanism of growth arrest in TSU-Pr1 cells that underwent TPA-induced differentiation were examined for factors in the signaling pathway downstream of MAP kinase that control the cell cycle. Upregulation of p21(WAF1/CIP1) cyclin-dependent kinase inhibitor protein was observed in a manner dependent on PKC or MAP kinase, Moreover, adenovirus-mediated overexpression of recombinant p21(WAF1/CP1) in TSU-Pr1 cells result in growth arrest, morphological change to microglia-like cells, and increased alpha -naphthyl acetate esterase activity, all of which are associated with cellular differentiation. Thus, our results indicate that p21(WAF1/CIP1) mediates TPA-induced growth arrest and differentiation of TSU-Pr1 cells.	Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, Tokyo 1620826, Japan; Sapporo Med Univ, Dept Mol Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Tokyo University of Science; Sapporo Medical University	Takeda, K (corresponding author), Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, 12 Ichigaya Funagawara Machi, Tokyo 1620826, Japan.							Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Barboule N, 1999, FEBS LETT, V444, P32, DOI 10.1016/S0014-5793(99)00022-8; BARENDSEN N, 1990, LEUKEMIA RES, V14, P467, DOI 10.1016/0145-2126(90)90034-7; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen J, 1996, ONCOGENE, V13, P1395; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Frey MR, 1997, J BIOL CHEM, V272, P9424; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; HEIKKILA J, 1993, BIOCHEM BIOPH RES CO, V197, P1185, DOI 10.1006/bbrc.1993.2602; HEIKKILA JE, 1989, J CELL PHYSIOL, V140, P593, DOI 10.1002/jcp.1041400326; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUPPI K, 1994, ONCOGENE, V9, P3017; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Itayasu T, 1998, ANTICANCER RES, V18, P113; JIANG HP, 1994, ONCOGENE, V9, P3397; Joshi US, 1998, PANCREAS, V16, P107, DOI 10.1097/00006676-199803000-00001; Joshi US, 1998, CANCER GENE THER, V5, P183; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Kiley S C, 1994, Trends Cell Biol, V4, P223, DOI 10.1016/0962-8924(94)90146-5; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Liu J, 2000, J BIOL CHEM, V275, P11846, DOI 10.1074/jbc.275.16.11846; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V264, P457, DOI 10.1006/bbrc.1999.1516; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIKAWA M, 1986, LIFE SCI, V39, P1101, DOI 10.1016/0024-3205(86)90202-X; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Takahashi N, 2000, PROSTATE, V44, P328, DOI 10.1002/1097-0045(20000901)44:4<328::AID-PROS10>3.0.CO;2-8; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; YAMAUCHI Y, 1989, BRIT J CANCER, V60, P15, DOI 10.1038/bjc.1989.211; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	59	13	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1220	1228		10.1038/sj.onc.1204206	http://dx.doi.org/10.1038/sj.onc.1204206			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313866				2022-12-28	WOS:000167570100009
J	Daniel, L; Durbec, P; Gautherot, E; Rouvier, E; Rougon, G; Figarella-Branger, D				Daniel, L; Durbec, P; Gautherot, E; Rouvier, E; Rougon, G; Figarella-Branger, D			A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process	ONCOGENE			English	Article						PSA; adhesion; metastasis; nude mice; carcinogenesis	CELL-ADHESION MOLECULE; N-CAM; NEUROECTODERMAL TUMORS; MONOCLONAL-ANTIBODY; NEURONAL MIGRATION; OLFACTORY-BULB; NCAM; EXPRESSION; PROGRESSION; MOUSE	PSA is an oncodevelopmental antigen usually expressed in human tumors with high metastatic potential. Here we set up a metastatic model in nude mice by using TE671 cells, which strongly express PSA-NCAM. We observed the formation of lung metastases when TE671 cells were injected intravenously, intramuscularly, and intraperitoneously, hut not subcutaneously. Intraperitoneous injections also induced peritoneal carcinosis, ascites, and liver metastases. To evaluate the putative role of PSA in the metastatic process we used a specific cleavage of PSA on NCAM by endoneuraminidase-N on intraperitoneous primary tumors. Mice with primary intramuscular tumors were taken as control. Repeated injections of endoneuraminidase-N led to a decrease in PSA expression in primary intraperitoneous nodules and ascites but not in intramuscular primary tumors. Endoneuraminidase-N also increased the delay in ascitic formation and decreased the number of lung or liver metastases in the case of intraperitoneous tumors but not in the case of intramuscular tumors. When metastases occurred in endoneuraminidase-N injected animals, they strongly expressed PSA-NCAM. Therefore, we established a relationship between PSA expression on the surface of primary tumor cells and the metastatic process.	Fac Med, Inst Biol Dev Marseille, Lab Biopathol Nerveuse & Musculaire, F-13385 Marseille 05, France; CNRS, Lab Genet & Physiol Dev, F-13288 Marseille 09, France; Immunotech SA, Dept Imagerie & Therapeut, F-13009 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Figarella-Branger, D (corresponding author), Fac Med, Inst Biol Dev Marseille, Lab Biopathol Nerveuse & Musculaire, JE2053,27 Bd Jean Moulin, F-13385 Marseille 05, France.		ROUGON, Genevieve/G-2578-2013; daniel, laurent/R-2826-2016	ROUGON, Genevieve/0000-0003-1316-8200; daniel, laurent/0000-0002-7539-0109				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; Barr FG, 1997, J PEDIAT HEMATOL ONC, V19, P483, DOI 10.1097/00043426-199711000-00001; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Daniel L, 2000, CANCER RES, V60, P80; DUBOIS C, 1995, J IMMUNOL METHODS, V181, P125, DOI 10.1016/0022-1759(94)00336-U; FigarellaBranger D, 1996, J CLIN ONCOL, V14, P2066, DOI 10.1200/JCO.1996.14.7.2066; FIGARELLABRANGER D, 1992, J NEUROPATH EXP NEUR, V51, P12, DOI 10.1097/00005072-199201000-00003; FIGARELLABRANGER DF, 1990, CANCER RES, V50, P6364; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; GAFFNEY EF, 1993, AM J SURG PATHOL, V17, P601, DOI 10.1097/00000478-199306000-00008; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; Gluer S, 1998, PEDIATR RES, V43, P145, DOI 10.1203/00006450-199801000-00022; GOKAL R, 1992, OXFORD TXB CLIN NEPH, P1477; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; HUSMANN M, 1989, EUR J IMMUNOL, V19, P1761, DOI 10.1002/eji.1830190935; KUBOTA T, 1994, J CELL BIOCHEM, V56, P4, DOI 10.1002/jcb.240560103; LACKIE PM, 1990, DEVELOPMENT, V110, P933; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; MCALLISTER RM, 1977, INT J CANCER, V20, P206, DOI 10.1002/ijc.2910200207; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; OUSMENAR BN, 1995, EUR J NEUROSCI, V7, P480; PARISH RW, 1987, J CELL SCI, P181; Rapoport J, 1999, NEPHRON, V81, P375, DOI 10.1159/000045319; ROUGON G, 1986, J BIOL CHEM, V261, P3396; ROUGON G, 1993, EUR J CELL BIOL, V61, P197; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; ROUGON G, 1993, POLYSIALIC ACID MICR, P323; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SILOBRCIC V, 1990, INT J CANCER, V45, P325, DOI 10.1002/ijc.2910450220; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; STRATTON MR, 1989, NATURE, V337, P311, DOI 10.1038/337311c0; Theodosis DT, 1999, J NEUROSCI, V19, P10228; TOGO S, 1995, CANCER RES, V55, P681; WANG C, 1994, J NEUROSCI, V14, P4446; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	42	61	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					997	1004		10.1038/sj.onc.1204176	http://dx.doi.org/10.1038/sj.onc.1204176			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314035				2022-12-28	WOS:000167097000011
J	Rozovskaia, T; Feinstein, E; Mor, O; Foa, R; Blechman, J; Nakamura, T; Croce, CM; Cimino, G; Canaani, E				Rozovskaia, T; Feinstein, E; Mor, O; Foa, R; Blechman, J; Nakamura, T; Croce, CM; Cimino, G; Canaani, E			Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality	ONCOGENE			English	Article						Meis1; HoxA9; acute lymphocytic leukemias	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; ALL-1 GENE; EXPRESSION; FUSION; CELLS; HRX; T(7-11)(P15-P15)	Rearrangements of the human ALL-1 gene are frequently encountered in acute lymphocytic leukemias (ALL) and acute myeloid leukemias (AML), These rearrangements are mostly due to chromosome translocations and result in production of chimeric proteins composed of the N-terminal fragment of ALL-1 and the C-terminal segments of the partner proteins. The most common chromosome translocation involving ALL-I is the t(4:11) associated with ALL. ALL-1 is the human homologue of Drosophila trithorax and directly activates transcription of multiple Hox genes. A preliminary DNA microarray screen indicated that the Meis1, HoxA9 and AC133 genes were overexpressed in ALLs with t(4:11), compared to ALLs with very similar phenotype but without the chromosomal abnormality. These genes, as well as additional five Hox genes, were subjected to comprehensive semi-quantitative or quantitative RT-PCR analysis in 57 primary ALL and AML tumors. Meis1 and HoxA9 were found expressed in 13/14 of ALLs with the t(4:11) and in 8/8 of AMLs with ALL-1 rearrangements. The two genes were not consistently transcribed in other types of ALL, AC133 was transcribed in 13/14 of ALLs with t(4:11), but in only 4/8 of AMLs with ALL-1 rearrangements. HoxA10 was expressed in most leukemias with ALL-1 alterations, but was also transcribed in PrePreB CD10(-) ALLs lacking the t(4 : 11). Expression of HoxA5, HoxA7, HoxC8 and HoxC10 did not correlate with ALL-1 rearrangements. Coexpression of Meis1 and HoxA9, overexpression of HoxA10, and overexpression or fusion of HoxA9 were previously implicated in certain acute myeloid leukemias in mice and humans. The present work suggests that upregulation of Meis1, HoxA9, and possibly HoxA10 might also play a role in pathogenesis of acute lymphocytic and acute myeloid leukemias associated with ALL-1 fusions.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, BLSB, Philadelphia, PA 19107 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ouark Biotech Inc, Pleasanton, CA USA; Univ La Sapienza, Dept Human Biopathol, I-00161 Rome, Italy	Jefferson University; Weizmann Institute of Science; Sapienza University Rome	Canaani, E (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, BLSB, Room 608,233 S 10th St, Philadelphia, PA 19107 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; CIMINO, Giuseppe/0000-0002-7781-0816	NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O., 1997, Blood, V90, p67A; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Buhring HJ, 1999, BLOOD, V94, P832, DOI 10.1182/blood.V94.2.832.414a50_832_833; CHEN CS, 1993, BLOOD, V81, P2386; CIMINO G, 1995, LEUKEMIA, V9, P391; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRIESINGER F, 1994, LEUKEMIA, V8, P542; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HOFFMAN R, 2000, HEMATOLOGY BASIC PRI; HUNGER SP, 1993, BLOOD, V81, P3197; Johansson B, 1998, LEUKEMIA, V12, P779, DOI 10.1038/sj.leu.2401012; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lee G, 1999, WINTROBES CLIN HEMAT; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MOSCOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Tillib S, 1999, MOL CELL BIOL, V19, P5189; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	39	131	138	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					874	878		10.1038/sj.onc.1204174	http://dx.doi.org/10.1038/sj.onc.1204174			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314021				2022-12-28	WOS:000166924400011
J	Fleisher, AS; Esteller, M; Tamura, G; Rashid, A; Stine, OC; Yin, J; Zou, TT; Abraham, JM; Kong, DH; Nishizuka, S; James, SP; Wilson, KT; Herman, JG; Meltzer, SJ				Fleisher, AS; Esteller, M; Tamura, G; Rashid, A; Stine, OC; Yin, J; Zou, TT; Abraham, JM; Kong, DH; Nishizuka, S; James, SP; Wilson, KT; Herman, JG; Meltzer, SJ			Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia	ONCOGENE			English	Article						hypermethylation; hMLH1; microsatellite instability; mismatch repair; gastric cancer; gastric neoplasia	HELICOBACTER-PYLORI INFECTION; REPLICATION ERROR PHENOTYPE; DIFFERENTIATED TYPE; CANCER; METHYLATION; EXPRESSION; CARCINOMA; DNA; TUMORS; INACTIVATION	A significant portion of gastric cancers exhibit defective DNA mismatch repair, manifested as microsatellite instability (MSI). High-frequency MSI (MSI-H) is associated with hypermethylation of the human mut-L homologue 1 (hMLH1) mismatch repair gene promoter and diminished hMLH1 expression in advanced gastric cancers, However, the relationship between MSI and hMLH1 hypermethylation has not been studied in early gastric neoplasms, We therefore investigated hMLH1 hypermethylation, hMLH1 expression and MSI in a group of early gastric cancers and gastric adenomas, Sixty-four early gastric neoplasms mere evaluated, comprising 28 adenomas, 18 mucosal carcinomas, and 18 carcinomas with superficial submucosal invasion but clear margins, MSI was evaluated using multiplex fluorescent PCR to amplify loci D2S123, D5S346, D17S250, BAT 25 and BAT 26, Methylation-specific PCR was performed to determine the methylation status of hMLH1. In two hypermethylated MSI-H cancers, hMLH1 protein expression was also evaluated by immunohistochemistry. Six of sixty-four early gastric lesions were MSI-H, comprising 1 adenoma, 4 mucosal carcinomas, and 1 carcinoma with superficial submucosal invasion, Two lesions tone adenoma and one mucosal carcinoma) demonstrated low-frequency MSI (MSI-L), The remaining 56 neoplasms were MSI-stable (MSI-S), Six of six MSI-H, one of two MSI-L, and none of thirty MSI-S lesions showed hMLH1 hypermethylation (P < 0.001), Diminished hMLH1 protein expression was demonstrated by immunohistochemistry in two of two MSI-H hypermethylated lesions, hMLH1 promoter hypermethylation is significantly associated with MSI and diminished hMLH1 expression in early gastric neoplasms, MSI and hypermethylation-associated inactivation of hMLH1 are more prevalent in early gastric cancers than in gastric adenomas, Thus, hypermethylation-associated inactivation of the hMLH1 gene can occur early in gastric carcinogenesis.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Genet Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Yamagata Univ, Sch Med, Dept Pathol, Yamagata 990, Japan; Univ Calif Irvine, Dept Mol Genet & Microbiol, Irvine, CA USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Yamagata University; University of California System; University of California Irvine	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Wilson, Keith/0000-0003-4421-1830	NATIONAL CANCER INSTITUTE [R01CA078843, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA85069, CA78843] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Boland CR, 1998, CANCER RES, V58, P5248; Claij N, 1999, EXP CELL RES, V246, P1, DOI 10.1006/excr.1998.4299; CORREA P, 1994, CANCER RES, V54, pS1941; CRAANEN ME, 1992, AM J GASTROENTEROL, V87, P572; Cunningham JM, 1998, CANCER RES, V58, P3455; DosSantos NR, 1996, GASTROENTEROLOGY, V110, P38, DOI 10.1053/gast.1996.v110.pm8536886; Driessen A, 1999, GASTROEN CLIN BIOL, V23, P747; ECKARDT VF, 1990, GASTROENTEROLOGY, V98, P708, DOI 10.1016/0016-5085(90)90292-9; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fleisher AS, 1999, CANCER RES, V59, P1090; FUKUTOMI H, 1984, JPN J CLIN ONCOL, V14, P169; Halling KC, 1999, AM J PATHOL, V155, P205, DOI 10.1016/S0002-9440(10)65114-0; HAN HJ, 1993, CANCER RES, V53, P5087; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoang JM, 1997, CANCER RES, V57, P300; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Isogaki J, 1999, CANCER DETECT PREV, V23, P204, DOI 10.1046/j.1525-1500.1999.99020.x; Kane MF, 1997, CANCER RES, V57, P808; Kang GH, 1999, LAB INVEST, V79, P903; Karran P, 1996, CANCER SURV, V28, P69; Keller G, 1998, AM J PATHOL, V152, P1281; Kuipers EJ, 1998, ALIMENT PHARM THER, V12, P25, DOI 10.1111/j.1365-2036.1998.00009.x; Leach FS, 1996, CANCER RES, V56, P235; Leung SY, 1999, CANCER RES, V59, P159; ORLOW I, 1994, CANCER RES, V54, P2848; Ottini L, 1997, CANCER RES, V57, P4523; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; RHYU MG, 1994, ONCOGENE, V9, P29; Sasaki I, 1999, CANCER, V85, P1719, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1719::AID-CNCR11>3.3.CO;2-M; SAVIDES C, 1999, TUMORS STOMACH, V1, P1500; Semba S, 1996, CANCER, V77, P1620, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1620::AID-CNCR30>3.3.CO;2-P; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; SUZUKI H, 1994, CANCER RES, V54, P4841; Tamura G, 1996, PATHOL INT, V46, P834, DOI 10.1111/j.1440-1827.1996.tb03556.x; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; TOMASULO J, 1971, CANCER-AM CANCER SOC, V27, P1346, DOI 10.1002/1097-0142(197106)27:6<1346::AID-CNCR2820270612>3.0.CO;2-V; Wu MS, 1997, J GASTROEN HEPATOL, V12, P425, DOI 10.1111/j.1440-1746.1997.tb00460.x; Yin J, 1997, HUM MUTAT, V10, P474, DOI 10.1002/(SICI)1098-1004(1997)10:6<474::AID-HUMU9>3.0.CO;2-D; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	50	97	104	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					329	335		10.1038/sj.onc.1204104	http://dx.doi.org/10.1038/sj.onc.1204104			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313962				2022-12-28	WOS:000166411000007
J	Schlichter, U; Burk, O; Worpenberg, S; Klempnauer, KH				Schlichter, U; Burk, O; Worpenberg, S; Klempnauer, KH			The chicken Pdcd4 gene is regulated by v-Myb	ONCOGENE			English	Article						v-myb oncogene; target gene; differential display; Pdcd4	RECEPTOR FUSION PROTEIN; 2 DIFFERENT MECHANISMS; C-MYB; MIM-1 GENE; CELL-LINES; TOPOISOMERASE INHIBITORS; SYNERGISTIC ACTIVATION; MYELOMONOCYTIC CELLS; TRANS-ACTIVATION; MYELOID CELLS	The retroviral oncogene v-myb encodes a transcription factor (v-Myb) which is responsible for the ability of avian myeloblastosis virus (AMV) to transform mlyelomonocytic cells. v-Myb is thought to disrupt the differentiation of myelomonocytic cells by affecting the expression of specific target genes. To identify such genes we have analysed the gene expression in a myelomonocytic chicken cell Line that carries an estrogen inducible version of v-Myb by differential display, Here me describe the identification of the chicken homolog of the mouse Pdcd4 gene as a novel v-Myb target gene. Pdcd4 is also known as MA-3, TIS and H731 and has recently been shown to suppress the transformation of epidermal cells by tumor promoters. Our results provide the first evidence that v-Myb directly regulates the expression of a potential tumor suppressor gene.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							AKIYAMA Y, 1974, BIKEN J, V17, P105; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; PLAZA S, 1995, ONCOGENE, V10, P329; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Sitzmann J, 1995, ONCOGENE, V11, P2273; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wagner C, 1998, MAR BIOL, V131, P411, DOI 10.1007/s002270050334; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179	52	49	55	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					231	239		10.1038/sj.onc.1204071	http://dx.doi.org/10.1038/sj.onc.1204071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313950				2022-12-28	WOS:000166410900010
J	Imai, Y; Kurokawa, M; Izutsu, K; Hangaishi, A; Maki, K; Ogawa, S; Chiba, S; Mitani, K; Hirai, H				Imai, Y; Kurokawa, M; Izutsu, K; Hangaishi, A; Maki, K; Ogawa, S; Chiba, S; Mitani, K; Hirai, H			Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis	ONCOGENE			English	Article						Smad; mutation; acute myelogeneous leukemia; leukemogenesis; transforming growth factor-beta	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; DPC4 GENE; CELLS; PROTEINS; PROMOTER; RECEPTOR; BINDING; TRANSACTIVATION	The Smad family proteins are critical components of the transforming growth factor (TGF)-beta signaling pathway, TGF-beta is a multipotent cytokine that elicits many biological functions. In particular, TGF-beta exhibits effects on the cell cycle manifested by G1-phase arrest, differentiation, or apoptosis of several target cells, suggesting that disruption of TGF-beta signaling pathway could be involved in cancer formation, Here we show one missense mutation of the Smad4 gene in the MH1 domain (P102L) and one frame shift mutation resulting in termination in the MH2 domain (Delta (483-552)) in acute myelogeneous leukemia, Both of the mutated Smad4 proteins lack transcriptional activities, Concomitant expression of the P102L mutant with wild-type Smad4 inactivates wild-type Smad4 through inhibiting its DNA-binding ability. The Delta (483-552) mutant blocks nuclear translocation of wild-type Smad4 and thus disrupts TGF-beta signaling. This is the first report showing that mutations in the Smad4 gene are associated with the pathogenesis of acute myelogeneous leukemia and the obtained results should provide useful insights into the mechanism whereby disruption of TGF-beta signaling pathway could lead to acute myelogeneous leukemia.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Hirai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Izutsu, Koji/AAI-1125-2019	Izutsu, Koji/0000-0001-9129-8057; Imai, Yoichi/0000-0002-2938-6133				BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Drexler H G, 1986, Tumour Biol, V6, P503; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaneko H, 1998, ACTA HAEMATOL-BASEL, V99, P187, DOI 10.1159/000040837; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDAI J, 1998, CANCER RES, V58, P4592; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PIACIBELLO W, 1991, HAEMATOLOGICA, V76, P460; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	38	62	71	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					88	96		10.1038/sj.onc.1204057	http://dx.doi.org/10.1038/sj.onc.1204057			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244507				2022-12-28	WOS:000166361400010
J	Li, RZ; Pei, HP; Watson, DK				Li, RZ; Pei, HP; Watson, DK			Regulation of Ets function by protein-protein interactions	ONCOGENE			English	Review						protein-protein interaction; Ets; transcriptional modulation; combinatorial control	SERUM RESPONSE FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTORS PU.1; TERNARY COMPLEX FACTORS; CORE-BINDING-FACTOR; DNA-BINDING; GENE-EXPRESSION; PHYSICAL INTERACTIONS; FUSION PROTEIN; C-FOS	Ets proteins are a family of transcription factors that share an 85 amino acid conserved DNA binding domain, the ETS domain. Over 25 mammalian Ets family members control important biological processes, including cellular proliferation, differentiation, lymphocyte development and activation, transformation and apoptosis by recognizing the GGA core motif in the promoter or enhancer of their target genes, Protein-protein interactions regulates DNA binding, subcellular localization, target gene selection and transcriptional activity of Ets proteins. Combinatorial control is a characteristic property of Ets family members, involving interaction between Ets and other key transcriptional factors such as AP-1, NF kappaB and Pax family members. Specific domains of Ets proteins interact with many protein motifs such as bHLH, bZipper and Paired domain. Such interactions coordinate cellular processes in response to diverse signals including cytokines, growth factors, antigen and cellular stresses.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Li, RZ (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St,Room 315, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; Bhat NK, 1996, INT J ONCOL, V8, P841; BHAT NK, 1994, CHALLENGES MODERN ME, V5, P63; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Dang W, 1998, MOL CELL BIOL, V18, P1477, DOI 10.1128/MCB.18.3.1477; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MAY M, 1993, BIOCHEMISTRY-US, V32, P11734, DOI 10.1021/bi00094a033; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOTHIAS JY, 1993, J VIROL, V67, P3036, DOI 10.1128/JVI.67.6.3036-3047.1993; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Perkel JM, 1998, J IMMUNOL, V160, P241; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1993, CANCER RES, V53, P215; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Tian G, 1999, MOL CELL BIOL, V19, P2946; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; Wara-Aswapati N, 1999, MOL CELL BIOL, V19, P6803; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WATSON DK, 2001, ENCY CANC; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhao B, 2000, J VIROL, V74, P5151, DOI 10.1128/JVI.74.11.5151-5160.2000	135	181	183	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6514	6523		10.1038/sj.onc.1204035	http://dx.doi.org/10.1038/sj.onc.1204035			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175367				2022-12-28	WOS:000166595000013
J	Maroulakou, IG; Bowe, DB				Maroulakou, IG; Bowe, DB			Expression and function of Ets transcription factors in mammalian development: a regulatory network	ONCOGENE			English	Review						Ets family; development; gene expression; gene regulation; mammalian	STIMULATING FACTOR-I; DNA-BINDING DOMAIN; GENE-EXPRESSION; FAMILY-MEMBER; ONCOGENE FAMILY; MICE LACKING; ERG GENE; T-CELLS; C-ETS; SPI-B	The Ets transcription factor family is involved in a variety of mammalian developmental processes at the cellular, tissue and organ levels. They are implicated in cellular proliferation, differentiation, migration, apoptosis and cell-cell interactions. This article reviews recent studies that demonstrate the integral importance of Ets in the dosage dependent regulation of development. The expression of many Ets genes is associated with mesenchymal - epithelial interactions and changes in extracellular matrix proteins, These inductive processes contribute to tissue remodeling and integrity, particularly during embryonic development. Overlapping as well as unique patterns of Ets expression are evident in developing tissues, including development of the lymphoid and myeloid lineages, brain and central nervous system, bone and mammary gland. Integration of these data will allow the development of predictive models for the regulation of complex developmental processes.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Maroulakou, IG (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA.							AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Anderson MK, 1999, DEVELOPMENT, V126, P3131; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Bassuk AG, 1998, MOL MED, V4, P392, DOI 10.1007/BF03401746; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BHAT NK, 1994, HYBRIDOMA, V13, P1, DOI 10.1089/hyb.1994.13.1; BOLON I, 1995, AM J PATHOL, V147, P1298; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Buttice G, 1996, ONCOGENE, V13, P2297; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JM, 1987, DEV BIOL, V120, P311, DOI 10.1016/0012-1606(87)90234-X; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Davis JN, 1996, GENE, V171, P265, DOI 10.1016/0378-1119(96)00013-3; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; FAUST EA, 1993, J EXP MED, V177, P915, DOI 10.1084/jem.177.4.915; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GANAN Y, 1996, INT J DEV BIOL S, pS189; Garrett-Sinha LA, 1999, IMMUNITY, V10, P399, DOI 10.1016/S1074-7613(00)80040-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GREVIN D, 1993, INT J DEV BIOL, V37, P519; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Henkel GW, 1999, BLOOD, V93, P2849; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BLOOD, V82, P2998; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kaya M, 1996, ONCOGENE, V12, P221; Kilpatrick LM, 1999, BIOL REPROD, V61, P120, DOI 10.1095/biolreprod61.1.120; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LaurentHuck FM, 1996, DEV BRAIN RES, V97, P107, DOI 10.1016/S0165-3806(96)00134-4; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LELIEVRE E, 2000, IN PRESS INT J BIOCH; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Luton D, 1997, EARLY HUM DEV, V47, P147, DOI 10.1016/S0378-3782(96)01775-6; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Melet F, 1996, MOL CELL BIOL, V16, P2708; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Neznanov N, 1999, CANCER RES, V59, P4242; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROSS IL, 1994, ONCOGENE, V9, P121; ROWE A, 1992, EXP CELL RES, V202, P199, DOI 10.1016/0014-4827(92)90420-D; Sapi E, 1998, CANCER RES, V58, P1027; Spain LM, 1999, J IMMUNOL, V163, P2681; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	131	154	164	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6432	6442		10.1038/sj.onc.1204039	http://dx.doi.org/10.1038/sj.onc.1204039			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175359				2022-12-28	WOS:000166595000005
J	Vernucci, M; Cerrato, F; Besnard, N; Casola, S; Pedone, PV; Bruni, CB; Riccio, A				Vernucci, M; Cerrato, F; Besnard, N; Casola, S; Pedone, PV; Bruni, CB; Riccio, A			The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis	ONCOGENE			English	Article						genomic imprinting; hepatocarcinogenesis; insulin-like growth factor; apoptosis	GROWTH-FACTOR-II; INDUCED HEPATOCELLULAR CARCINOMAS; INSULIN-LIKE GROWTH-FACTOR-2; SV40 LARGE T; TRANSGENIC MICE; GENE; EXPRESSION; TUMORIGENESIS; APOPTOSIS; RAT	The expression of the linked but reciprocally imprinted Igf2 and H19 genes is activated in adult liver in the course of tumor development. By in situ hybridization analysis we have shown that both the Igf2 and H19 RNAs are expressed in the majority of the neoplastic nodules, and that hepatocellular carcinomas are developed in an experimental model of liver carcinogenesis. H19 is also highly activated in smaller and less distinct hyperplastic regions, The few neoplastic areas showing Igf2 but no H19 RNA display loss of the maternally inherited allele at the Igf2/H19 locus. These data are compatible with the existence of a common activation mechanism of these two genes during liver carcinogenesis and with a stronger H19 induction in the pre-neoplastic lesions. By using mice carrying a deletion of the H19 endodermal enhancer, we show that this regulatory element is necessary for the activation of the lgf2 and H19 genes upon induction of liver carcinogenesis. Furthermore, multiple sites of the H19 endodermal enhancer region become hypersensitive to DNase I when the carcinogenesis process is induced. Lastly, liver tumors developed in mice paternally inheriting the H19 enhancer deletion are found to have marked growth delays, increased frequency of apoptotic nuclei, and lack of Igf2 mRNA expression, thus indicating that this regulatory element plays a major role in the progression of liver carcinogenesis, since it is required for the activation of the anti-apoptotic lgf2 gene.	CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; CNR, Ctr Biocristallog, I-80125 Naples, Italy; Univ Naples 2, Dipartimento Sci Ambientali, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli	Riccio, A (corresponding author), CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, Via S Pansini 5, I-80131 Naples, Italy.		Riccio, Andrea/AAY-7571-2020; Riccio, Andrea/A-4991-2015; Casola, Stefano/AAN-8319-2021; Casola, Stefano/O-3922-2014	Riccio, Andrea/0000-0001-7990-3576; Riccio, Andrea/0000-0001-7990-3576; Casola, Stefano/0000-0001-5580-0986; Pedone, Paolo Vincenzo/0000-0002-0828-5843				Allemand I, 1995, ONCOGENE, V11, P2583; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; CASOLA S, 1995, ONCOGENE, V11, P711; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEINBERG AP, 1999, CANCER RES, V59, P1743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haddad R, 1997, CANCER RES, V57, P4615; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Harris TM, 1998, ONCOGENE, V16, P203, DOI 10.1038/sj.onc.1201519; Ishihara K, 2000, GENOME RES, V10, P664, DOI 10.1101/gr.10.5.664; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Li M, 1998, AM J MED GENET, V79, P253; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; RUBIN R, 1995, LAB INVEST, V73, P311; RUTHER U, 1993, ONCOGENE, V8, P87; Sambrook J., 2002, MOL CLONING LAB MANU; Sohda T, 1996, LAB INVEST, V75, P307; Sperandeo MP, 2000, AM J HUM GENET, V66, P841, DOI 10.1086/302811; TAKAGI H, 1992, CANCER RES, V52, P5171; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; UENO T, 1988, CARCINOGENESIS, V9, P1779, DOI 10.1093/carcin/9.10.1779; Ungaro P, 1997, MOL CELL ENDOCRINOL, V135, P153, DOI 10.1016/S0303-7207(97)00201-3; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050; Zhang LJ, 1996, CANCER RES, V56, P1367	49	27	27	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6376	6385		10.1038/sj.onc.1204024	http://dx.doi.org/10.1038/sj.onc.1204024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175353				2022-12-28	WOS:000166210500022
J	Liu, Y; Zacksenhaus, E				Liu, Y; Zacksenhaus, E			E2F1 mediates ectopic proliferation and stage-specific p53-dependent apoptosis but not aberrant differentiation in the ocular lens of Rb deficient fetuses	ONCOGENE			English	Article						Rb; p53; E2F1; lens; crystallins; filensin	SKELETAL-MUSCLE CELLS; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; MOUSE LENS; TRANSCRIPTION FACTORS; EYE DEVELOPMENT; GROWTH CONTROL; FIBER CELL; IN-VIVO; S-PHASE	The retinoblastoma tumor suppressor, Rb, is a transcription cofactor that controls cell proliferation, survival and differentiation. Mutant mouse embryos lacking Rb exhibit ectopic proliferation and apoptosis that are mediated in some tissues by E2F1, a major partner of Rb, and by the p53 tumor suppressor. Whether E2F1 and p53 also mediate the differentiation defects in Rb mutant embryos is, however, not clear. Here we show that partially rescued mgRb:Rb-/- mutant fetuses exhibit ectopic lens epithelial cell proliferation, apoptosis and severe cataract. The abnormal cell proliferation and apoptosis were significantly suppressed in the lens of compound mutant fetuses lacking both Rb and E2F1 at embryonic day (E) E15.5, Interestingly however, at E18.5, only ectopic proliferation, not apoptosis, was dramatically reduced in mgRb:Rb-/-:E2F1-/- lenses. In contrast, p53 did not exert such a stage-specific effect and apoptosis was invariably suppressed in mgRb:Rb-/-:p53-/- composite mutant lenses throughout embryogenesis. Using RT-PCR and iir situ hybridization analyses, me identified a subset of lens specific genes, most notably the late differentiation marker filensin, which were not properly induced during lens development in mgRb:Rb-/- fetuses. Remarkably, despite the inhibition of cell proliferation and apoptosis, the degeneration of lens fibers and aberrant expression of filensin were only marginally corrected in mgRb:Rb-/-:E2F1-/- fetuses at E15.5 but not at all at E18.5 or in mgRb:Rb-/-:p53-/- mutant fetuses. Thus, inactivation of E2F1 reduces ectopic cell proliferation and stage-specific p53-dependent apoptosis but does not rescue the differentiation defects associated with loss of Rb during lens development.	Univ Toronto, Toronto Gen Hosp, Dept Med, Univ Hlth Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Toronto Gen Hosp, Inst Res, Dept Med Biophys,Univ Hlth Network, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Zacksenhaus, E (corresponding author), Univ Toronto, Toronto Gen Hosp, Dept Med, Univ Hlth Network, 67 Coll St, Toronto, ON M5G 2M1, Canada.		Zacksenhaus, Eldad/AAD-3584-2020					Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Du W, 2000, DEVELOPMENT, V127, P367; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Francis PJ, 1999, TRENDS GENET, V15, P191, DOI 10.1016/S0168-9525(99)01738-2; Fromm L, 1996, ONCOGENE, V12, P69; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Humbert PO, 2000, GENE DEV, V14, P690; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JIANG Z, 2000, IN PRESS DEV BIOL; JIANG Z, 2000, IN PRESS J BIOL CHEM; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Kumar J, 1997, GENE DEV, V11, P2023, DOI 10.1101/gad.11.16.2023; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Masaki S, 1997, GENE, V201, P11, DOI 10.1016/S0378-1119(97)00419-8; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vitelli L, 2000, MOL CELL BIOL, V20, P5330, DOI 10.1128/MCB.20.14.5330-5342.2000; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	50	27	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6065	6073		10.1038/sj.onc.1203996	http://dx.doi.org/10.1038/sj.onc.1203996			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146559				2022-12-28	WOS:000165827900014
J	Morini, M; Astigiano, S; Mora, M; Ricotta, C; Ferrari, N; Mantero, S; Levi, G; Rossini, M; Barbieri, O				Morini, M; Astigiano, S; Mora, M; Ricotta, C; Ferrari, N; Mantero, S; Levi, G; Rossini, M; Barbieri, O			Hyperplasia and impaired involution in the mammary gland of transgenic mice expressing human FGF4	ONCOGENE			English	Article						transgenic mice; fibroblast growth factors; mammary gland	GROWTH-FACTOR FAMILY; BREAST-CANCER; EPITHELIAL-CELLS; GENE-EXPRESSION; K-FGF; PROVIRAL INSERTION; TUMOR VIRUS; MCF-7 CELLS; INT-2; HST	Fgf4, a member of the fibroblast growth factor family, is frequently amplified in a variety of human cancers, however, its expression in neoplastic tissues is rarely detectable, This makes uncertain its involvement in tumour aetiology, although several in-vitro studies link Fgf4 overexpression to malignant transformation and metastatization of culture cells, We generated a transgenic mouse model in which the whey acidic protein (WAP) promoter directs expression of human Fgf4 to mammary tissues during late pregnancy and throughout lactation, with the purpose of studying the involvement of this growth factor in mammary tumorigenesis, Expression of the transgene was specifically detected in lobular-alveolar cells of lactating mammary glands that, by histological analysis, displayed hyperplastic areas and a disorganized structure, This was accompanied by an increased number of red blood cells and expression, in alveolar epithelial cells, of the vascular endothelial growth factor, which is absent in wild type controls, The most striking effect caused by FGF4 overexpression was on the remodelling of mammary tissue at the end of lactation, Indeed, transgenic animals showed a delayed involution of the gland due to a dramatic reduction in the overall number of apoptotic cells, which are normally present in the organ after weaning, Nevertheless, none of the animals examined developed neoplastic lesions of the mammary gland even after several pregnancies and at old age. Our work represents the first in-vivo demonstration of the anti-apoptotic and angiogenic properties of FGF4.	Univ Genoa, Dipartimento Oncol Biol & Genet, I-16132 Genoa, Italy; Univ Siena, Dipartimento Fisiopatol & Med Sperimentale, I-53100 Siena, Italy; MNHN, URA CNRS 8572, Lab Physiol Gen & Comparee, Paris, France; Chiron SPA, Iris, Siena, Italy; Ist Nazl Ric Canc, Unita Morfogenesi Mol, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Serv Biol Mol, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Unita Transgenici, I-16132 Genoa, Italy	University of Genoa; University of Siena; Museum National d'Histoire Naturelle (MNHN); Novartis; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST	Barbieri, O (corresponding author), Univ Genoa, Dipartimento Oncol Biol & Genet, Largo R Banzi 10, I-16132 Genoa, Italy.		Ferrari, Nicoletta/AAG-6049-2019; Barbieri, Ottavia/E-8768-2011; Mantero, Stefano/AAE-5515-2021; Astigiano, Simonetta/AAG-7766-2019	Ferrari, Nicoletta/0000-0002-6027-1035; Astigiano, Simonetta/0000-0002-8200-0666; Mantero, Stefano/0000-0003-0608-2724; Levi, Giovanni/0000-0002-7041-6787				ADNANE J, 1991, ONCOGENE, V6, P659; Baik MG, 1998, INT J MOL MED, V2, P39; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRUSTLE O, 1992, ONCOGENE, V7, P1177; Chodosh LA, 2000, DEV BIOL, V219, P259, DOI 10.1006/dbio.2000.9614; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Deroanne CF, 1997, CANCER RES, V57, P5590; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON RB, 1991, BIOESSAYS, V13, P591, DOI 10.1002/bies.950131109; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hajitou A, 2000, BREAST CANCER RES TR, V60, P15, DOI 10.1023/A:1006302602261; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hogan B, 1994, MANIPULATING MOUSE E; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jackson D, 1997, J CELL SCI, V110, P1261; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; Labosky PA, 1997, DEVELOPMENT, V124, P1263; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MERLO GR, 1994, ONCOGENE, V9, P443; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURPHY LJ, 1986, MOL ENDOCRINOL, V46, P4555; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Payson RA, 1996, ONCOGENE, V13, P47; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shimon I, 1996, J CLIN INVEST, V97, P187, DOI 10.1172/JCI118388; Shimon I, 1998, CLIN ENDOCRINOL, V48, P23, DOI 10.1046/j.1365-2265.1998.00332.x; Souttou B, 1996, INT J CANCER, V68, P675, DOI 10.1002/(SICI)1097-0215(19961127)68:5<675::AID-IJC19>3.0.CO;2-0; TALARICO D, 1993, MOL CELL BIOL, V13, P1998, DOI 10.1128/MCB.13.4.1998; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THEILLET C, 1989, ONCOGENE, V4, P915; Vaahtokari A, 1996, DEVELOPMENT, V122, P121; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	50	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6007	6014		10.1038/sj.onc.1204011	http://dx.doi.org/10.1038/sj.onc.1204011			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146552				2022-12-28	WOS:000165827900007
J	Pandolfi, PP				Pandolfi, PP			Transcription therapy for cancer	ONCOGENE			English	Review						transcription factors; transcription therapy; HDAC inhibitors; differentiation; cancer; APL; polyamides	ACUTE PROMYELOCYTIC LEUKEMIA; SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; TRANSFORMED-CELL DIFFERENTIATION; PLZF-RAR-ALPHA; RETINOIC ACID; IN-VITRO; ARSENIC TRIOXIDE; GENE-EXPRESSION	In the post genome era it will soon be possible to associate a specific tumor type with a specific gene expression profile and to define each molecular lesion characteristic of any given cancer. It is intuitive that a successful therapeutic strategy for cancer should aim at blocking the aberrant biochemical activity triggered by the oncogene or the lack of tumor suppressor gene activity that ultimately leads to full-blown neoplastic transformation. However, an attractive alternative approach entails the blockade of the transcriptional consequences of such oncogenic activities irrespective of their original biochemical nature, thus antagonizing the key transcriptional events underlying cancer pathogenesis in any specific neoplastic cellular population. This approach is now rendered possible by major advances along several lines of investigation: (i) the possibility of analysing gene expression through high throughput methods; (ii) a more detailed knowledge of the regulatory regions and of the transcription factors that control gene expression also facilitated in the future by a comprehensive whole genome comparative analysis of these regulatory sequences; (iii) the ability of modulating gene expression at the single gene level through various approaches both pharmacological and biochemical; (iv) the opportunity of directly antagonizing the aberrant activities of oncogenic transcription factors through a detailed knowledge of their abnormal transcriptional function; (v) the possibility of validating, in vivo, in animal models the relevance for neoplastic transformation of specific transcriptional events as well as of testing the efficacy of 'transcription therapy' in faithful animal models of human cancer. Here, we will review the facts, the existing applications and the hypothesis underlying such therapeutic modality for cancer therapy.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.							Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Baylin SB, 1998, ADV CANCER RES, V72, P141; Butler LM, 2000, CANCER RES, V60, P5165; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Coffey DC, 2000, MED PEDIATR ONCOL, V35, P577, DOI 10.1002/1096-911X(20001201)35:6<577::AID-MPO18>3.0.CO;2-3; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Dervan PB, 1999, CURR OPIN CHEM BIOL, V3, P688, DOI 10.1016/S1367-5931(99)00027-7; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, BLOOD, V92, p510A; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Janssen S, 2000, MOL CELL, V6, P999, DOI 10.1016/S1097-2765(00)00099-X; Jurcic JG, 2000, CLIN CANCER RES, V6, P372; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Kushner D M, 2000, Curr Oncol Rep, V2, P23, DOI 10.1007/s11912-000-0007-y; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU PQ, 2001, IN PRESS J BIOL CHEM; LO CF, 1994, BLOOD, V83, P1757; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; MAGRATH I, 1990, NONHODGKINS LYMPHOMA, P29; Mapp AK, 2000, P NATL ACAD SCI USA, V97, P3930, DOI 10.1073/pnas.97.8.3930; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Reich S, 2000, BLOOD, V96, P3357, DOI 10.1182/blood.V96.10.3357.h8003357_3357_3363; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Trauger JW, 1998, J AM CHEM SOC, V120, P3534, DOI 10.1021/ja9800378; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; White S, 1998, NATURE, V391, P468, DOI 10.1038/35106; WOLFFE AP, 2001, IN PRESS ONCOGENE; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	58	148	158	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3116	3127		10.1038/sj.onc.1204299	http://dx.doi.org/10.1038/sj.onc.1204299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420728				2022-12-28	WOS:000169308500016
J	Nakamura, K; Yano, H; Schaefer, E; Sabe, HA				Nakamura, K; Yano, H; Schaefer, E; Sabe, HA			Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies	ONCOGENE			English	Article						FAK; Pyk2; tyrosine phosphorylation; EMT; cell migration	FOCAL ADHESION KINASE; GROWTH-FACTOR; ANGIOTENSIN-II; PAXILLIN-ALPHA; SRC KINASE; IN-VITRO; V-SRC; PROTEIN; ACTIVATION; CALCIUM	Integrin signaling is activated during epithelial-mesenchymal transdifferentiation (EMT) and cell migration, processes serving as models for carcinogenesis, We have shown that paxillin and p130Cas become highly tyrosine phosphorylated during these processes in NMuMG cells. Here, we examined the regulation of Fak and Pyk2, kinases implicated in this phosphorylation, Pyk2 became phosphorylated at the major autophosphorylation site (Tyr-402) and the potential Grb2-binding site (Tyr-881) during EMT, In contrast, phosphorylation of Fak at the corresponding autophosphorylation site (Tyr-397) occurred even in sedentary epithelial cells, whereas phosphorylation at Tyr-407 and Tyr-861 was induced during EMT. During cell migration, these phosphorylation events, except Fak Tyr-397, were augmented further, and phosphorylation of Fak Tyr-577 and the corresponding Pyk2 Tyr-580, both within the kinase activation loops, was also induced. In all cases, phosphorylation of the putative Grb2-binding site in Fak (Tyr-925) was almost undetectable, Although Fak and Pyk2 have several phosphorylation sites in common, Tyr-407 and Tyr-861 are unique to Fak, Our results revealed that Fak and Pyk2 are non-equivalent in the tyrosine phosphorylation events and thereby likely to evoke different downstream signaling cascades during EMT and cell migration of NMuMG cells, We also show that Fak Tyr-397 phosphorylation occurs exclusively at the cytoplasm, but not at focal contacts, in the sedentary epithelial cells, In contrast, all other tyrosine phosphorylated forms of Fak and Pyk2 are predominantly localized to focal adhesions and the cell periphery in motile cells, all colocalized with paxillin and p130Cas.	Osaka Biosci Inst, Dept Mol Biol, Osaka 5650874, Japan; BioSource Int, Hopkinton, MA 01748 USA; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Sabe, HA (corresponding author), Osaka Biosci Inst, Dept Mol Biol, 6-2-4 Furuedai, Osaka 5650874, Japan.							Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, J BIOL CHEM, V270, P28440; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Herzog H, 1997, GENOMICS, V41, P315, DOI 10.1006/geno.1997.4684; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Maruyama T, 1999, ENDOCRINOLOGY, V140, P5982, DOI 10.1210/endo.140.12.7184; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tobe K, 1996, MOL CELL BIOL, V16, P4765; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	48	68	72	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2626	2635		10.1038/sj.onc.1204359	http://dx.doi.org/10.1038/sj.onc.1204359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420674				2022-12-28	WOS:000168652600003
J	Suzuki, T; Shiratori, M; Furuichi, Y; Matsumoto, T				Suzuki, T; Shiratori, M; Furuichi, Y; Matsumoto, T			Diverged nuclear localization of Werner helicase in human and mouse cells	ONCOGENE			English	Article						aging; nucleolar localization signal; rRNA transcription; Werner syndrome; WRN	SYNDROME PROTEIN; SYNDROME GENE; DNA HELICASE; WRN GENE; SEQUENCE; CLONING	Werner syndrome (WS) is a rare autosomal recessive genetic disorder causing premature aging and rare cancers. A gene responsible for WS (WRN) encodes a protein with 1432 amino acids (a.a.) homologous to the E. coli RecQ-type DNA helicase, Transcriptional activation facilitated nucleolar localization of human WRN protein (hWRNp) and serum starvation induced translocation of hWRNp from the nucleoli to the nucleoplasm in human cultured cells, suggesting a nucleolar-nucleoplasm trafficking of hWRNp depending on transcriptional state, Mutant hWRNp lacking the C-terminal 30 a.a. residues (Delta 1403-1432) failed to localize in the nucleolus, whereas Delta 1405-1432 can migrate into the nucleolus. Here we identify a region putative for nucleolar localization signal (NoLS) containing sequence of two positively charged amino acids (Arg(1403)-Lys(1404)) in the C-terminal area of hWRNp, By contrast, the mouse homolog (mWRNp) exists only in the nucleoplasm, We show that the inability of mWRNp to migrate into the nucleolus is due to a difference of a sequence in the region corresponding to the NoLS of hWRNp. In addition, mouse cells cannot recognize the NoLS of hWRNp, Our study suggests that defect in nucleolar function of hWRNp may be linked to the premature aging which is not observed in mWRN(-/-) mice.	AGENE Res Inst, Kanagawa 2470063, Japan		Matsumoto, T (corresponding author), AGENE Res Inst, 200 Kajiwara, Kanagawa 2470063, Japan.							CHIU SM, 1982, BIOCHIM BIOPHYS ACTA, V699, P15, DOI 10.1016/0167-4781(82)90166-X; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Imamura O, 1997, GENOMICS, V41, P298, DOI 10.1006/geno.1997.4661; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1998, INT J MOL MED, V1, P71; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Wang L, 2000, GENETICS, V154, P357; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	24	39	42	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2551	2558		10.1038/sj.onc.1204344	http://dx.doi.org/10.1038/sj.onc.1204344			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420665				2022-12-28	WOS:000168652500006
J	Bai, JN; Brody, JR; Kadkol, SHS; Pasternack, GR				Bai, JN; Brody, JR; Kadkol, SHS; Pasternack, GR			Tumor suppression and potentiation by manipulation of pp32 expression	ONCOGENE			English	Article						pp32; oncogene; transformation	PROTEIN; PHOSPHATASE; GENE; IDENTIFICATION; INHIBITION; ACTIVATION	Alternative use of genes of the closely-related pp32 family is a common occurrence in human prostate cancer, pp32r1 and pp32r2, the oncogenic members of the pp32 family, are expressed in prostatic adenocarcinoma, while adjacent benign prostate continues to express pp32, This study focuses upon the role of pp32 in tumor suppression, We demonstrate that antisense inhibition of pp32 in NIH3T3 cells leads to a variety of phenotypic changes associated with transformation including reduced serum dependence and loss of contact inhibition. NIH3T3 cells with antisense-inhibited pp32 are not tumorigenic, but are markedly more susceptible to oncogenic stimuli such as vas, In contrast, constitutive expression of pp32 abolishes ras mediated transformation in vitro and tumorigenesis in vivo. These data demonstrate, from the functional aspect, that pp32 acts as a tumor suppressor. Furthermore, inactivation of pp32 function through alternative gene use may be a critical event in tumor evolution and progression.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Room 512 Ross,720 Rutland Ave, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA54404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; HAMILTON SR, 1988, J PATHOL, V154, P205, DOI 10.1002/path.1711540302; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; KADKOL SS, 1999, J MOL DIAGN, V1, P58; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Mills JC, 1998, J CELL SCI, V111, P625; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WEINBERG RA, 1989, BIOCHEMISTRY-US, V28, P8263, DOI 10.1021/bi00447a001; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917	20	60	63	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2153	2160		10.1038/sj.onc.1204294	http://dx.doi.org/10.1038/sj.onc.1204294			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360199				2022-12-28	WOS:000168116700010
J	Kasten, M; Giordano, A				Kasten, M; Giordano, A			Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity	ONCOGENE			English	Article						Cdk; Ets2; transcription; cell cycle	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; PROSTATE-CANCER; PROTEIN-KINASE; FAMILY; ACTIVATION; EXPRESSION; PISSLRE; GROWTH; DOMAIN	Cdk10 is a Cdc2-related kinase that may play a role in regulating the G2/M phase of the cell cycle. However little is known about the proteins that interact with this putative kinase and contribute to its function in the cell. We report in this study that Cdk10 interacts with the N-terminus of the Ets2 transcription factor, which contains the highly conserved Pointed domain and transactivation domain. The Pointed domain has been implicated in protein-protein interactions and we find that Ets2 requires an intact Pointed domain to bind Cdk10, The Pointed domain of Ets1 is highly similar to Ets2, however Cdk10 does not recognize Ets1 in a two-hybrid assay thereby demonstrating significant binding specificity on the part of Cdk10, We find that Cdk10 binds full length Ets2 in vitro and in vivo and inhibits Ets2 transactivation in mammalian cells.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Anat, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Giordano, A (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [T32CA009137] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA 09137] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; GOLEMIS EA, 1997, CURRENT PROTOCOLS MO; GRANA X, 1994, ONCOGENE, V9, P2097; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; LI S, 1995, CANCER RES, V55, P3992; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Puri PL, 2000, GENE DEV, V14, P574; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Watson MA, 1996, BIOTECHNIQUES, V21, P255; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Yang BS, 1996, MOL CELL BIOL, V16, P538	31	85	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1832	1838		10.1038/sj.onc.1204295	http://dx.doi.org/10.1038/sj.onc.1204295			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313931				2022-12-28	WOS:000167908400004
J	Kalma, Y; Marash, L; Lamed, Y; Ginsberg, D				Kalma, Y; Marash, L; Lamed, Y; Ginsberg, D			Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2	ONCOGENE			English	Article						E2F; cell cycle; DNA chips; RPA	NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; CELL-CYCLE; TOPOISOMERASE-II; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; DEREGULATED EXPRESSION; MAMMALIAN CDC6	The transcription factor E2F-1 plays a pivotal role in the regulation of G1/S transition in higher eukaryotes cell cycle. We used a cell line containing an inducible E2F-1 and oligonucleotide microarray analysis to identify novel E2F target genes. We show that E2F-1 up-regulates the expression of a number of genes coding for components of the DNA replication machinery. Among them is the gene coding for the 32 Kd subunit of replication protein A (RPA2). Replication protein A is the most abundant single strand DNA binding complex and it is essential for DNA replication. We demonstrate that RPA2 is a novel E2F target gene whose expression can be directly regulated by E2F-1 via E2F binding sites in its promoter. In addition, expression of Topoisomerase II alpha and subunit IV of DNA polymerase alpha is also up-regulated upon E2F-1 induction. Taken together, these results provide novel links between components of the DNA replication machinery and the cell growth regulatory pathway involving the Rb tumor suppressor and E2F.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			ginsberg, doron/0000-0002-1257-4920				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HASEGAWA T, 1993, BIOCHEM BIOPH RES CO, V195, P409, DOI 10.1006/bbrc.1993.2058; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KENNY MK, 1990, J BIOL CHEM, V265, P769; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LI L, 1995, MOL CELL BIOL, V15, P5396; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nishikawa NS, 2000, NUCLEIC ACIDS RES, V28, P1525, DOI 10.1093/nar/28.7.1525; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	51	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1379	1387		10.1038/sj.onc.1204230	http://dx.doi.org/10.1038/sj.onc.1204230			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313881				2022-12-28	WOS:000167495000011
J	Law, W; Linial, ML				Law, W; Linial, ML			Transforming ability of Gag-Myc fusion proteins correlates with Gag-Myc protein stability and transcriptional repression	ONCOGENE			English	Article						myc; repression; avian retrovirus; Gag-Myc	ROUS-SARCOMA VIRUS; ORNITHINE DECARBOXYLASE GENE; UBIQUITIN-PROTEASOME PATHWAY; NUCLEOTIDE-SEQUENCE ANALYSIS; DNA-DAMAGING AGENTS; C-MYC; V-MYC; NEOPLASTIC TRANSFORMATION; NUCLEOCAPSID PROTEIN; CELL-TRANSFORMATION	Avian retroviruses that have transduced c-myc are useful tools to study the conditions necessary for cellular transformation. FH3, one such retrovirus which encodes a Gag-Myc fusion protein, is not transforming in quail embryonic fibroblasts, but a late variant of FH3 that arose after passaging FH3-infected cells is transforming. Mutational analysis of FH3 revealed that the presence of a portion of the retroviral protease in FH3 inhibited transformation and that this inhibition was transferable to more highly transforming retrovirus, MC29. Transforming and non-transforming FH3-derived and MC29-derived Gag-Myc proteins were used to further explore characteristics of Myc necessary for transformation. Gag-Myc proteins which were transforming were found to be the most stable in the cell, To distinguish whether transactivation and/or repression is correlated to transformation, the various Gag-Myc fusion proteins were tested for their ability to activate or repress c-Myc targets. Results indicated that a correlation exists between transforming Gag-Myc proteins and their ability to repress, whereas all Gag-Myc proteins could transactivate, regardless of their ability to transform, Taken together, these results suggest that protein stabilization of Myc and repression of target genes by Myc are important for cellular transformation.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Linial, ML (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Mail Stop A3-015,1100 Fairview Ave N, Seattle, WA 98109 USA.				NATIONAL CANCER INSTITUTE [R01CA018282, T32CA009657, R01CA058809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-18282, CA-58809, 5 T32 CA-09657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIEGALKE BJ, 1990, VIROLOGY, V177, P657, DOI 10.1016/0042-6822(90)90531-U; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRASIER AR, 1995, CURRENT PROTOCOLS MO; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CHEN CA, 1996, CURRENT PROTOCOLS MO; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Coffin JM, 1996, VIROLOGY, P1767; COHN SL, 1990, ONCOGENE, V5, P1821; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; DUPRAZ P, 1992, J VIROL, V66, P4662, DOI 10.1128/JVI.66.8.4662-4670.1992; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRYKBERG L, 1987, ONCOGENE, V1, P415; FU XD, 1988, J BIOL CHEM, V263, P2140; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; GELFAND CA, 1993, J BIOL CHEM, V268, P18450; GRINDE B, 1992, J BIOL CHEM, V267, P9481; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee CM, 1999, ONCOGENE, V18, P2997, DOI 10.1038/sj.onc.1202786; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MAO Y, 1993, BIOCHEM J, V295, P641, DOI 10.1042/bj2950641; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIN SY, 1992, ONCOGENE, V7, P1531; MLADENOV Z, 1967, JNCI-J NATL CANCER I, V38, P251; MOSHIER JA, 1993, CANCER RES, V53, P2618; OERTLE S, 1992, J VIROL, V66, P3873, DOI 10.1128/JVI.66.6.3873-3878.1992; PENA A, 1993, J BIOL CHEM, V268, P27277; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1993, J VIROL, V67, P3635, DOI 10.1128/JVI.67.6.3635-3638.1993; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	74	4	5	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1118	1127		10.1038/sj.onc.1204226	http://dx.doi.org/10.1038/sj.onc.1204226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314049				2022-12-28	WOS:000167232100012
J	Lin, RT; Genin, P; Mamane, Y; Sgarbanti, M; Battistini, A; Harrington, WJ; Barber, GN; Hiscott, J				Lin, RT; Genin, P; Mamane, Y; Sgarbanti, M; Battistini, A; Harrington, WJ; Barber, GN; Hiscott, J			HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators	ONCOGENE			English	Article						interferon; chemokines; herpes; vIRF-1; IRF-3; CBP/P300; transcription	SARCOMA-ASSOCIATED HERPESVIRUS; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; FUNCTIONAL-ANALYSIS; POSITIVE FEEDBACK; VIRUS-INFECTION; DNA-SEQUENCES; KAPPA-B; ACTIVATION; PROTEIN	Human herpes virus 8 (HHV-8) has developed unique mechanisms for altering cellular proliferative and apoptotic control pathways by incorporating viral homologs to several cellular regulatory genes into its genome. One of the, important pirated genes encoded by the ORF K9 reading frame is a viral homolog of the interferon regulatory factors (TRF), a family of cellular transcription proteins that regulates expression of genes involved in pathogen response, immune modulation and cell proliferation, vIRF-1 has been shown to downregulate the interferon- and IRF-mediated transcriptional activation of ISG and murine IFNA4 gene promoters. In this study we demonstrate that vIRF-1 efficiently inhibited virus-induced expression of endogenous interferon B, CC chemokine RANTES and CXC chemokine IP-10 genes, Go-expression analysis revealed that vIRF-1 selectively blocked IRF-3 but not IRF-7-mediated transactivation. vIRF-1 was able to bind to both IRF-3 and IRF-7 in vivo as detected by coimmunoprecipitation analysis, but did not affect IRF-3 dimerization, nuclear translocation and DNA binding activity, Rather, vIRF-1 interacted with the CBP/p300 coactivators and efficiently inhibited the formation of transcriptionally competent IRF-3-CBP/p300 complexes, These results illustrate that vIRF-1 is able to block the early stages of the IFN response to virus infection by interfering with the activation of IRF-3 responsive, immediate early IFN genes.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol & Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Ist Super Sanita, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; University of Miami; Istituto Superiore di Sanita (ISS)	Lin, RT (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008; BATTISTINI, ANGELA/C-2944-2016; SGARBANTI, MARCO/C-2962-2016	Lin, Rongtuan/0000-0002-2238-3503; SGARBANTI, MARCO/0000-0002-0433-5110; Genin, Pierre/0000-0002-7502-3851				Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Burysek L, 1999, J VIROL, V73, P7334; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kung AL, 2000, GENE DEV, V14, P272; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; LIN RT, 1994, J BIOL CHEM, V269, P17542; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; NGUYEN H, 1995, ONCOGENE, V11, P537; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Oike Y, 1999, BLOOD, V93, P2771; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Vescio RA, 1999, CURR TOP MICROBIOL, V246, P403; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	38	167	178	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					800	811		10.1038/sj.onc.1204163	http://dx.doi.org/10.1038/sj.onc.1204163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314014				2022-12-28	WOS:000166924400003
J	Niitsu, N; Hayashi, Y; Honma, Y				Niitsu, N; Hayashi, Y; Honma, Y			Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23;p13)	ONCOGENE			English	Article						differentiation; MLL-CBP; t(11;16)(q23;p13); RXR agonist, butyrate	RETINOID-X-RECEPTOR; ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; NUCLEAR-PROTEIN CBP; HISTONE ACETYLTRANSFERASE; BUTYRIC-ACID; SODIUM-BUTYRATE; TRANSCRIPTIONAL ACTIVATION; MYELOMONOCYTIC LEUKEMIA	The translocation t(11;16)(q23;p13) has only been documented in patients with acute leukemia or myelodysplasia secondary to therapy with drugs targeting DNA topoisomerase II. We have established a myeloid cell line (SN-1) with the MLL-CBP fusion gene from an acute leukemia patient with t(11;16)(q23;p13), Although SN-1 cells were not induced to differentiate by all-tr mw retinoic acid (ATRA) and 1 alpha ,25-dihydroxyvitamin D-3 (VD3), retinoid Ii receptor (RXR) agonists, such as 9-cis retinoic acid and Ro48-2250, effectively induced differentiation of the cells. Downregulation of the expression of the MLL-CBP fusion gene occurred during the differentiation of SN-1 cells, When SN-1 cells were treated with MLL-CBP antisense oligonucleotide, the cells were induced to differentiate by ATRA or VD3, suggesting that the MLL-CBP fusion gene dominant-negatively suppresses ATRA- or VD3-induced differentiation. Moreover, suboptimal concentrations of sodium butyrate, a histone deacetylase inhibitor, had a cooperative effect with ATRA or VD3 in inducing the differentiation of SN-1 cells, The downregulation of the expression of MLL-CBP mRNA was accompanied by the induction of differentiation. These findings suggest that RXR agonists or a clinically applicable combination of ATRA and butyrate derivatives might be useful for differentiation therapy in leukemia patients with the MLL-CBP fusion gene.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan; Toho Univ, Sch Med, Dept Internal Med 1, Tokyo 153, Japan; Univ Tokyo, Fac Med, Dept Pediat, Tokyo 113, Japan	Toho University; University of Tokyo	Honma, Y (corresponding author), Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan.							Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; AVIRAM A, 1994, INT J CANCER, V56, P906, DOI 10.1002/ijc.2910560625; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayashi Y, 2000, CANCER RES, V60, P1139; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONMA Y, 1983, EUR J CANCER CLIN ON, V19, P251, DOI 10.1016/0277-5379(83)90424-8; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iijima T, 1999, CHEM PHARM BULL, V47, P398; Joh T, 1999, ONCOGENE, V18, P1125, DOI 10.1038/sj.onc.1202400; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kasukabe T, 1997, BRIT J CANCER, V75, P850, DOI 10.1038/bjc.1997.151; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Makishima M, 1996, BLOOD, V87, P3384, DOI 10.1182/blood.V87.8.3384.bloodjournal8783384; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Niitsu N, 1997, CELL GROWTH DIFFER, V8, P319; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; NUDELMAN A, 1992, J MED CHEM, V35, P687, DOI 10.1021/jm00082a009; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRASAD KN, 1980, LIFE SCI, V27, P1351, DOI 10.1016/0024-3205(80)90397-5; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; Rowley JD, 1997, BLOOD, V90, P535; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1997, PEDIATRICS, V100, P101, DOI 10.1542/peds.100.1.101; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yokoyama A, 1996, BLOOD, V88, P3555, DOI 10.1182/blood.V88.9.3555.bloodjournal8893555; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4	54	12	15	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					375	384		10.1038/sj.onc.1204081	http://dx.doi.org/10.1038/sj.onc.1204081			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313967				2022-12-28	WOS:000166411000012
J	Ehrhardt, GRA; Korherr, C; Wieler, JS; Knaus, M; Schrader, JW				Ehrhardt, GRA; Korherr, C; Wieler, JS; Knaus, M; Schrader, JW			A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth	ONCOGENE			English	Article						Ras; exchange factor; negative regulation; Elk-1	NUCLEOTIDE DISSOCIATION STIMULATOR; GTPASE-ACTIVATING PROTEIN; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; KINASE; IDENTIFICATION; PATHWAY; FAMILY; PHOSPHORYLATION	Here, we report the identification and characterization of a new member of the RaIGDS-family, which is widely expressed and interacts strongly and selectively with the GTP-bound forms of M-Ras and p21 Ras, This Ras pathway modulator (RPM), also termed RGL3, exhibited Ras-binding and catalytic domains typical of the RalGDS-family of guanine nucleotide exchange factors, and nas most similar to Rlf (RalGDS-like factor), but ras distinguished by a unique proline-rich region with multiple candidate SH3-domain binding sites. RPM/ RGL3 resembled AF-6 and Nore1 in interacting strongly with constitutively active M-Ras and p21 Ras. In contrast to Rlf, transiently expressed RPM/RGL3 did not activate an Elk-1-indueible reporter gene alone or in combination with activated p21 Ras, but strongly inhibited induction of this reporter gene by co-expression of activated H-Ras or MEKK-1. This inhibitory effect was independent of the Ras binding domain and required a second signal provided by p21 Ras or MEKK-1, but not Raf-1 or M-Ras. Expression of RPM/RGL3 also strongly inhibited cell growth of fibroblasts transformed by an activated Src Y527F. Thus, RPM/RGL3 is a novel potential effector of both p21 Ras and M-Ras with the novel function of negatively regulating Elk-1-dependent gene induction downstream of p21 Ras or MEKK-1.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Orchansky PL, 1999, J BIOL CHEM, V274, P20818, DOI 10.1074/jbc.274.30.20818; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353	41	29	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					188	197		10.1038/sj.onc.1204053	http://dx.doi.org/10.1038/sj.onc.1204053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313946				2022-12-28	WOS:000166410900006
J	Fan, SJ; Ma, YX; Wang, CG; Yuan, RQ; Meng, QH; Wang, JA; Erdos, M; Goldberg, ID; Webb, P; Kushner, PJ; Pestell, RG; Rosen, EM				Fan, SJ; Ma, YX; Wang, CG; Yuan, RQ; Meng, QH; Wang, JA; Erdos, M; Goldberg, ID; Webb, P; Kushner, PJ; Pestell, RG; Rosen, EM			Role of direct interaction in BRCA1 inhibition of estrogen receptor activity	ONCOGENE			English	Article						BRCA1; estrogen receptor (ER); breast cancer; activation function-2 (AF-2)	TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; BREAST; MUTATIONS; BINDING	The BRCA1 gene was previously found to inhibit the transcriptional activity of the estrogen receptor [ER-alpha] in human breast and prostate cancer cell Lines. In this study, we found that breast cancer-associated mutations of BRCA1 abolish or reduce its ability to inhibit ER-alpha activity and that domains within the amino- and carboxyl-termini of the BRCA1 protein are required for the inhibition. BRCA1 inhibition of ER-alpha activity was demonstrated under conditions in which a BRCA1 transgene was transiently or stably over-expressed in cell lines with endogenous wild-type BRCA1 and in a breast cancer cell line that lacks endogenous functional BRCA1 (HCC1937), In addition, BRCA1 blocked the expression of two endogenous estrogen-regulated gene products in human breast cancer cells: pS2 and cathepsin D, The BRCA1 protein was found to associate with ER-alpha in vivo and to bind to ER-alpha in vitro, by an estrogen-independent interaction that mapped to the amino-terminal region of BRCA1 (ca, amino acid 1-300) and the conserved carboxyl-terminal activation function [AF-2] domain of ER-alpha, Furthermore, several truncated BRCA1 proteins containing the amino-terminal ER-alpha binding region blocked the ability of the full-length BRCA1 protein to inhibit ER-alpha activity. Our findings suggest that the amino-terminus of BRCA1 interacts with ER-alpha, while the carboxyl-terminus of BRCA1 may function as a transcriptional repression domain.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY 11040 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Duv Human Endocrine Tumor Biol, Bronx, NY 10461 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Univ Calif San Francisco, Sch Med, Metab Res Unit, San Francisco, CA 94143 USA	Northwell Health; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Francisco	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New York, NY 11040 USA.		Meng, Q./GSI-6185-2022		NCI NIH HHS [R01-CA70897] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169 , +] Funding Source: Medline; PHS HHS [R01-82599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chlebowski RT, 2000, NEW ENGL J MED, V343, P191, DOI 10.1056/NEJM200007203430307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tirkkonen M, 1997, CANCER RES, V57, P1222; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Webber MM, 1997, PROSTATE, V30, P58; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	21	203	218	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					77	87		10.1038/sj.onc.1204073	http://dx.doi.org/10.1038/sj.onc.1204073			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244506				2022-12-28	WOS:000166361400009
J	Raouf, A; Seth, A				Raouf, A; Seth, A			Ets transcription factors and targets in osteogenesis	ONCOGENE			English	Article						Ets1; Ets2; osteoblast; differentiation; mineralization; bone	RETINOIC ACID; C-ETS-1 PROTOONCOGENE; OSTEOBLASTIC DIFFERENTIATION; BINDING-SITES; C-FOS; EXPRESSION; CELL; PROTEIN; BONE; GENE	Bone formation in vivo is a complex phenomenon whereby recruitment and replication of mesenchymal precursors of osteoblasts, differentiation into preosteoblasts, osteoblasts, and mature osteoblasts ultimately result in the accumulation and mineralization of the extracellular matrix. MC3T3-E1, a clonal osteoblastic cell line, was derived from mouse calvaria and undergoes an ordered and time dependent developmental sequence leading to formation of multilayered bone nodules over a 30-35 day period. This developmental pattern is characterized by the replication of preosteoblasts followed by growth arrest and expression of mature osteoblastic characteristics such as matrix maturation and eventual formation of multilayered nodules with a mineralized extracellular matrix, We have found that Ets1 is expressed in proliferating preosteoblastic cells whereas Ets2 is expressed by differentiating and mature osteoblasts, In addition, the expression of Ets1 can be induced in MC3T3-E1 and fetal rat calvaria cells by retinoic acid (RA) which is known to exert profound effects on skeletal growth and development, bone turnover, and induce specific cellular responses in bone cells, Thus the multiple functions of RA in bone cells are likely to be mediated in part by Ets1. Also, Ets2 transgenic mice develop multiple neurocranial, viserocranial, and cervical skeletal abnormalities. Significantly, these abnormalities are similar to the skeletal anomalies found in trisomy-16 mice and in humans with Down's syndrome, wherein the dosage of Ets2 is known to be increased. These results indicate that Ets2 has an important role in skeletal development and that Ets2 overexpression in transgenics is responsible for the genesis of the same type of skeletal abnormalities that are seen in Down's syndrome. Thus the genetic programs regulated by Ets1 and Ets2 may significantly affect the development and differentiation of osteoblasts, and in fact, Ets1 has been shown to interact with the 'quintessential' osteoblast transcription factor CbfA1, This review will examine in detail the role and possible targets of Ets1 and Ets2 in osteoblast differentiation and bone formation.	Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Toronto, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Seth, A (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada.							Aperlo C, 1996, MOL CELL BIOL, V16, P6851; ASCIONE R, 1992, INT J ONCOL, V1, P631; Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; Chen ZQ, 1997, CANCER RES, V57, P2013; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FANG MA, 1995, CALCIFIED TISSUE INT, V57, P450, DOI 10.1007/BF00301949; Frick KK, 1997, AM J PHYSIOL-CELL PH, V272, pC1450, DOI 10.1152/ajpcell.1997.272.5.C1450; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; Hodge DR, 1996, ONCOGENE, V12, P11; ISEKI S, 1995, EXP CELL RES, V219, P339, DOI 10.1006/excr.1995.1237; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Karperien M, 1997, MOL ENDOCRINOL, V11, P1435, DOI 10.1210/me.11.10.1435; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KURIHARA N, 1986, ENDOCRINOLOGY, V118, P940, DOI 10.1210/endo-118-3-940; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; Mackie EJ, 1996, J CELL SCI, V109, P1597; MACKIE EJ, 1992, J CELL SCI, V103, P765; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; McKee MD, 1996, CONNECT TISSUE RES, V35, P197, DOI 10.3109/03008209609029192; McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MULKINS MA, 1983, J BIOL CHEM, V258, P6219; NAKAYAMA Y, 1990, FEBS LETT, V261, P93, DOI 10.1016/0014-5793(90)80644-X; NG KW, 1988, J BONE MINER RES, V3, P53; OHISHI K, 1994, J CELL PHYSIOL, V161, P544, DOI 10.1002/jcp.1041610318; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Raouf A, 2000, ONCOGENE, V19, P1969, DOI 10.1038/sj.onc.1203505; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Sato Y, 1998, Hum Cell, V11, P207; Seth A, 2000, J BONE MINER RES, V15, P1683, DOI 10.1359/jbmr.2000.15.9.1683; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; TRAIANEDES K, 1993, J CELL PHYSIOL, V157, P243, DOI 10.1002/jcp.1041570206; Varga F, 1997, CALCIFIED TISSUE INT, V61, P404, DOI 10.1007/s002239900356; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; Wang DY, 1997, IN VITRO CELL DEV-AN, V33, P248; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHOU H, 1991, J BONE MINER RES, V6, P767	67	109	112	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6455	6463		10.1038/sj.onc.1204037	http://dx.doi.org/10.1038/sj.onc.1204037			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175361				2022-12-28	WOS:000166595000007
J	Trojanowska, M				Trojanowska, M			Ets factors and regulation of the extracellular matrix	ONCOGENE			English	Article						Ets; ECM; stroma; fibrosis; MMP; collagen	EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; BINDING-SITES; TUMOR INVASION; STROMELYSIN PROMOTER; SIGNALING PATHWAY; EPITHELIAL-CELLS; TISSUE INHIBITOR; TRANSGENIC MICE	Ets factors are critical mediators of extracellular matrix (ECM) remodelling. As the spectrum of Ets-regulated target genes widens, so does their role in various pathological and physiological processes. Regulation of matrix degrading proteases by Ets factors in tumor invasion and metastasis is well established, Emerging evidence suggests that they may also play a role in the pathology of autoimmune diseases. Newly characterized Ets target genes such as tenascin-C and collagen type I suggest their role in diseases characterized by aberrant collagen deposition (fibrosis), Ets function is also critical in bone and cartilage development. There is increasing knowledge of the complex regulatory mechanisms involved in transcription of Ets target genes. Ets factors may function as activators or as repressors via association with specific cofactors depending on the promoter context. Signaling pathways can modulate the activation status of Ets factors and their transcriptional partners, Precise understanding of the role of Ets factors in the complex cellular network governing the expression of ECM proteins and the enzymes that degrade them will be a focus of future studies.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29401 USA	Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St, Charleston, SC 29401 USA.			Trojanowska, Maria/0000-0001-9550-7178				AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BOLON I, 1995, AM J PATHOL, V147, P1298; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Dooley S, 1996, ANN RHEUM DIS, V55, P298, DOI 10.1136/ard.55.5.298; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Georgiou P, 1996, INT J ONCOL, V9, P9; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Goodman RH, 2000, GENE DEV, V14, P1553; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Hida K, 1997, ORAL ONCOL, V33, P426, DOI 10.1016/S0964-1955(97)00047-X; Hida K, 1997, AM J PATHOL, V150, P2125; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HultgardhNilsson A, 1996, CIRC RES, V78, P589, DOI 10.1161/01.RES.78.4.589; Ito M, 1998, BIOCHEM BIOPH RES CO, V246, P123, DOI 10.1006/bbrc.1998.8585; Ito T, 1998, MODERN PATHOL, V11, P209; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Johansson N, 2000, HISTOL HISTOPATHOL, V15, P225, DOI 10.14670/HH-15.225; Kauppila S, 1998, J PATHOL, V186, P262, DOI 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3; Kauppila S, 1999, CANCER, V86, P1299, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1299::AID-CNCR27>3.0.CO;2-6; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; Kitange G, 1999, LAB INVEST, V79, P407; Kleinbaum LA, 1999, BIOCHEM BIOPH RES CO, V264, P119, DOI 10.1006/bbrc.1999.1493; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Malemud Charles J., 1999, Frontiers in Bioscience, V4, pd762; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Naito S, 2000, PATHOL RES PRACT, V196, P103, DOI 10.1016/S0344-0338(00)80041-2; Nakayama T, 1999, MODERN PATHOL, V12, P61; Nakayama T, 1996, AM J PATHOL, V149, P1931; NERLOV C, 1991, ONCOGENE, V6, P1583; Nishioka Y, 2000, JPN J CANCER RES, V91, P612, DOI 10.1111/j.1349-7006.2000.tb00989.x; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Patton SE, 1998, CANCER RES, V58, P2253; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; Rutter JL, 1998, CANCER RES, V58, P5321; Santala M, 1998, BRIT J CANCER, V77, P1825, DOI 10.1038/bjc.1998.303; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stracke M L, 1994, In Vivo, V8, P49; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Teitell MA, 1999, LAB INVEST, V79, P1535; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; WERNERT N, 1994, CANCER RES, V54, P5683; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	77	99	102	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6464	6471		10.1038/sj.onc.1204043	http://dx.doi.org/10.1038/sj.onc.1204043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175362				2022-12-28	WOS:000166595000008
J	Truong, AHL; Ben-David, Y				Truong, AHL; Ben-David, Y			The role of Fli-1 in normal cell function and malignant transformation	ONCOGENE			English	Article						Fli-1; transcription factor; gene regulation; cancer	MURINE LEUKEMIA-VIRUS; ETS TRANSCRIPTION FACTORS; TERNARY COMPLEX FACTORS; DNA-BINDING; EWINGS-SARCOMA; PROVIRAL INTEGRATION; INDUCED ERYTHROLEUKEMIA; GENE-EXPRESSION; FUSION GENE; F-MULV	Aberrant expression of the Fli-1 transcription factor following genetic mutation has been recognized as a seminal event in the initiation of certain types of malignant transformation. Indeed, the etiology of a number of virally induced leukemias, including Friend virus-induced erythroleukemia, has been associated with Fli-1 overexpression, The clinical relevance of Fli-1 becomes apparent in human Ewing's sarcoma in which Fli-1 is the target of a characteristic chromosomal translocation, As such, Fli-1 has generated considerable interest over the past several years for its role in malignant transformation and tumor progression. This review will present a synopsis of the current research on Fli-1 with emphasis on its function in malignant transformation. Moreover, the possible role of Fli-1 in cellular proliferation, differentiation and survival, as well as the recent development of transgenic and knock-out mice to investigate the function of Fli-1 will be discussed. Finally, the significance of identifying target genes that are regulated by Fli-1 and their role in cellular function will be reviewed.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; TSRCC, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, 2075 Bayview Ave,S Wing,Room S216, Toronto, ON M4N 3M5, Canada.							Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barbeau B, 1999, ONCOGENE, V18, P5535, DOI 10.1038/sj.onc.1202913; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Denicourt C, 1999, J VIROL, V73, P4439, DOI 10.1128/JVI.73.5.4439-4442.1999; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; GOBEL MG, 1990, CELL, V61, P1165; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; Lin PP, 1999, CANCER RES, V59, P1428; Mager AM, 1998, INT J DEV BIOL, V42, P561; MAO X, 1994, J BIOL CHEM, V269, P16216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Melet F, 1996, MOL CELL BIOL, V16, P2708; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PETER M, 1995, BRIT J CANCER, V72, P96, DOI 10.1038/bjc.1995.283; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PFLEIDERER C, 1995, INT J CANCER, V64, P135, DOI 10.1002/ijc.2910640211; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1993, ONCOGENE, V8, P2167; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; SELLERI L, 1994, CYTOGENET CELL GENET, V67, P129, DOI 10.1159/000133813; SELS FT, 1992, ONCOGENE, V7, P643; SETH A, 1993, ONCOGENE, V8, P1783; Seth A, 1999, CELL DEATH DIFFER, V6, P902, DOI 10.1038/sj.cdd.4400567; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Thompson AD, 1996, ONCOGENE, V13, P2649; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	69	99	105	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6482	6489		10.1038/sj.onc.1204042	http://dx.doi.org/10.1038/sj.onc.1204042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175364				2022-12-28	WOS:000166595000010
J	Verrecchia, F; Vindevoghel, L; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A				Verrecchia, F; Vindevoghel, L; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A			Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner	ONCOGENE			English	Article						TGF-beta; AP-1; Smad; gene regulation; Jun	GROWTH-FACTOR-BETA; COLLAGEN GENE COL7A1; C-JUN; COACTIVATOR P300; SMAD PROTEINS; DNA-BINDING; ACTIVATION; FIBROBLASTS; EXPRESSION; SEQUENCE	Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes either directly or in combination with other sequence-specific transcription factors, AP-1 sites and their cognate transcription factors also play important roles in the gene regulatory activities of TGF-beta. In this report, we have investigated the functional interactions of the Smad and AP-1 transcription factors. We demonstrate that Smad and AP-1 complexes specifically bind to their cognate cis-elements and do not interact with each other on-DNA, whereas off-DNA interactions occur between Smad3 and both c-Jun and JunB. Using both artificial constructs specific for either the Smad or AP-1 signaling pathways or natural promoters known to be TGF-beta -responsive, we have determined that Jun family members downregulate Smad3-mediated gene transactivation whereas AP-1-dependent promoters are synergistically activated by Smad3 and Jun proteins, We propose a model where the presence of Smad- and/or AP-1-specific cis-elements within TGF-beta -responsive genes allows dynamic modulation of gene expression, in contrast to the existing model where interactions between Smad and AP-1 proteins are merely an on/off mechanism to regulate TGF-beta /Smad targets.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mauviel, A (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439] Funding Source: NIH RePORTER; NIAMS NIH HHS [O1 AR41439] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PIU F, 1993, CR ACAD SCI III-VIE, V316, P772; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	38	154	159	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3332	3340		10.1038/sj.onc.1204448	http://dx.doi.org/10.1038/sj.onc.1204448			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423983				2022-12-28	WOS:000169248800003
J	Dohn, M; Zhang, SZ; Chen, XB				Dohn, M; Zhang, SZ; Chen, XB			p63 alpha and Delta Np63 alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes	ONCOGENE			English	Article						apoptosis; cell cycle arrest; p63; p53; p73	P53-REGULATED PROTEIN GADD45; TUMOR-SUPPRESSOR P53; KINASE C-ABL; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; HUMAN CANCERS; P73; P63; EXPRESSION	The p53 tumor suppressor protein plays a critical role in the regulation of the cell cycle and apoptosis, The importance of p53's functions is underscored by the high incidence of p53 mutations in human cancers, Recently, two p53-related proteins, p73 and p63, were identified as members of the p53 gene family, Multiple isoforms of p73 have been found, including DeltaN variants in which the N-termini are truncated, p63 is expressed as three major forms, p63 alpha, p63 beta and p63 gamma, each of which differ in their C-termini, All three forms can be alternatively transcribed from a cryptic promoter located within intron 3, producing Delta Np63 alpha, Delta Np63 beta and Delta Np63 gamma, The high degree of similarity of p73 and p63 to evolutionarily conserved regions of p53 suggests that these proteins play an important and potentially redundant role in regulating cell cycle arrest and apoptosis, Here we describe the characterization of cell lines generated to inducibly express p63 alpha and Delta Np63 alpha. We have found that p63 alpha and Delta Np63 alpha can differentially regulate endogenous p53 target genes and induce cell cycle arrest and apoptosis, Deletion of the N-terminal 26 amino acids of Delta Np63 alpha abolished its ability to transactivate p53 target genes and induce cell cycle arrest and apoptosis, This indicates that a putative transactivation domain exists within the N-terminus of the DeltaN variants of p63, Furthermore, the differential regulation of p53 target genes by p63a and Delta Np63 alpha suggests that p63 and p53 utilize both similar and different signaling pathways to execute their cellular functions.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA76069, R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Barbosa MS, 1996, CRIT REV ONCOGENESIS, V7, P1; Boyer SN, 1996, CANCER RES, V56, P4620; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Gong JG, 1999, NATURE, V399, P806; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shimada A, 1999, CANCER RES, V59, P2781; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	73	248	262	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3193	3205		10.1038/sj.onc.1204427	http://dx.doi.org/10.1038/sj.onc.1204427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423969				2022-12-28	WOS:000169163500003
J	Lu, WG; Chen, LH; Peng, YH; Chen, JD				Lu, WG; Chen, LH; Peng, YH; Chen, JD			Activation of p53 by roscovitine-mediated suppression of MDM2 expression	ONCOGENE			English	Article						roscovitine; p53; MDM2; cdk; transcription	CYCLIN-DEPENDENT KINASES; SOFT-TISSUE SARCOMAS; DNA-DAMAGE; SYNERGISTIC ACTIVATION; NUCLEAR EXCLUSION; HUMAN SKIN; IN-VIVO; PROTEIN; TRANSCRIPTION; INHIBITION	The p53 tumor suppressor is regulated by the MDM2 oncoprotein. Overexpression of MDM2 maintains p53 at low levels and contributes to the functional inactivation of p53 in a subset of tumors. We found that treatment with roscovitine and olomoucin, which were originally developed as cyclin-dependent kinase (CDK) inhibitors, can efficiently stabilize and activate nuclear p53 in tumor cells with MDM2 amplification or cytoplasmic p53. These inhibitors block the degradation of p53 without affecting p53-MDM2 binding and the nuclear shuttling function of p53 and MDM2. Roscovitine also induces stabilization of the p53 Ala-315 mutant, indicating that it does not act by regulating the CDK phosphorylation of serine 315, Roscovitine induces down-regulation of MDM2 expression at both protein and mRNA levels. Ectopic expression of MDM2 can abrogate the ability of roscovitine to induce p53 stabilization. Low concentrations of roscovitine cooperate with the DNA-damaging agent camptothecin to activate p53 in a synergistic fashion, These results show that the small molecule CDK inhibitors can be used to activate p53 through their potent inhibitory effect on MDM2 expression and may be useful as sensitizing agents for other DNA-damaging drugs.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADDISON C, 1990, ONCOGENE, V5, P423; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chehab NH, 2000, GENE DEV, V14, P278; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; CORDONCARDO C, 1994, CANCER RES, V54, P794; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hajduch M, 1999, ADV EXP MED BIOL, V457, P341; HALL PA, 1993, ONCOGENE, V8, P203; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; LEACH FS, 1993, CANCER RES, V53, P2231; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; McMasters KM, 1996, ONCOGENE, V13, P1731; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meng RD, 1998, CLIN CANCER RES, V4, P251; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; O'Grady A, 1998, HUM PATHOL, V29, P559, DOI 10.1016/S0046-8177(98)80003-8; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sankrithi N, 1999, J NEUROCHEM, V72, P605, DOI 10.1046/j.1471-4159.1999.0720605.x; Schang LM, 1999, J VIROL, V73, P2161, DOI 10.1128/JVI.73.3.2161-2172.1999; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	47	98	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3206	3216		10.1038/sj.onc.1204412	http://dx.doi.org/10.1038/sj.onc.1204412			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423970				2022-12-28	WOS:000169163500004
J	Mattila, MMT; Ruohola, JK; Valve, EM; Tasanen, MJ; Seppanen, JA; Harkonen, PL				Mattila, MMT; Ruohola, JK; Valve, EM; Tasanen, MJ; Seppanen, JA; Harkonen, PL			FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells	ONCOGENE			English	Article						FGF-8 isoforms; angiogenesis; breast cancer; tumorigenesis; androgen; hormone-independence	IN-VIVO; PROGNOSTIC INDICATOR; MOLECULAR-CLONING; STEROID-HORMONES; PROSTATE-CANCER; AUTOCRINE LOOP; STEP METHOD; EXPRESSION; MAMMARY; FGF8	Fibroblast growth factor 8 (FGF-8) is a secreted heparin-binding protein, which has transforming potential. Alternative splicing of the mouse Fgf-8 gene potentially codes for eight protein isoforms (a-h) which differ in their transforming capacity in transfected cells. S115 mouse mammary tumor cells express a transformed phenotype and secrete FGF-8 in an androgen-dependent manner. In order to study the role of FGF-8 isoforms in the induction of transformed phenotype of breast cancer cells, we over-expressed FGF-8 isoforms a, b and e in S115 cells. Over-expression of FGF-8b, but not FGF-8a or FGF-8e, induced androgen and anchorage independent growth of S115 cells. FGF-8b-transfected S115 eels formed rapidly growing tumors with increased vascularization when injected s.c, into nude mice. FGF-8a also slightly increased tumor growth and probably tumor vascularization but FGF-8e was not found to have any effects. The angiogenic activity of FGF-8b and heparin-binding growth factor fraction (HBGF) of S115 cell conditioned media was tested in in vitro and in vivo models for angiogenesis using immortomouse brain capillary endothelial cells (IBEC) and chorion allantoic membrane (CAM) assays. Recombinant FGF-8b protein was able to stimulate proliferation, migration, and vessellike tube formation of IBECs, In addition, stimulatory effect of S115-HBGF on IBE cell proliferation was evident. A positive angiogenic response to FGF-8b was also seen in CAM assay. The results demonstrate that the expression of Fgf-8b is able to promote vessel formation. Angiogenic capacity probably markedly contributes to the ability of FGF-8b to increase tumor growth of androgen-regulated S115 mouse breast cancer cells.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland	University of Turku; University of Turku	Harkonen, PL (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllnkatu 10, FIN-20520 Turku, Finland.							AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; DARBRE PD, 1987, CANCER RES, V47, P2937; DARBRE PD, 1988, BREAST CANCER CELLUL, P307; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; GOTO F, 1993, LAB INVEST, V69, P508; Guidi AJ, 1997, CANCER, V80, P1945, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1945::AID-CNCR11>3.0.CO;2-Y; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hansen S, 2000, CLIN CANCER RES, V6, P139; HARKONEN PL, 1990, EXP CELL RES, V186, P288, DOI 10.1016/0014-4827(90)90308-W; HARLEY CB, 1987, GENE ANAL TECH, V4, P17, DOI 10.1016/0735-0651(87)90013-6; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KOUHARA H, 1994, ONCOGENE, V9, P455; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Nicholson RI, 2000, BRIT J CANCER, V82, P501; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Relf M, 1997, CANCER RES, V57, P963; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; SATO B, 1993, J STEROID BIOCHEM, V47, P91, DOI 10.1016/0960-0760(93)90061-Z; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TAKATSUKA D, 1992, ANTICANCER RES, V12, P2001; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TOI M, 1995, BREAST CANCER RES TR, V36, P193, DOI 10.1007/BF00666040; TOI M, 1994, JAPANESE J CANC RES, V885, P1045; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; Valve E, 1997, BIOCHEM BIOPH RES CO, V232, P173, DOI 10.1006/bbrc.1997.6256; Valve EM, 1998, BIOCHEM BIOPH RES CO, V250, P805, DOI 10.1006/bbrc.1998.9397; Wang Q, 1999, J CLIN PATHOL, V52, P29, DOI 10.1136/jcp.52.1.29; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; YAMANISHI H, 1995, J STEROID BIOCHEM, V52, P49, DOI 10.1016/0960-0760(94)00148-F; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YAN GC, 1991, IN VITRO CELL DEV B, V27, P437; YATES J, 1981, CANCER RES, V41, P258	67	55	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2791	2804		10.1038/sj.onc.1204430	http://dx.doi.org/10.1038/sj.onc.1204430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420691				2022-12-28	WOS:000168712000007
J	Jochum, W; Passegue, E; Wagner, EF				Jochum, W; Passegue, E; Wagner, EF			AP-1 in mouse development and tumorigenesis	ONCOGENE			English	Review						AP-1; Fos proteins; Jun proteins; development; bone biology; tumorigenesis	PROGRAMMED CELL-DEATH; LACKING C-FOS; TERMINAL TRANSACTIVATION DOMAIN; INDUCED OSTEOSARCOMA FORMATION; MAMMALIAN UV RESPONSE; RAT EMBRYO CELLS; TRANSGENIC MICE; TRANSCRIPTION FACTOR; IN-VITRO; GENE-EXPRESSION	Genetically modified mice have provided important insights into the biological functions of the dimeric transcription factor complex AP-1, Extensive analyses of mice and cells with genetically modified Fos or Jun proteins provide novel insights into the physiological functions of AP-1 proteins. Using knock-out strategies it was found that some components, such as c-Fos, FosB and JunD are dispensable, whereas others, like c-Jun, JunB and Fra-1 are essential in embryonic development and/or in the adult organism. Besides the specific roles olf AP-1 proteins in developmental processes, we are beginning to obtain a better molecular understanding of the cell-context dependent function of AP-1 in cell proliferation and apoptosis, in bone biology as well as in multistep tumorigenesis.	Res Inst Mol Pathol, IMP, A-1030 Vienna, Austria; Univ Zurich Hosp, Inst Clin Pathol, CH-8091 Zurich, Switzerland	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Zurich; University Zurich Hospital	Wagner, EF (corresponding author), Res Inst Mol Pathol, IMP, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Passegue, Emmanuelle/0000-0002-3516-297X; Wagner, Erwin F/0000-0001-7872-0196				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BEHRENS A, 2001, IN PRESS PNAS; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; BROWN PH, 1993, ONCOGENE, V8, P877; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARRASCO D, 1995, ONCOGENE, V10, P1069; Carrozza ML, 1997, ONCOGENE, V14, P1083, DOI 10.1038/sj.onc.1200921; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Feng ZW, 1998, ONCOGENE, V17, P2593, DOI 10.1038/sj.onc.1202195; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; FOLETTA VC, 1994, ONCOGENE, V9, P3305; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; GACK S, 1994, J BIOL CHEM, V269, P10363; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Gruda MC, 1996, ONCOGENE, V12, P2177; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Hu L, 1996, J IMMUNOL, V157, P3804; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; JOOSS KU, 1995, ONCOGENE, V10, P603; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Liebermann DA, 1998, INT J ONCOL, V12, P685; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; MARTI A, 1994, ONCOGENE, V9, P1213; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McHenry JZ, 1998, ONCOGENE, V17, P1131, DOI 10.1038/sj.onc.1202044; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Owens JM, 1999, J CELL PHYSIOL, V179, P170, DOI 10.1002/(SICI)1097-4652(199905)179:2<170::AID-JCP7>3.0.CO;2-K; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pennypacker K, 1998, INT REV NEUROBIOL, V42, P169, DOI 10.1016/S0074-7742(08)60610-8; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Preston GA, 1996, MOL CELL BIOL, V16, P211; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; RUTHER U, 1989, ONCOGENE, V4, P861; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SAEZ E, 1995, CANCER RES, V55, P6196; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SANDBERG M, 1988, DEVELOPMENT, V102, P461; Schorpp M, 1996, NUCLEIC ACIDS RES, V24, P1787, DOI 10.1093/nar/24.9.1787; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Skinner M, 1997, MOL CELL BIOL, V17, P2372, DOI 10.1128/MCB.17.5.2372; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMEYNE RJ, 1992, MOL BRAIN RES, V16, P158, DOI 10.1016/0169-328X(92)90206-Q; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Thepot D, 2000, DEVELOPMENT, V127, P143; Thomas DP, 2000, J CELL SCI, V113, P439; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	127	589	617	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2401	2412		10.1038/sj.onc.1204389	http://dx.doi.org/10.1038/sj.onc.1204389			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402336				2022-12-28	WOS:000168568700007
J	Ivanov, VN; Fodstad, O; Ronai, Z				Ivanov, VN; Fodstad, O; Ronai, Z			Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNF alpha and suppression of NF-kappa B activities	ONCOGENE			English	Article						p38; TRAF2; melanoma; apoptosis; radiation; anisomycin; actinomycin D	RECEPTOR 1; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; DOWN-REGULATION; KINASE JNK; ACTIVATION; FAS; DEATH; COMPLEX; PROTEIN	Mechanisms underlying radiation and chemotherapy resistance, the hallmark of human melanoma, are not well understood. Here we demonstrate that expression levels of signal adaptor protein TRAF2 coincide with melanoma resistance to UV-irradiation. Altered TRAF2 signaling by a form of TRAF2, which lacks the ring finger domain (TRAF2 DeltaN), increases activities of p38 MAPK, ATF2, and the level of TNF alpha expression. Forced expression of TRAF2 DeltaN in HHMSX highly metastatic melanoma cells that lack Fas expression and thus utilize the TNF alpha -TNFR1 as the major apoptotic pathway sensitized cells to UV-induced apoptosis, An over twofold increase in degree of apoptosis was observed in TRAF2 DeltaN expressing cells that were treated with actinomycin D, anisomycin or with the radiomimetic drug neocarzinostatin, Sensitization by TRAF2 DeltaN is selective since it was not observed in response to either Taxol or cis-platinum treatment. TRAF2 DeltaN effects are primarily mediated via p38 since inhibition of p38 reduces, whereas activation of p38 promotes the level of UV-induced apoptosis, Conversely, activation of IKK attenuates the sensitization of melanoma by TRAF2 DeltaN, indicating that p38-mediated suppression of NF-kappaB activity is among TRAF2 DeltaN effects. Our finding identifies p38, TNF alpha and NF-kappaB among key players that efficiently sensitizes melanoma cells to UV-, ribotoxic (anisomycin) and radiomimetic chemicals-induced programmed cell death in response to aberrant TRAF2 signaling.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Norwegian Radium Hosp, Dept Tumor Biol, Oslo, Norway	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Oslo	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bakker TR, 1999, INT J CANCER, V80, P320; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MEIER F, 1998, BIOSCIENCE, V3, pD1005; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moretti S, 1999, INT J CANCER, V84, P160, DOI 10.1002/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.3.CO;2-I; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Peixoto JGP, 2000, PHYS MED BIOL, V45, P563, DOI 10.1088/0031-9155/45/3/301; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Ruller S, 1999, CLIN CANCER RES, V5, P2714; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; TYERS M, 2000, IN PRESS CURR OPIN G; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yang YM, 1996, ONCOGENE, V12, P2223; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2243	2253		10.1038/sj.onc.1204314	http://dx.doi.org/10.1038/sj.onc.1204314			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402319	Green Published			2022-12-28	WOS:000168404500006
J	Constantino, S; Santos, R; Lacronique, V; Bouchaert, I; Monni, R; Bernard, O; Gisselbrecht, S; Gouilleux, F				Constantino, S; Santos, R; Lacronique, V; Bouchaert, I; Monni, R; Bernard, O; Gisselbrecht, S; Gouilleux, F			Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway	ONCOGENE			English	Article						STAT5; PI 3-kinase; TEL-JAK2; survival	PERIPHERAL-BLOOD CELLS; BCR-ABL ONCOGENE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; CYCLE PROGRESSION; FUSION PROTEIN; ACTIVATION; RECEPTOR; KINASE	Signal Transducer and Activator of Transcription (STATs) are important mediators of cytokine and growth factor-induced signal transduction, STAT5A and STAT5B have been shown to play a role in survival and proliferation of hematopoietic cells both in vitro and in viro and to contribute to the growth and viability of cells transformed by the TEL-JAK2 oncoprotein, In this study, we investigated the molecular mechanisms by which constitutively active STAT5 proteins induce cell proliferation and survival of Ba/F3 cell lines expressing either dominant positive STAT5A or STAT5B variants or TEL-JAK2 or TEL-ABL fusion proteins. Our results showed that active STAT5 constitutively interacted with p85, the regulatory subunit of the PT 3-kinase, A constitutive activity of the PI 3-kinase/Akt pathway was observed in these cells and required for their cell cycle progression. In contrast, while activity of the PI 3-kinase/Akt pathway was required for survival of Ba/F3 cells expressing the constitutively active forms of STAT5A or STAT5B, it was dispensable for cells transformed by TEL-JAK2 or TEL-ABL fusion proteins, suggesting that additional survival pathways take place in these transformed cells.	Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France; INSERM, U434, CEPH, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gouilleux, F (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Penard-Lacronique, Virginie/R-1938-2019; Santos, Susana/AAM-8902-2021; Penard-Lacronique, Virginie/E-5729-2016; Bernard, Olivier A./E-5721-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Gouilleux, Fabrice/0000-0001-6047-1718; Bernard, Olivier/0000-0002-0463-9747; Constantino Rosa Santos, Susana/0000-0002-5711-1292				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DEL PL, 1997, SCIENCE, V278, P687; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kieslinger M, 2000, GENE DEV, V14, P232; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TOKER A, 1994, J BIOL CHEM, V269, P32358; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	39	63	62	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2080	2090		10.1038/sj.onc.1204308	http://dx.doi.org/10.1038/sj.onc.1204308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360192	Green Published			2022-12-28	WOS:000168116700003
J	Weterman, MAJ; van Groningen, JJM; den Hartog, A; van Kessel, AG				Weterman, MAJ; van Groningen, JJM; den Hartog, A; van Kessel, AG			Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes	ONCOGENE			English	Article						renal cell carcinoma; TFE3; PRCC; malignant transformation; t(X;1)	HELIX-LOOP-HELIX; TRANSLOCATION X-1; TUMORS; SUBTYPE; ADENOCARCINOMA; CLASSIFICATION; ZIPPER; CHILD	A recurrent chromosomal abnormality associated with a subset of papillary renal cell carcinomas is t(X;1)(p11;q21). This translocation leads to the formation of two fusion genes, TFE3PRCC and the reciprocal product PRCCTFE3. Both fusion genes are expressed in t(X;1)-positive renal cell carcinomas and contain major parts of the coding regions of the parental transcription factor PRCC and TFE3 genes, respectively. To find out whether these fusion genes possess transforming capacity, we transfected NIH3T3 and rat-1 cells with the fusion products, either separately or combined, When using soft agar assays, we observed colony formation in all cases. NIH3T3 cells transfected with PRCCTFE3 or PRCCTFE3 together with TFE3PRCC yielded the highest colony forming capacities. Examination of other characteristics associated with malignant transformation, i.e., growth under low-serum conditions and formation of tumors in athymic nude mice, revealed that cells transfected nith PRCCTFE3 exhibited all these transformation-associated characteristics. Upon transfection of the fusion products into conditionally immortalized kidney cells, derived from the proximal tubules of an H-2Kb-tsA58 transgenic mouse, and consecutive incubation under non-permissive conditions, growth arrest was observed, followed by differentiation except for those cells transfected with PRCCTFE3, Therefore, we conclude that PRCCTFE3 may be the t(X;1)-associated fusion product that is most critical for the development of papillary renal cell carcinomas.	Univ Nijmegen, Med Ctr, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Weterman, MAJ (corresponding author), Univ Nijmegen, Med Ctr, Dept Human Genet 417, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; Carcao MD, 1998, MED PEDIATR ONCOL, V31, P153, DOI 10.1002/(SICI)1096-911X(199809)31:3<153::AID-MPO5>3.0.CO;2-A; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; Desangles F, 1999, CANCER GENET CYTOGEN, V113, P141, DOI 10.1016/S0165-4608(98)00261-1; DIJKHUIZEN T, 1995, GENE CHROMOSOME CANC, V14, P43, DOI 10.1002/gcc.2870140108; HERNANDEZMARTI MJ, 1995, CANCER GENET CYTOGEN, V83, P82, DOI 10.1016/0165-4608(94)00184-7; KOVACS G, 1988, CYTOGENET CELL GENET, V48, P242, DOI 10.1159/000132637; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Perot C, 1999, CANCER GENET CYTOGEN, V110, P54, DOI 10.1016/S0165-4608(98)00181-2; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; VANDENBERG E, 1993, INT J CANCER, V55, P223, DOI 10.1002/ijc.2910550210; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 1996, HUM GENET, V98, P16, DOI 10.1007/s004390050153; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044	22	25	27	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1414	1424		10.1038/sj.onc.1204213	http://dx.doi.org/10.1038/sj.onc.1204213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313885				2022-12-28	WOS:000167595200002
J	Guiducci, C; Cerone, MA; Bacchetti, S				Guiducci, C; Cerone, MA; Bacchetti, S			Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability	ONCOGENE			English	Article						telomerase; hTR mutants; telomere malfunction	IN-VITRO; RNA COMPONENT; DNA-DAMAGE; PROTEIN; TRF2; RECONSTITUTION; LENGTH; YEAST; END; INSTABILITY	We have reconstituted wild type or mutant telomerase activity in two human cell lines that lack constitutive expression of both core subunits of the enzyme and maintain telomeres by a telomerase-independent mechanism (ALT cells). Wild type telomerase RNA and four telomerase RNAs with single point mutations in their template domain were used to express enzymes specifying different telomeric DNA sequences, Expression of wild type telomerase for up to 32 days had no detectable effect on cell growth or viability, In contrast, cells expressing mutant telomerases had slower growth rate, abnormal cell cycle and reduced viability. Dramatically aberrant nuclei, typical of cells undergoing mitotic catastrophe, and large numbers of fused chromosomes were also characteristic of these populations, Notably, all phenotypes were apparent within the first few cell divisions after expression of the enzymes. Unlike wild type, mutant telomerase activity was progressively selected against with cell culturing, and this correlated with the disappearance of cells with aberrant phenotypes. Our results suggest that even very limited synthesis of mutated sequences can affect telomere structure in human cells, and that the toxicity of mutant telomerases is due to telomere malfunction.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	McMaster University	Bacchetti, S (corresponding author), McMaster Med Ctr, Room 4H30,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1196; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Evans SK, 2000, J CELL SCI, V113, P3357; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Iijima M, 1996, INT J CANCER, V66, P698; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRK KE, 1997, SCIENCE, V275, P1748; Kurenova EV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1242; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; MCEACHERN M, 1995, NATURE, V376, P404; McEachern MJ, 2000, P NATL ACAD SCI USA, V97, P11409, DOI 10.1073/pnas.210388397; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Namba M, 1981, GANN MONOGR CANCER R, V27, P221; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	56	78	85	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					714	725		10.1038/sj.onc.1204145	http://dx.doi.org/10.1038/sj.onc.1204145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314005				2022-12-28	WOS:000166806000007
J	Bartke, T; Siegmund, D; Peters, N; Reichwein, M; Henkler, F; Scheurich, P; Wajant, H				Bartke, T; Siegmund, D; Peters, N; Reichwein, M; Henkler, F; Scheurich, P; Wajant, H			p53 upregulates cFLIP, inhibits transcription of NF-kappa B-regulated genes and induces caspase-8-independent cell death in DLD-1 cells	ONCOGENE			English	Article						apoptosis; FLIP; NF-kappa B; p53; caspase; death receptors	DOMAIN-CONTAINING PROTEIN; P53-DEPENDENT APOPTOSIS; CASPASE HOMOLOG; IN-VIVO; ACTIVATION; FLICE; FAS; EXPRESSION; INTERACTS; INDUCTION	One of the main functions of the tumor suppressor p53 is the induction of programmed cell death, Here we investigated in detail the molecular mechanisms that underlay p53 transactivation-dependent apoptosis in the human colon cancer cell line DLD-1, Although p53 upregulated the death receptors Fas, TRAIL-R1 and TRAIL-R2 in this cell line, p53-induced cell death occurred without detectable caspase-8 activation whereas, activation of caspase-9 and caspase-3 was readily observed. In addition to the upregulation of death receptors, p53 induced the pro-apoptotic Bcl-2 family members Bik and Bak and downregulated the anti-apoptotic Bcl-xL protein. Moreover, in RNase protection assay analyses as well as in reporter gene analyses we found a p53-dependent upregulation of the death receptor-inhibitory protein cFLIP. Together, these data argue for a p53-mediated activation of the mitochondrial pathway of apoptosis, In contrast to recently published data obtained in different cellular systems, there was no evidence for an essential role of NF-kappaB in p53-induced cell death. Moreover, induction of p53 interfered,with TNF-induced NF-kappaB activation independently from apoptosis-induction.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; EL DW, 1993, CELL, V75, P817; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Uberti D, 2000, AMINO ACIDS, V19, P253, DOI 10.1007/s007260070056; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	41	91	94	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					571	580		10.1038/sj.onc.1204124	http://dx.doi.org/10.1038/sj.onc.1204124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313989				2022-12-28	WOS:000166755000004
J	Sonneveld, E; Vrieling, H; Mullenders, LHF; van Hoffen, A				Sonneveld, E; Vrieling, H; Mullenders, LHF; van Hoffen, A			Mouse mismatch repair gene Msh2 is not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers	ONCOGENE			English	Article						mismatch repair; transcription-coupled repair; UV-damage; mouse fibroblasts	NUCLEOTIDE-EXCISION-REPAIR; INDUCED DNA-DAMAGE; CANCER; PREDISPOSITION; FIBROBLASTS; DEFICIENCY; CELLS	The human mutS homolog gene MSH2 is essential for DNA mismatch repair (MMR) and defects in this gene can result in increased mutagenesis, genomic instability and hereditary nonpolyposis colorectal cancer (HNPCC). Besides correcting mismatch errors arising from DNA replication, it mas shown that deficiencies in bacterial and human MMR genes including MSH2 resulted in defective transcription-coupled repair (TCR) of UV-induced photolesions. Here we show that MMR-deficient fibroblasts derived from two independent isogenic mouse strains,vith defined Msh2 deficiencies are as proficient in TCR of UV-induced cyclobutane pyrimidine dimers (CPD) as wildtype fibroblasts. Our results indicate that in mouse cells Msh2 is not essential for TCR of UV-induced CPD in contrast to bacteria and human cells and suggest that the biological effects of UV in mouse Msh2(-/-) cells and mice are not due to defective TCR.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis MGC, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Cell Biol & Genet MGC, NL-3000 DR Rotterdam, Netherlands; Interuniv Res Inst Radiopathol & Radiat Protect, JA Cohen Inst, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam	Mullenders, LHF (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis MGC, POB 9503, NL-2300 RA Leiden, Netherlands.		Vrieling, Harry/ABC-8068-2020	Vrieling, Harry/0000-0002-3034-2664				Berg RJW, 2000, CANCER RES, V60, P2858; Berry SE, 2000, CANCER RES, V60, P5773; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHEO DL, 1997, MUTAT RES, V4, P1; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Wind N, 1998, CANCER RES, V58, P248; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P99, DOI 10.1016/S0921-8777(99)00068-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Leadon SA, 1998, MUTAT RES-DNA REPAIR, V407, P177, DOI 10.1016/S0921-8777(98)00007-X; Leadon SA, 1997, CANCER RES, V57, P3784; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Reitmair AH, 1997, CANCER RES, V57, P3765; Rey O, 1999, ONCOGENE, V18, P6997, DOI 10.1038/sj.onc.1203180; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Sweder KS, 1996, GENETICS, V143, P1127; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; Van Sloun PPH, 1999, NUCLEIC ACIDS RES, V27, P3276, DOI 10.1093/nar/27.16.3276; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Wu JX, 1999, MOL CELL BIOL, V19, P8292	28	17	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					538	541		10.1038/sj.onc.1204125	http://dx.doi.org/10.1038/sj.onc.1204125			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313985				2022-12-28	WOS:000166562500014
J	Gatei, M; Shkedy, D; Khanna, KK; Uziel, T; Shiloh, Y; Pandita, TK; Lavin, MF; Rotman, G				Gatei, M; Shkedy, D; Khanna, KK; Uziel, T; Shiloh, Y; Pandita, TK; Lavin, MF; Rotman, G			Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; p53; p21(WAF1/CIP1); cdc2; alpha-lipoic acid; oxidative stress	DOUBLE-STRAND BREAKS; CELL-CYCLE CHECKPOINTS; ATM-DEFICIENT MICE; DNA-DAMAGE; OXIDATIVE DAMAGE; INDUCED PHOSPHORYLATION; GENOTOXIC STRESS; GENE-PRODUCT; P53; REPAIR	Cells from patients with the genetic disorder ataxia-telangiectasia (A-T) are hypersensitive to ionizing radiation and radiomimetic agents, both of which generate reactive oxygen species capable of causing oxidative damage to DNA and other macromolecules. We describe in A-T cells constitutive activation of pathways that normally respond to genotoxic stress, Basal levels of p53 and p21(WAF1/CIP1), phosphorylation on serine 15 of p53, and the Tyr15-phosphorylated form of cdc2 are chronically elevated in these cells. Treatment of A-T cells with the antioxidant alpha -lipoic acid significantly reduced the levels of these proteins, pointing to the involvement of reactive oxygen species in their chronic activation. These findings suggest that the absence of functional ATM results in a mild but continuous state of oxidative stress, which could account for several features of the pleiotropic phenotype of A-T.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; PO Royal Melbourne Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Labs, Brisbane, Qld 4029, Australia; Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Univ Queensland, PO Royal Melbourne Hosp, Dept Surg, Brisbane, Qld 4029, Australia	Tel Aviv University; Sackler Faculty of Medicine; QIMR Berghofer Medical Research Institute; Royal Melbourne Hospital; Columbia University; Royal Melbourne Hospital; University of Queensland	Rotman, G (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel.		Lavin, Martin F/F-5961-2014; Khanna, Kum Kum/I-1747-2013; Pandita, Tej K/AAM-9188-2020	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381	NINDS NIH HHS [NS31763, NS34746] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746, R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Appella E, 2000, PATHOL BIOL, V48, P227; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CANMAN CE, 1994, CANCER RES, V54, P5054; CONFORTH MN, 1985, SCIENCE, V227, P1589; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Pagano G, 1998, MED HYPOTHESES, V51, P253, DOI 10.1016/S0306-9877(98)90084-6; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PAULES RS, 1995, CANCER RES, V55, P1763; Reichenbach J, 1999, CLIN EXP IMMUNOL, V117, P535; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; SHILOH Y, 1985, ATAXIA TELANGIECTASI, P111; SiddooAtwal C, 1996, CANCER RES, V56, P443; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; TAYLOR AMR, 1989, INT J RADIAT BIOL, V56, P677, DOI 10.1080/09553008914551901; TEALE B, 1993, J BIOL CHEM, V268, P22450; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Varghese S, 1998, ARCH PHARM RES, V21, P640, DOI 10.1007/BF02976750; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Westphal CH, 1997, CANCER RES, V57, P1664; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	50	56	56	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					289	294		10.1038/sj.onc.1204111	http://dx.doi.org/10.1038/sj.onc.1204111			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313957				2022-12-28	WOS:000166411000002
J	Gross, AW; Ren, RB				Gross, AW; Ren, RB			Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells	ONCOGENE			English	Article						Bcr-Abl; v-Abl; CML; ALL; myeloid cells	CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; MOUSE BONE-MARROW; MYELOPROLIFERATIVE DISEASE; TRANSGENIC MICE; CONSTITUTIVE ACTIVATION; BCR/ABL; ONCOGENE; P210; DISTINCT	The Bcr-Abl/p210 fusion protein plays a primary role in the pathogenesis of chronic myelogenous leukemia (CML), Abelson murine leukemia virus, which encodes v-Abl/p160, induces a pre-B cell leukemia/lymphoma in mice. It has been unclear whether the apparent specificity of these two abl oncogenes for myeloid versus lymphoid neoplasms is due to specific intrinsic properties of these Abl oncoproteins, or due to the properties of the target cells expressing them. We have recently shown that expression of Bcr-Abl in bone marrow cells by retroviral transduction efficiently induces a myeloproliferative disorder in mice resembling human CML, In this study, we compared Ber-Abl/p210 and v-Abl/p160 in this mouse CML model. We found that early in the course of disease, both Bcr-Abl/p210 and v-Abl/p160 expanded early immature hematopoietic cells. Later Bcr-Abl/p210 selectively expanded myeloid cells while v-Abl/p160 primarily induced the rapid in vivo expansion of B lymphoblastic cells, along with a minor population of myeloid cells. In vitro, Bcr-Abl/p210 induced more growth of myeloid colonies from S-fluorouracil treated bone marrow than v-Abl/p160. These results, obtained under equal bone marrow transduction/transplantation conditions, indicate that Bcr-Abl/p210 has a greater intrinsic capacity than v-Abl/pl60 to induce the neoplastic growth of myeloid cells. In addition, we found that cultured cells expressing Bcr-Abl/p210 had more activated STAT5 than cells that expressed v-Abl/p160. This suggests that activation of STAT5 might be one part of the mechanism of abl oncogene disease specificity.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, Waltham, MA 02254 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, MS029, Waltham, MA 02254 USA.				NCI NIH HHS [CA68008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Coligan J.E., 1996, CURRENT PROTOCOLS IM; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Gross AW, 1999, MOL CELL BIOL, V19, P6918; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; Kieslinger M, 2000, GENE DEV, V14, P232; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; Shuai K, 1996, ONCOGENE, V13, P247; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Verfaillie CM, 1997, J LAB CLIN MED, V129, P584, DOI 10.1016/S0022-2143(97)90192-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	37	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6286	6296		10.1038/sj.onc.1204023	http://dx.doi.org/10.1038/sj.onc.1204023			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175343				2022-12-28	WOS:000166210500012
J	Ikeda, W; Nakanishi, H; Tanaka, Y; Tachibana, K; Takai, Y				Ikeda, W; Nakanishi, H; Tanaka, Y; Tachibana, K; Takai, Y			Cooperation of Cdc42 small G protein-activating and actin filament-binding activities of frabin in microspike formation	ONCOGENE			English	Article						frabin; Cdc42; microspikes; actin cytoskeleton; F-actin-binding activity	NUCLEOTIDE EXCHANGE FACTOR; CELL-CELL ADHESION; AARSKOG-SYNDROME; SYNDROME GENE; MDCK CELLS; N-WASP; RAC; DOMAIN; EXPRESSION; INVASION	Frabin is a GDP/GTP exchange protein for Cdc42 with actin filament (F-actin)-binding activity. Cdc42 is a small GTP-binding protein that forms filopodia-like microspikes in a variety of cells. Expression of frabin indeed forms microspikes through at Least activation of Cdc42 in MDCK cells and fibroblasts such as COS7, L, and NIH3T3 cells. However, the role of the F-actin-binding activity of frabin in the microspike formation remains unknown. We have examined here this role of frabin by expressing various frabin mutants, which have lost Cdc42-activating or F-actin-binding activity, with or without a dominant active mutant of Cdc42 in MDCK and COS7 cells. We show here that for the microspike formation, either of the Cdc42-activating and F- actin-binding activities of frabin alone is not sufficient and both the activities are necessary and that both the activities play a cooperative role in the microspike formation, The present results, together with the earlier finding that Cdc42 reorganizes the actin cytoskeleton at least through the N-WASP-Arp2/3 complex, suggest that frabin directly and indirectly reorganizes the actin cytoskeleton through its F-actin-binding and Cdc42-activating activities, respectively, in a cooperative manner, eventually leading to microspike formation.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058; Nakanishi, Hiroyuki/0000-0002-9765-0266				Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Gorski JL, 2000, DEV DYNAM, V218, P573, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1015>3.3.CO;2-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pasteris NG, 1999, GENOMICS, V60, P57, DOI 10.1006/geno.1999.5903; Pasteris NG, 2000, GENE, V242, P237, DOI 10.1016/S0378-1119(99)00518-1; PASTERIS NG, 1994, CELL, V79, P669; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Yasuda T, 2000, GENES CELLS, V5, P583, DOI 10.1046/j.1365-2443.2000.00349.x	26	23	23	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3457	3463		10.1038/sj.onc.1204463	http://dx.doi.org/10.1038/sj.onc.1204463			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429692				2022-12-28	WOS:000169478300001
J	Peters, DG; Klucher, KM; Perlingeiro, RCR; Dessain, SK; Koh, EY; Daley, GQ				Peters, DG; Klucher, KM; Perlingeiro, RCR; Dessain, SK; Koh, EY; Daley, GQ			Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice	ONCOGENE			English	Article						BCR/ABL; embryonic stem cell; chronic myeloid leukemia; interleukin-3	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; BCR-ABL; IN-VITRO; DIFFERENTIATION; GROWTH; EXPRESSION; ONCOGENE	During differentiation in vitro, Embryonic Stem (ES) cells generate both primitive erythroid and definitive myeloid lineages in a process that mimics hematopoiesis in the mammalian yolk sac, To investigate leukemic transformation of these embryonic hematopoietic progenitors, we infected differentiating cultures of ES cells with the Chronic Myeloid Leukemia-specific BCR/ABL oncoprotein. Following a period of liquid culture, we isolated two transformed subclones, EB57 and EB67, that retained characteristics of embryonic hematopoietic progenitors and induced a fatal leukemia in mice characterized by massive splenomegaly and granulocytosis, Histopathology of the spleen revealed an abundance of undifferentiated blast-like cells. Investigation of the clonal origins of the granulocytes in the peripheral blood demonstrated that the injected donor cells contributed modestly to the granulocyte population while the majority were host-derived, EB57 secretes IL-3 and unidentified cytokines that can stimulate autocrine and paracrine cell proliferation, presumably accounting for the reactive granulocytosis in diseased mice. These BCR/ABL transformed hematopoietic derivatives of ES cells recapitulate the relationship of BCR/ABL expression to IL-3 production that has been described for primitive hematopoietic progenitors from human CML patients, and illustrates the potential for autocrine and paracrine effects of BCR/ABL-infected cells in murine models.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Whitehead Inst, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute	Daley, GQ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R29CA076418, R01CA086991] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004463] Funding Source: NIH RePORTER; NCI NIH HHS [CA86991-01, CA76418-01] Funding Source: Medline; NHLBI NIH HHS [K08 HL 04463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson SM, 1996, BLOOD, V87, P238; Choi K, 1998, DEVELOPMENT, V125, P725; CROSS NCP, 1994, LEUKEMIA, V8, P186; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dexter T M, 1984, Prog Clin Biol Res, V148, P13; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EAVES AC, 1979, EXP HEMATOL, V7, P65; ELEFANTY AG, 1992, BLOOD, V79, P1271; FORSTEN KE, 1992, BIOPHYS J, V63, P857, DOI 10.1016/S0006-3495(92)81661-2; Ghaffari S, 1999, P NATL ACAD SCI USA, V96, P13186, DOI 10.1073/pnas.96.23.13186; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; Hariharan I K, 1988, Oncogene Res, V3, P387; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; ISSAAD C, 1994, BLOOD, V84, P3447; Jiang X, 2000, LEUKEMIA, V14, P1112, DOI 10.1038/sj.leu.2401752; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KOH EY, 2001, IN PRESS CHRONIC MYE; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Li S, 1999, BLOOD, V94, p600A; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; MANDANAS RA, 1992, LEUKEMIA, V6, P796; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SIRARD C, 1994, BLOOD, V83, P1575; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WILES MV, 1991, DEVELOPMENT, V111, P259; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	35	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2636	2646		10.1038/sj.onc.1204374	http://dx.doi.org/10.1038/sj.onc.1204374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420675				2022-12-28	WOS:000168652600004
J	Szutorisz, H; Palmqvist, R; Roos, G; Stenling, R; Schorderet, DF; Reddell, R; Lingner, J; Nabholz, M				Szutorisz, H; Palmqvist, R; Roos, G; Stenling, R; Schorderet, DF; Reddell, R; Lingner, J; Nabholz, M			Rearrangements of minisatellites in the human telomerase reverse transcriptase gene are not correlated with its expression in colon carcinomas	ONCOGENE			English	Article						hTERT; minisatellites; rearrangements; colon carcinoma	CATALYTIC SUBUNIT HTERT; SOMATIC MUTATIONS; SUSCEPTIBILITY LOCUS; VARIABLE NUMBER; INSULIN GENE; HUMAN THYMUS; ALLELIC LOSS; LIFE-SPAN; C-MYC; ACTIVATION	Telomerase activation is crucial in human carcinogenesis. The limiting component of telomerase, the catalytic subunit (hTERT), is undetectable in normal somatic cells but present in most tumor cells, including the earliest stages of colon carcinoma, The mechanisms involved in the differential expression in normal and tumor cells are not understood. In normal cells hTERT expression is shut down by a repressor, and upregulation could be a consequence of cis-acting changes in the hTERT gene, making it resistant to repression, We have identified a polymorphic and a monomorphic minisatellite in the second intron of the hTERT gene, and polymorphic one in intron 6, The polymorphic minisatellite in intron 2 contains binding sites for c-Myc, which has been shown to upregulate hTERT transcription, Screening colon carcinoma DNAs for rearrangements of hTERT minisatellites we detected no changes in 33 samples from tumors, most of which express hTERT, This indicates that size rearrangements of the hTERT minisatellites are not required for telomerase expression in colon carcinomas, Minor changes and one LOH were seen in five tumors.	Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; Childrens Med Res Inst, Westmead, NSW 2145, Australia	Umea University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Children's Medical Research Institute - Australia	Nabholz, M (corresponding author), Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Lingner, Joachim/0000-0002-2853-5803				Alakurtti K, 2000, GENE, V242, P65, DOI 10.1016/S0378-1119(99)00550-8; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; Fiskerstrand CE, 1999, FEBS LETT, V458, P171, DOI 10.1016/S0014-5793(99)01150-3; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gutierrez B, 1998, HUM GENET, V103, P319, DOI 10.1007/s004390050823; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; Horikawa I, 1999, CANCER RES, V59, P826; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; Larson GP, 1999, HUM MOL GENET, V8, P1985, DOI 10.1093/hmg/8.11.1985; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Murray J, 1999, GENOME RES, V9, P130; NAGEL S, 1995, CANCER RES, V55, P2866; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; Nikiforov YE, 1998, ONCOGENE, V17, P1983, DOI 10.1038/sj.onc.1202120; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Palmqvist R, 1998, BRIT J CANCER, V77, P917, DOI 10.1038/bjc.1998.152; Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Phillips NJ, 1996, CANCER RES, V56, P606; Prokhortchouk EB, 1998, J MOL BIOL, V280, P227, DOI 10.1006/jmbi.1998.1857; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shipman R, 1996, EUR J CANCER, V32A, P335, DOI 10.1016/0959-8049(95)00535-8; Takakura M, 1999, CANCER RES, V59, P551; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weitzel JN, 2000, CANCER RES, V60, P259; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yan P, 1999, J PATHOL, V189, P207, DOI 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yoshida R, 1999, ANTICANCER RES, V19, P2167	61	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2600	2605		10.1038/sj.onc.1204346	http://dx.doi.org/10.1038/sj.onc.1204346			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420670				2022-12-28	WOS:000168652500011
J	Toone, WM; Morgan, BA; Jones, N				Toone, WM; Morgan, BA; Jones, N			Redox control of AP-1-like factors in yeast and beyond	ONCOGENE			English	Review						AP-1; yeast; redox-control; stress	OXIDATIVE STRESS-RESPONSE; ATF1 TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; NUCLEAR EXPORT; GENE-EXPRESSION; BUDDING YEAST; CELL-CYCLE	Cells have evolved complex and efficient strategies for dealing with variable and often-harsh environments. A key aspect of these stress responses is the transcriptional activation of genes encoding defense and repair proteins. In yeast members of the AP-1 family of proteins are required for the transcriptional response to oxidative stress. This sub-family of AP-1 (called yAP-1) proteins are sensors of the redox-state of the cell and are activated directly by oxidative stress conditions. yAP-1 proteins are bZIP-containing factors that share homology to the mammalian AP-1 factor complex and bind to very similar DNA sequence sites, The generation of reactive oxygen species and the resulting potential for oxidative stress is common to all aerobically growing organisms, Furthermore, many of the features of this response appear to be evolutionarily conserved and consequently the study of model organisms, such as yeast, will have widespread utility. The important structural features of these factors, signaling pathways controlling their activity and the nature of the target genes they control will be discussed.	Christie Hosp NHS Trust, CRC, Cell Regulat Grp, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England; Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Newcastle University - UK	Jones, N (corresponding author), Christie Hosp NHS Trust, CRC, Cell Regulat Grp, Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Cottarel G, 1997, GENETICS, V147, P1043; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Millar JBA, 1999, BIOCHEM SOC SYMP, P49; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Ohmiya R, 1999, J BIOCHEM, V125, P1061, DOI 10.1093/oxfordjournals.jbchem.a022387; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Samejima I, 1997, EMBO J, V16, P6162, DOI 10.1093/emboj/16.20.6162; Samejima I, 1998, MOL BIOL CELL, V9, P2325, DOI 10.1091/mbc.9.8.2325; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; SHIMANUKI M, 1995, J CELL SCI, V108, P569; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Stitzel ML, 2001, GENE DEV, V15, P128, DOI 10.1101/gad.863801; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; VIDO K, 2001, IN PRESS J BIOL CHEM; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhang XT, 2000, MOL MICROBIOL, V36, P618, DOI 10.1046/j.1365-2958.2000.01877.x; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2000, BIOCHEM PHARMACOL, V59, P1, DOI 10.1016/S0006-2952(99)00289-0	75	129	137	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2336	2346		10.1038/sj.onc.1204384	http://dx.doi.org/10.1038/sj.onc.1204384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402331				2022-12-28	WOS:000168568700002
J	Vogt, PK				Vogt, PK			Jun, the oncoprotein	ONCOGENE			English	Review						oncogenic transformation; downstream target; dimerization; leucine zipper; transactivation	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; GROWTH-FACTOR-BETA; AP-1 TRANSCRIPTION FACTORS; ACTIVATED PROTEIN-KINASES; N-TERMINAL KINASE; TRANSFORMED AVIAN FIBROBLASTS; VASCULAR ENDOTHELIAL-CELLS; PUTATIVE TUMOR-SUPPRESSOR; LEUCINE ZIPPER DOMAIN	Cellular Jun (c-Jun) and viral Jun (v-Jun) can induce oncogenic transformation, For this activity, c-Jun requires an upstream signal, delivered by the,Jun N-terminal kinase (JNK), v-Jun does not interact with JNK; it is autonomous and constitutively active. v-Jun and c-Jun address overlapping but not identical sets of genes. Whether all genes essential for transformation reside within the overlap of the v-Jun and c-Jun target spectra remains to be determined. The search for transformation-relevant targets of Jun is moving into a new stage with the application of DNA microarrays technology. Genetic screens and functional tests remain a necessity for the identification of genes that control the oncogenic phenotype.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Dr, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Bornberg-Bauer E, 1998, NUCLEIC ACIDS RES, V26, P2740, DOI 10.1093/nar/26.11.2740; Bos T J, 1986, Princess Takamatsu Symp, V17, P23; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Chida K, 1999, CELL MOL LIFE SCI, V55, P297, DOI 10.1007/s000180050291; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN SB, IN PRESS ONCOGENE; DAI TN, 1995, ONCOGENE, V10, P849; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DeRisi J, 1996, NAT GENET, V14, P457; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Erlichman J, 1999, EUR J BIOCHEM, V263, P797, DOI 10.1046/j.1432-1327.1999.00561.x; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FRAME MC, 1991, ONCOGENE, V6, P205; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P8837, DOI 10.1073/pnas.90.19.8837; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GROSSI M, 1991, ONCOGENE, V6, P1767; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALUSKA FG, 1988, P NATL ACAD SCI USA, V85, P2215, DOI 10.1073/pnas.85.7.2215; Hartkamp J, 1999, CANCER RES, V59, P2195; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HARTL M, 1991, ONCOGENE, V6, P1623; HARTL M, 1992, CELL GROWTH DIFFER, V3, P909; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hirst JD, 1996, PROTEIN ENG, V9, P657, DOI 10.1093/protein/9.8.657; Hubank M, 1999, METHOD ENZYMOL, V303, P325; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Imafuku I, 1999, J CELL BIOL, V147, P121, DOI 10.1083/jcb.147.1.121; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; ITO T, 2000, IN PRESS J BIOL CHEM; JURDIC P, 1995, ONCOGENE, V11, P1699; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Kameda T, 1998, CANCER RES, V58, P867; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kilbey A, 1996, ONCOGENE, V12, P2409; Kim S, 1996, ONCOGENE, V12, P1043; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Kumazaki T, 1996, MECH AGEING DEV, V88, P111, DOI 10.1016/0047-6374(96)01712-5; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Ljungdahl S, 1997, EUR J BIOCHEM, V249, P648, DOI 10.1111/j.1432-1033.1997.t01-1-00648.x; Loftus TM, 1997, BIOCHEMISTRY-US, V36, P8224, DOI 10.1021/bi970288d; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL GM, 1992, VIROLOGY, V188, P373, DOI 10.1016/0042-6822(92)90768-K; MATTEI MG, 1990, ONCOGENE, V5, P151; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; METIVIER C, 1993, ONCOGENE, V8, P2311; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1994, ONCOGENE, V9, P2793; MORGAN JI, 1991, DISCUSS NEUROSCI, V7, P11; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Neyns B, 1999, INT J CANCER, V82, P687; NG L, 1993, NUCLEIC ACIDS RES, V21, P5831, DOI 10.1093/nar/21.25.5831; Nika J, 1997, YEAST, V13, P1155, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1155::AID-YEA166>3.3.CO;2-F; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; OEHLER T, 1993, ONCOGENE, V8, P1141; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Olman MA, 1999, BLOOD, V94, P2029, DOI 10.1182/blood.V94.6.2029.418k25_2029_2038; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PETRAK D, 1994, J IMMUNOL, V153, P2046; PULVERER BJ, 1993, ONCOGENE, V8, P407; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RANSONE LJ, 1989, INT J CANCER, P10; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAPP UR, 1994, ONCOGENE, V9, P3493; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RINAUDO JA, 1995, J CELL BIOCHEM, V58, P237, DOI 10.1002/jcb.240580212; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHERER SJ, 2000, J BIOL CHEM, V12, P12; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SCHUUR ER, 1995, CELL GROWTH DIFFER, V6, P219; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SU HY, 1991, ONCOGENE, V6, P1759; Sutcliffe JG, 2000, P NATL ACAD SCI USA, V97, P1976, DOI 10.1073/pnas.040537997; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; USUI H, 1994, J NEUROSCI, V14, P4915; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Watson A, 1998, J NEUROSCI, V18, P751; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Wong C, 1999, MOL CELL BIOL, V19, P1821; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xiao L, 2000, CANCER RES, V60, P400; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang WP, 2000, BIOCHEM BIOPH RES CO, V274, P872, DOI 10.1006/bbrc.2000.3244; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	222	250	262	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2365	2377		10.1038/sj.onc.1204443	http://dx.doi.org/10.1038/sj.onc.1204443			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402333				2022-12-28	WOS:000168568700004
J	Yin, ZN; Babaian, RJ; Troncoso, P; Strom, SS; Spitz, MR; Caudell, JJ; Stein, JD; Kagan, J				Yin, ZN; Babaian, RJ; Troncoso, P; Strom, SS; Spitz, MR; Caudell, JJ; Stein, JD; Kagan, J			Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q	ONCOGENE			English	Article						chromosome 18q; prostate cancer; loss of heterozygosity; tumor suppressor gene; Smad2; Smad4; DCC	IN-VIVO ALTERATIONS; GROWTH-FACTOR-BETA; HUMAN LUNG CANCERS; ALLELIC LOSS; DCC GENE; MUTATIONAL ANALYSIS; FREQUENT LOSS; COLORECTAL CARCINOMAS; CELL CARCINOMA; P53 PROTEIN	We studied loss of heterozygosity (LOH) on the long arm of human chromosome 18 in prostate cancer to determine the location of a putative tumor suppressor gene (TSG) and to correlate these losses with the pathological grade and stage of the cancer, Of 48 specimens analysed 17 (35.4%) lost at least one allele on chromosome 18q, All the specimens with allelic losses lost at least one allele within chromosomal region 18q21, Allelic losses picked at D18S51 (19%) and D18S858 (17%), A 0.58 cM DNA segment that includes the D18S858 locus and is flanked by the microsatellite loci D18S41 and D18S381, was lost in eight (47%) of 17 specimens with allelic losses, This segment was designated as a LOH cluster region 1 (LCR 1), Although Smad2 resides within LCR 1, it was not mutated in any of the six prostate cell lines (five prostate cancer cell lines and one immortalized prostate epithelial cell line) analysed, suggesting that it is not a candidate TSG in prostate cancer. A second LCR at 18q21, LCR 2, includes the D18S51 locus and is flanked by the D18S1109 and D18S68 loci, which are separated by 7.64 cM, LCR 2 was lost in six (35%) of the 17 specimens with chromosome 18q losses. These results suggest that chromosome 18q21 may harbor two candidate prostate cancer TSGs, The candidate TSGs DCC and Smad4 are located centromeric to the LCRs, No alleles were lost within or in close proximity to these genes, suggesting that they are not targets for inactivation by allelic losses in prostate cancer. Although there was no obvious correlation between chromosome 18q LOH and the pathological grade or stage, three (37.5%) of eight low-grade cancers and nine (32.1%) of 28 organ-confined cancers lost alleles at 18q21, suggesting that allelic losses are relatively early events in the development of invasive prostate cancer.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, 1515 Holcombe Blvd,Box 054, Houston, TX 77030 USA.				NCI NIH HHS [CA68578-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; [Anonymous], 1997, AJCC CANC STAGING MA; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOVA GS, 1993, CANCER RES, V53, P3869; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; Brooks JD, 1996, CANCER RES, V56, P3814; Cairns P, 1997, CANCER RES, V57, P5356; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CLIBY W, 1993, CANCER RES, V53, P2393; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooney KA, 1996, CANCER RES, V56, P1142; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; Crundwell MC, 1996, INT J CANCER, V69, P295, DOI 10.1002/(SICI)1097-0215(19960822)69:4<295::AID-IJC10>3.3.CO;2-#; Cunningham JM, 1996, CANCER RES, V56, P4475; DEGEORGES A, 1995, INT J CANCER, V62, P724, DOI 10.1002/ijc.2910620613; DEVILEE P, 1991, ONCOGENE, V6, P311; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1993, CANCER RES, V53, P2723; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Goggins M, 1998, CANCER RES, V58, P5329; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; HAHN SA, 1995, CANCER RES, V55, P4670; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HUANG Y, 1992, CANCER RES, V52, P6525; Ittmann M, 1996, CANCER RES, V56, P2143; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; KAGAN J, 1995, ONCOGENE, V11, P2121; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Latil A, 1999, PROSTATE, V40, P225, DOI 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MACOSKA JA, 1995, CANCER RES, V55, P5390; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Mottaz AE, 1997, PROSTATE, V31, P209; Nagatake M, 1996, CANCER RES, V56, P2718; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; REALE MA, 1994, CANCER RES, V54, P4493; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Salem CE, 1997, J UROLOGY, V158, P510, DOI 10.1016/S0022-5347(01)64520-8; Schutte M, 1996, CANCER RES, V56, P2527; SHIBAGAKI L, 1994, CANCER RES, V54, P2995; SHISEKI M, 1994, CANCER RES, V54, P5643; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; TAKITA J, 1995, ONCOGENE, V11, P1829; Teng DHF, 1997, CANCER RES, V57, P5221; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TRAPMAN J, 1994, CANCER RES, V54, P6061; Uchida K, 1996, CANCER RES, V56, P5583; UCHINO S, 1992, CANCER RES, V52, P3099; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; VISAKORPI T, 1995, CANCER RES, V55, P342; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; ZAR JH, 1991, BIOSTATISTICAL ANAL; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	70	21	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2273	2280		10.1038/sj.onc.1204310	http://dx.doi.org/10.1038/sj.onc.1204310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402322				2022-12-28	WOS:000168404500009
J	Belka, C; Schmid, B; Marini, P; Durand, E; Rudner, J; Faltin, H; Bamberg, M; Schulze-Osthoff, K; Budach, W				Belka, C; Schmid, B; Marini, P; Durand, E; Rudner, J; Faltin, H; Bamberg, M; Schulze-Osthoff, K; Budach, W			Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL	ONCOGENE			English	Article						TRAIL; radiation; caspase-8; Bcl-2; apoptosis	RADIATION-INDUCED APOPTOSIS; CYTOCHROME-C; TUMOR-CELLS; EXPRESSION; GENE; CASPASE-8; RECEPTORS; SURVIVAL; RELEASE; FADD	A combination of antitumor approaches acting on different death pathways seems ideal for increasing therapeutic responses, especially when defined resistance mechanisms interfere with individual cellular processes. Apoptosis pathways triggered by ionizing radiation (XRT) and the death ligand TRAIL were analysed in Jurkat lymphoma cells. Both induced the activation of caspase-8, caspase-3, BID and mitochondrial potential loss, TRAIL induced apoptosis required caspase-8, whereas it was not essential for radiation induced apoptosis. The inhibition of mitochondrial damage by Bcl-2 abrogated XRT induced apoptosis and caspase activation, but only marginally attenuated TRAIL induced cell death. The combined treatment with TRAIL and XRT exerted additive apoptotic effects in control cells, whereas highly synergistic effects occurred in cells overexpressing Bcl-2. In addition, a strong effect of TRAIL on radiation induced clonogenic cell death was found. In conclusion, TRAIL seems to be of high potential value for a combination with ionizing radiation in tumor therapy.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Munster, Inst Expt Dermatol, Dept Immunol & Cell Biol, D-48149 Muenster, Germany	Eberhard Karls University of Tubingen; University of Munster	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Rudner, Justine/ABD-1397-2021; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				ALDRIDGE DR, 1995, BRIT J CANCER, V71, P571, DOI 10.1038/bjc.1995.111; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong BD, 2000, CANCER RES, V60, P5754; GRECO WR, 1995, PHARMACOL REV, V47, P331; GREEN MHL, 1991, INT J RADIAT BIOL, V59, P749, DOI 10.1080/09553009114550661; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheikh MS, 1998, CANCER RES, V58, P1593; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	29	116	122	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2190	2196		10.1038/sj.onc.1204318	http://dx.doi.org/10.1038/sj.onc.1204318			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360204				2022-12-28	WOS:000168116700015
J	Zhou, HQ; Lee, KAW				Zhou, HQ; Lee, KAW			An hsRPB4/7-dependent yeast assay for trans-activation by the EWS oncogene	ONCOGENE			English	Article						EWS oncogene; transcriptional activation; yeast; RPB4; RPB7	RNA-POLYMERASE-II; 2 DISSOCIABLE SUBUNITS; TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONAL ACTIVATION; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; CHIMERIC PROTEIN; STRESS SURVIVAL; CELL VIABILITY; FUSION	Chromosomal fusions of the N-terminal region of the Ewings Sarcoma Oncogene (EWS-Activation-Domain, EAD) to the DNA-binding domains of a variety of cellular transcription factors, produce oncogenic proteins (EWS-fusion proteins (EFPs)) that cause a variety of malignancies. The EAD can act as a potent transcriptional activation domain and is required for the oncogenic activity of EFPs. Previous studies demonstrating a physical interaction between the EAD and the human RNA Polymerase II subunit hsRPB7 suggest a crucial role for RPB7 and its partner, RPB4, in EAD function. Homologues of hsRPB4/7 exist in S. cerevisiae, and here we describe an RPB4/7-dependent yeast assay for EAD-mediated trans-activation. Conditional yeast strains lacking RPB4 are defective for transactivation by a Gal4/EAD fusion protein at the permissive temperature. Introduction of hsRPB4 alone is unable to rescue trans-activation, while a combination of hsRPB4 and hsRPB7 significantly rescues activity. These findings provide the first functional evidence for a direct role of the RPB4/7 complex in EAD-mediated trans-activation. In addition, the yeast assay provides a tractable system for further molecular analysis of EAD and RPB4/7 action.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.		Zhou, Huiqing/B-1721-2013	Zhou, Huiqing/0000-0002-2434-3986				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BROWN AD, 1995, ONCOGENE, V10, P1749; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fujimura Y, 1996, ONCOGENE, V12, P159; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Khazak V, 1998, MOL CELL BIOL, V18, P1935, DOI 10.1128/MCB.18.4.1935; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kovar Heinrich, 1999, Current Opinion in Oncology, V11, P275, DOI 10.1097/00001622-199907000-00007; Larkin RM, 1998, J BIOL CHEM, V273, P5631, DOI 10.1074/jbc.273.10.5631; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; OHNO T, 1993, CANCER RES, V53, P5859; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; Sakurai H, 1999, MOL CELL BIOL, V19, P7511; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Schaller S, 1999, FEBS LETT, V461, P253, DOI 10.1016/S0014-5793(99)01441-6; Shen XQ, 1999, ENDOCRINE, V10, P281, DOI 10.1007/BF02738627; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	29	19	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1519	1524		10.1038/sj.onc.1204135	http://dx.doi.org/10.1038/sj.onc.1204135			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313895				2022-12-28	WOS:000167595200012
J	Zubilewicz, A; Hecquet, C; Jeanny, JC; Soubrane, G; Courtois, Y; Mascarelli, F				Zubilewicz, A; Hecquet, C; Jeanny, JC; Soubrane, G; Courtois, Y; Mascarelli, F			Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: A comparative study with VEGF	ONCOGENE			English	Article						FGF2; proliferation; endothelial cells; angiogenesis; VEGF	ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; NITRIC-OXIDE; EXPRESSION; MECHANISM; RAS; DIFFERENTIATION; APOPTOSIS	In the retina, angiogenesis is an important component of normal physiological events such as embryonic vascular development. It is also involved in pathological processes including diabetic retinopathies and age-related macular degeneration, and tumour growth such as choroidal melanoma, Fibroblast growth factor (FGF) 2 and vascular endothelial cell growth factor (VEGF) are the two major angiogenic factors in the retina. We investigated the mechanism of proliferation and regulation of the mitogenic properties of FGF2 VEGF in cultures of chorocapillary endothelial cells (CEC), FGF2 is a strong mitogen for CEC and induced a 2.5-fold increase in cell proliferation after 4 days in culture in the absence of serum. In contrast, VEGF is a poor mitogen for CEC, FGF2, but not VEGF induces a large activation of MEK1, ERK1/2 and P90(RSK) during CEC proliferation. Pharmacological inhibition of Ras processing, and of MEK1 and ERK1/2 activation reduced only by 50% FGF2-induced cell proliferation, suggesting that there is another signalling pathway for CEC proliferation. Pharmacological inhibition of the PI 3-Kinase also inhibits by half FGF2-induced CEC proliferation, FGF2 stimulates the activation of the PI 3-K, P70(S6K) and Akt, Inhibition of both ERK1/2 and PI 3-K activities suppressed FGF2-induced CEC proliferation, demonstrating that CEC proliferation requires both ERKs and PI 3-K pathways. These data on the molecular mechanism and signalling may have important implications for providing more selective methods for anti-angiogenic and anti-tumoural therapy.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; Med Sch Lublin, Dept Ophthalmol, PL-20079 Lublin, Poland	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Medical University of Lublin	Mascarelli, F (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.		Mascarelli, Frederic/L-8916-2018					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; BRIAN C, 1997, J BIOL CHEM, V272, P27665; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Bullard LE, 2000, INVEST OPHTH VIS SCI, V41, pS140; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; ENAIDA H, 1998, MED SCI, V44, P43; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; Guillonneau X, 1996, J CELL PHYSIOL, V166, P170, DOI 10.1002/(SICI)1097-4652(199601)166:1<170::AID-JCP19>3.0.CO;2-J; Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186; GUYER DR, 1994, RETINA, V1, P1831; Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145; Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Marumo T, 1999, J VASC RES, V36, P510, DOI 10.1159/000025694; Mounho BJ, 1999, TOXICOL APPL PHARM, V159, P125, DOI 10.1006/taap.1999.8740; O'Gorman DM, 2000, LEUKEMIA, V14, P602, DOI 10.1038/sj.leu.2401726; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; RYAN SJ, 1994, RETINA, V2, P1027; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063; SPAKS SH, 1973, BR J OPHTHALMOL, V57, P951; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TAZAKE K, 2000, JPN J CANCER RES, V90, P647; Tudan C, 1998, BIOCHEM J, V331, P531, DOI 10.1042/bj3310531; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	55	74	83	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2001	20	12					1403	1413		10.1038/sj.onc.1204231	http://dx.doi.org/10.1038/sj.onc.1204231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313884				2022-12-28	WOS:000167595200001
J	Mitin, N; Kudla, AJ; Konieczny, SF; Taparowsky, EJ				Mitin, N; Kudla, AJ; Konieczny, SF; Taparowsky, EJ			Differential effects of Ras signaling through NF kappa B on skeletal myogenesis	ONCOGENE			English	Article						Ras; myogenesis; NF kappa B; signal transduction	ACTIVATED PROTEIN-KINASE; CELL-CYCLE PROGRESSION; ONCOGENIC RAS; TRANSCRIPTIONAL ACTIVITY; MUSCLE DIFFERENTIATION; MAP KINASE; 3T3 CELLS; INHIBITION; GROWTH; TRANSFORMATION	Oncogenic Ras (H-Ras G12V) inhibits skeletal myogenesis through multiple signaling pathways. Previously, we demonstrated that the major downstream effecters of Ras (i.e., MEK/MAPK, RalGDS and Rac/Rho) play a minor, if any, role in the differentiation-defective phenotype of Ras myoblasts, Recently, NF kappaB, another Ras signaling target, has been shown to inhibit myogenesis presumably by stimulating cyclin D1 accumulation and cell cycle progression. In this study, we address the involvement of NF kappaB activation in the Ras-induced inhibition of myogenesis, Using H-Ras G12V and three G12V effector-loop variants, we detect high levels of NF kappaB transcriptional activity in C3H10T1/2-MyoD cells treated with differentiation medium. Myogenesis is blocked by all Ras proteins tested, yet only in the case of H-Ras G12V are cyclin D1 levels increased and cell cycle progression maintained, Expression of I kappaB alpha SR, an inhibitor of NF kappaB, does not reverse the differentiation-defective phenotype of Ras expressing cultures, but does induce differentiation in cultures treated with tumor necrosis factor (TNF alpha) or in cultures expressing the RelA/p65 subunit of NF kappaB, These data confirm that NF kappaB is a target of Ras and suggest that the cellular actions of NF kappaB require additional signals that are discriminated by the Ras effector-loop variants. Results with I kappaB alpha SR convincingly demonstrate that H-Ras G12V does not rely on NF kappaB activity to block myogenesis, an observation that continues to implicate another unidentified signaling pathway(s) in the inhibition of skeletal myogenesis by Ras.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.		Mitin, Natalia/E-8043-2012		NCI NIH HHS [T32 CA09634] Funding Source: Medline; NIAMS NIH HHS [AR41115-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	60	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1276	1286		10.1038/sj.onc.1204223	http://dx.doi.org/10.1038/sj.onc.1204223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313872				2022-12-28	WOS:000167495000002
J	Wood, LD; Halvorsen, TL; Dhar, S; Baur, JA; Pandita, RK; Wright, WE; Hande, MP; Calaf, G; Hei, TK; Levine, F; Shay, JW; Wang, JJY; Pandita, TK				Wood, LD; Halvorsen, TL; Dhar, S; Baur, JA; Pandita, RK; Wright, WE; Hande, MP; Calaf, G; Hei, TK; Levine, F; Shay, JW; Wang, JJY; Pandita, TK			Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression	ONCOGENE			English	Article						ATM; hTERT; senescence; immortal; ionizing radiation	DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; HUMAN-CELLS; END ASSOCIATIONS; ATM KINASE; KAPPA-B; C-ABL; PROTEIN; CANCER; GENE	Ataxia-telangiectasia (A-T) is an autosomal recessive disease characterized by progressive cerebellar degeneration, immunodeficiencies, genomic instability and gonadal atrophy, A-T patients are hypersensitive to ionizing radiation and have an elevated cancer risk, Cells derived from A-T patients require higher levels of serum factors, exhibit cytoskeletal defects and undergo premature senescence in culture, We show here that expression of the catalytic subunit of telomerase (hTERT) in primary A-T patient fibroblasts can rescue the premature senescence phenotype, Ectopic expression of hTERT does not rescue the radiosensitivity or the telomere fusions in A-T fibroblasts. The hTERT+AT cells also retain the characteristic defects in cell-cycle checkpoints, and show increased chromosome damage before and after ionizing radiation, Although A-T patients have an increased susteptibility to cancer, the expression of hTERT in A-T fibroblasts does not stimulate malignant transformation. These immortalized A-T cells provide a more stable cell system to investigate the molecular mechanisms underlying the cellular phenotypes of Ataxia-telangiectasia.	Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Columbia University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine	Pandita, TK (corresponding author), Columbia Univ, Ctr Radiol Res, VC11-213,630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020; Baur, Joseph A/D-8163-2011; Levine, Fred/L-2693-2013; Wood, Laura/ABF-1531-2020; Shay, Jerry W/F-7878-2011; Hande, M. Prakash/B-1645-2008	Levine, Fred/0000-0002-7336-2526; Hande, M. Prakash/0000-0002-4511-6256; Baur, Joseph/0000-0001-8262-6549	NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, CA43054, R37 CA043054] Funding Source: Medline; NIDDK NIH HHS [DK55065] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner BP, 1999, CANCER RES, V59, P5456; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Harley CB, 1997, CANCER SURV, V29, P263; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sawant SG, 1999, FASEB J, V13, P1047, DOI 10.1096/fasebj.13.9.1047; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shay JW, 1996, LEUKEMIA, V10, P1255; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	65	78	81	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					278	288		10.1038/sj.onc.1204072	http://dx.doi.org/10.1038/sj.onc.1204072			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313956				2022-12-28	WOS:000166411000001
J	Fournes, B; Sadekova, S; Turbide, C; Letourneau, S; Beauchemin, N				Fournes, B; Sadekova, S; Turbide, C; Letourneau, S; Beauchemin, N			The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity	ONCOGENE			English	Article						CEACAM1; CEA; BGP; CD66a; C-CAM; tumor suppressor; colon cancer; Ser phosphorylation; PMA	HUMAN CARCINOEMBRYONIC ANTIGEN; BILIARY GLYCOPROTEIN CD66A; MOLECULE C-CAM; ADHESION MOLECULE; CYTOPLASMIC DOMAIN; ENDOGENOUS SUBSTRATE; ECTO-ATPASE; NEISSERIA-GONORRHOEAE; TYROSINE KINASE; GENE FAMILY	CEACAM1 (also known as biliary glycoprotein, C-CAM or CD66a) is a cell adhesion molecule of the immunoglobulin family behaving as a tumor inhibitory protein in colon, prostate, liver, endometrial and breast cancers. Inhibition of tumor development is dependent upon the presence of the long 71-73 amino acid cytoplasmic domain of the CEACAM1 protein (CEACAM1-L). We have recently defined a number of cis-acting motifs within the long cytoplasmic domain participating in tumor cell growth inhibition. These are Tyr488, corresponding to an Immunoreceptor Tyrosine-based Inhibition Motif, as web as the three terminal lysine residues of the protein. In this study, we provide evidence that treatment with phorbol esters leads to increased phosphorylation of in vivo P-32-labeled CEACAM1-L in mouse CT51 carcinoma cells, in the mouse 1MEA 7R.1 liver carcinoma cells and in 293 human embryonic kidney cells transfected with the Ceacam1-L cDNA. Basal level Ser phosphorylation was abrogated by treatment with the staurosporine inhibitor, but not by the protein kinase C-specific inhibitor calphostin C or other inhibitors such as H7 or sphingosine. Specific inhibitors of protein kinase A or calmodulin kinase had only minimal effects on the levels of basal or PMA-induced Ser phosphorylation, Furthermore, PMA treatment of the CT51 cells induced cell spreading and cellular relocalization of the CEACAM1-L protein. Since Ser503 has been described as a PMA-induced phosphorylation site in other cell systems, we investigated whether Ser503 was involved in these responses in mouse intestinal cells, No differences were noticed in the basal or the PMA-induced phosphorylation levels, kinase inhibitor sensitivity or the PMA-induced relocalization of the protein between the wild-type and the Ser503Ala mutant CEACAM1-L. However, we provide evidence that Ser503 participates in CEACAM1-L-mediated tumor inhibition as its mutation to an Ala led to in vivo tumor development, contrary to the tumor inhibitory phenotype observed with the wild-type CEACAM1-L protein.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osier, Montreal, PQ H3G 1Y6, Canada.							Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1999, EXP CELL RES, V252, P243; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BRUMMER J, 1995, ONCOGENE, V11, P1649; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; Danilov V, 1996, RUSS J MATH PHYS, V4, P272; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; FRANGSMYR L, 1995, CANCER RES, V55, P2963; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HANSSON M, 1989, EXP CELL RES, V181, P63, DOI 10.1016/0014-4827(89)90182-1; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ilantzis C, 1997, LAB INVEST, V76, P703; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kunath T, 1995, ONCOGENE, V11, P2375; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1998, ONCOGENE, V16, P1141, DOI 10.1038/sj.onc.1201619; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MCENTIRE KD, 1989, CANCER RES, V49, P6795; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nollau P, 1997, CANCER RES, V57, P2354; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P314; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Turbide C, 1997, CANCER RES, V57, P2781; VANDERGEER P, 1994, CELL BIOL LAB HDB, P422; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x	58	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					219	230		10.1038/sj.onc.1204058	http://dx.doi.org/10.1038/sj.onc.1204058			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313949				2022-12-28	WOS:000166410900009
J	Wu, YL; Mehew, JW; Heckman, CA; Arcinas, M; Boxer, LM				Wu, YL; Mehew, JW; Heckman, CA; Arcinas, M; Boxer, LM			Negative regulation of bcl-2 expression by p53 in hematopoietic cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; p53	WILD-TYPE P53; TATA-BINDING PROTEIN; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR P53; FOLLICULAR LYMPHOMA; HISTONE DEACETYLASES; FUNCTIONAL DOMAIN; CREB PROTEINS; MDR1 GENE; BAX GENE	The p53 protein activates promoters containing p53 binding sites, and it represses other promoters. We examined the effect of p53 on bcl-2 expression in both the DHL-4 B cell line and the K562 erythroleukemia line. Transient transfection analyses revealed that wild-type p53 repressed the bcl-2 full-length promoter, The region of the bcl-2 promoter that was responsive to p53 was mapped to the bcl-2 P2 minimal promoter region, and we showed that p53 and the TATA binding protein bound to the bcl-2 TATA sequence. The TATA binding protein, p53, histone deacetylase-1 and mSin3a could be co-immunoprecipitated from K562 cell nuclear extract, The TATA binding protein and mSin3a could be recovered in a complex at the bcl-2 promoter TATA. sequence, however, the formation of this complex was not dependent on the presence of p53. Treatment of K562 cells,vith the histone deacetylase inhibitor, trichostatin ii, resulted in an increase in bcl-2 promoter activity whether p53 was present or not. Therefore, we demonstrated that p53 and the histone deacetylases repress the bcl-2 promoter independently. Similar results were obtained when endogenous bcl-2 mRNA or protein levels were measured in response to either p53 or trichostatin A, and p53 expression resulted in enhanced apoptosis, RNase protection assays demonstrated that transcription from the endogenous 3' bcl-2 promoter was decreased by p53. The regions of p53 that were required for repression of the bcl-2 promoter were defined. We conclude that the TATA sequence in the bcl-2 P2 minimal promoter is the target far repression by p53, and that the interaction between p53 and TBP is most likely responsible for the repression. Mutation of p53 may play a role in the up-regulation of bcl-2 expression in some B cell lymphomas.	Palo Alto Vet Affairs Med Ctr, Ctr Mol Biol Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Boxer, LM (corresponding author), Palo Alto Vet Affairs Med Ctr, Ctr Mol Biol Med, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARRANS S, 1995, BRIT J HAEMATOL, V90, P830, DOI 10.1111/j.1365-2141.1995.tb05203.x; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gotlieb T. M., 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Ilyas M, 1996, J PATHOL, V180, P249; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kramer MHH, 1996, J CLIN ONCOL, V14, P2131, DOI 10.1200/JCO.1996.14.7.2131; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEVINE AJ, 1997, CELL, V88, P232; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Miyazaki N., 1994, HDB MARINE MAMMALS, V5, P1; Moller MB, 1999, MODERN PATHOL, V12, P1010; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nguyen PL, 1996, AM J CLIN PATHOL, V105, P538; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SAID JW, 1992, AM J PATHOL, V141, P1343; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; SOINI Y, 1992, J CLIN PATHOL, V45, P1011, DOI 10.1136/jcp.45.11.1011; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Takano Y, 1997, PATHOL INT, V47, P90, DOI 10.1111/j.1440-1827.1997.tb03726.x; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VILLUENDAS R, 1992, J PATHOL, V166, P235, DOI 10.1002/path.1711660305; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang TTY, 1997, CANCER LETT, V116, P61, DOI 10.1016/S0304-3835(97)00175-4; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; YOSHIDA M, 1990, J BIOL CHEM, V265, P13062; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	59	182	186	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					240	251		10.1038/sj.onc.1204067	http://dx.doi.org/10.1038/sj.onc.1204067			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313951				2022-12-28	WOS:000166410900011
J	Morin, MJ				Morin, MJ			From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents	ONCOGENE			English	Article						tyrosine kinase inhibitors; anti-tumor; antiangiogenesis	GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; IN-VIVO; SELECTIVE INHIBITOR; SIGNAL-TRANSDUCTION; ANTICANCER AGENTS; POTENT INHIBITOR; CANCER-THERAPY; PHASE-I; C-KIT	The confluence of two distinct but related activities in the past 10 years has dramatically accelerated efforts towards the discovery and development of novel drugs to treat cancer. The first is a rapidly emerging understanding that a number of distinct tyrosine kinases play roles in diverse but fundamentally important aspects of tumor progression (growth, survival, metastasis and angiogenesis). The second is the discovery that small molecule compounds have the capacity to potently and selectively inhibit the biochemical function of tyrosine kinases by competing for ATP binding at the enzyme catalytic site. These observations have been conjoined in major efforts to bring forward into clinical development novel cancer drugs with the potential to provide both clinical efficacy and improved tolerability. The focus of this review is on the development of small molecule tyrosine kinase inhibitors, and does not extend to other approaches that could be applied to disrupt the same pathways in clinical tumors (receptor and/or ligand-competitive antibodies, intrabodies, antisense ribonucleotides, ribozymes, phosphatase inhibitors or SH2/SH3-directed agents). Selected tyrosine kinase inhibitors, known or believed to be in development in cancer treatment trials, are summarized as are some of the key issues that must be addressed if these compounds are to be developed into clinically useful cancer chemotherapeutic agents.	Pfizer Global R&D, Groton, CT 06340 USA	Pfizer	Morin, MJ (corresponding author), Pfizer Global R&D, Groton, CT 06340 USA.							ALLEN LF, 2000, P NCI EO RTC AACR S, V384; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; BARBACCI EG, 1997, P AN ASS CANC RES, V38, P3143; BARTLETT RR, 1985, INT J IMMUNOPHARMACO, V7, P7, DOI 10.1016/0192-0561(85)90003-7; BASELGA J, 2000, P AN M AM SOC CLIN, V19, P686; Bold G, 2000, J MED CHEM, V43, P2310, DOI 10.1021/jm9909443; BONOMI P, 2000, P NCI EO RTC AACR S, V386; Bridges AJ, 1999, CURR MED CHEM, V6, P825; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COHEN RB, 2000, P AN M AM SOC CLIN, V19, P1862; Cohen S, 2000, ARTHRITIS RHEUM, V43, pS270; Connell RD, 2000, EXPERT OPIN THER PAT, V10, P767, DOI 10.1517/13543776.10.6.767; CROPP G, 1999, P AN M AM SOC CLIN, V18, P619; Dowsett M, 2000, EUR J CANCER, V36, P170, DOI 10.1016/S0959-8049(99)00264-6; Drevs J, 2000, CANCER RES, V60, P4819; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eckhardt SG, 1999, J CLIN ONCOL, V17, P1095, DOI 10.1200/JCO.1999.17.4.1095; Eisenhauer EA, 1998, ANN ONCOL, V9, P1047, DOI 10.1023/A:1008497110734; FERRY D, 2000, P AN M AM SOC CLIN, V19, pE5; Fong TAT, 1999, CANCER RES, V59, P99; Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garber K, 2000, J NATL CANCER I, V92, P967, DOI 10.1093/jnci/92.12.967; Ghosh S, 1999, ANTI-CANCER DRUG DES, V14, P403; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; GOSS G, 2000, P AN M AM SOC CLIN, V19, P880; Hamby JM, 1999, PHARMACOL THERAPEUT, V82, P169, DOI 10.1016/S0163-7258(98)00053-9; Hamilton LC, 1999, BRIT J PHARMACOL, V127, P1589, DOI 10.1038/sj.bjp.0702708; HAMMOND LA, 2000, P NCI EO TRC AACR S, V385; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hudes G, 1999, J CLIN ONCOL, V17, P1093, DOI 10.1200/JCO.1999.17.4.1093; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; IWATA K, 1997, P AM ASSOC CANC RES, V38, P4248; Karp DD, 1999, P AN M AM SOC CLIN, V18, P1499; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLY HC, 2000, P AM ASSOC CANC RES, V41, P3896; Kuo EA, 1996, J MED CHEM, V39, P4608, DOI 10.1021/jm9604437; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Laird AD, 2000, CANCER RES, V60, P4152; Lawrence DS, 1998, PHARMACOL THERAPEUT, V77, P81, DOI 10.1016/S0163-7258(97)00052-1; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Levitzki A, 1998, ANTI-CANCER DRUG DES, V13, P731; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MATTAR T, 1993, FEBS LETT, V334, P161, DOI 10.1016/0014-5793(93)81704-4; MEDINA L, 2000, P AM ASSOC CANC RES, V41, P3078; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; Moyer JD, 1997, CANCER RES, V57, P4838; NELSON JM, 2000, P AM ASSOC CANC RES, V41, P1533; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739; Randal J, 2000, J NATL CANCER I, V92, P520, DOI 10.1093/jnci/92.7.520; ROSEN L, 2000, P AN M AM SOC CLIN, V19, P708; ROSEN L, 1999, P AN M AM SOC CLIN, V18, P618; Sausville EA, 2000, ANTI-CANCER DRUG DES, V15, P1; Sedlacek HH, 2000, DRUGS, V59, P435, DOI 10.2165/00003495-200059030-00004; Shawver LK, 1997, CLIN CANCER RES, V3, P1167; Sherwood V., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P723; SIROTNAK FM, 2000, P AM ASSOC CANC RES, V41, P3076; Siu L.L., 1999, P AN M AM SOC CLIN, V18, P1498; SIU LL, 2000, P NCI EO RTC AACR S, V387; Smolen JS, 2000, RHEUMATOLOGY, V39, P48, DOI 10.1093/oxfordjournals.rheumatology.a031495; Sungaran R, 2000, BLOOD, V95, P3094, DOI 10.1182/blood.V95.10.3094.009k05_3094_3101; TALPAZ M, 2000, P AN M AM SOC CLIN, V19, P6; Thompson WD, 1999, J PATHOL, V187, P503, DOI 10.1002/(SICI)1096-9896(199904)187:5<503::AID-PATH279>3.0.CO;2-2; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vincent P. W., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P117; Wakeling AE, 1996, BREAST CANCER RES TR, V38, P67, DOI 10.1007/BF01803785; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; Wedge SR, 2000, CANCER RES, V60, P970; WEDGE SR, 2000, P AM ASSOC CANC RES, V41, P3610; WEDGE SR, 1999, P AM ASSOC CANC RES, V40, P2741; Wood JM, 2000, CANCER RES, V60, P2178; WOODBURN JR, 1997, P ANN M AM ASS CANC, V38, pA4251; Workman P., 2000, CURR OPIN ONCOL ENDO, V2, P21; XU XL, 1995, J BIOL CHEM, V270, P12398, DOI 10.1074/jbc.270.21.12398; Zhou SY, 1998, METH MOL B, V87, P87	83	107	125	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6574	6583		10.1038/sj.onc.1204102	http://dx.doi.org/10.1038/sj.onc.1204102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426642				2022-12-28	WOS:000167704000003
J	Nestle, FO				Nestle, FO			Dendritic cell vaccination for cancer therapy	ONCOGENE			English	Article						melanoma; dendritic cells; immunotherapy; antigen-presenting cells; immunointervention	ANTIGEN-PRESENTING CELLS; T-HELPER-CELL; ANTITUMOR IMMUNITY; MELANOMA PATIENTS; PROSTATE-CANCER; TUMOR-CELLS; HUMAN BLOOD; PHASE-I; METASTATIC MELANOMA; PEPTIDE	A growing list of defined tumor-antigens opens the way to antigen specific immunotherapy of cancer. However current approaches are often limited in their potential to induce an effective anti-tumor response, Dendritic cells (DC) are natural adjuvants for the induction of antigen specific T cell response. They have been successfully used in clinical pilot trials to induce tumor specific immunity as well as clinical response in selected patients. Current research focuses on optimization of DC source, choice of antigen, antigen loading, mode of injection, as well as immune-monitoring. Finally, a variety of immune escape mechanisms are operative at the tumor site and have to be overcome for successful vaccination.	Univ Zurich, Sch Med, Dept Dermatol, CH-8091 Zurich, Switzerland	University of Zurich	Nestle, FO (corresponding author), Univ Zurich, Sch Med, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.							Almand B, 2000, CLIN CANCER RES, V6, P1755; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Becker Y, 1993, In Vivo, V7, P187; Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417; Boczkowski D, 2000, CANCER RES, V60, P1028; Borges L, 1999, J IMMUNOL, V163, P1289; BROCKER EB, 1982, IMMUNOBIOLOGY, V162, P333; Burch PA, 2000, CLIN CANCER RES, V6, P2175; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Eggert AAO, 1999, CANCER RES, V59, P3340; Enk AH, 1997, INT J CANCER, V73, P309, DOI 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3; FLAMMAND V, 1993, DENDRITIC CELLS FUND, P611; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; GRABBE S, 1991, J IMMUNOL, V146, P3656; Grassi F, 1998, J LEUKOCYTE BIOL, V64, P484, DOI 10.1002/jlb.64.4.484; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Holtl L, 1998, LANCET, V352, P1358, DOI 10.1016/S0140-6736(05)60748-9; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Hu XY, 1996, CANCER RES, V56, P2479; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; KNIGHT SC, 1985, P NATL ACAD SCI USA, V82, P4495, DOI 10.1073/pnas.82.13.4495; Lodge PA, 2000, CANCER RES, V60, P829; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; MARKOWICZ S, 1990, J CLIN INVEST, V85, P955, DOI 10.1172/JCI114525; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Morse MA, 1999, CLIN CANCER RES, V5, P1331; MUKHERJI B, 1995, P NATL ACAD SCI USA, V92, P8078, DOI 10.1073/pnas.92.17.8078; Murphy GP, 1999, PROSTATE, V38, P73; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; NESTLE FO, 1994, DERMATOL CLIN, V12, P271, DOI 10.1016/S0733-8635(18)30174-8; Nestle FO, 1997, AM J PATHOL, V150, P641; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nouri-Shirazi M, 2000, J IMMUNOL, V165, P3797, DOI 10.4049/jimmunol.165.7.3797; Panelli MC, 2000, J IMMUNOTHER, V23, P487, DOI 10.1097/00002371-200007000-00013; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; Reichardt VL, 1999, BLOOD, V93, P2411, DOI 10.1182/blood.V93.7.2411.407a24_2411_2419; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romero P, 1998, MOL MED TODAY, V4, P305, DOI 10.1016/S1357-4310(98)01280-5; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schreurs FWJ, 2000, CRIT REV ONCOGENESIS, V11, P1; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P2268, DOI 10.1073/pnas.96.5.2268; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 1999, ANNU REV MED, V50, P507; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	53	66	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6673	6679		10.1038/sj.onc.1204095	http://dx.doi.org/10.1038/sj.onc.1204095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426654				2022-12-28	WOS:000167704000015
J	Sementchenko, VI; Watson, DK				Sementchenko, VI; Watson, DK			Ets target genes: past, present and future	ONCOGENE			English	Review						Ets; transcription; target genes; expression arrays	COLONY-STIMULATING FACTOR; GA-BINDING-PROTEIN; NF-KAPPA-B; HEAVY-CHAIN GENE; VIRUS TYPE-I; TRANSCRIPTION FACTOR-BINDING; LONG TERMINAL REPEAT; CELL ANTIGEN RECEPTOR; SERUM RESPONSE FACTOR; CIS-ACTING ELEMENTS	Ets is a family of transcription factors present in species ranging from sponges to human. All family members contain an approximately 85 amino acid DNA binding domain, designated the Ets domain. Ets proteins bind to specific purine-rich DNA sequences with a core motif of GGAA/T, and transcriptionally regulate a number of viral and cellular genes. Thus, Ets proteins are an important family of transcription factors that control the expression of genes that are critical for several biological processes, including cellular proliferation, differentiation, development, transformation, and apoptosis. Here, we tabulate genes that are regulated by Ets factors and describe past, present and future strategies for the identification and validation of Ets target genes. Through definition of authentic target genes, we will begin to understand the mechanisms by which Ets factors control normal and abnormal cellular processes.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, 86 Jonathan Lucas St, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; Akbarali Y, 1996, J BIOL CHEM, V271, P26007, DOI 10.1074/jbc.271.42.26007; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDER WS, 1995, ONCOGENE, V10, P795; Amato SF, 1996, J IMMUNOL, V157, P146; ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Bamberger AM, 1997, MOL CELL ENDOCRINOL, V127, P71, DOI 10.1016/S0303-7207(96)03991-3; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Berland R, 1998, J IMMUNOL, V161, P277; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Boccia LM, 1996, MOL CELL BIOL, V16, P1929; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; Burk O, 1999, BBA-GENE STRUCT EXPR, V1446, P243, DOI 10.1016/S0167-4781(99)00097-4; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; CARDOT P, 1994, BIOCHEMISTRY-US, V33, P12139, DOI 10.1021/bi00206a017; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Cederberg A, 1999, J BIOL CHEM, V274, P165, DOI 10.1074/jbc.274.1.165; Chan YJ, 1996, J VIROL, V70, P8590, DOI 10.1128/JVI.70.12.8590-8605.1996; Chang LF, 1996, J BIOL CHEM, V271, P6467, DOI 10.1074/jbc.271.11.6467; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; Chen JH, 1996, ONCOGENE, V13, P1667; Chiang SY, 2000, J BIOL CHEM, V275, P24246, DOI 10.1074/jbc.M000820200; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Chotani MA, 2000, J BIOL CHEM, V275, P30432, DOI 10.1074/jbc.M003545200; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; COFFER P, 1994, ONCOGENE, V9, P911; Coles LS, 2000, J BIOL CHEM, V275, P14482, DOI 10.1074/jbc.275.19.14482; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, pR1; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; Doubeikovski A, 1997, J BIOL CHEM, V272, P24300, DOI 10.1074/jbc.272.39.24300; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; Edelman GM, 2000, P NATL ACAD SCI USA, V97, P3038, DOI 10.1073/pnas.040569897; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; Ernst P, 1996, MOL CELL BIOL, V16, P6121; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ezashi T, 1998, P NATL ACAD SCI USA, V95, P7882, DOI 10.1073/pnas.95.14.7882; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Flajolet M, 1997, ONCOGENE, V15, P1103, DOI 10.1038/sj.onc.1201257; Foulds CE, 1997, NUCLEIC ACIDS RES, V25, P2485, DOI 10.1093/nar/25.12.2485; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUJIMURA Y, 1994, NUCLEIC ACIDS RES, V22, P613, DOI 10.1093/nar/22.4.613; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Gagnon ML, 1999, J CELL BIOCHEM, V72, P492, DOI 10.1002/(SICI)1097-4644(19990315)72:4<492::AID-JCB5>3.0.CO;2-H; Gambarotta G, 1996, ONCOGENE, V13, P1911; GASTON K, 1995, GENE, V157, P257, DOI 10.1016/0378-1119(95)00120-U; GASTON K, 1995, NUCLEIC ACIDS RES, V23, P901, DOI 10.1093/nar/23.6.901; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GHYSDAEL J, 1997, PROG GENE EXPRESS, P29; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GOMOLIN HI, 1993, BLOOD, V82, P1868; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GOTO M, 1993, NUCLEIC ACIDS RES, V21, P209, DOI 10.1093/nar/21.2.209; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; Granger SW, 1998, J VIROL, V72, P8961, DOI 10.1128/JVI.72.11.8961-8970.1998; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Grombacher T, 1996, DNA CELL BIOL, V15, P581, DOI 10.1089/dna.1996.15.581; Groupp ER, 1996, J BIOL CHEM, V271, P12423, DOI 10.1074/jbc.271.21.12423; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Hermand P, 1996, BLOOD, V87, P2962, DOI 10.1182/blood.V87.7.2962.bloodjournal8772962; HEWETT PW, 1998, BIOCHEM BIOPH RES CO, V252, P456; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILFINGER JM, 1993, J VIROL, V67, P4448, DOI 10.1128/JVI.67.7.4448-4453.1993; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Inaba T, 1996, MOL CELL BIOL, V16, P2264; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Iwamoto S, 2000, J BIOL CHEM, V275, P27324; JABRANEFERRAT N, 1994, MOL CELL BIOL, V14, P7314, DOI 10.1128/MCB.14.11.7314; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; Kai H, 1999, J BIOL CHEM, V274, P20098, DOI 10.1074/jbc.274.29.20098; Kambe M, 1998, BBA-GENE STRUCT EXPR, V1395, P209, DOI 10.1016/S0167-4781(97)00152-8; Kamura T, 1997, J BIOL CHEM, V272, P11361; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kaya M, 1996, ONCOGENE, V12, P221; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Kienker LJ, 1998, J IMMUNOL, V161, P791; KISTLER B, 1995, ONCOGENE, V11, P1095; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; KOIZUMI H, 1993, MOL CELL BIOL, V13, P6690, DOI 10.1128/MCB.13.11.6690; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; Kondoh N, 1998, BRIT J CANCER, V78, P718, DOI 10.1038/bjc.1998.567; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; Kuprash DV, 1996, J IMMUNOL, V156, P2465; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lambert PF, 1997, MOL BIOL CELL, V8, P313, DOI 10.1091/mbc.8.2.313; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; Leduc I, 1996, MOL IMMUNOL, V33, P1277, DOI 10.1016/S0161-5890(96)00109-5; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; LEUNG S, 1993, ONCOGENE, V8, P989; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Li XR, 1999, J BIOL CHEM, V274, P35203, DOI 10.1074/jbc.274.49.35203; LIAO WC, 1994, NUCLEIC ACIDS RES, V22, P4044, DOI 10.1093/nar/22.20.4044; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Lin CS, 1997, DNA CELL BIOL, V16, P9, DOI 10.1089/dna.1997.16.9; LIN CS, 1993, J BIOL CHEM, V268, P2793; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; LIU SH, 1994, BIOCHEM BIOPH RES CO, V201, P1406, DOI 10.1006/bbrc.1994.1860; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Lok CN, 2000, J BIOL CHEM, V275, P24185, DOI 10.1074/jbc.M000944200; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma YS, 1998, J BIOL CHEM, V273, P8727, DOI 10.1074/jbc.273.15.8727; Mainguy G, 2000, NAT BIOTECHNOL, V18, P746, DOI 10.1038/77312; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; Markiewicz S, 1996, J BIOL CHEM, V271, P14849, DOI 10.1074/jbc.271.25.14849; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; Maul RS, 1998, J BIOL CHEM, V273, P33239, DOI 10.1074/jbc.273.50.33239; MAURY W, 1994, J VIROL, V68, P6270, DOI 10.1128/JVI.68.10.6270-6279.1994; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; McDonough J, 2000, J BIOL CHEM, V275, P28962, DOI 10.1074/jbc.M004181200; McKinlay LH, 1998, J IMMUNOL, V161, P4098; MCKNIGHT RA, 1995, MOL ENDOCRINOL, V9, P717, DOI 10.1210/me.9.6.717; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; MIYAJIMA I, 1995, BLOOD, V85, P1246, DOI 10.1182/blood.V85.5.1246.bloodjournal8551246; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Muller S, 1996, ONCOGENE, V13, P1955; Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588; Murakami K, 1997, DNA CELL BIOL, V16, P173, DOI 10.1089/dna.1997.16.173; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NERLOV C, 1991, ONCOGENE, V6, P1583; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; Nishiyama C, 1999, J IMMUNOL, V163, P623; NOTHIAS JY, 1993, J VIROL, V67, P3036, DOI 10.1128/JVI.67.6.3036-3047.1993; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Nozawa M, 2000, CANCER RES, V60, P1348; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OHBO K, 1995, J BIOL CHEM, V270, P7479, DOI 10.1074/jbc.270.13.7479; Olsen J, 1997, BIOCHEM J, V322, P899, DOI 10.1042/bj3220899; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Panitz F, 1998, EMBO J, V17, P4414, DOI 10.1093/emboj/17.15.4414; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; Pelczar H, 1997, BIOCHEM BIOPH RES CO, V239, P252, DOI 10.1006/bbrc.1997.7363; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; PUNTURIERI A, 1993, J IMMUNOL, V150, P139; Quan TH, 1999, J BIOL CHEM, V274, P28566, DOI 10.1074/jbc.274.40.28566; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Rao S, 1999, J BIOL CHEM, V274, P34245, DOI 10.1074/jbc.274.48.34245; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rebay I, 2000, GENETICS, V154, P695; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; Rehli M, 1999, J IMMUNOL, V162, P1559; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Rhodes K, 1998, J BIOL CHEM, V273, P26534, DOI 10.1074/jbc.273.41.26534; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; Rius C, 1998, BLOOD, V92, P4677; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; Rubin GM, 2000, SCIENCE, V287, P2216, DOI 10.1126/science.287.5461.2216; Rushton JJ, 1997, EUR J BIOCHEM, V245, P768, DOI 10.1111/j.1432-1033.1997.00768.x; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Sapi E, 1998, CANCER RES, V58, P1027; Sapru MK, 1998, P NATL ACAD SCI USA, V95, P1289, DOI 10.1073/pnas.95.3.1289; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1994, ONCOGENE, V9, P469; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; SIDERAS P, 1994, J IMMUNOL, V153, P5607; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Starck J, 1999, MOL CELL BIOL, V19, P121; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Stutz AM, 1999, J IMMUNOL, V163, P4383; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; Thompson AA, 1996, BLOOD, V87, P666, DOI 10.1182/blood.V87.2.666.bloodjournal872666; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Turque N, 1997, INT J DEV BIOL, V41, P103; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; van Dijk TB, 1998, BLOOD, V92, P3636, DOI 10.1182/blood.V92.10.3636.422k45_3636_3646; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Venanzoni MC, 1996, ONCOGENE, V12, P1199; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Watson D K, 2000, Methods Mol Biol, V130, P1; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 2001, ENCY CANC; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Wilkinson NC, 1999, J BIOL CHEM, V274, P438, DOI 10.1074/jbc.274.1.438; WOTTON D, 1993, LEUKEMIA, V7, pS55; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yan SQ, 2000, DNA CELL BIOL, V19, P79, DOI 10.1089/104454900314591; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yang ZY, 1998, J BIOL CHEM, V273, P891, DOI 10.1074/jbc.273.2.891; Ying H, 1998, J IMMUNOL, V160, P2287; YOGANATHAN T, 1992, EUR J BIOCHEM, V207, P195, DOI 10.1111/j.1432-1033.1992.tb17037.x; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355; Youn BS, 1996, J IMMUNOL, V157, P3499; Zhang CY, 1997, J BIOL CHEM, V272, P26236, DOI 10.1074/jbc.272.42.26236; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhang YG, 1997, J IMMUNOL, V158, P1734	344	308	320	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6533	6548		10.1038/sj.onc.1204034	http://dx.doi.org/10.1038/sj.onc.1204034			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175369				2022-12-28	WOS:000166595000015
J	Okamoto, T; Izumi, H; Imamura, T; Takano, H; Ise, T; Uchiumi, T; Kuwano, M; Kohno, K				Okamoto, T; Izumi, H; Imamura, T; Takano, H; Ise, T; Uchiumi, T; Kuwano, M; Kohno, K			Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression	ONCOGENE			English	Article						Y-box binding proteins; p53; protein binding; transcriptional regulation	COLD-SHOCK DOMAIN; C-TERMINAL DOMAIN; HUMAN MDR1 GENE; DNA-BINDING; MESSENGER-RNA; ACTIVATION; PHOSPHORYLATION; SEQUENCE; DAMAGE; PROMOTER	The Y-box binding protein, YB-1, belongs to a family of multifunctional proteins which regulate gene expression on both transcriptional and translational levels. The tumor suppressor gene p53 displays growth suppressive properties by regulating gene expression through transcriptional regulation, We now demonstrate that YB-1 directly interacts with p53 using an in vitro pull-down assay. Using immunochemical co-precipitation methods, we also found that the two proteins are bound in vivo. Deletion analysis showed that three independent domains of YB-1, one at the N-terminal and two at the C-terminal, interact with p53. Conversely, a 14 amino acid sequence at the C-terminal of p53 was required for its interaction with YB-1, Gel mobility shift assays showed that the interaction of YB-1 with p53 stimulated the sequence-specific DNA binding of p53 to its consensus sequence, By contrast, this interaction inhibited the binding of YB-1, Using a p53-responsive p21 promoter linked to a reporter gene, it can be shown that antisense expression of YB-1 inhibits the induction of this promoter by p53 in transient transfection assays, These findings delineate a straightforward mechanism for gene expression through p53-YB-1 interaction.	Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Biochem Med, Fukuoka 8128582, Japan	University of Occupational & Environmental Health - Japan; Kyushu University	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.							ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bargou RC, 1997, NAT MED, V3, P378; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gu W, 1998, BIOL REPROD, V59, P1266, DOI 10.1095/biolreprod59.5.1266; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Herbert TP, 1999, NUCLEIC ACIDS RES, V27, P1747, DOI 10.1093/nar/27.7.1747; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Ise T, 1999, CANCER RES, V59, P342; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; KOHNO K, 1994, J BIOL CHEM, V269, P20503; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LENZ J, 1990, P NATL ACAD SCI USA, V87, P3396, DOI 10.1073/pnas.87.9.3396; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MIYASHITA T, 1995, CELL, V80, P293; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Ruzanov PV, 1999, J CELL SCI, V112, P3487; Safak R, 1999, MOL CELL BIOL, V19, P2712; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	46	134	141	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6194	6202		10.1038/sj.onc.1204029	http://dx.doi.org/10.1038/sj.onc.1204029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175333				2022-12-28	WOS:000166210500002
J	Nahum, A; Hirsch, K; Danilenko, M; Watts, CKW; Prall, OWJ; Levy, J; Sharoni, Y				Nahum, A; Hirsch, K; Danilenko, M; Watts, CKW; Prall, OWJ; Levy, J; Sharoni, Y			Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes	ONCOGENE			English	Article						lycopene; breast cancer; endometrial cancer; cell cycle; cyclin D1; retinoblastoma; p27(kip1)	1,25-DIHYDROXYVITAMIN D-3; ALPHA-CAROTENE; EXPRESSION; GROWTH; DIFFERENTIATION; RETINOIDS; RISK; P21; KINASES; GENE	Numerous studies have demonstrated the anticancer activity of the tomato carotenoid, lycopene. However, the molecular mechanism of this action remains unknown. Lycopene inhibition of human breast and endometrial cancer cell growth is associated with inhibition of cell cycle progression at the G(1) phase. In this study we determined the lycopene-mediated changes in the cell cycle machinery. Cells synchronized in the G1 phase by serum deprivation were treated with lycopene or vehicle and restimulated with 5% serum. Lycopene treatment decreased serum-induced phosphorylation of the retinoblastoma protein and related pocket proteins. This effect was associated with reduced cyclin-dependent kinase (cdk4 and cdk2) activities with no alterations in CDK protein levels. Lycopene caused a decrease in cyclin D1 and D3 levels whereas cyclin E levels did not change. The CDK inhibitor p21(Cip1/Waf1) abundance was reduced while p27(Kip1) levels were unaltered in comparison to control cells. Serum stimulation of control cells resulted in reduction in the p27 content in the cyclin E-cdk2 complex and its accumulation in the cyclin D1-cdk4 complex. This change in distribution was largely prevented by lycopene treatment. These results suggest that lycopene inhibits cell cycle progression via reduction of the cyclin D level and retention of p27 in cyclin E-cdk2, thus leading to inhibition of G(1) CDK activities.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Soroka Med Ctr Kupat Holim, Beer Sheva, Israel; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sharoni, Y (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, POB 653, IL-84105 Beer Sheva, Israel.		Danilenko, Michael/F-2283-2012; SHARONI, YOAV/F-1223-2012	Danilenko, Michael/0000-0001-9466-6169				Amir H, 1999, NUTR CANCER, V33, P105, DOI 10.1080/01635589909514756; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; COUNTRYMAN C, 1991, Clinical Chemistry, V37, P1056; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Karas M, 2000, NUTR CANCER, V36, P101, DOI 10.1207/S15327914NC3601_14; Kim DJ, 1997, CANCER LETT, V120, P15, DOI 10.1016/S0304-3835(97)00281-4; Kobayashi T, 1996, ANTI-CANCER DRUG, V7, P195, DOI 10.1097/00001813-199602000-00008; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEVY J, 1995, NUTR CANCER, V24, P257, DOI 10.1080/01635589509514415; Liu Y, 1996, CANCER RES, V56, P31; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; Michaud DS, 2000, AM J CLIN NUTR, V72, P990; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; NAGASAWA H, 1995, ANTICANCER RES, V15, P1173; Narisawa T, 1996, CANCER LETT, V107, P137, DOI 10.1016/0304-3835(96)04354-6; Sharoni Y, 1997, CANCER DETECT PREV, V21, P118; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SILVA MDP, 1997, MOL CELL BIOL, V17, P4059; Sweeney K J, 1996, Cancer Treat Res, V83, P141; TABIBZADEH S, 1990, IN VITRO CELL DEV B, V26, P1173; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; WANG C-J, 1989, Proceedings of the National Science Council Republic of China Part B Life Sciences, V13, P176; WANG CJ, 1989, CANCER LETT, V48, P135, DOI 10.1016/0304-3835(89)90050-5; Wang QM, 1996, CANCER RES, V56, P264; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang SM, 1997, AM J CLIN NUTR, V66, P626, DOI 10.1093/ajcn/66.3.626; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	40	166	171	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3428	3436		10.1038/sj.onc.1204452	http://dx.doi.org/10.1038/sj.onc.1204452			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423993				2022-12-28	WOS:000169248800013
J	Umbricht, CB; Evron, E; Gabrielson, E; Ferguson, A; Marks, J; Sukumar, S				Umbricht, CB; Evron, E; Gabrielson, E; Ferguson, A; Marks, J; Sukumar, S			Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer	ONCOGENE			English	Article						breast cancer; 14-3-3 sigma; methylation; MSP; DCIS; preneoplasia	DNA METHYLATION; ADJACENT; TISSUE; LEADS; CELLS	We have identified 14-3-3 sigma (sigma) as a gene whose expression is lost in breast carcinomas, primarily by methylation-mediated silencing. In this report, we investigated the timing of loss of sigma gene expression during breast tumorigenesis in vivo. We analysed the methylation status of sigma in breast cancer precursor lesions using microdissection for selective tissue sampling. We found hypermethylation of sigma in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38%) of atypical hyperplasias. None of the five hyperplasias without atypia showed sigma -hypermethylation. Unexpectedly, patients with breast cancer showed sigma hypermethylation in adjacent histologically normal breast epithelium, while this was never observed in individuals without evidence of breast cancer. Also, samples of periductal stromal breast tissue were consistently hypermethylated, underscoring the importance of selective tissue sampling for accurate assessment of 14-3-3-sigma methylation in breast epithelium, These results suggest that hypermethylation of 14-3-3-sigma occurs at an early stage in the progression to invasive breast cancer, and may occur in apparently normal epithelium adjacent to breast cancer. These results provide evidence that loss of expression of sigma is an early event in neoplastic transformation.	Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Mol Devices Corp, Sunnyvale, CA 94085 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Duke University	Sukumar, S (corresponding author), Johns Hopkins Oncol Ctr, Breast Canc Program, CCRB Room 410,1650 Orleans St, Baltimore, MD 21231 USA.			Evron, Ella/0000-0002-1003-5042	NCI NIH HHS [P21 CA/ES 66204, P50 CA88843-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA088843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Botti C, 2000, J AM COLL SURGEONS, V190, P530, DOI 10.1016/S1072-7515(00)00252-0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Nacht M, 1999, CANCER RES, V59, P5464; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Soria JC, 1999, CLIN CANCER RES, V5, P971; Umbricht CB, 1999, ONCOGENE, V18, P3407, DOI 10.1038/sj.onc.1202714	15	254	271	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3348	3353		10.1038/sj.onc.1204438	http://dx.doi.org/10.1038/sj.onc.1204438			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423985				2022-12-28	WOS:000169248800005
J	Kim, H; You, S; Farris, J; Foster, LK; Foster, DN				Kim, H; You, S; Farris, J; Foster, LK; Foster, DN			Post-transcriptional inactivation of p53 in immortalized murine embryo fibroblast cells	ONCOGENE			English	Article						p53 mRNA; immortal MEF; half-life; cycloheximide; emetine; actinomycin D	MYC MESSENGER-RNA; DEGRADATION; PROMOTES; DECAY; MDM2	The steady-state levels of p53 mRNA and protein were barely detectable by Northern and Western blot analysis in spontaneously immortalized (10)3 and (10)7 murine embryo fibroblast (MEF) cells, But when cells were treated with cycloheximide (CHX) or emetine, expression levels were restored to those observed in primary and immortal (10)10 MEF cells. However, levels of p53 mRNA were not changed in primary or (10)10 MEF cells by CHX treatment. De novo p53 mRNA synthetic rates were similar in primary, (10)10, (10)3, and (10)7 MEF cells treated with or without CHX. Treatment with actinomycin D (ActD) showed that p53 mRNA in primary and (10)10 MEF cells had a relatively long half-life of 22 h, compared to less than 2 h for (10)3 and (10)7 MEF cells. Pulse-chase analysis of p53 mRNA turnover using CHX and ActD showed that the rapid destabilization of p53 mRNA in (10)3 and (10)7 MEF cells could be regulated at the transcriptional and translational levels. In addition, the destabilization of p53 mRNA appeared to occur in the nucleus for (10)3 and (10)7 cells, but not for primary and (10)10 MEF cells. Taken together, the present study demonstrates: that inactivation of the p53 gene occurs at the posttranscriptional level by rapid destabilization of its mRNA in the nucleus of spontaneously immortalized (10)3 and (10)7 MEF cells.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA.		Kang, Phil Jun/F-4716-2013; Kim, Hyunggee/F-2673-2013; You, Seungkwon/H-3067-2015	Kim, Hyunggee/0000-0002-4738-0990; 				Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Jarzembowski J A, 1997, Prog Mol Subcell Biol, V18, P141; JIANG D, 1993, ONCOGENE, V8, P2805; Kim H, 2001, ONCOGENE, V20, P2671, DOI 10.1038/sj.onc.1204378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749	16	17	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3306	3310		10.1038/sj.onc.1204423	http://dx.doi.org/10.1038/sj.onc.1204423			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423980				2022-12-28	WOS:000169163500014
J	Simon, MP; Navarro, M; Roux, D; Pouyssegur, J				Simon, MP; Navarro, M; Roux, D; Pouyssegur, J			Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma Protuberans (DP)	ONCOGENE			English	Article						dermatofibrosarcoma protuberans; translocations; COL1A1-PDGFB	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIMIAN SARCOMA-VIRUS; COLLAGEN GENE COL1A1; B-CHAIN GENE; PDGF-BB; V-SIS; FUSION; EXPRESSION; ACTIVATION	Dermatofibrosarcoma protuberans (DP), an infiltrative skin tumour of intermediate malignancy, presents specific cytogenetic features such as reciprocal translocations t(17;22)(q22;q13.1) or supernumerary ring chromosomes derived from t(17;22), We have previously shown that both rings and translocated chromosomes derived from t(17;22) presented the same molecular rearrangement with fusion of the COL1A1 gene on chromosome 17 to the PDGFB gene on chromosome 22, To study the structure and function of the COL1A1-PDGFB chimeric protein, we used a tumour-derived chimeric COL1A1-PDGFB cDNA to perform stable and transient transfections in the Chinese hamster lung fibroblastic cell line PS200 and the human epithelial cell line HEK293. We demonstrated that the stably transfected clones that expressed the COL1A1-PDGFB chimeric protein became growth factors independent and tumorigenic in nude mice. In addition, COL1A1-PDGFB transfected cell supernatants significantly stimulated fibroblastic cell growth, through the activation of the PDGFB receptor pathway. By using anti-PDGFB and specific anti-COL1A1-PDGFB antibodies, we showed that, similar to PDGFB, the COL1A1-PDGFB chimeric proteins are processed in transfected cells into mature PDGFB dimers, These results strongly suggest that the COL1A1-PDGFB chimeric gene expression associated with DP, induces tumours formation through production of mature PDGFB, in an autocrine or paracrine way, Strikingly, mutagenesis experiments indicated that uncleaved COL1A1-PDGFB forms are mitogenic and therefore could contribute, as well as mature PDGFB, to the establishment of a transformed phenotype. Oncogene (2001) 20, 2965-2975.	Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Simon, MP (corresponding author), Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice 2, France.		SIMON, Marie-Pierre/B-8017-2012					ALVES F, 1995, ONCOGENE, V10, P609; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; Fish FS, 1996, DERMATOL SURG, V22, P268, DOI 10.1111/j.1524-4725.1996.tb00318.x; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; Greco A, 1998, ONCOGENE, V17, P1313, DOI 10.1038/sj.onc.1202051; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; KIKUCHI K, 1993, BIOCHEM BIOPH RES CO, V196, P409, DOI 10.1006/bbrc.1993.2264; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Mentzel T, 1998, AM J SURG PATHOL, V22, P576, DOI 10.1097/00000478-199805000-00009; Navarro M, 1998, GENE CHROMOSOME CANC, V23, P263, DOI 10.1002/(SICI)1098-2264(199811)23:3<263::AID-GCC9>3.0.CO;2-#; O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.3.CO;2-R; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEDEUTOUR F, 1995, CANCER RES, V55, P2400; Pedeutour F, 1996, CYTOGENET CELL GENET, V72, P171, DOI 10.1159/000134178; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Shimizu A, 1999, CANCER RES, V59, P3719; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SMITS A, 1992, AM J PATHOL, V140, P639; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang J, 1999, DIAGN MOL PATHOL, V8, P113, DOI 10.1097/00019606-199909000-00002; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Westermark B, 1993, CYTOKINES, V5, P1	31	66	69	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2965	2975		10.1038/sj.onc.1204426	http://dx.doi.org/10.1038/sj.onc.1204426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420709				2022-12-28	WOS:000168901800012
J	Paweletz, CP; Charboneau, L; Bichsel, VE; Simone, NL; Chen, T; Gillespie, JW; Emmert-Buck, MR; Roth, MJ; Petricoin, EF; Liotta, LA				Paweletz, CP; Charboneau, L; Bichsel, VE; Simone, NL; Chen, T; Gillespie, JW; Emmert-Buck, MR; Roth, MJ; Petricoin, EF; Liotta, LA			Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front	ONCOGENE			English	Article						laser capture microdissection; protein microarrays; apoptosis; Akt; mitogen activated protein kinase; tumor progression	PROSTATIC INTRAEPITHELIAL NEOPLASIA; GLYCOGEN-SYNTHASE KINASE-3; PROTEOMIC ANALYSIS; GENE-EXPRESSION; GROWTH; APOPTOSIS; AKT; IMMUNOASSAY; SPECIFICITY	Protein arrays are described for screening of molecular markers and pathway targets in patient matched human tissue during disease progression. In contrast to previous protein arrays that immobilize the probe, our reverse phase protein array immobilizes the whole repertoire of patient proteins that represent the state of individual tissue cell populations undergoing disease transitions. A high degree of sensitivity, precision and linearity was achieved, making it possible to quantify the phosphorylated status of signal proteins in human tissue cell subpopulations, Using this novel protein microarray we have longitudinally analysed the state of pro-survival checkpoint proteins at the microscopic transition stage from patient matched histologically normal prostate epithelium to prostate intraepithelial neoplasia (PIN) and then to invasive prostate cancer. Cancer progression was associated with increased phosphorylation of Akt (P < 0.04), suppression of apoptosis pathways (P < 0.03), as well as decreased phosphorylation of ERK (P < 0.01), At the transition from histologically normal epithelium to PIN we observed a statistically significant surge in phosphorylated Akt (P < 0.03) and a concomitant suppression of downstream apoptosis pathways which proceeds the transition into invasive carcinoma.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Tissue Prote Unit, Bethesda, MD 20892 USA; NCI, Canc Prevent Studies Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathogenet Unit, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Canc Genome Anat Project, Off Director, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Dept Chem, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University	Liotta, LA (corresponding author), NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.			Simone, Nicole/0000-0002-7662-7470				Arenkov P, 2000, ANAL BIOCHEM, V278, P123, DOI 10.1006/abio.1999.4363; BOSTWICK DG, 1995, CANCER-AM CANCER SOC, V75, P1823, DOI 10.1002/1097-0142(19950401)75:7+<1823::AID-CNCR2820751612>3.0.CO;2-7; Buckholz Richard G., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P135; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeRisi J, 1996, NAT GENET, V14, P457; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; EKINS RP, 1991, CLIN CHEM, V37, P1955; Emili AQ, 2000, NAT BIOTECHNOL, V18, P393, DOI 10.1038/74442; Emmert-Buck MR, 2000, MOL CARCINOGEN, V27, P158, DOI 10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Englert CR, 2000, CANCER RES, V60, P1526; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frey RS, 1997, CANCER RES, V57, P628; Ge H, 2000, Nucleic Acids Res, V28, pe3, DOI 10.1093/nar/28.2.e3; Gioeli D, 1999, CANCER RES, V59, P279; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Haab BB, 2001, GENOME BIOL, V2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones VW, 1998, ANAL CHEM, V70, P1233, DOI 10.1021/ac971125y; Koch M, 2000, VIRCHOWS ARCH, V436, P413, DOI 10.1007/s004280050468; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q; MALINDZAK D., 1997, PROTEOME RES NEW FRO; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Ornstein DK, 2000, ELECTROPHORESIS, V21, P2235, DOI 10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.3.CO;2-1; PAGE MJ, 2000, PNAS, V96, P12589; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paweletz CP, 2000, CANCER RES, V60, P6293; Rowe CA, 1999, ANAL CHEM, V71, P3846, DOI 10.1021/ac981425v; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Xie W, 2000, PROSTATE, V44, P31; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	39	754	806	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1981	1989		10.1038/sj.onc.1204265	http://dx.doi.org/10.1038/sj.onc.1204265			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360182				2022-12-28	WOS:000168043800006
J	El-Tanani, MK; Barraclough, R; Wilkinson, MC; Rudland, PS				El-Tanani, MK; Barraclough, R; Wilkinson, MC; Rudland, PS			Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4	ONCOGENE			English	Article						metastasis-inducing DNA; osteopontin promoter; Tcf-4; metastasis	BETA-CATENIN; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; HMG BOX; OSTEOPONTIN; CANCER; EXPRESSION; CARCINOMA; IDENTIFICATION; ACTIVATION	Small 1000 bp fragments of DNA derived from human malignant breast cancer cells have been isolated which, when transfected into a benign rat mammary cell line induce the production of osteopontin and thereby endow those cells with the capability to metastasize in syngeneic rats. Using transient transfections of an osteopontin promoter-reporter construct, we have now identified the active moiety in the metastasis-inducing DNA as the binding site for the T cell factor (Tcf) family of transcription factors and located Tcf-4, beta -catenin and E-cadherin in the relevant DNA complex in vitro. The regulatory effects of the metastasis-inducing DNAs are therefore exerted, at least in part, by a CAAAG sequence which can sequester Tcf-4, thereby promoting transcription of the direct effector for metastasis in this system, osteopontin.	Univ Liverpool, Canc & Polio Res Fund Labs, Mol Med Grp, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Rudland, PS (corresponding author), Univ Liverpool, Canc & Polio Res Fund Labs, Mol Med Grp, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England.		Barraclough, Roger/AAH-6516-2020	Wilkinson, Mark/0000-0003-3109-6888; Barraclough, Roger/0000-0002-7203-1194; El-Tanani, Mohamed/0000-0002-4735-5445				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen DS, 1997, J BIOL CHEM, V272, P20283, DOI 10.1074/jbc.272.32.20283; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DAVIES BR, 1994, CANCER RES, V54, P2785; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oates AJ, 1996, ONCOGENE, V13, P97; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; RUDLAND PS, 1997, Patent No. 9725443; Schilham MW, 1998, SEMIN IMMUNOL, V10, P127, DOI 10.1006/smim.1998.0114; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x	19	33	34	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1793	1797		10.1038/sj.onc.1204358	http://dx.doi.org/10.1038/sj.onc.1204358			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313926				2022-12-28	WOS:000167750900012
J	Wolff, A; Technau, A; Ihling, C; Technau-Ihling, K; Erber, R; Bosch, FX; Brandner, G				Wolff, A; Technau, A; Ihling, C; Technau-Ihling, K; Erber, R; Bosch, FX; Brandner, G			Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex	ONCOGENE			English	Article						p53-localization; neuroblastoma; PAb1801; p53-conformation; TPEN; Cd2+; leptomycin B	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CYTOPLASMIC SEQUESTRATION; MONOCLONAL-ANTIBODIES; NUCLEAR-LOCALIZATION; BINDING; PHOSPHORYLATION; CYCLE; MDM2; TRANSACTIVATION	Neuroblastoma (NB) cells reportedly accumulate wildtype p53 exclusively in the cytoplasm, However, immunofluorescence assays with five different antibodies showed that p53 accumulates in the nucleus of up to 10% of NB cells. PAb1801 detected cytoplasmic 'punctate structures' which were also found in p53-null cells, rendering this antibody unsuitable for p53 detection, A comparison of DO-1 and PAb1801 staining in NB tissue sections confirmed the results obtained with NB cells. Nuclear accumulation of p53 was induced in NB cells using substances which disturb p53's tertiary structure at its zinc finger motif, or by treatment with mitomycin C, Constitutive nuclear accumulation was observed in an SK-N-SH variant, AW-1, which has a point mutation in p53 at Cys176>Ser, disturbing the same motif, Even though p53 showed DNA-binding capability after mitomycin C treatment of NB cells, the target gene products MDM2 and p21(WAF1.CIP1.SDI1) were not synthesized and no p53 transactivating activity measured in a reporter gene assay. Therefore we suggest that p53 in NB cells might be predominantly in a conformation refractory to integration into the transcriptional complex, resulting in at Least partial transcriptional inactivity, hyperactive nuclear export and resistance to degradation by exogenously expressed MDM2.	Univ Freiburg, Inst Med Microbiol & Hyg, Dept Virol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany; Univ Heidelberg, ENT Univ Hosp, Mol Biol Lab, D-69120 Heidelberg, Germany	University of Freiburg; University of Freiburg; Ruprecht Karls University Heidelberg	Technau, A (corresponding author), Univ Freiburg, Inst Med Microbiol & Hyg, Dept Virol, Hermann Herder Str 11, D-79104 Freiburg, Germany.		Erber, Ralf/B-6790-2008; Erber, Ralf/AAF-3002-2020; Wolff, Antonio C./T-8796-2019	Wolff, Antonio C./0000-0003-3734-1063				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; BOSARI S, 1995, AM J PATHOL, V147, P790; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GOLDER H, 1996, ARION, V4, P1; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Komarova EA, 1997, CANCER RES, V57, P5217; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Merlin T, 1998, INT J ONCOL, V13, P1007; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Plaumann B, 1996, ONCOGENE, V13, P1605; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schwab M, 1999, NATURWISSENSCHAFTEN, V86, P71, DOI 10.1007/s001140050574; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SIEGEL J, 1995, ONCOGENE, V11, P1363; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TECHNAU A, 2001, IN PRESS INT J ONCOL, V18; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wolff A, 1997, INT J ONCOL, V11, P123; WOLFF A, 1999, J CANC RES CLIN ON S, V125, P24; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474	53	33	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1307	1317		10.1038/sj.onc.1204251	http://dx.doi.org/10.1038/sj.onc.1204251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313875				2022-12-28	WOS:000167495000005
J	Patterson, T; Vuong, H; Liaw, YS; Wu, R; Kalvakolanu, DV; Reddy, SPM				Patterson, T; Vuong, H; Liaw, YS; Wu, R; Kalvakolanu, DV; Reddy, SPM			Mechanism of repression of squamous differentiation marker, SPRR1B, in malignant bronchial epithelial cells: role of critical TRE-sites and its transacting factors	ONCOGENE			English	Article						SPRR1; squamous cell differentiation; AP-1 proteins; bronchial epithelial cells	KERATINOCYTE TERMINAL DIFFERENTIATION; PROLINE-RICH PROTEIN; C-FOS; IN-VITRO; EXPRESSION; TRANSCRIPTION; BINDING; FRA-2; AP-1; SPR1	The overexpression of SPRR1B in bronchial epithelium is a marker for early metaplastic changes and the loss of its expression is associated with an irreversible malignant transformation. In the present study, we have used a model system consisting of normal and malignant bronchial epithelial (BE) cells to elucidate the differential transcriptional control of SPRR1B, SPRR1B expression is either detectable or PMA (phorbol 13-myristate 12-acetate) including squamous, adeno, small and large cell carcinomas. Loss of SPRR1B expression is correlated well with the lack of strong in vivo protein-DNA interactions at the -152 bp promoter, which contains two functional TRE sites. Even though the basal level AP-1 protein DNA binding pattern is different between normal and malignant cells, PMA significantly enhances Jun and Fos binding to the consensus TRE site in both cell types. Intriguingly, the composition of AP-1 protein binding to the -152 to -86 bp SPRR1B promoter is quite different. In untreated cells, SPRR1B promoter is predominantly occupied by JunD and Fra2, PMA significantly induced binding of JunB and Fra1 in normal cells, while JunB and Fra2 bound to TREs in the malignant cells. Overexpression of fr nl in malignant cells significantly enhanced SPRRIB promoter activity. In contrast, overexpression of fra2, but not fra1, strongly reduced both basal and PMA-inducible promoter activities in normal cells. Together, these results indicate that either temporal expression and/or differential activation of AP-1 proteins, especially Fra1 and Fra2, might contribute to the dysregulation of terminal differentiation marker, SPRR1B, expression in various BE cells.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; University of California System; University of California Davis; University System of Maryland; University of Maryland Baltimore	Reddy, SPM (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.				NCI NIH HHS [CA-71401, CA-78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NIEHS NIH HHS [ES-06230, ES03819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, R01ES006230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; Anisowicz A, 1999, MOL MED, V5, P526, DOI 10.1007/BF03401980; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; CARRASCO D, 1995, ONCOGENE, V10, P1069; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P25, DOI 10.1165/ajrcmb.19.1.3078; Deng J, 2000, J BIOL CHEM, V275, P5739, DOI 10.1074/jbc.275.8.5739; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lau D, 2000, AM J RESP CELL MOL, V22, P92, DOI 10.1165/ajrcmb.22.1.3637; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147	39	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					634	644		10.1038/sj.onc.1204134	http://dx.doi.org/10.1038/sj.onc.1204134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313996				2022-12-28	WOS:000166755000011
J	Ruediger, R; Pham, HT; Walter, G				Ruediger, R; Pham, HT; Walter, G			Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene	ONCOGENE			English	Article						PP2A; A alpha subunit; mutation; human cancer; tumor suppressor	SERINE THREONINE PHOSPHATASES; REGULATORY B-SUBUNITS; PP2A CORE ENZYME; MOLECULAR-CLONING; CATALYTIC SUBUNIT; SEQUENCE-ANALYSIS; TUMOR-ANTIGENS; OKADAIC ACID; PPP2R1B GENE; T-ANTIGENS	The A subunit of protein phosphatase 2A (PP2A) consists of 15 nonidentical repeats. The catalytic C subunit binds to C-terminal repeats 11-15 and regulatory B subunits bind to N-terminal repeats 1-10, Recently, four cancer-associated mutants of the A alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64 --> Gly in breast carcinoma, Arg418 --> Trp in melanoma, and Delta 171-589 in breast carcinoma, Based on our model of PP2A, we predicted that Glu64-->Asp and Glu64-->Gly might be defective in B subunit binding, whereas Arg418-->Trp and Delta 171 - 589 might bind neither B nor C subunits, We generated these mutants by site-directed mutagenesis and assayed their ability to associate with different forms of B subunits (B, B', B") or with the catalytic C subunit, The results demonstrate that all mutants are defective in binding either B or B and C subunits, Specifically, the N-terminal mutants, Glu64-->Asp and Glu64-->Gly, are defective in B' but normal in B, B", and C subunit binding, whereas the C-terminal mutants Arg418-->Trp and Delta 171-589 bind none of the B subunits nor the C subunit, The implications of these findings with regard to the potential role of PP2A as a tumor suppressor are discussed.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Walter, G (corresponding author), Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, J BIOL CHEM, V264, P21435; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagase T, 1997, J BIOCHEM, V122, P178; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	45	128	134	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					10	15		10.1038/sj.onc.1204059	http://dx.doi.org/10.1038/sj.onc.1204059			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244497				2022-12-28	WOS:000166361400002
J	Lu, ML; Arrick, BA				Lu, ML; Arrick, BA			Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms	ONCOGENE			English	Article						BRCA1; transcriptional activation; p21; alternative splicing	SPORADIC BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; RING FINGER; MUTATIONS; PROTEIN; LOCALIZATION; EXPRESSION; INTERACT; GROWTH; CYCLE	We have evaluated the transcriptional activation of a human p21 promoter reporter construct by transfection of BRCA1 expression constructs into tumorigenic and nontumorigenic human breast cell lines. Two cell lines with wildtype p53 (MCF-7 and MCF10A) demonstrated: transcriptional activation of the p21 promoter by full-length BRCA1 (BRCA1(L)) as well as by two splice variants that lack most of exon 11 (BRCA1(S) and BRCA1(S-9,10)). In contrast, two cell lines with mutant p53 (MDA-231 and HCC1937) were inactive. Co-transfection of BRCA1L with BRCA1(S) or BRCA1(S-9,10) exhibited synergistic p21 promoter activation, due to augmented expression of the cytomegalovirus promoter-based BRCA1 expression constructs. We examined the transcriptional activity of two known sequence alterations in BRCA1, one that results in a carboxy-terminal truncation of BRCA1 and is clearly pathogenic, and the other a missense mutation that is suspected of predisposing to cancer. Although both mutations have been shown to be defective in some assays of transactivation, we observed both mutations to be fully active in activation of the p21 promoter when incorporated in the full-length BRCA1(L). In contrast, these mutations rendered BRCA1(S) inactive. These observations indicate that such transcriptional assays cannot serve as the basis for a functional appraisal of BRCA1 sequence alterations encountered in the course of genetic testing.	Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA	Dartmouth College	Arrick, BA (corresponding author), Dartmouth Med Sch, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.				NCI NIH HHS [R01 CA-77772] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077772] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Hayes F, 2000, CANCER RES, V60, P2411; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Klemp J, 2000, EUR J CANCER, V36, P1209, DOI 10.1016/S0959-8049(00)00112-X; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson E.O., 1997, BIODIVERSITY, P1; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	33	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6351	6360		10.1038/sj.onc.1204025	http://dx.doi.org/10.1038/sj.onc.1204025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175350	Bronze			2022-12-28	WOS:000166210500019
J	Posern, G; Rapp, UR; Feller, SM				Posern, G; Rapp, UR; Feller, SM			The Crk signaling pathway contributes to the bombesin-induced activation of the small GTPase Rap1 in Swiss 3T3 cells	ONCOGENE			English	Article						Crk; CRKL; Rap1; bombesin; SH3 domains; signal transduction	NUCLEOTIDE-EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; ADAPTER PROTEINS; BINDING PROTEINS; GROWTH-FACTOR; FACTOR C3G; KINASE; RAS; FAMILY; GENE	Rap1 is a small GTPase implicated in cell proliferation and differentiation, The mechanisms how endogenous Rapt is activated by many mitogenic stimuli including the neuropeptide bombesin remained unclear. Here we analyse which signaling pathways are necessary for Rapt activation. Bombesin-mediated Rap1 activation in Swiss 3T3 and primary mouse embryo fibroblasts requires signaling components similar to those being essential for complex formation between p130Cas and Crk adapter proteins. The Crk/CRKL-binding region of the Rap1-specific exchange factor C3G (CBR) inhibits the bombesin-stimulated Rap1 activity in transfected Swiss 3T3 cells. Further characterization in COS cells showed that the CBR or a c-Crk I SH3 mutant specifically reduces both the basal as well as the stimulated Rap1 activity in a dose-dependent manner, whereas Ras is not affected. The CBR is complexed with endogenous c-Crk II and CRKL and blocks the protein association with catalytically active C3G, Such suppressors of Crk signaling do not affect Erk-phosphorylation induced by bombesin, Embryonic fibroblasts from b-raf knockout mice showed a bombesin-inducible Erk-phosphorylation, providing evidence that B-Raf does not link Rap1, to Erk-activation in bombesin-stimulated fibroblasts, We conclude that cellular Crk/CRKL complexes, recruited to upstream signaling components, contribute to basal and bombesin-induced Rapt activity, which is independent from the Ras-Raf-Erk pathway under these circumstances.	Univ Wurzburg, MSZ, Inst Med Strahlenkunde & Zellforschung, D-97078 Wurzburg, Germany	University of Wurzburg	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Inst Med Strahlenkunde & Zellforschung, Versbacher Str 5, D-97078 Wurzburg, Germany.							Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PIZON V, 1988, ONCOGENE, V3, P201; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	38	10	11	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6361	6368		10.1038/sj.onc.1204027	http://dx.doi.org/10.1038/sj.onc.1204027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175351				2022-12-28	WOS:000166210500020
J	Muchardt, C; Yaniv, M				Muchardt, C; Yaniv, M			When the SWI/SNF complex remodels ... the cell cycle	ONCOGENE			English	Review						N-CoR; HDAC; cyclin A; cyclin E; G0	SWI-SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; C-MYC; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; DROSOPHILA-BRAHMA; GCN5 BROMODOMAIN; HIV-1 INTEGRASE; GROWTH ARREST	Mammalian cells contain several chromatin-remodeling complexes associated with the Brm and Brg1 helicase-like proteins. These complexes likely represent the functional homologs of the SWI/SNF and RSC complexes found in Saccharomyces cerevisiae. The mammalian chromatin-remodeling complexes are involved in both activation and repression of a variety of genes. Several lines of evidence also indicate that they play a specific role in the regulation of cell growth. Brm is down-regulated by ras signaling and its forced reexpression suppresses transformation by this oncogene, Besides, the Brg1 gene is silenced or mutated in several tumors cell lines and a Brg1-associated complex was recently found to co-purify with BRCA1, involved in breast and ovarian cancers, Finally, the gene encoding SNF5/Ini1, a subunit common to all mammalian SWI/SNF complexes, is inactivated in rhabdoid sarcomas, a very aggressive form of pediatric cancer, The current review will address observations made upon inactivation of Brm, Brg1 and SNF5/Ini1 by homologous recombination in the mouse, as well as the possible implication of these factors in the regulation of the Retinoblastoma pRb-mediated repression of the transcription factor E2F.	Inst Pasteur, Dept Biotechnol, CNRS, URA1644,Unite Virus Oncogenes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Muchardt, C (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS, URA1644,Unite Virus Oncogenes, 25 Rue Docteur Roux, F-75724 Paris 15, France.							Adler HT, 1999, MOL CELL BIOL, V19, P7050; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Callebaut I, 1999, FEBS LETT, V446, P189, DOI 10.1016/S0014-5793(99)00132-5; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Du J, 1998, GENETICS, V150, P987; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kal AJ, 2000, GENE DEV, V14, P1058; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Parissi V, 2000, GENE, V247, P129, DOI 10.1016/S0378-1119(00)00108-6; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Staehling-Hampton K, 1999, GENETICS, V153, P275; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Takayama M, 2000, GENES CELLS, V5, P481, DOI 10.1046/j.1365-2443.2000.00338.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Tsuchiya E, 1998, NUCLEIC ACIDS RES, V26, P3286, DOI 10.1093/nar/26.13.3286; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Yukawa M, 1999, GENES CELLS, V4, P99, DOI 10.1046/j.1365-2443.1999.00242.x; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	79	166	169	1	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3067	3075		10.1038/sj.onc.1204331	http://dx.doi.org/10.1038/sj.onc.1204331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420722				2022-12-28	WOS:000169308500010
J	Chinenov, Y; Kerppola, TK				Chinenov, Y; Kerppola, TK			Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity	ONCOGENE			English	Review						transcription factor cooperativity; nucleoprotein complex architecture; transcriptional synergy; composite regulatory elements; orientation of heterodimer binding	GROWTH-FACTOR-BETA; FACTOR-ALPHA GENE; ANTIOXIDANT RESPONSE ELEMENT; MAF NUCLEAR ONCOPROTEIN; CREB-BINDING-PROTEIN; FACTOR-KAPPA-B; DNA-BINDING; C-JUN; AP-1 SITE; CRYSTAL-STRUCTURE	Fos and Jun family proteins regulate the expression of a myriad of genes in a variety of tissues and cell types. This functional versatility emerges from their interactions with related bZIP proteins and with structurally unrelated transcription factors. These interactions at composite regulatory elements produce nucleoprotein complexes with high sequence-specificity and regulatory selectivity. Several general principles including binding cooperativity and conformational adaptability have emerged from studies of regulatory complexes containing Fos-Jun family proteins. The structural properties of Fos-Jun family proteins including opposite orientations of heterodimer binding and the ability to bend DNA can contribute to the assembly and functions of such complexes. The cooperative recruitment of transcription factors, coactivators and chromatin remodeling factors to promoter and enhancer regions generates multiprotein transcription regulatory complexes with cell- and stimulus-specific transcriptional activities. The gene-specific architecture of these complexes can mediate the selective control of transcriptional activity.	Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kerppola, TK (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Kerppola, Tom/AFK-6155-2022; Kerppola, Tom/AAG-4457-2022	Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aho S, 2000, J CELL BIOL, V148, P1165, DOI 10.1083/jcb.148.6.1165; Alam J, 2000, J BIOL CHEM, V275, P27694; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Buttice G, 1996, ONCOGENE, V13, P2297; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chytil M, 1998, P NATL ACAD SCI USA, V95, P14076, DOI 10.1073/pnas.95.24.14076; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; DeCesare D, 1997, J BIOL CHEM, V272, P23921, DOI 10.1074/jbc.272.38.23921; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diebold RJ, 1998, P NATL ACAD SCI USA, V95, P7915, DOI 10.1073/pnas.95.14.7915; Dlakic M, 2001, EMBO J, V20, P828, DOI 10.1093/emboj/20.4.828; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; Echlin DR, 2000, ONCOGENE, V19, P1752, DOI 10.1038/sj.onc.1203491; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Falvo JV, 2000, P NATL ACAD SCI USA, V97, P3925, DOI 10.1073/pnas.97.8.3925; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fujii Y, 2000, NAT STRUCT BIOL, V7, P889; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hernandez-Munain C, 1998, MOL CELL BIOL, V18, P3223, DOI 10.1128/MCB.18.6.3223; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Iacobelli M, 2000, J IMMUNOL, V165, P860, DOI 10.4049/jimmunol.165.2.860; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; JOHNSTONE B, 1992, J SOC CLIN PSYCHOL, V11, P71, DOI 10.1521/jscp.1992.11.1.71; JOHNSTONE IB, 1993, J VET INTERN MED, V7, P130; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1998, STRUCT FOLD DES, V6, P549, DOI 10.1016/S0969-2126(98)00057-4; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Leonard DA, 1998, NAT STRUCT BIOL, V5, P877, DOI 10.1038/2316; Leonard DA, 1997, P NATL ACAD SCI USA, V94, P4913, DOI 10.1073/pnas.94.10.4913; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; McBride K, 1998, MOL CELL BIOL, V18, P5073, DOI 10.1128/MCB.18.9.5073; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; Min W, 1996, MOL CELL BIOL, V16, P359; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; Moreau A, 1998, MOL CELL BIOL, V18, P1312, DOI 10.1128/MCB.18.3.1312; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Palazzolo M, 2000, EUR J BIOCHEM, V267, P5427, DOI 10.1046/j.1432-1327.2000.01604.x; Perini G, 1999, J BIOL CHEM, V274, P13970, DOI 10.1074/jbc.274.20.13970; Perkins D, 1996, J IMMUNOL, V156, P4154; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Qian Z, 1996, J VIROL, V70, P7161, DOI 10.1128/JVI.70.10.7161-7170.1996; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Rajaram N, 1997, EMBO J, V16, P2917, DOI 10.1093/emboj/16.10.2917; Ramirez-Carrozzi VR, 2001, P NATL ACAD SCI USA, V98, P4893, DOI 10.1073/pnas.091095998; Ramirez-Carrozzi VR, 2001, J MOL BIOL, V305, P411, DOI 10.1006/jmbi.2000.4286; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sato M, 1999, BIOCHEM BIOPH RES CO, V254, P384, DOI 10.1006/bbrc.1998.9918; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; Spicuglia S, 2000, EMBO J, V19, P2034, DOI 10.1093/emboj/19.9.2034; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Stranick KS, 1997, J BIOL CHEM, V272, P16453, DOI 10.1074/jbc.272.26.16453; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thepot D, 2000, DEVELOPMENT, V127, P143; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Virbasius CMA, 1999, MOL CELL, V4, P219, DOI 10.1016/S1097-2765(00)80369-X; WANG S, 1994, APPL LASER, V14, P1; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Wong C, 1999, MOL CELL BIOL, V19, P1821; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8	160	546	567	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2438	2452		10.1038/sj.onc.1204385	http://dx.doi.org/10.1038/sj.onc.1204385			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402339				2022-12-28	WOS:000168568700010
J	Liu, BL; Fang, M; Lu, Y; Mendelsohn, J; Fan, Z				Liu, BL; Fang, M; Lu, Y; Mendelsohn, J; Fan, Z			Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody	ONCOGENE			English	Article						EGF receptor; monoclonal antibody; apoptosis; cell cycle arrest; bFGF; IGF-1	PROTEIN-KINASE PATHWAY; EPITHELIAL-CELLS; G(1) ARREST; BAD PHOSPHORYLATION; CARCINOMA-CELLS; INHIBITION; ACTIVATION; SURVIVAL; ALPHA; AKT	DiFi human colon carcinoma cells are stimulated by the transforming growth factor-alpha (TGF-alpha)/epidermal growth factor (EGF) receptor autocrine loop. Exposure of DiFi cells to monoclonal antibody (mAb) 225, which blocks ligand-induced activation of the EGF receptor, induces G1 arrest and subsequent cell death via apoptosis, We investigated the signal pathways by which basic fibroblast growth factor (bFGF) and insulin-like growth factor-1 (IGF-1) modulate mAb 225-induced G1 arrest and apoptosis in DiFi cells. Both bFGF and IGF-1 activated the mitogen-activated protein kinase (MAPK) kinase (MEK) pathway in DiFi cells, Additionally, IGF-1 activated the phosphoinositide 3-kinase (PI-3K)/Akt pathway. Both bFGF and IGF-1 inhibited mAb 225-induced apoptosis; however, bFGF provided sustained protection against apoptosis, while the protection by IGF-1 was only temporary. Also, bFGF reversed the mAb 225-induced increase in the p27(Kip1) level, inhibition of cyclin-dependent kinase-2 (CDK-2) activity, dephosphorylation of the retinoblastoma (Rb) protein and the resultant G1 arrest of the cells. In contrast, IGF-1 did not reverse such effects by mAb 225, The prevention of mAb 225-induced G1 arrest and apoptosis in DiFi cells by bFGF was sensitive to the MEK/MAPK inhibitor PD98059 but not to the PI-3K inhibitor LY294002. In contrast, inhibition of apoptosis by IGF-1 in DiFi cells was sensitive only to LY294002 and not to PD98059, These results further our understanding of how mAb 225 induces apoptosis in DiFi cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 36,1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caraglia M, 1999, CELL DEATH DIFFER, V6, P773, DOI 10.1038/sj.cdd.4400550; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROSS ME, 1991, CANCER RES, V51, P1452; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Lan L, 1999, FEBS LETT, V444, P90, DOI 10.1016/S0014-5793(99)00032-0; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Liu B, 2000, BRIT J CANCER, V82, P1991; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Peng D, 1996, CANCER RES, V56, P3666; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; Sato J D, 1983, Mol Biol Med, V1, P511; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; ULLRICH A, 1990, CELL, V61, P303; UNTAWALE S, 1993, CANCER RES, V53, P1630; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu XP, 1996, ONCOGENE, V12, P1397; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	39	96	103	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1913	1922		10.1038/sj.onc.1204277	http://dx.doi.org/10.1038/sj.onc.1204277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313939				2022-12-28	WOS:000167908400012
J	Lucas, L; Hernandez-Alcoceba, R; Penalva, V; Lacal, JC				Lucas, L; Hernandez-Alcoceba, R; Penalva, V; Lacal, JC			Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity	ONCOGENE			English	Article						phospholipase D; antitumor drug; hexadecylphosphorylcholine; choline kinase	CHOLINE KINASE INHIBITORS; XENOPUS-LAEVIS OOCYTES; CANINE KIDNEY-CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ANALOG HEXADECYLPHOSPHOCHOLINE; GROWTH-FACTORS; SIGNAL-TRANSDUCTION; D ACTIVATION; PROTEIN; RAS	Hexadecylphosphorylcholine (HePC, D-18506, INN: Mitelfosine) belongs to the family of alkylphosphocholines with anticancer activity. Previous reports have related its antitumoral activity to their ability to interfere with phospholipid metabolism, However a clear mechanism of action has not been established yet, We have investigated the effect of HePC on two enzymes recently reported to play a role in cell growth proliferation, phospholipase D (PLD) and choline kinase (ChoK). Our results demonstrate that treatment with HePC induces a rapid stimulation of PLD, that may be achieved by PKC dependent or independent mechanisms, depending on the cell line investigated. Both PLD1 and PLD2 isoenzymes are sensitive to HePC activation. By contrast, no effect was observed by HePC on Cho, a new target for anticancer drug development. Furthermore, in all cell lines tested, a chronic exposure of the cells to HePC abrogates PLD activation by either phorbol esters or HePC itself with no effect on total cellular PLD levels. This is reflected in a strong inhibition of PLD activity. We suggest that the inhibitory effects on PLD by HePC may be related to its antitumoral action.	CSIC, Inst Invest Biomed, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid, Spain.		Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				BERKOVIC D, 1994, EUR J CANCER, V30A, P509, DOI 10.1016/0959-8049(94)90428-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bhakoo KK, 1996, CANCER RES, V56, P4630; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CUADRADO A, 1993, ONCOGENE, V8, P2959; DECHAVES EP, 1995, BIOCHEM J, V312, P411, DOI 10.1042/bj3120411; delPeso L, 1997, BIOCHEM J, V322, P519; DELPESO L, 1996, J CELL BIOCHEM, V60, P1; DETMAR M, 1994, J INVEST DERMATOL, V102, P490, DOI 10.1111/1523-1747.ep12373109; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; Han JS, 1998, BIOCHEM MOL BIOL INT, V45, P1089; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HOULIHAN WJ, 1995, MED RES REV, V15, P157, DOI 10.1002/med.2610150302; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1990, J BIOL CHEM, V265, P12232; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; Malcolm KC, 1996, BIOCHEM BIOPH RES CO, V225, P514, DOI 10.1006/bbrc.1996.1204; MALY K, 1995, ANTI-CANCER DRUG DES, V10, P411; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; PAZIT BA, 1989, FEBS LETT, V259, P64; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; POWIS G, 1995, MED RES REV, V15, P121, DOI 10.1002/med.2610150204; SEEWALD MJ, 1990, CANCER RES, V50, P4458; SINGER S, 1995, CANCER RES, V55, P5140; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; STORME G, 1983, P AM ASSOC CANC RES, V24, P31; UBERALL F, 1991, CANCER RES, V51, P807; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WIEDER T, 1993, BIOCHEM J, V291, P561, DOI 10.1042/bj2910561; Wieder T, 1996, CANCER LETT, V100, P71, DOI 10.1016/0304-3835(95)04072-2; Wieder T, 1999, PROG LIPID RES, V38, P249, DOI 10.1016/S0163-7827(99)00004-1; ZENG B, 1990, CANCER RES, V50, P3025	50	37	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1110	1117		10.1038/sj.onc.1204216	http://dx.doi.org/10.1038/sj.onc.1204216			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314048				2022-12-28	WOS:000167232100011
J	Monni, R; Santos, SCR; Mauchauffe, M; Berger, R; Ghysdael, J; Gouilleux, F; Gisselbrecht, S; Bernard, O; Penard-Lacronique, V				Monni, R; Santos, SCR; Mauchauffe, M; Berger, R; Ghysdael, J; Gouilleux, F; Gisselbrecht, S; Bernard, O; Penard-Lacronique, V			The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells	ONCOGENE			English	Article						leukemogenesis; TEL-Jak2; Socs1; Ba/F3; interferon-gamma	GENE-EXPRESSION; IFN-GAMMA; PROTEINS; STAT5; MICE; FAMILY; ALPHA; JAK2; TEL; CIS	The leukemia-associated TEL-Jak2 fusion protein possesses a constitutive tyrosine kinase activity and transforming properties in hematopoietic cell lines and animal models, In the murine pro-B Ba/F3 cell line, this fusion constitutively activates the Signal Transducer and Activator of Transcription 5 (Stat5) factors and, as a consequence, induces the sustained expression of various Stat5-target genes including the Cytokine Inducible SH2-containing protein (Cis) gene, which codes for a member of the Suppressor of Cytokine Signaling (Socs) protein family, In TEL-Jak2-transformed Ba/F3 cells, me also observed the upregulation of the Socs1 gene, whose product has been reported to negatively regulate the Jak kinase activity. In transient transfection experiments, Socs1 physically interacts with TEL-Jak2 and interferes with the TEL-Jak2-induced phosphorylation and activation of Stat5 factors, probably through the Socs1-induced proteasome-mediated degradation of the fusion protein. Interestingly, TEL-Jak2-expressing Ba/F3 cells were found to be resistant to the antiproliferative activities of gamma interferon (IFN-gamma) seemingly as a consequence of Socs1 constitutive expression. These results indicate that the Socs1-dependent cytokine feedback loop, although active, is bypassed by the TEL-Jak2 fusion, but may play a role in the leukemogenic process by altering the cytokine responses of the leukemic cells. Our results also suggest that Socs1 plays a role in shutting down the signaling from the normally activated Jak2 kinase by inducing its proteasome-dependent degradation.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Paris 05, Inst Cochin Genet Mol, INSERM, U363, F-75014 Paris, France; Ctr Univ, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Penard-Lacronique, V (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.		GHYSDAEL, Jacques/F-3377-2013; Santos, Susana/AAM-8902-2021; Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019; Bernard, Olivier A./E-5721-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747; Constantino Rosa Santos, Susana/0000-0002-5711-1292; Gouilleux, Fabrice/0000-0001-6047-1718				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Carron C, 2000, BLOOD, V95, P3891; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 1999, EMBO J, V18, P904; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	38	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					849	858		10.1038/sj.onc.1204201	http://dx.doi.org/10.1038/sj.onc.1204201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314018	Green Published			2022-12-28	WOS:000166924400008
J	Zucker, S; Cao, J; Chen, WT				Zucker, S; Cao, J; Chen, WT			Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment	ONCOGENE			English	Article						matrix metalloproteinases (MMPs); MMP inhibitors; cancer; emmprin	TISSUE INHIBITOR; TUMOR INVASION; ENDOTHELIAL-CELLS; IV COLLAGENASE; SURFACE; GROWTH; ANGIOGENESIS; GELATINASE; MATRILYSIN; EXPRESSION	Experimental studies performed prior to 1990 led to the widely held belief that matrix metalloproteinases (MMPs) produced by cancer cells are of critical importance in tumor invasion and metastasis. Based on this evidence, the pharmaceutical industry produced several web tolerated, orally active MMP inhibitors (MMPIs) which demonstrated efficacy in mouse cancer models. Phase III clinical trials initiated in 1997-98 using marimastat, prinomastat (AG3340), and BAY 12-9566 alone or in combination with standard chemotherapy in patients with advanced cancers (lung, prostate, pancreas, brain, GI tract) have recently been reported; no clinical efficacy was demonstrated. Bayer and Agouron have discontinued their ongoing Phase III drug trials of MMPIs in advanced cancer, In retrospect, the failure of MMPIs to alter disease progression in metastatic cancer might have been anticipated since MMPs appear to be important in early aspects of cancer progression (local invasion and micrometastasis) and may no longer be required once metastases have been established. Our understanding of MMP pathophysiology in cancer has expanded considerably in the past 10 years. Current views indicate that: (1) most MMPs in tumors are made by stromal cells, not carcinoma cells; (2) cancer cells induce stromal cells to synthesize MMPs using extracellular matrix metalloproteinase inducer (EMMPRIN) and cytokine stimulatory mechanisms; and (3) MMPs promote cell migration and the release of growth factors sequestered in the extracellular matrix. MMPs have a dual function in tumor angiogenesis: MMP-2 and MT1-MMP are required in breaking down basement membrane barriers in the early stage of angiogenesis, while other MMPs are involved in the generation of an angiogenic inhibitor, angiostatin. In spite of considerable recent progress in identifying multiple roles of MMPs in disease, our understanding of MMP function in cancer is far from complete (see Table 1). Based on accumulated data, it is recommended that future MMPI trials focus on: (1) patients with early stage cancer; (2) the use of MMPIs along with chemotherapy; (3) the measurement of MMPs in tumor tissue and blood as a means of identifying patients who are more likely to respond to MMPI therapy; and (4) identification of biomarkers that reflect activation or inhibition of MMPs lit vivo.	Vet Affairs Med Ctr, Northport, NY 11768 USA; SUNY Stony Brook, Stony Brook, NY 11794 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zucker, S (corresponding author), Vet Affairs Med Ctr, Northport, NY 11768 USA.							BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Beckett RP, 1998, EXPERT OPIN THER PAT, V8, P259, DOI 10.1517/13543776.8.3.259; Belotti D, 1999, INT J BIOL MARKER, V14, P232, DOI 10.1177/172460089901400406; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BISWAS C, 1995, CANCER RES, V55, P434; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown PD, 1999, CANC DRUG DISC DEV, V3, P205; Cameron MD, 2000, CANCER RES, V60, P2541; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DAVIES B, 1993, BRIT J CANCER, V67, P1126, DOI 10.1038/bjc.1993.207; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; ECCLES SA, 1996, CANCER RES, V56, P460; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FIELDING J, 2000, P AN M AM SOC CLIN, V19, pA240; Gatto C, 1999, CLIN CANCER RES, V5, P3603; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Giavazzi R, 1998, CLIN CANCER RES, V4, P985; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; GREENWALD RA, 1999, ANN NY ACAD SCI, V878, P1; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guo HM, 2000, CANCER RES, V60, P888; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Itoh T, 1998, CANCER RES, V58, P1048; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Kieseier BC, 1999, NEUROLOGY, V53, P20, DOI 10.1212/WNL.53.1.20; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; Long L, 1998, CANCER RES, V58, P3243; Lopez-Boado YS, 2000, J CELL BIOL, V148, P1305, DOI 10.1083/jcb.148.6.1305; LU XQ, 1991, CANCER RES, V51, P6231; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MOORE MJ, 2000, P AN M AM SOC CLIN, V19, pA240; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nicolson G L, 1991, Semin Cancer Biol, V2, P143; Noel A, 1997, INVAS METAST, V17, P221; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Parks WC, 1998, BIOL EXTRAC, P263; Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1002/bjs.1800840206; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Polette M, 1997, J HISTOCHEM CYTOCHEM, V45, P703, DOI 10.1177/002215549704500508; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Rasmussen HS, 1999, CANC DRUG DISC DEV, V3, P399; Saren P, 1996, J IMMUNOL, V157, P4159; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Shalinsky DR, 1999, INVEST NEW DRUG, V16, P303, DOI 10.1023/A:1006204901140; Shalinsky DR, 2000, CANC DRUG DISC DEV, P143; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; ZUCKER S, 1992, INT J CANCER, V52, P366, DOI 10.1002/ijc.2910520307; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A; ZUCKER S, 1994, ANN NY ACAD SCI, V732, P273	78	441	478	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6642	6650		10.1038/sj.onc.1204097	http://dx.doi.org/10.1038/sj.onc.1204097			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426650				2022-12-28	WOS:000167704000011
J	de Toledo, SM; Azzam, EI; Dahlberg, WK; Gooding, TB; Little, JB				de Toledo, SM; Azzam, EI; Dahlberg, WK; Gooding, TB; Little, JB			ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation	ONCOGENE			English	Article						MDM2; ATM; p53; ionizing radiation; UV	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; GENOTOXIC STRESS; MDM-2 ONCOGENE; UV IRRADIATION; IN-VIVO; PROTEIN; FIBROBLASTS; DEGRADATION	To further understand the mechanism(s) by which DNA damage activates p53, we analysed the expression levels of p53 and HDM2 (the human homolog of murine MDM2) in various human diploid fibroblast and tumor cell strains during the period that precedes activation of known downstream effecters of p53, In X-irradiated human cells, HDM2 protein was rapidly phosphorylated in serine/threonine residues in a p53, p14(ARF) and p73-independent manner. In p53 wild-type cells, HDM2 phosphorylation precedes a detectable increase in the levels of p53 and is not observed in ataxia telangiectasia (AT) fibroblasts, The transfection of AT cells with a vector expressing ATM restored the ability to rapidly phosphorylate HDM2 following X-irradiation, confirming a role for ATM in its phosphorylation, We also show that ATM complexes with HDM2, The DNA lesions signaling the early rapid phosphorylation of HDM2 are a result of X-ray and not UV-type damage. The ATM-promoted early covalent modification of HDM2 in X-irradiated human cells may provide a mechanism to activate p53.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Radiobiol Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Little, JB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Radiobiol Lab, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DETOLEDO SM, 1995, INT J RADIAT BIOL, V67, P135, DOI 10.1080/09553009514550171; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; KUBUTTAT MHG, 1997, NATURE, V387, P299; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Landers JE, 1997, CANCER RES, V57, P3562; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	49	52	52	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6185	6193		10.1038/sj.onc.1204020	http://dx.doi.org/10.1038/sj.onc.1204020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175332				2022-12-28	WOS:000166210500001
J	Nakaya, N; Lowe, SW; Taya, Y; Chenchik, A; Enikolopov, G				Nakaya, N; Lowe, SW; Taya, Y; Chenchik, A; Enikolopov, G			Specific pattern of p53 phosphorylation during nitric oxide-induced cell cycle arrest	ONCOGENE			English	Article						nitric oxide; p53; proliferation; cell cycle arrest; phosphorylation	DNA-DAMAGE; RIBONUCLEOTIDE REDUCTASE; DROSOPHILA DEVELOPMENT; GROWTH; APOPTOSIS; DIFFERENTIATION; PROLIFERATION; ACTIVATION; INHIBITION; RADIATION	Nitric oxide (NO) is an efficient inhibitor of cell proliferation. Here we show that part of the antiproliferative activity of NO in fibroblasts is mediated through p53 signaling pathway. Cells from p53-/- knockout mice are compromised in their ability to stop dividing in the presence of NO, NO strongly induces expression of genes which are transcriptional targets of p53, and p53 is necessary for some, but not all, of the transcription activation effects of NO, Furthermore, NO strongly increases the cellular level of p53 protein. Since phosphorylation of particular residues of the p53 molecule has been correlated with its functional activity, we determined the phosphorylation pattern of p53 molecule after exposure to NO and compared it with the phosphorylation patterns that develop upon treatment with gamma-irradiation, UV light, and adriamycin. We found that NO induces a specific signature pattern of p53 phosphorylation, distinct from the patterns evoked by other inducers. This study suggests that NO activates specific signaling pathways that may partially overlap, but that do not coincide, with signaling pathways activated by other known inducers of p53 activity.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Clontech Labs Inc, Palo Alto, CA 94303 USA	Cold Spring Harbor Laboratory; National Cancer Center - Japan	Enikolopov, G (corresponding author), Cold Spring Harbor Lab, POB 100,1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GARG UC, 1990, BIOCHEM BIOPH RES CO, V171, P474, DOI 10.1016/0006-291X(90)91417-Q; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Ishida A, 1997, J BIOL CHEM, V272, P10050; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Keefer LK, 1996, ADV EXP MED BIOL, V387, P177; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Tamir S, 1996, METHOD ENZYMOL, V269, P230; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	38	57	58	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6369	6375		10.1038/sj.onc.1204100	http://dx.doi.org/10.1038/sj.onc.1204100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175352				2022-12-28	WOS:000166210500021
J	Ababou, M; Dutertre, S; Lecluse, Y; Onclercq, R; Chatton, B; Amor-Gueret, M				Ababou, M; Dutertre, S; Lecluse, Y; Onclercq, R; Chatton, B; Amor-Gueret, M			ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation	ONCOGENE			English	Article						Bloom's syndrome; ATM; phosphorylation; ionizing radiation; cell cycle checkpoints	SYNDROME GENE-PRODUCT; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; CHROMATID EXCHANGES; BLOOM-SYNDROME; INSTABILITY; CANCER; BRCA1; P53; LYMPHOCYTES	Bloom's syndrome (BS), a rare genetic disease, arises through mutations in both alleles of the BLM gene which encodes a 3'-5' DNA helicase identified as a member of the RecQ family, BS patients exhibit a high predisposition to development of all types of cancer affecting the general population and BLM-deficient cells display a strong genetic instability. We recently showed that ELM protein expression is regulated during the cell cycle, accumulating to high levels in S phase, persisting in G2/M and sharply declining in G1, suggesting a possible implication of BLM in a replication (S phase) and/or post-replication (G2 phase) process, Here we show that, in response to ionizing radiation, BLM-deficient cells exhibit a normal p53 response as well as an intact G1/S cell cycle checkpoint, which indicates that ATM and p53 pathways are functional in BS cells. We also show that the BLM defect is associated with a partial escape of cells from the gamma -irradiation-induced G2/M cell cycle checkpoint. Finally, we present data demonstrating that, in response to ionizing radiation, BLM protein is phosphorylated and accumulates through an ATM-dependent pathway. Altogether, our data indicate that BLM participates in the cellular response to ionizing radiation by acting as an ATM kinase downstream effector.	Inst Gustave Roussy, Unite Mixte Rech 1598, CNRS, F-94805 Villejuif, France; Inst Gustave Roussy, IFR 54, Serv Cytomet Flux, F-94805 Villejuif, France; CU Strasbourg, Inst Genet & Biol Mol & Cellulaire, CNRS, ULP,INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, Unite Mixte Rech 1598, CNRS, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; ababou, mouna/0000-0003-4276-3754				AURIAS A, 1985, CANCER GENET CYTOGEN, V16, P131, DOI 10.1016/0165-4608(85)90006-8; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barakat A, 2000, Hum Mutat, V15, P584, DOI 10.1002/1098-1004(200006)15:6<584::AID-HUMU28>3.0.CO;2-I; BARTRAM CR, 1976, ANN HUM GENET, V40, P79, DOI 10.1111/j.1469-1809.1976.tb00166.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GALLOWAY SM, 1977, MUTAT RES, V45, P343, DOI 10.1016/0027-5107(77)90144-0; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM ST, 2000, J BIOL CHEM, V274, P613; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEYN MS, 1995, CANCER RES, V55, P5991; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; ZHOU S, 1993, J BIOL CHEM, V268, P17754	33	74	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					5955	5963		10.1038/sj.onc.1204003	http://dx.doi.org/10.1038/sj.onc.1204003			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146546				2022-12-28	WOS:000165827900001
J	Powell, DJ; Russell, JP; Li, GQ; Kuo, BA; Fidanza, V; Huebner, K; Rothstein, JL				Powell, DJ; Russell, JP; Li, GQ; Kuo, BA; Fidanza, V; Huebner, K; Rothstein, JL			Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53 mice	ONCOGENE			English	Article						anaplastic carcinoma; Fhit; neoplasia; RET/PTC; SCID; thyroid carcinoma	THYROTROPIN RECEPTOR GENE; RET TYROSINE KINASE; PAPILLARY CARCINOMA; FHIT GENE; ONCOGENE ACTIVATION; P53 GENE; NEOPLASTIC TRANSFORMATION; CLINICAL IMPLICATIONS; PREMALIGNANT LESIONS; EPITHELIAL-CELLS	Cancers develop and progress via activation of oncogenes and loss of tumor suppressor genes, a progression that can be recapitulated through cross breeding mouse strains harboring genetic mutations. To define the role of RET/PTC3, p53 and Fhit in thyroid carcinogenesis, we intercrossed RET/PTC3 transgenics with p53-/-mice. This new strain, RET/PTC3(p53-/-), succumb to rapidly growing and strikingly large multilobed thyroid tumors containing mixtures of both well and poorly differentiated, highly proliferative follicular epithelial cells. Interestingly, transplanted tumors from RET/PTC3(p53-/-) mice grew in SCID but not syngeneic immunocompetent mice indicating that these advanced tumors were immunogenic, RET/PTC3 protein expression was reduced to undetectable levels in tumors of older mice suggesting that the continued elevated expression of RET/PTC3 may not be necessary for tumor progression. Similarly, expression of Fhit protein was reduced in early tumors and undetected in older tumors irrespective of tumor histopathology, In contrast to RET/PTC3(p53-/-) mice, RET/PTC3(Fhit-/-) mice did not develop advanced thyroid carcinomas, These studies support a model of human thyroid cancer whereby thyroid epithelium expresses RET/PTC3 protein at early stages of tumor development, followed by the reduction of RET/PTC3 and loss of p53 function with progressive reduction of Fhit protein expression coincident with malignant progression.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol & Otolaryngol Head & Neck, Philadelphia, PA 19107 USA	Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol & Otolaryngol Head & Neck, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA21124, T32-CA09678, T32-CA72318, CA76259] Funding Source: Medline; NIAID NIH HHS [T32-AI07492] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021124, P01CA076259, T32CA072318, T32CA009678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007492] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arezzo A, 1998, AM SURGEON, V64, P307; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BATTISTA S, 1995, ONCOGENE, V11, P2029; BECKER KL, 1995, PRINCIPLES PRACTICES; Birrer MJ, 1999, CANCER RES, V59, P5270; BOUNACER A, 1997, ONCOGENE, V15, P1236; BRAVERMAN LE, 1995, THYROID FUNDAMENTAL; CALIFANO D, 1995, ONCOGENE, V11, P107; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; CARCANGIU ML, 1985, AM J CLIN PATHOL, V83, P135, DOI 10.1093/ajcp/83.2.135; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chang RS, 1998, ACAD EMERG MED, V5, P247, DOI 10.1111/j.1553-2712.1998.tb02621.x; Chen ST, 2000, J ENDOCRINOL, V165, P379, DOI 10.1677/joe.0.1650379; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUH QY, 1995, SURG CLIN N AM, V75, P421; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FABBRO D, 1994, CANCER RES, V54, P4744; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; FUSCO A, 1995, J ENDOCRINOL INVEST, V18, P127, DOI 10.1007/BF03349720; Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.3.CO;2-9; Giannini R, 2000, INT J ONCOL, V16, P485; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; Glover TW, 1998, CANCER RES, V58, P3409; Hao XP, 2000, CANCER RES, V60, P18; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jossart GH, 1996, J CLIN ENDOCR METAB, V81, P3498, DOI 10.1210/jc.81.10.3498; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kholodnyuk ID, 2000, CANCER RES, V60, P7119; Klugbauer S, 2000, CANCER RES, V60, P7028; Komminoth P, 1997, VIRCHOWS ARCH, V431, P1, DOI 10.1007/s004280050062; La Perle KMD, 2000, AM J PATHOL, V157, P671, DOI 10.1016/S0002-9440(10)64577-4; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; Marchetti A, 1998, J PATHOL, V184, P240, DOI 10.1002/(SICI)1096-9896(199803)184:3<240::AID-PATH20>3.0.CO;2-B; Mayr B, 1999, LANGENBECK ARCH SURG, V384, P54, DOI 10.1007/s004230050174; McIver B, 2000, CLIN ENDOCRINOL, V52, P749, DOI 10.1046/j.1365-2265.2000.01009.x; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; Moretti F, 1997, ONCOGENE, V14, P729, DOI 10.1038/sj.onc.1200887; Mori M, 2000, CANCER RES, V60, P1177; Mueller J, 2000, Recent Results Cancer Res, V155, P29; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; OKAYASU I, 1995, CANCER-AM CANCER SOC, V76, P2312, DOI 10.1002/1097-0142(19951201)76:11<2312::AID-CNCR2820761120>3.0.CO;2-H; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Papadimitrakopoulou VA, 1996, CANCER METAST REV, V15, P53, DOI 10.1007/BF00049487; Pellegrini S, 1999, INT J MOL MED, V4, P419; Pisarchik AV, 2000, THYROID, V10, P25, DOI 10.1089/thy.2000.10.25; Powell DJ, 1998, CANCER RES, V58, P5523; Qin GZ, 1999, INT J CANCER, V80, P345, DOI 10.1002/(SICI)1097-0215(19990129)80:3<345::AID-IJC2>3.3.CO;2-E; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; ROSAI J, 1990, TUMORS THYROID GLAND; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Salassidis K, 2000, CANCER RES, V60, P2786; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; SHI YF, 1993, CLIN ENDOCRINOL, V39, P269, DOI 10.1111/j.1365-2265.1993.tb02365.x; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Soravia C, 1999, AM J PATHOL, V154, P127, DOI 10.1016/S0002-9440(10)65259-5; Sozzi G, 1998, CANCER RES, V58, P5032; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Sweetser DA, 1997, ONCOGENE, V15, P2783, DOI 10.1038/sj.onc.1201452; Tallini G, 1998, CLIN CANCER RES, V4, P287; THOMPSON TC, 1995, ONCOGENE, V10, P869; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; VINETTE DSJ, 1991, DIAGN CYTOPATHOL, V7, P75, DOI 10.1002/dc.2840070120; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Xiao GH, 1997, AM J PATHOL, V151, P1541; Yokota T, 2000, J HUM GENET, V45, P6, DOI 10.1007/s100380050002; Yoshino K, 2000, INT J CANCER, V85, P6, DOI 10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.0.CO;2-6; Zou M, 1999, EUR J CANCER, V35, P467, DOI 10.1016/S0959-8049(98)00370-0; ZOU MJ, 1993, J CLIN ENDOCR METAB, V77, P1054, DOI 10.1210/jc.77.4.1054	80	37	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3235	3246		10.1038/sj.onc.1204425	http://dx.doi.org/10.1038/sj.onc.1204425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423973				2022-12-28	WOS:000169163500007
J	Urnov, FD; Wolffe, AP				Urnov, FD; Wolffe, AP			Chromatin remodeling and transcriptional activation: the cast (in order of appearance)	ONCOGENE			English	Review						chromatin; transcription; histone deacetylase; histone acetyltransferase; chromatin remodeling	THYROID-HORMONE RECEPTOR; YEAST SWI/SNF COMPLEX; IFN-BETA ENHANCEOSOME; CORE HISTONE ACETYLATION; IN-VIVO; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; NUCLEOSOMAL DNA; SWI-SNF	The number of chromatin modifying and remodeling complexes implicated in genome control is growing faster than our understanding of the functional roles they play. We discuss recent in vitro experiments with biochemically defined chromatin templates that illuminate new aspects of action by histone acetyltransferases and ATP-dependent chromatin remodeling engines in facilitating transcription. We review a number of studies that present an 'ordered recruitment' view of transcriptional activation, according to which various complexes enter and exit their target promoter in a set sequence, and at specific times, such that action by one complex sets the stage for the arrival of the next one. A consensus emerging from all these experiments is that the joint action by several types of chromatin remodeling machines can lead to a more profound alteration of the infrastructure of chromatin over a target promoter than could be obtained by these enzymes acting independently. In addition, it appears that in specific cases one type of chromatin structure alteration (e.g., histone hyperacetylation) is contingent upon prior alterations of a different sort (i.e., ATP-dependent remodeling of histone-DNA contacts), The striking differences between the precise sequence of action by various cofactors observed in these studies may be - at least in part - due to differences between the specific promoters studied, and distinct requirements exhibited by specific loci for chromatin remodeling based on their pre-existing nucleoprotein architecture.	Sangamo Biosci, Pt Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Urnov, FD (corresponding author), Sangamo Biosci, Pt Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.	furnov@sangamo.com						Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1989, STEROID THYROID HORM, P221; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRIZUELA BJ, 1994, GENETICS, V137, P803; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Bultman S, 2000, MAMM GENOME, V11, P251, DOI 10.1007/s003350010049; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Collins RT, 2000, GENE DEV, V14, P3140, DOI 10.1101/gad.854300; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Di Croce L, 1999, Nucleic Acids Res, V27, pe11, DOI 10.1093/nar/27.16.e11; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Goodman RH, 2000, GENE DEV, V14, P1553; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Guschin D, 2000, J BIOL CHEM, V275, P35248, DOI 10.1074/jbc.M006041200; Hager GL, 2001, PROG NUCLEIC ACID RE, V66, P279; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, V2, P949; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Jiang W, 2000, J BIOL CHEM, V275, P39819, DOI 10.1074/jbc.C000713200; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Kung AL, 2000, GENE DEV, V14, P272; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, V2, P1193; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pile LA, 2000, J BIOL CHEM, V275, P1398, DOI 10.1074/jbc.275.2.1398; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; RUBINSTEIN JH, 1990, AM J MED GENET, P3; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SAMUELS HH, 1982, RECENT PROG HORM RES, V38, P557; Sawa H, 2000, MOL CELL, V6, P617, DOI 10.1016/S1097-2765(00)00060-5; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schubeler D, 2000, GENE DEV, V14, P940; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Vazquez M, 1999, DEVELOPMENT, V126, P733; Verreault A, 2000, GENE DEV, V14, P1430; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; WEISENBERGER D, 1995, J CELL BIOL, V129, P561, DOI 10.1083/jcb.129.3.561; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	150	151	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					2991	3006		10.1038/sj.onc.1204323	http://dx.doi.org/10.1038/sj.onc.1204323			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420714				2022-12-28	WOS:000169308500002
J	Dell'Era, P; Belleri, M; Stabile, H; Massardi, ML; Ribatti, D; Presta, M				Dell'Era, P; Belleri, M; Stabile, H; Massardi, ML; Ribatti, D; Presta, M			Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells	ONCOGENE			English	Article						angiogenesis; cell transfection; endothelium; FGF; FGF receptor; hemangioma	NIH 3T3 CELLS; FACTOR RECEPTOR; FGF RECEPTOR; KAPOSIS-SARCOMA; BIOLOGICAL PROPERTIES; ANGIOGENIC ACTIVITY; FACTOR FAMILY; HEPARIN; EXPRESSION; PROTEIN	Recombinant Fibroblast Growth Factor-4 (FGF4) and FGF2 induce extracellular signal-regulated kinase-1/2 activation and DNA synthesis in murine aortic endothelial (MAE) cells. These cells co-express the IIIc/Ig-3 loops and the novel glyccpsaminoglycan-modified Illc/Ig-2 loops isoforms of FGF receptor-2 (FGFR2). The affinity of FGP4/FGFR2 interaction is 20-30 times lower than that of FGF2 and is enhanced by heparin, Overexpression of FGF2 or FGF4 cDNA in MAE cells results in a transformed phenotype and increased proliferative capacity, more evident for FGF2 than FGF4 transfectants, Both transfectants induce angiogenesis when applied on the top of the chick embryo chorioallantoic membrane. However, in contrast with FG2-transfected cells, FGF4 transfectants show a limited capacity to growth under anchorage-independent conditions and lack the ability to invade 3D fibrin gel and to undergo morphogenesis in vitro. Also, they fail to induce hemangiomas when injected into the allantoic sac of the chick embryo. In conclusion, although exogenous FGF2 and FGF4 exert a similar response in MAE cells, significant differences are observed in the biological behavior of FGF4 ver sus FGF2 transfectants, indicating that the expression of the various members of the FGF family can differently affect the behavior of endothelial cells and, possibly, of other cell types, including tumor cells.	Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Bari, Dept Human Anat & Histol, I-70124 Bari, Italy	University of Brescia; Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy.		Presta, Marco/B-4345-2010; Dell'Era, Patrizia/ABD-5848-2020; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010	Dell'Era, Patrizia/0000-0001-6682-6321; PRESTA, Marco/0000-0002-4398-8376				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLTRINI D, 1994, BIOCHEM J, V303, P583, DOI 10.1042/bj3030583; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Oliver R T, 1999, Curr Opin Oncol, V11, P236; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Ribatti D, 1999, J PATHOL, V189, P590; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti D, 1999, J CELL SCI, V112, P4213; Sakaguchi K, 1999, MOL CELL BIOL, V19, P6754; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shimon I, 1998, CLIN ENDOCRINOL, V48, P23, DOI 10.1046/j.1365-2265.1998.00332.x; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; Twigg SRF, 1998, HUM MOL GENET, V7, P685, DOI 10.1093/hmg/7.4.685; Uematsu F, 2000, BIOCHEM BIOPH RES CO, V272, P830, DOI 10.1006/bbrc.2000.2872; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	51	46	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2655	2663		10.1038/sj.onc.1204368	http://dx.doi.org/10.1038/sj.onc.1204368			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420677				2022-12-28	WOS:000168652600006
J	Suliman, A; Lam, A; Datta, R; Srivastava, RK				Suliman, A; Lam, A; Datta, R; Srivastava, RK			Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways	ONCOGENE			English	Article						TRAIL; death receptor; FADD; caspase; mitochondria; Bcl-2; Bcl-X-L	CYTOCHROME-C RELEASE; CYTOTOXIC LIGAND TRAIL; PROGRAMMED CELL-DEATH; NF-KAPPA-B; MEDIATED APOPTOSIS; CANCER-CELLS; FAS LIGAND; IONIZING-RADIATION; BACULOVIRUS P35; CD95 APO-1/FAS	Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines that promotes apoptosis, TRAIL induces apoptosis via death receptors (DR4 and DR5) in a wide variety of tumor cells but not in normal cells. The objectives of this study are to investigate the intracellular mechanisms by which TRAIL induces apoptosis, The death receptor Fas, upon ligand binding, trimerizes and recruits the adaptor protein FADD through the cytoplasmic death domain of Fas, FADD then binds and activates procaspase-8. It is unclear whether FADD is required for TRAIL-induced apoptosis, Here we show that the signaling complex of DR4/DR5 is assembled in response to TRAIL binding. FADD and caspase-8, but not caspase-10, are recruited to the receptor, and cells deficient in either FADD or caspase-8 blocked TRAIL-induced apoptosis, In addition, TRAIL initiates the activation of caspases, the loss of mitochondrial transmembrane potential (Delta psi (m)), the cleavage of BID, and the redistribution of mitochondrial cytochrome c, Treatment of Jurkat cells with cyclosporin A delayed TRAIL-induced Delta psi (m), caspase-3 activation and apoptosis, Similarly, Overexpression of Bcl-2 or Bcl-X-L delayed, but did not inhibit, TRAIL-induced Delta psi (m) and apoptosis, In contrast, XIAP, cowpox virus CrmA and baculovirus p35 inhibited TRAIL-induced apoptosis, These data suggest that death receptors (DR4 and DR5) and Fas receptors induced apoptosis through identical signaling pathway, and TRAIL-induced apoptosis via both mitochondrial-dependent and -independent pathways.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CLEN RJ, 1994, MOL CELL BIOL, V14, P5212; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Decaudin D, 1997, CANCER RES, V57, P62; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Enari M, 2000, SEIKAGAKU, V72, P6; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Han ZY, 1999, MOL CELL BIOL, V19, P1381; HAY BA, 1994, DEVELOPMENT, V120, P2121; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Srivastava RK, 1999, ONCOGENE, V18, P1755, DOI 10.1038/sj.onc.1202464; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tanaka M, 1997, J IMMUNOL, V158, P2303; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	87	310	324	0	20	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2122	2133		10.1038/sj.onc.1204282	http://dx.doi.org/10.1038/sj.onc.1204282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360196				2022-12-28	WOS:000168116700007
J	Kurokawa, K; Iwashita, T; Murakami, H; Hayashi, H; Kawai, K; Takahashi, M				Kurokawa, K; Iwashita, T; Murakami, H; Hayashi, H; Kawai, K; Takahashi, M			Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction	ONCOGENE			English	Article						SNT/FRS2; RET; SHC; GDNF; MEN2	PHOSPHOTYROSINE-DEPENDENT INTERACTION; FIBROBLAST-GROWTH-FACTOR; NEOPLASIA TYPE 2B; NEUROTROPHIC FACTOR; TRANSFORMING ACTIVITY; CELL-DIFFERENTIATION; ADAPTER PROTEINS; INSULIN-RECEPTOR; PC12 CELLS; NPEY MOTIF	SNT/FRS2 is a lipid anchored docking protein that contains an amino-terminal myristylation signal, followed by a phosphotyrosine-binding (PTB) domain and a carboxy-terminal region with multiple tyrosine residues. Here we show that the SNT/FRS2 PTB domain binds to RET receptor tyrosine kinase activated by glial cell line-derived neurotrophic factor (GDNF) or multiple endocrine neoplasia (MEN) 2 mutations. Analyses by site directed-mutagenesis revealed that it binds to tyrosine 1062 in RET that is also known to be a binding site for the SHC adaptor protein. Whereas SHC bound to RET was associated with GRB2 and GAB1 proteins, SNT/FRS2 was associated with GRB2 only, suggesting that SNT/FRS2 is involved mainly in the activation of the RAS/mitogen activated protein kinase (MAPK) pathway but not the phosphatidylinositol 3-kinase (PI3-K)/AKT pathway. In addition, phosphorylated SNT/FRS2 appeared to directly complex with SHP-2 tyrosine phosphatase. These results suggest that tyrosine 1062 in RET provides a site for the interaction of multiple signaling molecules and that the balance of SHC and SNT/FRS2 binding may affect the nature of the intracellular signaling for cell proliferation, differentiation and survival induced by activated RET.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kumi, Kawai/I-6275-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Kumi, Kawai/0000-0002-7772-2605; Takahashi, Masahide/0000-0002-2803-2683; 				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	30	80	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					1929	1938		10.1038/sj.onc.1204290	http://dx.doi.org/10.1038/sj.onc.1204290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360177				2022-12-28	WOS:000168043800001
J	Zhang, ZT; Pak, J; Huang, HY; Shapiro, E; Sun, TT; Pellicer, A; Wu, XR				Zhang, ZT; Pak, J; Huang, HY; Shapiro, E; Sun, TT; Pellicer, A; Wu, XR			Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation	ONCOGENE			English	Article						urothelial carcinoma; progression pathways; Ha-ras oncogene; transgenic mice; uroplakin	TRANSITIONAL-CELL-CARCINOMA; HUMAN BLADDER-TUMORS; URINARY-BLADDER; TRANSGENIC MICE; IN-SITU; GENETIC ALTERATIONS; ONCOGENIC RAS; K-RAS; CANCER; EXPRESSION	Urothelial tumors develop along two distinctive phenotypic pathways (superficial papillary non-invasive tumors versus flat carcinoma in situ lesions), with markedly different biological behavior and prognosis. Although multiple genetic alterations have been identified in human bladder cancer, their cause-effect relationship with the two pathways has not been firmly established, Using a urothelium-specific promoter of the uroplakin TT gene, we showed earlier in transgenic mice that the urothelial expression of SV40T antigen, which inactivates p53 and pRb, induced carcinoma in situ and invasive and metastatic bladder cancer. In striking contrast, we demonstrate here that the urothelial expression of an activated Ha-ras in transgenic mice caused urothelial hyperplasia and superficial papillary non-invasive bladder tumors. These results provide strong, direct experimental evidence that the two phenotypical pathways of bladder tumorigenesis are caused by distinctive genetic defects, Our results indicate that Ha-ras activation can induce urothelial proliferation in vivo; and that urothelial hyperplasia is a precursor of low-grade, superficial papillary bladder tumors. Our transgenic models provide unique opportunities to study the detailed molecular events underlying different types of bladder neoplasms, and can serve as useful preclinical models for evaluating the in vivo efficacy of preventive and therapeutic agents that act on various signaling pathways in bladder cancer.	NYU, Sch Med, Dept Urol, New York, NY 10016 USA; Dept Vet Affairs Med Ctr, New York, NY 10010 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University	Wu, XR (corresponding author), NYU, Sch Med, Dept Urol, 550 1st Ave,Room Skirball 10U, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Pellicer, Angel/0000-0002-5062-0692; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039753, R01DK056903, P01DK052206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56903, DK52769, DK52206, DK39753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Balazs M, 1997, GENE CHROMOSOME CANC, V19, P84, DOI 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.3.CO;2-U; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BOS JL, 1989, CANCER RES, V49, P4682; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BRINSTER RL, 1986, HARVEY LECT, V80, P1; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; BURCHILL SA, 1991, BR J CANCER S13, V63, P62; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Campbell SC, 1998, CANCER RES, V58, P1298; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Cordon-Cardo C, 1994, Important Adv Oncol, P71; COROMINAS M, 1991, ENVIRON HEALTH PERSP, V93, P19, DOI 10.2307/3431163; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DUNN TL, 1988, J PATHOL, V156, P59, DOI 10.1002/path.1711560112; ENOMOTO T, 1990, CARCINOGENESIS, V11, P2233; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Grossman H B, 1996, Oncology (Williston Park), V10, P1617; KNOWLES MA, 1993, CANCER RES, V53, P133; KOSS LG, 1992, J CELL BIOCHEM, P23; KUNZE E, 1990, PATHOLOGY TUMOURS LA, V1, P345; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; LEVESQUE P, 1993, INT J CANCER, V55, P785, DOI 10.1002/ijc.2910550516; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; MASUI T, 1993, TERATOGEN CARCIN MUT, V13, P225, DOI 10.1002/tcm.1770130504; MESSING EM, 1992, SEMIN SURG ONCOL, V8, P285, DOI 10.1002/ssu.2980080507; Ogawa K, 1998, MOL CARCINOGEN, V21, P70, DOI 10.1002/(SICI)1098-2744(199801)21:1<70::AID-MC9>3.0.CO;2-T; OHTANI M, 1986, CANCER RES, V46, P2001; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Orntoft TF, 1998, UROL RES, V26, P223, DOI 10.1007/s002400050050; OYASU R, 1995, FOOD CHEM TOXICOL, V33, P747, DOI 10.1016/0278-6915(95)00042-Z; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RASSOULZADEGAN M, 1987, ONCOGENE RES, V1, P1; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; ROSIN MP, 1995, CANCER RES, V55, P5213; SAITO S, 1992, Keio Journal of Medicine, V41, P80; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHALKEN JA, 1992, SEMIN SURG ONCOL, V8, P274, DOI 10.1002/ssu.2980080505; SCHNEIDER BL, 1992, MOL CARCINOGEN, V6, P1, DOI 10.1002/mc.2940060102; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPRUCK CH, 1994, CANCER RES, V54, P784; STEINBERG GD, 1992, UROL CLIN N AM, V19, P735; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Vageli D, 1996, CANCER LETT, V107, P241, DOI 10.1016/0304-3835(96)04372-8; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WAGNER U, 1995, HUM PATHOL, V26, P970, DOI 10.1016/0046-8177(95)90086-1; WALKER BE, 1960, AM J ANAT, V107, P95, DOI 10.1002/aja.1001070202; YAMAMOTO S, 1995, CARCINOGENESIS, V16, P2363, DOI 10.1093/carcin/16.10.2363; YE DW, 1993, UROL RES, V21, P39; Zhang ZT, 1999, CANCER RES, V59, P3512	56	133	137	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1973	1980		10.1038/sj.onc.1204315	http://dx.doi.org/10.1038/sj.onc.1204315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360181				2022-12-28	WOS:000168043800005
J	Drane, P; Bravard, A; Bouvard, V; May, E				Drane, P; Bravard, A; Bouvard, V; May, E			Reciprocal down-regulation of p53 and SOD2 gene expression - implication in p53 mediated apoptosis	ONCOGENE			English	Article						p53; superoxide dismutase; apoptosis; gene regulation; NF-kappa B	MANGANESE SUPEROXIDE-DISMUTASE; WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; NF-KAPPA-B; TRANSCRIPTIONAL REPRESSION; DNA-BINDING; IN-VIVO; MALIGNANT PHENOTYPE; OXIDATIVE STRESS	p53 regulates the transcription of a number of genes among which are different redox-related genes. It has been proposed that these genes can induce a cellular oxidative stress leading to p53-dependent apoptosis (Polyak er al., 1997). MnSOD, the product of superoxide dismutase 2 (SOD2) gene, is one of the major cellular defences against oxidative stress. We demonstrate here that p53 is able to repress SOD2 gene expression and that this repression takes place at promoter level. We show the importance of this regulation for the p53 function, by demonstrating that an overexpression of MnSOD decreases p53-mediated induction of apoptosis. Moreover, we demonstrate that MnSOD overexpression decreases p53-gene expression at the promoter level. These findings raise the hypothesis that p53 and SOD2 genes are mutually regulated leading to the modulation of various cellular processes including apoptosis.	CEA, Lab Cancerogenese Mol, CNRS,UMR 217, DRR,DSV, F-92265 Fontenay Aux Roses, France; CEA, Lab Radiobiol Cellulaire, DRR, DSV, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); CEA	May, E (corresponding author), CEA, Lab Cancerogenese Mol, CNRS,UMR 217, DRR,DSV, BP6, F-92265 Fontenay Aux Roses, France.			BRAVARD, Anne/0000-0002-0314-9092				BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Borgstahl GEO, 1996, BIOCHEMISTRY-US, V35, P4287, DOI 10.1021/bi951892w; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cho G, 1997, BIOCHEM MOL BIOL INT, V42, P949; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Frei B, 1999, FASEB J, V13, P963, DOI 10.1096/fasebj.13.9.963; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6; Iotsova V, 1996, ONCOGENE, V13, P2331; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; Kaluzova M, 2000, BBA-GENE STRUCT EXPR, V1491, P20, DOI 10.1016/S0167-4781(00)00015-4; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kuo SY, 1999, J BIOL CHEM, V274, P3345, DOI 10.1074/jbc.274.6.3345; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; LI JJ, 1995, ONCOGENE, V10, P1989; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Pani G, 2000, CANCER RES, V60, P4654; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRICE BD, 1993, ONCOGENE, V8, P3055; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shatrov VA, 2000, INT J CANCER, V85, P93, DOI 10.1002/(SICI)1097-0215(20000101)85:1<93::AID-IJC17>3.0.CO;2-I; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sheng-Tanner X, 1998, RADIAT RES, V150, P636, DOI 10.2307/3579886; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Wang QJ, 1998, CANCER RES, V58, P5762; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WU HY, 1994, J BIOL CHEM, V269, P20067; YonishRouach E, 1995, ONCOGENE, V11, P2197; Zhao RB, 2000, GENE DEV, V14, P981; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	63	128	135	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					430	439		10.1038/sj.onc.1204101	http://dx.doi.org/10.1038/sj.onc.1204101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313974				2022-12-28	WOS:000166562500003
J	Fukuhara, H; Maruyama, T; Nomura, S; Oshimura, M; Kitamura, T; Sekiya, T; Murakami, Y				Fukuhara, H; Maruyama, T; Nomura, S; Oshimura, M; Kitamura, T; Sekiya, T; Murakami, Y			Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers	ONCOGENE			English	Article						prostate cancer; tumor suppressor gene; chromosome 10p15; microcell-mediated chromosome transfer	CELL-LINE; ALLELIC LOSS; SHORT ARM; MALIGNANT PHENOTYPE; METASTASIS; LOCI; FRAGMENTS; CARCINOMA; DELETION; HETEROZYGOSITY	Loss of heterozygosity on chromosome 10p was observed frequently in human prostate cancers. Studies have demonstrated that the introduction of the short arm of human chromosome 10 into a human prostate cancer cell line, PPC-I, by microcell-mediated chromosome transfer (MMCT), suppressed the malignant phenotype, suggesting the presence of a prostate tumor suppressor gene(s) within a region of 17 cM at distal 10p, To narrow down the candidate region harboring the tumor suppressor gene, a series of 10p fragments were transferred into PPC-1 cells by MMCT using a panel of hamster-human hybrid cells containing various portions of 10p, Pour of the six hybrid tells obtained showed decreased tumorigenicity when injected subcutaneously irate athymic nude mice. Tumors developed only at six of 40 injection sites for these four hybrid cells. In contrast, the other two hybrid cells, as well as parental PPC-1 cells, were judged to he fully tumorigenic because tumors appeared at a total 26 of 32 sites for the two hybrid cells and 15 of 16 sites for PPC-I, Allelotyping of 10p combined with fluorescence in situ hybridization in these hybrid cells suggested that a prostate tumor suppressor gene was located within a fragment of approximately 1.2 Mb flanked by D10S1172 and D10S226 on 10p15.1.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; BML, R&D Ctr, Kawagoe, Saitama 3501101, Japan; Tottori Univ, Fac Med, Sch Life Sci, Yonago, Tottori 6838503, Japan; Univ Tokyo, Sch Med, Dept Urol, Tokyo 1138655, Japan	National Cancer Center - Japan; Tottori University; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022; Kitamura, Toshio/AAA-2071-2021	Nomura, Sachio/0000-0001-9214-4041; 				ALBERTSEN H, 1994, AM J HUM GENET, V54, P516; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOVA GS, 1993, CANCER RES, V53, P3869; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; BROTHMAN AR, 1990, CANCER RES, V50, P3795; BROTHMAN AR, 1995, GENE CHROMOSOME CANC, V13, P278, DOI 10.1002/gcc.2870130408; BROTHMAN AR, 1992, CYTOGENET CELL GENET, V60, P8, DOI 10.1159/000133283; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EFFERT PJ, 1992, J UROLOGY, V147, P789, DOI 10.1016/S0022-5347(17)37387-1; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISAACS WB, 1991, CANCER RES, V51, P4716; Ittmann M, 1996, CANCER RES, V56, P2143; Kawana Y, 1997, PROSTATE, V32, P205; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1993, GENE CHROMOSOME CANC, V8, P88, DOI 10.1002/gcc.2870080205; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; MURAKAMI Y, 2000, IN PRESS J HUM GENET; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; Nihei N, 1996, GENE CHROMOSOME CANC, V17, P260, DOI 10.1002/(SICI)1098-2264(199612)17:4<260::AID-GCC8>3.0.CO;2-1; Nihei N, 1999, GENE CHROMOSOME CANC, V24, P1, DOI 10.1002/(SICI)1098-2264(199901)24:1<1::AID-GCC1>3.0.CO;2-A; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; Robertson GP, 1999, CANCER RES, V59, P3596; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Shimura M, 1999, CANCER RES, V59, P2259; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Trybus TM, 1996, CANCER RES, V56, P2263; VISAKORPI T, 1995, CANCER RES, V55, P342; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	48	21	21	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					314	319		10.1038/sj.onc.1204079	http://dx.doi.org/10.1038/sj.onc.1204079			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313960				2022-12-28	WOS:000166411000005
J	Stewart, ZA; Tang, LJ; Pietenpol, JA				Stewart, ZA; Tang, LJ; Pietenpol, JA			Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner	ONCOGENE			English	Article						taxol; vincristine; nocodazole; adriamycin; ionizing radiation; ATM	ACTIVATED PROTEIN-KINASE; DAMAGE-INDUCED PHOSPHORYLATION; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; SPINDLE DISRUPTION; IN-VITRO; CHECKPOINT; BINDING; MDM2	p53 is present at low levels in unstressed cells. Numerous cellular insults, including DNA damage and microtubule disruption, elevate p53 protein levels. Phosphorylation of p53 is proposed to be important for p53 stabilization and activation after genotoxic stress; however, p53 phosphorylation after microtubule disruption has not been analysed. The goal of the current study was to determine if p53 phosphorylation increases after microtubule disruption, and if so, to identify specific p53 residues necessary for microtubule inhibitor-induced phosphorylation, Two dimensional gel analyses demonstrated that the number of p53 phosphoforms in cells increased after treatment with microtubule inhibitors (MTIs) and that the pattern of p53 phosphorylation was distinct from that observed after DNA damage, p53 phosphorylation also varied in a MTI-dependent manner, as Taxol and Vincristine induced more p53 phospho-forms than nocodazole. Further, MTI treatment increased phosphorylation of p53 on serine-15 in epithelial tumor cells, In contrast, serine-15 phosphorylation of p53 did not increase in MTI-treated primary cultures of human fibroblasts. Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol- and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53, Taken together, the results of this study demonstrate that distinct p53 phospho-forms are induced by MTI treatment as compared to DNA damage and that p53 phosphorylation is mediated in a MTI- and cell-specific manner.	Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA070856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347 , +] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hecker D, 1996, ONCOGENE, V12, P953; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Khan SH, 1998, CANCER RES, V58, P396; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lavin MF, 1996, CURR OPIN IMMUNOL, V8, P459, DOI 10.1016/S0952-7915(96)80030-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mayo LD, 1997, CANCER RES, V57, P5013; MILNE DM, 1992, ONCOGENE, V7, P1361; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stewart ZA, 1999, CANCER RES, V59, P3831; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691	51	56	57	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					113	124		10.1038/sj.onc.1204060	http://dx.doi.org/10.1038/sj.onc.1204060			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244509				2022-12-28	WOS:000166361400013
J	McCormick, F				McCormick, F			ONYX-015 selectivity and the p14ARF pathway	ONCOGENE			English	Article						p53; ONYX-015; adenovirus; p14ARF	TUMOR-CELLS; P53 STATUS; ADENOVIRUS MUTANT; MESSENGER-RNA; REPLICATION; PROTEIN; INFECTION; INDUCTION; P19(ARF); EFFICACY	ONYX-015, dl1520, is an adenovirus that lacks the E1B 55K gene and therefore lacks the capacity to neutralize p53 during infection. This virus induces high levels of p53 and fails to grow efficiently in primary epithelial cells. However, it does replicate in many tumor cells, including those expressing wild-type p53. In these cells, ONYX-015 fails to induce active p53. This is because the pathway from Ela to p53 is disrupted through loss of p14ARF. We propose that high levels of Mdm2 activity resulting from loss of p14ARF, and high levels of Mdm2 protein resulting from activated Ras prevent accumulation of functional p53 during infection of tumor cells that retain wild-type p53.	Univ Calif San Francisco, Ctr Comprehens Canc, Inst Canc Res, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	McCormick, F (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94115 USA.							BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Howley P M, 1989, Princess Takamatsu Symp, V20, P199; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Wildner O, 1999, GENE THER, V6, P57, DOI 10.1038/sj.gt.3300810	19	31	34	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 27	2000	19	56					6670	6672		10.1038/sj.onc.1204096	http://dx.doi.org/10.1038/sj.onc.1204096			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426653				2022-12-28	WOS:000167704000014
J	Mendelsohn, J; Baselga, J				Mendelsohn, J; Baselga, J			The EGF receptor family as targets for cancer therapy	ONCOGENE			English	Review						EGF receptor; ERBB2; IMC-C225; ZD1939; trastuzumab	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; HUMAN-BREAST-CANCER; HER2/NEU-OVEREXPRESSING METASTATIC BREAST; HUMAN PANCREATIC-CARCINOMA; HIGH-AFFINITY RECEPTORS; ERBB SIGNALING NETWORK; TUMOR-NECROSIS-FACTOR; CELLS IN-VITRO; MONOCLONAL-ANTIBODY	Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been associated with a more aggressive clinical behavior. Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype. For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments, In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed, These MAbs have shown promising preclinical activity and 'chimeric' and 'humanized' MAbs have been produced in order to obviate the problem of host immune reactions. Clinical activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC-C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy, In addition to antibodies, compounds that directly inhibit receptor tyrosine kinases have shown preclinical activity and early clinical activity has been reported. A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and mill further address the role of these active anti-receptor agents in the treatment of patients,vith cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA; Univ Autonoma Barcelona, Valle Hebron Hosp, Med Oncol Serv, E-08193 Barcelona, Spain	University of Texas System; UTMD Anderson Cancer Center; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron	Mendelsohn, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.							ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ARTEAGA CL, 1994, CANCER RES, V54, P3758; ARTEAGA CL, 1993, P AN M AM SOC CLIN, V12, pA103; Baly D. L., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P27; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P380; Baselga J, 1998, CANCER RES, V58, P2825; BASELGA J, P ANN M AM SOC CLIN, V19, pA177; BONNER JA, 2000, P AN M AM SOC CLIN, V19, pA4; Bos M, 1997, CLIN CANCER RES, V3, P2099; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Bruns CJ, 2000, CANCER RES, V60, P2926; Bruns CJ, 2000, CLIN CANCER RES, V6, P1936; Budillon Alfredo, 2000, Proceedings of the American Association for Cancer Research Annual Meeting, V41, P773; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAN KC, 2000, P AM ASSOC CANC RES, V41, P482; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHINKERS M, 1981, NATURE, V290, P516, DOI 10.1038/290516a0; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Ciardiello F, 1996, JNCI-J NATL CANCER I, V88, P1770, DOI 10.1093/jnci/88.23.1770; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Codony-Servat J, 1999, CANCER RES, V59, P1196; CODONYSERVAT J, 2000, P AM ASSOC CANC RES, V41, P68; COHEN RB, 2000, P AN M AM SOC CLIN, V19, pA474; COHEN S, 1980, J BIOL CHEM, V255, P4834; COHEN S, 1962, J BIOL CHEM, V237, P1555; Colomer R, 2000, CLIN CANCER RES, V6, P2356; COOPER JA, 1981, J CELL BIOL, V91, P878, DOI 10.1083/jcb.91.3.878; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; FENDLY BM, 1990, CANCER RES, V50, P1550; Fennell M, 2000, P AM ASSOC CANC RES, V41, P402; FERRY D, 2000, P AN M AM SOC CLIN, V19, pA3; FONG CJ, 1992, CANCER RES, V52, P5887; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GILL GN, 1984, J BIOL CHEM, V259, P7755; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANCOCK MC, 1991, CANCER RES, V51, P4575; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Harris LN, 1996, P AN M AM SOC CLIN, V15, P108; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Huang SM, 1999, CANCER RES, V59, P1935; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; Kelly HC, 1998, ANN ONCOL, V9, P109; Khazaeli MLA, 2000, P AN M AM SOC CLIN, V19, p207a; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Klohs Wayne D., 1997, Current Opinion in Oncology, V9, P562, DOI 10.1097/00001622-199711000-00012; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LIPTON A, 2000, P AN M AM SOC CLIN, V19, pA71; Liu B, 2000, BRIT J CANCER, V82, P1991; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; Lydon NB, 1998, INT J CANCER, V76, P154, DOI 10.1002/(SICI)1097-0215(19980330)76:1<154::AID-IJC24>3.0.CO;2-B; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MASUI H, 1984, CANCER RES, V44, P1002; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MENDELSOHN J, 1999, P AN M AM SOC CLIN, V18, pA389; MENDELSOHN J, 1995, BIOL THERAPY CANC, P607; Milas L, 2000, CLIN CANCER RES, V6, P701; Modjtahedi H, 1996, BRIT J CANCER, V73, P228, DOI 10.1038/bjc.1996.40; Moyer JD, 1997, CANCER RES, V57, P4838; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; NAKAGAWA K, 2000, P AN M AM SOC CLIN, V19, pA183; NEILANDS JB, 1981, J BIOL CHEM, V256, P3831; Norton L, 1999, P AN M AM SOC CLIN, V18, p127a; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram M. D., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P602; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Peng D, 1996, CANCER RES, V56, P3666; PEREZSOLER R, 1994, J CLIN ONCOL, V12, P730, DOI 10.1200/JCO.1994.12.4.730; PEREZSOLER R, 1998, P AN M AM SOC CLIN, V17, pA393; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Pietras RJ, 1999, CANCER RES, V59, P1347; Reese D., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P51; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; RODECK U, 1987, CANCER RES, V47, P3692; RUBIN MS, 2000, P AN M AM SOC CLIN, V19, pA474; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Sato J D, 1983, Mol Biol Med, V1, P511; Sepp-Lorenzino L., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P421; SIROTNAK FM, 2000, P AM ASSOC CANC RES, V41, P482; SLAMON D, 1998, P AN M AM SOC CLIN, V17, P98; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Smaill JB, 1999, J MED CHEM, V42, P1803, DOI 10.1021/jm9806603; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Tokuda Y, 1996, BRIT J CANCER, V73, P1362, DOI 10.1038/bjc.1996.259; Tortora G, 1999, CLIN CANCER RES, V5, P875; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vincent PW, 2000, CANCER CHEMOTH PHARM, V45, P231, DOI 10.1007/s002800050034; VOGEL C, 2000, P AN M AM SOC CLIN, V19, pA71; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; Woodburn J. R., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P633; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu XP, 1996, ONCOGENE, V12, P1397; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YANG X, 2000, P ANN M AM SOC CLIN, V19, pA48; Yang XD, 1999, CANCER RES, V59, P1236; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	153	1106	1232	8	300	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6550	6565		10.1038/sj.onc.1204082	http://dx.doi.org/10.1038/sj.onc.1204082			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426640				2022-12-28	WOS:000167704000001
J	Remy, P; Baltzinger, M				Remy, P; Baltzinger, M			The Ets-transcription factor family in embryonic development: lessons from the amphibian and bird	ONCOGENE			English	Review						Xenopus; chicken; cell migration; epithelium/mesenchyme transition; adhesion; vascularization	NICOTINIC ACETYLCHOLINE-RECEPTOR; VASCULAR ENDOTHELIAL-CADHERIN; HEPATOCYTE GROWTH-FACTOR; TRANSGENIC MICE DEVELOP; TERNARY COMPLEX FACTORS; DEVELOPING AVIAN HEART; GA-BINDING-PROTEIN; NEURAL CREST CELLS; ONCOGENE C-ETS; XI-FLI GENE	This chapter reviews the expression and role of Ets-genes during embryogenesis of amphibians and birds. In addition to overlapping expression domains, some of them exhibit cell type-specific expression. Many of them are expressed in migratory cells: neural crest, endothelial and pronephric duct cells for instance. They are also transcribed in embryonic areas affected by epitheliomesenchymal transitions. Both processes involve modifications of cellular adhesion. Ets-family genes appear to coordinate changes in the expression of adhesion molecules and degradation of the extracellular matrix upon regulation of matrix metalloproteinases and their specific inhibitors. These functions are essential for physiological processes like tissue remodelling during embryogenesis or wound healing. Unfortunately they also play a harmful role in metastasis. Recent studies in the nervous system showed that Ets-genes contribute to the establishment of a cellular identity. This identity could rely on definite cell-surface determinants, among which cadherins could play an important role. In addition to cell-type specific expression, other factors contribute to the specificity of function of Ets-genes, These genes have a broad specificity of recognition of target sequences in gene promoters, insufficient for accurate control of gene expression. A fine tuning could arise from combinatorial interactions with other Ets- or accessory proteins.	IPCB, CNRS, FRE 2168, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Remy, P (corresponding author), IPCB, CNRS, FRE 2168, 21 Rue Rene Descartes, F-67084 Strasbourg, France.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; Anderson MK, 1999, DEVELOPMENT, V126, P3131; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Baltzinger M, 1999, DEV DYNAM, V216, P420, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<420::AID-DVDY10>3.0.CO;2-C; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Begue A, 1997, GENE EXPRESSION, V6, P333; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BISCHOFF J, 1995, TRENDS CELL BIOL, V5, P69, DOI 10.1016/S0962-8924(00)88949-7; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURDETT LA, 1992, NUCLEIC ACIDS RES, V20, P371, DOI 10.1093/nar/20.2.371; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chang LF, 1996, J BIOL CHEM, V271, P6467, DOI 10.1074/jbc.271.11.6467; Charron G, 1995, J BIOL CHEM, V270, P30604, DOI 10.1074/jbc.270.51.30604; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Chen ZQ, 1997, CANCER RES, V57, P2013; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; COLLAZO A, 1993, DEVELOPMENT, V118, P363; CORNISH JA, 1993, DEV BIOL, V159, P338, DOI 10.1006/dbio.1993.1245; Crepieux Pascale, 1993, Gene Expression, V3, P215; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Davies JA, 1996, ACTA ANAT, V156, P187; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; Edel MJ, 1999, ANTICANCER RES, V19, P2945; Edel MJ, 1998, ANTICANCER RES, V18, P4505; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; EKBLOM P, 1989, FASEB J, V3, P2142; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; FEENEY JF, 1946, J MORPHOL, V78, P231, DOI 10.1002/jmor.1050780205; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gambarotta G, 1996, ONCOGENE, V13, P1911; Ghosh A, 1998, CELL, V95, P303, DOI 10.1016/S0092-8674(00)81762-6; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GHYSDAEL J, 1997, PROG GENE EXPRESS, P29; GOLTZENE F, 2000, IN PRESS EXP CELL RE; GORGONI B, 1995, BIOCHEM BIOPH RES CO, V215, P1088, DOI 10.1006/bbrc.1995.2575; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Habelhah H, 1999, ONCOGENE, V18, P1771, DOI 10.1038/sj.onc.1202465; Hagedorn L, 2000, DEV BIOL, V219, P44, DOI 10.1006/dbio.1999.9595; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Hay ED, 1995, ACTA ANAT, V154, P8; Hendricks T, 1999, J NEUROSCI, V19, P10348; HENRY JJ, 1990, DEV BIOL, V141, P149, DOI 10.1016/0012-1606(90)90110-5; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HROMAS R, 1994, INT J HEMATOL, V59, P257; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JORCYK CL, 1991, ONCOGENE, V6, P523; Kamura T, 1997, J BIOL CHEM, V272, P11361; Kao HY, 2000, GENE DEV, V14, P55; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kherrouche Z, 1998, ONCOGENE, V16, P1357, DOI 10.1038/sj.onc.1201650; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitange G, 1999, LAB INVEST, V79, P407; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Luton D, 1997, EARLY HUM DEV, V47, P147, DOI 10.1016/S0378-3782(96)01775-6; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Mager AM, 1998, INT J DEV BIOL, V42, P561; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; Majka SM, 1997, MECH DEVELOP, V68, P127, DOI 10.1016/S0925-4773(97)00138-X; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; McDonough J, 1997, J NEUROSCI, V17, P2273; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; MEDONOUGH J, 2000, IN PRESS J BIOL CHEM; Meyer D, 1997, INT J DEV BIOL, V41, P607; Meyer D, 1995, INT J DEV BIOL, V39, P909; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Munchberg SR, 1999, MECH DEVELOP, V80, P53, DOI 10.1016/S0925-4773(98)00193-2; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Pardanaud L, 1996, DEVELOPMENT, V122, P1363; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; QUEVA C, 1993, ONCOGENE, V8, P2511; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Remy P, 1996, INT J DEV BIOL, V40, P577; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; SADAGHIANI B, 1987, DEV BIOL, V124, P91, DOI 10.1016/0012-1606(87)90463-5; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Starck J, 1999, EXP HEMATOL, V27, P630, DOI 10.1016/S0301-472X(99)00006-5; Stehelin Dominique, 1998, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V192, P217; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; STIEGLER P, 1993, MECH DEVELOP, V41, P163, DOI 10.1016/0925-4773(93)90046-Z; STOCKER M, 1987, NATURE, V327, P239; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; Tamir A, 1999, MOL CELL BIOL, V19, P4452; THIBAUDEAU G, 1993, DEV BIOL, V159, P657, DOI 10.1006/dbio.1993.1272; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Turque N, 1997, INT J DEV BIOL, V41, P103; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WATSON DK, 1988, VIROLOGY, V167, P1, DOI 10.1016/0042-6822(88)90047-5; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Wheat W, 1999, MOL CELL BIOL, V19, P2231; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; WOLFF CM, 1990, NUCLEIC ACIDS RES, V18, P4603, DOI 10.1093/nar/18.15.4603; Yagi T, 2000, GENE DEV, V14, P1169; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZACKSON SL, 1986, DEV BIOL, V117, P342, DOI 10.1016/0012-1606(86)90304-0; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	206	33	35	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6417	6431		10.1038/sj.onc.1204044	http://dx.doi.org/10.1038/sj.onc.1204044			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175358				2022-12-28	WOS:000166595000004
J	Germani, A; Bruzzoni-Giovanelli, H; Fellous, A; Gisselbrecht, S; Varin-Blank, N; Calvo, F				Germani, A; Bruzzoni-Giovanelli, H; Fellous, A; Gisselbrecht, S; Varin-Blank, N; Calvo, F			SIAH-1 interacts with alpha-tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis	ONCOGENE			English	Article						SIAH-1; kid; mitosis; ubiquitin degradation; kinesin	ELONGATION-FACTOR 1-ALPHA; TUMOR SUPPRESSION; MURINE HOMOLOGS; BINDING-PROTEIN; SINA GENE; DROSOPHILA; APOPTOSIS; ABSENTIA; CHROMOSOMES; ACTIVATION	SIAH-1, a human homologue of the Drosophila seven in absentia (Sina), has been implicated in ubiquitin-mediated proteolysis of different target proteins through its N-terminal RING finger domain, SIAH-1 is also induced during p53-mediated apoptosis, Furthermore, SIAH-1-transfected breast cancer cell line MCF-7 exhibits an altered mitotic process resulting in multi-nucleated giant cells, Now, using the two-hybrid system, we identified two new SIAH interacting proteins: Kid (kinesin like DNA binding protein) and a-tubulin. We demonstrate that SIAH is involved in the degradation of Kid via the ubiquitin-proteasome pathway. Our results suggest that SIAH-1 but not its N-terminal deletion mutant, affects the mitosis by an enhanced reduction of kinesin levels, Our results imply, for the first time, SIAH-1 in regulating the degradation of proteins directly implicated in the mitotic process.	Hop Cochin, Unite 363 INSERM, Inst Cochin Genet Mol, F-75014 Paris, France; Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt & Clin, INSERM EP9932, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Germani, A (corresponding author), Hop Cochin, Unite 363 INSERM, Inst Cochin Genet Mol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Varin-Blank, Nadine/G-4396-2013	VARIN-BLANK, Nadine/0000-0003-2769-018X; calvo, fabien/0000-0002-0298-7633				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Germani A, 1999, MOL CELL BIOL, V19, P3798; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Holloway AJ, 1997, GENOMICS, V41, P160, DOI 10.1006/geno.1997.4642; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pfleger CM, 2000, GENE DEV, V14, P655; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	32	73	78	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5997	6006		10.1038/sj.onc.1204002	http://dx.doi.org/10.1038/sj.onc.1204002			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146551				2022-12-28	WOS:000165827900006
J	Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Perez-Mancera, PA; Pintado, B; Flores, T; Battaner, E; Sanchez-Garcia, I				Perez-Losada, J; Sanchez-Martin, M; Rodriguez-Garcia, MA; Perez-Mancera, PA; Pintado, B; Flores, T; Battaner, E; Sanchez-Garcia, I			Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical Pole in the pathogenesis of liposarcoma	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	HUMAN MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; CHROMOSOMAL TRANSLOCATION; MYXOID LIPOSARCOMA; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; CHIMERIC PROTEIN; TLS-CHOP; GENE; FUSION	The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS/TLS-CHOP fusion gene. We previously developed a mouse model of liposarcoma by expressing PUS-CHOP in murine mesenchymal stem cells. In order to understand how PUS-CHOP can initiate liposarcoma, we have now generated transgenic mice expressing altered forms of the PUS-CHOP protein. Transgenic mice expressing high levels of CHOP, which lacks the FUS domain, do not develop any tumor despite its tumorigenicity in vitro and widespread activity of the EF1 alpha promoter, These animals consistently show the accumulation of a glycoprotein material within the terminally differentiated adipocytes, a characteristic figure of liposarcomas associated with PUS-CHOP. On the contrary, transgenic mice expressing the altered form of PUS-CHOP created by the in frame fusion of the PUS domain to the carboxy end of CHOP (CHOP-FUS) developed liposarcomas. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1 alpha promoter. The characteristics of the liposarcomas arising in the CHOP-PUS mice were very similar to those previously observed in our PUS-CHOP transgenic mice indicating that the FUS domain is required not only for transformation but also influences the phenotype of the tumor cells. These results provide evidence that the FUS domain of PUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Bilogia Mol & Celular Canc, E-37008 Salamanca, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Serv Anat Patol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Bilogia Mol & Celular Canc, E-37008 Salamanca, Spain.		Sanchez-Martin, Manuel/N-5327-2016; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pérez-Losada, Jesús/A-5883-2019; Pintado, Belen/N-3233-2014	Sanchez-Martin, Manuel/0000-0001-8370-1336; Pérez-Losada, Jesús/0000-0003-2400-624X; Pintado, Belen/0000-0002-8485-2520; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	28	55	59	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6015	6022		10.1038/sj.onc.1204018	http://dx.doi.org/10.1038/sj.onc.1204018			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146553				2022-12-28	WOS:000165827900008
J	Kannan, K; Kaminski, N; Rechavi, G; Jakob-Hirsch, J; Amariglio, N; Givol, D				Kannan, K; Kaminski, N; Rechavi, G; Jakob-Hirsch, J; Amariglio, N; Givol, D			DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1	ONCOGENE			English	Article						apoptosis; ts-p53; DNA microarray; clustering; Apaf-1	TEMPERATURE-SENSITIVE MUTANT; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; EXPRESSION PATTERNS; SUMO-1 MODIFICATION; CELL-DEATH; C-JUN; INTERLEUKIN-6; INHIBITION; GELSOLIN	The transcription regulation activity of p53 controls cellular response to a variety of stress conditions, leading to growth arrest and apoptosis. Despite major progress in the understanding of the global effects of p53 on cellular function the pathways by which p53 activates apoptosis are not well defined. To study genes activated in the p53 induced apoptotic process, we used a mouse myeloid leukemic cell line (LTR6) expressing the temperature-sensitive p53 (val135) that undergoes apoptosis upon shifting the temperature to 32 degreesC. We analysed the gene expression profile at different time points after p53 activation using oligonucleotide microarray capable of detecting similar to 11 000 mRNA species. Cluster analysis of the p53-regulated genes indicate a pattern of early and late induced sets of genes. We show that 91 and 44 genes were substantially up and down regulated, respectively, by p53. Functional classification of these genes reveals that they are involved in many aspects of cell function, in addition to growth arrest and apoptosis, Comparison of p53 regulated gene expression profile in LTR6 cells to that of a human lung cancer cell line (H1299) that undergoes growth arrest but not apoptosis demonstrates that only 15% of the genes are common to both systems. This observation supports the presence of two distinct transcriptional programs in response to p53 signaling, one leading to growth arrest and the other to apoptosis. The proapoptotic genes induced only in LTR6 cells like Apaf-1, Sumo-1 and gelsolin among others may suggest a possible explanation for apoptosis in LTR6 cells.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Funct Genom Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Kaminski, Naftali/0000-0001-5917-4601				Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kaminski N, 2000, Ann N Y Acad Sci, V919, P1; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	30	126	132	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3449	3455		10.1038/sj.onc.1204446	http://dx.doi.org/10.1038/sj.onc.1204446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423996				2022-12-28	WOS:000169248800016
J	Tsukasaki, K; Miller, CW; Greenspun, E; Eshaghian, S; Kawabata, H; Fujimoto, T; Tomonaga, M; Sawyers, C; Said, JW; Koeffler, HP				Tsukasaki, K; Miller, CW; Greenspun, E; Eshaghian, S; Kawabata, H; Fujimoto, T; Tomonaga, M; Sawyers, C; Said, JW; Koeffler, HP			Mutations in the mitotic check point gene, MAD1L1, in human cancers	ONCOGENE			English	Article						MAD1L1; mitotic checkpoint; chromosomal instability; prostate cancer; breast cancer; adult T-cell leukemia/lymphoma	HUMAN LUNG CANCERS; VIRUS TYPE-I; SPINDLE CHECKPOINT; INSTABILITY; LYMPHOMA; CELLS; FRESH	Aneuploidy is a characteristic of the majority of human cancers, and recent studies suggest that defects of mitotic checkpoints play a role in carcinogenesis. MAD1L1 is a checkpoint gene, and its dysfunction is associated with chromosomal instability. Rare mutations of this gene have been reported in colon and lung cancers. We examined a total of 44 cell lines (hematopoietic, prostate, osteosarcoma, breast, glioblastoma and lung) and 133 fresh cancer cells (hematopoietic, prostate, breast and glioblastoma) for alterations of MAD1L1 by RT-PCR-SSCP and nucleotide sequencing. Eight mutations consisting of missense, nonsense and frameshift mutations were found, together with a number of nucleotide polymorphisms. All the alterations in cell lines were heterozygous, Frequency of mutations was relatively high in prostate cancer (2/7 cell lines and 2/33 tumor specimens). We placed a mutant truncated MAD1L1, found in a lymphoma sample, into HOS, Ht161 and SJSA cell lines and found that it was less inhibitory than wild type MAD1L1 at decreasing cell proliferation. Go-expression experiments showed that the mutant form had a dominant-negative effect. Furthermore, this mutant impaired the mitotic checkpoint as shown by decreased mitotic indices in HOS cells expressing mutant MAD1L1 after culture with the microtubule-disrupting agent, nocodazole, Our results suggest a pathogenic role of MAD1L1 mutations in various types of human cancer.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA; Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Hematol, Nagasaki 852, Japan; Univ Calif Los Angeles, Sch Med, Hlth Sci Ctr, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Hlth Sci Ctr, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Nagasaki University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tsukasaki, K (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Sawyers, Charles/G-5327-2016					Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Cunningham JM, 1996, CANCER RES, V56, P4475; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GOMBART AF, 1995, BLOOD, V86, P1534, DOI 10.1182/blood.V86.4.1534.bloodjournal8641534; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMIHIRA S, 1994, LEUKEMIA RES, V18, P79, DOI 10.1016/0145-2126(94)90122-8; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Said JW, 1996, BLOOD, V87, P4937, DOI 10.1182/blood.V87.12.4937.bloodjournal87124937; Sciavolino PJ, 1998, ANN MED, V30, P357, DOI 10.3109/07853899809029935; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tsukasaki K, 1999, BRIT J HAEMATOL, V105, P369, DOI 10.1111/j.1365-2141.1999.01323.x; Tsukasaki K, 2000, BEST PRACT RES CL HA, V13, P231, DOI 10.1053/beha.1999.0070	22	76	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3301	3305		10.1038/sj.onc.1204421	http://dx.doi.org/10.1038/sj.onc.1204421			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423979				2022-12-28	WOS:000169163500013
J	Rountree, MR; Bachman, KE; Herman, JG; Baylin, SB				Rountree, MR; Bachman, KE; Herman, JG; Baylin, SB			DNA methylation, chromatin inheritance, and cancer	ONCOGENE			English	Review						DNA methylation; histone acetylation; chromatin inheritance; cancer	MESSENGER-RNA EXPRESSION; DE-NOVO METHYLATION; APRT GENE PROMOTER; HISTONE DEACETYLASE; METHYLTRANSFERASE GENE; HUMAN BREAST; CPG ISLAND; TRANSCRIPTIONAL REPRESSION; EPIGENETIC INACTIVATION; CHROMOSOME INSTABILITY	Cancer is a process driven by the accumulation of abnormalities in gene function. While many of these changes are genetic, epigenetically mediated changes in gene expression are being increasingly appreciated. This latter process emphasizes the need to understand two key components of heritable, but reversible, modulation of gene promoter function that are closely tied to one another - formation of chromatin which modulates transcription and establishing patterns of DNA methylation, The link lies first in the recruitment to methylated cytosines of a family of methyl-CpG binding domain proteins (MBDs), which are direct transcriptional repressors and can complex with transcriptional core-pressors including histone deacetylases (HDACs), Additionally, the proteins that catalyze DNA methylation, DNA methyltransferases (DNMTs), also directly repress transcription and associate with HDACs. Regulation of these above chromatin-DNA methylation interactions as a function of DNA replication timing is emerging as a key event in the inheritance of transcriptionally repressed domains of the genome. Importantly, synergy between HDAC activity and DNA methylation is operative for a key epigenetic abnormality in cancer cells, transcriptional silencing of tumor suppressor genes. This change has now been recognized for genes that are essential for normal regulation of virtually every major cell function including cell growth, differentiation, apoptosis, DNA repair, and cell-cell, cell-substratum interaction. Understanding the molecular determinants of both normal and abnormal patterns of chromatin formation and DNA methylation thus holds great promise for our understanding of cancer and for means to better diagnose, prevent, and treat this means to better disease.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Tumor Biol Lab, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Rountree, MR (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Tumor Biol Lab, Baltimore, MD 21231 USA.		Rountree, Michael R/C-6332-2018	Rountree, Michael R/0000-0003-2371-6389				Aguirre-Arteta AM, 2000, CELL GROWTH DIFFER, V11, P551; Amiel A, 1998, CANCER, V83, P1966, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1966::AID-CNCR12>3.0.CO;2-E; Amiel A, 1998, GENE CHROMOSOME CANC, V22, P225, DOI 10.1002/(SICI)1098-2264(199807)22:3<225::AID-GCC8>3.0.CO;2-Y; Amiel A, 1999, CANCER GENET CYTOGEN, V108, P32, DOI 10.1016/S0165-4608(98)00107-1; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 1998, ADV CANCER RES, V72, P141; Baylin Stephen B., 2000, P293; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cheng NC, 1996, ONCOGENE, V13, P1737; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Conway KE, 2000, CANCER RES, V60, P6236; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eads CA, 1999, CANCER RES, V59, P2302; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ENVER T, 1988, GENE DEV, V2, P698, DOI 10.1101/gad.2.6.698; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2000, CANCER RES, V60, P129; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; GRAFF JR, 1995, CANCER RES, V55, P5195; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KASS SU, 1996, EPIGENETIC MECH GENE, P529; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; Krude T, 1999, CURR BIOL, V9, pR394, DOI 10.1016/S0960-9822(99)80251-6; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Lyko F, 2000, MECH DEVELOP, V95, P215, DOI 10.1016/S0925-4773(00)00325-7; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Mertineit C, 1998, DEVELOPMENT, V125, P889; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Nass SJ, 1999, ONCOGENE, V18, P7453, DOI 10.1038/sj.onc.1203138; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Roder K, 2000, MOL CELL BIOL, V20, P7401, DOI 10.1128/MCB.20.19.7401-7409.2000; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sado T, 2000, DEV BIOL, V225, P294, DOI 10.1006/dbio.2000.9823; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057	107	320	335	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3156	3165		10.1038/sj.onc.1204339	http://dx.doi.org/10.1038/sj.onc.1204339			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420732				2022-12-28	WOS:000169308500020
J	Joseph, B; Ekedahl, J; Lewensohn, R; Marchetti, P; Formstecher, P; Zhivotovsky, B				Joseph, B; Ekedahl, J; Lewensohn, R; Marchetti, P; Formstecher, P; Zhivotovsky, B			Defective caspase-3 relocalization in non-small cell lung carcinoma	ONCOGENE			English	Article						lung cancer; sensitivity; caspase; apoptosis	T-LYMPHOCYTE STIMULATION; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; IONIZING-RADIATION; DNA FRAGMENTATION; INDUCED APOPTOSIS; ANTICANCER DRUGS; FAMILY MEMBERS; DEATH; ACTIVATION	Many anticancer drugs exert their cytotoxicity through DNA damage and induction of apoptosis, Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) have different sensitivity to treatment,vith radiation and chemotherapeutic agents with SCLC being more sensitive than NSCLC both in vitro and in vivo, This difference might be related to the different susceptibility of small and non-small cell lung carcinoma to undergo apoptosis, The aim of this study was to investigate if deficiencies in the apoptotic pathways can explain the intrinsic resistance of NSCLC to anti-cancer treatment, Three different triggers were used to induce apoptosis, Etoposide and gamma -radiation, which are important parts of clinical lung cancer treatment, induce DNA-damage, whereas Fas ligation induces receptor-mediated apoptotic pathways. NSCLC cells were cross-resistant to all treatments, whereas SCLC cells, which do not express pro-caspase-8, were resistant to alpha Fas-, but not to DNA-damage-induced apoptosis. Cytochrome c release, activation of caspase-9 and the executioner caspase-3 were observed in both types of lung cancer cells, However, cleavage of known nuclear substrates for caspase-3, such as PARP and DFF45/ICAD, was documented only in the sensitive SCLC cells but not in the resistant NSCLC cells. Moreover, relocalization of active caspase-3 from the cytosol into the nucleus upon treatment was observed only in the SCLC cell line. These results indicate that the inhibition of apoptosis in NSCLC occurs downstream of mitochondrial changes and caspase activation, and upstream of nuclear events. Oncogene (2001) 20, 2877-2888.	Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Canc Ctr Karolinska R800, Unit Med Radiobiol, S-17176 Stockholm, Sweden; Fac Med Lille, Biol Cellulaire Lab, INSERM, U459, F-59045 Lille, France	Karolinska Institutet; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Dept Toxicol, Box 210, S-17177 Stockholm, Sweden.		Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; MARCHETTI, Philippe/0000-0002-4663-6800; Joseph, Bertrand/0000-0001-5655-9979				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; BERGH J, 1982, ACTA PATH MICRO IM A, V90, P149; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawara A, 1997, CANCER RES, V57, P4578; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; OWENS AH, 1985, MED ONCOL, P715; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Sirzen F, 1998, LUNG CANCER-J IASLC, V22, P1, DOI 10.1016/S0169-5002(98)00066-X; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1999, CELL DEATH DIFFER, V6, P493, DOI 10.1038/sj.cdd.4400523; Watanabe Y, 1999, J CELL PHYSIOL, V179, P45, DOI 10.1002/(SICI)1097-4652(199904)179:1<45::AID-JCP6>3.0.CO;2-H; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	47	60	63	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2877	2888		10.1038/sj.onc.1204402	http://dx.doi.org/10.1038/sj.onc.1204402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420700				2022-12-28	WOS:000168901800003
J	Daniel, R; Chung, SW; Eisenstein, TK; Sultzer, BM; Wong, PMC				Daniel, R; Chung, SW; Eisenstein, TK; Sultzer, BM; Wong, PMC			Specific association of type I c-abl with ran GTPase in lipopolysaccharide-mediated differentiation	ONCOGENE			English	Article						Ran; LPS; endotoxin; sepsis; c-Abl isoform	TYROSINE KINASE INHIBITORS; TUMOR-NECROSIS-FACTOR; 3' UNTRANSLATED REGION; ALPHA MESSENGER-RNA; CELL-CYCLE; ANTISENSE SEQUENCES; RETROVIRAL TRANSFER; MURINE MACROPHAGES; PROTEIN; BINDING	Each of several isoforms of c-Abl may be involved in different biological functions. Type I c-Abl has been shown to be involved in LPS-induced differentiation and Type IV c-Abl, apoptosis, Ran has recently been shown to be involved in LPS endotoxin signal transduction, Here we show that Type I c-Abl associates with Ran. Formation of this complex is specific, as Ran did not associate with the highly homologous Type IV c-Abl isoform, In non-stimulated lymphoid B cells, Type I c-Abl tyrosine kinase is inactive, whereas Type IV kinase is active. Formation of Type I c-Abl/Ran complex and activation of Type I c-Abl kinase activity are LPS dose-dependent. This complex is detectable in B cells of endotoxin-sensitive inbred mice but absent in B cells of endotoxin-resistant mice. These findings therefore suggest that Type I c-Abl and Ran are important targets in lipopolysaccharide-induced biological responses of hematopoietic cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Stem Cell Therapeut, King Of Prussia, PA 19406 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Wong, PMC (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA.			Daniel, Rene/0000-0002-3876-6242	NCI NIH HHS [R01CA70854] Funding Source: Medline; NIAID NIH HHS [R01AI39159] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Belasco J.G., 2012, CONTROL MESSENGER RN; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; Daniel R, 1996, CELL GROWTH DIFFER, V7, P1141; Daniel R, 1998, J BIOMED SCI, V5, P383; DANIEL R, 1995, ONCOGENE, V10, P1607; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; DONG ZY, 1993, J IMMUNOL, V151, P2717; Dorsch M, 1996, P NATL ACAD SCI USA, V93, P13131, DOI 10.1073/pnas.93.23.13131; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Goldfield EM, 1997, CHEM PHYS LETT, V276, P1, DOI 10.1016/S0009-2614(97)00818-X; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Hel Z, 1998, NUCLEIC ACIDS RES, V26, P2803, DOI 10.1093/nar/26.11.2803; Kang AD, 1996, INFECT IMMUN, V64, P4612, DOI 10.1128/IAI.64.11.4612-4617.1996; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Le Q, 1998, J IMMUNOL, V160, P3330; Moore MS, 1996, SCIENCE, V272, P47, DOI 10.1126/science.272.5258.47; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Orlicek SL, 1996, J INFECT DIS, V174, P638, DOI 10.1093/infdis/174.3.638; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SULTZER BM, 1972, INFECT IMMUN, V5, P107, DOI 10.1128/IAI.5.1.107-113.1972; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wong HW, 1999, DUKE MATH J, V96, P1, DOI 10.1215/S0012-7094-99-09601-1; WONG KK, 1995, ONCOGENE, V10, P705; Wong PMC, 2000, SCAND J IMMUNOL, V51, P123; Wong PMC, 2000, J HEMATOTH STEM CELL, V9, P629, DOI 10.1089/15258160050196669; Yuan Q, 2000, P NATL ACAD SCI USA, V97, P2852, DOI 10.1073/pnas.040567797; ZHAO F, 2001, IN PRESS J ENDO RES	50	6	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2618	2625		10.1038/sj.onc.1204361	http://dx.doi.org/10.1038/sj.onc.1204361			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420673				2022-12-28	WOS:000168652600002
J	Garcia, R; Bowman, TL; Niu, GL; Yu, H; Minton, S; Muro-Cacho, CA; Cox, CE; Falcone, R; Fairclough, R; Parsons, S; Laudano, A; Gazit, A; Levitzki, A; Kraker, A; Jove, R				Garcia, R; Bowman, TL; Niu, GL; Yu, H; Minton, S; Muro-Cacho, CA; Cox, CE; Falcone, R; Fairclough, R; Parsons, S; Laudano, A; Gazit, A; Levitzki, A; Kraker, A; Jove, R			Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells	ONCOGENE			English	Article						STAT proteins; breast cancer; Src; JAK; EGF receptor; tyrosine kinase inhibitors	FACTOR RECEPTOR FAMILY; DNA-BINDING ACTIVITY; OVEREXPRESSING C-SRC; V-SRC; TRANSCRIPTION FACTORS; EPITHELIAL-CELLS; MITOGENIC RESPONSIVENESS; CELLULAR-TRANSFORMATION; MYELOID DIFFERENTIATION; MAMMARY TUMORIGENESIS	Constitutive activation of signal transducer and activator of transcription (STAT) proteins has been detected in a wide variety of human primary tumor specimens and tumor cell lines including blood malignancies, head and neck cancer, and breast cancer. We have previously demonstrated a high frequency of Stat3 DNA-binding activity that is constitutively-induced by an unknown mechanism in human breast cancer cell lines possessing elevated EGF receptor (EGF-R) and c-Src kinase activities. Using tyrosine kinase selective inhibitors, we show here that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines. Inhibition of Scr or JAKs results in dose-dependent suppression of Stat3 DNA-binding activity, which is accompanied by growth inhibition and induction of programmed cell death. In addition, transfection of a dominant-negative form Stat3 leads to growth inhibition involving apoptosis of breast cancer cells. These results indicate that the biological effects of the Src and JAK tyrosine kinase inhibitors are at least partially mediated by blocking Stat3 signaling. While EGF-R kinase activity is not required for constitutive Stat3 activation in breast cancer cells, EGF stimulation further increases STAT DNA-binding activity, consistent with an important role for EGF-R in STAT signaling and malignant progression. Analysis of primary breast tumor specimens from patients with advanced disease revealed that the majority exhibit elevated STAT DNA-binding activity compared to adjacent non-tumor tissues. Our findings, taken together, suggest that tyrosine kinases transduce signals through Stat3 protein that contribute to the growth and survival of human breast cancer cells in culture and potentially in vivo.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Clin Invest Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Pfizer Global Res & Dev, Ann Arbor, MI 48106 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Virginia; University System Of New Hampshire; University of New Hampshire; Hebrew University of Jerusalem; Pfizer	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.			YU, Hua/0000-0003-0931-1000	NATIONAL CANCER INSTITUTE [R01CA055652, P01CA082533] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Besser D, 1999, MOL CELL BIOL, V19, P1401; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Dearolf CR, 1999, CELL MOL LIFE SCI, V55, P1578, DOI 10.1007/s000180050397; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Demoulin JB, 2000, CANCER RES, V60, P3971; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Frank DA, 1996, LEUKEMIA, V10, P1724; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ihle JN, 1998, CANCER J SCI AM, V4, pS84; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KLOTH MT, 2001, UNPU; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Moasser MM, 1999, CANCER RES, V59, P6145; Morrissey JJ, 1998, CELL BIOL INT, V22, P413, DOI 10.1006/cbir.1998.0269; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Niu GL, 1999, CANCER RES, V59, P5059; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sartor CI, 1997, CANCER RES, V57, P978; Schindler C, 1999, CELL MOL LIFE SCI, V55, P1509, DOI 10.1007/s000180050391; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Shuai K, 1996, ONCOGENE, V13, P247; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; ZUYAO N, 2000, CANCER RES, V60, P1225	81	637	697	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2499	2513		10.1038/sj.onc.1204349	http://dx.doi.org/10.1038/sj.onc.1204349			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420660				2022-12-28	WOS:000168652500001
J	Mechta-Grigoriou, F; Gerald, D; Yaniv, M				Mechta-Grigoriou, F; Gerald, D; Yaniv, M			The mammalian Jun proteins: redundancy and specificity	ONCOGENE			English	Review						cell cycle; transcription; ras signaling; apoptosis	CELL-CYCLE PROGRESSION; SIGNAL-TRANSDUCTION PATHWAY; STRESS-INDUCED APOPTOSIS; RAT EMBRYO CELLS; C-JUN; TRANSCRIPTION FACTOR; DNA-BINDING; FOS-JUN; MOUSE FIBROBLASTS; PROTO-ONCOGENE	The AP-1 transcription factor is composed of a mixture of homo- and hetero-dimers formed between Jun and Fos proteins, The different Jun and Fos family members vary significantly in their relative abundance and their interactions with additional proteins generating a complex network of transcriptional regulators. Thus, the functional activity of AP-1 in any given cell depends on the relative amount of specific Jun/Fos proteins which are expressed, as well as other potential interacting proteins, This diversity of AP-1 components has complicated our understanding of AP-1 function and resulted in a paucity of information about the precise role of individual AP-1 members in distinct cellular processes. We shall discuss recent studies which suggest that different Jun and Fos family members may have both opposite and overlapping functions in cellular proliferation and cell fate.	Inst Pasteur, Unite Virus Oncogenes, CNRS, URA 1644, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Yaniv, M (corresponding author), Inst Pasteur, Unite Virus Oncogenes, CNRS, URA 1644, 25 Rue Dr Roux, F-75724 Paris 15, France.		MECHTA-GRIGORIOU, Fatima/C-5253-2017	MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; BRACH MA, 1992, EMBO J, V11, P1479, DOI 10.1002/j.1460-2075.1992.tb05192.x; BRENNER DA, 1989, DNA-J MOLEC CELL BIO, V8, P279, DOI 10.1089/dna.1.1989.8.279; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1995, ONCOGENE, V10, P985; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Herzog KH, 1999, J NEUROSCI, V19, P4349; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KAWAKAMI Z, 1992, NUCLEIC ACIDS RES, V20, P914, DOI 10.1093/nar/20.4.914; Kawasaki M, 1999, EMBO J, V18, P3604, DOI 10.1093/emboj/18.13.3604; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; Knochel S, 2000, MECH DEVELOP, V98, P29, DOI 10.1016/S0925-4773(00)00448-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MECHTA F, 1989, New Biologist, V1, P297; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MECHTA F, 1994, FOS JUN FAMILIES TRA, P115; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Neyns B, 1996, ONCOGENE, V12, P1247; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PHINNEY DG, 1994, ONCOGENE, V9, P2353; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PIETTE J, 1987, MOL ASPECTS PAPOVAVI, P87; Preston GA, 1996, MOL CELL BIOL, V16, P211; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYSECK RP, 1991, ONCOGENE, V6, P533; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MJ, 1992, BLOOD, V79, P2107; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Thepot D, 2000, DEVELOPMENT, V127, P143; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1989, INT S PRINCESS TAKAM, V20, P127; Wang HL, 2000, CARCINOGENESIS, V21, P1313, DOI 10.1093/carcin/21.7.1313; WANG ZQ, 1995, CANCER RES, V55, P6244; Watson A, 1998, J NEUROSCI, V18, P751; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	134	273	284	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2378	2389		10.1038/sj.onc.1204381	http://dx.doi.org/10.1038/sj.onc.1204381			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402334				2022-12-28	WOS:000168568700005
J	Shah, V; Bharadwaj, S; Kaibuchi, K; Prasad, GL				Shah, V; Bharadwaj, S; Kaibuchi, K; Prasad, GL			Cytoskeletal organization in tropomyosin-mediated reversion of ras-transformation: Evidence for Rho kinase pathway	ONCOGENE			English	Article						tropomyosin; cytoskeleton; Rho kinase	SERUM RESPONSE FACTOR; BINDING PROTEIN-RHO; ACTIN CYTOSKELETON; FOCAL ADHESIONS; GELSOLIN EXPRESSION; NONMUSCLE CALDESMON; STRESS FIBERS; ONCOGENIC RAS; CELLS; SUPPRESSION	Tropomyosin (TM) family of cytoskeletal proteins is implicated in stabilizing actin microfilaments. Many TM isoforms, including tropomyosin-1 (TM1), are downregulated in transformed cells. Previously we demonstrated that TM1 is a suppressor of the malignant transformation, and that TM1 reorganizes microfilaments in the transformed cells, To investigate how TM1 induces microfilament organization in transformed cells, we utilized uas-transformed NIH3T3 (DT) cells, and those transduced to express TM1, and/or TM2, Enhanced expression of TM1 alone, but not TM2, results in re-emergence of microfilaments; TM1, together with TM2 remarkably improves microfilament architecture. TM1 induced cytoskeletal reorganization involves an enhanced expression of caldesmon, but not vinculin, alpha -actinin, or gelsolin, In addition, TM1-induced cytoskeletal reorganization and the revertant phenotype appears to involve re-activation of RhoA controlled pathways in DT cells. RhoA expression, which is suppressed in DT cells, is significantly increased in TM1-expressing cells, without detectable changes in the expression of Pac or Cdc42, Furthermore, expression of a dominant negative Rho kinase, or treatment with Y-27632 disassembled microfilaments in normal NIH3T3 and in TM1 expressing cells. These data suggest that reactivation of Rho kinase directed pathways are critical for TM1-mediated microfilament assemblies.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wistar Inst Anat & Cell Biol, Philadelphia, PA USA; Nara Inst Sci & Technol, Ikoma, Japan	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; The Wistar Institute; Nara Institute of Science & Technology	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Asch HL, 1999, BREAST CANCER RES TR, V55, P179; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Braverman RH, 1996, ONCOGENE, V13, P537; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Huber PAJ, 1997, INT J BIOCHEM CELL B, V29, P1047, DOI 10.1016/S1357-2725(97)00004-6; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; JANCSO A, 1991, J BIOL CHEM, V266, P5891; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KUMAR A, 1993, INDIAN J HETEROCY CH, V3, P1; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; Lin SK, 1997, MOLECULES, V2, P1, DOI 10.3390/jan97p1; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; NOVY RE, 1991, J BIOL CHEM, V266, P16917; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Shah V, 1998, SOMAT CELL MOLEC GEN, V24, P273, DOI 10.1023/B:SCAM.0000007130.08611.fc; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	56	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2112	2121		10.1038/sj.onc.1204291	http://dx.doi.org/10.1038/sj.onc.1204291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360195				2022-12-28	WOS:000168116700006
J	Ishii, T; Kwon, H; Hiscott, J; Mosialos, G; Koromilas, AE				Ishii, T; Kwon, H; Hiscott, J; Mosialos, G; Koromilas, AE			Activation of the I kappa B alpha kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR	ONCOGENE			English	Article						cytokines; double-stranded RNA; protein phosphorylation; NF-kappa B; DNA-binding; transcription	EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; TUMOR-SUPPRESSOR P53; RIBOSOMAL S6 KINASE; MALIGNANT TRANSFORMATION; VIRAL-INFECTION; HA-RAS; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; APOPTOSIS	The interferon (IFN)-inducible double stranded (ds) RNA-activated protein kinase PKR plays an important role in protein synthesis by modulating the phosphorylation of the alpha -subunit of eukaryotic initiation fact 2 (eIF-2 alpha), In addition to translational control, PKR has been implicated in several signaling pathways leading to gene transcription. For example, PKR induces I kappaB alpha kinase (IKK) activity and I kappaB alpha phosphorylation leading to the induction of NF-kappaB-mediated gene transcription. Recent findings suggested that NF-kappaB activation by PKR does not require the catalytic activity of the kinase, Here, we provide novel evidence that induction of IKK and NF-kappaB activities proceeds independently of the dsRNA-binding properties of PKR and also verify the kinase-free role of PKR in this process. We also show that the effects of PKR mutants on IKK and NF-kappaB activation are independent of cell transformation but are dependent on the amount of the mutant PKR proteins expressed in cells. These data strongly support an indirect role of PKR in I kappaB alpha phosphorylation by modulating IKK activity through pathways that do not utilize the enzymatic and dsRNA-binding properties of PKR.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Cell Biol & Anat, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Fleming Biores Ctr, Athens, Greece	McGill University; McGill University; McGill University; McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.				NATIONAL CANCER INSTITUTE [R29CA071705] Funding Source: NIH RePORTER; NCI NIH HHS [CA71705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Campbell IK, 2000, J CLIN INVEST, V105, P1799, DOI 10.1172/JCI8298; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CLEMENS JM, 1977, J INTERFER CYTO RES, V17, P503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee R, 1997, VIROLOGY, V234, P277, DOI 10.1006/viro.1997.8642; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Nagai K, 1997, J VIROL, V71, P1718, DOI 10.1128/JVI.71.2.1718-1725.1997; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; WONG AHT, 2001, IN PRESS J BIOL CHEM; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	62	52	54	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1900	1912		10.1038/sj.onc.1204267	http://dx.doi.org/10.1038/sj.onc.1204267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313938				2022-12-28	WOS:000167908400011
J	Alberghina, L; Porro, D; Cazzador, L				Alberghina, L; Porro, D; Cazzador, L			Towards a blueprint of the cell cycle	ONCOGENE			English	Article						cell cycle; CDK; CKI; cyclin; budding yeast; cancer	YEAST SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; G1 CYCLINS; FLOW-CYTOMETRY; G2 CYCLINS; GROWTH; G(1); PROGRESSION; PATHWAY; PHASE	The understanding of the organisation of cell cycle events is of utmost importance. to devise effective therapeutic strategies for cancer, In this article we gather evidences from the literature in support of a system model of the cell cycle, in which a growth-sensitive threshold controls entry into S phase and the sequential activation of cyclin-dependent kinases, The cycle is terminated by an End function, that comprises events from the onset of mitosis to cell division and that may also be modulated by the increase of cell size, This blueprint allows quantitative predictions by computer simulations of steady and transitory states. In fact, we show that the proposed control system applies to budding yeast populations during nutritional shift-up and following hyperactivation of the cAMP signalling pathway, Besides the growth-sensitive control system it is shown to apply to mammalian cells both in the exit from quiescence and in active proliferation, The putative molecular determinants that set the threshold controlling S phase entry are consistently altered in cancer cells, Finally, we discuss an input/output analysis based on the simulated behaviour derived from the blueprint as a new tool to investigate the road to cancer.	Univ Milan, Biocca, Dept Biosci & Biotechnol, I-20126 Milan, Italy; Natl Res Council, Inst Syst Sci & Biomed Engn, I-35127 Padua, Italy	University of Milan	Alberghina, L (corresponding author), Univ Milan, Biocca, Dept Biosci & Biotechnol, Pzza Sci 2, I-20126 Milan, Italy.			Alberghina, Lilia/0000-0003-1694-931X; PORRO, DANILO/0000-0001-5723-3700				Alberghina L, 1998, J BACTERIOL, V180, P3864, DOI 10.1128/JB.180.15.3864-3872.1998; ALBERGHINA L, 1977, J THEOR BIOL, V69, P633, DOI 10.1016/0022-5193(77)90372-1; ALBERGHINA L, 1983, BIOSYSTEMS, V16, P297, DOI 10.1016/0303-2647(83)90012-6; ALBERGHINA L, 1993, YEAST, V9, P815, DOI 10.1002/yea.320090802; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Anghileri P, 1999, EXP CELL RES, V250, P510, DOI 10.1006/excr.1999.4531; BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; Baserga R., 1976, MULTIPLICATION DIVIS; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; COOPER S, 1979, NATURE, V280, P17, DOI 10.1038/280017a0; Futcher B, 1996, YEAST, V12, P1635; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUTCHISON C, 1995, CELL CYCLE CONTROL; Jeoung DI, 1998, MOL CELL BIOL, V18, P433, DOI 10.1128/MCB.18.1.433; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; MARIANI L, 1986, IEE PROC-D, V133, P210, DOI 10.1049/ip-d.1986.0035; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OConnor PM, 1997, CANCER SURV, V29, P151; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Palsson BO, 1997, NAT BIOTECHNOL, V15, P3, DOI 10.1038/nbt0197-3; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOMPAYRAC L, 1973, NATURE-NEW BIOL, V241, P133, DOI 10.1038/newbio241133a0; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; Tanaka S, 1996, GENES CELLS, V1, P905, DOI 10.1046/j.1365-2443.1996.d01-213.x; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYSON CB, 1979, J BACTERIOL, V138, P92, DOI 10.1128/JB.138.1.92-98.1979; VANONI M, 1983, J BACTERIOL, V156, P1282, DOI 10.1128/JB.156.3.1282-1291.1983; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZETTERBERG A, 1995, CELL CYCLE CONTROL	44	22	22	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1128	1134		10.1038/sj.onc.1204263	http://dx.doi.org/10.1038/sj.onc.1204263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314050				2022-12-28	WOS:000167232100013
J	Vivo, C; Levy, F; Pilatte, Y; Fleury-Feith, J; Chretien, P; Monnet, I; Kheuang, L; Jaurand, MC				Vivo, C; Levy, F; Pilatte, Y; Fleury-Feith, J; Chretien, P; Monnet, I; Kheuang, L; Jaurand, MC			Control of cell cycle progression in human mesothelioma cells treated with gamma interferon	ONCOGENE			English	Article						human mesothelioma cell lines; cell cycle control; cyclin dependent kinase inhibitors; cyclin; r-hu-IFN gamma	MAMMARY EPITHELIAL-CELLS; KINASE INHIBITOR P21; DEPENDENT KINASE; GROWTH ARREST; INDOLEAMINE 2,3-DIOXYGENASE; GENE-EXPRESSION; DNA-DAMAGE; ALPHA; INTERLEUKIN-6; TRANSCRIPTION	Recombinant human interferon gamma (r-hu-IFN gamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFN gamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFN gamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFN gamma. Except in the resistant cell line r-hu-IFN gamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a GZ-arrest in r-hu-IFN gamma -treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFN gamma seems to depend on cyclin regulation through p21(WAF1/C1P1)- and p27(KiP1)-independent mechanisms and is not directly related to the induced DNA damage.	Univ Paris 12, INSERM U99 09, EA 2345, F-94010 Creteil, France; Hop Tenon, Serv Histol & Biol Tumorale, F-75020 Paris, France; Ctr Hosp Intercommunal, Serv Immunohematol, F-94010 Creteil, France; Ctr Hosp Intercommunal, Serv Pneumol, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil	Jaurand, MC (corresponding author), Univ Paris 12, INSERM U99 09, EA 2345, 8 Rue Gen Sarrail, F-94010 Creteil, France.		JAURAND, MARIE-CLAUDE/S-3538-2017; Pilatte, Yannick/AAD-1943-2019; Pilatte, Yannick/N-4422-2018	JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; 				Astoul P, 1998, CANCER, V83, P2099, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; BIELEFELDTOHMANN H, 1995, CANCER IMMUNOL IMMUN, V40, P241, DOI 10.1007/s002620050169; BIELEFELDTOHMANN H, 1995, J INTERF CYTOK RES, V15, P213, DOI 10.1089/jir.1995.15.213; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOUTIN C, 1994, CANCER, V74, P2460, DOI 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N; BOWMAN RV, 1991, CANCER CHEMOTH PHARM, V28, P420, DOI 10.1007/BF00685817; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Buard A, 1998, CANCER RES, V58, P840; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHRISTMAS TI, 1993, J INTERFERON RES, V13, P9, DOI 10.1089/jir.1993.13.9; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FITZPATRICK DR, 1995, AM J RESP CELL MOL, V12, P455, DOI 10.1165/ajrcmb.12.5.7742009; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Grander D, 1997, EUR J HAEMATOL, V59, P129; Grousson J, 2000, J INVEST DERMATOL, V114, P581, DOI 10.1046/j.1523-1747.2000.00905.x; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; HERZINGER T, 1995, ONCOGENE, V11, P2151; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Jaiswal M, 2000, CANCER RES, V60, P184; JAURAND MC, 1986, MUTAT RES, V169, P141, DOI 10.1016/0165-1218(86)90093-5; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; KOSAKA C, 1992, ATHEROSCLEROSIS, V97, P75, DOI 10.1016/0021-9150(92)90053-J; Lazutka JR, 1996, MUTAT RES-ENVIR MUTA, V361, P95, DOI 10.1016/S0165-1161(96)00027-1; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MARTIN DM, 1993, J NEUROSCI RES, V34, P489, DOI 10.1002/jnr.490340502; MONTI G, 1994, CANCER RES, V54, P4419; Moro A, 1998, BIOCHEM BIOPH RES CO, V245, P752, DOI 10.1006/bbrc.1998.8512; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105; PhanBich L, 1997, AM J RESP CELL MOL, V16, P178, DOI 10.1165/ajrcmb.16.2.9032125; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; Ungar S, 1996, BRIT J CANCER, V74, P1534, DOI 10.1038/bjc.1996.585; Urashima M, 1997, BLOOD, V90, P279; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; XU JH, 1995, BLOOD, V86, P2774; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; ZENG L, 1993, INT J CANCER, V55, P515, DOI 10.1002/ijc.2910550331	52	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1085	1093		10.1038/sj.onc.1204199	http://dx.doi.org/10.1038/sj.onc.1204199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314045				2022-12-28	WOS:000167232100008
J	Kataoka, H; Miura, Y; Joh, T; Seno, K; Tada, T; Tamaoki, T; Nakabayashi, H; Kawaguchi, M; Asai, K; Kato, T; Itoh, M				Kataoka, H; Miura, Y; Joh, T; Seno, K; Tada, T; Tamaoki, T; Nakabayashi, H; Kawaguchi, M; Asai, K; Kato, T; Itoh, M			Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1	ONCOGENE			English	Article						AFP (Alpha-fetoprotein); AFP-GC (AFP producing gastric cancer); ATBF1 (AT motif binding factor 1); HNF1 (hepatocyte nuclear factor 1)	CELL-LINES; GASTROINTESTINAL-TRACT; CLINICOPATHOLOGICAL FEATURES; CARCINOMA; EXPRESSION; ESTABLISHMENT; PROTEIN; LIVER; GENE; DIFFERENTIATION	Alpha-fetoprotein (AFP) producing gastric cancer (AFP-GC) is very malignant and highly metastatic compared with common gastric cancer. However, the causal relationship between AFP production and the high malignancy of AFP-GC is unclear. We investigated AFP gene regulation in AFP-GC by an active transcription factor, HNF1 (hapatocyte nuclear factor 1) and a repressive transcription factor, ATBF1 (AT motif binding factor 1), RNase protection assays revealed that the production of AFP in gastric cancer cells did not directly associate with HNF1 expression. An inverse relation between the expressions of ATBF1 and AFP was clearly observed in gastric cancer cells. CAT assays showed the direct inhibition of AFP gene expression by ATBF1, Methylation analysis of the AFP promoter region in gastric cancer cells suggested that methylation itself could not explain the silencing of the AFP gene. Immunohistochemistry of resected clinical samples revealed that AFP producing cells lacked ATBF1 immunoreactivity, Our data suggests that the absence of ATBF1 is responsible for AFP gene expression in gastric cancer, and the absence of ATBF1 is a distinct characteristic of AFP-GC and might be important for its highly malignant nature.	Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuhi Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Nursing, Dept Pathol, Mizuhi Ku, Nagoya, Aichi 4678601, Japan; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Hokkaido Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 060, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Pathol, Toyama 9300194, Japan	Nagoya City University; Nagoya City University; Nagoya City University; University of Calgary; Hokkaido University; University of Toyama	Miura, Y (corresponding author), Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuhi Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.		Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251				BOURREILLE J, 1970, PRESSE MED, V78, P1277; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHANG YC, 1992, AM J GASTROENTEROL, V87, P321; CHANG YC, 1990, AM J GASTROENTEROL, V85, P1480; Chen HM, 1997, CRIT REV EUKAR GENE, V7, P11, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.20; DIGIOVANNI J, 1984, CANCER RES, V44, P2878; FUJIWARA T, 1993, INT J CANCER, V54, P965, DOI 10.1002/ijc.2910540617; GITLIN D, 1972, CANCER RES, V32, P979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; Ido A, 1996, GENE, V168, P227, DOI 10.1016/0378-1119(95)00740-7; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; KOYAMA K, 1990, JPN J CANCER RES, V81, P967, DOI 10.1111/j.1349-7006.1990.tb03332.x; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MCINTIRE KR, 1975, CANCER RES, V35, P991; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NAKATA K, 1992, J BIOL CHEM, V267, P1331; PENG SY, 1993, HEPATOLOGY, V17, P35, DOI 10.1016/0270-9139(93)90188-S; Ramsay RG, 2000, CANCER RES, V60, P1805; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; TAKETA K, 1990, GASTROENTEROLOGY, V99, P508, DOI 10.1016/0016-5085(90)91034-4; TERASHIMA M, 1991, JPN J CANCER RES, V82, P883, DOI 10.1111/j.1349-7006.1991.tb01915.x; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395	26	54	59	1	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					869	873		10.1038/sj.onc.1204160	http://dx.doi.org/10.1038/sj.onc.1204160			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314020				2022-12-28	WOS:000166924400010
J	Adamsky, K; Schilling, J; Garwood, J; Faissner, A; Peles, E				Adamsky, K; Schilling, J; Garwood, J; Faissner, A; Peles, E			Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTP beta) to tenascin C	ONCOGENE			English	Article						tyrosine phosphatase; extracellular matrix; cell adhesion molecule	CHONDROITIN SULFATE PROTEOGLYCAN; GROWTH-ASSOCIATED MOLECULE; HIGH-AFFINITY LIGAND; NERVOUS-SYSTEM; HOMOPHILIC BINDING; NEURITE OUTGROWTH; FOCAL ADHESIONS; PTP-MU; ZETA/BETA; EXPRESSION	The extracellular domain of receptor protein tyrosine phosphatase beta (RPTP beta) is composed of several domains which mediate its interactions with distinct ligands present on the surface of either neurons or glial cells. Here, we demonstrate that the fibronectin type III domain (FNIII) of RPTP beta binds to glial tumor-derived cell lines and primary astrocytes, We used affinity purification to isolate several proteins that specifically bind to the FNIII domain of RPTP beta. One of these, a 240 kDa protein that was purified from U118MG glioblastoma cell, was identified as tenascin C based on the amino acid sequence of several tryptic peptides. The interaction of RPTP beta with tenascin C was found to mediate cell adhesion. Adhesion and spreading of SF763T astrocytoma cells expressing RPTP beta on tenascin C,was specifically abolished by the addition of a soluble fragment containing the FNIII domain of the receptor, RPTP beta -dependent cell adhesion was mediated by binding to the alternatively spliced FNIII repeats A1,2,4 (TnfnA1,2,4) of tenascin C, Furthermore, COS cells expressing RPTP beta adhere to TnfnA1,2,4, while the parental cells did not. These results demonstrate that the FNIII domain of RPTP beta binds to tenascin C and suggest that RPTP beta present on glial tumor cells is a primary adhesion receptor system to the extracellular matrix.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ctr Neurochim, Unite CNRS UPR 1352, F-67084 Strasbourg, France; Sugen Inc, S San Francisco, CA 94080 USA	Weizmann Institute of Science; Pfizer	Peles, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259; Peles, Elior/0000-0002-3325-0597				Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Canoll PD, 1996, J NEUROSCI RES, V44, P199, DOI 10.1002/(SICI)1097-4547(19960501)44:3<199::AID-JNR1>3.0.CO;2-B; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; FAISSNER A, 1997, CELL TISSUE RES, V290, P385; Fashena SJ, 1997, MOL CELL BIOL, V17, P6859, DOI 10.1128/MCB.17.12.6859; Garwood J, 1999, J NEUROSCI, V19, P3888; Giese A, 1996, J CELL SCI, V109, P2161; Goldmann T, 2000, FOLIA HISTOCHEM CYTO, V38, P19; GRUMET M, 1994, J BIOL CHEM, V269, P12142; JONES FS, 2000, AM J RESP CRIT CARE, V161, P2086; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PHILLIPS GR, 1998, MOL BIOL CELL, V9, P1425; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; SAP J, 1994, MOL CELL BIOL, V14, P1; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Scholze A, 1996, INT J DEV NEUROSCI, V14, P315, DOI 10.1016/0736-5748(96)00016-0; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shenoi H, 1999, J IMMUNOL, V162, P7120; Snyder SE, 1996, MOL BRAIN RES, V40, P79; Stoker A, 1998, BIOESSAYS, V20, P463, DOI 10.1002/(SICI)1521-1878(199806)20:6<463::AID-BIES4>3.0.CO;2-N; Walzel H, 1999, IMMUNOL LETT, V67, P193, DOI 10.1016/S0165-2478(99)00012-7; Wang J, 1999, MOL CELL NEUROSCI, V14, P370, DOI 10.1006/mcne.1999.0789; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092; YOKOSAKI Y, 1998, J CELL SCI, V111, P1095; ZAGZAG D, 1995, CANCER RES, V55, P907; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203; Zondag GCM, 1997, BIOCHIMIE, V79, P477, DOI 10.1016/S0300-9084(97)82739-3	57	40	44	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					609	618		10.1038/sj.onc.1204119	http://dx.doi.org/10.1038/sj.onc.1204119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313993				2022-12-28	WOS:000166755000008
J	Poon, R; Smits, R; Li, C; Jagmohan-Changur, S; Kong, M; Cheon, S; Yu, CY; Fodde, R; Alman, BA				Poon, R; Smits, R; Li, C; Jagmohan-Changur, S; Kong, M; Cheon, S; Yu, CY; Fodde, R; Alman, BA			Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)	ONCOGENE			English	Article						aggressive fibromatosis; adenomatous polyposis coli; cyclooxygenase; beta-catenin; non-steroidal anti-inflammatory drugs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; ANTI-INFLAMMATORY DRUGS; COLON-CANCER CELLS; BETA-CATENIN; COLORECTAL-CANCER; CARCINOMA CELLS; GENE MUTATION; GROWTH-FACTOR; MOUSE MODEL	Aggressive fibromatosis is a locally invasive soft tissue lesion. Seventy-five per cent of cases harbor a somatic mutation in either the APC or beta -catenin genes, resulting in beta -catenin protein stabilization, Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin synthesis that modulates the formation of colonic neoplasia, especially in cases due to mutations resulting in beta -catenin stabilization, Human aggressive fibromatoses and lesions from the Apc+/Apc1638N mouse (a murine model for Ape-driven fibromatosis) demonstrated elevated COX-2 levels. COX-2 blockade either by the selective agent DFU or by non-selective COX blocking agents results in reduced proliferation in human tumor cell cultures. Breeding mice with Cox-2-/- mice resulted in no difference in number of aggressive fibromatoses formed, but in a smaller tumor size, while there was a decrease in number of GI lesions by 50%. Mice fed various COX blocking agents also showed a decline in tumor size. COX-2 expression was regulated by tcf-dependent transcription in this lesion, COX-2 partially regulates proliferation due to beta -catenin stabilization in aggressive fibromatosis, Although COX blockade alone does not cause tumor regression, this data suggests that it may have a role as an adjuvant therapy to slow tumor growth in this lesion.	Hosp Sick Children, Program Dev Biol, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Alman, BA (corresponding author), Hosp Sick Children, Program Dev Biol, Div Orthopaed Surg, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324				ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Alman BA, 1996, J ORTHOP RES, V14, P722, DOI 10.1002/jor.1100140507; ALMAN BA, 1992, J PEDIATR ORTHOPED, V12, P1; ALMAN BA, 1995, J ORTHOP RES, V13, P67, DOI 10.1002/jor.1100130111; BELIVEAU P, 1984, COLON RECTUM, V27, P53; Black SC, 1998, J CARDIOVASC PHARM, V32, P686, DOI 10.1097/00005344-199811000-00002; Castano E, 2000, J PHARMACOL EXP THER, V293, P509; Chan CC, 1997, EUR J PHARMACOL, V327, P221, DOI 10.1016/S0014-2999(97)89664-1; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, CANCER RES, V56, P733; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Giardiello FM, 1997, GUT, V40, P521, DOI 10.1136/gut.40.4.521; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HIAL V, 1977, J PHARMACOL EXP THER, V202, P446; Hsi LC, 1999, CARCINOGENESIS, V20, P2045, DOI 10.1093/carcin/20.11.2045; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KIRSCH WM, 1991, AM J SURG, V161, P416; Lackner H, 1997, CANCER, V80, P334, DOI 10.1002/(SICI)1097-0142(19970715)80:2<334::AID-CNCR22>3.0.CO;2-U; LATTES R, 1980, TUMORS SOFT TISSUES, P1; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Mei JM, 1999, CARCINOGENESIS, V20, P737, DOI 10.1093/carcin/20.4.737; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NGUYEN KD, 1993, EXP EYE RES, V57, P97, DOI 10.1006/exer.1993.1103; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; POSNER MC, 1989, ARCH SURG-CHICAGO, V124, P191; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Sparks AB, 1998, CANCER RES, V58, P1130; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; WADDELL WR, 1983, J SURG ONCOL, V22, P197, DOI 10.1002/jso.2930220314; Watson AJM, 1998, HISTOL HISTOPATHOL, V13, P591, DOI 10.14670/HH-13.591; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wolf Leslie A., 1999, Cell Biochemistry and Biophysics, V30, P353, DOI 10.1007/BF02738119; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	51	74	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					451	460		10.1038/sj.onc.1204107	http://dx.doi.org/10.1038/sj.onc.1204107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313976				2022-12-28	WOS:000166562500005
J	Luo, JL; Yang, Q; Tong, WM; Hergenhahn, M; Wang, ZQ; Hollstein, M				Luo, JL; Yang, Q; Tong, WM; Hergenhahn, M; Wang, ZQ; Hollstein, M			Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool	ONCOGENE			English	Article						p53 mouse model; gene targeting; mutagenesis	TUMOR-SUPPRESSOR GENE; MUTATIONS; RECOMBINATION; APOPTOSIS; THERAPY; PATHWAY; PROTEIN	The high prevalence and great diversity of p53 tumor suppressor gene mutations in human tumors call for development of therapeutic molecules that rescue function of aberrant p53 protein. P53 mutations also offer new approaches to the study of the origins of mutations in human cancer. An experimental mouse model with a genetically modified but normal functioning p53 gene harboring the human rather than the murine core domain, would be of considerable benefit to research on both cancer therapeutics and etiology; however, it is uncertain whether such mice would permit biological functions of p53 to be retained. Using a Cre/lox P gene-targeting approach, we have constructed a human p53 knock-in (hupki) mouse strain in which exons 4-9 of the endogenous mouse p53 allele were replaced with the homologous, normal human p53 gene sequence, The chimeric p53 allele (p53(KI)) is properly spliced, transcribed in various tissues at levels equivalent to wild-type mice, and yields cDNA with the anticipated sequence, that is, with a core domain matching that of humans. The hupki p53 protein binds to p53 consensus sequences in gel mobility shift assays and accumulates in the nucleus of hupki fibroblasts in response to UV irradiation, as is characteristic of wild-type p53, Induction of various p53-regulated genes in spleen of gamma -irradiated homozygous hupki mice (p53(KI/KI)), and the kinetics of p53-dependent apoptosis in thymocytes are similar to results with wild-type (p53(+/+)) mice, further indicating normal p53 pathway function in the hupki strain, The mice are phenotypically normal and do not develop spontaneous tumors at an early age, in contrast to knock-out (p53(-/-)) strains with a defective p53 gene. The chimeric (p53(KI)) allele thus appears to provide a biological equivalent to the endogenous murine (p53(+)) gene. This strain is a unique tool for examining in vivo spontaneous and induced mutations in human p53 gene sequences for comparison with published human tumor p53 mutation spectra, In addition, the hupki strain paves the way for mouse models in pre-clinical testing of pharmaceuticals designed to modulate DNA-binding activity of human p53.	Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Genet Alterat Carcinogenesis C0700, D-69120 Heidelberg, Germany; Int Agcy Res Canc, Unit Gene Environm Interact, F-69008 Lyon, France	Helmholtz Association; German Cancer Research Center (DKFZ); World Health Organization; International Agency for Research on Cancer (IARC)	Hollstein, M (corresponding author), Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Genet Alterat Carcinogenesis C0700, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.				NCI NIH HHS [R01CA79493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BAKER SJ, 1990, CANCER RES, V50, P7717; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hollstein M, 1998, MUTAT RES-FUND MOL M, V405, P145, DOI 10.1016/S0027-5107(98)00131-6; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HURSTING SD, 1995, CANCER RES, V55, P3949; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kleihues P, 1997, AM J PATHOL, V150, P1; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lane DP, 1996, ONCOGENE, V12, P2461; Lane DP, 1999, BRIT J CANCER, V80, P1; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shamsher M, 1996, GENE, V176, P259, DOI 10.1016/0378-1119(96)00000-5; USHIJIMA T, 1995, MOL CARCINOGEN, V12, P23, DOI 10.1002/mc.2940120105; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhao RB, 2000, GENE DEV, V14, P981	38	116	124	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					320	328		10.1038/sj.onc.1204080	http://dx.doi.org/10.1038/sj.onc.1204080			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313961				2022-12-28	WOS:000166411000006
J	Sebti, SM; Hamilton, AD				Sebti, SM; Hamilton, AD			Design of growth factor antagonists with antiangiogenic and antitumor properties	ONCOGENE			English	Article						platelet-derived growth factor; angiogenesis; oncogenesis; cancer drug discovery	PDGF BETA-RECEPTOR; CRYSTAL-STRUCTURE; FACTOR-BB; BINDING; IDENTIFICATION; RECOGNITION; MOLECULE; REGION; DOMAIN; CHAIN	This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase, A key step is the construction of synthetic agents that contain a large (>400 Angstrom (2)) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work,ve have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis, The binding affinity for PDGF is high (IC50=250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRG beta, In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol & Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol & Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA.				NCI NIH HHS [P01 CA78038-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z; BACH AC, 1994, J AM CHEM SOC, V116, P3207, DOI 10.1021/ja00087a006; Blaskovich MA, 2000, NAT BIOTECHNOL, V18, P1065, DOI 10.1038/80257; BRANDON C, 1991, INTRO PROTEIN STRUCT; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; FENSTERMAKER RA, 1993, J BIOL CHEM, V268, P10482; FIONA J, 1994, NEW MOL TARGETS CANC, P52; Hamuro Y, 1997, ANGEW CHEM INT EDIT, V36, P2680, DOI 10.1002/anie.199726801; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HENRIKSEN R, 1993, CANCER RES, V53, P4550; JOHNSSON A, 1985, P NATL ACAD SCI USA, V82, P1721, DOI 10.1073/pnas.82.6.1721; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; Rockwell Patricia, 1995, Molecular and Cellular Differentiation, V3, P315; SEBTI SM, 2000, EXPERT OPINION INVES; SEYMOUR L, 1993, BREAST CANCER RES TR, V26, P247, DOI 10.1007/BF00665802; Sun JZ, 1999, CANCER RES, V59, P4919; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006	26	39	43	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 27	2000	19	56					6566	6573		10.1038/sj.onc.1204121	http://dx.doi.org/10.1038/sj.onc.1204121			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426641				2022-12-28	WOS:000167704000002
J	Turkson, J; Jove, R				Turkson, J; Jove, R			STAT proteins: novel molecular targets for cancer drug discovery	ONCOGENE			English	Review						STAT proteins; tyrosine kinases; human cancer; therapeutics	GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION PATHWAY; DNA-BINDING ACTIVITY; KINASE INHIBITOR P21(WAF1/CIP1); PERIPHERAL-BLOOD CELLS; CONSTITUTIVE ACTIVATION; SERINE PHOSPHORYLATION; INTERFERON-ALPHA; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION	Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic proteins with roles as signal messengers and transcription factors that participate in normal cellular responses to cytokines and growth factors. Frequently, however, abnormal activity of certain STAT family members, particularly Stat3 and Stat5, is associated with a wide variety of human malignancies, including hematologic, breast, head and neck, and prostate cancers. Application of molecular biology and pharmacology tools in disease-relevant models has confirmed Stat3 as having a causal role in oncogenesis, and provided validation of Stat3 as a target for cancer drug discovery and therapeutic intervention. Futhermore, a constitutively-active mutant form of Stat3 is sufficient to induce oncogenic transformation of cells, which form tumors in vivo. Constitutive activation of Stat3 signaling is accompanied by upregulation of cyclin D1, c-Myc, and Bcl-x, changes consistent with subversion of normal cellular growth and survival control mechanisms. Block of constitutive Stat3 signaling results in growth inhibition and apoptosis of Stat3-positive tumor cells in vitro and in vivo. The observed dependence of certain tumors on constitutive Stat3 signaling for growth and survival has wide implications for cancer therapy, offering the potential for preferential tumor cell killing. This review evaluates constitutive Stat3 activation as a 'cancer-causing' factor, and proposes a number of molecular strategies for targeting Stat3 signaling for therapeutic intervention.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADEREM AA, 1993, J INFECT DIS, V167, pS2, DOI 10.1093/infdis/167.Supplement_1.S2; Agrawal S, 2000, MOL MED TODAY, V6, P72, DOI 10.1016/S1357-4310(99)01638-X; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; Amoah-Apraku B, 2000, KIDNEY INT, V57, P83, DOI 10.1046/j.1523-1755.2000.00809.x; Azemar M, 2000, INT J CANCER, V86, P269, DOI 10.1002/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO;2-8; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Ben-Bassat H, 2000, CURR PHARM DESIGN, V6, P933, DOI 10.2174/1381612003400182; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Bovolenta C, 1999, BLOOD, V94, P4202, DOI 10.1182/blood.V94.12.4202.424k22_4202_4209; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BOWMAN T, 2000, UNPUB; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BURDELYA L, 2000, UNPUB; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; CATLETTFALCONE R, 2000, UNPUB; Cattaneo E, 1998, ANTICANCER RES, V18, P2381; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Collum RG, 2000, P NATL ACAD SCI USA, V97, P10120, DOI 10.1073/pnas.170192197; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Demartis A, 1996, CANCER RES, V56, P4213; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; EPLINGBURNETTE PK, 2000, UNPUB; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; Frank DA, 1996, LEUKEMIA, V10, P1724; Frank DA, 1999, MOL MED, V5, P432; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GARCIA RA, 2000, UNPUB; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Gollob JA, 1999, J IMMUNOL, V162, P4472; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Green DW, 2000, J AM COLL SURGEONS, V191, P93, DOI 10.1016/S1072-7515(00)00305-7; Griesenbach U, 2000, GENE THER, V7, P306, DOI 10.1038/sj.gt.3301078; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Huang JS, 1999, BIOCHEM J, V342, P231, DOI 10.1042/0264-6021:3420231; HUANG M, 2000, UNPUB; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Karras JG, 2000, CELL IMMUNOL, V202, P124, DOI 10.1006/cimm.2000.1661; Kirkwood JM, 1999, MOL MED, V5, P11, DOI 10.1007/BF03402135; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; Kuratsukuri K, 1999, PROSTATE, V41, P121; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu RY, 1999, BLOOD, V93, P2369, DOI 10.1182/blood.V93.7.2369.407k18_2369_2379; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Lund T, 1997, J VIROL, V71, P378, DOI 10.1128/JVI.71.1.378-382.1997; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; Magrassi L, 1999, J NEUROSURG, V91, P440, DOI 10.3171/jns.1999.91.3.0440; Marcusson EG, 1999, MOL BIOTECHNOL, V12, P1, DOI 10.1385/MB:12:1:1; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Muller-Ladner U, 2000, J IMMUNOL, V164, P3894, DOI 10.4049/jimmunol.164.7.3894; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Ni Z, 2000, CANCER RES, V60, P1225; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 1999, CANCER RES, V59, P5059; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OSHIRO MM, 2000, UNPUB; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Petrucci MT, 1999, ANN HEMATOL, V78, P13, DOI 10.1007/s002770050465; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Planas AM, 1997, J NEUROCHEM, V68, P1345; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Ray DW, 1998, ANN NY ACAD SCI, V840, P162, DOI 10.1111/j.1749-6632.1998.tb09560.x; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REDDY KB, 1992, CANCER RES, V52, P3636; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; Roh H, 1999, SURGERY, V126, P413, DOI 10.1016/S0039-6060(99)70186-8; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sartor CI, 1997, CANCER RES, V57, P978; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schrell UMH, 1998, J NEUROSURG, V88, P541, DOI 10.3171/jns.1998.88.3.0541; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; SINIBALDI N, 2000, UNPUB; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; STACEY DW, 1991, ONCOGENE, V6, P2297; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Stephens JM, 1996, J BIOL CHEM, V271, P10441, DOI 10.1074/jbc.271.18.10441; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Vincent PW, 2000, CANCER CHEMOTH PHARM, V45, P231, DOI 10.1007/s002800050034; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WeberNordt RM, 1996, BLOOD, V88, P809; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; Xie W, 1997, ANTICANCER RES, V17, P2627; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamada K, 2000, INT J HEMATOL, V71, P46; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J IMMUNOL, V159, P5206; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuen AR, 1999, CLIN CANCER RES, V5, P3357; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	201	522	571	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6613	6626		10.1038/sj.onc.1204086	http://dx.doi.org/10.1038/sj.onc.1204086			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426647				2022-12-28	WOS:000167704000008
J	Kashiwagi, M; Ohba, M; Watanabe, H; Ishino, K; Kasahara, K; Sanai, Y; Taya, Y; Kuroki, T				Kashiwagi, M; Ohba, M; Watanabe, H; Ishino, K; Kasahara, K; Sanai, Y; Taya, Y; Kuroki, T			PKC eta associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes	ONCOGENE			English	Article						PKC eta; cell cycle; keratinocytes; p21	PLECKSTRIN HOMOLOGY DOMAIN; CAPILLARY ENDOTHELIAL-CELLS; PROTEIN-KINASE; PHORBOL ESTER; C-DELTA; MOUSE KERATINOCYTES; ACTIVATING KINASE; BINDING PROTEIN; NPKC-ETA; DIFFERENTIATION	PKC is activated on the cell membrane by phospholipids, thereby transducing signals to intracellular pathways. We provide here another function of PKC, namely, regulating cell cycle by interaction with the cyclin E/cdk2/p21 complex. Among the 10 isoforms of PKC, PKC eta is predominantly expressed in squamous cell epithelia and induces terminal differentiation of keratinocytes, PKC eta that is endogenously expressed or overexpressed was found to associate with the cyclin E/cdk2/p21 complex in keratinocytes of mice and humans. Requirement of a possible adaptor protein to the binding was suggested by the reconstitution of PKC eta and the cyclin E/cdk2/p21 complex which were prepared from human keratinocytes or Sf9 insect cells. Colocalization of PKC eta with cdk2 and cyclin E was observed in the cytoplasm, particularly in the perinuclear region. p21 was phosphorylated in the complex in a PKC-activator dependent manner. Association of PKC eta with cdk2 resulted in marked inhibition of cdk2-kinase activity when measured by phosphorylation of Rb, Dominant negative PKC eta associated with the cyclin E/cdk2/p21 complex, but caused a little inhibition of cdk2 kinase activity. Among the known regulatory mechanisms of cdk2 activity, dephosphorylation of Thr160 was demonstrated.	Showa Univ, Inst Mol Oncol, Shinagawa Ku, Tokyo 1428555, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1130021, Japan; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; National Cancer Center - Japan	Kuroki, T (corresponding author), Showa Univ, Inst Mol Oncol, Shinagawa Ku, 1-5-8 Katanodai, Tokyo 1428555, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351; Kasahara, Kohji/0000-0001-7010-8365				Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUJISE A, 1994, J BIOL CHEM, V269, P31642; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; Ishino K, 1998, JPN J CANCER RES, V89, P1126, DOI 10.1111/j.1349-7006.1998.tb00507.x; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jaumot M, 1997, BIOCHEM BIOPH RES CO, V241, P434, DOI 10.1006/bbrc.1997.7787; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Livneh E, 1996, ONCOGENE, V12, P1545; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mochly-Rosen D, 1998, FASEB J, V12, P35; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morrow TA, 1999, MOL CELL BIOL, V19, P5608; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1990, J BIOL CHEM, V265, P22434; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	51	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6334	6341		10.1038/sj.onc.1204028	http://dx.doi.org/10.1038/sj.onc.1204028			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175348				2022-12-28	WOS:000166210500017
J	Yu, DH; Hung, MC				Yu, DH; Hung, MC			Overexpression of ErbB2 in cancer and ErbB2-targeting strategies	ONCOGENE			English	Article						HER2/neu; metastasis; therapeutic resistance; ErbB2-targeting therapy; E1A	HUMAN-BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; FACTOR-INDUCED APOPTOSIS; C-ERBB-2 SERUM-PROTEIN; TYROSINE KINASE; MONOCLONAL-ANTIBODY; NEU PROTOONCOGENE; PROGNOSTIC-SIGNIFICANCE; FACTOR RECEPTOR	This past decade has witnessed the remarkable advances in the understanding of the role of the erbB2 gene in cancers and the stunning progress in developing targeted therapies for erbB2-overexpressing cancers. Activation of the ErbB2 receptor signaling pathways can enhance various metastasis-associated properties that lead to an increase of cancer metastasis. Additionally, ErbB2 overexpression confers therapeutic resistance via receptor-mediated antiapoptotic signals. To limit these disastrous effects of the overexpressed ErbB2, various ErbB2-blocking strategies have been developed in the laboratories and several have been tested in clinical trials or approved as therapies for ErbB2 overexpressing cancers. In this article, we will discuss the detrimental effects of the erbB2 gene in cancers, with a focus on breast cancer. We will also outline ErbB2-targeting strategies as potential therapies for ErbB2-overexpressing cancers. Progress in understanding the molecular biology of ErbB2 and in molecular-based treatment of ErbB2-overexpressing tumors will bring great benefits to cancer patients.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, DH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [2RO1CA60488, R01CA58880, R01CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R01CA060856, R01CA060488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; Amici A, 2000, GENE THER, V7, P703, DOI 10.1038/sj.gt.3301151; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Barnes MN, 1996, CLIN CANCER RES, V2, P1089; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; Burke HB, 1998, CANCER-AM CANCER SOC, V82, P874, DOI 10.1002/(SICI)1097-0142(19980301)82:5<874::AID-CNCR11>3.0.CO;2-Y; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Colomer R, 2000, CLIN CANCER RES, V6, P2356; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; Deshane J, 1996, CANCER GENE THER, V3, P89; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1988, ONCOGENE, V2, P387; Fehm T, 1998, ONCOLOGY-BASEL, V55, P33, DOI 10.1159/000011832; Fehm T, 1997, BREAST CANCER RES TR, V43, P87, DOI 10.1023/A:1005700812422; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Giannios J, 1997, EUR J GYNAECOL ONCOL, V18, P387; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grunt TW, 1998, BRIT J CANCER, V78, P79, DOI 10.1038/bjc.1998.446; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARRIS JD, 1994, GENE THER, V1, P170; Haynes NM, 1999, CANCER IMMUNOL IMMUN, V47, P278, DOI 10.1007/s002620050532; Hong RL, 1999, CLIN CANCER RES, V5, P1884; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUNG MC, 1999, NONVIRAL VECTORS GEN, V16, P358; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; Jarvinen TAH, 1998, BRIT J CANCER, V77, P2267, DOI 10.1038/bjc.1998.377; KING MC, 1998, HER 2, pR11; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Mehta RR, 1998, J CLIN ONCOL, V16, P2409, DOI 10.1200/JCO.1998.16.7.2409; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nelson NJ, 2000, J NATL CANCER I, V92, P366, DOI 10.1093/jnci/92.5.366; Noonberg SB, 2000, DRUGS, V59, P753, DOI 10.2165/00003495-200059040-00003; Pandha HS, 1999, J CLIN ONCOL, V17, P2180, DOI 10.1200/JCO.1999.17.7.2180; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Petit AMV, 1997, AM J PATHOL, V151, P1523; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Pirollo KF, 1997, BIOCHEM BIOPH RES CO, V230, P196, DOI 10.1006/bbrc.1996.5922; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Rao GN, 1999, BREAST CANCER RES TR, V58, P241; RUSSELL KS, 1992, CANCER RES, V52, P6624; Russell KS, 1996, ONCOL REP, V3, P433; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; Tan M, 1997, CANCER RES, V57, P1199; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; VANAGTHOVEN T, 1994, MOL ENDOCRINOL, V8, P1474, DOI 10.1210/me.8.11.1474; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yamauchi H, 1997, J CLIN ONCOL, V15, P2518, DOI 10.1200/JCO.1997.15.7.2518; YU D, 1995, MOL BASIS ONCOLOGY, V5, P131; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; Yu DH, 1998, ONCOGENE, V16, P2087, DOI 10.1038/sj.onc.1201729; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; ZHANG LS, 1995, CANCER RES, V55, P3890; ZHANG Y, 1997, ONCOGENE, V14, P561; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	87	317	336	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6115	6121		10.1038/sj.onc.1203972	http://dx.doi.org/10.1038/sj.onc.1203972			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156524				2022-12-28	WOS:000166121400004
J	Cui, XS; Donehower, LA				Cui, XS; Donehower, LA			Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53	ONCOGENE			English	Article						p53; mouse mammary tumor; Wnt-1; p21(WAF1/CIP1); c-kit; cyclin B1	TUMOR-CELL PROLIFERATION; MUSCLE ALPHA-ACTIN; CYCLIN-G; TRANSCRIPTIONAL TARGET; TRANSGENIC MICE; SUPPRESSOR P53; BREAST-CANCER; GROWTH; P21; ARREST	The tumor suppressor p53 transcriptionally regulates a large number of target genes that may affect cell growth and cell death pathways. To better understand the role of p53 loss in tumorigenesis, me have developed a mouse mammary cancer model, the Wnt-1 TG/p53 model. Wnt-1 transgenic females that are p53-/- develop mammary adenocarcinomas that arise sooner, grow faster, appear more anaplastic, and have higher levels of chromosomal instability than their Wnt-1 transgenic p53+/+ counterparts. In this study, we used several assays to determine whether the presence or absence of p53 affects gene expression patterns in the mammary adenocarcinomas. Most of the differentially expressed genes are increased in p53+/+ tumors and many of these represent known target genes of p53 (p21(WAF1/C1P1) cyclin G1, alpha smooth muscle actin, and cytokeratin 19), Some of these genes (cytokeratin 19, alpha smooth muscle actin, and kappa casein) represent mammary gland differentiation markers which may contribute to the inhibited tumor progression and are consistent with the more differentiated histopathology observed in the p53+/+ tumors. Several differentially expressed genes are growth regulatory in function (p21, c-kit, and cyclin B1) and their altered expression levels correlate well with the differing growth properties of the p53+/+ and p53-/- tumors. Thus, while tumors can arise and progress in the presence of functioning wild type p53, p53 may directly or indirectly regulate expression of an array of genes that facilitate differentiation and inhibit proliferation, contributing to a more differentiated, slow growing, and genomically stable phenotype.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.							Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ginger MR, 1999, COMP BIOCHEM PHYS B, V124, P133, DOI 10.1016/S0305-0491(99)00110-8; Gorospe M, 1999, GENE EXPRESSION, V7, P377; GUGLIOTTA P, 1988, J HISTOCHEM CYTOCHEM, V36, P659, DOI 10.1177/36.6.3367051; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIBI K, 1991, ONCOGENE, V6, P2291; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; MAZARS R, 1992, CANCER RES, V52, P3918; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 1998, CRIT REV ORAL BIOL M, V9, P23, DOI 10.1177/10454411980090010101; MUSUNURU K, 1997, CELL CYCLE REGULATOR; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NATALI PG, 1995, CANCER RES, V55, P1787; Nishida K, 1996, ANTICANCER RES, V16, P3397; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RUDLAND PS, 1993, J HISTOCHEM CYTOCHEM, V41, P543, DOI 10.1177/41.4.8450194; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	47	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					5988	5996		10.1038/sj.onc.1203993	http://dx.doi.org/10.1038/sj.onc.1203993			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146550				2022-12-28	WOS:000165827900005
J	Zhang, M; Shi, Y; Magit, D; Furth, PA; Sager, R				Zhang, M; Shi, Y; Magit, D; Furth, PA; Sager, R			Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice	ONCOGENE			English	Article						maspin; WAP-TAg transgenic mice; mammary tumor progression	BREAST-CANCER; T-ANTIGEN; SERPIN; CELLS; EXPRESSION; SUPPRESSOR; SV40; GENE; TRANSACTIVATION; INVASION	Maspin is a unique serpin involved in the suppression of tumor growth and metastasis. To investigate whether increased levels of maspin protect against tumor progression in vivo, we established a transgenic model in which maspin is targeted to mammary epithelial cells by the Whey Acidic Protein (WAP) promoter for overexpression. We crossed these WAP-maspin transgenic mice with the WAP-TAg mouse model of tumor progression. Maspin overexpression increased the rate of apoptosis of both preneoplastic and carcinomatous mammary epithelial cells. Maspin reduced tumor growth through a combination of reduced angiogenesis and increased apoptosis, The number of pulmonary metastases was reduced in the presence of maspin overexpression, These data demonstrate that targeted overexpression of maspin can inhibit tumor progression in vivo, likely through a combination of increased apoptosis, decreased angiogenesis, and inhibition of tumor cell migration.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Maryland, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Baylor College of Medicine; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA079736] Funding Source: NIH RePORTER; NCI NIH HHS [CA79736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Faraldo MM, 1998, EMBO J, V17, P2139, DOI 10.1093/emboj/17.8.2139; Hendrix MJC, 2000, NAT MED, V6, P374, DOI 10.1038/74624; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Obermair A, 1997, J NATL CANCER I, V89, P1212, DOI 10.1093/jnci/89.16.1212; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TZENG YJ, 1993, ONCOGENE, V8, P1965; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	27	62	68	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6053	6058		10.1038/sj.onc.1204006	http://dx.doi.org/10.1038/sj.onc.1204006			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146557				2022-12-28	WOS:000165827900012
J	Demeret, C; Vassetzky, Y; Mechali, M				Demeret, C; Vassetzky, Y; Mechali, M			Chromatin remodelling and DNA replication: from nucleosomes to loop domains	ONCOGENE			English	Review						chromatin remodelling; DNA replication; DNA loop domains	YEAST SWI/SNF COMPLEX; SIMIAN VIRUS-40 DNA; TRANSCRIPTIONAL ACTIVATION DOMAIN; ASSEMBLY FACTOR-I; XENOPUS-LAEVIS; TOPOISOMERASE-II; DEVELOPMENTAL REGULATION; CHROMOSOME-REPLICATION; HISTONE DEACETYLASE; REPLICON CLUSTERS	Organization of DIVA into chromatin is likely to participate in the control of the timing and selection of DNA replication origins. Reorganization of the chromatin is carried out by chromatin remodelling machines, which may affect the choice of replication origins and efficiency of replication. Replication itself causes a profound rearrangement in the chromatin structure, from nucleosomes to DNA loop domains, allowing to retain or switch an epigenetic state. The present review considers the effects of chromatin remodelling on replication and vice versa.	CNRS, Inst Human Genet, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mechali, M (corresponding author), CNRS, Inst Human Genet, 141 Rue Cardonille, F-34396 Montpellier 5, France.		Vassetzky, Yegor S/C-6447-2008; Vassetzky, Yegor/M-3383-2019	Vassetzky, Yegor S/0000-0003-3101-7043; Vassetzky, Yegor/0000-0003-3101-7043; Demeret, caroline/0000-0002-1103-6805				Alexiadis V, 2000, GENE DEV, V14, P1308; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; Benham C, 1997, J MOL BIOL, V274, P181, DOI 10.1006/jmbi.1997.1385; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; BUONGIORNONARDELLI M, 1982, NATURE, V298, P100, DOI 10.1038/298100a0; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; COOK PR, 1976, J CELL SCI, V22, P287; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Flanagan JF, 1999, NUCLEIC ACIDS RES, V27, P2022, DOI 10.1093/nar/27.9.2022; Francon P, 1999, FEBS LETT, V452, P87, DOI 10.1016/S0014-5793(99)00585-2; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gomez M, 1999, EMBO J, V18, P5683, DOI 10.1093/emboj/18.20.5683; Halmer L, 1998, J BIOL CHEM, V273, P34792, DOI 10.1074/jbc.273.52.34792; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ISHIMI Y, 1992, MOL CELL BIOL, V12, P4007, DOI 10.1128/MCB.12.9.4007; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKSON DA, 1990, BIOESSAYS, V12, P87, DOI 10.1002/bies.950120207; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lagarkova MA, 1998, J CELL BIOCHEM, V69, P13, DOI 10.1002/(SICI)1097-4644(19980401)69:1<13::AID-JCB2>3.0.CO;2-Y; Leach TJ, 2000, MOL CELL BIOL, V20, P6308, DOI 10.1128/MCB.20.17.6308-6316.2000; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lemaitre JM, 1998, J CELL BIOL, V142, P1159, DOI 10.1083/jcb.142.5.1159; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; Logie C, 1999, METHOD ENZYMOL, V304, P726; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; MAJUMDER S, 1994, J CELL BIOCHEM, V55, P59, DOI 10.1002/jcb.240550107; Maric C, 1999, J MOL BIOL, V291, P775, DOI 10.1006/jmbi.1999.3017; MARILLEY M, 1989, EXP CELL RES, V180, P475, DOI 10.1016/0014-4827(89)90074-8; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MEISSNER B, 1991, CHROMOSOMA, V101, P222, DOI 10.1007/BF00365154; MICHELI G, 1993, CHROMOSOMA, V102, P478, DOI 10.1007/BF00357103; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Mizushima T, 2000, GENE DEV, V14, P1631; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; RAZIN SV, 1986, NUCLEIC ACIDS RES, V14, P8189, DOI 10.1093/nar/14.20.8189; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; Ridgway P, 2000, J CELL SCI, V113, P2647; Sasaki T, 1999, MOL CELL BIOL, V19, P547; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SMITH HC, 1984, J CELL BIOL, V99, P1794, DOI 10.1083/jcb.99.5.1794; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; VANDERVELDEN HMW, 1984, FEBS LETT, V171, P13, DOI 10.1016/0014-5793(84)80451-2; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Vassetzky Y, 2000, GENE DEV, V14, P1541; Vestner B, 1998, J BIOL CHEM, V273, P9409, DOI 10.1074/jbc.273.16.9409; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe A., 1998, CHROMATIN STRUCTURE; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	96	45	46	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3086	3093		10.1038/sj.onc.1204333	http://dx.doi.org/10.1038/sj.onc.1204333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420724				2022-12-28	WOS:000169308500012
J	Wolffe, AP				Wolffe, AP			Chromatin remodeling: why it is important in cancer	ONCOGENE			English	Review						cell cycle; acetyltransferase; reacetylase methyltransferase; ATPase; RNA polymerase	CORE HISTONE ACETYLATION; NUCLEOSOME MOBILITY; POSITIVE ROLE; TRANSCRIPTION; DNA; COMPLEX; GENE	A typical human cell expresses only a few thousand of the more than 30000 genes contained within our chromosomes. The chromosomal infrastructure is essential for gene control, determining both active and repressed states. It is important not only to turn the right genes on but also to turn the right genes off. Histones and chromatin components have key roles in this decision making process. Mistakes ha re severe consequences. If as few as three inappropriate genes are turned off, a normal cell can be converted into a cancer cell. This epigenetic silencing of genes underlies a new approach to cancer therapy. Advances in the biochemistry and genetics of chromatin remodeling reveal that gene inactivation depends on the recruitment of enzymes that control the display of DNA within the chromosome. Mistargeting of these enzymes leads to tumorigenesis, but inhibition of their activity presents a novel approach to therapy.	Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Wolffe, AP (corresponding author), Sangamo Biosci Inc, Point Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.							GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, V2, P949; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIU PQ, 2001, IN PRESS J BIOL CHEM; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; VETESSEDADEY M, 1996, EMBO J, V15, P2508; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Wolffe A., 1998, CHROMATIN STRUCTURE; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	20	90	93	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					2988	2990		10.1038/sj.onc.1204322	http://dx.doi.org/10.1038/sj.onc.1204322			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420713				2022-12-28	WOS:000169308500001
J	Lutzker, SG; Mathew, R; Taller, DR				Lutzker, SG; Mathew, R; Taller, DR			A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells	ONCOGENE			English	Article						p53; apoptosis; DNA damage; teratocarcinoma cells	APOPTOSIS; GENE; EXPRESSION; CISPLATIN; PROTEIN; TUMORS	Teratocarcinomas are tumors that arise from primordial germ cells and are readily curable with DNA-damaging chemotherapeutic drugs. Teratocarcinoma cells ex vivo in tissue culture are also relatively chemosensitive and undergo apoptotic death in response to DNA damage, We have previously hypothesized that the observed sensitivity of this tumor type to DNA damage is related to high basal expression of wild-type p53 protein, We have now addressed this issue by characterizing the DNA damage response of isogenic teratocarcinoma cells that differ only in their level of expression of wild-type p53 protein, We find a clear p53 dose-response relationship in these cells for rapid apoptosis following DNA damage that correlates with diminished colony formation in clonogenic survival assays. These results suggest that strategies to increase basal wild-type p53 protein expression prior to treatment with DNA-damaging drugs may improve curability in other tumor types. Oncogene (2001) 20, 2982-2986.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Genet & Microbiol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Inst Canc, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lutzker, SG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08901 USA.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; Brown JM, 1999, CANCER RES, V59, P1391; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Chresta CM, 1996, CANCER RES, V56, P1834; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Eid H, 1997, ANTICANCER RES, V17, P2663; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Roy B, 1996, ONCOGENE, V13, P2359; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SCHMID P, 1991, DEVELOPMENT, V113, P857; Schmidt-Kastner PK, 1998, ONCOGENE, V16, P3003, DOI 10.1038/sj.onc.1201835; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	25	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2982	2986		10.1038/sj.onc.1204394	http://dx.doi.org/10.1038/sj.onc.1204394			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420711				2022-12-28	WOS:000168901800014
J	Kockel, L; Homsy, JG; Bohmann, D				Kockel, L; Homsy, JG; Bohmann, D			Drosophila AP-1: lessons from an invertebrate	ONCOGENE			English	Review						Drosophila; AP-1; Fos; Jun; transcription factor; JNK	SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; EMBRYONIC DORSAL CLOSURE; CELL SHEET MOVEMENT; PLANAR POLARITY; MAP KINASE; ENDODERM INDUCTION; C-JUN; PATTERN-FORMATION; GENE-EXPRESSION	In recent years, studies in the model organism Drosophila melanogaster have contributed significant insights into the molecular and developmental biology of the AP-1 transcription factors Jun and Fos, Powerful genetic and biochemical approaches uncovered a baffling complexity and variability of the signaling connections to and from AP-1, The range of biological processes that Jun and Fos regulate in this organism is equally multifaceted, Regulatory interactions between AP-1 and JNK, ERK, TGF beta, Notch or other signaling systems have been implicated in the control of a multitude of embryonic and adult events, including tissue closure processes, patterning of eye, gut and wing, as well as apoptosis, Here we review the information that has been gathered on Drosophila AP-1 in signal transduction and on the developmental and cellular functions controlled by AP-1-mediated signals in the fly. Lessons learned from the studies on AP-1 in Drosophila may contribute to our general understanding, beyond species boundaries, of this fundamental class of transcriptional regulators.	Univ Rochester, Med Ctr, Ctr Canc Biol, Rochester, NY 14642 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	University of Rochester; European Molecular Biology Laboratory (EMBL); Harvard University; Harvard Medical School	Bohmann, D (corresponding author), Univ Rochester, Med Ctr, Ctr Canc Biol, 601 Elmwood Ave,Box 633, Rochester, NY 14642 USA.							Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Agnes F, 1999, DEVELOPMENT, V126, P5453; Andrew DJ, 1997, DEVELOPMENT, V124, P181; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; BASDRA EK, 1994, BBA-MOL CELL RES, V1222, P315, DOI 10.1016/0167-4889(94)90185-6; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Bienz M, 1997, CURR OPIN GENET DEV, V7, P683, DOI 10.1016/S0959-437X(97)80017-2; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; Blair SS, 1999, CURR BIOL, V9, pR356, DOI 10.1016/S0960-9822(99)80226-7; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bray S, 2000, CURR BIOL, V10, pR155, DOI 10.1016/S0960-9822(00)00330-4; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Byars CL, 1999, DEVELOPMENT, V126, P4913; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chen YJ, 1998, DEVELOPMENT, V125, P1759; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Fanto M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Fernandez R, 2000, GENE DEV, V14, P604; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GUBB D, 1993, DEVELOPMENT, P269; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Harden N, 1996, MOL CELL BIOL, V16, P1896; HARDEN N, 1995, DEVELOPMENT, V121, P903; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hewes RS, 2000, GENETICS, V155, P1711; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Hudson JB, 1998, DEVELOPMENT, V125, P1407; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacinto A, 2000, CURR BIOL, V10, P1420, DOI 10.1016/S0960-9822(00)00796-X; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Knust E, 1996, CURR BIOL, V6, P379, DOI 10.1016/S0960-9822(02)00500-6; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lisi S, 2000, GENETICS, V154, P669; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Martin-Blanco E, 2000, P NATL ACAD SCI USA, V97, P7888, DOI 10.1073/pnas.97.14.7888; McEwen DG, 2000, DEVELOPMENT, V127, P3607; MIHALY J, 2001, IN PRESS MECH DEV; Mlodzik M, 1999, EMBO J, V18, P6873, DOI 10.1093/emboj/18.24.6873; Morimura S, 1996, DEV BIOL, V177, P136, DOI 10.1006/dbio.1996.0151; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Paricio N, 1999, EMBO J, V18, P4669, DOI 10.1093/emboj/18.17.4669; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; Raabe T, 2000, BBA-MOL CELL RES, V1496, P151, DOI 10.1016/S0167-4889(00)00020-3; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Ricos MG, 1999, J CELL SCI, V112, P1225; Riese J, 1997, DEVELOPMENT, V124, P3353; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; RING JM, 1993, DEVELOPMENT, P251; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; Simin K, 1998, GENETICS, V148, P801; Sluss HK, 1997, J CELL BIOCHEM, V67, P1; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Strutt H, 1999, CURR OPIN GENET DEV, V9, P442, DOI 10.1016/S0959-437X(99)80067-7; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Szuts D, 2000, MECH DEVELOP, V98, P71, DOI 10.1016/S0925-4773(00)00455-X; Szuts D, 2000, P NATL ACAD SCI USA, V97, P5351, DOI 10.1073/pnas.97.10.5351; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tomlinson A, 1999, DEVELOPMENT, V126, P5725; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREMML G, 1992, DEVELOPMENT, V116, P447; Usui K, 2000, DEV BIOL, V225, P13, DOI 10.1006/dbio.2000.9766; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Watson L, 2000, EUR J CLIN INVEST, V30, P11; Weber U, 2000, DEVELOPMENT, V127, P3619; Wehrli M, 1998, DEVELOPMENT, V125, P1421; WOLFF T, 1993, BIOL DROSOPHILA MELA; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342; Zeidler MP, 2000, DEV BIOL, V228, P181, DOI 10.1006/dbio.2000.9940; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; ZHENG L, 1995, DEVELOPMENT, V121, P3045	124	102	106	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2347	2364		10.1038/sj.onc.1204300	http://dx.doi.org/10.1038/sj.onc.1204300			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402332				2022-12-28	WOS:000168568700003
J	Gil, J; Rullas, J; Garcia, MA; Alcami, J; Esteban, M				Gil, J; Rullas, J; Garcia, MA; Alcami, J; Esteban, M			The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappa B activation	ONCOGENE			English	Article						PKR; IKK; NF-kappa B; dsRNA	DOUBLE-STRANDED-RNA; IKK-BETA; IN-VIVO; INTERFERON; EXPRESSION; ALPHA; PHOSPHORYLATION; REPLICATION; INHIBITION; COMPLEX	The double stranded RNA-dependent protein kinase (PKR), in addition to its role as a translational controlling factor, is a key transcriptional regulator exerting antiviral and antitumoral activities. We have previously shown that induction of NF-kappaB by PKR is involved in apoptosis commitment and this process is mediated through activation of the IKK complex. To gain insights into the mechanism of activation of NF-kappaB by PKR, we have analysed the domains of PKR involved in IKK activation and subsequent NF-kappaB induction. In PKR0/0 cells infected with a collection of vaccinia virus (VV) recombinants expressing different mutant forms of PKR, we found that only PKR forms conserving the catalytic activity are able to activate NF-kappaB. An inactive PKR mutant (K296R), was unable to induce NF-kappaB activation despite full expression of the protein in a wide range of concentrations, as defined by Western blot, EMSA, IKK kinase activity and NF-kappaB transactivation assays. Moreover, the mutant PKR (K296R) acts as a dominant negative of PKR-induced eIF-2 alpha phosphorylation and NF-kappaB activation. However, PKR mutants unable to activate NF-kappaB still retain their ability to associate with the IKK complex, as confirmed by immunoprecipitation analysis. We conclude that the catalytic activity of PKR and not only a protein-protein interaction with the IKK complex, is needed for activation of the transcription factor NF-kappaB.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, E-28049 Madrid, Spain; Inst Salud Carlos III, Ctr Biol Fundamental, AIDS Immunopathogenesis Unit, Madrid 28220, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Instituto de Salud Carlos III	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, E-28049 Madrid, Spain.		Esteban, Mariano/ABG-5375-2020; Gil, Jesus/C-7739-2012; Garcia, Maria Angel MA/I-5116-2016; Alcami, Pepe/T-2242-2018	Esteban, Mariano/0000-0003-0846-2827; Gil, Jesus/0000-0002-4303-6260; Garcia, Maria Angel MA/0000-0003-2003-3769; Alcami, Pepe/0000-0003-0023-7377				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; DiazGuerra M, 1997, VIROLOGY, V227, P220, DOI 10.1006/viro.1996.8294; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; George CX, 1996, VIROLOGY, V221, P180, DOI 10.1006/viro.1996.0364; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rivas C, 1999, J INTERF CYTOK RES, V19, P1229, DOI 10.1089/107999099312885; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	54	56	61	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					385	394		10.1038/sj.onc.1204109	http://dx.doi.org/10.1038/sj.onc.1204109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313968	Bronze			2022-12-28	WOS:000166411000013
J	Bacus, SS; Gudkov, AV; Lowe, M; Lyass, L; Yung, Y; Komarov, AP; Keyomarsi, K; Yarden, Y; Seger, R				Bacus, SS; Gudkov, AV; Lowe, M; Lyass, L; Yung, Y; Komarov, AP; Keyomarsi, K; Yarden, Y; Seger, R			Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53	ONCOGENE			English	Article						taxol; MAP kinase; apoptosis; cell cycle; p53; Her-2	ACTIVATED PROTEIN-KINASE; INDUCED CELL-DEATH; EPIDERMAL-GROWTH-FACTOR; HUMAN TUMOR-CELLS; HUMAN BREAST; PHOSPHOINOSITIDE 3-KINASE; DIFFERENTIAL MODULATION; MEDIATED APOPTOSIS; PHOSPHORYLATION; PACLITAXEL	The anti-cancer agent paclitaxel (Taxol) stabilizes microtubules leading to G2/M cell cycle arrest and apoptotic cell death. In order to analyse the molecular mechanisms of Taxol-induced cytotoxicity, we studied the involvement of mitogen-activated protein kinases (MAPK) ERK and p38 as well as the p53 pathways in Taxol-induced apoptosis, The human breast carcinoma cell line MCF7 and its derivatives, MCF7/HER-2 and MDD2, sere used in the study. We found that Taxol treatment strongly activated ERK, p38 MAP kinase and p53 in MAP kinase MCF9 cells prior to apoptosis, PD98059 or SB203580, specific inhibitors of ERK and p38 kinase activities, significantly decreased apoptosis, leaving the surviving cells arrested in G2/M. These inhibitors did not significantly affect Taxol-induced alterations in the cell cycle regulatory proteins Rb, p53, p11/Waf1 and Cdk-2, In addition, inactivation of p53 did not affect cellular sensitivity to Taxol killing. However, cells with inactivated p53, unlike cells harboring wild type p53, failed to arrest in G2/M after treatment with Taxol and continued to divide or go into apoptosis, Our data show that both ERK and p38 MAP kinase cascades are essential for apoptotic response to Taxol-induced cellular killing and are independent of p53 activity, However, p53 may serve as a survival factor in breast carcinoma cells treated with Taxol by blocking cells in G2/M phase of the cell cycle.	Quantitat Diagnost Labs Inc, Elmhurst, IL 60126 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; Weizmann Inst Sci, IL-76100 Rehovot, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Weizmann Institute of Science	Bacus, SS (corresponding author), Quantitat Diagnost Labs Inc, Elmhurst, IL 60126 USA.		YARDEN, YOSEF/K-1467-2012; Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179, CA60730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179, R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 1996, ONCOGENE, V12, P2535; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blagosklonny MV, 2000, CANCER RES, V60, P3425; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fang M, 2000, ANTICANCER RES, V20, P103; Goldspiel BR, 1997, PHARMACOTHERAPY, V17, pS110; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Kandioler-Eckersberger D, 2000, CLIN CANCER RES, V6, P50; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KEYOMARSI K, 1994, CANCER RES, V54, P380; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lieu CH, 1998, CELL GROWTH DIFFER, V9, P767; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Torres K, 1998, CANCER RES, V58, P3620; TURNER PF, 1984, J CELL BIOL, V99, P940, DOI 10.1083/jcb.99.3.940; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WANG X, 2000, J BIOL CHEM, V10, P1074; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu DH, 1996, ONCOGENE, V13, P1359; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0	60	315	326	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					147	155		10.1038/sj.onc.1204062	http://dx.doi.org/10.1038/sj.onc.1204062			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313944				2022-12-28	WOS:000166410900002
J	Mavrothalassitis, G; Ghysdael, J				Mavrothalassitis, G; Ghysdael, J			Proteins of the ETS family with transcriptional repressor activity	ONCOGENE			English	Review						ets; repression; transcription; proliferation	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DROSOPHILA EYE DEVELOPMENT; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; DNA-BINDING ACTIVITY; GENE FAMILY; DOMAIN PROTEIN; EGF RECEPTOR; TYROSINE KINASE	ETS proteins form one of the largest families of signal-dependent transcriptional regulators, mediating cellular proliferation, differentiation and tumorigenesis, Most of the known ETS proteins have been shown to activate transcription. However, four ETS proteins (YAN, ERF, NET and TEL) can act as transcriptional repressors. In three cases (ERF, NET and TEL) distinct repression domains have been identified and there are indications that NET and TEL may mediate transcription via Histone Deacetylase recruitment. All four proteins appear to be regulated by MAPKs, though for YAN and ERF this regulation seems to be restricted to ERKs, YAN, ERF and TEL have been implicated in cellular proliferation although there are indications suggesting a possible involvement of YAN and TEL in differentiation as well. Other ETS-domain proteins have been shown to repress transcription in a context specific manner, and there are suggestions that the ETS DNA-binding domain may act as a transcriptional repressor. Transcriptional repression by ETS domain proteins adds an other level in the orchestrated regulation by this diverse family of transcription factors that often recognize similar if not identical binding sites on DNA and are believed to regulate critical genes in a variety of biological processes. Definitive assessment of the importance of this novel regulatory level will require the identification of ETS proteins target genes and the further analysis of transcriptional control and biological function of these proteins in defined pathways.	Univ Crete, Sch Med, Heraklion 71409, Crete, Greece; FORTH, IMBB, Heraklion 71409, Crete, Greece; Ctr Univ Orsay, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	University of Crete; Foundation for Research & Technology - Hellas (FORTH); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Mavrothalassitis, G (corresponding author), Univ Crete, Sch Med, Heraklion 71409, Crete, Greece.		GHYSDAEL, Jacques/F-3377-2013					Athanasiou M, 2000, CANCER GENE THER, V7, P1188, DOI 10.1038/sj.cgt.7700220; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carron C, 2000, BLOOD, V95, P3891; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Cowley DO, 2000, GENE DEV, V14, P366; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Dominguez M, 1998, CURR BIOL, V8, P1039, DOI 10.1016/S0960-9822(98)70441-5; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Ghosh A, 1998, CELL, V95, P303, DOI 10.1016/S0092-8674(00)81762-6; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Goldman D, 1998, BIOCHEM J, V335, P267, DOI 10.1042/bj3350267; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guidez F, 2000, BLOOD, V96, P2557; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HALDER G, 1995, CURR OPIN GENET DEV, V5, P602, DOI 10.1016/0959-437X(95)80029-8; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Im YH, 2000, CANCER RES, V60, P1536; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lai ZC, 1997, GENETICS, V147, P1131; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Metcalf D, 1999, ANN NY ACAD SCI, V872, P289, DOI 10.1111/j.1749-6632.1999.tb08473.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Ogawa M, 1999, INT J HEMATOL, V69, P2; OHagan RC, 1996, ONCOGENE, V13, P1323; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; POIREL H, 2000, IN PRESS ONCOGENE; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Price MD, 1999, DEV GENES EVOL, V209, P207, DOI 10.1007/s004270050245; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rebay I, 2000, GENETICS, V154, P695; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RIESGOESCOVAR JR, 1994, J COMP PHYSIOL A, V175, P687; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; Rogge R, 1995, DEVELOPMENT, V121, P3947; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Rossi F, 1996, CURR BIOL, V6, P866, DOI 10.1016/S0960-9822(02)00610-3; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; SCHOLZ H, 1993, GENETICS, V135, P455; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SPYROPOULOS, 2000, ONCOGENE; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Van Buskirk C, 1999, TRENDS CELL BIOL, V9, P1, DOI 10.1016/S0962-8924(98)01413-5; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wasylyk B, 1997, MOL B INT U, P253; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Young MW, 1997, PERSPECT DEV NEUROBI, V4, P345; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	110	106	110	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6524	6532		10.1038/sj.onc.1204045	http://dx.doi.org/10.1038/sj.onc.1204045			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175368				2022-12-28	WOS:000166595000014
J	Kruzelock, RP; Cuevas, BD; Wiener, JR; Xu, FJ; Yu, YH; Cabeza-Arvelaiz, Y; Pershouse, M; Lovell, MM; Killary, AM; Mills, GB; Bast, RC				Kruzelock, RP; Cuevas, BD; Wiener, JR; Xu, FJ; Yu, YH; Cabeza-Arvelaiz, Y; Pershouse, M; Lovell, MM; Killary, AM; Mills, GB; Bast, RC			Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer	ONCOGENE			English	Article						ovarian cancer; human chromosome 22; tumor suppressor genes; microcell-mediated chromosome transfer	NEUROFIBROMATOSIS TYPE-2 GENE; ADENOCARCINOMA CELL-LINES; FREQUENT LOSS; ALLELE LOSS; LONG ARM; SPORADIC MENINGIOMAS; MAMMALIAN-CELLS; LOW-GRADE; NF2 GENE; HETEROZYGOSITY	The identity of many tumor suppressor genes important in epithelial ovarian cancer tumorigenesis remains unknown. In an effort to localize a novel tumor suppressor on chromosome 22, a psv(2)neo tagged human chromosome 22 was transferred into the malignant epithelial ovarian cancer cell line, SKOV-3, by microcell-mediated chromosome transfer. Complete suppression of the transformed phenotype was observed in 16 of 18 individual microcell hybrid clones as evidenced by the complete abrogation of cell growth under anchorage-independent conditions. In vitro doubling times were also dramatically reduced, as was the ability to, form subcutaneous tumors in CD1 nu/nu mice. Only one polymorphic marker, D22S429, segregated with decreased transformation and tumorigenic potential, suggesting that an unrecognized tumor suppressor may localize to chromosome 22q11-q12, These data provide functional support for the presence of a novel tumor suppressor locus (or loci) on chromosome 22 that is important in ovarian cancer tumorigenesis.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Lab Med, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77225 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kruzelock, RP (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.		Yu, Yan/GYV-4514-2022; Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462				AKAGI K, 1995, INT J CANCER, V60, P178, DOI 10.1002/ijc.2910600208; ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P236, DOI 10.1159/000130814; ALLAN GJ, 1994, HUM MUTAT, V3, P283, DOI 10.1002/humu.1380030317; AMFO K, 1995, ONCOGENE, V11, P351; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; Bandera CA, 1997, CANCER RES, V57, P513; BIEGEL JA, 1996, GENE CHROMOSOME CANC, V16, P84; Boente Matthew P., 1993, Current Opinion in Oncology, V5, P900, DOI 10.1097/00001622-199309000-00020; BOLGER GB, 1985, NEW ENGL J MED, V312, P564, DOI 10.1056/NEJM198502283120907; Bryan EJ, 1996, CANCER RES, V56, P719; BUICK RN, 1985, CANCER RES, V45, P3668; BUIJS A, 1995, ONCOGENE, V10, P1511; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CLIBY W, 1993, CANCER RES, V53, P2393; COGEN PH, 1991, CANCER GENET CYTOGEN, V53, P271, DOI 10.1016/0165-4608(91)90104-3; COLLINS JE, 1995, NATURE, V377, P367; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DODSON MK, 1993, CANCER RES, V53, P4456; DRACOPLOI NC, 1997, CURRENT PROTOCOLS HU; DUMANSKI JP, 1990, CANCER RES, V50, P5863; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; ECCLES DM, 1992, DIS MARKERS, V10, P95; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; EHLEN T, 1990, ONCOGENE, V5, P219; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; Gallion HH, 1996, AM J OBSTET GYNECOL, V174, P1102, DOI 10.1016/S0002-9378(96)70651-8; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; IRVING RM, 1993, ARCH OTOLARYNGOL, V119, P1222; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; Kerr J, 1996, ONCOGENE, V13, P1815; KILLARY AM, 1995, METHOD ENZYMOL, V254, P133; KINZLER KW, 1993, NATURE, V363, P495, DOI 10.1038/363495a0; Kruzelock RP, 1997, CANCER RES, V57, P106; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MENDEZ MJ, 1991, GENOMICS, V10, P661, DOI 10.1016/0888-7543(91)90449-O; NG HK, 1995, NEUROSURGERY, V37, P764, DOI 10.1227/00006123-199510000-00022; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAPI L, 1995, HUM GENET, V95, P347, DOI 10.1007/BF00225206; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; RIMESSI P, 1994, ONCOGENE, V9, P3467; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAITO S, 1992, CANCER RES, V52, P5815; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANSON M, 1993, HUM MOL GENET, V2, P1215, DOI 10.1093/hmg/2.8.1215; SATO T, 1991, CANCER RES, V51, P5118; SCHNEIDER G, 1992, HUM GENET, V88, P579, DOI 10.1007/BF00219348; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SHISEKI M, 1994, CANCER RES, V54, P5643; SILVERMAN M, 1997, P AM ASSOC CANC RES, V38, P1018; SMIDT M, 1990, J CLIN INVEST, V86, P1151, DOI 10.1172/JCI114820; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; YANA I, 1995, INT J CANCER, V60, P174, DOI 10.1002/ijc.2910600207; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359	70	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6277	6285		10.1038/sj.onc.1204013	http://dx.doi.org/10.1038/sj.onc.1204013			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175342				2022-12-28	WOS:000166210500011
J	Hutchinson, JN; Muller, WJ				Hutchinson, JN; Muller, WJ			Transgenic mouse models of human breast cancer	ONCOGENE			English	Article						transgenic mice; knockout mice; mammary gland; cancer; oncogenes; tumor suppressors	MAMMARY-TUMOR VIRUS; GROWTH-FACTOR-ALPHA; C-MYC GENE; V-HA-RAS; NEU ONCOGENE; PROVIRAL INSERTION; PROGNOSTIC FACTORS; GLAND DEVELOPMENT; SYNERGISTIC INTERACTION; C-ERBB-2 PROTOONCOGENE	The pathogenesis of human breast cancer is thought to involve multiple genetic events, the majority of which fall into two categories, gain of function mutations in protooncogenes such as c-myc, cyclin D1, ErbB-2 and various growth factors which are involved in supporting cell growth, division and survival, and loss of function mutations in so called 'tumor suppressor' genes, such as p53, which are involved in preventing unrestrained cellular growth. A number of mouse systems exist to address the significance of these mutations in the pathogenesis of breast cancer including transgenic mice expressing high levels of a specific gene in target tissues and knockout mice in which specific genes have been ablated via homologous recombination. More recently, the:combination of these techniques to create bigenics as well as the use of 'knockin' and conditional tissue specific gene targeting strategies have allowed the models more reflective of the human disease to be devised. Studies with these models have not only implicated particular genetic events in the progression of the disease but have emphasized the complex, multi-step nature of breast cancer progression. These models also provide the opportunity to study various aspects of the pathogenesis of this disease, from hormonal effects to responses to chemotherapeutic drugs. It is hoped that through the combined use of these models, and the further development of more relevant models, that a deeper understanding of this disease and the generation of new therapeutic agents will result.	McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Muller, WJ (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.		Hutchinson, John/AAA-1976-2020	Hutchinson, John/0000-0002-7804-7576				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERNS EMJJ, 1992, J STEROID BIOCHEM, V43, P13, DOI 10.1016/0960-0760(92)90182-I; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CARDIFF RD, 1993, CANCER SURV, V16, P97; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Cool M, 1999, CANCER RES, V59, P2438; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; HALTER SA, 1992, AM J PATHOL, V140, P1131; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lamszus K, 1997, LAB INVEST, V76, P339; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LEMOINE NR, 1990, ONCOGENE, V5, P237; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LIDEREAU R, 1988, BIOCHIMIE, V70, P951, DOI 10.1016/0300-9084(88)90237-4; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lydon JP, 1999, CANCER RES, V59, P4276; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; MATSUI Y, 1990, CELL, V61, P1141; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; Ritland SR, 1997, CANCER RES, V57, P3520; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; Tuck AB, 1996, AM J PATHOL, V148, P225; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; XIE YM, 1995, ONCOGENE, V10, P2409; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZOLL B, 1992, J CANCER RES CLIN, V118, P468, DOI 10.1007/BF01629432	94	104	113	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6130	6137		10.1038/sj.onc.1203970	http://dx.doi.org/10.1038/sj.onc.1203970			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156526				2022-12-28	WOS:000166121400006
J	Johnstone, RW; Wei, W; Greenway, A; Trapani, JA				Johnstone, RW; Wei, W; Greenway, A; Trapani, JA			Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16	ONCOGENE			English	Article						transcription; IFI 16; p53; interferon	NUCLEAR DIFFERENTIATION ANTIGEN; TUMOR-SUPPRESSOR P53; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; CELL-PROLIFERATION; PROTEIN P202; INHIBITION; GENE; EXPRESSION; CLUSTER	Interferons are important in regulating cell growth and differentiation, immune function and initiating anti-viral responses. While the pleotrophic actions of interferons have been well documented, the molecular mechanisms underpinning their biological effects have not been fully characterized. IFI 16 is a member of the interferon-inducible HIN-200 family of nuclear proteins, which we have recently shown can function as a potent transcriptional repressor. A murine member of the HIN-200 family, p202, can indirectly interact with p53 via the p53 binding protein (p53bp) and inhibit p53-mediated transcriptional activation. The binding activity of p202 to p53bp was shown to require the conserved MFHATVAT motif present in all 200 amino acid repeat regions of HIN-200 proteins. Given that IFI 16 contains two MFHATVAT motifs, we sought to determine whether IFI 16 may form a complex with p53 and if so to ascertain the functional significance of this interaction. We demonstrate that IFI 16 can directly bind to the C-terminal region of p53 and augment p53-mediated transcriptional activation without altering the steady state levels of p53. Thus, in addition to its ability to directly regulate gene expression, IFI 16 can also modulate the transcription function of other cellular transcription factors. These findings demonstrate a possible link between gene induction following interferon stimulation and p53-mediated cellular events.	Peter MacCallum Canc Inst, Gene Regulat Lab, Canc Immunol Div, Melbourne, Vic 3002, Australia; Macfarlane Burnet Ctr Med Res, Fairfield, Vic 3078, Australia	Peter Maccallum Cancer Center	Johnstone, RW (corresponding author), Peter MacCallum Canc Inst, Gene Regulat Lab, Canc Immunol Div, Smorgon Family Bldg,St Andrews Pl, Melbourne, Vic 3002, Australia.		Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				Arany I, 1996, IN VIVO, V10, P119; BURRUS GR, 1992, J CELL BIOCHEM, V48, P190, DOI 10.1002/jcb.240480210; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DAWSON MJ, 1996, J LEUKOCYTE BIOL, V60, P1; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DUHL DM, 1989, J CELL PHYSIOL, V141, P148, DOI 10.1002/jcp.1041410122; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hobeika AC, 1999, J INTERF CYTOK RES, V19, P1351, DOI 10.1089/107999099312812; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Min W, 1996, MOL CELL BIOL, V16, P359; MIYASHITA T, 1995, CELL, V80, P293; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shaw P, 1996, ONCOGENE, V12, P921; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; WANG ZY, 1993, J BIOL CHEM, V268, P9972; Xie JP, 1998, J CELL BIOCHEM, V70, P489, DOI 10.1002/(SICI)1097-4644(19980915)70:4<489::AID-JCB6>3.0.CO;2-F; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	56	79	85	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6033	6042		10.1038/sj.onc.1204005	http://dx.doi.org/10.1038/sj.onc.1204005			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146555				2022-12-28	WOS:000165827900010
J	Dilworth, FJ; Chambon, P				Dilworth, FJ; Chambon, P			Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription	ONCOGENE			English	Review						nuclear receptors; histone acetyltransferases; ATP-dependent chromatin remodeling coactivators; in vitro transcription; RAR/RXR heterodimers	THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASE; ACTIVATE TRANSCRIPTION; DEPENDENT ACTIVATION; CRYSTAL-STRUCTURE; DNA-BINDING; IN-VITRO	Recent advances in the field of in vitro chromatin assembly have led to in vitro transcription systems which reproduce in the test tube, in vivo characteristics of ligand-dependent transcriptional activation by nuclear receptors. Dissection of these systems has begun to provide us with information concerning the underlying molecular mechanisms. Through recruitment of coactivator proteins, nuclear receptors act first to remodel chromatin within the promoter region and then to recruit the transcriptional machinery to the promoter region in order to initiate transcription. Here we present a possible sequential mechanism for ligand-dependent transcriptional activation by nuclear receptors and discuss the in vitro and in vivo data that support this model.	Coll France, ULP, INSERM, CNRS,IGBMC, F-67404 Illkirch Graffenstaden, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Coll France, ULP, INSERM, CNRS,IGBMC, BP163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.			Dilworth, F. Jeffrey/0000-0002-6265-8102				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; CLEVER U, 1965, CHROMOSOMA, V17, P309, DOI 10.1007/BF00348790; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dilworth FJ, 1999, P NATL ACAD SCI USA, V96, P1995, DOI 10.1073/pnas.96.5.1995; Driscoll MD, 1996, J STEROID BIOCHEM, V58, P45, DOI 10.1016/0960-0760(96)00015-5; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Giguere V, 1990, Genet Eng (N Y), V12, P183; Glass CK, 2000, GENE DEV, V14, P121; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito T, 2000, GENE DEV, V14, P1899; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kal AJ, 2000, GENE DEV, V14, P1058; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Minucci S, 1998, MOL ENDOCRINOL, V12, P315, DOI 10.1210/me.12.3.315; Morales V, 2000, MOL CELL BIOL, V20, P7230, DOI 10.1128/MCB.20.19.7230-7237.2000; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Savoldi G, 1997, DNA CELL BIOL, V16, P1467, DOI 10.1089/dna.1997.16.1467; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THOMPSON EB, 1966, P NATL ACAD SCI USA, V56, P296, DOI 10.1073/pnas.56.1.296; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108	82	203	205	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3047	3054		10.1038/sj.onc.1204329	http://dx.doi.org/10.1038/sj.onc.1204329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420720				2022-12-28	WOS:000169308500008
J	Zhang, HS; Dean, DC				Zhang, HS; Dean, DC			Rb-mediated chromatin structure regulation and transcriptional repression	ONCOGENE			English	Review						chromatin remodeling; cell cycle; Rb	CELL-CYCLE ARREST; HISTONE DEACETYLASE COMPLEX; SWI-SNF COMPLEX; RETINOBLASTOMA PROTEIN; GROWTH ARREST; REMODELING COMPLEX; PRB-FAMILY; S-PHASE; E2F; RECRUITMENT		Washington Univ, Sch Med, Div Mol Oncol, St Louis, MO 63110 USA; Sangamo Biosci Inc, Richmond, CA 94804 USA	Washington University (WUSTL); Sangamo Therapeutics, Inc.	Dean, DC (corresponding author), Washington Univ, Sch Med, Div Mol Oncol, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.							Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Staehling-Hampton K, 1999, GENETICS, V153, P275; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Takahashi Y, 2000, GENE DEV, V14, P804; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong AKC, 2000, CANCER RES, V60, P6171; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	43	80	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3134	3138		10.1038/sj.onc.1204338	http://dx.doi.org/10.1038/sj.onc.1204338			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420730				2022-12-28	WOS:000169308500018
J	Prasher, JM; Elenitoba-Johnson, KSJ; Kelley, LL				Prasher, JM; Elenitoba-Johnson, KSJ; Kelley, LL			Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia	ONCOGENE			English	Article						p53; erythroleukemia; Friend virus	VIRUS-INDUCED ERYTHROLEUKEMIA; MURINE LEUKEMIA-VIRUS; MULV-INDUCED-ERYTHROLEUKEMIAS; TRANSGENIC MICE DEVELOP; ERYTHROPOIETIN RECEPTOR; F-MULV; CELL-DEATH; GENE; GROWTH; ONCOGENE	A role for p53 in the in vivo progression of Friend virus-induced erythroleukemia has been suggested but not clearly defined, We developed a Friend virus-sensitive, p53-deficient mouse model to directly address the role of p53 in Friend erythroleukemia. When infected with the polycythemia-inducing strain of Friend virus (FVP), p53 null mice exhibited accelerated progression to erythroleukemia and accelerated death following diagnosis when compared to wild type mice. Confirmation that p53 mutations were required for disease progression was provided by sequence analysis of p53 transcripts in leukemic wild type and heterozygous mice. All transcripts evaluated had point mutations, deletions or insertions in the p53 gene. The ability to grow tumor colonies in vitro and derive cell lines was enhanced in FVP-infected p53 null animals, Although PU.1 oncogene overexpression is a common mutation observed in cell lines derived from Friend virus-infected p53 wild type mice, it was not a universal finding in cell lines derived from p53 null animals. Our data conclusively demonstrate that loss of p53 function is a requirement for progression of Friend erythroleukemia in vivo. Further, the data demonstrate that erythroleukemias arising in Friend virus-infected p53 null mice are biologically and genetically distinct from those that occur in wild type animals, suggesting that the temporal order of PU.1 and p53 mutations is an important parameter in the pathogenesis of leukemic development. Oncogene (2001) 20, 3946-2955.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Huntsman Canc Inst, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Kelley, LL (corresponding author), Univ Utah, Dept Med, Div Hematol, SOM 4C416, Salt Lake City, UT 84102 USA.	linda.kelley@hsc.utah.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545	NCI NIH HHS [CA83984-01] Funding Source: Medline; NIDDK NIH HHS [P50DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA083984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Koury MJ, 1997, BLOOD, V90, P4054, DOI 10.1182/blood.V90.10.4054; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; MUNROE DG, 1988, ONCOGENE, V2, P621; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SOUSSI T, 2001, ANN NY ACAD SCI, P121; TAMBOURIN PE, 1973, BRIT J HAEMATOL, V24, P511, DOI 10.1111/j.1365-2141.1973.tb01677.x; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2946	2955		10.1038/sj.onc.1204395	http://dx.doi.org/10.1038/sj.onc.1204395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420707				2022-12-28	WOS:000168901800010
J	D'Agnano, I; Valentini, A; Fornari, C; Bucci, B; Starace, G; Felsani, A; Citro, G				D'Agnano, I; Valentini, A; Fornari, C; Bucci, B; Starace, G; Felsani, A; Citro, G			Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels	ONCOGENE			English	Article						c-myc; melanoma; p27; apoptosis	ANTISENSE OLIGODEOXYNUCLEOTIDES ENHANCE; KINASE INHIBITOR P27(KIP1); C-MYC; CYCLE PROGRESSION; GROWTH ARREST; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GENE-EXPRESSION; IN-VITRO; PROTEIN; DEATH	In recent years, increasing evidence indicated the importance of a deregulated c-myc gene in the melanoma pathogenesis, We have previously demonstrated that treatment of melanoma cells with c-myc antisense oligodeoxynucleotides can inhibit cell proliferation and activate apoptosis, To gain insight into the mechanisms activated by Myc down-regulation, we have now developed an experimental model that allows modulating Myc protein expression in melanoma cells. This was achieved by originating stable melanoma cell clones expressing ecdysone-inducible c-myc antisense RNA. We show that the induction of c-myc antisense RNA in M14 melanoma cells leads to an inhibition of cell proliferation characterized by accumulation of cells in the G(1) phase of the cell cycle (up to 80%) and activation of apoptosis (50%), These data are associated with an increase of p27(kipl) levels and a significant reduction of the cdk2-associated kinase activity, In addition, we show that an ectopic overexpression of p27(kiPl) in this experimental model can enhance the apoptotic rate. Our results indicate that down-regulation of Myc protein induces a G(1) arrest and activates apoptosis by increasing p27(kipl) content in melanoma cells, that are known to be defective for the p16-cyclinD/cdk4-pRb G(1) checkpoint. This is particularly relevant for identifying new therapeutic strategies based on the re-establishment of the apoptotic pathways in cancer cells.	CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy; Ist Regina Elena, I-00158 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	D'Agnano, I (corresponding author), CNR, Ist Tecnol Biomed, V Marx 43, I-00137 Rome, Italy.		Felsani, Armando/D-1784-2010; bucci, barbara/K-6694-2012; D'Agnano, Igea/AAR-7282-2020	Felsani, Armando/0000-0001-8851-6295; D'Agnano, Igea/0000-0002-2646-9224				Bartkova J, 1996, CANCER RES, V56, P5475; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Citro G, 1998, CANCER RES, V58, P283; Crooke ST, 1996, ANTISENSE NUCLEIC A, V6, P145, DOI 10.1089/oli.1.1996.6.145; D'Agnano I, 1998, ENVIRON MOL MUTAGEN, V32, P56, DOI 10.1002/(SICI)1098-2280(1998)32:1<56::AID-EM7>3.0.CO;2-9; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Katayose Y, 1997, CANCER RES, V57, P5441; KIMURA S, 1995, CANCER RES, V55, P1379; KRIEG AM, 1995, ANTISENSE RES DEV, V5, P241, DOI 10.1089/ard.1995.5.241; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LESNIKOWSKI ZJ, 1990, NUCLEIC ACIDS RES, V18, P2109, DOI 10.1093/nar/18.8.2109; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Ross DA, 1998, BRIT J SURG, V85, P46; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Schlagbauer-Wadl H, 1999, J INVEST DERMATOL, V112, P332, DOI 10.1046/j.1523-1747.1999.00506.x; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Stein CA, 1998, ANTISENSE NUCLEIC A, V8, P129, DOI 10.1089/oli.1.1998.8.129; Stein CA, 1996, J NATL CANCER I, V88, P391, DOI 10.1093/jnci/88.7.391; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wu M, 1999, J IMMUNOL, V163, P6530	43	47	49	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2814	2825		10.1038/sj.onc.1204392	http://dx.doi.org/10.1038/sj.onc.1204392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420693				2022-12-28	WOS:000168712000009
J	Ludes-Meyers, JH; Liu, YM; Munoz-Medellin, D; Hilsenbeck, SG; Brown, PH				Ludes-Meyers, JH; Liu, YM; Munoz-Medellin, D; Hilsenbeck, SG; Brown, PH			AP-1 blockade inhibits the growth of normal and malignant breast cells	ONCOGENE			English	Article						AP-1; breast cancer; signal transduction; human mammary epithelial cells; carcinogenesis	MAMMARY EPITHELIAL-CELLS; C-JUN; INDUCED TRANSFORMATION; DELETION MUTANT; P53 MUTATIONS; CANCER CELLS; EXPRESSION; LINES; ACTIVATION; INDUCTION	We have previously demonstrated that basal AP-1 transcriptional activity is high in normal human mammary epithelial cells, intermediate in immortal breast cells, and relatively low in breast cancer cells. In this study we investigated whether differences in AP-1 transcriptional activity reflect differences in breast cells' dependence on AP-I for proliferation. The cJun dominant negative, TAM-67, was used to determine the effect of AP-1 blockade on the growth of normal, immortal and malignant breast cells. We first showed that TAM-67 inhibits AP-1 activity in normal and malignant breast cells. We then determined whether this AP-1 inhibitor affected colony forming efficiency of the immortalized and malignant breast cells. The AP-I inhibitor reduced colony formation of immortal breast cells by over 50% (by 58% in 184B5 cells and 62% in MCF10A cells), and reduced colony formation in the breast cancer cell line MCF7 by 43%, but did not reduce colony formation in the other breast cancer cell lines (T47D, MDA MB231 and MDA MB 435), We also determined the effect of AP-1 blockade on the growth of normal breast cells using a single cell proliferation assay. Using this assay, the growth of normal breast cells was extremely sensitive to AP-1 blockade, while immortal breast cells were moderately sensitive. We next directly tested the effect of TAM-67 expression on the growth of MCF7 breast cancer cells, using cells stably transfected with TAM-67 under the control of a doxycycline-inducible promoter. Upon induction, TAM-67 was expressed and AP-1 activity was inhibited in these cells. We then measured the growth of these cells in the presence or absence of TAM-67, The results of these studies show that the growth of MCF7 cells was suppressed by the AP-1 inhibitor, TAM-67. These results demonstrate that normal and immortalized breast cells, and some breast cancer cells (such as MCF7), require AP-1 to transduce proliferative signals, while other breast cancer cells (such as T47D, MDA MB231 and MDA MB 435) do not. These studies suggest that the AP-1 transcription factor is a potential target for future agents for the prevention or treatment of breast cancer.	Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Alkek 570-N,MS 600,1 Baylor Plaza, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NCI NIH HHS [CA70091] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070091] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BERENBLUM I, 1947, BRIT J CANCER, V1, P379, DOI 10.1038/bjc.1947.35; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katayose D, 1995, CLIN CANCER RES, V1, P889; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PETRAK D, 1994, J IMMUNOL, V153, P2046; Smith LM, 1997, CANCER RES, V57, P3046; SOULE HD, 1990, CANCER RES, V50, P6075; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P117; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRIPATHY D, 1993, ACTIVATED ONCOGENES, P15; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZAJCHOWSKI D, 1988, CANCER RES, V48, P7041	32	51	53	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2771	2780		10.1038/sj.onc.1204377	http://dx.doi.org/10.1038/sj.onc.1204377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420689				2022-12-28	WOS:000168712000005
J	Agarwal, ML; Ramana, CV; Hamilton, M; Taylor, WR; DePrimo, SE; Bean, LJH; Agarwal, A; Agarwal, MK; Wolfman, A; Stark, GR				Agarwal, ML; Ramana, CV; Hamilton, M; Taylor, WR; DePrimo, SE; Bean, LJH; Agarwal, A; Agarwal, MK; Wolfman, A; Stark, GR			Regulation of p53 expression by the RAS-MAP kinase pathway	ONCOGENE			English	Article						mutant cells; p53; mRNA levels; p21 expression	TUMOR-SUPPRESSOR P53; ALPHA-INTERFERON; SIGNALING PATHWAY; MAMMALIAN-CELLS; IN-VIVO; PROTEIN; GENE; TRANSFORMATION; SENESCENCE; CASCADE	Activation of MAP kinase leads to the activation of p53-dependent pathways, and vice-versa. Although the amount of p53 protein increases in response to MAP kinase-dependent signaling, the basis of this increase is not yet fully understood. We have isolated the mutant cell line AP14, defective in p53 expression, from human HT1080 fibrosarcoma cells, which have an activated ras allele, The expression of p53 mRNA and protein is similar to 10-fold lower in AP14 cells than in the parental cells. The high constitutive phosphorylation and activities of the MAP kinases ERK1 and ERK2 in HT1080 cells are greatly reduced in AP14 cells, although the levels of these proteins are unchanged, suggesting that the defect in the mutant cells affects the steady-state phosphorylation of ERK1 and ERK2, Overexpression of ERK2 in AP14 cells restored both MAP kinase activity and p53 expression, and incubation of the mutant cells with the phosphatase inhibitor orthovanadate resulted in strong coordinate elevation of MAP kinase activity and p53 expression. The levels of expression of the p53-regulated gene p21 parallel those of p53 throughout, showing that basal p21 expression depends on p53, The levels of p53 mRNA increased by 5-8-fold when activated ras was introduced into wild-type cells, and the levels of the p53 and p21 proteins decreased substantially in wild-type cells treated with the MEK inhibitor U0216, We conclude that MAP kinase-dependent pathways help to regulate p53 levels by regulating the expression of p53 mRNA.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.			chilakamarti, ramana/0000-0002-5153-8252	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Harlow E., 1988, ANTIBODIES LAB MANUA; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; SAMBROOK J, 1989, MOL CLONING, V9, P14; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CANCER RES, V60, P3689; Stark GR, 1999, HUM MOL GENET, V8, P1925, DOI 10.1093/hmg/8.10.1925; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	42	42	43	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2527	2536		10.1038/sj.onc.1204353	http://dx.doi.org/10.1038/sj.onc.1204353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420662				2022-12-28	WOS:000168652500003
J	Macian, F; Lopez-Rodriguez, C; Rao, A				Macian, F; Lopez-Rodriguez, C; Rao, A			Partners in transcription: NFAT and AP-1	ONCOGENE			English	Review						nuclear factor of activated T cells; Fos; Jun; transcriptional regulation	ACTIVATED T-CELLS; FAS LIGAND EXPRESSION; DNA-BINDING ACTIVITY; KINASE C-THETA; NUCLEAR FACTOR; GENE-EXPRESSION; PHOSPHATASE CALCINEURIN; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; IL-2 PROMOTER	Combinatorial regulation is a powerful mechanism that enables tight control of gene expression, via integration of multiple signaling pathways that induce different transcription factors required for enhanceosome assembly. The four calcium-regulated transcription factors of the NFAT family act synergistically with AP-1 (Fos/Jun) proteins on composite DNA elements which contain adjacent NFAT and AP-1 binding sites, where they form highly stable ternary complexes to regulate the expression of diverse inducible genes. Concomitant induction of NFAT and AP-1 requires concerted activation of two different signaling pathways: calcium/calcineurin, which promotes NFAT dephosphorylation, nuclear translocation and activation; and protein kinase C (PKC)/Ras, which promotes the synthesis, phosphorylation and activation of members of the Fos and Jun families of transcription factors. A fifth member of the NFAT family, NFAT5, controls the cellular response to osmotic stress, by a mechanism that requires dimer formation and is independent of calcineurin or of interaction with AP-1. Pharmacological interference with the NFAT:AP-1 interaction may be useful in selective manipulation of the immune response. Balanced activation of NFAT and AP-1 is known to be required for productive immune responses, but the role of NFAT:AP-1 interactions in other cell types and biological processes remains to be understood.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Rao, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Lopez-Rodriguez, C/G-4482-2014	Lopez-Rodriguez, C/0000-0002-2311-2406; Macian, Fernando/0000-0003-2666-035X	NCI NIH HHS [CA42471] Funding Source: Medline; NIAID NIH HHS [AI40127] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042471, R37CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040127] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Avni O, 2000, CURR OPIN IMMUNOL, V12, P654, DOI 10.1016/S0952-7915(00)00158-8; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bert AG, 2000, J IMMUNOL, V165, P5646, DOI 10.4049/jimmunol.165.10.5646; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Burke TF, 2000, BIOCHEM BIOPH RES CO, V270, P1016, DOI 10.1006/bbrc.2000.2508; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; Cockerill PN, 1999, P NATL ACAD SCI USA, V96, P15097, DOI 10.1073/pnas.96.26.15097; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; Diebold RJ, 1998, P NATL ACAD SCI USA, V95, P7915, DOI 10.1073/pnas.95.14.7915; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Feske S, 2000, IMMUNOBIOLOGY, V202, P134, DOI 10.1016/S0171-2985(00)80060-1; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; FISCHER MB, 1994, BLOOD, V84, P4234, DOI 10.1182/blood.V84.12.4234.bloodjournal84124234; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; Garcia-Rodriguez C, 2000, EUR J IMMUNOL, V30, P2432, DOI 10.1002/1521-4141(2000)30:8<2432::AID-IMMU2432>3.0.CO;2-F; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Hayden-Martinez K, 2000, J IMMUNOL, V165, P3713, DOI 10.4049/jimmunol.165.7.3713; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Iacobelli M, 2000, J IMMUNOL, V165, P860, DOI 10.4049/jimmunol.165.2.860; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu J, 1999, J IMMUNOL, V162, P4755; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lopez P, 1999, BIOORGAN MED CHEM, V7, P517, DOI 10.1016/S0968-0896(98)00273-9; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Noel PJ, 1998, CELL IMMUNOL, V187, P131, DOI 10.1006/cimm.1998.1332; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; Norian LA, 2000, J IMMUNOL, V164, P4471, DOI 10.4049/jimmunol.164.9.4471; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Pan S, 2000, BIOCHEM BIOPH RES CO, V272, P765, DOI 10.1006/bbrc.2000.2831; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Samoilova EB, 1997, INT IMMUNOL, V9, P1663, DOI 10.1093/intimm/9.11.1663; Schuh K, 1998, J EXP MED, V188, P1369, DOI 10.1084/jem.188.7.1369; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takemoto N, 1997, INT IMMUNOL, V9, P1329, DOI 10.1093/intimm/9.9.1329; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Villalba M, 1999, J IMMUNOL, V163, P5813; Wenner CA, 1997, J IMMUNOL, V158, P765; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	112	574	603	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2476	2489		10.1038/sj.onc.1204386	http://dx.doi.org/10.1038/sj.onc.1204386			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402342				2022-12-28	WOS:000168568700013
J	Jiang, YX; Cui, L; Yie, TA; Rom, WN; Cheng, H; Tchou-Wong, KM				Jiang, YX; Cui, L; Yie, TA; Rom, WN; Cheng, H; Tchou-Wong, KM			Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by I kappa B beta	ONCOGENE			English	Article						I kappa B beta; anchorage-independent; growth in low serum; apoptosis; metastasis	TRANSCRIPTION FACTOR; CANCER CELLS; TUMOR-GROWTH; ACTIVATION; ALPHA; TUMORIGENICITY; EXPRESSION; APOPTOSIS; RAS; TRANSFORMATION	To evaluate the role of the NF-kappaB signaling pathway in oncogenic transformation, we expressed I kappaB beta, a specific inhibitor of NF-kappaB, in two human lung adenocarcinoma cell lines, A549 and H441, Expression of I kappaB beta significantly reduced NF-kappaB activation induced by cotransfection with p65/RelA or TNF-alpha and abrogated the basal NF-kappaB activity in A549 cells. Transfection of I kappaB beta into A549, H441 and K-uas-transformed NIH3T3 cells suppressed anchorage-independent growth as measured by colony formation in soft agar, Anchorage-independent growth of vector-transfected A549 cells in reduced serum could be enhanced by both EGF and IGF-I. In contrast, only EGF but not IGF-I could induce anchorage-independent growth of I kappaB beta -expressing A549 cells, suggesting that the IGF-I signaling pathway regulating growth and survival may be blocked by I kappaB beta. Interestingly, expression of I kappaB beta suppressed growth of A549 cells in low serum in vitro without affecting in vivo growth subcutaneously in nude mice, However, metastatic growth of I kappaB beta -expressing A549 cells in the lungs of nude mice was significantly inhibited, These results provide evidence that NF kappaB plays an important role in anchorage-independent growth and metastatic growth of lung carcinoma cells.	NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Environm Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Tchou-Wong, KM (corresponding author), NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, 550 1st Ave,MSB 147, New York, NY 10016 USA.			Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832, R01HL062055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009161] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62055, R01 HL59832] Funding Source: Medline; NIEHS NIH HHS [R01 ES09161] Funding Source: Medline; PHS HHS [M0100096 GCRC] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Batra RK, 1999, AM J RESP CELL MOL, V21, P238, DOI 10.1165/ajrcmb.21.2.3470; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Bost F, 1999, MOL CELL BIOL, V19, P1938; DODSON MG, 1981, CANCER RES, V41, P1441; Duffey DC, 1999, CANCER RES, V59, P3468; Feig BW, 1999, SURGERY, V126, P399, DOI 10.1067/msy.1999.98787; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Foo SY, 1999, TRENDS GENET, V15, P229; HASTINGS RJ, 1981, INT J CANCER, V27, P15, DOI 10.1002/ijc.2910270104; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; OVADIA H, 1975, EUR J CANCER, V11, P413, DOI 10.1016/0014-2964(75)90072-9; Piette J, 1997, BIOL CHEM, V378, P1237; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharma HW, 1996, ANTICANCER RES, V16, P589; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEGFRIED JM, 1987, CANCER RES, V47, P2903; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	35	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2254	2263		10.1038/sj.onc.1204293	http://dx.doi.org/10.1038/sj.onc.1204293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402320				2022-12-28	WOS:000168404500007
J	Lin, F; Monaco, G; Sun, T; Liu, JX; Lin, H; Stephens, C; Belmont, J; Arlinghaus, RB				Lin, F; Monaco, G; Sun, T; Liu, JX; Lin, H; Stephens, C; Belmont, J; Arlinghaus, RB			BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model	ONCOGENE			English	Article						Bcr; Bcr-Abl; chronic myelogenous leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; 1ST EXON; P160 BCR; IN-VIVO; C-ABL; MICE; SEQUENCES; ONCOGENE	It is well accepted that the Bcr-Abl oncoprotein encoded by the Philadelphia chromosome is responsible for causing chronic myelogenous leukemia (CML), We have previously demonstrated that expression of Bcr interferes with the oncogenic effects of Bcr-Abl, To examine the effects of increased Bcr expression on Bcr-Abl oncogenic effects in a more physiological system, we tested the leukemogenic potential of a clone of K562 cells (K6 K562) containing an inducible BCR gene in NOD/scid mice. In this clone, the BCR gene was placed under the control of a tetracycline (Tet) repression system with a cytomegalovirus (CMV) promoter. Induction of exogenous Bcr protein by removal of Tet from the culture medium caused a dramatic increase in Bcr serine kinase activity, yielding predominantly phosphoserine Bcr, despite the presence of Bcr-Abl in the kinase reaction mixture. Prior to induction, the endogenous Bcr was predominantly in the phosphotyrosine form because of phosphorylation by Bcr-Abl, which we previously have shown suppresses Bcr serine/threonine kinase activity, Injection of K6 K562 cells into NOD/scid mice under conditions where BCR expression was suppressed resulted in death or terminal illness in 100% of the mice within 35 days after injection. These mice had a severe wasting syndrome characterized by atrophy of bone marrow hematopoiesis, and/or neoplasia of liver, bone marrow and spleen. Neoplastic spleens from these mice usually contained b3a2 Bcr-Abl transcripts. In contrast, induction of BCR expression at the time of injection allowed 80% survival; these healthy mice had no detectable microscopic lesions in blood forming organs. This difference in survival was significant with P<0.0001, Of interest, mire that were fed Tet for 19 days to initiate the disease syndrome and then released from the BCR transcriptional block had a significantly better survival pattern than mice exposed to Tet throughout the entire period. Moreover, 30% of these mice (three mice) survived through day 50, We conclude from these findings that BCR gene expression strongly inhibits the oncogenic effects of Bcr-Abl in NOD/scid mice, yielding healthy mice in most cases.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.		Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019	Belmont, John W/0000-0001-7409-3578	NCI NIH HHS [CA49639] Funding Source: Medline; PHS HHS [A16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CAMPBELL ML, 1990, ONCOGENE, V5, P773; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dazzi F, 1998, BLOOD, V92, P1390, DOI 10.1182/blood.V92.4.1390.416k09_1390_1396; DAZZI F, 1997, BLOOD S1, V90, P8; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hawk N., 1997, Blood, V90, p277B; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HU AZX, 1997, CANCER RES, V57, P3339; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; LI WJ, 1989, ONCOGENE, V4, P127; Lin F, 1996, BLOOD, V87, P4473, DOI 10.1182/blood.V87.10.4473.bloodjournal87104473; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524	26	24	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1873	1881		10.1038/sj.onc.1204409	http://dx.doi.org/10.1038/sj.onc.1204409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313935				2022-12-28	WOS:000167908400008
J	Michael, D; Rajewsky, MF				Michael, D; Rajewsky, MF			Induction of the common fragile site FRA3B does not affect FHIT expression	ONCOGENE			English	Article						FHIT gene; FRA3B; fragile sites; human chromosome 3	CANCER; GENE; TUMORIGENICITY; PROTEIN; CELLS; REPLICATION; 3P14.2; P53	A long-standing issue concerns the extent to which fragile sites predispose to cancer-associated chromosomal rearrangements. The FHIT gene at chromosome 3p14.2 spans the most common fragile site, FRA3B, in the human genome. Although the FHIT gene is altered in many human cancers, its status as a tumor suppressor gene has remained controversial, particularly since functional studies provided contradictory results. It had been suggested the FHIT alterations result from FRA3B induction promoted by the interference of carcinogens with DNA replication. Here we investigated the effect of FRA3B induction on FHIT expression. Common fragile sites were induced by treatment with aphidicolin and scored cytogenetically, FHIT transcription was analysed by RT-PCR and RNase protection analysis. Unexpectedly, FHIT transcription proceeded unchanged after fragile site induction. Aberrant FHIT transcripts lacking one or more exons were not observed. Morevover, Western blots revealed that the levels of FHIT prior to and following fragile site induction was unchanged, whereas p53 was found at elevated levels after induction. FRA3B induction thus has no direct effect on FHIT transcription and translation.	Univ Essen, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Univ Essen, Sch Med, Dept Internal Med Canc Res, D-45122 Essen, Germany; W German Canc Ctr, D-45122 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Michael, D (corresponding author), Univ Essen, Sch Med, Inst Cell Biol Canc Res, Hufeland Str 55, D-45122 Essen, Germany.							Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; GILMANN M, 1993, CURRENT PROTOCOLS MO; GLOVER TW, 1987, AM J HUM GENET, V41, P882; Gustashaw KM., 1991, ACT CYTOGENETICS LAB, V2; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; MOSNER J, 1994, ONCOGENE, V9, P3321; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Thiagalingam S, 1996, CANCER RES, V56, P2936; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; WENGER SL, 1987, AM J MED GENET, V26, P909, DOI 10.1002/ajmg.1320260419; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	24	6	6	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1798	1801		10.1038/sj.onc.1204243	http://dx.doi.org/10.1038/sj.onc.1204243			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313927				2022-12-28	WOS:000167750900013
J	Heasley, LE				Heasley, LE			Autocrine and paracrine signaling through neuropeptide receptors in human cancer	ONCOGENE			English	Review						neuropeptides; autocrine; paracrine; cancer cells; G proteins; receptors	CELL LUNG-CANCER; GASTRIN-RELEASING PEPTIDE; ELEVATES CYTOSOLIC CALCIUM; ACTIVATED PROTEIN-KINASE; GTPASE-DEFICIENT G-ALPHA(16); BOMBESIN-LIKE PEPTIDES; STRESS FIBER FORMATION; HUMAN PROSTATE-CANCER; PHOSPHOLIPASE C-BETA; MULTIPLE NEUROPEPTIDES	Autocrine and paracrine signaling leading to stimulation of tumor cell growth is a common theme in human cancers. In addition to polypeptide growth factors such as EGF family members which signal through receptor tyrosine kinases, accumulating evidence supports the autocrine and paracrine involvement of specific neuropeptides with defined physiologic actions as neurotransmitters and gut hormones in lung, gastric, colorectal, pancreatic and prostatic cancers. These neuropeptides, including gastrin-releasing peptide, neuromedin B, neurotensin, gastrin, cholecystokinin and arginine vasopressin bind seven transmembrane-spanning receptors that couple to heterotrimeric G proteins. Studies with human small cell lung cancer (SCLC) cells support a requirement for balanced signaling through G(q) and G(12/13) proteins leading to intracellular Ca2+ mobilization, PKC activation and regulation of the ERK and JNK MAP kinase pathways. While specific neuropeptide antagonists offer promise for interrupting the single neuropeptide autocrine systems operating in pancreatic and prostatic cancers, SCLC is exemplified by multiple, redundant neuropeptide autocrine systems such that tumor growth cannot be inhibited with a single specific antagonist. However, a novel class of neuropeptide derivatives based on the substance P sequence have been defined that exhibit broad specificity for neuropeptide receptors and induce apoptosis in SCLC by functioning as biased agonists that stimulate discordant signal transduction, Thus, interruption of autocrine and paracrine neuropeptide signaling with specific antagonists or broad-spectrum biased agonists offer promising new therapeutic approaches to the treatment of human cancers.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Heasley, LE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Med, C-281,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NCI NIH HHS [CA58157] Funding Source: Medline; NIDDK NIH HHS [DK19928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1998, PROSTATE, P52; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bartholdi MF, 1998, INT J CANCER, V79, P82, DOI 10.1002/(SICI)1097-0215(19980220)79:1<82::AID-IJC16>3.0.CO;2-J; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; Beekman A, 1998, CANCER RES, V58, P910; BLACKMORE M, 1992, BRIT J CANCER, V66, P32, DOI 10.1038/bjc.1992.212; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUNN PA, 1992, CANCER RES, V52, P24; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; CARDONA C, 1991, CANCER RES, V51, P5205; Chatzistamou I, 2000, BRIT J CANCER, V83, P906, DOI 10.1054/bjoc.2000.1374; Chave HS, 2000, BRIT J CANCER, V82, P124; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; Coulson JM, 1999, BRIT J CANCER, V80, P1935, DOI 10.1038/sj.bjc.6690623; Coulson JM, 1999, CANCER RES, V59, P5123; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS TP, 1991, PEPTIDES, V12, P17, DOI 10.1016/0196-9781(91)90160-Q; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; EVERARD MJ, 1993, EUR J CANCER, V29A, P1450, DOI 10.1016/0959-8049(93)90019-C; FATHI Z, 1993, J BIOL CHEM, V268, P5979; Fruhwald MC, 1998, ANN NY ACAD SCI, V865, P420, DOI 10.1111/j.1749-6632.1998.tb11208.x; GEIJER T, 1990, FEBS LETT, V270, P30, DOI 10.1016/0014-5793(90)81227-F; Goetze JP, 2000, CANCER, V88, P2487, DOI 10.1002/1097-0142(20000601)88:11<2487::AID-CNCR9>3.0.CO;2-E; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; GROSS AJ, 1993, CANCER RES, V53, P67; HAMILTON BP, 1972, J CLIN ENDOCR METAB, V35, P764, DOI 10.1210/jcem-35-5-764; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; HONG M, 1991, PEPTIDES, V12, P1315, DOI 10.1016/0196-9781(91)90213-9; IVELL R, 1983, NEUROENDOCRINOLOGY, V37, P235, DOI 10.1159/000123549; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LANGDON S, 1992, CANCER RES, V52, P4554; Lawlor ER, 1998, CANCER RES, V58, P2469; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; MAHMOUD S, 1991, CANCER RES, V51, P1798; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MARKOWITZ S, 1988, J CLIN INVEST, V82, P808, DOI 10.1172/JCI113683; Markwalder R, 1999, CANCER RES, V59, P1152; MILLER YE, 1989, AM REV RESPIR DIS, V140, P283, DOI 10.1164/ajrccm/140.2.283; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MOODY TW, 1992, J PHARMACOL EXP THER, V263, P311; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOODY TW, 1985, LIFE SCI, V36, P1727, DOI 10.1016/0024-3205(85)90555-7; NAGALLA SR, 1994, CANCER RES, V54, P4461; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nelson JB, 2000, CANCER INVEST, V18, P87, DOI 10.3109/07357900009023066; Nemenoff Raphael A., 1998, Frontiers in Bioscience, V3, pD194; North WG, 1998, CANCER RES, V58, P1866; NORTH WG, 1991, J CLIN ENDOCR METAB, V73, P1316, DOI 10.1210/jcem-73-6-1316; Nyeki O, 1998, J PEPT SCI, V4, P486, DOI 10.1002/(SICI)1099-1387(199812)4:8<486::AID-PSC168>3.3.CO;2-E; Ohki-Hamazaki H, 2000, PROG NEUROBIOL, V62, P297, DOI 10.1016/S0301-0082(00)00004-6; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Paolucci L, 1999, CANCER RES, V59, P572; PICON A, 1995, J MOL ENDOCRINOL, V15, P187, DOI 10.1677/jme.0.0150187; Quick MW, 1996, J BIOL CHEM, V271, P32021, DOI 10.1074/jbc.271.50.32021; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; Reubi JC, 1997, CANCER RES, V57, P1377; Rosati R, 1998, PEPTIDES, V19, P1519, DOI 10.1016/S0196-9781(98)00116-8; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Seckl MJ, 1997, CANCER RES, V57, P51; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; SETHI T, 1992, CANCER RES, V52, P6031; SETHI T, 1993, CANCER RES, V53, P5208; Seufferlein T, 1996, CANCER RES, V56, P5758; Smith JP, 1996, AM J PHYSIOL-REG I, V270, pR1078, DOI 10.1152/ajpregu.1996.270.5.R1078; SMITH JP, 1994, AM J PHYSIOL, V266, pR277, DOI 10.1152/ajpregu.1994.266.1.R277; STALEY J, 1989, BIOCHEM BIOPH RES CO, V163, P605, DOI 10.1016/0006-291X(89)92180-3; STALEY J, 1990, PEPTIDES, V11, P1033, DOI 10.1016/0196-9781(90)90029-5; Strassheim D, 2000, CANCER RES, V60, P2730; Sun BD, 2000, REGUL PEPTIDES, V90, P77, DOI 10.1016/S0167-0115(00)00114-2; Sun BD, 2000, PROSTATE, V42, P295; SUNDLER F, 1991, ACTA ONCOL, V30, P419, DOI 10.3109/02841869109092396; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; ToiScott M, 1996, LUNG CANCER-J IASLC, V15, P341, DOI 10.1016/0169-5002(95)00597-8; VARAPRASAD MVV, 1995, J BIOL CHEM, V270, P18655; VERBEECK MAE, 1992, PATHOBIOLOGY, V60, P136, DOI 10.1159/000163712; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WATANAPA P, 1993, BRIT J CANCER, V67, P877, DOI 10.1038/bjc.1993.165; Weinberg DS, 1997, J CLIN INVEST, V100, P597, DOI 10.1172/JCI119570; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777; WOLL PJ, 1989, BIOCHEM BIOPH RES CO, V164, P66, DOI 10.1016/0006-291X(89)91683-5; WOLL PJ, 1990, CANCER RES, V50, P3968; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	101	172	181	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1563	1569		10.1038/sj.onc.1204183	http://dx.doi.org/10.1038/sj.onc.1204183			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313903				2022-12-28	WOS:000168089800006
J	Park, SH; Kim, YS; Park, BK; Hougaard, S; Kim, SJ				Park, SH; Kim, YS; Park, BK; Hougaard, S; Kim, SJ			Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TCF-beta type II receptor expression	ONCOGENE			English	Article						TGF-beta type II receptor; ets transcription factor; promoter; enhancer; gastric cancer	GROWTH-FACTOR-BETA; ETS TRANSCRIPTION FACTOR; TGF-BETA; MICROSATELLITE INSTABILITY; GENOMIC ORGANIZATION; FAMILY; MEMBER; INACTIVATION; REPRESSION; RESISTANCE	Transcriptional repression of the TGF-beta type II receptor (RII) is one of the mechanisms leading to TGF-beta resistance. The newly identified epithelium-specific ets transcription factor ERT/ESX/ELF-3/ESE-1/jen binds to the TGF-beta RII promoter and induces promoter activity. The human gastric cancer cell lines, which show undetectable level of TGF-beta RII mRNA, do not express ERT mRNA, To study the molecular mechanisms of loss of ERT expression, we have cloned and characterized the human ERT promoter, DNA transfection experiments and electrophoretic mobility shift assays have revealed the existence of a distinct enhancer element (-186 to -177) which we named ESE ((E) under bar RT promoter Specific element). Deletion of the ESE markedly decreased expression of the target gene. ESE interacts with two distinct nuclear protein complexes, at least one of which appears to be inactivated in a cell line which does not express the ERT mRNA, compared to a cell line expressing the ERT mRNA, These results suggest the possibility that inactivation of the sequence-specific DNA binding protein to the region from -186 to -177 contributes to the loss of ERT expression, leading to the loss of TGF-beta type II receptor mRNA in human gastric cancer cell lines.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Gyeongsang Natl Univ, Coll Med, Dept Pediat, Chinju 660702, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gyeongsang National University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.							Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Horie K, 1998, J CELL PHYSIOL, V175, P305, DOI 10.1002/(SICI)1097-4652(199806)175:3<305::AID-JCP8>3.0.CO;2-S; Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161; KADIN M, 1994, P NATL ACAD SCI USA, V9, P6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim DH, 1997, J BIOL CHEM, V272, P688; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MYEROFF LL, 1995, CANCER RES, V55, P5545; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Reiss M, 1997, ONCOL RES, V9, P447; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535	32	17	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1235	1245		10.1038/sj.onc.1204227	http://dx.doi.org/10.1038/sj.onc.1204227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313868				2022-12-28	WOS:000167570100011
J	Baker, SJ; Sumerson, R; Reddy, CD; Berrebi, AS; Flynn, DC; Reddy, EP				Baker, SJ; Sumerson, R; Reddy, CD; Berrebi, AS; Flynn, DC; Reddy, EP			Characterization of an alternatively spliced AATYK mRNA: Expression pattern of AATYK in the brain and neuronal cells	ONCOGENE			English	Article						AATYK; alternative splicing; brain; neuron; differentiation; P19 cells	APOPTOSIS; KINASE; DEATH; ORGANIZATION; PROTEINS; GROWTH; SYSTEM	The AATYK gene encodes a tyrosine kinase whose expression is up-regulated during the apoptosis and differentiation of 32Dcl3 myelobalstic cells. Because high levels of AATYK mRNA have also been detected in the brain, and because these transcripts differ in size from that observed in the 32Dcl3 cell line, it was of interest to determine whether this gene encodes mRNAs that are alternatively spliced and whether these mRNAs are expressed in a tissue-specific manner. We have isolated a novel, alternatively spliced AATYK mRNA using cDNA library screening and RT-PCR, whose expression is readily detected in the brain but not myeloid cells. Western blot analysis revealed that the AATYK protein was expressed in virtually all regions of the adult rat brain in which neurons are present, including olfactory bulb, forebrain, cortex, midbrain, cerebellum and pens. Immunohistochemical labeling of adult brain sections showed the highest levels of AATYK expression in the cerebellum and olfactory bulb. Expression of AATYK was also up-regulated as a function of RA-induced neuronal differentiation of p19 embryonal carcinoma cells, supporting a role for this protein in mature neurons and neuronal differentiation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurooncol, Philadelphia, PA 19104 USA; W Virginia Univ, Sch Med, Dept Otolaryngol, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Anat Head & Neck Surg, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; West Virginia University; West Virginia University; West Virginia University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09225] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTMAN J, 1975, J COMP NEUROL, V163, P427, DOI 10.1002/cne.901630404; Berrebi AS, 1998, NEUROSCIENCE, V83, P535, DOI 10.1016/S0306-4522(97)00407-7; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; Palay S. L., 1974, CEREBELLAR CORTEX CY; Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6	14	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1015	1021		10.1038/sj.onc.1204209	http://dx.doi.org/10.1038/sj.onc.1204209			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314039				2022-12-28	WOS:000167232100001
J	Fulda, S; Meyer, E; Friesen, C; Susin, SA; Kroemer, G; Debatin, KM				Fulda, S; Meyer, E; Friesen, C; Susin, SA; Kroemer, G; Debatin, KM			Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis	ONCOGENE			English	Article						apoptosis; drugs; mitochondria; CD95; caspases	CYTOCHROME-C RELEASE; RADIATION-INDUCED APOPTOSIS; CD95 APO-1/FAS SYSTEM; SIGNALING COMPLEX; ANTICANCER DRUGS; ACTIVATION; LIGAND; FAS; INDUCTION; BCL-2	Apoptosis in response to cellular stress such as treatment with cytotoxic drugs is mediated by effector caspases (caspase-3) which can be activated by different initiator pathways, Here, we report on a cell type specific triggering of death receptor and/or mitochondrial pathways upon drug treatment. In type I cells (BJAB), both the receptor and the mitochondrial pathway were activated upon drug treatment, since blockade of either the receptor pathway by overexpression of dominant negative FADD (FADD-DN) or of the mitochondrial pathway by overexpression of Bcl-X-L only partially inhibited apoptosis, Drug treatment induced formation of a FADD- and caspase-8-containing CD95 death-inducing signaling complex (DISC) in type I cells resulting in activation of caspase-8 as the most apical caspase. Tn contrast, in type II cells (Jurkat), apoptosis was predominantly controlled by mitochondria, since overexpression of Bcl-2 completely blocked drug-induced apoptosis, while overexpression of FADD-DN had no protective effect. In these cells, caspases including caspase-8 were activated by mitochondria-driven signaling events and no DISC was detected despite expression levels of CD95, FADD and caspase-8 proteins comparable to type I cells. Likewise, drug-induced CD95 aggregation was predominantly found in type I cells. Bid was cleaved prior to mitochondrial alterations in type I cells providing a molecular link between caspase-8 activation and mitochondrial perturbations, whereas in type. TT cells, Bid was cleaved downstream of mitochondria, Our findings of a cell type specific response to cytotoxic drugs have implications for the identification of molecular parameters for chemosensitivity or resistance in different tumor cells.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France	Ulm University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Debatin, Klaus-Michael/J-9704-2014; Susin, Santos A/Q-6754-2017; Fulda, Simone/D-5864-2011	KROEMER, Guido/0000-0002-9334-4405; Debatin, Klaus-Michael/0000-0002-8397-1886; Susin, Santos A/0000-0002-3366-1628; Fulda, Simone/0000-0002-0459-6417				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Caricchio R, 1998, J IMMUNOL, V161, P241; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1999, CELL DEATH DIFFER, V6, P471, DOI 10.1038/sj.cdd.4400512; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ibrado AM, 1996, CANCER RES, V56, P4743; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McGahon AJ, 1998, BRIT J HAEMATOL, V101, P539, DOI 10.1046/j.1365-2141.1998.00745.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	64	185	194	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1063	1075		10.1038/sj.onc.1204141	http://dx.doi.org/10.1038/sj.onc.1204141			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314043				2022-12-28	WOS:000167232100006
J	Tomomura, M; Fernandez-Gonzales, A; Yano, R; Yuzaki, M				Tomomura, M; Fernandez-Gonzales, A; Yano, R; Yuzaki, M			Characterization of the apoptosis-associated tyrosine kinase (AATYK) expressed in the CNS	ONCOGENE			English	Article						apoptosis; tyrosine kinase; phosphorylation; brain; cerebellum; Purkinje cells	CEREBELLAR GRANULE NEURONS; CELL-DEATH; C-JUN; PURKINJE-CELLS; MESSENGER-RNA; GROWTH-FACTOR; SURVIVAL; PROTEIN; DEPOLARIZATION; ACTIVATION	We isolated three related cDNA clones from a mouse cerebellar library; the type I cDNA was identical to the gene encoding the apoptosis-associated tyrosine kinase (AATYK), whose expression in myeloid precursor cells is increased during growth arrest or apoptosis, Low levels of AATYK mRNA expression mere seen in adult mouse brains but not in embryos. In situ hybridization confirmed the widespread expression of AATYK mRNA in neurons throughout the adult brain. AATYK possessed tyrosine kinase activity and was autophosphorylated when expressed in 293 cells. AATYK mRNA expression was rapidly induced in cultured cerebellar granule cells during apoptosis induced by a low concentration of KCl (5 mid). Levels of endogenous AATYK protein were increased only slightly, but they were accompanied by an increase in molecular weight during apoptosis, Results of the tyrosine phosphatase treatments indicated that the increase in molecular weight was partly caused by tyrosine phosphorylation, The number of apoptotic granule cells overexpressing mild-type AATYK protein was significantly greater than the number of apoptotic granule cells overexpressing a mutant AATYK that lacked tyrosine kinase activity in low concentrations of RCl. These findings suggest that through its tyrosine kinase activity, AATYK is involved in the apoptosis of mature neurons.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; RIKEN, Brain Sci Inst, Lab Cellular Informat Proc, Wako, Saitama 35101, Japan	St Jude Children's Research Hospital; RIKEN	Yuzaki, M (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Yuzaki, Michisuke/K-5328-2013	Yuzaki, Michisuke/0000-0002-5750-3544	NCI NIH HHS [CA21765] Funding Source: Medline; NINDS NIH HHS [NS36925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; BORASIO GD, 1989, NEURON, V2, P1087; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Damgaard I, 1996, NEUROCHEM RES, V21, P267, DOI 10.1007/BF02529144; DRISCOLL BF, 1991, J NEUROCHEM, V56, P1201, DOI 10.1111/j.1471-4159.1991.tb11411.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eilers A, 1998, J NEUROSCI, V18, P1713; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLO V, 1987, J NEUROSCI, V7, P2203; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Gilmore EC, 2000, TRENDS NEUROSCI, V23, P100, DOI 10.1016/S0166-2236(99)01503-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Kurschner C, 1999, J NEUROSCI, V19, P7770; LI Y, 1995, STROKE, V26, P1252, DOI 10.1161/01.STR.26.7.1252; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; Miller TM, 1996, J NEUROSCI, V16, P7487; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P543; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Watson A, 1998, J NEUROSCI, V18, P751; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; YUZAKI M, 1992, J NEUROSCI, V12, P4253; Yuzaki M, 1996, J NEUROSCI, V16, P4651; YUZAKI M, 1994, LEARN MEMORY, V1, P230	44	34	36	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1022	1032		10.1038/sj.onc.1204210	http://dx.doi.org/10.1038/sj.onc.1204210			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314040				2022-12-28	WOS:000167232100002
J	Zvara, A; Fajardo, JE; Escalante, M; Cotton, G; Muir, T; Kirsch, KH; Birge, RB				Zvara, A; Fajardo, JE; Escalante, M; Cotton, G; Muir, T; Kirsch, KH; Birge, RB			Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II	ONCOGENE			English	Article						Crk; adaptor proteins; SH3 linker region; C-terminal SH3 domain; tyrosine phosphorylation; focal adhesion kinase	MEDIATED CELL-ADHESION; TYROSINE-PHOSPHORYLATION; ADAPTER PROTEIN; SH3 DOMAIN; PTP-PEST; V-CRK; SRC; P130(CAS); SUBSTRATE; RAS	The Crk II adaptor protein encodes an SH2/SH3-domain containing adaptor protein with an SH2-SH3-SH3 domain structure that transmits signals from tyrosine kinases, The two SH3 domains are separated by a 54 amino acid linker region, whose length is highly conserved in xenopus, chicken, and mamalian Crk II proteins. To gain a better understanding into the role of the C-terminal region of Crk, we generated a series of C-terminal SH3 domain and SH3 linker mutants and examined their role in tyrosine kinase pathways. Expression of point mutations in the C-terminal SH3 domain (W276K Crk), at the tyrosine phosphorylation site (Y222F Crk II), or truncation of the entire C-terminus (Crk I or Crk Delta 242), all increased c-Abl binding to the N-terminal SH3 domain of Crk and, where relevant, increased Tyr(222) phosphorylation, Deletion analysis of c-Crk II also revealed the presence of a C-terminal segment important for transactivation of FAK. Such mutants, Crk Delta 255 or Crk Delta 242 Extended Linker (Crk Delta 242([EL])), characterized by a disruption in the SH3 linker/C-terminal SH3 boundary, induced robust hyperphosphorylation of focal adhesion kinase (FAK) on Tyr(397), hyperphosphorylation of focal adhesion proteins p130(cas) and paxillin and increased focal adhesion formation in NIH3T3 cells. The effects of Crk Delta 242([EL]) could be abrogated by co-expression of dominant negative c-Src or the protein tyrosine phosphatase PTP - PEST, but not by dominant negative Abl. Our results suggest that the C-terminal region of Crk contains negative regulatory elements important for both Abl and FAK dependent signal pathways, and offers a paradigm for an autoinhibitory region in the SH3 linker/C-terminal SH3 domain.	Rockefeller Univ, Oncol Mol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Birge, RB (corresponding author), Rockefeller Univ, Oncol Mol Lab, 1230 York Ave, New York, NY 10021 USA.		Muir, Tom/AHD-0860-2022	Muir, Tom/0000-0001-9635-0344; Kirsch, Kathrin/0000-0003-1532-1715	NIGMS NIH HHS [GM55760] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Ling P, 1999, MOL CELL BIOL, V19, P1359; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4	53	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					951	961		10.1038/sj.onc.1204173	http://dx.doi.org/10.1038/sj.onc.1204173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314030				2022-12-28	WOS:000167097000006
J	Karayan, L; Riou, JF; Seite, P; Migeon, J; Cantereau, A; Larsen, CJ				Karayan, L; Riou, JF; Seite, P; Migeon, J; Cantereau, A; Larsen, CJ			Human ARF protein interacts with Topoisomerase I and stimulates its activity	ONCOGENE			English	Article						p14(ARF); Topoisomerase I; protein interactions	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; BETA-TRANSCRIPT; DNA; P19(ARF); MDM2; GENE; LOCUS; PRODUCT	The ARF gene (p19(ARF) in mouse and p14(ARF) in man) has become a central actor of the cell cycle regulation process as it participates to the ARF-MDM2-p53 pathway and the Rh-E2F-1 pathway. By use of immunoprecipitation and Western blotting (IP/WB), we now show that ARF physically associates with Topoisomerase I(Topo I), ARF-Topo I immune complexes were detected in SF9 insect cells infected with recombinant baculoviruses encoding the two genes as well as in 293 cells that express endogeneously these proteins. Preparations of a GST-ARF recombinant protein stimulated the DNA relaxation activity of Topo I but, in contrast, had no effect an the decatenation activity of Topo TT, The Topo I stimulation was also detected in cell extracts of SF9 cells expressing both proteins, A confocal microscopy study indicated that part of ARF and Topo I colocalized in the granular component structure of the nucleolus. As a whole, our data indicate that Topo I is a new partner of ARF and suggest that ARF is involved in cell reactions that require Topo I.	CHU Poitiers, Lab Biochim Prot, Poitiers, France; Oncol Mol Lab, CNRS, FRE 2224, Poitiers, France; IFR Commun Intercellulaire, CNRS, UMR 6558, Serv Cytofluorometrie, F-86021 Poitiers, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Aventis Pharma, F-94403 Vitry Sur Seine, France	CHU Poitiers; Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Sanofi-Aventis; Sanofi France	Larsen, CJ (corresponding author), CHU Poitiers, Lab Biochim Prot, Poitiers, France.			riou, jean-francois/0000-0002-0055-6506; Seite, Paule/0000-0002-7809-7610				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Becker T., 1902, MITTEILUNGEN ZOOLOGI, V2, P1, DOI [10.1002/mmnz.4830020237, DOI 10.1002/MMNZ.4830020237]; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DURO D, 1995, ONCOGENE, V11, P21; EYMIN B, 2000, IN PRESS ONCOGENE; Gazzeri S, 1998, CANCER RES, V58, P3926; Gimenez-Abian JF, 2000, CHROMOSOMA, V109, P235, DOI 10.1007/s004120000065; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hao YW, 1997, BIOCHEM BIOPH RES CO, V234, P194, DOI 10.1006/bbrc.1997.6539; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kill IR, 1996, J CELL SCI, V109, P1253; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Kwon Y, 2000, J BIOL CHEM, V275, P18503, DOI 10.1074/jbc.M002081200; Larsen A K, 1999, Pathol Oncol Res, V5, P171, DOI 10.1053/paor.1999.0209; LARSEN CJ, 1997, PROGR CELL CYCLE RES, P109; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MAO L, 1995, CANCER RES, V55, P2995; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; NITISS JL, 1996, DNA TOPOISOMERASE DN; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; RUAS, 1998, BIOCH BIPHYS ACTA, V1378, P115; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; TAN KB, 1992, CANCER RES, V52, P231; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tazi J, 1997, J MOL MED, V75, P786, DOI 10.1007/s001090050168; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	77	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					836	848		10.1038/sj.onc.1204170	http://dx.doi.org/10.1038/sj.onc.1204170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314011				2022-12-28	WOS:000166924400007
J	Benaud, CM; Dickson, RB				Benaud, CM; Dickson, RB			Regulation of the expression of c-Myc by beta 1 integrins in epithelial cells	ONCOGENE			English	Article						c-Myc; adhesion; integrin; Src; PKC; MAPK	ACTIVATED PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; BETA(1C) INTEGRIN; EGF RECEPTOR; CYCLIN D1; IN-VIVO; ADHESION; SRC; GROWTH; INDUCTION	Cell adhesion promotes cellular proliferation through the regulation of gene expression, including the immediate early genes. However, the precise role of cell adhesion in the regulation of the c-Myc proto-oncogene is not clear, and the adhesion-dependent signaling pathway(s) regulating the expression of c-Myc has yet to be defined. We now show that integrin signaling directly regulates the expression of c-Myc in the mammary epithelial cell line 184A1N4 (A1N4), Adhesion of quiescent A1N4 cells to fibronectin, and to collagen types IV or I, induces the expression of c-Myc in an ECM concentration-dependent fashion. Cytoskeletal rearrangement, and integrin engagement and integrin clustering are required for the induction of c-Myc by fibronectin. Furthermore, beta1 integrin function-blocking antibodies prevent the adhesion-dependent induction of c-Myc. Adhesion of A1N4 cells results in the activation both of c-Src and of the Erk 1/2 mitogen-activated protein kinase (MAPK), each of which precedes the induction of c-Myc. Pharmacological inhibitors specific for either the c-Src family of kinases or for MEK1 block the adhesion-dependent induction of c-Myc. These observations indicate that pi integrins regulate the expression of c-Myc through the activation of the Src family of tyrosine kinases and the MAI( kinase pathway.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.		Benaud, Christelle/M-1178-2018		NIA NIH HHS [R01AG1496] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aziz N, 1999, MOL CELL BIOL, V19, P1101; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dike LE, 1996, J CELL SCI, V109, P2855; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faraldo MM, 1998, EMBO J, V17, P2139, DOI 10.1093/emboj/17.8.2139; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Fornaro M, 1998, AM J PATHOL, V153, P1079, DOI 10.1016/S0002-9440(10)65652-0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; Manzotti M, 2000, AM J PATHOL, V156, P169, DOI 10.1016/S0002-9440(10)64716-5; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MORTARINI R, 1995, CANCER RES, V55, P4702; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; UDAGAWA T, 1995, CLIN EXP METASTAS, V13, P427, DOI 10.1007/BF00118182; VUORI K, 1993, J BIOL CHEM, V268, P21459; WATT R, 1983, NATURE, V303, P231; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; YAMADA KM, 1990, CANCER RES, V50, P4485	43	24	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					759	768		10.1038/sj.onc.1204152	http://dx.doi.org/10.1038/sj.onc.1204152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314009				2022-12-28	WOS:000166806000011
J	Kelley, ML; Winge, P; Heaney, JD; Stephens, RE; Farell, JH; Van Beneden, RJ; Reinisch, CL; Lesser, MP; Walker, CW				Kelley, ML; Winge, P; Heaney, JD; Stephens, RE; Farell, JH; Van Beneden, RJ; Reinisch, CL; Lesser, MP; Walker, CW			Expression of homologues for p53 and p73 in the softshell clam (Mya arenaria), a naturally-occurring model for human cancer	ONCOGENE			English	Article						p53; p73; Burkitt's lymphoma; cancer; Mya arenaria clam; nuclear exclusion	ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; P53-RELATED PROTEIN; NUCLEAR EXCLUSION; FUNCTIONAL DOMAIN; BREAST-CANCER; MUTANT P53; MDM2; LYMPHOMA	Homologues for human p53 (Hsp53) and p73 (Hsp73) genes were cloned and expression patterns for their corresponding proteins analysed in tissues from normal and leukemic softshell clams (Mya arenaria). These are the first structural and functional data for p53 and p73 cDNAs and gene products in a naturally occurring, nonmammalian disease model. Core sequence of the predicted clam p53 (Map53) and p73 (Map73) proteins is virtually identical and includes the following a highly conserved regions: the transcriptional activation domain (TAD), MDM2 binding site, ATM phosphorylation site, proline rich domain, DSA binding domains (DBDs) II-V, nuclear import and export signals and the tetramerization domain. The core sequence is a structural mosaic of the corresponding human proteins, with the TAD and DBDs resembling Hsp53 and Hsp73, respectively. This suggests that Map53 and Map73 proteins mag function similarly to human proteins. Clam proteins have either a short (Map53) or long (Map73) C-terminal extension, These features suggest that Map53 and Map73 mag be alternate splice variants of a p63/p73-like ancestral gene. Map73 is significantly upregulated in hemocytes and adductor muscle from leukemic clams. In leukemic hemocytes, both proteins are absent from the nucleus and sequestered in the cytoplasm, This observation suggests that a non-mutational p53/p73-dependent mechanism may be in col,ed in the clam disease. Further studies of these gene products in clams may reveal p53/p73-related molecular mechanisms that are held in common with Burkitt's lymphoma or other human cancers.	Univ New Hampshire, Dept Zool, Durham, NH 03824 USA; Univ New Hampshire, Marine Biomed Res Grp, Durham, NH 03824 USA; Univ Maine, Dept Biochem Microbiol & Mol Biol, Orono, ME 04469 USA; Univ Maine, Sch Marine Sci, Orono, ME 04469 USA; Univ Trondheim, Ctr Mol Biol, UNIGEN, N-7005 Trondheim, Norway; Marine Biol Lab, Woods Hole, MA 02543 USA; Boston Univ, Sch Med, Dept Physiol L720, Boston, MA 02118 USA	University System Of New Hampshire; University of New Hampshire; University System Of New Hampshire; University of New Hampshire; University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; Marine Biological Laboratory - Woods Hole; Boston University	Walker, CW (corresponding author), Univ New Hampshire, Dept Zool, Rudman Hall, Durham, NH 03824 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD028204] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA044307] Funding Source: NIH RePORTER; NCI NIH HHS [CA44307] Funding Source: Medline; NICHD NIH HHS [HD28204-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUFFRET M, 1988, AM FISH SOC SPEC PUB, V18, P169; Avramis VI, 1998, ANTICANCER RES, V18, P2327; Bain BJ, 1999, LEUKEMIA DIAGNOSIS, P1; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barker CM, 1997, EXP CELL RES, V232, P240, DOI 10.1006/excr.1997.3513; Bhaskaran A, 2000, COMP BIOCHEM PHYS B, V126, P49, DOI 10.1016/S0305-0491(00)00174-7; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cheng T.C., 1981, INVERTEBRATE BLOOD C, P233; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Corn PG, 1999, CANCER RES, V59, P3352; DANG CV, 1989, J BIOL CHEM, V264, P18019; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; ELSTON RA, 1992, REV AQUAT SCI, V6, P405; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GROGAN TM, 1982, CANCER-AM CANCER SOC, V49, P1817, DOI 10.1002/1097-0142(19820501)49:9<1817::AID-CNCR2820490914>3.0.CO;2-F; Harlow E., 1999, USING ANTIBODIES LAB, P1; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Humason GL, 1979, ANIMAL TISSUE TECHNI, P1; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; MARIN MC, 2000, BIOCHIM BIOPHYS ACTA, V1470, P94; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIOSKY DL, 1989, J INVERTEBR PATHOL, V53, P32, DOI 10.1016/0022-2011(89)90071-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nagai J, 1998, LEUKEMIA LYMPHOMA, V28, P591, DOI 10.3109/10428199809058368; Nishimori H, 2000, J NEURO-ONCOL, V46, P17, DOI 10.1023/A:1006404110073; OConnor PM, 1997, CANCER RES, V57, P4285; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Peters UR, 1999, CANCER RES, V59, P4233; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; PROKOCIMER M, 1986, BLOOD, V68, P113; REINISCH CL, 1984, HAZARD WASTE HAZARD, V1, P73, DOI 10.1089/hzw.1984.1.73; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; SHAULSKY G, 1991, CANCER RES, V51, P5232; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Steller H, 2000, NAT CELL BIOL, V2, pE100, DOI 10.1038/35014093; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Van Beneden RJ, 1998, MAR ENVIRON RES, V46, P209, DOI 10.1016/S0141-1136(97)00093-7; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	70	76	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					748	758		10.1038/sj.onc.1204144	http://dx.doi.org/10.1038/sj.onc.1204144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314008				2022-12-28	WOS:000166806000010
J	Reiss, K; Wang, JY; Romano, G; Tu, X; Peruzzi, F; Baserga, R				Reiss, K; Wang, JY; Romano, G; Tu, X; Peruzzi, F; Baserga, R			Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; cell adhesion; cell motility; signal transduction	GROWTH-FACTOR-I; SERINE KINASE PHOSPHORYLATES; DOMINANT-NEGATIVE MUTANT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; RETROVIRAL VECTORS; LIGAND OCCUPANCY; BINDING-PROTEINS	LNCaP cells are human prostatic cancer cells that have a frame-shift mutation of the tumor suppressor gene PTEN and do not express the insulin receptor substrate-1 (IRS-I), a major substrate of the type 1 insulin-like growth factor receptor (IGF-IR). Ectopic expression of IRS-1 in LNCaP cells increases cell adhesion and decreases cell motility by an IGF-I-independent mechanism. We show nom that these effects of IRS-1 are accompanied by serine phosphorylation of IRS-1 and are inhibited by inhibitors of phosphatidylinositol 3-kinase (PI3K), We have confirmed the requirement for PI3K activity and serine phosphorylation by the use of IRS-1 mutants, expressed in LNCaP cells. Serine phosphorylation inhibits IGF-I-induced tyrosyl phosphorylation of IRS-1, which is restored by the expression of wild-type PTEN or by inhibition of PI3K activity. Finally, IRS-1 in LNCaP cells co-immunoprecipitates with integrin alpha 5 beta 1, and the association is again IGF-I-independent. We conclude that in LNCaP cells, IRS-1 is serine phosphorylated by PI3K, generating effects that are different, and even opposite, from those generated by IGF-I.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 624 Biol Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.		Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NINDS NIH HHS [P0-1 NS 36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baserga R, 1999, CONT ENDOCRINOL, V17, P329; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Carson JP, 1999, CANCER RES, V59, P1449; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Davies MA, 1999, CANCER RES, V59, P2551; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; Furnari FB, 1998, CANCER RES, V58, P5002; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HAWLEY RG, 1994, GENE THER, V1, P136; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; LAM K, 1994, J BIOL CHEM, V269, P20648; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zheng DQ, 1999, CANCER RES, V59, P1655	61	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					490	500		10.1038/sj.onc.1204112	http://dx.doi.org/10.1038/sj.onc.1204112			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313980				2022-12-28	WOS:000166562500009
J	Sebolt-Leopold, JS				Sebolt-Leopold, JS			Development of anticancer drugs targeting the MAP kinase pathway	ONCOGENE			English	Article						mitogen-activated protein kinase (MAPK); extracellular signal-regulated kinase (ERK); MAP kinase kinase (MEK); raf	ACTIVATED PROTEIN-KINASES; EPIDERMAL-GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; BAD PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CARCINOMA CELLS; IN-VITRO; RAF; INHIBITION; MEK	Since the discovery of the role of ras oncogenes in tumorigenesis, me have witnessed an explosion of research in the signal transduction area. In the quest to understand how Pas transmits extracellular growth signals, the MAP kinase (MAPK) pathway has emerged as the crucial route between membrane-bound Ras and the nucleus, The MAPK pathway encompasses a cascade of phosphorylation events involving three key kinases, namely Raf, MEK (MAP kinase kinase) and ERK (MAP kinase). This kinase cascade presents novel opportunities for the development of new cancer therapies designed to be less toxic than conventional chemotherapeutic drugs, Furthermore, as a signal transduction-based approach to cancer treatment, inhibition of any one of these targets has the potential for translational pharmacodynamic evaluation of target suppression. The rationale for targeting the MAP kinase pathway will be reviewed here along with a discussion of various pharmacological approaches and the promise they hold for a new generation of anticancer drugs.	Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA	Pfizer	Sebolt-Leopold, JS (corresponding author), Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAYER CORPORATION, 2000, Patent No. 200042012; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUMAS J, 1999, Patent No. 9932455; Dumas J., 1999, Patent, P163, Patent No. [9932106, WO 9,932,106 A1]; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gioeli D, 1999, CANCER RES, V59, P279; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P409; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Herrera R, 1998, J CELL SCI, V111, P1039; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li WQ, 2000, GENE DEV, V14, P895; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McDonald OB, 1999, ANAL BIOCHEM, V268, P318, DOI 10.1006/abio.1998.3030; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Miller S., 1999, [No title captured], Patent No. [9932436, WO9932436]; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Persons DL, 1999, CLIN CANCER RES, V5, P1007; PERSONS DL, 2000, IN PRESS J BIOL CHEM; Petit AMV, 1997, AM J PATHOL, V151, P1523; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1992, J BIOL CHEM, V267, P14373; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stevenson JP, 1999, J CLIN ONCOL, V17, P2227, DOI 10.1200/JCO.1999.17.7.2227; Stewart S, 1999, MOL CELL BIOL, V19, P5523; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG X, 2000, IN PRESS J BIOL CHEM; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Welch DR, 2000, CANCER RES, V60, P1552; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; YUEN AR, 2000, FRONT BIOSCI, pD588; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; ZENECA LTD, 1998, Patent No. 9822103; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	75	270	294	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6594	6599		10.1038/sj.onc.1204083	http://dx.doi.org/10.1038/sj.onc.1204083			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426644	Bronze			2022-12-28	WOS:000167704000005
J	Bartel, FO; Higuchi, T; Spyropoulos, DD				Bartel, FO; Higuchi, T; Spyropoulos, DD			Mouse models in the study of the Ets family of transcription factors	ONCOGENE			English	Article						Ets family; knockout; targeted disruption; hematopoiesis; angiogenesis	EMBRYONIC STEM-CELLS; FACTOR PU.1; SPI-B; MICE LACKING; BONE-MARROW; DIFFERENTIATION; HEMATOPOIESIS; GENE; PROTOONCOGENE; PROGENITORS	The Ets family of transcription factors is one of a growing number of master regulators of development. This family was originally defined by the presence of a conserved DNA binding domain, the Ets domain. To date, nearly 30 members of this family have been identified and implicated in a wide range of physiological and pathological processes. Despite the likely importance of Ets-family members, each of their precise roles has not been delineated. Herein, we describe the elucidation of essential functions of a few of these family members in vivo using knockout mouse models, Of the knockouts generated to date, the majority shows important functions in hematopoiesis, ranging from PU.1, a principle regulator of myelo-lymphopoiesis, to Spi-B which regulates the proper function of terminally differentiated cells. Ets1 was shown to be of intermediate importance as a regulator of pan-lymphoid development. Other Ets family members such as Fli1 and TEL1 display distinct and/or overlapping functions in vasculo/angiogenesis, hemostasis and hematopoiesis. The remaining knockouts generated, Ets2 and Er81, show non-hematopoietic defects related to extraembryonic development and neurogenesis, respectively. The pioneering group of knockout models described reveals only the most distinct functions of each of these Ets family members. A better understanding of the roles and hierarchies of Ets family members in cellular differentiation will come with the generation of new null alleles in previously untargeted family members, more mutant alleles in members already disrupted, double knockouts, ES cell differentiation and chimera rescue experiments, and tissue-specific inducible knockouts.	Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Spyropoulos, DD (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA.				NCI NIH HHS [P01CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; Garrett-Sinha LA, 1999, IMMUNITY, V10, P399, DOI 10.1016/S1074-7613(00)80040-0; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Henkel GW, 1999, BLOOD, V93, P2849; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Melet F, 1996, MOL CELL BIOL, V16, P2708; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Orkin SH, 1999, CANCER RES, V59, p1784S; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Simon MC, 1998, SEMIN IMMUNOL, V10, P111, DOI 10.1006/smim.1998.0112; Spain LM, 1999, J IMMUNOL, V163, P2681; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WATSON DK, 2001, ENCY CANC; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	44	90	94	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6443	6454		10.1038/sj.onc.1204038	http://dx.doi.org/10.1038/sj.onc.1204038			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175360				2022-12-28	WOS:000166595000006
J	Hsu, T; Schulz, RA				Hsu, T; Schulz, RA			Sequence and functional properties of Ets genes in the model organism Drosophila	ONCOGENE			English	Article						Drosophila; ets; pointed; yan; D-elg; E74	DOMAIN TRANSCRIPTION FACTOR; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; VENTRAL NEUROBLASTS; MAP KINASE; FACTOR CF2; D-ELG; OOGENESIS; PATHWAY; ACTIVATION	Detailed molecular and genetic studies, coupled with the recent sequencing of the fly genome, have identified eight Ets-related genes in the model organism Drosophila. All show homology to genes in vertebrate species. Functional analyses of some of the Drosophila ets genes have revealed their essential roles in developmental processes such as metamorphosis, oogenesis, neurogenesis, myogenesis, and eye development. Such studies have yielded important insights into our understanding of the genetic control of hormonally-regulated gene expression, programmed cell death, and signal transduction during cell fate determination and differentiation. The developmental roles of E74 (ELF1), pointed (Ets 1), yan (TEL), and D-elg (GABP alpha) will be reviewed in this article, The context of their participation in signal transduction and gene regulation will also be discussed. The information should be of significant value to the study of related processes in higher organisms due to the growing evidence for the cross species conservation of developmental mechanisms.	Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA	Medical University of South Carolina; Medical University of South Carolina; University of Texas System; UTMD Anderson Cancer Center	Hsu, T (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.			Hsu, Tien/0000-0003-2308-4297				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Andrew DJ, 2000, MECH DEVELOP, V92, P5, DOI 10.1016/S0925-4773(99)00321-4; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buff E, 1998, DEVELOPMENT, V125, P2075; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; Chinenov Y, 2000, J BIOL CHEM, V275, P7749, DOI 10.1074/jbc.275.11.7749; Chu H, 1998, GENE DEV, V12, P3613, DOI 10.1101/gad.12.22.3613; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLETCHER JC, 1995, DEVELOPMENT, V121, P1455; Fletcher JC, 1997, P NATL ACAD SCI USA, V94, P4582, DOI 10.1073/pnas.94.9.4582; Gabay L, 1996, DEVELOPMENT, V122, P3355; GAJEWSKI KM, 1995, ONCOGENE, V11, P1033; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Hsu T, 1996, GENE DEV, V10, P1411, DOI 10.1101/gad.10.11.1411; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; Jiang CA, 2000, MOL CELL, V5, P445, DOI 10.1016/S1097-2765(00)80439-6; Jiang CG, 1997, DEVELOPMENT, V124, P4673; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Mantrova EY, 1998, GENE DEV, V12, P1166; Mantrova EY, 1999, P NATL ACAD SCI USA, V96, P11889, DOI 10.1073/pnas.96.21.11889; McDonald JA, 1998, GENE DEV, V12, P3603, DOI 10.1101/gad.12.22.3603; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Michelson AM, 1998, DEV GENET, V22, P212, DOI 10.1002/(SICI)1520-6408(1998)22:3<212::AID-DVG4>3.0.CO;2-9; Morimoto AM, 1996, DEVELOPMENT, V122, P3745; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Rebay I, 2000, GENETICS, V154, P695; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Riddiford Lynn M., 1993, P899; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; Schulz RA, 1999, ONCOGENE, V18, P6818, DOI 10.1038/sj.onc.1203081; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Spradling AC, 1999, GENETICS, V153, P135; Spradling Allan C., 1993, P1; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Twombly V, 1996, DEVELOPMENT, V122, P1555; Urness LD, 1995, EMBO J, V14, P6239, DOI 10.1002/j.1460-2075.1995.tb00314.x; Van Buskirk C, 1999, TRENDS CELL BIOL, V9, P1, DOI 10.1016/S0962-8924(98)01413-5; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5	56	55	57	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6409	6416		10.1038/sj.onc.1204033	http://dx.doi.org/10.1038/sj.onc.1204033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175357				2022-12-28	WOS:000166595000003
